start	original_mutation_description	alias	gene	gene_name	gene_symbol	strand_orientation	gene_orientation	product	protein_alias	protein_name	protein_symbol	protein_id	alias_protein_id	locus_tag	ps_filter	ps_exc	mat_pep	mat_pep_desc	mat_pep_acc	ro	ao	dp	obs_sample_size	reference_seq	variant_seq	nt_name	aa_name	hgvs_nt	hgvs_aa	hgvs_alias	heterozygosity	vcf_gene	mutation_type	viral_lineages	clade	multi_aa_name	multiaa_comb_mutation	alternate_frequency	measured_variant_functional_effect	inferred_variant_functional_effect	viral_life_cycle_functional_effect	author	publication_year	doi	pmid	url	peer_review_status	citation	comb_mutation	variant_functional_effect_description	mutation_functional_annotation_resource	functional_annotation_resource	curator	clade_defining	variant	variant_type	voi_designation_date	voc_designation_date	vum_designation_date	status	organism	reference_accession	reference_database_name	cvx_code	drugbank_accession_number	antibody_registry_id
241	g.C-25T	n/a	intergenic	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C-25T	n/a	NC_045512.2:g.25C>T	n/a	n/a	n/a	ORF1ab	n/a	KP.2.3.5	n/a	n/a	n/a	1.0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	Pokay	n/a	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	n/a	n/a	n/a	n/a	n/a	n/a
670	S135R	S135R	ORF1ab	open reading frame 1ab gene (SARS-CoV-2)	orf1ab gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	ORF1ab polyprotein	ORF1a	open reading frame 1a polyprotein (SARS-CoV-2)	Orf1a protein (SARS-CoV-2)	YP_009724389.1	YP_009725297.1	GU280_gp01	n/a	n/a	nsp1	nsp1%3B produced by both pp1a and pp1ab	id-YP_009724389.1:1..180	0	1	1	1	T	G	g.T405G	p.S135R	NC_045512.2(GU280_gp01):g.405T>G	YP_009724389.1:p.Ser135Arg	YP_009725297.1:Ser135Arg	n/a	ORF1ab	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	Pokay	n/a	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	n/a	n/a	n/a	n/a	n/a	n/a
897	A211D	A31D	ORF1ab	open reading frame 1ab gene (SARS-CoV-2)	orf1ab gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	ORF1ab polyprotein	ORF1a	open reading frame 1a polyprotein (SARS-CoV-2)	Orf1a protein (SARS-CoV-2)	YP_009724389.1	YP_009725298.1	GU280_gp01	n/a	n/a	nsp2	produced by both pp1a and pp1ab	id-YP_009724389.1:181..818	0	1	1	1	C	A	g.C632A	p.A211D	NC_045512.2(GU280_gp01):g.632C>A	YP_009724389.1:p.Ala211Asp	YP_009725298.1:Ala31Asp	n/a	ORF1ab	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	Pokay	n/a	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	n/a	n/a	n/a	n/a	n/a	n/a
1087	V274V	V94V	ORF1ab	open reading frame 1ab gene (SARS-CoV-2)	orf1ab gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	ORF1ab polyprotein	ORF1a	open reading frame 1a polyprotein (SARS-CoV-2)	Orf1a protein (SARS-CoV-2)	YP_009724389.1	YP_009725298.1	GU280_gp01	n/a	n/a	nsp2	produced by both pp1a and pp1ab	id-YP_009724389.1:181..818	0	1	1	1	A	G	g.A822G	p.V274V	NC_045512.2(GU280_gp01):g.822A>G	YP_009724389.1:p.Val274Val	YP_009725298.1:Val94Val	n/a	ORF1ab	SILENT	KP.2.3.5	n/a	n/a	n/a	1.0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	Pokay	n/a	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	n/a	n/a	n/a	n/a	n/a	n/a
2790	T842I	n/a	ORF1ab	open reading frame 1ab gene (SARS-CoV-2)	orf1ab gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	ORF1ab polyprotein	ORF1a	open reading frame 1a polyprotein (SARS-CoV-2)	Orf1a protein (SARS-CoV-2)	YP_009724389.1	n/a	GU280_gp01	n/a	n/a	PL_proPLpro	former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab	id-YP_009724389.1:819..2763	0	1	1	1	C	T	g.C2525T	p.T842I	NC_045512.2(GU280_gp01):g.2525C>T	YP_009724389.1:p.Thr842Ile	n/a	n/a	ORF1ab	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	Pokay	n/a	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	n/a	n/a	n/a	n/a	n/a	n/a
3037	F924F	n/a	ORF1ab	open reading frame 1ab gene (SARS-CoV-2)	orf1ab gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	ORF1ab polyprotein	ORF1a	open reading frame 1a polyprotein (SARS-CoV-2)	Orf1a protein (SARS-CoV-2)	YP_009724389.1	n/a	GU280_gp01	n/a	n/a	PL_proPLpro	former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab	id-YP_009724389.1:819..2763	0	1	1	1	C	T	g.C2772T	p.F924F	NC_045512.2(GU280_gp01):g.2772C>T	YP_009724389.1:p.Phe924Phe	n/a	n/a	ORF1ab	SILENT	KP.2.3.5	n/a	n/a	n/a	1.0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	Pokay	n/a	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	n/a	n/a	n/a	n/a	n/a	n/a
3431	V1056L	n/a	ORF1ab	open reading frame 1ab gene (SARS-CoV-2)	orf1ab gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	ORF1ab polyprotein	ORF1a	open reading frame 1a polyprotein (SARS-CoV-2)	Orf1a protein (SARS-CoV-2)	YP_009724389.1	n/a	GU280_gp01	n/a	n/a	PL_proPLpro	former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab	id-YP_009724389.1:819..2763	0	1	1	1	G	T	g.G3166T	p.V1056L	NC_045512.2(GU280_gp01):g.3166G>T	YP_009724389.1:p.Val1056Leu	n/a	n/a	ORF1ab	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	Pokay	n/a	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	n/a	n/a	n/a	n/a	n/a	n/a
3565	G1100G	n/a	ORF1ab	open reading frame 1ab gene (SARS-CoV-2)	orf1ab gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	ORF1ab polyprotein	ORF1a	open reading frame 1a polyprotein (SARS-CoV-2)	Orf1a protein (SARS-CoV-2)	YP_009724389.1	n/a	GU280_gp01	n/a	n/a	PL_proPLpro	former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab	id-YP_009724389.1:819..2763	0	1	1	1	T	C	g.T3300C	p.G1100G	NC_045512.2(GU280_gp01):g.3300T>C	YP_009724389.1:p.Gly1100Gly	n/a	n/a	ORF1ab	SILENT	KP.2.3.5	n/a	n/a	n/a	1.0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	Pokay	n/a	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	n/a	n/a	n/a	n/a	n/a	n/a
4184	G1307S	n/a	ORF1ab	open reading frame 1ab gene (SARS-CoV-2)	orf1ab gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	ORF1ab polyprotein	ORF1a	open reading frame 1a polyprotein (SARS-CoV-2)	Orf1a protein (SARS-CoV-2)	YP_009724389.1	n/a	GU280_gp01	n/a	n/a	PL_proPLpro	former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab	id-YP_009724389.1:819..2763	0	1	1	1	G	A	g.G3919A	p.G1307S	NC_045512.2(GU280_gp01):g.3919G>A	YP_009724389.1:p.Gly1307Ser	n/a	n/a	ORF1ab	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	Pokay	n/a	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	n/a	n/a	n/a	n/a	n/a	n/a
4321	A1352A	n/a	ORF1ab	open reading frame 1ab gene (SARS-CoV-2)	orf1ab gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	ORF1ab polyprotein	ORF1a	open reading frame 1a polyprotein (SARS-CoV-2)	Orf1a protein (SARS-CoV-2)	YP_009724389.1	n/a	GU280_gp01	n/a	n/a	PL_proPLpro	former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab	id-YP_009724389.1:819..2763	0	1	1	1	C	T	g.C4056T	p.A1352A	NC_045512.2(GU280_gp01):g.4056C>T	YP_009724389.1:p.Ala1352Ala	n/a	n/a	ORF1ab	SILENT	KP.2.3.5	n/a	n/a	n/a	1.0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	Pokay	n/a	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	n/a	n/a	n/a	n/a	n/a	n/a
6183	K1973R	n/a	ORF1ab	open reading frame 1ab gene (SARS-CoV-2)	orf1ab gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	ORF1ab polyprotein	ORF1a	open reading frame 1a polyprotein (SARS-CoV-2)	Orf1a protein (SARS-CoV-2)	YP_009724389.1	n/a	GU280_gp01	n/a	n/a	PL_proPLpro	former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab	id-YP_009724389.1:819..2763	0	1	1	1	A	G	g.A5918G	p.K1973R	NC_045512.2(GU280_gp01):g.5918A>G	YP_009724389.1:p.Lys1973Arg	n/a	n/a	ORF1ab	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	Pokay	n/a	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	n/a	n/a	n/a	n/a	n/a	n/a
7113	T2283I	n/a	ORF1ab	open reading frame 1ab gene (SARS-CoV-2)	orf1ab gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	ORF1ab polyprotein	ORF1a	open reading frame 1a polyprotein (SARS-CoV-2)	Orf1a protein (SARS-CoV-2)	YP_009724389.1	n/a	GU280_gp01	n/a	n/a	PL_proPLpro	former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab	id-YP_009724389.1:819..2763	0	1	1	1	C	T	g.C6848T	p.T2283I	NC_045512.2(GU280_gp01):g.6848C>T	YP_009724389.1:p.Thr2283Ile	n/a	n/a	ORF1ab	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	Pokay	n/a	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	n/a	n/a	n/a	n/a	n/a	n/a
7842	N2526S	n/a	ORF1ab	open reading frame 1ab gene (SARS-CoV-2)	orf1ab gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	ORF1ab polyprotein	ORF1a	open reading frame 1a polyprotein (SARS-CoV-2)	Orf1a protein (SARS-CoV-2)	YP_009724389.1	n/a	GU280_gp01	n/a	n/a	PL_proPLpro	former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab	id-YP_009724389.1:819..2763	0	1	1	1	A	G	g.A7577G	p.N2526S	NC_045512.2(GU280_gp01):g.7577A>G	YP_009724389.1:p.Asn2526Ser	n/a	n/a	ORF1ab	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	Pokay	n/a	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	n/a	n/a	n/a	n/a	n/a	n/a
8293	T2676T	n/a	ORF1ab	open reading frame 1ab gene (SARS-CoV-2)	orf1ab gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	ORF1ab polyprotein	ORF1a	open reading frame 1a polyprotein (SARS-CoV-2)	Orf1a protein (SARS-CoV-2)	YP_009724389.1	n/a	GU280_gp01	n/a	n/a	PL_proPLpro	former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab	id-YP_009724389.1:819..2763	0	1	1	1	C	T	g.C8028T	p.T2676T	NC_045512.2(GU280_gp01):g.8028C>T	YP_009724389.1:p.Thr2676Thr	n/a	n/a	ORF1ab	SILENT	KP.2.3.5	n/a	n/a	n/a	1.0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	Pokay	n/a	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	n/a	n/a	n/a	n/a	n/a	n/a
8393	A2710T	n/a	ORF1ab	open reading frame 1ab gene (SARS-CoV-2)	orf1ab gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	ORF1ab polyprotein	ORF1a	open reading frame 1a polyprotein (SARS-CoV-2)	Orf1a protein (SARS-CoV-2)	YP_009724389.1	n/a	GU280_gp01	n/a	n/a	PL_proPLpro	former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab	id-YP_009724389.1:819..2763	0	1	1	1	G	A	g.G8128A	p.A2710T	NC_045512.2(GU280_gp01):g.8128G>A	YP_009724389.1:p.Ala2710Thr	n/a	n/a	ORF1ab	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	Pokay	n/a	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	n/a	n/a	n/a	n/a	n/a	n/a
9344	L3027F	L264F	ORF1ab	open reading frame 1ab gene (SARS-CoV-2)	orf1ab gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	ORF1ab polyprotein	ORF1a	open reading frame 1a polyprotein (SARS-CoV-2)	Orf1a protein (SARS-CoV-2)	YP_009724389.1	YP_009725300.1	GU280_gp01	n/a	n/a	nsp4	nsp4B_TM%3B contains transmembrane domain 2 (TM2)%3B produced by both pp1a and pp1ab	id-YP_009724389.1:2764..3263	0	1	1	1	C	T	g.C9079T	p.L3027F	NC_045512.2(GU280_gp01):g.9079C>T	YP_009724389.1:p.Leu3027Phe	YP_009725300.1:Leu264Phe	n/a	ORF1ab	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	Pokay	n/a	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	n/a	n/a	n/a	n/a	n/a	n/a
9424	V3053V	V290V	ORF1ab	open reading frame 1ab gene (SARS-CoV-2)	orf1ab gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	ORF1ab polyprotein	ORF1a	open reading frame 1a polyprotein (SARS-CoV-2)	Orf1a protein (SARS-CoV-2)	YP_009724389.1	YP_009725300.1	GU280_gp01	n/a	n/a	nsp4	nsp4B_TM%3B contains transmembrane domain 2 (TM2)%3B produced by both pp1a and pp1ab	id-YP_009724389.1:2764..3263	0	1	1	1	A	G	g.A9159G	p.V3053V	NC_045512.2(GU280_gp01):g.9159A>G	YP_009724389.1:p.Val3053Val	YP_009725300.1:Val290Val	n/a	ORF1ab	SILENT	KP.2.3.5	n/a	n/a	n/a	1.0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	Pokay	n/a	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	n/a	n/a	n/a	n/a	n/a	n/a
9534	T3090I	T327I	ORF1ab	open reading frame 1ab gene (SARS-CoV-2)	orf1ab gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	ORF1ab polyprotein	ORF1a	open reading frame 1a polyprotein (SARS-CoV-2)	Orf1a protein (SARS-CoV-2)	YP_009724389.1	YP_009725300.1	GU280_gp01	n/a	n/a	nsp4	nsp4B_TM%3B contains transmembrane domain 2 (TM2)%3B produced by both pp1a and pp1ab	id-YP_009724389.1:2764..3263	0	1	1	1	C	T	g.C9269T	p.T3090I	NC_045512.2(GU280_gp01):g.9269C>T	YP_009724389.1:p.Thr3090Ile	YP_009725300.1:Thr327Ile	n/a	ORF1ab	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	Pokay	n/a	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	n/a	n/a	n/a	n/a	n/a	n/a
10029	T3255I	T492I	ORF1ab	open reading frame 1ab gene (SARS-CoV-2)	orf1ab gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	ORF1ab polyprotein	ORF1a	open reading frame 1a polyprotein (SARS-CoV-2)	Orf1a protein (SARS-CoV-2)	YP_009724389.1	YP_009725300.1	GU280_gp01	n/a	n/a	nsp4	nsp4B_TM%3B contains transmembrane domain 2 (TM2)%3B produced by both pp1a and pp1ab	id-YP_009724389.1:2764..3263	0	1	1	1	C	T	g.C9764T	p.T3255I	NC_045512.2(GU280_gp01):g.9764C>T	YP_009724389.1:p.Thr3255Ile	YP_009725300.1:Thr492Ile	n/a	ORF1ab	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	Pokay	n/a	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	n/a	n/a	n/a	n/a	n/a	n/a
10198	D3311D	D48D	ORF1ab	open reading frame 1ab gene (SARS-CoV-2)	orf1ab gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	ORF1ab polyprotein	ORF1a	open reading frame 1a polyprotein (SARS-CoV-2)	Orf1a protein (SARS-CoV-2)	YP_009724389.1	YP_009725301.1	GU280_gp01	n/a	n/a	3CL	nsp5A_3CLpro and nsp5B_3CLpro%3B main proteinase (Mpro)%3B mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al.%2C 2003)%3B produced by both pp1a and pp1ab	id-YP_009724389.1:3264..3569	0	1	1	1	C	T	g.C9933T	p.D3311D	NC_045512.2(GU280_gp01):g.9933C>T	YP_009724389.1:p.Asp3311Asp	YP_009725301.1:Asp48Asp	n/a	ORF1ab	SILENT	KP.2.3.5	n/a	n/a	n/a	1.0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	Pokay	n/a	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	n/a	n/a	n/a	n/a	n/a	n/a
10447	P3395H	P132H	ORF1ab	open reading frame 1ab gene (SARS-CoV-2)	orf1ab gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	ORF1ab polyprotein	ORF1a	open reading frame 1a polyprotein (SARS-CoV-2)	Orf1a protein (SARS-CoV-2)	YP_009724389.1	YP_009725301.1	GU280_gp01	n/a	n/a	3CL	nsp5A_3CLpro and nsp5B_3CLpro%3B main proteinase (Mpro)%3B mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al.%2C 2003)%3B produced by both pp1a and pp1ab	id-YP_009724389.1:3264..3569	0	1	1	1	GCC	ACA	g.GCC10182_10184ACA	p.P3395H	n/a	YP_009724389.1:p.Pro3395His	YP_009725301.1:Pro132His	n/a	ORF1ab	n/a	KP.2.3.5	n/a	n/a	n/a	1.0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	Pokay	n/a	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	n/a	n/a	n/a	n/a	n/a	n/a
11042	V3593F	V24F	ORF1ab	open reading frame 1ab gene (SARS-CoV-2)	orf1ab gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	ORF1ab polyprotein	ORF1a	open reading frame 1a polyprotein (SARS-CoV-2)	Orf1a protein (SARS-CoV-2)	YP_009724389.1	YP_009725302.1	GU280_gp01	n/a	n/a	nsp6	nsp6_TM%3B putative transmembrane domain%3B produced by both pp1a and pp1ab	id-YP_009724389.1:3570..3859	0	1	1	1	G	T	g.G10777T	p.V3593F	NC_045512.2(GU280_gp01):g.10777G>T	YP_009724389.1:p.Val3593Phe	YP_009725302.1:Val24Phe	n/a	ORF1ab	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	Pokay	n/a	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	n/a	n/a	n/a	n/a	n/a	n/a
11287	S3675del	S106_F108del	ORF1ab	open reading frame 1ab gene (SARS-CoV-2)	orf1ab gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	ORF1ab polyprotein	ORF1a	open reading frame 1a polyprotein (SARS-CoV-2)	Orf1a protein (SARS-CoV-2)	YP_009724389.1	YP_009725302.1	GU280_gp01	n/a	n/a	nsp6	nsp6_TM%3B putative transmembrane domain%3B produced by both pp1a and pp1ab	id-YP_009724389.1:3570..3859	0	1	1	1	GTCTGGTTTT	G	g.11023_11031delTCTGGTTTT	p.S3675_F3677del	NC_045512.2(GU280_gp01):g.11023_11031del	YP_009724389.1:p.Ser3675_Phe3677del	YP_009725302.1:Ser106_Phe108del	n/a	ORF1ab	n/a	KP.2.3.5	n/a	S3675_F3677del	3676del,F3677del	1.0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	Pokay	n/a	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	n/a	n/a	n/a	n/a	n/a	n/a
11287	3676del	S106_F108del	ORF1ab	open reading frame 1ab gene (SARS-CoV-2)	orf1ab gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	ORF1ab polyprotein	ORF1a	open reading frame 1a polyprotein (SARS-CoV-2)	Orf1a protein (SARS-CoV-2)	YP_009724389.1	YP_009725302.1	GU280_gp01	n/a	n/a	nsp6	nsp6_TM%3B putative transmembrane domain%3B produced by both pp1a and pp1ab	id-YP_009724389.1:3570..3859	0	1	1	1	GTCTGGTTTT	G	g.11023_11031delTCTGGTTTT	p.S3675_F3677del	NC_045512.2(GU280_gp01):g.11023_11031del	YP_009724389.1:p.Ser3675_Phe3677del	YP_009725302.1:Ser106_Phe108del	n/a	ORF1ab	n/a	KP.2.3.5	n/a	S3675_F3677del	S3675del,F3677del	1.0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	Pokay	n/a	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	n/a	n/a	n/a	n/a	n/a	n/a
11287	F3677del	S106_F108del	ORF1ab	open reading frame 1ab gene (SARS-CoV-2)	orf1ab gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	ORF1ab polyprotein	ORF1a	open reading frame 1a polyprotein (SARS-CoV-2)	Orf1a protein (SARS-CoV-2)	YP_009724389.1	YP_009725302.1	GU280_gp01	n/a	n/a	nsp6	nsp6_TM%3B putative transmembrane domain%3B produced by both pp1a and pp1ab	id-YP_009724389.1:3570..3859	0	1	1	1	GTCTGGTTTT	G	g.11023_11031delTCTGGTTTT	p.S3675_F3677del	NC_045512.2(GU280_gp01):g.11023_11031del	YP_009724389.1:p.Ser3675_Phe3677del	YP_009725302.1:Ser106_Phe108del	n/a	ORF1ab	n/a	KP.2.3.5	n/a	S3675_F3677del	S3675del,3676del	1.0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	Pokay	n/a	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	n/a	n/a	n/a	n/a	n/a	n/a
11727	R3821K	R252K	ORF1ab	open reading frame 1ab gene (SARS-CoV-2)	orf1ab gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	ORF1ab polyprotein	ORF1a	open reading frame 1a polyprotein (SARS-CoV-2)	Orf1a protein (SARS-CoV-2)	YP_009724389.1	YP_009725302.1	GU280_gp01	n/a	n/a	nsp6	nsp6_TM%3B putative transmembrane domain%3B produced by both pp1a and pp1ab	id-YP_009724389.1:3570..3859	0	1	1	1	G	A	g.G11462A	p.R3821K	NC_045512.2(GU280_gp01):g.11462G>A	YP_009724389.1:p.Arg3821Lys	YP_009725302.1:Arg252Lys	n/a	ORF1ab	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	Pokay	n/a	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	n/a	n/a	n/a	n/a	n/a	n/a
12789	T4175I	T35I	ORF1ab	open reading frame 1ab gene (SARS-CoV-2)	orf1ab gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	ORF1ab polyprotein	ORF1a	open reading frame 1a polyprotein (SARS-CoV-2)	Orf1a protein (SARS-CoV-2)	YP_009724389.1	YP_009725305.1	GU280_gp01	n/a	n/a	nsp9	ssRNA-binding protein%3B produced by both pp1a and pp1ab	id-YP_009724389.1:4141..4253	0	1	1	1	C	T	g.C12524T	p.T4175I	NC_045512.2(GU280_gp01):g.12524C>T	YP_009724389.1:p.Thr4175Ile	YP_009725305.1:Thr35Ile	n/a	ORF1ab	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	Pokay	n/a	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	n/a	n/a	n/a	n/a	n/a	n/a
12815	L4184L	L44L	ORF1ab	open reading frame 1ab gene (SARS-CoV-2)	orf1ab gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	ORF1ab polyprotein	ORF1a	open reading frame 1a polyprotein (SARS-CoV-2)	Orf1a protein (SARS-CoV-2)	YP_009724389.1	YP_009725305.1	GU280_gp01	n/a	n/a	nsp9	ssRNA-binding protein%3B produced by both pp1a and pp1ab	id-YP_009724389.1:4141..4253	0	1	1	1	C	T	g.C12550T	p.L4184L	NC_045512.2(GU280_gp01):g.12550C>T	YP_009724389.1:p.Leu4184Leu	YP_009725305.1:Leu44Leu	n/a	ORF1ab	SILENT	KP.2.3.5	n/a	n/a	n/a	1.0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	Pokay	n/a	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	n/a	n/a	n/a	n/a	n/a	n/a
12880	I4205I	I65I	ORF1ab	open reading frame 1ab gene (SARS-CoV-2)	orf1ab gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	ORF1ab polyprotein	ORF1a	open reading frame 1a polyprotein (SARS-CoV-2)	Orf1a protein (SARS-CoV-2)	YP_009724389.1	YP_009725305.1	GU280_gp01	n/a	n/a	nsp9	ssRNA-binding protein%3B produced by both pp1a and pp1ab	id-YP_009724389.1:4141..4253	0	1	1	1	C	T	g.C12615T	p.I4205I	NC_045512.2(GU280_gp01):g.12615C>T	YP_009724389.1:p.Ile4205Ile	YP_009725305.1:Ile65Ile	n/a	ORF1ab	SILENT	KP.2.3.5	n/a	n/a	n/a	1.0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	Pokay	n/a	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	n/a	n/a	n/a	n/a	n/a	n/a
13339	N4358N	N105N	ORF1ab	open reading frame 1ab gene (SARS-CoV-2)	orf1ab gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	ORF1ab polyprotein	ORF1a	open reading frame 1a polyprotein (SARS-CoV-2)	Orf1a protein (SARS-CoV-2)	YP_009724389.1	YP_009725306.1	GU280_gp01	n/a	n/a	nsp10	nsp10_CysHis%3B formerly known as growth-factor-like protein (GFL)%3B produced by both pp1a and pp1ab	id-YP_009724389.1:4254..4392	0	1	1	1	T	C	g.T13074C	p.N4358N	NC_045512.2(GU280_gp01):g.13074T>C	YP_009724389.1:p.Asn4358Asn	YP_009725306.1:Asn105Asn	n/a	ORF1ab	SILENT	KP.2.3.5	n/a	n/a	n/a	1.0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	Pokay	n/a	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	n/a	n/a	n/a	n/a	n/a	n/a
14408	P4715L	n/a	ORF1ab	open reading frame 1ab gene (SARS-CoV-2)	orf1ab gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	ORF1ab polyprotein-i	ORF1b,ORF1ab	open reading frame 1a polyprotein (SARS-CoV-2)	Orf1a protein (SARS-CoV-2)	YP_009724389.1	n/a	GU280_gp01	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C14144T	p.P4715L	NC_045512.2(GU280_gp01):g.14144C>T	YP_009724389.1:p.Pro4715Leu	n/a	n/a	ORF1ab	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	Pokay	n/a	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	n/a	n/a	n/a	n/a	n/a	n/a
15714	L5150L	n/a	ORF1ab	open reading frame 1ab gene (SARS-CoV-2)	orf1ab gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	ORF1ab polyprotein-i	ORF1b,ORF1ab	open reading frame 1a polyprotein (SARS-CoV-2)	Orf1a protein (SARS-CoV-2)	YP_009724389.1	n/a	GU280_gp01	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C15450T	p.L5150L	NC_045512.2(GU280_gp01):g.15450C>T	YP_009724389.1:p.Leu5150Leu	n/a	n/a	ORF1ab	SILENT	KP.2.3.5	n/a	n/a	n/a	1.0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	Pokay	n/a	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	n/a	n/a	n/a	n/a	n/a	n/a
15756	S5164S	n/a	ORF1ab	open reading frame 1ab gene (SARS-CoV-2)	orf1ab gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	ORF1ab polyprotein-i	ORF1b,ORF1ab	open reading frame 1a polyprotein (SARS-CoV-2)	Orf1a protein (SARS-CoV-2)	YP_009724389.1	n/a	GU280_gp01	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	A	g.T15492A	p.S5164S	NC_045512.2(GU280_gp01):g.15492T>A	YP_009724389.1:p.Ser5164Ser	n/a	n/a	ORF1ab	SILENT	KP.2.3.5	n/a	n/a	n/a	1.0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	Pokay	n/a	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	n/a	n/a	n/a	n/a	n/a	n/a
15963	G5233G	n/a	ORF1ab	open reading frame 1ab gene (SARS-CoV-2)	orf1ab gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	ORF1ab polyprotein-i	ORF1b,ORF1ab	open reading frame 1a polyprotein (SARS-CoV-2)	Orf1a protein (SARS-CoV-2)	YP_009724389.1	n/a	GU280_gp01	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C15699T	p.G5233G	NC_045512.2(GU280_gp01):g.15699C>T	YP_009724389.1:p.Gly5233Gly	n/a	n/a	ORF1ab	SILENT	KP.2.3.5	n/a	n/a	n/a	1.0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	Pokay	n/a	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	n/a	n/a	n/a	n/a	n/a	n/a
17334	T5690T	T366T	ORF1ab	open reading frame 1ab gene (SARS-CoV-2)	orf1ab gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	ORF1ab polyprotein-i	ORF1b,ORF1ab	open reading frame 1a polyprotein (SARS-CoV-2)	Orf1a protein (SARS-CoV-2)	YP_009724389.1	YP_009725308.1	GU280_gp01	n/a	n/a	nsp13	nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only	id-YP_009724389.1:5325..5925	0	1	1	1	G	T	g.G17070T	p.T5690T	NC_045512.2(GU280_gp01):g.17070G>T	YP_009724389.1:p.Thr5690Thr	YP_009725308.1:Thr366Thr	n/a	ORF1ab	SILENT	KP.2.3.5	n/a	n/a	n/a	1.0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	Pokay	n/a	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	n/a	n/a	n/a	n/a	n/a	n/a
17410	R5716C	R392C	ORF1ab	open reading frame 1ab gene (SARS-CoV-2)	orf1ab gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	ORF1ab polyprotein-i	ORF1b,ORF1ab	open reading frame 1a polyprotein (SARS-CoV-2)	Orf1a protein (SARS-CoV-2)	YP_009724389.1	YP_009725308.1	GU280_gp01	n/a	n/a	nsp13	nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only	id-YP_009724389.1:5325..5925	0	1	1	1	C	T	g.C17146T	p.R5716C	NC_045512.2(GU280_gp01):g.17146C>T	YP_009724389.1:p.Arg5716Cys	YP_009725308.1:Arg392Cys	n/a	ORF1ab	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	Pokay	n/a	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	n/a	n/a	n/a	n/a	n/a	n/a
17499	Y5745Y	Y421Y	ORF1ab	open reading frame 1ab gene (SARS-CoV-2)	orf1ab gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	ORF1ab polyprotein-i	ORF1b,ORF1ab	open reading frame 1a polyprotein (SARS-CoV-2)	Orf1a protein (SARS-CoV-2)	YP_009724389.1	YP_009725308.1	GU280_gp01	n/a	n/a	nsp13	nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only	id-YP_009724389.1:5325..5925	0	1	1	1	T	C	g.T17235C	p.Y5745Y	NC_045512.2(GU280_gp01):g.17235T>C	YP_009724389.1:p.Tyr5745Tyr	YP_009725308.1:Tyr421Tyr	n/a	ORF1ab	SILENT	KP.2.3.5	n/a	n/a	n/a	1.0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	Pokay	n/a	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	n/a	n/a	n/a	n/a	n/a	n/a
18163	I5967V	I42V	ORF1ab	open reading frame 1ab gene (SARS-CoV-2)	orf1ab gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	ORF1ab polyprotein-i	ORF1b,ORF1ab	open reading frame 1a polyprotein (SARS-CoV-2)	Orf1a protein (SARS-CoV-2)	YP_009724389.1	YP_009725309.1	GU280_gp01	n/a	n/a	nsp14	nsp14A2_ExoN and nsp14B_NMT%3B produced by pp1ab only	id-YP_009724389.1:5926..6452	0	1	1	1	A	G	g.A17899G	p.I5967V	NC_045512.2(GU280_gp01):g.17899A>G	YP_009724389.1:p.Ile5967Val	YP_009725309.1:Ile42Val	n/a	ORF1ab	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	Pokay	n/a	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	n/a	n/a	n/a	n/a	n/a	n/a
18492	P6076P	P151P	ORF1ab	open reading frame 1ab gene (SARS-CoV-2)	orf1ab gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	ORF1ab polyprotein-i	ORF1b,ORF1ab	open reading frame 1a polyprotein (SARS-CoV-2)	Orf1a protein (SARS-CoV-2)	YP_009724389.1	YP_009725309.1	GU280_gp01	n/a	n/a	nsp14	nsp14A2_ExoN and nsp14B_NMT%3B produced by pp1ab only	id-YP_009724389.1:5926..6452	0	1	1	1	A	G	g.A18228G	p.P6076P	NC_045512.2(GU280_gp01):g.18228A>G	YP_009724389.1:p.Pro6076Pro	YP_009725309.1:Pro151Pro	n/a	ORF1ab	SILENT	KP.2.3.5	n/a	n/a	n/a	1.0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	Pokay	n/a	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	n/a	n/a	n/a	n/a	n/a	n/a
18894	C6210C	C285C	ORF1ab	open reading frame 1ab gene (SARS-CoV-2)	orf1ab gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	ORF1ab polyprotein-i	ORF1b,ORF1ab	open reading frame 1a polyprotein (SARS-CoV-2)	Orf1a protein (SARS-CoV-2)	YP_009724389.1	YP_009725309.1	GU280_gp01	n/a	n/a	nsp14	nsp14A2_ExoN and nsp14B_NMT%3B produced by pp1ab only	id-YP_009724389.1:5926..6452	0	1	1	1	C	T	g.C18630T	p.C6210C	NC_045512.2(GU280_gp01):g.18630C>T	YP_009724389.1:p.Cys6210Cys	YP_009725309.1:Cys285Cys	n/a	ORF1ab	SILENT	KP.2.3.5	n/a	n/a	n/a	1.0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	Pokay	n/a	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	n/a	n/a	n/a	n/a	n/a	n/a
19955	T6564I	T112I	ORF1ab	open reading frame 1ab gene (SARS-CoV-2)	orf1ab gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	ORF1ab polyprotein-i	ORF1b,ORF1ab	open reading frame 1a polyprotein (SARS-CoV-2)	Orf1a protein (SARS-CoV-2)	YP_009724389.1	YP_009725310.1	GU280_gp01	n/a	n/a	nsp15	nsp15-A1 and nsp15B-NendoU%3B produced by pp1ab only	id-YP_009724389.1:6453..6798	0	1	1	1	C	T	g.C19691T	p.T6564I	NC_045512.2(GU280_gp01):g.19691C>T	YP_009724389.1:p.Thr6564Ile	YP_009725310.1:Thr112Ile	n/a	ORF1ab	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	Pokay	n/a	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	n/a	n/a	n/a	n/a	n/a	n/a
20055	E6597E	E145E	ORF1ab	open reading frame 1ab gene (SARS-CoV-2)	orf1ab gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	ORF1ab polyprotein-i	ORF1b,ORF1ab	open reading frame 1a polyprotein (SARS-CoV-2)	Orf1a protein (SARS-CoV-2)	YP_009724389.1	YP_009725310.1	GU280_gp01	n/a	n/a	nsp15	nsp15-A1 and nsp15B-NendoU%3B produced by pp1ab only	id-YP_009724389.1:6453..6798	0	1	1	1	A	G	g.A19791G	p.E6597E	NC_045512.2(GU280_gp01):g.19791A>G	YP_009724389.1:p.Glu6597Glu	YP_009725310.1:Glu145Glu	n/a	ORF1ab	SILENT	KP.2.3.5	n/a	n/a	n/a	1.0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	Pokay	n/a	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	n/a	n/a	n/a	n/a	n/a	n/a
21618	TTR19ITT	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	CAACCAG	TAACTAC	g.CAACCAG56_62TAACTAC	p.TTR19ITT	n/a	YP_009724390.1:p.ThrThrArg19IleThrThr	n/a	n/a	S	n/a	KP.2.3.5	n/a	n/a	n/a	1.0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	Pokay	n/a	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	n/a	n/a	n/a	n/a	n/a	n/a
21632	L24_A27delinsS	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	TTACCCCCTG	T	g.71_79delTACCCCCTG	p.L24_A27delinsS	NC_045512.2(GU280_gp02):g.71_79del	YP_009724390.1:p.Leu24_Ala27delinsSer	n/a	n/a	S	n/a	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron BA.2 have higher sensitivity to inhibition by soluble angiotensin converting enzyme 2 (ACE2) and the endosomal inhibitor chloroquine compared  to D614G	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21632	L24_A27delinsS	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	TTACCCCCTG	T	g.71_79delTACCCCCTG	p.L24_A27delinsS	NC_045512.2(GU280_gp02):g.71_79del	YP_009724390.1:p.Leu24_Ala27delinsSer	n/a	n/a	S	n/a	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs Bi-Nab35B5-47D10. Omicron BA.2 has an IC50 fold change of 0.07x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21632	L24_A27delinsS	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	TTACCCCCTG	T	g.71_79delTACCCCCTG	p.L24_A27delinsS	NC_045512.2(GU280_gp02):g.71_79del	YP_009724390.1:p.Leu24_Ala27delinsSer	n/a	n/a	S	n/a	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs 35B5. Omicron BA.2 has an IC50 fold change of 0.09x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21632	L24_A27delinsS	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	TTACCCCCTG	T	g.71_79delTACCCCCTG	p.L24_A27delinsS	NC_045512.2(GU280_gp02):g.71_79del	YP_009724390.1:p.Leu24_Ala27delinsSer	n/a	n/a	S	n/a	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs 47D10. Omicron BA.2 has an IC50 fold change of 0.08x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21632	L24_A27delinsS	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	TTACCCCCTG	T	g.71_79delTACCCCCTG	p.L24_A27delinsS	NC_045512.2(GU280_gp02):g.71_79del	YP_009724390.1:p.Leu24_Ala27delinsSer	n/a	n/a	S	n/a	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs Bi-Nab47D10-35B5. Omicron BA.2 has an IC50 fold change of 0.04x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21632	L24_A27delinsS	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	TTACCCCCTG	T	g.71_79delTACCCCCTG	p.L24_A27delinsS	NC_045512.2(GU280_gp02):g.71_79del	YP_009724390.1:p.Leu24_Ala27delinsSer	n/a	n/a	S	n/a	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron BA.2 neutralization of the Omicron variants by antibodies induced by three doses of Pfizer/BNT162b2 mRNA vaccine was 7-8-fold less potent than the D614G, and  the Omicron variants still evade neutralization more efficiently.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21632	L24_A27delinsS	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	TTACCCCCTG	T	g.71_79delTACCCCCTG	p.L24_A27delinsS	NC_045512.2(GU280_gp02):g.71_79del	YP_009724390.1:p.Leu24_Ala27delinsSer	n/a	n/a	S	n/a	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Kumar	2022	doi:10.1101/2022.05.13.491770	n/a	https://doi.org/10.1101/2022.05.13.491770	False	Kumar et al. (2022)	n/a	BnAb 002-S21F2 IC50 on the Omicron BA.2 variant is 0.8x fold the wildtype.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21646	Y28Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C84T	p.Y28Y	NC_045512.2(GU280_gp02):g.84C>T	YP_009724390.1:p.Tyr28Tyr	n/a	n/a	S	SILENT	KP.2.3.5	n/a	n/a	n/a	1.0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	Pokay	n/a	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	n/a	n/a	n/a	n/a	n/a	n/a
21651	S31del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATTC	A	g.92_94delCTT	p.S31del	NC_045512.2(GU280_gp02):g.92_94del	YP_009724390.1:p.Ser31del	n/a	n/a	S	n/a	KP.2.3.5	n/a	n/a	n/a	1.0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	Pokay	n/a	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	n/a	n/a	n/a	n/a	n/a	n/a
21711	S50L	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C149T	p.S50L	NC_045512.2(GU280_gp02):g.149C>T	YP_009724390.1:p.Ser50Leu	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	Pokay	n/a	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	n/a	n/a	n/a	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	convalescent plasma escape	n/a	n/a	Schmidt	2021	doi:10.1101/2021.08.06.455491	n/a	https://doi.org/10.1101/2021.08.06.455491	False	Schmidt et al. (2021)	n/a	Artificially constructed HIV-1 pseudovirus with set of mutations drawn from plasma passage escape experiments and mutations from variants of concern completely ablates neutralization in 19 of 21 convalescents plasma collected mean 1.3 months post infection. [actual Y145del from manuscript substituted with more common Y144del description]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	vaccine neutralization efficacy	n/a	n/a	Choi	2021	doi:10.1101/2021.06.28.449914	n/a	https://doi.org/10.1101/2021.06.28.449914	False	Choi et al. (2021)	n/a	Neutralization efficiency (ID50) against B.1.525 reduced 4.2x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	pharmaceutical effectiveness	n/a	n/a	Cathcart	2021	doi:10.1101/2021.03.09.434607v9	n/a	https://doi.org/10.1101/2021.03.09.434607v9	False	Cathcart et al. (2021)	n/a	Omicron (a.k.a. B.1.1.529) Spike pseudotyped VSV and Vero E6 cells has somewhat  reduced neutralization (2.7x) vs wild type with monoclonal antibody Sotrovimab (a.k.a. VIR-7831).  [delins at 214 omitted for syntax compatibility]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	vaccine neutralization efficacy	n/a	n/a	Wang	2022	doi:10.1101/2022.08.11.503601	n/a	https://doi.org/10.1101/2022.08.11.503601	False	Wang et al. (2022)	n/a	Omicron breakthrough infection after 3-dose vaccination resulted in a further 3.5-fold and 2.9-fold increase of Omicron BA.1 and BA.2 neutralizing titers. Omicron  BA.4/5 showed the highest neutralization resistance of all variants tested, resulting in low geometric mean neutralizing titers in plasma samples  obtained after  the second vaccine dose (NT50	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs Bi-Nab47D10-35B5. Omicron BA.1 has an IC50 fold change of 0.08x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	vaccine neutralization efficacy	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron B.1.1.529 (BA.1) neutralization of the Omicron variants by antibodies induced by three doses of Pfizer/BNT162b2 mRNA vaccine was 7-8-fold less potent than  the D614G, and the Omicron variants still evade neutralization more efficiently.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	pharmaceutical effectiveness	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron (B.1.1.529 [BA.1]) have higher sensitivity to inhibition by soluble angiotensin converting enzyme 2 (ACE2) and the endosomal inhibitor chloroquine compared  to D614G	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs Bi-Nab35B5-47D10. Omicron BA.1 has an IC50 fold change of 0.30x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	vaccine neutralization efficacy	n/a	n/a	Uhal B	2022	doi:10.1101/2022.06.23.497326	n/a	https://doi.org/10.1101/2022.06.23.497326	False	Uhal B et al. (2022)	n/a	Paradigms’ ACE-2 variant LVE/STR chimera binds to SARS-2 Omicron variant B.1.1.529 spike protein trimer with high affinity. Determined using Surrogate Viral Neutralization Tests.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	ACE2 receptor binding affinity	n/a	n/a	Uhal B	2022	doi:10.1101/2022.06.23.497326	n/a	https://doi.org/10.1101/2022.06.23.497326	False	Uhal B et al. (2022)	n/a	L27, V34 and E90 mutation resulted in ultrahigh affinity binding of the LVE-ACE-2 domain to the widest variety of VOCs, with KDs of 73 pM for binding to the Omicron  B.1.1.529. Values were obtained with LVE-ACE-2/mAB chimeras containing the Y-T-E sequence that enhances binding to the FcRn receptor, which in turn is expected to  extend biological half-life 3-4-fold.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs 35B5. Omicron BA.1 has an IC50 fold change of 0.38x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	vaccinee plasma binding	n/a	n/a	Arora	2022	doi:10.1038/s41423-022-00870-5	pmid:35581351	https://doi.org/10.1038/s41423-022-00870-5	True	Arora et al. (2022)	n/a	All 10 individuals with 2 doses of the BNT162b2/BNT162b2 vaccine had a neutralizing titer in B.1 variant at an average of 729 NT50.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	antibody epitope effects	n/a	n/a	Shete	2022	doi:10.1101/2022.05.12.491584	n/a	https://doi.org/10.1101/2022.05.12.491584	False	Shete et al. (2022)	n/a	Plaque reduction neutralization test (PRNT) was used uring primary infection, post sixty daysof second dose vaccination, pre-reinfection and reinfection against Delta variant and was used to determine neutralizing antibodytitres. There was a 24.63x fold increase in antibody response from first infection to recovered and vaccinated with 2 doses (60 days). There was a 4.21x fold increase in antibody response pre-reinfection. There was a 39.27x fold increase in antibody response during reinfection.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	antibody epitope effects	n/a	n/a	Shete	2022	doi:10.1101/2022.05.12.491584	n/a	https://doi.org/10.1101/2022.05.12.491584	False	Shete et al. (2022)	n/a	Plaque reduction neutralization test (PRNT) was used uring primary infection, post sixty daysof second dose vaccination, pre-reinfection and reinfection against B.1 variant and was used to determine neutralizing antibodytitres. There was a 6.76x fold increase in antibody response from first infection to recovered and vaccinated with 2 doses (60 days). There was a 2.06x fold increase in antibody response pre-reinfection. There was a 8.18x fold increase in antibody response during reinfection.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	vaccinee plasma binding	n/a	n/a	Arora	2022	doi:10.1038/s41423-022-00870-5	pmid:35581351	https://doi.org/10.1038/s41423-022-00870-5	True	Arora et al. (2022)	n/a	All 10 individuals with 3 doses of the BNT162b2/BNT162b2 vaccine had a neutralizing titer in B.1 variant at an average of 3319 NT50.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	antibody epitope effects	n/a	n/a	Shete	2022	doi:10.1101/2022.05.12.491584	n/a	https://doi.org/10.1101/2022.05.12.491584	False	Shete et al. (2022)	n/a	Plaque reduction neutralization test (PRNT) was used uring primary infection, post sixty daysof second dose vaccination, pre-reinfection and reinfection against Omicron variant and was used to determine neutralizing antibodytitres. There was a 114.84x fold increase in antibody response from first infection to recovered and vaccinated with 2 doses (60 days). There was a 6.61x fold increase in antibody response pre-reinfection. There was a 1194.9x fold increase in antibody response during reinfection.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	antibody epitope effects	n/a	n/a	Kumar	2022	doi:10.1101/2022.05.13.491770	n/a	https://doi.org/10.1101/2022.05.13.491770	False	Kumar et al. (2022)	n/a	BnAb 002-S21F2 IC50 on the Omicron BA.1 variant is 1.0x fold the wildtype.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs 47D10. Omicron BA.1 has an IC50 fold change of 1.26x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	pharmaceutical effectiveness	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron BA.3 have higher sensitivity to inhibition by soluble angiotensin converting enzyme 2 (ACE2) and the endosomal inhibitor chloroquine compared  to D614G	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	vaccine neutralization efficacy	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron BA.3 neutralization of the Omicron variants by antibodies induced by three doses of Pfizer/BNT162b2 mRNA vaccine was 7-8-fold less potent than the D614G, and  the Omicron variants still evade neutralization more efficiently.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.3 (from South Africa/NICD-N22404/2021) were 4.2x-fold lower (95% CI: 0.15x-0.20x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.3 (from South Africa/NICD-N22404/2021) were 6.2-fold lower (95% CI: 11.8x-14.3x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	vaccine neutralization efficacy	n/a	n/a	Hao	2022	doi:10.1101/2022.08.12.22278720	pmid:36032965	https://doi.org/10.1101/2022.08.12.22278720	False	Hao et al. (2022)	n/a	paired testing of vaccine sera against ancestral virus compared to Omicron BA.1 shows that 3-dose vaccine regimen provides over 50x fold increase in protection against Omicron(B.1.1.529 [BA.1]) compared to a 2-dose regimen.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	pharmaceutical effectiveness	n/a	n/a	Wang	2022	doi:10.1101/2022.08.11.503601	n/a	https://doi.org/10.1101/2022.08.11.503601	False	Wang et al. (2022)	n/a	4th antigenic exposure with Omicron (B.1.1.529 [BA.1])(n	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.1 (from Botswana/R40B59_BHP_3321001248/2021) were 3.4-fold lower (95% CI: 3.2x-3.6x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.1 (from Botswana/R40B59_BHP_3321001248/2021) were 28.7x-fold lower (95% CI: 0.03x-0.05) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	vaccinee plasma binding	n/a	n/a	Shen	2021	doi:10.1101/2021.01.27.428516	pmid:33532764	https://doi.org/10.1101/2021.01.27.428516	False	Shen et al. (2021)	n/a	Neutralization activity of almost all Moderna Phase 1 sera tested actually *increased*.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	immunosuppression variant emergence	n/a	n/a	Kemp	2020	doi:10.1101/2020.12.14.422555	n/a	https://doi.org/10.1101/2020.12.14.422555	False	Kemp et al. (2020)	n/a	The delH69/V70 enhances viral infectivity, indicating its effect on virus fitness is independent to the N501Y RBM change [with which it is found in lineage B.1.1.7] Possibly arisen as a result of the virus evolving from immune selection pressure in infected individuals and possibly only one chronic infection in the case of lineage B.1.1.7.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	convalescent plasma escape	n/a	n/a	Alenquer	2021	doi:10.1101/2021.04.22.441007	n/a	https://doi.org/10.1101/2021.04.22.441007	False	Alenquer et al. (2021)	n/a	One convalescent sera tested showed 4-fold or greater reduction in neutralization efficiency.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	convalescent plasma escape	n/a	n/a	Shen	2021	doi:10.1101/2021.01.27.428516	pmid:33532764	https://doi.org/10.1101/2021.01.27.428516	False	Shen et al. (2021)	n/a	Neutralization activity of almost all convalescent sera tested decreased ~2x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	convalescent plasma escape	n/a	n/a	Shen	2021	doi:10.1101/2021.01.27.428516	pmid:33532764	https://doi.org/10.1101/2021.01.27.428516	False	Shen et al. (2021)	n/a	Neutralization activity of convalescent sera tested decreased ~2x with this B.1.1.7 pseudotyped virus.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	antibody epitope effects	n/a	n/a	Rees-Spear	2021	doi:10.1101/2021.01.15.426849	n/a	https://doi.org/10.1101/2021.01.15.426849	False	Rees-Spear et al. (2021)	n/a	Reduces neutralization by structurally unmapped mAb COVA1-21 (cluster XI).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	convalescent plasma binding	n/a	n/a	Tada	2021	doi:10.1101/2021.02.05.430003	pmid:33564768	https://doi.org/10.1101/2021.02.05.430003	False	Tada et al. (2021)	n/a	Viruses containing the point mutations of B.1.1.7 showed that the single point mutations (Δ69-70 and N501Y) were neutralized as efficiently as D614G across 10 convalescent sera from April 2020 infectees.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	anthropozoonotic events	n/a	n/a	Li	2023	doi:10.1038/s41396-023-01368-2	pmid:36690780	https://doi.org/10.1038/s41396-023-01368-2	True	Li et al. (2023)	n/a	This deletion outside the receptor binding domain in pseudotyped VSV promoted the capacity of pseudotyped VSV to transduce black flying fox (Pteropus alecto) kidney PabKi.1 cells (17.8%) to a level twice that of human epithelial-like Huh-7 cells (9.8%)	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	convalescent plasma binding	n/a	n/a	Alenquer	2021	doi:10.1101/2021.04.22.441007	n/a	https://doi.org/10.1101/2021.04.22.441007	False	Alenquer et al. (2021)	n/a	No notable change in neutralization efficiency, despite N439K by itself showing a ~2x decrease on average in 16 health workers' convalescent sera.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	vaccine neutralization efficacy	n/a	n/a	Chen	2021	doi:10.1038/s41591-021-01294-w	pmid:33664494	https://doi.org/10.1038/s41591-021-01294-w	True	Chen et al. (2021)	n/a	The neutralizing activity of vaccine was somewhat lower against B.1.1.7 in sera tested from most of the 24 patients with the BNT162b2 mRNA vaccine. (Fig. 4)	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	antibody epitope effects	n/a	n/a	Chen	2021	doi:10.1038/s41591-021-01294-w	pmid:33664494	https://doi.org/10.1038/s41591-021-01294-w	True	Chen et al. (2021)	n/a	B.1.1.7 variant constellation ablates Class 3 N-terminal domain targeting antibody COV2-2489.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	vaccine neutralization efficacy	n/a	n/a	Bates	2021	doi:10.1101/2021.04.04.21254881	pmid:33851185	https://doi.org/10.1101/2021.04.04.21254881	False	Bates et al. (2021)	n/a	Observed 8.8-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose) against cultured B.1.1.7 sample. Contrast this with 1.3-fold reduction for just the pseudovirus combination of 'key' B.1.1.7 mutation N501Y.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	trafficking	n/a	n/a	Tada	2021	doi:10.1101/2021.02.05.430003	pmid:33564768	https://doi.org/10.1101/2021.02.05.430003	False	Tada et al. (2021)	n/a	Lentiviral pseudotyped with this mutation set from Mink Cluster 5 lineage, was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing slight decrease in infection rate amongst the cells, much closer to D614G activity level than Y453F alone, suggesting compensatory effects between the  deletion and the mutation in human cell entry fitness.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	trafficking	n/a	n/a	Tada	2021	doi:10.1101/2021.02.05.430003	pmid:33564768	https://doi.org/10.1101/2021.02.05.430003	False	Tada et al. (2021)	n/a	Lentiviral pseudotyped with this mutation set from Mink Cluster 5 lineage, was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing moderate decrease in infection rate amongst the cells, significantly lower than the  deletion or Y453F alone, or their combination, suggesting a synergistic effect on  poorer human cell entry fitness.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	vaccine neutralization efficacy	n/a	n/a	Garcia-Beltran	2021	doi:10.1016/j.cell.2021.03.013	pmid:33743213	https://doi.org/10.1016/j.cell.2021.03.013	True	Garcia-Beltran et al. (2021)	n/a	Pseudotyped B.1.1.298 virus has reduced neutralization activity vs wild type: 1.4x (30 sera Pfizer median 9 days post 2nd dose)  and 1.3x (35 sera Moderna median 18 days post 2nd dose). This was NOT significant by ANOVA.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	trafficking	n/a	n/a	Tada	2021	doi:10.1101/2021.02.05.430003	pmid:33564768	https://doi.org/10.1101/2021.02.05.430003	False	Tada et al. (2021)	n/a	Lentiviral pseudotyped with this mutation set from Mink Cluster 5 lineage, was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing mild to modest decrease in infection rate amongst the cells, suggesting a net mild  negative effect on human cell entry fitness.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	convalescent plasma binding	n/a	n/a	Tada	2021	doi:10.1101/2021.02.05.430003	pmid:33564768	https://doi.org/10.1101/2021.02.05.430003	False	Tada et al. (2021)	n/a	Lentiviral pseudotyped with the key mutations from Mink Cluster 5 was neutralized more easily than D614G in 10 convalescent sera from April 2020 infectees.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	trafficking	n/a	n/a	Tada	2021	doi:10.1101/2021.02.05.430003	pmid:33564768	https://doi.org/10.1101/2021.02.05.430003	False	Tada et al. (2021)	n/a	Lentiviral pseudotyped with this mutation set from Mink Cluster 5 lineage, was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing no change in infection rate amongst the cells, markedly higher infectivity than  either mutation alone, suggesting a synergistic net neutral effect on human cell entry fitness.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	trafficking	n/a	n/a	Tada	2021	doi:10.1101/2021.02.05.430003	pmid:33564768	https://doi.org/10.1101/2021.02.05.430003	False	Tada et al. (2021)	n/a	Lentiviral pseudotyped with all key mutations from Mink Cluster 5 lineage, was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing major (~50%) decrease in infection rate amongst the cells, suggesting that this  anthropozoonotic event is driven by other factors at the expense of human cell entry fitness.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	vaccine neutralization efficacy	n/a	n/a	Choi	2021	doi:10.1101/2021.06.28.449914	n/a	https://doi.org/10.1101/2021.06.28.449914	False	Choi et al. (2021)	n/a	Neutralization efficiency (ID50) against B.1.1.7+E484K reduced 2.8x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster. Compare with 1.2x reduction for B.1.1.7 without E484K.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	vaccine neutralization efficacy	n/a	n/a	Collier	2021	doi:10.1038/s41586-021-03412-7	n/a	https://doi.org/10.1038/s41586-021-03412-7	True	Collier et al. (2021)	n/a	Sera after the second dose of Pfizer showed an average reduction in neutralization titres against the B.1.1.7 + E484K  variant of ~6.7x, markedly higher than B.1.1.7 alone. For first dose sera, a 9.7x drop was observed.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	convalescent plasma escape	n/a	n/a	Collier	2021	doi:10.1038/s41586-021-03412-7	n/a	https://doi.org/10.1038/s41586-021-03412-7	True	Collier et al. (2021)	n/a	Neutralization capacity GMT of 27 subjects' sera post-infection was markedly worse against B.1.1.7 + E484K than the lineage alone, with a 11.4x drop.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	antibody epitope effects	n/a	n/a	Chen	2021	doi:10.1038/s41591-021-01294-w	pmid:33664494	https://doi.org/10.1038/s41591-021-01294-w	True	Chen et al. (2021)	n/a	Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	trafficking	n/a	n/a	Tada	2021	doi:10.1101/2021.02.05.430003	pmid:33564768	https://doi.org/10.1101/2021.02.05.430003	False	Tada et al. (2021)	n/a	Lentiviral pseudotyped with this mutation set from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing significant (40%) increase in infection rate amongst the cells, much more than the effect of  either the deletion or the point mutation alone, suggetsing that this combination has a synergistic effect  contributing to cell entry fitness, moreso than this combination with the addition of P681H.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	symptom prevalence	n/a	n/a	van Loon	2021	doi:10.1101/2021.04.15.21255389	n/a	https://doi.org/10.1101/2021.04.15.21255389	False	van Loon et al. (2021)	n/a	In comparison of B.1.1.7 lineage (193 cases) vs. 'wildtype' (125) in Berlin Jan 18 to March 29 2021,  significant symptom changes are absent loss of smell/taste (P	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	ACE2 receptor binding affinity	n/a	n/a	Tada	2021	doi:10.1101/2021.02.05.430003	pmid:33564768	https://doi.org/10.1101/2021.02.05.430003	False	Tada et al. (2021)	n/a	This mutation combination causes major increase in binding affinity vs. wild type as measured by IC50 vs pseudotyped  lentivirus, but combined with the complete set of B.1.1.7   lineage variants no major change vs wild type affnity is observed.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	antibody epitope effects	n/a	n/a	Shen	2021	doi:10.1101/2021.01.27.428516	pmid:33532764	https://doi.org/10.1101/2021.01.27.428516	False	Shen et al. (2021)	n/a	Reduction in neutralization by mAbs COVA1-18 (~4x), COVA2-15 (~9x). PG: these effects are laregly missing in the deletion-alone data	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	symptom prevalence	n/a	n/a	Snell	2021	doi:10.1101/2021.03.16.21253377	n/a	https://doi.org/10.1101/2021.03.16.21253377	False	Snell et al. (2021)	n/a	A higher proportion of cases infected with the B.1.1.7 variant were hypoxic on admission compared to other variants (70.0% vs 62.5%, p	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	virion structure	n/a	n/a	Tada	2021	doi:10.1101/2021.02.05.430003	pmid:33564768	https://doi.org/10.1101/2021.02.05.430003	False	Tada et al. (2021)	n/a	The Ratio of S2 (processed Spike) to full length Spike is higher for this mutation combination,  due to a drop in the full length Spike measured, suggesting that this mutation compensates for decreased Spike production by improved proteolytic processing.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	vaccine neutralization efficacy	n/a	n/a	Reynolds	2021	doi:10.1126/science.abh1282	pmid:33931567	https://doi.org/10.1126/science.abh1282	True	Reynolds et al. (2021)	n/a	After one dose, individuals with prior infection showed enhanced T cell immunity,  antibody secreting memory B cell response to spike and neutralizing antibodies effective  against B.1.1.7 (authentic cell culture supernatants). By comparison, HCW receiving one vaccine dose without prior  infection showed reduced immunity against variants. B.1.1.7 spike mutations  resulted in increased, abrogated or unchanged T cell responses depending on human leukocyte  antigen (HLA) polymorphisms. Study was 26 each post-infection and post first dose HCWs.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	convalescent plasma escape	n/a	n/a	Uriu	2021	doi:10.1101/2021.09.06.459005	n/a	https://doi.org/10.1101/2021.09.06.459005	False	Uriu et al. (2021)	n/a	Mean 2.6x reduction of NT50 value B.1.1.7 (Alpha) relative to wild type in 8 sera from older convalescent patients (52-92yo) collected 1-3m post symptom onset.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	vaccine neutralization efficacy	n/a	n/a	Pegu	2021	doi:10.1101/2021.05.13.444010	pmid:34031659	https://doi.org/10.1101/2021.05.13.444010	False	Pegu et al. (2021)	n/a	Detectable antibodies against B.1.1.7 at various time points using pseudotyped lentivirus neutralization in Moderna vaccinee cohort: Day 29 33%, Day 43 100%, Day 119 100%, Day 209 96%. Detectable antibodies against B.1.1.7 at various time points using live virus FRNT neutralization in Moderna vaccinee cohort: Day 29 54%, Day 43 100%, Day 119 100%, Day 209 88%. Detectable antibodies against B.1.1.7 at various time points using ACE2 blocking assay in Moderna vaccinee cohort: Day 29 83%, Days 43,119,209 100%.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	vaccine neutralization efficacy	n/a	n/a	Haas	2021	doi:10.1016/S0140-6736(21	n/a	https://doi.org/10.1016/S0140-6736(21	n/a	Haas et al. (2021)	n/a	Using national surveillance data from Israel, using Pfizer vaccine and an estimated prevalence of the B.1.1.7 variant of 94.5% among SARS-CoV-2 infections: Adjusted estimates of vaccine effectiveness 7+ days after second dose were 95·3% (95% CI 94.9–95.7):  91.5% against asymptomatic SARS-CoV-2 infection (90·7–92·2: 40.9 vs 1.8 per 100 000 person-days), 97·0% against symptomatic  COVID-19 (96.7–97.2%), 97.2% against COVID-19-related hospitalisation (96.8–97.5%),  97.5% against severe or critical COVID-19-related hospitalisation (97.1–97.8%), and 96.7% against COVID-19-related death (96.0–97.3%).  In all age groups, as vaccine coverage increased, the incidence of SARS-CoV-2 outcomes declined	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	vaccine neutralization efficacy	n/a	n/a	Luftig	2021	doi:10.1056/NEJMc2104036	pmid:33826815	https://doi.org/10.1056/NEJMc2104036	True	Luftig et al. (2021)	n/a	In sera 1-2 weeks after BNT162b2 first dose, from six patients previously infected with B.1, antibody titer in a microneutralization assay  was on average 8192 for B.1.351 virus. This compares favorably (stronger) to post-infection neutralization titer against all variants tested in the same sera (wild type, B.1.1.7, B.1.351, and P.1).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	virion structure	n/a	n/a	Cai	2021	doi:10.1101/2021.04.13.439709	pmid:33880477	https://doi.org/10.1101/2021.04.13.439709	False	Cai et al. (2021)	n/a	CryoEM analysis of B.1.1.7 demonstrates an increased propensity for 'up', receptor accessible conformation of the Spike protein trimer.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	vaccine neutralization efficacy	n/a	n/a	Loconsole	2021	doi:10.1016/j.cmi.2021.05.007	pmid:33984489	https://doi.org/10.1016/j.cmi.2021.05.007	True	Loconsole et al. (2021)	n/a	SARS-CoV-2 infection was confirmed in three HCWs working a single shift: all presented with mild symptoms of COVID-19. The two physicians  were fully vaccinated with BNT162b2 vaccine, with the second dose administered 1 month before symptom onset. Both had high titres of IgG  anti-spike antibodies at the time of diagnosis. WGS confirmed that all virus strains were VOC 202012/01-lineage B.1.1.7, suggesting a  common source of exposure. Epidemiological investigation revealed that the suspected source was a SARS-CoV-2-positive patient who  required endotracheal intubation due to severe COVID-19. All procedures were carried out using a full suite of personal protective equipment (PPE).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	vaccine efficacy	n/a	n/a	Bruxvoort	2021	doi:10.1101/2021.09.29.21264199	n/a	https://doi.org/10.1101/2021.09.29.21264199	False	Bruxvoort et al. (2021)	n/a	In a 1:5 test-negative matched control study of 8153 individuals who received the Moderna mRNA-1273 vaccine, 1422 test-positive were Alpha. Two dose vaccine efficacy against Alpha was 98.4% [96.9-99.1%], one dose VE was 90.1% (82.9-94.2%).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	convalescent plasma escape	n/a	n/a	Planas	2021	doi:10.1038/s41591-021-01318-5	n/a	https://doi.org/10.1038/s41591-021-01318-5	True	Planas et al. (2021)	n/a	Using a new rapid neutralization assay, based on reporter cells that become positive for GFP after overnight infection, sera from 58  convalescent individuals collected up to 9 months after symptoms, similarly neutralized B.1.1.7 and D614G.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs Bi-Nab35B5-47D10. Alpha (B.1.1.7) has an IC50 fold change of 1.19x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	antibody epitope effects	n/a	n/a	Wang	2021	doi:10.1038/s41586-021-03398-2	n/a	https://doi.org/10.1038/s41586-021-03398-2	True	Wang et al. (2021)	n/a	B.1.1.7 pseudotyped virus model impairs binding by RBD-directed mAb 910-30. B.1.1.7 pseudotyped virus model abolishes N-terminal-domain-directed mAbs 5-24, 4-8, and 4A8. B.1.1.7 pseudotyped virus model impairs binding by N-terminal-domain-directed mAbs 2-17, 4-19, 5-7.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	vaccine neutralization efficacy	n/a	n/a	Wang	2021	doi:10.1056/NEJMc2103022	pmid:33822491	https://doi.org/10.1056/NEJMc2103022	True	Wang et al. (2021)	n/a	1.4x improvement in neutralization by serum collected 2 to 3 weeks after the second dose from vaccinees who had received  BBIBP-CorV (pVNT50 against VSV pseudotyped as B.1.1.7). Convalescent plasma had similar titer against wild type as the BBIBP-CorV vaccinee sera. 2x reduction in neutralization by serum collected 2 to 3 weeks after the second dose from vaccinees who had received  CoronaVac (pVNT50 against VSV pseudotyped as B.1.1.7). Convalescent plasma had similar titer against wild type as the CoronaVac vaccinee sera.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	aerosolization	n/a	n/a	Adenaiye	2021	doi:10.1093/cid/ciab797	pmid:34519774	https://doi.org/10.1093/cid/ciab797	True	Adenaiye et al. (2021)	n/a	Alpha variant cases in a large campus study showed fine-aerosol shedding amongst unmasked participants remained significantly greater for alpha variant infections (18-fold, 95% CI, 3.4 to 92-fold) after adjusting for the increased viral RNA in MTS and saliva, the number of coughs during sampling sessions, and symptom. After controlling for the effect of masks and numbers of coughs during sampling, alpha variant infection was associated with a 100-fold (95% CI, 16 to 650-fold) increase in coarse- and a 73-fold (95% CI, 15 to 350-fold) increase in fine-aerosol RNA shedding.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	environmental condition stability	n/a	n/a	Schuit	2021	doi:10.1093/infdis/jiab171	pmid:33822064	https://doi.org/10.1093/infdis/jiab171	True	Schuit et al. (2021)	n/a	No differences in the stability of B.1.1.7 observed in the absence of simulated sunlight at either 20°C or 40°C (with a mean time for  a 90% loss of viral infectivity across all dark conditions of 6.2 hours). However, a small but statistically  significant difference in the stability was observed in simulated sunlight at 20°C and 20% relative humidity, with B.1.1.7 restoring  wild type 90% loss time of 11 minutes vs. 7 and 8 minutes for B.1.319 (D614G) and B.28 (V367F) early 2020 viruses respectively.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	trafficking	n/a	n/a	Liu	2021	doi:10.1101/2021.08.12.456173v3	n/a	https://doi.org/10.1101/2021.08.12.456173v3	False	Liu et al. (2021)	n/a	Modelling the Alpha variant in primary human airway epithelial (HAE) cultures, S1 to full length Spike ratio  (measuring Spike furin cleavage processivity) increase 3.9x relative to wild type (5.4 vs 1.4). This is less efficient than Delta (11x vs wildtype using a P681R mutation instead). [del ~144 changed due to ambiguity] Furthermore the RNA ratio of Delta versus Alpha-spike/Delta-backbone continuously increased from 2.8 on day 1  to 9.8 on day 5 post infection in a co-infection model in HAEs, suggesting the spike gene drives the improved replication of Delta variant.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	vaccine neutralization efficacy	n/a	n/a	Woldemeskel	2021	doi:10.1172/JCI149335	pmid:33822770	https://doi.org/10.1172/JCI149335	True	Woldemeskel et al. (2021)	n/a	No significant difference in T-cell response to B.1.1.7 was observed (vs. ancestral) in blood drawn from 28 participants received the Pfizer-BioNTech vaccine  and 2 received the Moderna vaccine. This is despite three mutations (Y144del, D614G, and P681H) overlapping T-cell epitope hotspots.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	environmental condition stability	n/a	n/a	Meister	2021	doi:10.1093/infdis/jiab260	pmid:33993274	https://doi.org/10.1093/infdis/jiab260	True	Meister et al. (2021)	n/a	Treatment with heat, soap and ethanol revealed similar inactivation profiles indicative of a comparable susceptibility  towards disinfection. Furthermore, we observed comparable surface stability on steel, silver, copper and face masks.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	vaccine neutralization efficacy	n/a	n/a	Sapkal	2021	doi:10.1093/jtm/taab051	pmid:33772577	https://doi.org/10.1093/jtm/taab051	True	Sapkal et al. (2021)	n/a	The NAb titers (PRNT50) of sera collected from 38 vaccine recipients four-weeks after the second dose of inactivated whole-virion SARS-CoV-2 BBV152/COVAXIN vaccine [which contains D614G] were not significantly  different between B.1.1.7 virus and ancestral D614G virus.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	vaccine neutralization efficacy	n/a	n/a	Tarke	2021	doi:10.1101/2021.02.27.433180	pmid:33688655	https://doi.org/10.1101/2021.02.27.433180	False	Tarke et al. (2021)	n/a	PBMCs of Pfizer/BioNTech BNT162b2 (n	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	vaccine neutralization efficacy	n/a	n/a	Hall	2021	doi:10.1016/S0140-6736(21	n/a	https://doi.org/10.1016/S0140-6736(21	n/a	Hall et al. (2021)	n/a	A single dose of BNT162b2 vaccine demonstrated vaccine effectiveness [symptomatic or asymptomatic in cohort opf routinely NAAT-monitored UK HCWs]  of 72% (95% CI 58-86) 21 days after first dose and 86% (95% CI 76-97) seven days after two doses in the antibody negative cohort.  This cohort was vaccinated when the dominant variant in circulation was B.1.1.7 and demonstrates effectiveness against this variant.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	vaccine neutralization efficacy	n/a	n/a	Amit	2021	doi:10.1016/S0140-6736(21	n/a	https://doi.org/10.1016/S0140-6736(21	n/a	Amit et al. (2021)	n/a	Between December 19, 2020 and Jan 24, 2021, 7214 of 9109 eligible HCWs at Sheba Medical Center in Israel had received one or more doses of  BNT162b2 (Pfizer) vaccine. Adjusted rate reduction in SARS-CoV-2 NAAT positivity infection compared with unvaccinated workers 1-14 days  after 1st dose was 30% (95% CI: 2-50), and 75% (95% CI: 72-84) after 15-28 days. Adjusted rate reduction in symptomatic COVID-19 compared with  unvaccinated workers 1-14 days after 1st dose was 47% (95% CI: 17-66), and 85% (95% CI: 71-92) after 15-28 days. [Though often cited as an indicator of VE for B.1.1.7, during this time period in Israel, the prevalence of the B.1.1.7 variant increased from ~20% to 50% of  cases (covariants.org), therefore these VE numbers likely represent a mix of B.1.1.7 and other lineage effects.]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	vaccine neutralization efficacy	n/a	n/a	Lopez Bernal	2021	doi:10.1136/bmj.n1088	pmid:33985964	https://doi.org/10.1136/bmj.n1088	True	Lopez Bernal et al. (2021)	n/a	We found that a single dose of the BNT162b2 vaccine is about 60-70% effective at preventing symptomatic disease in adults aged 70 years  and older in England and that two doses are about 85-90% effective. Those who were vaccinated and went on to have symptoms had a 44%  lower risk of being admitted hospital and a 51% lower risk of death compared with people who were unvaccinated. We also found that a single dose  of the ChAdOx1-S vaccine was about 60-75% effective against symptomatic disease and provided an additional protective effect against hospital  admission—it is too early to assess the effect on mortality. The B.1.1.7 variant now dominates in the UK and these results will largely  reflect vaccine effectiveness against this variant.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the 47D10. Alpha (B.1.1.7) has an IC50 fold change of 0.40x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	anthropozoonotic events	n/a	n/a	Hamer	2021	doi:10.1111/tbed.14122	pmid:33955193	https://doi.org/10.1111/tbed.14122	True	Hamer et al. (2021)	n/a	First documented cases of domestic cat and dog infections with the B.1.1.7 strain.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	vaccine efficacy	n/a	n/a	Lopez Bernal	2021	doi:10.1056/NEJMoa2108891	pmid:34289274	https://doi.org/10.1056/NEJMoa2108891	True	Lopez Bernal et al. (2021)	n/a	Effectiveness after one dose of vaccine (BNT162b2 or ChAdOx1 nCoV-19) with the delta variant was (48.7%: 95% confidence interval [CI], 45.5 to 51.7): the results were similar for both vaccines.  With the BNT162b2 vaccine, the effectiveness of two doses was 93.7% (95% CI, 91.6 to 95.3) among those with the alpha variant.  With the ChAdOx1 nCoV-19 vaccine, the effectiveness of two doses was 74.5% (95% CI, 68.4 to 79.4) among those with the alpha variant.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	antibody epitope effects	n/a	n/a	Shen	2021	doi:10.1101/2021.01.27.428516	pmid:33532764	https://doi.org/10.1101/2021.01.27.428516	False	Shen et al. (2021)	n/a	Reduction in neutralization by mAbs COVA2-15 (~9x), B38 (~14x), S309 (~190x) by this B.1.1.7 pseudotyped virus model.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	vaccine neutralization efficacy	n/a	n/a	Munitz	2021	doi:10.1016/j.xcrm.2021.100264	pmid:33899031	https://doi.org/10.1016/j.xcrm.2021.100264	True	Munitz et al. (2021)	n/a	We observed a sharp decline in cases when ∼50% of the elderly population was 2 weeks beyond their first  vaccination dose and at a time point during which the B.1.1.7 variant gained transmission dominance.  In support of this finding, it was suggested that, after the first vaccination dose, more than 70% of  patients develop neutralization antibodies,15 and the vaccine efficiency can reach 85%.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	convalescent plasma escape	n/a	n/a	Hu	2021	doi:10.1101/2021.01.22.427749	n/a	https://doi.org/10.1101/2021.01.22.427749	False	Hu et al. (2021)	n/a	Neutralizing antibody titers of 2/20 (10%) samples showed >10x reduction (sera collected ~1mo post Jan 2020 first wave in China). Neutralizing antibody titers of 8/20 samples (40%) decreased below an ID50 threshold of 40 (sera  collected ~8mo post Jan 2020 first wave in China).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	antibody epitope effects	n/a	n/a	Rees-Spear	2021	doi:10.1101/2021.01.15.426849	n/a	https://doi.org/10.1101/2021.01.15.426849	False	Rees-Spear et al. (2021)	n/a	Lessens the potency of mAbs COVA2-17 (~5x, similar to N501Y alone), COVA1-12 (~11x) and COVA1-21 (>100x), which do not compete allosterically.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	reinfection	n/a	n/a	Graham	2021	doi:10.1016/s2468-2667(21	n/a	https://doi.org/10.1016/s2468-2667(21	n/a	Graham et al. (2021)	n/a	36920 COVID Symptom Study app users reported SARS-CoV-2 test positivity in late 2020. Possible reinfections were  identified in 249 (0.7% [95% CI 0.6-0.8]) of 36509 app users who reported a positive swab test before Oct 1, 2020,  but there was no evidence that the frequency of reinfections was higher for the B.1.1.7 variant than for pre-existing variants.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	vaccine neutralization efficacy	n/a	n/a	Garcia-Beltran	2021	doi:10.1016/j.cell.2021.03.013	pmid:33743213	https://doi.org/10.1016/j.cell.2021.03.013	True	Garcia-Beltran et al. (2021)	n/a	Pseudotyped B.1.1.7 virus has reduced neutralization activity vs wild type: 2.1x (30 sera Pfizer median 9 days post 2nd dose)  and 2.3x (35 sera Moderna median 18 days post 2nd dose). This was NOT significant by ANOVA. Note that Y145del was actually noted in the paper as the effect of their DNA construct, but this is  equivalent at the protein level to the more commonly annotated Y144del.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	vaccine neutralization efficacy	n/a	n/a	Planas	2021	doi:10.1038/s41591-021-01318-5	n/a	https://doi.org/10.1038/s41591-021-01318-5	True	Planas et al. (2021)	n/a	The sera of 16 individuals with time course collection was evaulated against VSV pseudotypes: neutralized D614G at week 2,  whereas B.1.1.7 started to be neutralized at week 3, although less efficiently than D614G. B.1.1.7 and D614G strains were  similarly neutralized at week 4 (1 week after booster dose).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	vaccine neutralization efficacy	n/a	n/a	Supasa	2021	doi:10.1016/j.cell.2021.02.033	pmid:33743891	https://doi.org/10.1016/j.cell.2021.02.033	True	Supasa et al. (2021)	n/a	Neutralization assays of B.1.1.7 virus showed a reduction of 2.5-fold (14 days post 2nd dose AstraZeneca, n	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs 35B5. Alpha (B.1.1.7) has an IC50 fold change of 1.39x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	vaccine efficacy	n/a	n/a	Puranik	2021	doi:10.1101/2021.08.06.21261707	pmid:34401884	https://doi.org/10.1101/2021.08.06.21261707	False	Puranik et al. (2021)	n/a	In Minnesota in early 2021 when Alpha was prevalent, vaccine efficacy was estimated as: mRNA-1273 86% (95%CI: 81-90.6%) and BNT162b2: 76% (95%CI: 69-81%) using age, sex, race, PCR testing and vaccination date matched cohorts of unvaccinated, Pfizer and Moderna vaccinees.  [variant list included is ancestral Alpha, as this was an observational study no variant list was given]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	antibody epitope effects	n/a	n/a	Hu	2021	doi:10.1101/2021.01.22.427749	n/a	https://doi.org/10.1101/2021.01.22.427749	False	Hu et al. (2021)	n/a	~20x resistence to mAb CQ038 by B.1.1.7 pseudotyped virus	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	reinfection	n/a	n/a	Marquez	2021	doi:10.1017/ice.2021.195	pmid:33934744	https://doi.org/10.1017/ice.2021.195	True	Marquez et al. (2021)	n/a	Reinfection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) B.1.1.7 variant in an immunocompromised 16yo female with end stage renal disease 94 days after initial infection with a B.1.2 lineage virus. Both lineages were the prevalent one at the time of 1st and 2nd infections respectively in Texas, where the patient was located (suggesting exposure risk rather than lineage immune evasion).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	vaccine neutralization efficacy	n/a	n/a	Uhal B	2022	doi:10.1101/2022.06.23.497326	n/a	https://doi.org/10.1101/2022.06.23.497326	False	Uhal B et al. (2022)	n/a	Paradigm’s ACE-2 variant LVE/STR chimera neutralizes Alpha Variant B.1.1.7 RBD significantly better than GenScript IgG FL18-740 w.t. ACE-2 mAB. Determined using Surrogate Viral Neutralization Tests.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs Bi-Nab47D10-35B5. Alpha (B.1.1.7) has an IC50 fold change of 1.44x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	vaccine neutralization efficacy	n/a	n/a	Hall	2021	doi:10.1016/S0140-6736(21	n/a	https://doi.org/10.1016/S0140-6736(21	n/a	Hall et al. (2021)	n/a	A single dose of BNT162b2 (Pfizer) vaccine showed vaccine effectiveness of 70% (95% CI 55-85) 21 days after first dose  and 85% (74-96) 7 days after two doses in the study population. Our findings show that the BNT162b2 vaccine can prevent both symptomatic and asymptomatic infection in working-age adults. This cohort (8203 treatment, 15121 control) was vaccinated when the  dominant variant in circulation was B.1.1.7 and shows effectiveness against this variant.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	convalescent plasma escape	n/a	n/a	Graham	2021	doi:10.1016/j.immuni.2021.03.023	pmid:33836142	https://doi.org/10.1016/j.immuni.2021.03.023	True	Graham et al. (2021)	n/a	NTD-specific nAbs showed a substantial (3-450x) decrease in neutralization potency against the recently reported highly  transmissible B.1.1.7 variant of concern, whereas RBD-specific nAbs were either unaffected or showed lower decreases in potency.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	tissue specific neutralization	n/a	n/a	Planas	2021	doi:10.1038/s41591-021-01318-5	n/a	https://doi.org/10.1038/s41591-021-01318-5	True	Planas et al. (2021)	n/a	The nasal mucosa of Pfizer vaccinees with time course collection was evaluated against VSV pseudotypes: results (only one nasal  swab from different previously infected vacinee neutralizing at weeks 3 and 6 against B.1.1.7 and D614G) suggest that vaccinees probably  do not elicit an early humoral response detectable at mucosal surfaces even though sera neutralization was observed. They strengthen the hypothesis that some vaccines may not protect against  viral acquisition and infection of the oral–nasal region, but may prevent severe disease associated with viral dissemination in the lower respiratory tract.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	pharmaceutical effectiveness	n/a	n/a	Rosenke	2022	doi:10.1172/jci.insight.160108	pmid:35579953	https://doi.org/10.1172/jci.insight.160108	True	Rosenke et al. (2022)	n/a	Infectious viral titers in lung tissue determined using a tissue culture infectious dose (TCID) assay in 10 hamsters showed that Alpha Molnupiravir (MK-4482) had ~2.75x fold drop.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	vaccine neutralization efficacy	n/a	n/a	Choi	2021	doi:10.1101/2021.06.28.449914	n/a	https://doi.org/10.1101/2021.06.28.449914	False	Choi et al. (2021)	n/a	Neutralization efficiency (ID50) against B.1.1.7 reduced 1.2x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	reinfection	n/a	n/a	Harrington	2021	doi:10.1093/cid/ciab014	pmid:33421056	https://doi.org/10.1093/cid/ciab014	True	Harrington et al. (2021)	n/a	Second infection in December 2020 with B.1.1.7 after April 2020 initial infection with B.2 in a 78-year-old man with a history of Type 2 diabetes mellitus,  diabetic nephropathy on hemodialysis, chronic obstructive pulmonary disease (COPD), mixed central  and obstructive sleep apnea, ischemic heart disease, with no history of immunosuppression.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	trafficking	n/a	n/a	Hu	2021	doi:10.1101/2021.01.22.427749	n/a	https://doi.org/10.1101/2021.01.22.427749	False	Hu et al. (2021)	n/a	The entry efficiencies of Spike pseudotyped viruses bearing N501Y Variant 1 (B.1.1.7) mutant were about 3 to 4.4 times higher than that of the WT pseudovirus when viral input was normalized, suggesting that these spike variants promote the infectivity of SARS-CoV-2.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	trafficking	n/a	n/a	Esclera	2021	doi:10.1101/2021.08.05.455290	n/a	https://doi.org/10.1101/2021.08.05.455290	False	Esclera et al. (2021)	n/a	~2.5x cleavage of S2 relative to WA1 (D614G) wildtype by Alpha variant variant as measured by mass spectrometry of Vero-TMPRSS culture.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	vaccine neutralization efficacy	n/a	n/a	Emary	2021	doi:10.2139/ssrn.3779160	n/a	https://doi.org/10.2139/ssrn.3779160	False	Emary et al. (2021)	n/a	Virus neutralisation activity (using a live SARS-CoV-2 microneutralisation assay (ND50)) by vaccine induced antibodies was 9-fold lower  against the B.1.1.7 variant than against a canonical non B.1.1.7 lineage. Vaccine efficacy against symptomatic NAAT positive infection  was similar for B.1.1.7 and non-B.1.1.7 lineages (74.6% [95%CI 41.6-88.9] and 84% [95% CI 70.7-91.4] respectively). Furthermore, vaccination with ChAdOx1 nCoV-19 results in a reduction in the duration of shedding and viral load, which may translate into a material impact on transmission of disease.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	antibody epitope effects	n/a	n/a	Kumar	2022	doi:10.1101/2022.05.13.491770	n/a	https://doi.org/10.1101/2022.05.13.491770	False	Kumar et al. (2022)	n/a	BnAb 002-S21F2 IC50 on the Alpha (B.1.1.7) variant is 1.0x fold the wildtype in 42 COVI.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	vaccine neutralization efficacy	n/a	n/a	Gallagher	2021	doi:10.1101/2021.05.03.442455	pmid:33972942	https://doi.org/10.1101/2021.05.03.442455	False	Gallagher et al. (2021)	n/a	ELISpot assays show T cell neutralization reduced by 15.4% in this B.1.1.7 pseudotype relative to wild type in 18-20 pooled patient samples post second mRNA vaccine dose, with no significant difference between Pfizer and Moderna cohorts. Reduction was stronger in the S1 subunit than S2 (separate peptide pools were used).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	vaccine neutralization efficacy	n/a	n/a	Edara	2021	doi:10.1101/2021.02.02.21250799	pmid:33564782	https://doi.org/10.1101/2021.02.02.21250799	False	Edara et al. (2021)	n/a	2.1x drop in neutralization using sera collected from 14 healthy adult participants that received two injections of the mRNA-1273 (Moderna) vaccine  at a dose of 100 µg (18-55 years: day 1 (n	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	vaccine neutralization efficacy	n/a	n/a	Ikegame	2021	doi:10.21203/rs.3.rs-400230/v1	pmid:33851150	https://doi.org/10.21203/rs.3.rs-400230/v1	False	Ikegame et al. (2021)	n/a	B.1.1.7 pseudotyped VSV was tested for neutralization in a clonal HEK-293T ACE2 TMPRSS2 cell line optimized for highly efficient  S-mediated infection. A cohort of 12 Argentinian recipients of the Gamaleya Sputnik V Ad26 / Ad5 vaccine showed no statistically sognificant change in neutralization effiacacy.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	vaccine neutralization efficacy	n/a	n/a	Heath	2021	doi:10.1101/2021.05.13.21256639	n/a	https://doi.org/10.1101/2021.05.13.21256639	False	Heath et al. (2021)	n/a	NVX-CoV2373 [Novavax] vaccine in phase 3 trial was 89.7% (95% CI, 80.2-94.6) effective in preventing COVID-19, with no hospitalizations or  deaths reported. There were five cases of severe Covid-19, all in the placebo group. Post hoc analysis revealed efficacies of  96.4% (73.8-99.5) and 86.3% (71.3-93.5) against the prototype strain and B.1.1.7 variant, respectively.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	vaccine neutralization efficacy	n/a	n/a	Shen	2021	doi:10.1101/2021.01.27.428516	pmid:33532764	https://doi.org/10.1101/2021.01.27.428516	False	Shen et al. (2021)	n/a	Pseudotyped B.1.1.7 Spike variants lentivirus. 3.5x reduction in neutralization with Moderna vaccinated patient sera after 29 days (1st dose). 2.0x reduction in neutralization with Moderna vaccinated patient sera after 57 days (2nd dose). 2.1x reduction in neutralization with Novavax Phase 1 post-vaccination sera.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	clinical indicators	n/a	n/a	Song	2021	doi:10.1101/2021.05.04.21256655	n/a	https://doi.org/10.1101/2021.05.04.21256655	False	Song et al. (2021)	n/a	After adjusting for the age factor, in a prospective Chinese cohort study B.1.1.7 variant infection (compared to B.1.140) was the risk factor for  C-reactive protein (P 	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	vaccine efficacy	n/a	n/a	Nasreen	2021	doi:10.1101/2021.06.28.21259420	n/a	https://doi.org/10.1101/2021.06.28.21259420	False	Nasreen et al. (2021)	n/a	Using a test-negative design using Ontario data between Dec 14, 2020 and May 30, 2021, 421,073 symptomatic community-dwelling individuals were tested. Against symptomatic infection caused by Alpha, vaccine effectiveness with partial vaccination (≥14 days after dose 1) was higher for mRNA-1273 (83%) than BNT162b2 (66%) and ChAdOx1 (64%), and full vaccination (≥7 days after dose 2) increased vaccine effectiveness for BNT162b2 (89%) and mRNA-1273 (92%).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	trafficking	n/a	n/a	Touret	2021	doi:10.1101/2021.03.22.436427	n/a	https://doi.org/10.1101/2021.03.22.436427	False	Touret et al. (2021)	n/a	Live virus was tested ex vivo in reconstituted brochial epithelium, and out competed wild type.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	vaccine neutralization efficacy	n/a	n/a	Uriu	2021	doi:10.1101/2021.09.06.459005	n/a	https://doi.org/10.1101/2021.09.06.459005	False	Uriu et al. (2021)	n/a	Mean 1.7x reduction of NT50 value B.1.1.7 (Alpha) relative to wild type in 8 sera from adult BNT162b2 vaccinees (28-47yo) collected ~1m post booster.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	ACE2 receptor binding affinity	n/a	n/a	Planas	2021	doi:10.1038/s41591-021-01318-5	n/a	https://doi.org/10.1038/s41591-021-01318-5	True	Planas et al. (2021)	n/a	Flow cytometry was used on recombinant VSV proteins and yeast surface display to assess the binding of a labeled soluble ACE2  protein to cells expressing B.1.1.7. We observed a dramatic increase (relative to D614G) in binding of soluble  ACE2 to B.1.1.7, and to a lesser extent to B.1.351, which both carry the N501Y mutation (see Fig 3).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	ACE2 receptor binding affinity	n/a	n/a	Uhal B	2022	doi:10.1101/2022.06.23.497326	n/a	https://doi.org/10.1101/2022.06.23.497326	False	Uhal B et al. (2022)	n/a	L27, V34 and E90 mutation resulted in ultrahigh affinity binding of the LVE-ACE-2 domain to the widest variety of VOCs, with KDs of 93 pM for binding to the Alpha  B1.1.7. Values were obtained with LVE-ACE-2/mAB chimeras containing the Y-T-E sequence that enhances binding to the FcRn receptor, which in turn is expected to  extend biological half-life 3-4-fold.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	vaccine neutralization efficacy	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	1.5x reduction in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees)	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	vaccine neutralization efficacy	n/a	n/a	UNKNOWN	n/a	n/a	n/a	,	n/a	UNKNOWN et al. ()	n/a	n/a	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	vaccine neutralization efficacy	n/a	n/a	UNKNOWN	n/a	n/a	n/a	,	n/a	UNKNOWN et al. ()	n/a	In Qatar, where Pfizer vaccine use is prevalent (<10% of the population covered in the time period of the study ending Mar 31, 2021), any time after one dose  (including the 2 weeks where no major effect is expected) B.1.1.7 lineage effectiveness was observed as 29.5% (95% CI [22.9,35.5]) against infection, and 54.1% against severe/critical/fatal disease  (95% CI [26.1-71.9]). Two weeks or more after 2nd dose, effectiveness climbed to 89.5% [85.9,92.3] against infection, and 100% against  severe/critical/fatal disease (95% CI [81.7,100]).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	pharmaceutical effectiveness	n/a	n/a	Dejnirattisai	2021	doi:10.1016/j.cell.2021.03.055	pmid:33852911	https://doi.org/10.1016/j.cell.2021.03.055	True	Dejnirattisai et al. (2021)	n/a	Lilly's LY-CoV16 showed marked reduction in neutralization of B.1.1.7.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	convalescent plasma escape	n/a	n/a	Skelly	2021	doi:10.21203/rs.3.rs-226857/v1	n/a	https://doi.org/10.21203/rs.3.rs-226857/v1	False	Skelly et al. (2021)	n/a	Sera neutralized the B1.1.7 isolate with a lower potency (2-fold: 95% CL: 1.5 – 3-fold), and those with the lowest homotypic neutralizing potency had undetectable heterotypic potency (2/25).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	tissue specific replication effects	n/a	n/a	Mok	2021	doi:10.1101/2021.04.19.440414	n/a	https://doi.org/10.1101/2021.04.19.440414	False	Mok et al. (2021)	n/a	In this report, by using a lower infectious dose, we demonstrate that B.1.1.7  (cultured sample Hong Kong/HKPU-00015/2021) exhibits higher infectivity and/or  replication efficiency in the nasal epithelium. (Hamster model of infection)	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	convalescent plasma escape	n/a	n/a	Collier	2021	doi:10.1038/s41586-021-03412-7	n/a	https://doi.org/10.1038/s41586-021-03412-7	True	Collier et al. (2021)	n/a	Neutralization capacity GMT of 27 subjects' sera post-infection was considerably higher (stronger) than after the second  Pfizer dose, and 4.5x drop in B.1.1.7 neutralization was observed.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	vaccine neutralization efficacy	n/a	n/a	Collier	2021	doi:10.1038/s41586-021-03412-7	n/a	https://doi.org/10.1038/s41586-021-03412-7	True	Collier et al. (2021)	n/a	20/29 sera after the first dose of Pfizer showed an average reduction in neutralization titres against the B.1.1.7 variant of 3.2 ± 5.7. After the second dose, the GMT was markedly increased compared with the first-dose titres, with a fold change of 1.9 ± 0.9 (mean ± s.d.). Neutralization GMT of 27 subjects post-infection was considerably higher (stronger) than after the second Pfizer dose, and 4.5x drop in B.1.1.7 neutralization was observed.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	transmissibility	n/a	n/a	Davies	2021	doi:10.1126/science.abg3055	pmid:33658326	https://doi.org/10.1126/science.abg3055	True	Davies et al. (2021)	n/a	We estimate that this [B.1.1.17] variant has a 43–90% (range of 95% credible intervals 38–130%) higher reproduction number than preexisting variants. Data from other countries yield similar results: we estimate that R for VOC 202012/01 relative to other lineages is 55% (45–66%) higher in Denmark,  74% (66–82%) higher in Switzerland, and 59% (56–63%) higher in the United States, with consistent rates of displacement across regions within each country.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	vaccine neutralization efficacy	n/a	n/a	Muik	2021	doi:10.1126/science.abg6105	pmid:33514629	https://doi.org/10.1126/science.abg6105	True	Muik et al. (2021)	n/a	Lineage B.1.1.7 spike–pseudotyped VSV was tested for neutralization vs Wuhan reference genome pseudotype in 40 sera collected 7 or 21 days post-booster dose. Statistically significant change (22%) in neutralization was observed among the 26 sera from those <	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	transmissibility	n/a	n/a	Stefanelli	2021	doi:10.1101/2021.04.06.21254923	n/a	https://doi.org/10.1101/2021.04.06.21254923	False	Stefanelli et al. (2021)	n/a	At the national level (Italy), we estimated a mean relative transmissibility of B.1.1.7 (compared to historical lineages) ranging  between 1.55 and 1.57 (with confidence intervals between 1.45 and 1.66).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	outcome hazard ratio	n/a	n/a	Funk	2021	doi:10.2807/1560-7917.ES.2021.26.16.2100348	pmid:33890566	https://doi.org/10.2807/1560-7917.ES.2021.26.16.2100348	True	Funk et al. (2021)	n/a	On average across 7 European countries studied, using B.1.1.7 defining mutations: Significant shift to asymptomatic cases (27.4% vs 18.6% for non-VOC cases).  Significant shift to infection in those without pre-existing conditions (44.8% vs 89% for non-VOC cases). Significant increase in hospitalization rate (11% vs 7.5% for non-VOC cases). Significant increase in ICU rate (1.4% vs 0.6% for non-VOC cases). Significant decrease in death rate (2.0% vs vs 4.0% for non-VOC cases).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	vaccine neutralization efficacy	n/a	n/a	Tada	2021	doi:10.1101/2021.02.05.430003	pmid:33564768	https://doi.org/10.1101/2021.02.05.430003	False	Tada et al. (2021)	n/a	Vaccine elicited antibodies neutralized virus with the B.1.1.7 spike protein with titers similar to D614G virus. Serum specimens  from individuals vaccinated with the BNT162b2 mRNA vaccine neutralized D614G virus with titers that were on average 7-fold greater than convalescent sera.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	transmissibility	n/a	n/a	Lindstrøm	2021	doi:10.1101/2021.03.29.21254122	n/a	https://doi.org/10.1101/2021.03.29.21254122	False	Lindstrøm et al. (2021)	n/a	Oslo, Norway: Within households, we find an increase in the secondary attack rate by 60% (20% 114%) compared to other variants.  In general, we find a significant increase in the estimated reproduction number of 24% (95% CI 0% - 52%), or an absolute  increase of 0.19 compared to other variants.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	transmissibility	n/a	n/a	Munitz	2021	doi:10.1016/j.xcrm.2021.100264	pmid:33899031	https://doi.org/10.1016/j.xcrm.2021.100264	True	Munitz et al. (2021)	n/a	Based on ∼300,000 RT-PCR samples collected from December 6th 2020 to February 10th 2021 in Israel,  the B.1.1.7 is 45% (95% CI:20-60%) more transmissible than the wild-type strain, and become dominant in Israel within 3.5 weeks.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	outcome hazard ratio	n/a	n/a	Nyberg	2021	doi:10.48550/arXiv.2104.05560	n/a	https://doi.org/10.48550/arXiv.2104.05560	False	Nyberg et al. (2021)	n/a	The matching-adjusted conditional odds ratio of hospitalisation was 1.58 (95% confidence interval 1.50 to 1.67) for COVID-19 patients  infected with a SGTF-associated variant [primarily B.1.1.7], compared to those infected with non-SGTF-associated variants.  The effect was modified by age (p<0.001), with ORs of 0.96-1.13 below age 20 years and 1.57-1.67 in age groups 40 years or older.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	outcome hazard ratio	n/a	n/a	Davies	2021	doi:10.1038/s41586-021-03426-1	pmid:33723411	https://doi.org/10.1038/s41586-021-03426-1	True	Davies et al. (2021)	n/a	Using UK data 1 November 2020 to 14 February 2021, while correcting for misclassification of PCR test Spike Gene Target Failure (SGTF) and missingness in SGTF status, we estimate that the hazard of death associated with B.1.1.7 is 61% (42–82%) higher than with  pre-existing variants after adjustment for age, sex, ethnicity, deprivation, residence in a care home, the local authority of residence and test date.  This corresponds to the absolute risk of death for a 55–69-year-old man increasing from  0.6% to 0.9% (95% confidence interval, 0.8–1.0%) within 28 days of a positive test in the community.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	viral load	n/a	n/a	Roquebert	2021	doi:10.1101/2021.03.19.21253971	n/a	https://doi.org/10.1101/2021.03.19.21253971	False	Roquebert et al. (2021)	n/a	B.1.1.7 samples showed average Ct cycle threshold of 21.9 vs 23 for wildtype (i.e. ~2x higher viral load) comparing 37758 and 22535 samples respectively.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	transmissibility	n/a	n/a	Graham	2021	doi:10.1016/s2468-2667(21	n/a	https://doi.org/10.1016/s2468-2667(21	n/a	Graham et al. (2021)	n/a	Based on 36920 COVID Symptom Study app users reported SARS-CoV-2 test positivity in late 2020,  Rt of B.1.1.7 was 1.35x (95% CI 1.02-1.69) relative to pre-existing variants. However, Rt fell below 1 during regional and  national lockdowns, even in regions with high proportions of infections with the B.1.1.7 variant.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	outcome hazard ratio	n/a	n/a	Frampton	2021	doi:10.1016/s1473-3099(21	n/a	https://doi.org/10.1016/s1473-3099(21	n/a	Frampton et al. (2021)	n/a	341 samples collected Nov 9 to Dec 20, 2020 were sequenced from two London (UK) hospitals.  198 (58%) of 341 had B.1.1.7 infection and 143 (42%) had non-B.1.1.7 infection. No evidence was found of an association  between severe disease and death and lineage (B.1.1.7 vs non-B.1.1.7) in unadjusted analyses (prevalence ratio [PR] 0·97  [95% CI 0·72-1·31]), or in analyses adjusted for hospital, sex, age, comorbidities, and ethnicity (adjusted PR 1·02 [0·76-1·38]).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	outcome hazard ratio	n/a	n/a	Graham	2021	doi:10.1016/s2468-2667(21	n/a	https://doi.org/10.1016/s2468-2667(21	n/a	Graham et al. (2021)	n/a	From Sept 28 to Dec 27, 2020, positive COVID-19 tests were reported by 36 920 COVID Symptom Study app users whose region was  known and who reported as healthy on app sign-up. We found no changes in reported symptoms or disease duration associated with B.1.1.7.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	viral load	n/a	n/a	Teyssou	2021	doi:10.1101/2021.03.21.21253498	n/a	https://doi.org/10.1101/2021.03.21.21253498	False	Teyssou et al. (2021)	n/a	The 249 B.1.1.7 (a.k.a. N501Y.V1) variant cases in three Paris hospital labs had a ~10-fold viral load increase  (~3.3 Ct drop in N gene probe) compared to 332 ancestral lineage cases from the same time frame (2020-12-20 to 2021-02-26).  PG: BUT there is a discrepancy in drop between the ORF1ab and N probes, with the former suggesting only a 2-fold drop,  consistent with the drop observed in B.1.351. This might indicate higher subgenomic RNA content in B.1.1.7 skewing the change.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	viral load	n/a	n/a	Couzens	2021	doi:10.1101/2021.04.02.21254832	n/a	https://doi.org/10.1101/2021.04.02.21254832	False	Couzens et al. (2021)	n/a	Using lack of S probe detection as a proxy for B.1.1.7 status, 275 putative B.1.1.7 samples and 390 'wild type' SARS-CoV-2 positive samples in Wales were compared for Ct values, suggesting ~12-fold increase (~3.5 Ct decrease) in viral load for B.1.1.7 samples.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	outcome hazard ratio	n/a	n/a	Challen	2021	doi:10.1136/bmj.n579	pmid:33687922	https://doi.org/10.1136/bmj.n579	True	Challen et al. (2021)	n/a	The mortality hazard ratio associated with infection with [B.1.1.7] compared with infection with previously circulating variants was  1.64 (95% confidence interval 1.32 to 2.04) in patients who tested positive for covid-19 in the community (54906 matched pairs of  participants who tested positive for SARS-CoV-2 in pillar 2 between 1 October 2020 and 29 January 2021). In this comparatively low risk  group, this represents an increase in deaths from 2.5 to 4.1 per 1000 detected cases.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	viral load	n/a	n/a	Ratcliff	2021	doi:10.1101/2021.02.24.21251989	n/a	https://doi.org/10.1101/2021.02.24.21251989	False	Ratcliff et al. (2021)	n/a	In a study of 1260 ICU subjects, viral load distributions (collected within 48h of admission) were elevated in  both seropositive and seronegative subjects infected with B.1.1.7 ('UK variant').  PG: The PANGO tool defining Spike variants for B.1.1.7 are listed here, whereas the paper only used a test for D1118H.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	viral load	n/a	n/a	Nyayanit	2021	doi:10.1101/2021.04.30.442222	n/a	https://doi.org/10.1101/2021.04.30.442222	False	Nyayanit et al. (2021)	n/a	This study reveals that B.1.1.7 SARS-CoV-2 variant is a slower-growing virus than parental B.1. Further, a higher replication along with reduced infectious viral titer was hypothesized to be linked to higher transmission with reduced pathogenicity.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	viral load	n/a	n/a	Lamers	2021	doi:10.1101/2021.05.03.441080	n/a	https://doi.org/10.1101/2021.05.03.441080	False	Lamers et al. (2021)	n/a	We found that the British variant (clade B.1.1.7), compared to an ancestral SARS-CoV-2 clade B virus, produced higher  levels of infectious virus late in infection and had a higher replicative fitness in human airway, alveolar and intestinal organoid models.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	outcome hazard ratio	n/a	n/a	Bager	2021	doi:10.2139/ssrn.3792894	n/a	https://doi.org/10.2139/ssrn.3792894	False	Bager et al. (2021)	n/a	Danish study of the B.1.1.7 lineage shows hospital admission odds ratio of 1.63 vs other lineages. The adjusted OR was increased in all strata of age.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	ACE2 receptor binding affinity	n/a	n/a	Tada	2021	doi:10.1101/2021.02.05.430003	pmid:33564768	https://doi.org/10.1101/2021.02.05.430003	False	Tada et al. (2021)	n/a	This mutation causes major decrease in binding affinity vs. wild type as measured by IC50 vs pseudotyped lentivirus.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	transmissibility	n/a	n/a	Buchan	2021	n/a	n/a	https://www.medrxiv.org/content/10.1101/2021.03.31.21254502v1	n/a	Buchan et al. (2021)	n/a	Ontario, Feb 2021: The secondary attack rate for VOC index cases in this matched cohort was 1.31 times higher than non-VOC index cases (RR	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	viral load	n/a	n/a	Song	2021	doi:10.1101/2021.05.04.21256655	n/a	https://doi.org/10.1101/2021.05.04.21256655	False	Song et al. (2021)	n/a	The median Ct value of RT-qPCR tests of the N-gene target in the Daxing B.1.1.7 group was significantly lower than the Shunyi B.1.470 group (P	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	transmissibility	n/a	n/a	Lyngse	2021	doi:10.1101/2021.04.16.21255459	n/a	https://doi.org/10.1101/2021.04.16.21255459	False	Lyngse et al. (2021)	n/a	Primary cases infected with B.1.1.7 had an increased transmissibility of 1.5-1.7 times that of primary cases infected with other  lineages. The increased transmissibility of B.1.1.7 was multiplicative across age and viral load.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	vaccine neutralization efficacy	n/a	n/a	Hoffman	2021	doi:10.1016/j.cell.2021.03.036	pmid:33794143	https://doi.org/10.1016/j.cell.2021.03.036	True	Hoffman et al. (2021)	n/a	VSV pseudotype B.1.1.7 showed 1.77-fold reduction in neutralization efficiency vs wild type in 15 Pfizer BNT162b2 vaccinee sera 13-15 days post second dose. Cell fusion proficiency was unchanged.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	vaccine neutralization efficacy	n/a	n/a	Leier	2021	doi:10.1101/2021.04.25.21256049	pmid:33948601	https://doi.org/10.1101/2021.04.25.21256049	False	Leier et al. (2021)	n/a	Neutralizing antibody titers increased in previously infected vaccinees relative to uninfected vaccinees  5.2-fold against B.1.1.7 (contrast with 3.4 fold against original SARS-CoV-2).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	outcome hazard ratio	n/a	n/a	UNKNOWN	2021	n/a	n/a	https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/961042/S1095_NERVTAG_update_note_on_B.1.1.7_severity_20210211.pdf	False	UNKNOWN et al. (2021)	n/a	Using primarily S-defining mutations for lineage B.1.1.7, most models of hospitalization and fatality risk ratios from consortium members show elevated ratios (~1.3-1.7x).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	trafficking	n/a	n/a	Hoffman	2021	doi:10.1016/j.cell.2021.03.036	pmid:33794143	https://doi.org/10.1016/j.cell.2021.03.036	True	Hoffman et al. (2021)	n/a	VSV pseudotype B.1.1.7 showed no significant difference in cell entry relative to wild type in 6 cell lines. Cell fusion proficiency was unchanged.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	ACE2 receptor binding affinity	n/a	n/a	Collier	2021	doi:10.1038/s41586-021-03412-7	n/a	https://doi.org/10.1038/s41586-021-03412-7	True	Collier et al. (2021)	n/a	Six fold increase in affinity for ACE2 by the B.1.1.7 lineage vs wild type is driven by a drop in observed dissociation rate constant.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	environmental condition stability	n/a	n/a	Tada	2021	doi:10.1101/2021.02.05.430003	pmid:33564768	https://doi.org/10.1101/2021.02.05.430003	False	Tada et al. (2021)	n/a	Relative to D614G, this mutation demonstrated significant increase in infectivity (i.e. heat stability) after incubation at 50C after 1 hour.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	trafficking	n/a	n/a	Tada	2021	doi:10.1101/2021.02.05.430003	pmid:33564768	https://doi.org/10.1101/2021.02.05.430003	False	Tada et al. (2021)	n/a	Lentiviral pseudotyped with this mutation set from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing significant (40%) increase in infection rate amongst the cells, much more than the effect of  either the deletion or the point mutation alone, suggetsing that this combination has a synergistic effect  contributing to cell entry fitness, but to a smaller extent than N501Y and the deletion alone.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	convalescent plasma binding	n/a	n/a	Tada	2021	doi:10.1101/2021.02.05.430003	pmid:33564768	https://doi.org/10.1101/2021.02.05.430003	False	Tada et al. (2021)	n/a	These key B.1.1.7 mutations as a combination neutralized slightly less well than D614G and this was noticeable in the lack of sera with high neutralizing titer for the viruses  across 10 convalescent sera from April 2020 infectees.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	convalescent plasma binding	n/a	n/a	Alenquer	2021	doi:10.1101/2021.04.22.441007	n/a	https://doi.org/10.1101/2021.04.22.441007	False	Alenquer et al. (2021)	n/a	Slight neutralization improvement on average in 16 health workers' convalescent sera.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.4/5 (from ) were 17.2x-fold lower (95% CI: 0.6x-0.7x) than against 208-428 972-1834 4.3-4.7 US-WA1/2020 usiong an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.4/5 (from ) were 13.0-fold lower (95% CI: 4.2x-4.6x) than against 208-428 972-1834 4.3-4.7 US-WA1/2020 usiong an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	outcome hazard ratio	n/a	n/a	Ulloa	2021	doi:10.1101/2021.12.24.21268382	n/a	https://doi.org/10.1101/2021.12.24.21268382	False	Ulloa et al. (2021)	n/a	In Ontario, using a retrospective matched case (age, gender and onset date) study of 6,312 Omicron cases vs 8,875 Delta,  the adjusted risk of hospitalization or death was 54% lower (HR	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	reinfection	n/a	n/a	Pulliam	2021	doi:10.1101/2021.11.11.21266068	n/a	https://doi.org/10.1101/2021.11.11.21266068	False	Pulliam et al. (2021)	n/a	Population-level evidence suggests that the Omicron variant is associated with substantial ability to evade  immunity from prior infection, evidenced by a reinfection hazard ratio of 2.39 (CI95: 1.88-3.11) relative to primary infection in the initial part of South Africa's 4th covid-19 wave (November 2021).  In contrast, there is no population-wide epidemiological evidence of immune escape associated with the Beta or Delta variants. [minimal variant signature for Omicron (B.1.1.529) used based on H69del PCR dropout observed in November 2021 coincident with the rise of Omicron]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	immunosuppression variant emergence	n/a	n/a	Bazykin	2021	n/a	n/a	https://virological.org/t/emergence-of-y453f-and-69-70hv-mutations-in-a-lymphoma-patient-with-long-term-covid-19/580	False	Bazykin et al. (2021)	n/a	The so-called 'delta F' variant combination previously observed in mink spillover events also emerged in a lymphoma  patient (non-Hodgkin diffuse B-cell lymphoma IV stage B) with a long-term COVID-19 infection (4 months) where 18 de novo mutation occureed overall. Patient was taking rituximab, the B-cell-depleting agent, and had no detectable neutralizing antibody response.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	vaccinee plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	1.14x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	ACE2 receptor binding affinity	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.51x increase in binding (KD) relative to D614G, mostly due to decreased in 'off-rate' a.k.a. dissociation rate (Kdis).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	convalescent plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	1.33x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	ACE2 receptor binding affinity	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing B.1.1.7 aka Alpha) had 5.43x increased binding relative to D614G alone.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	convalescent plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	This variant combination (representing B.1.1.7 aka Alpha) showed a 1.15x increase in Spike binding  (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	H69del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	V70del	1.0	vaccinee plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	This variant combination (representing B.1.1.7 aka Alpha) showed no change in Spike binding  (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.28x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of  Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	convalescent plasma escape	n/a	n/a	Schmidt	2021	doi:10.1101/2021.08.06.455491	n/a	https://doi.org/10.1101/2021.08.06.455491	False	Schmidt et al. (2021)	n/a	Artificially constructed HIV-1 pseudovirus with set of mutations drawn from plasma passage escape experiments and mutations from variants of concern completely ablates neutralization in 19 of 21 convalescents plasma collected mean 1.3 months post infection. [actual Y145del from manuscript substituted with more common Y144del description]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	vaccine neutralization efficacy	n/a	n/a	Choi	2021	doi:10.1101/2021.06.28.449914	n/a	https://doi.org/10.1101/2021.06.28.449914	False	Choi et al. (2021)	n/a	Neutralization efficiency (ID50) against B.1.525 reduced 4.2x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	pharmaceutical effectiveness	n/a	n/a	Cathcart	2021	doi:10.1101/2021.03.09.434607v9	n/a	https://doi.org/10.1101/2021.03.09.434607v9	False	Cathcart et al. (2021)	n/a	Omicron (a.k.a. B.1.1.529) Spike pseudotyped VSV and Vero E6 cells has somewhat  reduced neutralization (2.7x) vs wild type with monoclonal antibody Sotrovimab (a.k.a. VIR-7831).  [delins at 214 omitted for syntax compatibility]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	vaccine neutralization efficacy	n/a	n/a	Wang	2022	doi:10.1101/2022.08.11.503601	n/a	https://doi.org/10.1101/2022.08.11.503601	False	Wang et al. (2022)	n/a	Omicron breakthrough infection after 3-dose vaccination resulted in a further 3.5-fold and 2.9-fold increase of Omicron BA.1 and BA.2 neutralizing titers. Omicron  BA.4/5 showed the highest neutralization resistance of all variants tested, resulting in low geometric mean neutralizing titers in plasma samples  obtained after  the second vaccine dose (NT50	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs Bi-Nab47D10-35B5. Omicron BA.1 has an IC50 fold change of 0.08x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	vaccine neutralization efficacy	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron B.1.1.529 (BA.1) neutralization of the Omicron variants by antibodies induced by three doses of Pfizer/BNT162b2 mRNA vaccine was 7-8-fold less potent than  the D614G, and the Omicron variants still evade neutralization more efficiently.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	pharmaceutical effectiveness	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron (B.1.1.529 [BA.1]) have higher sensitivity to inhibition by soluble angiotensin converting enzyme 2 (ACE2) and the endosomal inhibitor chloroquine compared  to D614G	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs Bi-Nab35B5-47D10. Omicron BA.1 has an IC50 fold change of 0.30x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	vaccine neutralization efficacy	n/a	n/a	Uhal B	2022	doi:10.1101/2022.06.23.497326	n/a	https://doi.org/10.1101/2022.06.23.497326	False	Uhal B et al. (2022)	n/a	Paradigms’ ACE-2 variant LVE/STR chimera binds to SARS-2 Omicron variant B.1.1.529 spike protein trimer with high affinity. Determined using Surrogate Viral Neutralization Tests.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	ACE2 receptor binding affinity	n/a	n/a	Uhal B	2022	doi:10.1101/2022.06.23.497326	n/a	https://doi.org/10.1101/2022.06.23.497326	False	Uhal B et al. (2022)	n/a	L27, V34 and E90 mutation resulted in ultrahigh affinity binding of the LVE-ACE-2 domain to the widest variety of VOCs, with KDs of 73 pM for binding to the Omicron  B.1.1.529. Values were obtained with LVE-ACE-2/mAB chimeras containing the Y-T-E sequence that enhances binding to the FcRn receptor, which in turn is expected to  extend biological half-life 3-4-fold.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs 35B5. Omicron BA.1 has an IC50 fold change of 0.38x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	vaccinee plasma binding	n/a	n/a	Arora	2022	doi:10.1038/s41423-022-00870-5	pmid:35581351	https://doi.org/10.1038/s41423-022-00870-5	True	Arora et al. (2022)	n/a	All 10 individuals with 2 doses of the BNT162b2/BNT162b2 vaccine had a neutralizing titer in B.1 variant at an average of 729 NT50.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	antibody epitope effects	n/a	n/a	Shete	2022	doi:10.1101/2022.05.12.491584	n/a	https://doi.org/10.1101/2022.05.12.491584	False	Shete et al. (2022)	n/a	Plaque reduction neutralization test (PRNT) was used uring primary infection, post sixty daysof second dose vaccination, pre-reinfection and reinfection against Delta variant and was used to determine neutralizing antibodytitres. There was a 24.63x fold increase in antibody response from first infection to recovered and vaccinated with 2 doses (60 days). There was a 4.21x fold increase in antibody response pre-reinfection. There was a 39.27x fold increase in antibody response during reinfection.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	antibody epitope effects	n/a	n/a	Shete	2022	doi:10.1101/2022.05.12.491584	n/a	https://doi.org/10.1101/2022.05.12.491584	False	Shete et al. (2022)	n/a	Plaque reduction neutralization test (PRNT) was used uring primary infection, post sixty daysof second dose vaccination, pre-reinfection and reinfection against B.1 variant and was used to determine neutralizing antibodytitres. There was a 6.76x fold increase in antibody response from first infection to recovered and vaccinated with 2 doses (60 days). There was a 2.06x fold increase in antibody response pre-reinfection. There was a 8.18x fold increase in antibody response during reinfection.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	vaccinee plasma binding	n/a	n/a	Arora	2022	doi:10.1038/s41423-022-00870-5	pmid:35581351	https://doi.org/10.1038/s41423-022-00870-5	True	Arora et al. (2022)	n/a	All 10 individuals with 3 doses of the BNT162b2/BNT162b2 vaccine had a neutralizing titer in B.1 variant at an average of 3319 NT50.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	antibody epitope effects	n/a	n/a	Shete	2022	doi:10.1101/2022.05.12.491584	n/a	https://doi.org/10.1101/2022.05.12.491584	False	Shete et al. (2022)	n/a	Plaque reduction neutralization test (PRNT) was used uring primary infection, post sixty daysof second dose vaccination, pre-reinfection and reinfection against Omicron variant and was used to determine neutralizing antibodytitres. There was a 114.84x fold increase in antibody response from first infection to recovered and vaccinated with 2 doses (60 days). There was a 6.61x fold increase in antibody response pre-reinfection. There was a 1194.9x fold increase in antibody response during reinfection.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	antibody epitope effects	n/a	n/a	Kumar	2022	doi:10.1101/2022.05.13.491770	n/a	https://doi.org/10.1101/2022.05.13.491770	False	Kumar et al. (2022)	n/a	BnAb 002-S21F2 IC50 on the Omicron BA.1 variant is 1.0x fold the wildtype.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs 47D10. Omicron BA.1 has an IC50 fold change of 1.26x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	pharmaceutical effectiveness	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron BA.3 have higher sensitivity to inhibition by soluble angiotensin converting enzyme 2 (ACE2) and the endosomal inhibitor chloroquine compared  to D614G	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	vaccine neutralization efficacy	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron BA.3 neutralization of the Omicron variants by antibodies induced by three doses of Pfizer/BNT162b2 mRNA vaccine was 7-8-fold less potent than the D614G, and  the Omicron variants still evade neutralization more efficiently.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.3 (from South Africa/NICD-N22404/2021) were 4.2x-fold lower (95% CI: 0.15x-0.20x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.3 (from South Africa/NICD-N22404/2021) were 6.2-fold lower (95% CI: 11.8x-14.3x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	vaccine neutralization efficacy	n/a	n/a	Hao	2022	doi:10.1101/2022.08.12.22278720	pmid:36032965	https://doi.org/10.1101/2022.08.12.22278720	False	Hao et al. (2022)	n/a	paired testing of vaccine sera against ancestral virus compared to Omicron BA.1 shows that 3-dose vaccine regimen provides over 50x fold increase in protection against Omicron(B.1.1.529 [BA.1]) compared to a 2-dose regimen.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	pharmaceutical effectiveness	n/a	n/a	Wang	2022	doi:10.1101/2022.08.11.503601	n/a	https://doi.org/10.1101/2022.08.11.503601	False	Wang et al. (2022)	n/a	4th antigenic exposure with Omicron (B.1.1.529 [BA.1])(n	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.1 (from Botswana/R40B59_BHP_3321001248/2021) were 3.4-fold lower (95% CI: 3.2x-3.6x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.1 (from Botswana/R40B59_BHP_3321001248/2021) were 28.7x-fold lower (95% CI: 0.03x-0.05) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	vaccinee plasma binding	n/a	n/a	Shen	2021	doi:10.1101/2021.01.27.428516	pmid:33532764	https://doi.org/10.1101/2021.01.27.428516	False	Shen et al. (2021)	n/a	Neutralization activity of almost all Moderna Phase 1 sera tested actually *increased*.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	immunosuppression variant emergence	n/a	n/a	Kemp	2020	doi:10.1101/2020.12.14.422555	n/a	https://doi.org/10.1101/2020.12.14.422555	False	Kemp et al. (2020)	n/a	The delH69/V70 enhances viral infectivity, indicating its effect on virus fitness is independent to the N501Y RBM change [with which it is found in lineage B.1.1.7] Possibly arisen as a result of the virus evolving from immune selection pressure in infected individuals and possibly only one chronic infection in the case of lineage B.1.1.7.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	convalescent plasma escape	n/a	n/a	Alenquer	2021	doi:10.1101/2021.04.22.441007	n/a	https://doi.org/10.1101/2021.04.22.441007	False	Alenquer et al. (2021)	n/a	One convalescent sera tested showed 4-fold or greater reduction in neutralization efficiency.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	convalescent plasma escape	n/a	n/a	Shen	2021	doi:10.1101/2021.01.27.428516	pmid:33532764	https://doi.org/10.1101/2021.01.27.428516	False	Shen et al. (2021)	n/a	Neutralization activity of almost all convalescent sera tested decreased ~2x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	convalescent plasma escape	n/a	n/a	Shen	2021	doi:10.1101/2021.01.27.428516	pmid:33532764	https://doi.org/10.1101/2021.01.27.428516	False	Shen et al. (2021)	n/a	Neutralization activity of convalescent sera tested decreased ~2x with this B.1.1.7 pseudotyped virus.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	antibody epitope effects	n/a	n/a	Rees-Spear	2021	doi:10.1101/2021.01.15.426849	n/a	https://doi.org/10.1101/2021.01.15.426849	False	Rees-Spear et al. (2021)	n/a	Reduces neutralization by structurally unmapped mAb COVA1-21 (cluster XI).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	convalescent plasma binding	n/a	n/a	Tada	2021	doi:10.1101/2021.02.05.430003	pmid:33564768	https://doi.org/10.1101/2021.02.05.430003	False	Tada et al. (2021)	n/a	Viruses containing the point mutations of B.1.1.7 showed that the single point mutations (Δ69-70 and N501Y) were neutralized as efficiently as D614G across 10 convalescent sera from April 2020 infectees.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	anthropozoonotic events	n/a	n/a	Li	2023	doi:10.1038/s41396-023-01368-2	pmid:36690780	https://doi.org/10.1038/s41396-023-01368-2	True	Li et al. (2023)	n/a	This deletion outside the receptor binding domain in pseudotyped VSV promoted the capacity of pseudotyped VSV to transduce black flying fox (Pteropus alecto) kidney PabKi.1 cells (17.8%) to a level twice that of human epithelial-like Huh-7 cells (9.8%)	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	convalescent plasma binding	n/a	n/a	Alenquer	2021	doi:10.1101/2021.04.22.441007	n/a	https://doi.org/10.1101/2021.04.22.441007	False	Alenquer et al. (2021)	n/a	No notable change in neutralization efficiency, despite N439K by itself showing a ~2x decrease on average in 16 health workers' convalescent sera.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	vaccine neutralization efficacy	n/a	n/a	Chen	2021	doi:10.1038/s41591-021-01294-w	pmid:33664494	https://doi.org/10.1038/s41591-021-01294-w	True	Chen et al. (2021)	n/a	The neutralizing activity of vaccine was somewhat lower against B.1.1.7 in sera tested from most of the 24 patients with the BNT162b2 mRNA vaccine. (Fig. 4)	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	antibody epitope effects	n/a	n/a	Chen	2021	doi:10.1038/s41591-021-01294-w	pmid:33664494	https://doi.org/10.1038/s41591-021-01294-w	True	Chen et al. (2021)	n/a	B.1.1.7 variant constellation ablates Class 3 N-terminal domain targeting antibody COV2-2489.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	vaccine neutralization efficacy	n/a	n/a	Bates	2021	doi:10.1101/2021.04.04.21254881	pmid:33851185	https://doi.org/10.1101/2021.04.04.21254881	False	Bates et al. (2021)	n/a	Observed 8.8-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose) against cultured B.1.1.7 sample. Contrast this with 1.3-fold reduction for just the pseudovirus combination of 'key' B.1.1.7 mutation N501Y.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	trafficking	n/a	n/a	Tada	2021	doi:10.1101/2021.02.05.430003	pmid:33564768	https://doi.org/10.1101/2021.02.05.430003	False	Tada et al. (2021)	n/a	Lentiviral pseudotyped with this mutation set from Mink Cluster 5 lineage, was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing slight decrease in infection rate amongst the cells, much closer to D614G activity level than Y453F alone, suggesting compensatory effects between the  deletion and the mutation in human cell entry fitness.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	trafficking	n/a	n/a	Tada	2021	doi:10.1101/2021.02.05.430003	pmid:33564768	https://doi.org/10.1101/2021.02.05.430003	False	Tada et al. (2021)	n/a	Lentiviral pseudotyped with this mutation set from Mink Cluster 5 lineage, was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing moderate decrease in infection rate amongst the cells, significantly lower than the  deletion or Y453F alone, or their combination, suggesting a synergistic effect on  poorer human cell entry fitness.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	vaccine neutralization efficacy	n/a	n/a	Garcia-Beltran	2021	doi:10.1016/j.cell.2021.03.013	pmid:33743213	https://doi.org/10.1016/j.cell.2021.03.013	True	Garcia-Beltran et al. (2021)	n/a	Pseudotyped B.1.1.298 virus has reduced neutralization activity vs wild type: 1.4x (30 sera Pfizer median 9 days post 2nd dose)  and 1.3x (35 sera Moderna median 18 days post 2nd dose). This was NOT significant by ANOVA.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	trafficking	n/a	n/a	Tada	2021	doi:10.1101/2021.02.05.430003	pmid:33564768	https://doi.org/10.1101/2021.02.05.430003	False	Tada et al. (2021)	n/a	Lentiviral pseudotyped with this mutation set from Mink Cluster 5 lineage, was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing mild to modest decrease in infection rate amongst the cells, suggesting a net mild  negative effect on human cell entry fitness.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	convalescent plasma binding	n/a	n/a	Tada	2021	doi:10.1101/2021.02.05.430003	pmid:33564768	https://doi.org/10.1101/2021.02.05.430003	False	Tada et al. (2021)	n/a	Lentiviral pseudotyped with the key mutations from Mink Cluster 5 was neutralized more easily than D614G in 10 convalescent sera from April 2020 infectees.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	trafficking	n/a	n/a	Tada	2021	doi:10.1101/2021.02.05.430003	pmid:33564768	https://doi.org/10.1101/2021.02.05.430003	False	Tada et al. (2021)	n/a	Lentiviral pseudotyped with this mutation set from Mink Cluster 5 lineage, was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing no change in infection rate amongst the cells, markedly higher infectivity than  either mutation alone, suggesting a synergistic net neutral effect on human cell entry fitness.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	trafficking	n/a	n/a	Tada	2021	doi:10.1101/2021.02.05.430003	pmid:33564768	https://doi.org/10.1101/2021.02.05.430003	False	Tada et al. (2021)	n/a	Lentiviral pseudotyped with all key mutations from Mink Cluster 5 lineage, was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing major (~50%) decrease in infection rate amongst the cells, suggesting that this  anthropozoonotic event is driven by other factors at the expense of human cell entry fitness.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	vaccine neutralization efficacy	n/a	n/a	Choi	2021	doi:10.1101/2021.06.28.449914	n/a	https://doi.org/10.1101/2021.06.28.449914	False	Choi et al. (2021)	n/a	Neutralization efficiency (ID50) against B.1.1.7+E484K reduced 2.8x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster. Compare with 1.2x reduction for B.1.1.7 without E484K.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	vaccine neutralization efficacy	n/a	n/a	Collier	2021	doi:10.1038/s41586-021-03412-7	n/a	https://doi.org/10.1038/s41586-021-03412-7	True	Collier et al. (2021)	n/a	Sera after the second dose of Pfizer showed an average reduction in neutralization titres against the B.1.1.7 + E484K  variant of ~6.7x, markedly higher than B.1.1.7 alone. For first dose sera, a 9.7x drop was observed.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	convalescent plasma escape	n/a	n/a	Collier	2021	doi:10.1038/s41586-021-03412-7	n/a	https://doi.org/10.1038/s41586-021-03412-7	True	Collier et al. (2021)	n/a	Neutralization capacity GMT of 27 subjects' sera post-infection was markedly worse against B.1.1.7 + E484K than the lineage alone, with a 11.4x drop.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	antibody epitope effects	n/a	n/a	Chen	2021	doi:10.1038/s41591-021-01294-w	pmid:33664494	https://doi.org/10.1038/s41591-021-01294-w	True	Chen et al. (2021)	n/a	Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	trafficking	n/a	n/a	Tada	2021	doi:10.1101/2021.02.05.430003	pmid:33564768	https://doi.org/10.1101/2021.02.05.430003	False	Tada et al. (2021)	n/a	Lentiviral pseudotyped with this mutation set from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing significant (40%) increase in infection rate amongst the cells, much more than the effect of  either the deletion or the point mutation alone, suggetsing that this combination has a synergistic effect  contributing to cell entry fitness, moreso than this combination with the addition of P681H.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	symptom prevalence	n/a	n/a	van Loon	2021	doi:10.1101/2021.04.15.21255389	n/a	https://doi.org/10.1101/2021.04.15.21255389	False	van Loon et al. (2021)	n/a	In comparison of B.1.1.7 lineage (193 cases) vs. 'wildtype' (125) in Berlin Jan 18 to March 29 2021,  significant symptom changes are absent loss of smell/taste (P	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	ACE2 receptor binding affinity	n/a	n/a	Tada	2021	doi:10.1101/2021.02.05.430003	pmid:33564768	https://doi.org/10.1101/2021.02.05.430003	False	Tada et al. (2021)	n/a	This mutation combination causes major increase in binding affinity vs. wild type as measured by IC50 vs pseudotyped  lentivirus, but combined with the complete set of B.1.1.7   lineage variants no major change vs wild type affnity is observed.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	antibody epitope effects	n/a	n/a	Shen	2021	doi:10.1101/2021.01.27.428516	pmid:33532764	https://doi.org/10.1101/2021.01.27.428516	False	Shen et al. (2021)	n/a	Reduction in neutralization by mAbs COVA1-18 (~4x), COVA2-15 (~9x). PG: these effects are laregly missing in the deletion-alone data	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	symptom prevalence	n/a	n/a	Snell	2021	doi:10.1101/2021.03.16.21253377	n/a	https://doi.org/10.1101/2021.03.16.21253377	False	Snell et al. (2021)	n/a	A higher proportion of cases infected with the B.1.1.7 variant were hypoxic on admission compared to other variants (70.0% vs 62.5%, p	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	virion structure	n/a	n/a	Tada	2021	doi:10.1101/2021.02.05.430003	pmid:33564768	https://doi.org/10.1101/2021.02.05.430003	False	Tada et al. (2021)	n/a	The Ratio of S2 (processed Spike) to full length Spike is higher for this mutation combination,  due to a drop in the full length Spike measured, suggesting that this mutation compensates for decreased Spike production by improved proteolytic processing.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	vaccine neutralization efficacy	n/a	n/a	Reynolds	2021	doi:10.1126/science.abh1282	pmid:33931567	https://doi.org/10.1126/science.abh1282	True	Reynolds et al. (2021)	n/a	After one dose, individuals with prior infection showed enhanced T cell immunity,  antibody secreting memory B cell response to spike and neutralizing antibodies effective  against B.1.1.7 (authentic cell culture supernatants). By comparison, HCW receiving one vaccine dose without prior  infection showed reduced immunity against variants. B.1.1.7 spike mutations  resulted in increased, abrogated or unchanged T cell responses depending on human leukocyte  antigen (HLA) polymorphisms. Study was 26 each post-infection and post first dose HCWs.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	convalescent plasma escape	n/a	n/a	Uriu	2021	doi:10.1101/2021.09.06.459005	n/a	https://doi.org/10.1101/2021.09.06.459005	False	Uriu et al. (2021)	n/a	Mean 2.6x reduction of NT50 value B.1.1.7 (Alpha) relative to wild type in 8 sera from older convalescent patients (52-92yo) collected 1-3m post symptom onset.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	vaccine neutralization efficacy	n/a	n/a	Pegu	2021	doi:10.1101/2021.05.13.444010	pmid:34031659	https://doi.org/10.1101/2021.05.13.444010	False	Pegu et al. (2021)	n/a	Detectable antibodies against B.1.1.7 at various time points using pseudotyped lentivirus neutralization in Moderna vaccinee cohort: Day 29 33%, Day 43 100%, Day 119 100%, Day 209 96%. Detectable antibodies against B.1.1.7 at various time points using live virus FRNT neutralization in Moderna vaccinee cohort: Day 29 54%, Day 43 100%, Day 119 100%, Day 209 88%. Detectable antibodies against B.1.1.7 at various time points using ACE2 blocking assay in Moderna vaccinee cohort: Day 29 83%, Days 43,119,209 100%.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	vaccine neutralization efficacy	n/a	n/a	Haas	2021	doi:10.1016/S0140-6736(21	n/a	https://doi.org/10.1016/S0140-6736(21	n/a	Haas et al. (2021)	n/a	Using national surveillance data from Israel, using Pfizer vaccine and an estimated prevalence of the B.1.1.7 variant of 94.5% among SARS-CoV-2 infections: Adjusted estimates of vaccine effectiveness 7+ days after second dose were 95·3% (95% CI 94.9–95.7):  91.5% against asymptomatic SARS-CoV-2 infection (90·7–92·2: 40.9 vs 1.8 per 100 000 person-days), 97·0% against symptomatic  COVID-19 (96.7–97.2%), 97.2% against COVID-19-related hospitalisation (96.8–97.5%),  97.5% against severe or critical COVID-19-related hospitalisation (97.1–97.8%), and 96.7% against COVID-19-related death (96.0–97.3%).  In all age groups, as vaccine coverage increased, the incidence of SARS-CoV-2 outcomes declined	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	vaccine neutralization efficacy	n/a	n/a	Luftig	2021	doi:10.1056/NEJMc2104036	pmid:33826815	https://doi.org/10.1056/NEJMc2104036	True	Luftig et al. (2021)	n/a	In sera 1-2 weeks after BNT162b2 first dose, from six patients previously infected with B.1, antibody titer in a microneutralization assay  was on average 8192 for B.1.351 virus. This compares favorably (stronger) to post-infection neutralization titer against all variants tested in the same sera (wild type, B.1.1.7, B.1.351, and P.1).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	virion structure	n/a	n/a	Cai	2021	doi:10.1101/2021.04.13.439709	pmid:33880477	https://doi.org/10.1101/2021.04.13.439709	False	Cai et al. (2021)	n/a	CryoEM analysis of B.1.1.7 demonstrates an increased propensity for 'up', receptor accessible conformation of the Spike protein trimer.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	vaccine neutralization efficacy	n/a	n/a	Loconsole	2021	doi:10.1016/j.cmi.2021.05.007	pmid:33984489	https://doi.org/10.1016/j.cmi.2021.05.007	True	Loconsole et al. (2021)	n/a	SARS-CoV-2 infection was confirmed in three HCWs working a single shift: all presented with mild symptoms of COVID-19. The two physicians  were fully vaccinated with BNT162b2 vaccine, with the second dose administered 1 month before symptom onset. Both had high titres of IgG  anti-spike antibodies at the time of diagnosis. WGS confirmed that all virus strains were VOC 202012/01-lineage B.1.1.7, suggesting a  common source of exposure. Epidemiological investigation revealed that the suspected source was a SARS-CoV-2-positive patient who  required endotracheal intubation due to severe COVID-19. All procedures were carried out using a full suite of personal protective equipment (PPE).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	vaccine efficacy	n/a	n/a	Bruxvoort	2021	doi:10.1101/2021.09.29.21264199	n/a	https://doi.org/10.1101/2021.09.29.21264199	False	Bruxvoort et al. (2021)	n/a	In a 1:5 test-negative matched control study of 8153 individuals who received the Moderna mRNA-1273 vaccine, 1422 test-positive were Alpha. Two dose vaccine efficacy against Alpha was 98.4% [96.9-99.1%], one dose VE was 90.1% (82.9-94.2%).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	convalescent plasma escape	n/a	n/a	Planas	2021	doi:10.1038/s41591-021-01318-5	n/a	https://doi.org/10.1038/s41591-021-01318-5	True	Planas et al. (2021)	n/a	Using a new rapid neutralization assay, based on reporter cells that become positive for GFP after overnight infection, sera from 58  convalescent individuals collected up to 9 months after symptoms, similarly neutralized B.1.1.7 and D614G.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs Bi-Nab35B5-47D10. Alpha (B.1.1.7) has an IC50 fold change of 1.19x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	antibody epitope effects	n/a	n/a	Wang	2021	doi:10.1038/s41586-021-03398-2	n/a	https://doi.org/10.1038/s41586-021-03398-2	True	Wang et al. (2021)	n/a	B.1.1.7 pseudotyped virus model impairs binding by RBD-directed mAb 910-30. B.1.1.7 pseudotyped virus model abolishes N-terminal-domain-directed mAbs 5-24, 4-8, and 4A8. B.1.1.7 pseudotyped virus model impairs binding by N-terminal-domain-directed mAbs 2-17, 4-19, 5-7.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	vaccine neutralization efficacy	n/a	n/a	Wang	2021	doi:10.1056/NEJMc2103022	pmid:33822491	https://doi.org/10.1056/NEJMc2103022	True	Wang et al. (2021)	n/a	1.4x improvement in neutralization by serum collected 2 to 3 weeks after the second dose from vaccinees who had received  BBIBP-CorV (pVNT50 against VSV pseudotyped as B.1.1.7). Convalescent plasma had similar titer against wild type as the BBIBP-CorV vaccinee sera. 2x reduction in neutralization by serum collected 2 to 3 weeks after the second dose from vaccinees who had received  CoronaVac (pVNT50 against VSV pseudotyped as B.1.1.7). Convalescent plasma had similar titer against wild type as the CoronaVac vaccinee sera.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	aerosolization	n/a	n/a	Adenaiye	2021	doi:10.1093/cid/ciab797	pmid:34519774	https://doi.org/10.1093/cid/ciab797	True	Adenaiye et al. (2021)	n/a	Alpha variant cases in a large campus study showed fine-aerosol shedding amongst unmasked participants remained significantly greater for alpha variant infections (18-fold, 95% CI, 3.4 to 92-fold) after adjusting for the increased viral RNA in MTS and saliva, the number of coughs during sampling sessions, and symptom. After controlling for the effect of masks and numbers of coughs during sampling, alpha variant infection was associated with a 100-fold (95% CI, 16 to 650-fold) increase in coarse- and a 73-fold (95% CI, 15 to 350-fold) increase in fine-aerosol RNA shedding.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	environmental condition stability	n/a	n/a	Schuit	2021	doi:10.1093/infdis/jiab171	pmid:33822064	https://doi.org/10.1093/infdis/jiab171	True	Schuit et al. (2021)	n/a	No differences in the stability of B.1.1.7 observed in the absence of simulated sunlight at either 20°C or 40°C (with a mean time for  a 90% loss of viral infectivity across all dark conditions of 6.2 hours). However, a small but statistically  significant difference in the stability was observed in simulated sunlight at 20°C and 20% relative humidity, with B.1.1.7 restoring  wild type 90% loss time of 11 minutes vs. 7 and 8 minutes for B.1.319 (D614G) and B.28 (V367F) early 2020 viruses respectively.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	trafficking	n/a	n/a	Liu	2021	doi:10.1101/2021.08.12.456173v3	n/a	https://doi.org/10.1101/2021.08.12.456173v3	False	Liu et al. (2021)	n/a	Modelling the Alpha variant in primary human airway epithelial (HAE) cultures, S1 to full length Spike ratio  (measuring Spike furin cleavage processivity) increase 3.9x relative to wild type (5.4 vs 1.4). This is less efficient than Delta (11x vs wildtype using a P681R mutation instead). [del ~144 changed due to ambiguity] Furthermore the RNA ratio of Delta versus Alpha-spike/Delta-backbone continuously increased from 2.8 on day 1  to 9.8 on day 5 post infection in a co-infection model in HAEs, suggesting the spike gene drives the improved replication of Delta variant.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	vaccine neutralization efficacy	n/a	n/a	Woldemeskel	2021	doi:10.1172/JCI149335	pmid:33822770	https://doi.org/10.1172/JCI149335	True	Woldemeskel et al. (2021)	n/a	No significant difference in T-cell response to B.1.1.7 was observed (vs. ancestral) in blood drawn from 28 participants received the Pfizer-BioNTech vaccine  and 2 received the Moderna vaccine. This is despite three mutations (Y144del, D614G, and P681H) overlapping T-cell epitope hotspots.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	environmental condition stability	n/a	n/a	Meister	2021	doi:10.1093/infdis/jiab260	pmid:33993274	https://doi.org/10.1093/infdis/jiab260	True	Meister et al. (2021)	n/a	Treatment with heat, soap and ethanol revealed similar inactivation profiles indicative of a comparable susceptibility  towards disinfection. Furthermore, we observed comparable surface stability on steel, silver, copper and face masks.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	vaccine neutralization efficacy	n/a	n/a	Sapkal	2021	doi:10.1093/jtm/taab051	pmid:33772577	https://doi.org/10.1093/jtm/taab051	True	Sapkal et al. (2021)	n/a	The NAb titers (PRNT50) of sera collected from 38 vaccine recipients four-weeks after the second dose of inactivated whole-virion SARS-CoV-2 BBV152/COVAXIN vaccine [which contains D614G] were not significantly  different between B.1.1.7 virus and ancestral D614G virus.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	vaccine neutralization efficacy	n/a	n/a	Tarke	2021	doi:10.1101/2021.02.27.433180	pmid:33688655	https://doi.org/10.1101/2021.02.27.433180	False	Tarke et al. (2021)	n/a	PBMCs of Pfizer/BioNTech BNT162b2 (n	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	vaccine neutralization efficacy	n/a	n/a	Hall	2021	doi:10.1016/S0140-6736(21	n/a	https://doi.org/10.1016/S0140-6736(21	n/a	Hall et al. (2021)	n/a	A single dose of BNT162b2 vaccine demonstrated vaccine effectiveness [symptomatic or asymptomatic in cohort opf routinely NAAT-monitored UK HCWs]  of 72% (95% CI 58-86) 21 days after first dose and 86% (95% CI 76-97) seven days after two doses in the antibody negative cohort.  This cohort was vaccinated when the dominant variant in circulation was B.1.1.7 and demonstrates effectiveness against this variant.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	vaccine neutralization efficacy	n/a	n/a	Amit	2021	doi:10.1016/S0140-6736(21	n/a	https://doi.org/10.1016/S0140-6736(21	n/a	Amit et al. (2021)	n/a	Between December 19, 2020 and Jan 24, 2021, 7214 of 9109 eligible HCWs at Sheba Medical Center in Israel had received one or more doses of  BNT162b2 (Pfizer) vaccine. Adjusted rate reduction in SARS-CoV-2 NAAT positivity infection compared with unvaccinated workers 1-14 days  after 1st dose was 30% (95% CI: 2-50), and 75% (95% CI: 72-84) after 15-28 days. Adjusted rate reduction in symptomatic COVID-19 compared with  unvaccinated workers 1-14 days after 1st dose was 47% (95% CI: 17-66), and 85% (95% CI: 71-92) after 15-28 days. [Though often cited as an indicator of VE for B.1.1.7, during this time period in Israel, the prevalence of the B.1.1.7 variant increased from ~20% to 50% of  cases (covariants.org), therefore these VE numbers likely represent a mix of B.1.1.7 and other lineage effects.]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	vaccine neutralization efficacy	n/a	n/a	Lopez Bernal	2021	doi:10.1136/bmj.n1088	pmid:33985964	https://doi.org/10.1136/bmj.n1088	True	Lopez Bernal et al. (2021)	n/a	We found that a single dose of the BNT162b2 vaccine is about 60-70% effective at preventing symptomatic disease in adults aged 70 years  and older in England and that two doses are about 85-90% effective. Those who were vaccinated and went on to have symptoms had a 44%  lower risk of being admitted hospital and a 51% lower risk of death compared with people who were unvaccinated. We also found that a single dose  of the ChAdOx1-S vaccine was about 60-75% effective against symptomatic disease and provided an additional protective effect against hospital  admission—it is too early to assess the effect on mortality. The B.1.1.7 variant now dominates in the UK and these results will largely  reflect vaccine effectiveness against this variant.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the 47D10. Alpha (B.1.1.7) has an IC50 fold change of 0.40x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	anthropozoonotic events	n/a	n/a	Hamer	2021	doi:10.1111/tbed.14122	pmid:33955193	https://doi.org/10.1111/tbed.14122	True	Hamer et al. (2021)	n/a	First documented cases of domestic cat and dog infections with the B.1.1.7 strain.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	vaccine efficacy	n/a	n/a	Lopez Bernal	2021	doi:10.1056/NEJMoa2108891	pmid:34289274	https://doi.org/10.1056/NEJMoa2108891	True	Lopez Bernal et al. (2021)	n/a	Effectiveness after one dose of vaccine (BNT162b2 or ChAdOx1 nCoV-19) with the delta variant was (48.7%: 95% confidence interval [CI], 45.5 to 51.7): the results were similar for both vaccines.  With the BNT162b2 vaccine, the effectiveness of two doses was 93.7% (95% CI, 91.6 to 95.3) among those with the alpha variant.  With the ChAdOx1 nCoV-19 vaccine, the effectiveness of two doses was 74.5% (95% CI, 68.4 to 79.4) among those with the alpha variant.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	antibody epitope effects	n/a	n/a	Shen	2021	doi:10.1101/2021.01.27.428516	pmid:33532764	https://doi.org/10.1101/2021.01.27.428516	False	Shen et al. (2021)	n/a	Reduction in neutralization by mAbs COVA2-15 (~9x), B38 (~14x), S309 (~190x) by this B.1.1.7 pseudotyped virus model.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	vaccine neutralization efficacy	n/a	n/a	Munitz	2021	doi:10.1016/j.xcrm.2021.100264	pmid:33899031	https://doi.org/10.1016/j.xcrm.2021.100264	True	Munitz et al. (2021)	n/a	We observed a sharp decline in cases when ∼50% of the elderly population was 2 weeks beyond their first  vaccination dose and at a time point during which the B.1.1.7 variant gained transmission dominance.  In support of this finding, it was suggested that, after the first vaccination dose, more than 70% of  patients develop neutralization antibodies,15 and the vaccine efficiency can reach 85%.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	convalescent plasma escape	n/a	n/a	Hu	2021	doi:10.1101/2021.01.22.427749	n/a	https://doi.org/10.1101/2021.01.22.427749	False	Hu et al. (2021)	n/a	Neutralizing antibody titers of 2/20 (10%) samples showed >10x reduction (sera collected ~1mo post Jan 2020 first wave in China). Neutralizing antibody titers of 8/20 samples (40%) decreased below an ID50 threshold of 40 (sera  collected ~8mo post Jan 2020 first wave in China).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	antibody epitope effects	n/a	n/a	Rees-Spear	2021	doi:10.1101/2021.01.15.426849	n/a	https://doi.org/10.1101/2021.01.15.426849	False	Rees-Spear et al. (2021)	n/a	Lessens the potency of mAbs COVA2-17 (~5x, similar to N501Y alone), COVA1-12 (~11x) and COVA1-21 (>100x), which do not compete allosterically.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	reinfection	n/a	n/a	Graham	2021	doi:10.1016/s2468-2667(21	n/a	https://doi.org/10.1016/s2468-2667(21	n/a	Graham et al. (2021)	n/a	36920 COVID Symptom Study app users reported SARS-CoV-2 test positivity in late 2020. Possible reinfections were  identified in 249 (0.7% [95% CI 0.6-0.8]) of 36509 app users who reported a positive swab test before Oct 1, 2020,  but there was no evidence that the frequency of reinfections was higher for the B.1.1.7 variant than for pre-existing variants.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	vaccine neutralization efficacy	n/a	n/a	Garcia-Beltran	2021	doi:10.1016/j.cell.2021.03.013	pmid:33743213	https://doi.org/10.1016/j.cell.2021.03.013	True	Garcia-Beltran et al. (2021)	n/a	Pseudotyped B.1.1.7 virus has reduced neutralization activity vs wild type: 2.1x (30 sera Pfizer median 9 days post 2nd dose)  and 2.3x (35 sera Moderna median 18 days post 2nd dose). This was NOT significant by ANOVA. Note that Y145del was actually noted in the paper as the effect of their DNA construct, but this is  equivalent at the protein level to the more commonly annotated Y144del.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	vaccine neutralization efficacy	n/a	n/a	Planas	2021	doi:10.1038/s41591-021-01318-5	n/a	https://doi.org/10.1038/s41591-021-01318-5	True	Planas et al. (2021)	n/a	The sera of 16 individuals with time course collection was evaulated against VSV pseudotypes: neutralized D614G at week 2,  whereas B.1.1.7 started to be neutralized at week 3, although less efficiently than D614G. B.1.1.7 and D614G strains were  similarly neutralized at week 4 (1 week after booster dose).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	vaccine neutralization efficacy	n/a	n/a	Supasa	2021	doi:10.1016/j.cell.2021.02.033	pmid:33743891	https://doi.org/10.1016/j.cell.2021.02.033	True	Supasa et al. (2021)	n/a	Neutralization assays of B.1.1.7 virus showed a reduction of 2.5-fold (14 days post 2nd dose AstraZeneca, n	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs 35B5. Alpha (B.1.1.7) has an IC50 fold change of 1.39x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	vaccine efficacy	n/a	n/a	Puranik	2021	doi:10.1101/2021.08.06.21261707	pmid:34401884	https://doi.org/10.1101/2021.08.06.21261707	False	Puranik et al. (2021)	n/a	In Minnesota in early 2021 when Alpha was prevalent, vaccine efficacy was estimated as: mRNA-1273 86% (95%CI: 81-90.6%) and BNT162b2: 76% (95%CI: 69-81%) using age, sex, race, PCR testing and vaccination date matched cohorts of unvaccinated, Pfizer and Moderna vaccinees.  [variant list included is ancestral Alpha, as this was an observational study no variant list was given]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	antibody epitope effects	n/a	n/a	Hu	2021	doi:10.1101/2021.01.22.427749	n/a	https://doi.org/10.1101/2021.01.22.427749	False	Hu et al. (2021)	n/a	~20x resistence to mAb CQ038 by B.1.1.7 pseudotyped virus	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	reinfection	n/a	n/a	Marquez	2021	doi:10.1017/ice.2021.195	pmid:33934744	https://doi.org/10.1017/ice.2021.195	True	Marquez et al. (2021)	n/a	Reinfection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) B.1.1.7 variant in an immunocompromised 16yo female with end stage renal disease 94 days after initial infection with a B.1.2 lineage virus. Both lineages were the prevalent one at the time of 1st and 2nd infections respectively in Texas, where the patient was located (suggesting exposure risk rather than lineage immune evasion).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	vaccine neutralization efficacy	n/a	n/a	Uhal B	2022	doi:10.1101/2022.06.23.497326	n/a	https://doi.org/10.1101/2022.06.23.497326	False	Uhal B et al. (2022)	n/a	Paradigm’s ACE-2 variant LVE/STR chimera neutralizes Alpha Variant B.1.1.7 RBD significantly better than GenScript IgG FL18-740 w.t. ACE-2 mAB. Determined using Surrogate Viral Neutralization Tests.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs Bi-Nab47D10-35B5. Alpha (B.1.1.7) has an IC50 fold change of 1.44x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	vaccine neutralization efficacy	n/a	n/a	Hall	2021	doi:10.1016/S0140-6736(21	n/a	https://doi.org/10.1016/S0140-6736(21	n/a	Hall et al. (2021)	n/a	A single dose of BNT162b2 (Pfizer) vaccine showed vaccine effectiveness of 70% (95% CI 55-85) 21 days after first dose  and 85% (74-96) 7 days after two doses in the study population. Our findings show that the BNT162b2 vaccine can prevent both symptomatic and asymptomatic infection in working-age adults. This cohort (8203 treatment, 15121 control) was vaccinated when the  dominant variant in circulation was B.1.1.7 and shows effectiveness against this variant.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	convalescent plasma escape	n/a	n/a	Graham	2021	doi:10.1016/j.immuni.2021.03.023	pmid:33836142	https://doi.org/10.1016/j.immuni.2021.03.023	True	Graham et al. (2021)	n/a	NTD-specific nAbs showed a substantial (3-450x) decrease in neutralization potency against the recently reported highly  transmissible B.1.1.7 variant of concern, whereas RBD-specific nAbs were either unaffected or showed lower decreases in potency.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	tissue specific neutralization	n/a	n/a	Planas	2021	doi:10.1038/s41591-021-01318-5	n/a	https://doi.org/10.1038/s41591-021-01318-5	True	Planas et al. (2021)	n/a	The nasal mucosa of Pfizer vaccinees with time course collection was evaluated against VSV pseudotypes: results (only one nasal  swab from different previously infected vacinee neutralizing at weeks 3 and 6 against B.1.1.7 and D614G) suggest that vaccinees probably  do not elicit an early humoral response detectable at mucosal surfaces even though sera neutralization was observed. They strengthen the hypothesis that some vaccines may not protect against  viral acquisition and infection of the oral–nasal region, but may prevent severe disease associated with viral dissemination in the lower respiratory tract.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	pharmaceutical effectiveness	n/a	n/a	Rosenke	2022	doi:10.1172/jci.insight.160108	pmid:35579953	https://doi.org/10.1172/jci.insight.160108	True	Rosenke et al. (2022)	n/a	Infectious viral titers in lung tissue determined using a tissue culture infectious dose (TCID) assay in 10 hamsters showed that Alpha Molnupiravir (MK-4482) had ~2.75x fold drop.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	vaccine neutralization efficacy	n/a	n/a	Choi	2021	doi:10.1101/2021.06.28.449914	n/a	https://doi.org/10.1101/2021.06.28.449914	False	Choi et al. (2021)	n/a	Neutralization efficiency (ID50) against B.1.1.7 reduced 1.2x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	reinfection	n/a	n/a	Harrington	2021	doi:10.1093/cid/ciab014	pmid:33421056	https://doi.org/10.1093/cid/ciab014	True	Harrington et al. (2021)	n/a	Second infection in December 2020 with B.1.1.7 after April 2020 initial infection with B.2 in a 78-year-old man with a history of Type 2 diabetes mellitus,  diabetic nephropathy on hemodialysis, chronic obstructive pulmonary disease (COPD), mixed central  and obstructive sleep apnea, ischemic heart disease, with no history of immunosuppression.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	trafficking	n/a	n/a	Hu	2021	doi:10.1101/2021.01.22.427749	n/a	https://doi.org/10.1101/2021.01.22.427749	False	Hu et al. (2021)	n/a	The entry efficiencies of Spike pseudotyped viruses bearing N501Y Variant 1 (B.1.1.7) mutant were about 3 to 4.4 times higher than that of the WT pseudovirus when viral input was normalized, suggesting that these spike variants promote the infectivity of SARS-CoV-2.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	trafficking	n/a	n/a	Esclera	2021	doi:10.1101/2021.08.05.455290	n/a	https://doi.org/10.1101/2021.08.05.455290	False	Esclera et al. (2021)	n/a	~2.5x cleavage of S2 relative to WA1 (D614G) wildtype by Alpha variant variant as measured by mass spectrometry of Vero-TMPRSS culture.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	vaccine neutralization efficacy	n/a	n/a	Emary	2021	doi:10.2139/ssrn.3779160	n/a	https://doi.org/10.2139/ssrn.3779160	False	Emary et al. (2021)	n/a	Virus neutralisation activity (using a live SARS-CoV-2 microneutralisation assay (ND50)) by vaccine induced antibodies was 9-fold lower  against the B.1.1.7 variant than against a canonical non B.1.1.7 lineage. Vaccine efficacy against symptomatic NAAT positive infection  was similar for B.1.1.7 and non-B.1.1.7 lineages (74.6% [95%CI 41.6-88.9] and 84% [95% CI 70.7-91.4] respectively). Furthermore, vaccination with ChAdOx1 nCoV-19 results in a reduction in the duration of shedding and viral load, which may translate into a material impact on transmission of disease.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	antibody epitope effects	n/a	n/a	Kumar	2022	doi:10.1101/2022.05.13.491770	n/a	https://doi.org/10.1101/2022.05.13.491770	False	Kumar et al. (2022)	n/a	BnAb 002-S21F2 IC50 on the Alpha (B.1.1.7) variant is 1.0x fold the wildtype in 42 COVI.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	vaccine neutralization efficacy	n/a	n/a	Gallagher	2021	doi:10.1101/2021.05.03.442455	pmid:33972942	https://doi.org/10.1101/2021.05.03.442455	False	Gallagher et al. (2021)	n/a	ELISpot assays show T cell neutralization reduced by 15.4% in this B.1.1.7 pseudotype relative to wild type in 18-20 pooled patient samples post second mRNA vaccine dose, with no significant difference between Pfizer and Moderna cohorts. Reduction was stronger in the S1 subunit than S2 (separate peptide pools were used).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	vaccine neutralization efficacy	n/a	n/a	Edara	2021	doi:10.1101/2021.02.02.21250799	pmid:33564782	https://doi.org/10.1101/2021.02.02.21250799	False	Edara et al. (2021)	n/a	2.1x drop in neutralization using sera collected from 14 healthy adult participants that received two injections of the mRNA-1273 (Moderna) vaccine  at a dose of 100 µg (18-55 years: day 1 (n	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	vaccine neutralization efficacy	n/a	n/a	Ikegame	2021	doi:10.21203/rs.3.rs-400230/v1	pmid:33851150	https://doi.org/10.21203/rs.3.rs-400230/v1	False	Ikegame et al. (2021)	n/a	B.1.1.7 pseudotyped VSV was tested for neutralization in a clonal HEK-293T ACE2 TMPRSS2 cell line optimized for highly efficient  S-mediated infection. A cohort of 12 Argentinian recipients of the Gamaleya Sputnik V Ad26 / Ad5 vaccine showed no statistically sognificant change in neutralization effiacacy.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	vaccine neutralization efficacy	n/a	n/a	Heath	2021	doi:10.1101/2021.05.13.21256639	n/a	https://doi.org/10.1101/2021.05.13.21256639	False	Heath et al. (2021)	n/a	NVX-CoV2373 [Novavax] vaccine in phase 3 trial was 89.7% (95% CI, 80.2-94.6) effective in preventing COVID-19, with no hospitalizations or  deaths reported. There were five cases of severe Covid-19, all in the placebo group. Post hoc analysis revealed efficacies of  96.4% (73.8-99.5) and 86.3% (71.3-93.5) against the prototype strain and B.1.1.7 variant, respectively.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	vaccine neutralization efficacy	n/a	n/a	Shen	2021	doi:10.1101/2021.01.27.428516	pmid:33532764	https://doi.org/10.1101/2021.01.27.428516	False	Shen et al. (2021)	n/a	Pseudotyped B.1.1.7 Spike variants lentivirus. 3.5x reduction in neutralization with Moderna vaccinated patient sera after 29 days (1st dose). 2.0x reduction in neutralization with Moderna vaccinated patient sera after 57 days (2nd dose). 2.1x reduction in neutralization with Novavax Phase 1 post-vaccination sera.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	clinical indicators	n/a	n/a	Song	2021	doi:10.1101/2021.05.04.21256655	n/a	https://doi.org/10.1101/2021.05.04.21256655	False	Song et al. (2021)	n/a	After adjusting for the age factor, in a prospective Chinese cohort study B.1.1.7 variant infection (compared to B.1.140) was the risk factor for  C-reactive protein (P 	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	vaccine efficacy	n/a	n/a	Nasreen	2021	doi:10.1101/2021.06.28.21259420	n/a	https://doi.org/10.1101/2021.06.28.21259420	False	Nasreen et al. (2021)	n/a	Using a test-negative design using Ontario data between Dec 14, 2020 and May 30, 2021, 421,073 symptomatic community-dwelling individuals were tested. Against symptomatic infection caused by Alpha, vaccine effectiveness with partial vaccination (≥14 days after dose 1) was higher for mRNA-1273 (83%) than BNT162b2 (66%) and ChAdOx1 (64%), and full vaccination (≥7 days after dose 2) increased vaccine effectiveness for BNT162b2 (89%) and mRNA-1273 (92%).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	trafficking	n/a	n/a	Touret	2021	doi:10.1101/2021.03.22.436427	n/a	https://doi.org/10.1101/2021.03.22.436427	False	Touret et al. (2021)	n/a	Live virus was tested ex vivo in reconstituted brochial epithelium, and out competed wild type.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	vaccine neutralization efficacy	n/a	n/a	Uriu	2021	doi:10.1101/2021.09.06.459005	n/a	https://doi.org/10.1101/2021.09.06.459005	False	Uriu et al. (2021)	n/a	Mean 1.7x reduction of NT50 value B.1.1.7 (Alpha) relative to wild type in 8 sera from adult BNT162b2 vaccinees (28-47yo) collected ~1m post booster.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	ACE2 receptor binding affinity	n/a	n/a	Planas	2021	doi:10.1038/s41591-021-01318-5	n/a	https://doi.org/10.1038/s41591-021-01318-5	True	Planas et al. (2021)	n/a	Flow cytometry was used on recombinant VSV proteins and yeast surface display to assess the binding of a labeled soluble ACE2  protein to cells expressing B.1.1.7. We observed a dramatic increase (relative to D614G) in binding of soluble  ACE2 to B.1.1.7, and to a lesser extent to B.1.351, which both carry the N501Y mutation (see Fig 3).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	ACE2 receptor binding affinity	n/a	n/a	Uhal B	2022	doi:10.1101/2022.06.23.497326	n/a	https://doi.org/10.1101/2022.06.23.497326	False	Uhal B et al. (2022)	n/a	L27, V34 and E90 mutation resulted in ultrahigh affinity binding of the LVE-ACE-2 domain to the widest variety of VOCs, with KDs of 93 pM for binding to the Alpha  B1.1.7. Values were obtained with LVE-ACE-2/mAB chimeras containing the Y-T-E sequence that enhances binding to the FcRn receptor, which in turn is expected to  extend biological half-life 3-4-fold.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	vaccine neutralization efficacy	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	1.5x reduction in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees)	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	vaccine neutralization efficacy	n/a	n/a	UNKNOWN	n/a	n/a	n/a	,	n/a	UNKNOWN et al. ()	n/a	n/a	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	vaccine neutralization efficacy	n/a	n/a	UNKNOWN	n/a	n/a	n/a	,	n/a	UNKNOWN et al. ()	n/a	In Qatar, where Pfizer vaccine use is prevalent (<10% of the population covered in the time period of the study ending Mar 31, 2021), any time after one dose  (including the 2 weeks where no major effect is expected) B.1.1.7 lineage effectiveness was observed as 29.5% (95% CI [22.9,35.5]) against infection, and 54.1% against severe/critical/fatal disease  (95% CI [26.1-71.9]). Two weeks or more after 2nd dose, effectiveness climbed to 89.5% [85.9,92.3] against infection, and 100% against  severe/critical/fatal disease (95% CI [81.7,100]).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	pharmaceutical effectiveness	n/a	n/a	Dejnirattisai	2021	doi:10.1016/j.cell.2021.03.055	pmid:33852911	https://doi.org/10.1016/j.cell.2021.03.055	True	Dejnirattisai et al. (2021)	n/a	Lilly's LY-CoV16 showed marked reduction in neutralization of B.1.1.7.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	convalescent plasma escape	n/a	n/a	Skelly	2021	doi:10.21203/rs.3.rs-226857/v1	n/a	https://doi.org/10.21203/rs.3.rs-226857/v1	False	Skelly et al. (2021)	n/a	Sera neutralized the B1.1.7 isolate with a lower potency (2-fold: 95% CL: 1.5 – 3-fold), and those with the lowest homotypic neutralizing potency had undetectable heterotypic potency (2/25).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	tissue specific replication effects	n/a	n/a	Mok	2021	doi:10.1101/2021.04.19.440414	n/a	https://doi.org/10.1101/2021.04.19.440414	False	Mok et al. (2021)	n/a	In this report, by using a lower infectious dose, we demonstrate that B.1.1.7  (cultured sample Hong Kong/HKPU-00015/2021) exhibits higher infectivity and/or  replication efficiency in the nasal epithelium. (Hamster model of infection)	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	convalescent plasma escape	n/a	n/a	Collier	2021	doi:10.1038/s41586-021-03412-7	n/a	https://doi.org/10.1038/s41586-021-03412-7	True	Collier et al. (2021)	n/a	Neutralization capacity GMT of 27 subjects' sera post-infection was considerably higher (stronger) than after the second  Pfizer dose, and 4.5x drop in B.1.1.7 neutralization was observed.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	vaccine neutralization efficacy	n/a	n/a	Collier	2021	doi:10.1038/s41586-021-03412-7	n/a	https://doi.org/10.1038/s41586-021-03412-7	True	Collier et al. (2021)	n/a	20/29 sera after the first dose of Pfizer showed an average reduction in neutralization titres against the B.1.1.7 variant of 3.2 ± 5.7. After the second dose, the GMT was markedly increased compared with the first-dose titres, with a fold change of 1.9 ± 0.9 (mean ± s.d.). Neutralization GMT of 27 subjects post-infection was considerably higher (stronger) than after the second Pfizer dose, and 4.5x drop in B.1.1.7 neutralization was observed.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	transmissibility	n/a	n/a	Davies	2021	doi:10.1126/science.abg3055	pmid:33658326	https://doi.org/10.1126/science.abg3055	True	Davies et al. (2021)	n/a	We estimate that this [B.1.1.17] variant has a 43–90% (range of 95% credible intervals 38–130%) higher reproduction number than preexisting variants. Data from other countries yield similar results: we estimate that R for VOC 202012/01 relative to other lineages is 55% (45–66%) higher in Denmark,  74% (66–82%) higher in Switzerland, and 59% (56–63%) higher in the United States, with consistent rates of displacement across regions within each country.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	vaccine neutralization efficacy	n/a	n/a	Muik	2021	doi:10.1126/science.abg6105	pmid:33514629	https://doi.org/10.1126/science.abg6105	True	Muik et al. (2021)	n/a	Lineage B.1.1.7 spike–pseudotyped VSV was tested for neutralization vs Wuhan reference genome pseudotype in 40 sera collected 7 or 21 days post-booster dose. Statistically significant change (22%) in neutralization was observed among the 26 sera from those <	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	transmissibility	n/a	n/a	Stefanelli	2021	doi:10.1101/2021.04.06.21254923	n/a	https://doi.org/10.1101/2021.04.06.21254923	False	Stefanelli et al. (2021)	n/a	At the national level (Italy), we estimated a mean relative transmissibility of B.1.1.7 (compared to historical lineages) ranging  between 1.55 and 1.57 (with confidence intervals between 1.45 and 1.66).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	outcome hazard ratio	n/a	n/a	Funk	2021	doi:10.2807/1560-7917.ES.2021.26.16.2100348	pmid:33890566	https://doi.org/10.2807/1560-7917.ES.2021.26.16.2100348	True	Funk et al. (2021)	n/a	On average across 7 European countries studied, using B.1.1.7 defining mutations: Significant shift to asymptomatic cases (27.4% vs 18.6% for non-VOC cases).  Significant shift to infection in those without pre-existing conditions (44.8% vs 89% for non-VOC cases). Significant increase in hospitalization rate (11% vs 7.5% for non-VOC cases). Significant increase in ICU rate (1.4% vs 0.6% for non-VOC cases). Significant decrease in death rate (2.0% vs vs 4.0% for non-VOC cases).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	vaccine neutralization efficacy	n/a	n/a	Tada	2021	doi:10.1101/2021.02.05.430003	pmid:33564768	https://doi.org/10.1101/2021.02.05.430003	False	Tada et al. (2021)	n/a	Vaccine elicited antibodies neutralized virus with the B.1.1.7 spike protein with titers similar to D614G virus. Serum specimens  from individuals vaccinated with the BNT162b2 mRNA vaccine neutralized D614G virus with titers that were on average 7-fold greater than convalescent sera.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	transmissibility	n/a	n/a	Lindstrøm	2021	doi:10.1101/2021.03.29.21254122	n/a	https://doi.org/10.1101/2021.03.29.21254122	False	Lindstrøm et al. (2021)	n/a	Oslo, Norway: Within households, we find an increase in the secondary attack rate by 60% (20% 114%) compared to other variants.  In general, we find a significant increase in the estimated reproduction number of 24% (95% CI 0% - 52%), or an absolute  increase of 0.19 compared to other variants.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	transmissibility	n/a	n/a	Munitz	2021	doi:10.1016/j.xcrm.2021.100264	pmid:33899031	https://doi.org/10.1016/j.xcrm.2021.100264	True	Munitz et al. (2021)	n/a	Based on ∼300,000 RT-PCR samples collected from December 6th 2020 to February 10th 2021 in Israel,  the B.1.1.7 is 45% (95% CI:20-60%) more transmissible than the wild-type strain, and become dominant in Israel within 3.5 weeks.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	outcome hazard ratio	n/a	n/a	Nyberg	2021	doi:10.48550/arXiv.2104.05560	n/a	https://doi.org/10.48550/arXiv.2104.05560	False	Nyberg et al. (2021)	n/a	The matching-adjusted conditional odds ratio of hospitalisation was 1.58 (95% confidence interval 1.50 to 1.67) for COVID-19 patients  infected with a SGTF-associated variant [primarily B.1.1.7], compared to those infected with non-SGTF-associated variants.  The effect was modified by age (p<0.001), with ORs of 0.96-1.13 below age 20 years and 1.57-1.67 in age groups 40 years or older.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	outcome hazard ratio	n/a	n/a	Davies	2021	doi:10.1038/s41586-021-03426-1	pmid:33723411	https://doi.org/10.1038/s41586-021-03426-1	True	Davies et al. (2021)	n/a	Using UK data 1 November 2020 to 14 February 2021, while correcting for misclassification of PCR test Spike Gene Target Failure (SGTF) and missingness in SGTF status, we estimate that the hazard of death associated with B.1.1.7 is 61% (42–82%) higher than with  pre-existing variants after adjustment for age, sex, ethnicity, deprivation, residence in a care home, the local authority of residence and test date.  This corresponds to the absolute risk of death for a 55–69-year-old man increasing from  0.6% to 0.9% (95% confidence interval, 0.8–1.0%) within 28 days of a positive test in the community.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	viral load	n/a	n/a	Roquebert	2021	doi:10.1101/2021.03.19.21253971	n/a	https://doi.org/10.1101/2021.03.19.21253971	False	Roquebert et al. (2021)	n/a	B.1.1.7 samples showed average Ct cycle threshold of 21.9 vs 23 for wildtype (i.e. ~2x higher viral load) comparing 37758 and 22535 samples respectively.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	transmissibility	n/a	n/a	Graham	2021	doi:10.1016/s2468-2667(21	n/a	https://doi.org/10.1016/s2468-2667(21	n/a	Graham et al. (2021)	n/a	Based on 36920 COVID Symptom Study app users reported SARS-CoV-2 test positivity in late 2020,  Rt of B.1.1.7 was 1.35x (95% CI 1.02-1.69) relative to pre-existing variants. However, Rt fell below 1 during regional and  national lockdowns, even in regions with high proportions of infections with the B.1.1.7 variant.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	outcome hazard ratio	n/a	n/a	Frampton	2021	doi:10.1016/s1473-3099(21	n/a	https://doi.org/10.1016/s1473-3099(21	n/a	Frampton et al. (2021)	n/a	341 samples collected Nov 9 to Dec 20, 2020 were sequenced from two London (UK) hospitals.  198 (58%) of 341 had B.1.1.7 infection and 143 (42%) had non-B.1.1.7 infection. No evidence was found of an association  between severe disease and death and lineage (B.1.1.7 vs non-B.1.1.7) in unadjusted analyses (prevalence ratio [PR] 0·97  [95% CI 0·72-1·31]), or in analyses adjusted for hospital, sex, age, comorbidities, and ethnicity (adjusted PR 1·02 [0·76-1·38]).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	outcome hazard ratio	n/a	n/a	Graham	2021	doi:10.1016/s2468-2667(21	n/a	https://doi.org/10.1016/s2468-2667(21	n/a	Graham et al. (2021)	n/a	From Sept 28 to Dec 27, 2020, positive COVID-19 tests were reported by 36 920 COVID Symptom Study app users whose region was  known and who reported as healthy on app sign-up. We found no changes in reported symptoms or disease duration associated with B.1.1.7.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	viral load	n/a	n/a	Teyssou	2021	doi:10.1101/2021.03.21.21253498	n/a	https://doi.org/10.1101/2021.03.21.21253498	False	Teyssou et al. (2021)	n/a	The 249 B.1.1.7 (a.k.a. N501Y.V1) variant cases in three Paris hospital labs had a ~10-fold viral load increase  (~3.3 Ct drop in N gene probe) compared to 332 ancestral lineage cases from the same time frame (2020-12-20 to 2021-02-26).  PG: BUT there is a discrepancy in drop between the ORF1ab and N probes, with the former suggesting only a 2-fold drop,  consistent with the drop observed in B.1.351. This might indicate higher subgenomic RNA content in B.1.1.7 skewing the change.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	viral load	n/a	n/a	Couzens	2021	doi:10.1101/2021.04.02.21254832	n/a	https://doi.org/10.1101/2021.04.02.21254832	False	Couzens et al. (2021)	n/a	Using lack of S probe detection as a proxy for B.1.1.7 status, 275 putative B.1.1.7 samples and 390 'wild type' SARS-CoV-2 positive samples in Wales were compared for Ct values, suggesting ~12-fold increase (~3.5 Ct decrease) in viral load for B.1.1.7 samples.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	outcome hazard ratio	n/a	n/a	Challen	2021	doi:10.1136/bmj.n579	pmid:33687922	https://doi.org/10.1136/bmj.n579	True	Challen et al. (2021)	n/a	The mortality hazard ratio associated with infection with [B.1.1.7] compared with infection with previously circulating variants was  1.64 (95% confidence interval 1.32 to 2.04) in patients who tested positive for covid-19 in the community (54906 matched pairs of  participants who tested positive for SARS-CoV-2 in pillar 2 between 1 October 2020 and 29 January 2021). In this comparatively low risk  group, this represents an increase in deaths from 2.5 to 4.1 per 1000 detected cases.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	viral load	n/a	n/a	Ratcliff	2021	doi:10.1101/2021.02.24.21251989	n/a	https://doi.org/10.1101/2021.02.24.21251989	False	Ratcliff et al. (2021)	n/a	In a study of 1260 ICU subjects, viral load distributions (collected within 48h of admission) were elevated in  both seropositive and seronegative subjects infected with B.1.1.7 ('UK variant').  PG: The PANGO tool defining Spike variants for B.1.1.7 are listed here, whereas the paper only used a test for D1118H.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	viral load	n/a	n/a	Nyayanit	2021	doi:10.1101/2021.04.30.442222	n/a	https://doi.org/10.1101/2021.04.30.442222	False	Nyayanit et al. (2021)	n/a	This study reveals that B.1.1.7 SARS-CoV-2 variant is a slower-growing virus than parental B.1. Further, a higher replication along with reduced infectious viral titer was hypothesized to be linked to higher transmission with reduced pathogenicity.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	viral load	n/a	n/a	Lamers	2021	doi:10.1101/2021.05.03.441080	n/a	https://doi.org/10.1101/2021.05.03.441080	False	Lamers et al. (2021)	n/a	We found that the British variant (clade B.1.1.7), compared to an ancestral SARS-CoV-2 clade B virus, produced higher  levels of infectious virus late in infection and had a higher replicative fitness in human airway, alveolar and intestinal organoid models.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	outcome hazard ratio	n/a	n/a	Bager	2021	doi:10.2139/ssrn.3792894	n/a	https://doi.org/10.2139/ssrn.3792894	False	Bager et al. (2021)	n/a	Danish study of the B.1.1.7 lineage shows hospital admission odds ratio of 1.63 vs other lineages. The adjusted OR was increased in all strata of age.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	ACE2 receptor binding affinity	n/a	n/a	Tada	2021	doi:10.1101/2021.02.05.430003	pmid:33564768	https://doi.org/10.1101/2021.02.05.430003	False	Tada et al. (2021)	n/a	This mutation causes major decrease in binding affinity vs. wild type as measured by IC50 vs pseudotyped lentivirus.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	transmissibility	n/a	n/a	Buchan	2021	n/a	n/a	https://www.medrxiv.org/content/10.1101/2021.03.31.21254502v1	n/a	Buchan et al. (2021)	n/a	Ontario, Feb 2021: The secondary attack rate for VOC index cases in this matched cohort was 1.31 times higher than non-VOC index cases (RR	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	viral load	n/a	n/a	Song	2021	doi:10.1101/2021.05.04.21256655	n/a	https://doi.org/10.1101/2021.05.04.21256655	False	Song et al. (2021)	n/a	The median Ct value of RT-qPCR tests of the N-gene target in the Daxing B.1.1.7 group was significantly lower than the Shunyi B.1.470 group (P	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	transmissibility	n/a	n/a	Lyngse	2021	doi:10.1101/2021.04.16.21255459	n/a	https://doi.org/10.1101/2021.04.16.21255459	False	Lyngse et al. (2021)	n/a	Primary cases infected with B.1.1.7 had an increased transmissibility of 1.5-1.7 times that of primary cases infected with other  lineages. The increased transmissibility of B.1.1.7 was multiplicative across age and viral load.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	vaccine neutralization efficacy	n/a	n/a	Hoffman	2021	doi:10.1016/j.cell.2021.03.036	pmid:33794143	https://doi.org/10.1016/j.cell.2021.03.036	True	Hoffman et al. (2021)	n/a	VSV pseudotype B.1.1.7 showed 1.77-fold reduction in neutralization efficiency vs wild type in 15 Pfizer BNT162b2 vaccinee sera 13-15 days post second dose. Cell fusion proficiency was unchanged.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	vaccine neutralization efficacy	n/a	n/a	Leier	2021	doi:10.1101/2021.04.25.21256049	pmid:33948601	https://doi.org/10.1101/2021.04.25.21256049	False	Leier et al. (2021)	n/a	Neutralizing antibody titers increased in previously infected vaccinees relative to uninfected vaccinees  5.2-fold against B.1.1.7 (contrast with 3.4 fold against original SARS-CoV-2).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	outcome hazard ratio	n/a	n/a	UNKNOWN	2021	n/a	n/a	https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/961042/S1095_NERVTAG_update_note_on_B.1.1.7_severity_20210211.pdf	False	UNKNOWN et al. (2021)	n/a	Using primarily S-defining mutations for lineage B.1.1.7, most models of hospitalization and fatality risk ratios from consortium members show elevated ratios (~1.3-1.7x).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	trafficking	n/a	n/a	Hoffman	2021	doi:10.1016/j.cell.2021.03.036	pmid:33794143	https://doi.org/10.1016/j.cell.2021.03.036	True	Hoffman et al. (2021)	n/a	VSV pseudotype B.1.1.7 showed no significant difference in cell entry relative to wild type in 6 cell lines. Cell fusion proficiency was unchanged.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	ACE2 receptor binding affinity	n/a	n/a	Collier	2021	doi:10.1038/s41586-021-03412-7	n/a	https://doi.org/10.1038/s41586-021-03412-7	True	Collier et al. (2021)	n/a	Six fold increase in affinity for ACE2 by the B.1.1.7 lineage vs wild type is driven by a drop in observed dissociation rate constant.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	environmental condition stability	n/a	n/a	Tada	2021	doi:10.1101/2021.02.05.430003	pmid:33564768	https://doi.org/10.1101/2021.02.05.430003	False	Tada et al. (2021)	n/a	Relative to D614G, this mutation demonstrated significant increase in infectivity (i.e. heat stability) after incubation at 50C after 1 hour.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	trafficking	n/a	n/a	Tada	2021	doi:10.1101/2021.02.05.430003	pmid:33564768	https://doi.org/10.1101/2021.02.05.430003	False	Tada et al. (2021)	n/a	Lentiviral pseudotyped with this mutation set from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing significant (40%) increase in infection rate amongst the cells, much more than the effect of  either the deletion or the point mutation alone, suggetsing that this combination has a synergistic effect  contributing to cell entry fitness, but to a smaller extent than N501Y and the deletion alone.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	convalescent plasma binding	n/a	n/a	Tada	2021	doi:10.1101/2021.02.05.430003	pmid:33564768	https://doi.org/10.1101/2021.02.05.430003	False	Tada et al. (2021)	n/a	These key B.1.1.7 mutations as a combination neutralized slightly less well than D614G and this was noticeable in the lack of sera with high neutralizing titer for the viruses  across 10 convalescent sera from April 2020 infectees.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	convalescent plasma binding	n/a	n/a	Alenquer	2021	doi:10.1101/2021.04.22.441007	n/a	https://doi.org/10.1101/2021.04.22.441007	False	Alenquer et al. (2021)	n/a	Slight neutralization improvement on average in 16 health workers' convalescent sera.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.4/5 (from ) were 17.2x-fold lower (95% CI: 0.6x-0.7x) than against 208-428 972-1834 4.3-4.7 US-WA1/2020 usiong an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.4/5 (from ) were 13.0-fold lower (95% CI: 4.2x-4.6x) than against 208-428 972-1834 4.3-4.7 US-WA1/2020 usiong an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	immunosuppression variant emergence	n/a	n/a	Bazykin	2021	n/a	n/a	https://virological.org/t/emergence-of-y453f-and-69-70hv-mutations-in-a-lymphoma-patient-with-long-term-covid-19/580	False	Bazykin et al. (2021)	n/a	The so-called 'delta F' variant combination previously observed in mink spillover events also emerged in a lymphoma  patient (non-Hodgkin diffuse B-cell lymphoma IV stage B) with a long-term COVID-19 infection (4 months) where 18 de novo mutation occureed overall. Patient was taking rituximab, the B-cell-depleting agent, and had no detectable neutralizing antibody response.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	vaccinee plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	1.14x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	ACE2 receptor binding affinity	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.51x increase in binding (KD) relative to D614G, mostly due to decreased in 'off-rate' a.k.a. dissociation rate (Kdis).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	convalescent plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	1.33x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	ACE2 receptor binding affinity	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing B.1.1.7 aka Alpha) had 5.43x increased binding relative to D614G alone.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	convalescent plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	This variant combination (representing B.1.1.7 aka Alpha) showed a 1.15x increase in Spike binding  (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21764	V70del	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATACATG	A	g.204_209delACATGT	p.H69_V70del	NC_045512.2(GU280_gp02):g.204_209del	YP_009724390.1:p.His69_Val70del	n/a	n/a	S	n/a	KP.2.3.5	n/a	H69_V70del	H69del	1.0	vaccinee plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	This variant combination (representing B.1.1.7 aka Alpha) showed no change in Spike binding  (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.28x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of  Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
21941	V127F	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G379T	p.V127F	NC_045512.2(GU280_gp02):g.379G>T	YP_009724390.1:p.Val127Phe	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	Pokay	n/a	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	n/a	n/a	n/a	n/a	n/a	n/a
21987	G142_Y144delinsDV	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	GTGTTTA	ATGT	g.GTGTTTA425_431ATGT	p.G142_Y144delinsDV	n/a	YP_009724390.1:p.Gly142_Tyr144delinsAspVal	n/a	n/a	S	n/a	KP.2.3.5	n/a	n/a	n/a	1.0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	Pokay	n/a	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	n/a	n/a	n/a	n/a	n/a	n/a
22000	H146Q	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	A	g.C438A	p.H146Q	NC_045512.2(GU280_gp02):g.438C>A	YP_009724390.1:p.His146Gln	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	Pokay	n/a	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	n/a	n/a	n/a	n/a	n/a	n/a
22032	FR157SG	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	TCA	CAG	g.TCA470_472CAG	p.FR157SG	n/a	YP_009724390.1:p.PheArg157SerGly	n/a	n/a	S	n/a	KP.2.3.5	n/a	n/a	n/a	1.0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	Pokay	n/a	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	n/a	n/a	n/a	n/a	n/a	n/a
22194	N211_V213delinsIG	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	ATTTAGT	TAGG	g.ATTTAGT632_638TAGG	p.N211_V213delinsIG	n/a	YP_009724390.1:p.Asn211_Val213delinsIleGly	n/a	n/a	S	n/a	KP.2.3.5	n/a	n/a	n/a	1.0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	Pokay	n/a	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	n/a	n/a	n/a	n/a	n/a	n/a
22208	L216F	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C646T	p.L216F	NC_045512.2(GU280_gp02):g.646C>T	YP_009724390.1:p.Leu216Phe	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	Pokay	n/a	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	n/a	n/a	n/a	n/a	n/a	n/a
22295	H245N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	A	g.C733A	p.H245N	NC_045512.2(GU280_gp02):g.733C>A	YP_009724390.1:p.His245Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	Pokay	n/a	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	n/a	n/a	n/a	n/a	n/a	n/a
22353	A264D	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	A	g.C791A	p.A264D	NC_045512.2(GU280_gp02):g.791C>A	YP_009724390.1:p.Ala264Asp	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	Pokay	n/a	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	n/a	n/a	n/a	n/a	n/a	n/a
22556	I332V	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A994G	p.I332V	NC_045512.2(GU280_gp02):g.994A>G	YP_009724390.1:p.Ile332Val	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	Pokay	n/a	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	n/a	n/a	n/a	n/a	n/a	n/a
22577	G339H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	GG	CA	g.GG1015_1016CA	p.G339H	n/a	YP_009724390.1:p.Gly339His	n/a	n/a	S	n/a	KP.2.3.5	n/a	n/a	n/a	1.0	gene expression increase	n/a	n/a	Starr	2020	doi:10.1016/j.cell.2020.08.012	pmid:32841599	https://doi.org/10.1016/j.cell.2020.08.012	True	Starr et al. (2020)	n/a	Experimentally, Spike gene expression increased 0.15 fold	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22577	G339H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	GG	CA	g.GG1015_1016CA	p.G339H	n/a	YP_009724390.1:p.Gly339His	n/a	n/a	S	n/a	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Yue	2023	doi:10.1101/2023.01.03.522427	n/a	https://doi.org/10.1101/2023.01.03.522427	False	Yue et al. (2023)	n/a	The hACE2-binding affinity of XBB.1.5 RBD has a dissociation constant KD of 3.4 nM, where S486P is the distinguishing Spike mutation vs parent  XBB.1 RBD with a much weaker KD (19 nM), as measured by surface plasmon resonance (SPR) assays.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22599	R346T	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	C	g.G1037C	p.R346T	NC_045512.2(GU280_gp02):g.1037G>C	YP_009724390.1:p.Arg346Thr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Yue	2023	doi:10.1101/2023.01.03.522427	n/a	https://doi.org/10.1101/2023.01.03.522427	False	Yue et al. (2023)	n/a	The hACE2-binding affinity of XBB.1.5 RBD has a dissociation constant KD of 3.4 nM, where S486P is the distinguishing Spike mutation vs parent  XBB.1 RBD with a much weaker KD (19 nM), as measured by surface plasmon resonance (SPR) assays.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22599	R346T	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	C	g.G1037C	p.R346T	NC_045512.2(GU280_gp02):g.1037G>C	YP_009724390.1:p.Arg346Thr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	gene expression increase	n/a	n/a	Starr	2020	doi:10.1016/j.cell.2020.08.012	pmid:32841599	https://doi.org/10.1016/j.cell.2020.08.012	True	Starr et al. (2020)	n/a	Experimentally, Spike gene expression increased 0.15 fold	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22599	R346T	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	C	g.G1037C	p.R346T	NC_045512.2(GU280_gp02):g.1037G>C	YP_009724390.1:p.Arg346Thr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Starr	2020	doi:10.1016/j.cell.2020.08.012	pmid:32841599	https://doi.org/10.1016/j.cell.2020.08.012	True	Starr et al. (2020)	n/a	Experimentally, ACE2 binding affinity increased 0.06 fold	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22629	K356T	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	C	g.A1067C	p.K356T	NC_045512.2(GU280_gp02):g.1067A>C	YP_009724390.1:p.Lys356Thr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	gene expression increase	n/a	n/a	Starr	2020	doi:10.1016/j.cell.2020.08.012	pmid:32841599	https://doi.org/10.1016/j.cell.2020.08.012	True	Starr et al. (2020)	n/a	Experimentally, Spike gene expression increased 0.14 fold	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22674	S371F	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1112T	p.S371F	NC_045512.2(GU280_gp02):g.1112C>T	YP_009724390.1:p.Ser371Phe	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron BA.2 have higher sensitivity to inhibition by soluble angiotensin converting enzyme 2 (ACE2) and the endosomal inhibitor chloroquine compared  to D614G	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22674	S371F	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1112T	p.S371F	NC_045512.2(GU280_gp02):g.1112C>T	YP_009724390.1:p.Ser371Phe	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs Bi-Nab35B5-47D10. Omicron BA.2 has an IC50 fold change of 0.07x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22674	S371F	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1112T	p.S371F	NC_045512.2(GU280_gp02):g.1112C>T	YP_009724390.1:p.Ser371Phe	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs 35B5. Omicron BA.2 has an IC50 fold change of 0.09x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22674	S371F	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1112T	p.S371F	NC_045512.2(GU280_gp02):g.1112C>T	YP_009724390.1:p.Ser371Phe	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs 47D10. Omicron BA.2 has an IC50 fold change of 0.08x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22674	S371F	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1112T	p.S371F	NC_045512.2(GU280_gp02):g.1112C>T	YP_009724390.1:p.Ser371Phe	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs Bi-Nab47D10-35B5. Omicron BA.2 has an IC50 fold change of 0.04x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22674	S371F	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1112T	p.S371F	NC_045512.2(GU280_gp02):g.1112C>T	YP_009724390.1:p.Ser371Phe	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron BA.2 neutralization of the Omicron variants by antibodies induced by three doses of Pfizer/BNT162b2 mRNA vaccine was 7-8-fold less potent than the D614G, and  the Omicron variants still evade neutralization more efficiently.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22674	S371F	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1112T	p.S371F	NC_045512.2(GU280_gp02):g.1112C>T	YP_009724390.1:p.Ser371Phe	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Kumar	2022	doi:10.1101/2022.05.13.491770	n/a	https://doi.org/10.1101/2022.05.13.491770	False	Kumar et al. (2022)	n/a	BnAb 002-S21F2 IC50 on the Omicron BA.2 variant is 0.8x fold the wildtype.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22674	S371F	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1112T	p.S371F	NC_045512.2(GU280_gp02):g.1112C>T	YP_009724390.1:p.Ser371Phe	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.2 (from South Africa/CERI-KRISP-K032307/2021) were 3.9x-fold lower (95% CI: 0.14x-0.17x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22674	S371F	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1112T	p.S371F	NC_045512.2(GU280_gp02):g.1112C>T	YP_009724390.1:p.Ser371Phe	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Uhal B	2022	doi:10.1101/2022.06.23.497326	n/a	https://doi.org/10.1101/2022.06.23.497326	False	Uhal B et al. (2022)	n/a	L27, V34 and E90 mutation resulted in ultrahigh affinity binding of the LVE-ACE-2 domain to the widest variety of VOCs, with KDs of 78fM for binding to the Omicron  BA.2. Values were obtained with LVE-ACE-2/mAB chimeras containing the Y-T-E sequence that enhances binding to the FcRn receptor, which in turn is expected to  extend biological half-life 3-4-fold.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22674	S371F	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1112T	p.S371F	NC_045512.2(GU280_gp02):g.1112C>T	YP_009724390.1:p.Ser371Phe	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.2 (from South Africa/CERI-KRISP-K032307/2021) were 4.5-fold lower (95% CI: 4.3x-4.7x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22674	S371F	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1112T	p.S371F	NC_045512.2(GU280_gp02):g.1112C>T	YP_009724390.1:p.Ser371Phe	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.2.12.1 (from USA/NY-CDC-ASC210722700/2022) were 4.2-fold lower (95% CI: 5.8x-6.6x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22674	S371F	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1112T	p.S371F	NC_045512.2(GU280_gp02):g.1112C>T	YP_009724390.1:p.Ser371Phe	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.2.12.1 (from USA/NY-CDC-ASC210722700/2022) were 3.9x-fold lower (95% CI: 0.14x-0.18x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22674	S371F	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1112T	p.S371F	NC_045512.2(GU280_gp02):g.1112C>T	YP_009724390.1:p.Ser371Phe	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron BA.3 have higher sensitivity to inhibition by soluble angiotensin converting enzyme 2 (ACE2) and the endosomal inhibitor chloroquine compared  to D614G	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22674	S371F	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1112T	p.S371F	NC_045512.2(GU280_gp02):g.1112C>T	YP_009724390.1:p.Ser371Phe	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron BA.3 neutralization of the Omicron variants by antibodies induced by three doses of Pfizer/BNT162b2 mRNA vaccine was 7-8-fold less potent than the D614G, and  the Omicron variants still evade neutralization more efficiently.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22674	S371F	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1112T	p.S371F	NC_045512.2(GU280_gp02):g.1112C>T	YP_009724390.1:p.Ser371Phe	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.3 (from South Africa/NICD-N22404/2021) were 4.2x-fold lower (95% CI: 0.15x-0.20x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22674	S371F	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1112T	p.S371F	NC_045512.2(GU280_gp02):g.1112C>T	YP_009724390.1:p.Ser371Phe	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.3 (from South Africa/NICD-N22404/2021) were 6.2-fold lower (95% CI: 11.8x-14.3x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22674	S371F	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1112T	p.S371F	NC_045512.2(GU280_gp02):g.1112C>T	YP_009724390.1:p.Ser371Phe	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.4/5 (from ) were 17.2x-fold lower (95% CI: 0.6x-0.7x) than against 208-428 972-1834 4.3-4.7 US-WA1/2020 usiong an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22674	S371F	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1112T	p.S371F	NC_045512.2(GU280_gp02):g.1112C>T	YP_009724390.1:p.Ser371Phe	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.4/5 (from ) were 13.0-fold lower (95% CI: 4.2x-4.6x) than against 208-428 972-1834 4.3-4.7 US-WA1/2020 usiong an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22674	S371F	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1112T	p.S371F	NC_045512.2(GU280_gp02):g.1112C>T	YP_009724390.1:p.Ser371Phe	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Yue	2023	doi:10.1101/2023.01.03.522427	n/a	https://doi.org/10.1101/2023.01.03.522427	False	Yue et al. (2023)	n/a	The hACE2-binding affinity of XBB.1.5 RBD has a dissociation constant KD of 3.4 nM, where S486P is the distinguishing Spike mutation vs parent  XBB.1 RBD with a much weaker KD (19 nM), as measured by surface plasmon resonance (SPR) assays.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22679	S373P	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	C	g.T1117C	p.S373P	NC_045512.2(GU280_gp02):g.1117T>C	YP_009724390.1:p.Ser373Pro	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron BA.2 have higher sensitivity to inhibition by soluble angiotensin converting enzyme 2 (ACE2) and the endosomal inhibitor chloroquine compared  to D614G	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22679	S373P	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	C	g.T1117C	p.S373P	NC_045512.2(GU280_gp02):g.1117T>C	YP_009724390.1:p.Ser373Pro	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs Bi-Nab35B5-47D10. Omicron BA.2 has an IC50 fold change of 0.07x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22679	S373P	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	C	g.T1117C	p.S373P	NC_045512.2(GU280_gp02):g.1117T>C	YP_009724390.1:p.Ser373Pro	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs 35B5. Omicron BA.2 has an IC50 fold change of 0.09x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22679	S373P	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	C	g.T1117C	p.S373P	NC_045512.2(GU280_gp02):g.1117T>C	YP_009724390.1:p.Ser373Pro	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs 47D10. Omicron BA.2 has an IC50 fold change of 0.08x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22679	S373P	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	C	g.T1117C	p.S373P	NC_045512.2(GU280_gp02):g.1117T>C	YP_009724390.1:p.Ser373Pro	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs Bi-Nab47D10-35B5. Omicron BA.2 has an IC50 fold change of 0.04x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22679	S373P	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	C	g.T1117C	p.S373P	NC_045512.2(GU280_gp02):g.1117T>C	YP_009724390.1:p.Ser373Pro	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron BA.2 neutralization of the Omicron variants by antibodies induced by three doses of Pfizer/BNT162b2 mRNA vaccine was 7-8-fold less potent than the D614G, and  the Omicron variants still evade neutralization more efficiently.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22679	S373P	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	C	g.T1117C	p.S373P	NC_045512.2(GU280_gp02):g.1117T>C	YP_009724390.1:p.Ser373Pro	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Kumar	2022	doi:10.1101/2022.05.13.491770	n/a	https://doi.org/10.1101/2022.05.13.491770	False	Kumar et al. (2022)	n/a	BnAb 002-S21F2 IC50 on the Omicron BA.2 variant is 0.8x fold the wildtype.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22679	S373P	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	C	g.T1117C	p.S373P	NC_045512.2(GU280_gp02):g.1117T>C	YP_009724390.1:p.Ser373Pro	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.2 (from South Africa/CERI-KRISP-K032307/2021) were 3.9x-fold lower (95% CI: 0.14x-0.17x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22679	S373P	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	C	g.T1117C	p.S373P	NC_045512.2(GU280_gp02):g.1117T>C	YP_009724390.1:p.Ser373Pro	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Uhal B	2022	doi:10.1101/2022.06.23.497326	n/a	https://doi.org/10.1101/2022.06.23.497326	False	Uhal B et al. (2022)	n/a	L27, V34 and E90 mutation resulted in ultrahigh affinity binding of the LVE-ACE-2 domain to the widest variety of VOCs, with KDs of 78fM for binding to the Omicron  BA.2. Values were obtained with LVE-ACE-2/mAB chimeras containing the Y-T-E sequence that enhances binding to the FcRn receptor, which in turn is expected to  extend biological half-life 3-4-fold.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22679	S373P	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	C	g.T1117C	p.S373P	NC_045512.2(GU280_gp02):g.1117T>C	YP_009724390.1:p.Ser373Pro	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.2 (from South Africa/CERI-KRISP-K032307/2021) were 4.5-fold lower (95% CI: 4.3x-4.7x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22679	S373P	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	C	g.T1117C	p.S373P	NC_045512.2(GU280_gp02):g.1117T>C	YP_009724390.1:p.Ser373Pro	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.2.12.1 (from USA/NY-CDC-ASC210722700/2022) were 4.2-fold lower (95% CI: 5.8x-6.6x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22679	S373P	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	C	g.T1117C	p.S373P	NC_045512.2(GU280_gp02):g.1117T>C	YP_009724390.1:p.Ser373Pro	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.2.12.1 (from USA/NY-CDC-ASC210722700/2022) were 3.9x-fold lower (95% CI: 0.14x-0.18x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22679	S373P	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	C	g.T1117C	p.S373P	NC_045512.2(GU280_gp02):g.1117T>C	YP_009724390.1:p.Ser373Pro	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs Bi-Nab47D10-35B5. Omicron BA.1 has an IC50 fold change of 0.08x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22679	S373P	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	C	g.T1117C	p.S373P	NC_045512.2(GU280_gp02):g.1117T>C	YP_009724390.1:p.Ser373Pro	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron B.1.1.529 (BA.1) neutralization of the Omicron variants by antibodies induced by three doses of Pfizer/BNT162b2 mRNA vaccine was 7-8-fold less potent than  the D614G, and the Omicron variants still evade neutralization more efficiently.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22679	S373P	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	C	g.T1117C	p.S373P	NC_045512.2(GU280_gp02):g.1117T>C	YP_009724390.1:p.Ser373Pro	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron (B.1.1.529 [BA.1]) have higher sensitivity to inhibition by soluble angiotensin converting enzyme 2 (ACE2) and the endosomal inhibitor chloroquine compared  to D614G	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22679	S373P	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	C	g.T1117C	p.S373P	NC_045512.2(GU280_gp02):g.1117T>C	YP_009724390.1:p.Ser373Pro	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs Bi-Nab35B5-47D10. Omicron BA.1 has an IC50 fold change of 0.30x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22679	S373P	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	C	g.T1117C	p.S373P	NC_045512.2(GU280_gp02):g.1117T>C	YP_009724390.1:p.Ser373Pro	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Uhal B	2022	doi:10.1101/2022.06.23.497326	n/a	https://doi.org/10.1101/2022.06.23.497326	False	Uhal B et al. (2022)	n/a	Paradigms’ ACE-2 variant LVE/STR chimera binds to SARS-2 Omicron variant B.1.1.529 spike protein trimer with high affinity. Determined using Surrogate Viral Neutralization Tests.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22679	S373P	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	C	g.T1117C	p.S373P	NC_045512.2(GU280_gp02):g.1117T>C	YP_009724390.1:p.Ser373Pro	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Uhal B	2022	doi:10.1101/2022.06.23.497326	n/a	https://doi.org/10.1101/2022.06.23.497326	False	Uhal B et al. (2022)	n/a	L27, V34 and E90 mutation resulted in ultrahigh affinity binding of the LVE-ACE-2 domain to the widest variety of VOCs, with KDs of 73 pM for binding to the Omicron  B.1.1.529. Values were obtained with LVE-ACE-2/mAB chimeras containing the Y-T-E sequence that enhances binding to the FcRn receptor, which in turn is expected to  extend biological half-life 3-4-fold.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22679	S373P	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	C	g.T1117C	p.S373P	NC_045512.2(GU280_gp02):g.1117T>C	YP_009724390.1:p.Ser373Pro	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs 35B5. Omicron BA.1 has an IC50 fold change of 0.38x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22679	S373P	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	C	g.T1117C	p.S373P	NC_045512.2(GU280_gp02):g.1117T>C	YP_009724390.1:p.Ser373Pro	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Arora	2022	doi:10.1038/s41423-022-00870-5	pmid:35581351	https://doi.org/10.1038/s41423-022-00870-5	True	Arora et al. (2022)	n/a	All 10 individuals with 2 doses of the BNT162b2/BNT162b2 vaccine had a neutralizing titer in B.1 variant at an average of 729 NT50.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22679	S373P	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	C	g.T1117C	p.S373P	NC_045512.2(GU280_gp02):g.1117T>C	YP_009724390.1:p.Ser373Pro	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Shete	2022	doi:10.1101/2022.05.12.491584	n/a	https://doi.org/10.1101/2022.05.12.491584	False	Shete et al. (2022)	n/a	Plaque reduction neutralization test (PRNT) was used uring primary infection, post sixty daysof second dose vaccination, pre-reinfection and reinfection against Delta variant and was used to determine neutralizing antibodytitres. There was a 24.63x fold increase in antibody response from first infection to recovered and vaccinated with 2 doses (60 days). There was a 4.21x fold increase in antibody response pre-reinfection. There was a 39.27x fold increase in antibody response during reinfection.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22679	S373P	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	C	g.T1117C	p.S373P	NC_045512.2(GU280_gp02):g.1117T>C	YP_009724390.1:p.Ser373Pro	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Shete	2022	doi:10.1101/2022.05.12.491584	n/a	https://doi.org/10.1101/2022.05.12.491584	False	Shete et al. (2022)	n/a	Plaque reduction neutralization test (PRNT) was used uring primary infection, post sixty daysof second dose vaccination, pre-reinfection and reinfection against B.1 variant and was used to determine neutralizing antibodytitres. There was a 6.76x fold increase in antibody response from first infection to recovered and vaccinated with 2 doses (60 days). There was a 2.06x fold increase in antibody response pre-reinfection. There was a 8.18x fold increase in antibody response during reinfection.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22679	S373P	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	C	g.T1117C	p.S373P	NC_045512.2(GU280_gp02):g.1117T>C	YP_009724390.1:p.Ser373Pro	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Arora	2022	doi:10.1038/s41423-022-00870-5	pmid:35581351	https://doi.org/10.1038/s41423-022-00870-5	True	Arora et al. (2022)	n/a	All 10 individuals with 3 doses of the BNT162b2/BNT162b2 vaccine had a neutralizing titer in B.1 variant at an average of 3319 NT50.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22679	S373P	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	C	g.T1117C	p.S373P	NC_045512.2(GU280_gp02):g.1117T>C	YP_009724390.1:p.Ser373Pro	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Shete	2022	doi:10.1101/2022.05.12.491584	n/a	https://doi.org/10.1101/2022.05.12.491584	False	Shete et al. (2022)	n/a	Plaque reduction neutralization test (PRNT) was used uring primary infection, post sixty daysof second dose vaccination, pre-reinfection and reinfection against Omicron variant and was used to determine neutralizing antibodytitres. There was a 114.84x fold increase in antibody response from first infection to recovered and vaccinated with 2 doses (60 days). There was a 6.61x fold increase in antibody response pre-reinfection. There was a 1194.9x fold increase in antibody response during reinfection.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22679	S373P	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	C	g.T1117C	p.S373P	NC_045512.2(GU280_gp02):g.1117T>C	YP_009724390.1:p.Ser373Pro	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Kumar	2022	doi:10.1101/2022.05.13.491770	n/a	https://doi.org/10.1101/2022.05.13.491770	False	Kumar et al. (2022)	n/a	BnAb 002-S21F2 IC50 on the Omicron BA.1 variant is 1.0x fold the wildtype.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22679	S373P	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	C	g.T1117C	p.S373P	NC_045512.2(GU280_gp02):g.1117T>C	YP_009724390.1:p.Ser373Pro	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs 47D10. Omicron BA.1 has an IC50 fold change of 1.26x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22679	S373P	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	C	g.T1117C	p.S373P	NC_045512.2(GU280_gp02):g.1117T>C	YP_009724390.1:p.Ser373Pro	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron BA.3 have higher sensitivity to inhibition by soluble angiotensin converting enzyme 2 (ACE2) and the endosomal inhibitor chloroquine compared  to D614G	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22679	S373P	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	C	g.T1117C	p.S373P	NC_045512.2(GU280_gp02):g.1117T>C	YP_009724390.1:p.Ser373Pro	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron BA.3 neutralization of the Omicron variants by antibodies induced by three doses of Pfizer/BNT162b2 mRNA vaccine was 7-8-fold less potent than the D614G, and  the Omicron variants still evade neutralization more efficiently.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22679	S373P	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	C	g.T1117C	p.S373P	NC_045512.2(GU280_gp02):g.1117T>C	YP_009724390.1:p.Ser373Pro	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.3 (from South Africa/NICD-N22404/2021) were 4.2x-fold lower (95% CI: 0.15x-0.20x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22679	S373P	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	C	g.T1117C	p.S373P	NC_045512.2(GU280_gp02):g.1117T>C	YP_009724390.1:p.Ser373Pro	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.3 (from South Africa/NICD-N22404/2021) were 6.2-fold lower (95% CI: 11.8x-14.3x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22679	S373P	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	C	g.T1117C	p.S373P	NC_045512.2(GU280_gp02):g.1117T>C	YP_009724390.1:p.Ser373Pro	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Hao	2022	doi:10.1101/2022.08.12.22278720	pmid:36032965	https://doi.org/10.1101/2022.08.12.22278720	False	Hao et al. (2022)	n/a	paired testing of vaccine sera against ancestral virus compared to Omicron BA.1 shows that 3-dose vaccine regimen provides over 50x fold increase in protection against Omicron(B.1.1.529 [BA.1]) compared to a 2-dose regimen.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22679	S373P	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	C	g.T1117C	p.S373P	NC_045512.2(GU280_gp02):g.1117T>C	YP_009724390.1:p.Ser373Pro	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Wang	2022	doi:10.1101/2022.08.11.503601	n/a	https://doi.org/10.1101/2022.08.11.503601	False	Wang et al. (2022)	n/a	4th antigenic exposure with Omicron (B.1.1.529 [BA.1])(n	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22679	S373P	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	C	g.T1117C	p.S373P	NC_045512.2(GU280_gp02):g.1117T>C	YP_009724390.1:p.Ser373Pro	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.1 (from Botswana/R40B59_BHP_3321001248/2021) were 3.4-fold lower (95% CI: 3.2x-3.6x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22679	S373P	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	C	g.T1117C	p.S373P	NC_045512.2(GU280_gp02):g.1117T>C	YP_009724390.1:p.Ser373Pro	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.1 (from Botswana/R40B59_BHP_3321001248/2021) were 28.7x-fold lower (95% CI: 0.03x-0.05) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22679	S373P	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	C	g.T1117C	p.S373P	NC_045512.2(GU280_gp02):g.1117T>C	YP_009724390.1:p.Ser373Pro	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.4/5 (from ) were 17.2x-fold lower (95% CI: 0.6x-0.7x) than against 208-428 972-1834 4.3-4.7 US-WA1/2020 usiong an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22679	S373P	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	C	g.T1117C	p.S373P	NC_045512.2(GU280_gp02):g.1117T>C	YP_009724390.1:p.Ser373Pro	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.4/5 (from ) were 13.0-fold lower (95% CI: 4.2x-4.6x) than against 208-428 972-1834 4.3-4.7 US-WA1/2020 usiong an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22679	S373P	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	C	g.T1117C	p.S373P	NC_045512.2(GU280_gp02):g.1117T>C	YP_009724390.1:p.Ser373Pro	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  XD (from ) were 1.5x-fold lower (95% CI: 0.05x-0.07x) than against 208-428 972-1834 4.3-4.7 US-WA1/2020 usiong an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22679	S373P	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	C	g.T1117C	p.S373P	NC_045512.2(GU280_gp02):g.1117T>C	YP_009724390.1:p.Ser373Pro	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  XD (from ) were 4.4-fold lower (95% CI: 4.3x-4.7x) than against 208-428 972-1834 4.3-4.7 US-WA1/2020 usiong an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22679	S373P	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	C	g.T1117C	p.S373P	NC_045512.2(GU280_gp02):g.1117T>C	YP_009724390.1:p.Ser373Pro	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Yue	2023	doi:10.1101/2023.01.03.522427	n/a	https://doi.org/10.1101/2023.01.03.522427	False	Yue et al. (2023)	n/a	The hACE2-binding affinity of XBB.1.5 RBD has a dissociation constant KD of 3.4 nM, where S486P is the distinguishing Spike mutation vs parent  XBB.1 RBD with a much weaker KD (19 nM), as measured by surface plasmon resonance (SPR) assays.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22679	S373P	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	C	g.T1117C	p.S373P	NC_045512.2(GU280_gp02):g.1117T>C	YP_009724390.1:p.Ser373Pro	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	monoclonal antibody serial passage escape	n/a	n/a	Long	2020	doi:10.1128/mBio.02707-20	pmid:33127862	https://doi.org/10.1128/mBio.02707-20	True	Long et al. (2020)	n/a	Reduce affinity for mildly cross-reactive CR3022 (2003 pandemic SARS monoclonal antibody cross-reactive to SARS-CoV-2)	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22679	S373P	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	C	g.T1117C	p.S373P	NC_045512.2(GU280_gp02):g.1117T>C	YP_009724390.1:p.Ser373Pro	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	transmissibility	n/a	n/a	UNKNOWN	2021	doi:10.47326/ocsat.dashboard.2021.1.0	n/a	https://doi.org/10.47326/ocsat.dashboard.2021.1.0	False	UNKNOWN et al. (2021)	n/a	On December 7, 2021 the estimate of Omicron effective reproduction rate (Rt) is 3.12 [presumably R0 is higher],  compared to 1.12 for the dominant Delta VOC at that time. [shorthand of variant list shraed by all contemporary BA lineage used here]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22686	ST375FA	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	CCA	TCG	g.CCA1124_1126TCG	p.ST375FA	n/a	YP_009724390.1:p.SerThr375PheAla	n/a	n/a	S	n/a	KP.2.3.5	n/a	n/a	n/a	1.0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	Pokay	n/a	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	n/a	n/a	n/a	n/a	n/a	n/a
22770	R403K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	A	g.G1208A	p.R403K	NC_045512.2(GU280_gp02):g.1208G>A	YP_009724390.1:p.Arg403Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	Pokay	n/a	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	n/a	n/a	n/a	n/a	n/a	n/a
22775	D405N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	A	g.G1213A	p.D405N	NC_045512.2(GU280_gp02):g.1213G>A	YP_009724390.1:p.Asp405Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron BA.2 have higher sensitivity to inhibition by soluble angiotensin converting enzyme 2 (ACE2) and the endosomal inhibitor chloroquine compared  to D614G	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22775	D405N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	A	g.G1213A	p.D405N	NC_045512.2(GU280_gp02):g.1213G>A	YP_009724390.1:p.Asp405Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs Bi-Nab35B5-47D10. Omicron BA.2 has an IC50 fold change of 0.07x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22775	D405N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	A	g.G1213A	p.D405N	NC_045512.2(GU280_gp02):g.1213G>A	YP_009724390.1:p.Asp405Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs 35B5. Omicron BA.2 has an IC50 fold change of 0.09x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22775	D405N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	A	g.G1213A	p.D405N	NC_045512.2(GU280_gp02):g.1213G>A	YP_009724390.1:p.Asp405Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs 47D10. Omicron BA.2 has an IC50 fold change of 0.08x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22775	D405N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	A	g.G1213A	p.D405N	NC_045512.2(GU280_gp02):g.1213G>A	YP_009724390.1:p.Asp405Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs Bi-Nab47D10-35B5. Omicron BA.2 has an IC50 fold change of 0.04x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22775	D405N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	A	g.G1213A	p.D405N	NC_045512.2(GU280_gp02):g.1213G>A	YP_009724390.1:p.Asp405Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron BA.2 neutralization of the Omicron variants by antibodies induced by three doses of Pfizer/BNT162b2 mRNA vaccine was 7-8-fold less potent than the D614G, and  the Omicron variants still evade neutralization more efficiently.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22775	D405N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	A	g.G1213A	p.D405N	NC_045512.2(GU280_gp02):g.1213G>A	YP_009724390.1:p.Asp405Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Kumar	2022	doi:10.1101/2022.05.13.491770	n/a	https://doi.org/10.1101/2022.05.13.491770	False	Kumar et al. (2022)	n/a	BnAb 002-S21F2 IC50 on the Omicron BA.2 variant is 0.8x fold the wildtype.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22775	D405N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	A	g.G1213A	p.D405N	NC_045512.2(GU280_gp02):g.1213G>A	YP_009724390.1:p.Asp405Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.2 (from South Africa/CERI-KRISP-K032307/2021) were 3.9x-fold lower (95% CI: 0.14x-0.17x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22775	D405N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	A	g.G1213A	p.D405N	NC_045512.2(GU280_gp02):g.1213G>A	YP_009724390.1:p.Asp405Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Uhal B	2022	doi:10.1101/2022.06.23.497326	n/a	https://doi.org/10.1101/2022.06.23.497326	False	Uhal B et al. (2022)	n/a	L27, V34 and E90 mutation resulted in ultrahigh affinity binding of the LVE-ACE-2 domain to the widest variety of VOCs, with KDs of 78fM for binding to the Omicron  BA.2. Values were obtained with LVE-ACE-2/mAB chimeras containing the Y-T-E sequence that enhances binding to the FcRn receptor, which in turn is expected to  extend biological half-life 3-4-fold.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22775	D405N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	A	g.G1213A	p.D405N	NC_045512.2(GU280_gp02):g.1213G>A	YP_009724390.1:p.Asp405Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.2 (from South Africa/CERI-KRISP-K032307/2021) were 4.5-fold lower (95% CI: 4.3x-4.7x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22775	D405N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	A	g.G1213A	p.D405N	NC_045512.2(GU280_gp02):g.1213G>A	YP_009724390.1:p.Asp405Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.2.12.1 (from USA/NY-CDC-ASC210722700/2022) were 4.2-fold lower (95% CI: 5.8x-6.6x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22775	D405N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	A	g.G1213A	p.D405N	NC_045512.2(GU280_gp02):g.1213G>A	YP_009724390.1:p.Asp405Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.2.12.1 (from USA/NY-CDC-ASC210722700/2022) were 3.9x-fold lower (95% CI: 0.14x-0.18x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22775	D405N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	A	g.G1213A	p.D405N	NC_045512.2(GU280_gp02):g.1213G>A	YP_009724390.1:p.Asp405Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron BA.3 have higher sensitivity to inhibition by soluble angiotensin converting enzyme 2 (ACE2) and the endosomal inhibitor chloroquine compared  to D614G	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22775	D405N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	A	g.G1213A	p.D405N	NC_045512.2(GU280_gp02):g.1213G>A	YP_009724390.1:p.Asp405Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron BA.3 neutralization of the Omicron variants by antibodies induced by three doses of Pfizer/BNT162b2 mRNA vaccine was 7-8-fold less potent than the D614G, and  the Omicron variants still evade neutralization more efficiently.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22775	D405N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	A	g.G1213A	p.D405N	NC_045512.2(GU280_gp02):g.1213G>A	YP_009724390.1:p.Asp405Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.3 (from South Africa/NICD-N22404/2021) were 4.2x-fold lower (95% CI: 0.15x-0.20x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22775	D405N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	A	g.G1213A	p.D405N	NC_045512.2(GU280_gp02):g.1213G>A	YP_009724390.1:p.Asp405Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.3 (from South Africa/NICD-N22404/2021) were 6.2-fold lower (95% CI: 11.8x-14.3x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22775	D405N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	A	g.G1213A	p.D405N	NC_045512.2(GU280_gp02):g.1213G>A	YP_009724390.1:p.Asp405Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.4/5 (from ) were 17.2x-fold lower (95% CI: 0.6x-0.7x) than against 208-428 972-1834 4.3-4.7 US-WA1/2020 usiong an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22775	D405N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	A	g.G1213A	p.D405N	NC_045512.2(GU280_gp02):g.1213G>A	YP_009724390.1:p.Asp405Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.4/5 (from ) were 13.0-fold lower (95% CI: 4.2x-4.6x) than against 208-428 972-1834 4.3-4.7 US-WA1/2020 usiong an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22775	D405N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	A	g.G1213A	p.D405N	NC_045512.2(GU280_gp02):g.1213G>A	YP_009724390.1:p.Asp405Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Yue	2023	doi:10.1101/2023.01.03.522427	n/a	https://doi.org/10.1101/2023.01.03.522427	False	Yue et al. (2023)	n/a	The hACE2-binding affinity of XBB.1.5 RBD has a dissociation constant KD of 3.4 nM, where S486P is the distinguishing Spike mutation vs parent  XBB.1 RBD with a much weaker KD (19 nM), as measured by surface plasmon resonance (SPR) assays.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22786	R408S	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	C	g.A1224C	p.R408S	NC_045512.2(GU280_gp02):g.1224A>C	YP_009724390.1:p.Arg408Ser	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron BA.2 have higher sensitivity to inhibition by soluble angiotensin converting enzyme 2 (ACE2) and the endosomal inhibitor chloroquine compared  to D614G	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22786	R408S	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	C	g.A1224C	p.R408S	NC_045512.2(GU280_gp02):g.1224A>C	YP_009724390.1:p.Arg408Ser	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs Bi-Nab35B5-47D10. Omicron BA.2 has an IC50 fold change of 0.07x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22786	R408S	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	C	g.A1224C	p.R408S	NC_045512.2(GU280_gp02):g.1224A>C	YP_009724390.1:p.Arg408Ser	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs 35B5. Omicron BA.2 has an IC50 fold change of 0.09x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22786	R408S	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	C	g.A1224C	p.R408S	NC_045512.2(GU280_gp02):g.1224A>C	YP_009724390.1:p.Arg408Ser	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs 47D10. Omicron BA.2 has an IC50 fold change of 0.08x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22786	R408S	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	C	g.A1224C	p.R408S	NC_045512.2(GU280_gp02):g.1224A>C	YP_009724390.1:p.Arg408Ser	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs Bi-Nab47D10-35B5. Omicron BA.2 has an IC50 fold change of 0.04x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22786	R408S	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	C	g.A1224C	p.R408S	NC_045512.2(GU280_gp02):g.1224A>C	YP_009724390.1:p.Arg408Ser	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron BA.2 neutralization of the Omicron variants by antibodies induced by three doses of Pfizer/BNT162b2 mRNA vaccine was 7-8-fold less potent than the D614G, and  the Omicron variants still evade neutralization more efficiently.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22786	R408S	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	C	g.A1224C	p.R408S	NC_045512.2(GU280_gp02):g.1224A>C	YP_009724390.1:p.Arg408Ser	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Kumar	2022	doi:10.1101/2022.05.13.491770	n/a	https://doi.org/10.1101/2022.05.13.491770	False	Kumar et al. (2022)	n/a	BnAb 002-S21F2 IC50 on the Omicron BA.2 variant is 0.8x fold the wildtype.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22786	R408S	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	C	g.A1224C	p.R408S	NC_045512.2(GU280_gp02):g.1224A>C	YP_009724390.1:p.Arg408Ser	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.2 (from South Africa/CERI-KRISP-K032307/2021) were 3.9x-fold lower (95% CI: 0.14x-0.17x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22786	R408S	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	C	g.A1224C	p.R408S	NC_045512.2(GU280_gp02):g.1224A>C	YP_009724390.1:p.Arg408Ser	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Uhal B	2022	doi:10.1101/2022.06.23.497326	n/a	https://doi.org/10.1101/2022.06.23.497326	False	Uhal B et al. (2022)	n/a	L27, V34 and E90 mutation resulted in ultrahigh affinity binding of the LVE-ACE-2 domain to the widest variety of VOCs, with KDs of 78fM for binding to the Omicron  BA.2. Values were obtained with LVE-ACE-2/mAB chimeras containing the Y-T-E sequence that enhances binding to the FcRn receptor, which in turn is expected to  extend biological half-life 3-4-fold.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22786	R408S	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	C	g.A1224C	p.R408S	NC_045512.2(GU280_gp02):g.1224A>C	YP_009724390.1:p.Arg408Ser	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.2 (from South Africa/CERI-KRISP-K032307/2021) were 4.5-fold lower (95% CI: 4.3x-4.7x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22786	R408S	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	C	g.A1224C	p.R408S	NC_045512.2(GU280_gp02):g.1224A>C	YP_009724390.1:p.Arg408Ser	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.2.12.1 (from USA/NY-CDC-ASC210722700/2022) were 4.2-fold lower (95% CI: 5.8x-6.6x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22786	R408S	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	C	g.A1224C	p.R408S	NC_045512.2(GU280_gp02):g.1224A>C	YP_009724390.1:p.Arg408Ser	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.2.12.1 (from USA/NY-CDC-ASC210722700/2022) were 3.9x-fold lower (95% CI: 0.14x-0.18x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22786	R408S	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	C	g.A1224C	p.R408S	NC_045512.2(GU280_gp02):g.1224A>C	YP_009724390.1:p.Arg408Ser	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.4/5 (from ) were 17.2x-fold lower (95% CI: 0.6x-0.7x) than against 208-428 972-1834 4.3-4.7 US-WA1/2020 usiong an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22786	R408S	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	C	g.A1224C	p.R408S	NC_045512.2(GU280_gp02):g.1224A>C	YP_009724390.1:p.Arg408Ser	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.4/5 (from ) were 13.0-fold lower (95% CI: 4.2x-4.6x) than against 208-428 972-1834 4.3-4.7 US-WA1/2020 usiong an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22786	R408S	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	C	g.A1224C	p.R408S	NC_045512.2(GU280_gp02):g.1224A>C	YP_009724390.1:p.Arg408Ser	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Yue	2023	doi:10.1101/2023.01.03.522427	n/a	https://doi.org/10.1101/2023.01.03.522427	False	Yue et al. (2023)	n/a	The hACE2-binding affinity of XBB.1.5 RBD has a dissociation constant KD of 3.4 nM, where S486P is the distinguishing Spike mutation vs parent  XBB.1 RBD with a much weaker KD (19 nM), as measured by surface plasmon resonance (SPR) assays.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22786	R408S	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	C	g.A1224C	p.R408S	NC_045512.2(GU280_gp02):g.1224A>C	YP_009724390.1:p.Arg408Ser	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	gene expression increase	n/a	n/a	Starr	2020	doi:10.1016/j.cell.2020.08.012	pmid:32841599	https://doi.org/10.1016/j.cell.2020.08.012	True	Starr et al. (2020)	n/a	Experimentally, Spike gene expression increased 0.21 fold	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22786	R408S	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	C	g.A1224C	p.R408S	NC_045512.2(GU280_gp02):g.1224A>C	YP_009724390.1:p.Arg408Ser	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine efficacy	n/a	n/a	Zhou	2022	doi:10.1101/2022.05.09.491254	n/a	https://doi.org/10.1101/2022.05.09.491254	False	Zhou et al. (2022)	n/a	In a study of 481 vaccinees going from lowest to highest infection rate, 2 doses of CoronaVac and 1 dose of BNT162b2 had the lowest infection rate at 6.3%, then it was 3 doses of BNT162b2 having a infection rate of 16.6%. 2 and 3 doses of CoronaVac had 48.6% and 20.6% infection rate respectively. 2 doses of BNT162b2 has  the highest infection rate at 49.2%.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron BA.2 have higher sensitivity to inhibition by soluble angiotensin converting enzyme 2 (ACE2) and the endosomal inhibitor chloroquine compared  to D614G	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs Bi-Nab35B5-47D10. Omicron BA.2 has an IC50 fold change of 0.07x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs 35B5. Omicron BA.2 has an IC50 fold change of 0.09x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs 47D10. Omicron BA.2 has an IC50 fold change of 0.08x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs Bi-Nab47D10-35B5. Omicron BA.2 has an IC50 fold change of 0.04x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron BA.2 neutralization of the Omicron variants by antibodies induced by three doses of Pfizer/BNT162b2 mRNA vaccine was 7-8-fold less potent than the D614G, and  the Omicron variants still evade neutralization more efficiently.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Kumar	2022	doi:10.1101/2022.05.13.491770	n/a	https://doi.org/10.1101/2022.05.13.491770	False	Kumar et al. (2022)	n/a	BnAb 002-S21F2 IC50 on the Omicron BA.2 variant is 0.8x fold the wildtype.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Schmidt	2021	doi:10.1101/2021.08.06.455491	n/a	https://doi.org/10.1101/2021.08.06.455491	False	Schmidt et al. (2021)	n/a	Artificially constructed HIV-1 pseudovirus with set of mutations drawn from plasma passage escape experiments and mutations from variants of concern completely ablates neutralization in 19 of 21 convalescents plasma collected mean 1.3 months post infection. [actual Y145del from manuscript substituted with more common Y144del description]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Cele	2021	doi:10.1038/s41586-021-03471-w	pmid:33780970	https://doi.org/10.1038/s41586-021-03471-w	True	Cele et al. (2021)	n/a	The 501Y.V2 to first wave IC50 ratio ranged from 6 to 200-fold. Averaging across all 7 participant convalescent sera highlighted the dramatic decrease in sensitivity to neutralization of authentic 501Y.V2 variants. PG: I'm purposefully ignoring D614G and A701V as contributors	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Andrade	2021	doi:10.1101/2021.04.14.439719	n/a	https://doi.org/10.1101/2021.04.14.439719	False	Andrade et al. (2021)	n/a	In human sera 8 weeks post-vaccination with INO-4800, a ~7-fold reduction in B.1.351 neutralization was observed.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Riddell	2021	doi:10.1101/2021.04.17.440246	n/a	https://doi.org/10.1101/2021.04.17.440246	False	Riddell et al. (2021)	n/a	Four fold reduction in neutralization efficiency was observed in sera of ferrets post-vaccination with  INO-4800 (DNA plasmid pGX9501 encoding full length Spike).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Wu	2021	doi:10.1101/2021.04.13.439482	pmid:33880468	https://doi.org/10.1101/2021.04.13.439482	False	Wu et al. (2021)	n/a	Monovalent mRNA-1273.351 encodes for the S protein found in the B.1.351 lineage and (2) mRNA-1273.211 comprising a 1:1 mix of mRNA-1273 and mRNA-1273.351.  In a mouse study, primary vaccination series of mRNA-1273.351 was effective at increasing neutralizing antibody titers against the B.1.351 lineage,  while mRNA-1273.211 was most effective at providing broad cross-variant neutralization. In addition, these results demonstrated a third dose of  mRNA-1273.351 significantly increased both wild-type and B.1.351-specific neutralization titers.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kustin	2021	doi:10.1101/2021.04.06.21254882	n/a	https://doi.org/10.1101/2021.04.06.21254882	False	Kustin et al. (2021)	n/a	Pzifer vaccinees that tested positive at least a week after the second dose were indeed disproportionally infected with B.1.351,  as compared with unvaccinated individuals (odds ratio of 8:1), but were all infected before 14 days post second vaccination.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Uriu	2021	doi:10.1101/2021.09.06.459005	n/a	https://doi.org/10.1101/2021.09.06.459005	False	Uriu et al. (2021)	n/a	Mean 8.2x reduction of NT50 value B.1.351 (Beta) relative to wild type in 8 sera from older convalescent patients (52-92yo) collected 1-3m post symptom onset.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Uriu	2021	doi:10.1101/2021.09.06.459005	n/a	https://doi.org/10.1101/2021.09.06.459005	False	Uriu et al. (2021)	n/a	Mean 6.3x reduction of NT50 value B.1.351 (Beta) relative to wild type in 8 sera from adult BNT162b2 vaccinees (28-47yo) collected ~1m post booster.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Skelly	2021	doi:10.21203/rs.3.rs-226857/v1	n/a	https://doi.org/10.21203/rs.3.rs-226857/v1	False	Skelly et al. (2021)	n/a	In over 90% of two dose mRNA vaccinees, heterotypic neutralizing titres (NT50) against B.1.1.7 and B.1.351 remain comfortably  above the level associated with immune protection in recent vaccine trials. However, in over 50% of convalescent COVID-19  individuals (5/9) and recipients of a only a single dose of mRNA vaccine (10/11) – heterotypic neutralization dropped to negligible levels,  particularly against B.1.351.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma binding	n/a	n/a	Luftig	2021	doi:10.1056/NEJMc2104036	pmid:33826815	https://doi.org/10.1056/NEJMc2104036	True	Luftig et al. (2021)	n/a	In sera from six patients collected 1 to 12 weeks post-infection with B.1, antibody titer in a microneutralization assay was on average 8 for B.1.351 virus. Compare to much stronger neutralization titers for B.1.1.7 (256) and wild type (456.1) in the same sera.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Bates	2021	doi:10.1101/2021.04.04.21254881	pmid:33851185	https://doi.org/10.1101/2021.04.04.21254881	False	Bates et al. (2021)	n/a	Observed 8.8-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose) against cultured B.1.351 sample. Contrast this with 1.4-fold reduction for just the pseudovirus combination of 'key' B.1.351 mutations K417N+E484K+N501Y. WA1 and B.1.351 FRNT50 titers correlated weakly at the individual level, with some individual’s serum potently neutralizing WA1 while having FRNT50 for B.1.351 below the assay limit of detection (1:20).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma binding	n/a	n/a	UNKNOWN	2021	n/a	n/a	https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1009243/Technical_Briefing_20.pdf	False	UNKNOWN et al. (2021)	n/a	Sera from individuals who have been infected with Delta does not have strong neutralising activity against Beta.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Planas	2021	doi:10.1038/s41591-021-01318-5	n/a	https://doi.org/10.1038/s41591-021-01318-5	True	Planas et al. (2021)	n/a	Using a new rapid neutralization assay, based on reporter cells that become positive for GFP after overnight infection, sera from 58  convalescent individuals collected up to 9 months after symptoms had mean ~6x reduction in neutralizing titers, and 40% of the samples  lacked any activity against B.1.351.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	UNKNOWN	2021	n/a	n/a	https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1009243/Technical_Briefing_20.pdf	False	UNKNOWN et al. (2021)	n/a	Sera from individuals who have been vaccinated and have had subsequent recent Delta infection have a high level of neutralising activity against Beta.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Uhal B	2022	doi:10.1101/2022.06.23.497326	n/a	https://doi.org/10.1101/2022.06.23.497326	False	Uhal B et al. (2022)	n/a	Paradigm’s ACE-2 variant LVE/STR chimera neutralizes Beta Variant B.1.351 RBD significantly better than w.t. SARS-CoV-2 RBD. Determined using Surrogate Viral Neutralization Tests.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Garcia-Beltran	2021	doi:10.1016/j.cell.2021.03.013	pmid:33743213	https://doi.org/10.1016/j.cell.2021.03.013	True	Garcia-Beltran et al. (2021)	n/a	Pseudotyped B.1.351 v2 virus has reduced neutralization activity vs wild type: 41.2x (30 sera Pfizer median 9 days post 2nd dose)  and 20.8x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA. Notably, 36.7% (11/30) recipients of two-dose Pfizer and 42.9% (15/35) recipients of two-dose Moderna vaccines did not have  detectable neutralization of at least one of the B.1.351 variants.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Tada	2021	doi:10.1101/2021.02.05.430003	pmid:33564768	https://doi.org/10.1101/2021.02.05.430003	False	Tada et al. (2021)	n/a	Pseudotype lentivirus for the full B.1.351 Spike variant list shows increase affinity for ACE2 as measured by IC50. This is in contrast to B.1.1.7 which showed no major change, indicating that the shared N501Y mutation is the driver of affinity change, attentuated in the B.1.1.7 mutatioon set, but maintained in the B.1.351 lineage.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Voysey	2021	doi:10.1016/S0140-6736(20	n/a	https://doi.org/10.1016/S0140-6736(20	n/a	Voysey et al. (2021)	n/a	[Contrary to how this paper has been cited, Voysey et al. do NOT show evidence of decreased effectiveness of ChAdOx1 (AstraZeneca) against  the South African B.1.351 lineage. Insufficient numbers reaching the primary study endpoint were available in that arm of the vaccine study to report any statistics from the South African participants. Additionally, the study period of the paper ended in November 2020, while the earliest reported case of this lineage is October (covariants.org), only becoming dominant by mid-November.]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Planas	2021	doi:10.1038/s41591-021-01318-5	n/a	https://doi.org/10.1038/s41591-021-01318-5	True	Planas et al. (2021)	n/a	Flow cytometry was used on recombinant VSV proteins and yeast surface display to assess the binding of a labeled soluble ACE2  protein to cells expressing B.1.351. We observed an increase (relative to D614G) in binding of soluble  ACE2 to B.1.351, and to a much gearter extent to B.1.1.7, which both carry the N501Y mutation (see Fig 3).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Tarke	2021	doi:10.1101/2021.02.27.433180	pmid:33688655	https://doi.org/10.1101/2021.02.27.433180	False	Tarke et al. (2021)	n/a	PBMCs of Pfizer/BioNTech BNT162b2 (n	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Madhi	2021	doi:10.1056/NEJMoa2102214	pmid:33725432	https://doi.org/10.1056/NEJMoa2102214	True	Madhi et al. (2021)	n/a	Relative to B.1.1.117, PRNT50 line virus neutralizating antibody activity assay of B.1.351 showed ~11x reduction in 13 vacinees's sera  collected through 41 days after vaccination. Neutralization by a placebo control group of 6 naturally infected patients showed a smaller ~8x drop (starting from a ~50% higher PRNT50 value than vacinees for B.1.1.117 neutralization). Serum samples obtained from 13 ChAdOx1 nCoV-19 vaccine recipients without SARS-CoV-2 infection through 41 days after vaccination  showed ~4x reduction in neutralization (ID50) for full B.1.351 pseudotype HIV-1 virus compared to D614G alone. This  RBD variant combination's neutralization by a placebo control  group of 6 naturally infected patients showed a slightly higher 4.6x drop (though with D614G starting at a 1.7x higher titre than vaccinee sera).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	McEvoy C	2022	doi:10.1101/2022.06.24.22276144	n/a	https://doi.org/10.1101/2022.06.24.22276144	False	McEvoy C et al. (2022)	n/a	Log10ID50 of Beta neutralizing antibodies is 0.899x the WT 1 month post-third dose of pfizer-BioNTech BNT162b2 in 13 Kidney transplant recipients (KTR) with median  age of 55.5.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Bates	2021	doi:10.1101/2021.04.04.21254881	pmid:33851185	https://doi.org/10.1101/2021.04.04.21254881	False	Bates et al. (2021)	n/a	A 1.8-fold drop in FRNT50 for B.1.351 was observed in 44 sera collected between 1 and 301 post-infection.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	3.2x reduction in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees)	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Choi	2021	doi:10.1101/2021.06.28.449914	n/a	https://doi.org/10.1101/2021.06.28.449914	False	Choi et al. (2021)	n/a	Neutralization efficiency (ID50) against B.1.1.351-v1 reduced 6.9x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	T cell evasion	n/a	n/a	Skelly	2021	doi:10.21203/rs.3.rs-226857/v1	n/a	https://doi.org/10.21203/rs.3.rs-226857/v1	False	Skelly et al. (2021)	n/a	Encouragingly, we find that the majority of T cell responses in recipients of two doses of the BNT162b2 vaccine are generated  by epitopes that are invariant between the [wildtype] and two of the current variants of concern (B.1.1.7 and B.1.351). In over 90% of two dose mRNA vaccinees, heterotypic neutralizing titres (NT50) against B.1.1.7 and B.1.351 remain comfortably  above the level associated with immune protection in recent vaccine trials. However, in over 50% of convalescent COVID-19  individuals and recipients of a only a single dose of mRNA vaccine – heterotypic neutralization dropped to negligible levels,  particularly against B.1.351.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Wang	2021	doi:10.1038/s41586-021-03398-2	n/a	https://doi.org/10.1038/s41586-021-03398-2	True	Wang et al. (2021)	n/a	The neutralizing activity of 16/20 convalescent sera was significantly lower against this pseudotyped virus model of B.1.351, with similar results for the live virus.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	McEvoy C	2022	doi:10.1101/2022.06.24.22276144	n/a	https://doi.org/10.1101/2022.06.24.22276144	False	McEvoy C et al. (2022)	n/a	Log10ID50 of Beta neutralizing antibodies is 0.803x the WT pre-third dose of pfizer-BioNTech BNT162b2 in 13 Kidney transplant recipients (KTR) with median age of  55.5.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Wang	2021	doi:10.1038/s41586-021-03398-2	n/a	https://doi.org/10.1038/s41586-021-03398-2	True	Wang et al. (2021)	n/a	B.1.351 pseudotyped virus model ablates neutralization by RBD-directed mAbs CB6, 4-20, 2-4, 2-43, 910-30, 2-302-15, LY-Cov555, C121. B.1.351 pseudotyped virus model severely impairs neutralization by RBD-directed mAb 1-20. B.1.351 pseudotyped virus model impairs neutralization by RBD-directed mAb REGN10933. B.1.351 pseudotyped virus model ablates neutralization by N-terminal-domain-directed mAbs 5-24, 4-8, 4A8, 4-19. B.1.351 pseudotyped virus model severely impairs neutralization by N-terminal-domain-directed mAb 2-17. B.1.351 pseudotyped virus model impairs neutralization by N-terminal-domain-directed mAb 5-7. PG: Live virus data for the same mAbs is similar, but 1-20 becomes severally impaired, REGN10933 activity is ablated, and Brii-196 becomes impaired.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Wang	2021	doi:10.1038/s41586-021-03398-2	n/a	https://doi.org/10.1038/s41586-021-03398-2	True	Wang et al. (2021)	n/a	The neutralizing activity of vaccine was significantly lower against B.1.351 (12.4x in twelve Moderna-recipient sera: 10.3x in ten Pfizer-recipient sera). [this is a larger list of B.1.351 than modeled by Wang et al. (2021) by including L18F and R246I, less effective at neutralizing]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Planas	2021	doi:10.1038/s41591-021-01318-5	n/a	https://doi.org/10.1038/s41591-021-01318-5	True	Planas et al. (2021)	n/a	The sera of 16 individuals with time course collection was evaluated against VSV pseudotypes: while BD614G and B.1.1.7 were  neutralized earlier, the anti-B.1.351 response was negative up to week 3, and became detectable at week 4 (1 week after booster dose), at a level lower  than the two other viruses (~10x vs D614G) through week 6, the last timepoint measured. Three vaccinees never showed detectable neutralization to B.1.351 even after second dose.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Chonira	2022	doi:10.1101/2022.05.30.493765	pmid:35677079	https://doi.org/10.1101/2022.05.30.493765	False	Chonira et al. (2022)	n/a	DARPin SR16m molecule had a 0.036x fold change in IC50 in B.1.351 Beta	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	tissue specific neutralization	n/a	n/a	Planas	2021	doi:10.1038/s41591-021-01318-5	n/a	https://doi.org/10.1038/s41591-021-01318-5	True	Planas et al. (2021)	n/a	The nasal mucosa of Pfizer vaccinees with time course collection was evaluated against VSV pseudotypes: while B.1.1.7 and D614G showed neutralization by nasal swab from only one different previously infected vacinee neutralizing at weeks 3 and 6, B.1.351 showed zero neutralization at either time point in any sample (and relatively impaired serum neutralization).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Choi	2021	doi:10.1101/2021.06.28.449914	n/a	https://doi.org/10.1101/2021.06.28.449914	False	Choi et al. (2021)	n/a	Neutralization efficiency (ID50) against B.1.1.351-v2 reduced 7.3x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Woldemeskel	2021	doi:10.1172/JCI149335	pmid:33822770	https://doi.org/10.1172/JCI149335	True	Woldemeskel et al. (2021)	n/a	No significant difference in T-cell response to B.1.351 was observed (vs. ancestral) in blood drawn from 28 participants received the Pfizer-BioNTech vaccine  and 2 received the Moderna vaccine.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Ikegame	2021	doi:10.21203/rs.3.rs-400230/v1	pmid:33851150	https://doi.org/10.21203/rs.3.rs-400230/v1	False	Ikegame et al. (2021)	n/a	B.1.351 pseudotyped VSV was tested for neutralization in a clonal HEK-293T ACE2 TMPRSS2 cell line optimized for highly efficient  S-mediated infection. Only 1 out of 12 serum samples from a cohort of Argentinian recipients of the Gamaleya Sputnik V Ad26 / Ad5 vaccine  showed effective neutralization (IC90) at full serum strength (average realtive decrease was 6.1x vs wild type).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Chonira	2022	doi:10.1101/2022.05.30.493765	pmid:35677079	https://doi.org/10.1101/2022.05.30.493765	False	Chonira et al. (2022)	n/a	Trimeric proteins FSR22 had a 0.07x fold change in IC50 in B.1.351 Beta	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Shinde	2021	doi:10.1056/NEJMoa2103055	pmid:33951374	https://doi.org/10.1056/NEJMoa2103055	True	Shinde et al. (2021)	n/a	In a randomized phase 2a-b control trial of the Novavax (NVX-CoV2373) vaccine in South Africa, where B.1.351 virus dominates, efficacy was 60.1% (95% CI, 19.9 to 80.1) in HIV-negative and initially SARS-CoV-2 seronegative participants using the  primary endpoint of laboratory-confirmed symptomatic Covid-19 at 7 days or more after the second dose among participants.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Chonira	2022	doi:10.1101/2022.05.30.493765	pmid:35677079	https://doi.org/10.1101/2022.05.30.493765	False	Chonira et al. (2022)	n/a	DARPin SR22 molecule had a 1.57x fold change in IC50 in B.1.351 Beta	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Chonira	2022	doi:10.1101/2022.05.30.493765	pmid:35677079	https://doi.org/10.1101/2022.05.30.493765	False	Chonira et al. (2022)	n/a	Trimeric proteins FSR16m had a 0.054x fold change in IC50 in B.1.351 Beta	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Dejnirattisai	2021	doi:10.1016/j.cell.2021.03.055	pmid:33852911	https://doi.org/10.1016/j.cell.2021.03.055	True	Dejnirattisai et al. (2021)	n/a	B.1.351 virus neutralization (as tested using biolayer interferometry) of both Lilly antibodies was severely impacted, with LY-CoV16 and LY-CoV555  (due to mutations at 416 and 484 respectively) shows almost complete loss of neutralization of B.1.351. There was also escape from neutralization of B.1.351 by REGN10933 and a modest reduction in neutralization of B.1.351 by AZD8895  (while AZD1061 and AZD7442 showed equal neutralization of all SARS-CoV-2 variants tested). The three Adagio antibodies neutralized B.1.351.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Chonira	2022	doi:10.1101/2022.05.30.493765	pmid:35677079	https://doi.org/10.1101/2022.05.30.493765	False	Chonira et al. (2022)	n/a	DARPin SR16m molecule had a 6.7x fold change in IC50 in B.1.617.2 Delta	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Chonira	2022	doi:10.1101/2022.05.30.493765	pmid:35677079	https://doi.org/10.1101/2022.05.30.493765	False	Chonira et al. (2022)	n/a	DARPin SR16m molecule had a 99.7x fold change in IC50 in B.1.617.2 Delta	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	trafficking	n/a	n/a	Tada	2021	doi:10.1101/2021.02.05.430003	pmid:33564768	https://doi.org/10.1101/2021.02.05.430003	False	Tada et al. (2021)	n/a	Lentiviral pseudotyped with all key mutations from B.1.351 lineage was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing modest decrease in infection rate amongst the cells, suggesting some synergy between the mutations to decrease cell entry fitness (i.e. cell entry is liklely not the driver of this lineage's dominance).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Tang	2021	doi:10.1101/2021.03.19.436183	n/a	https://doi.org/10.1101/2021.03.19.436183	False	Tang et al. (2021)	n/a	The most significant loss of neutralizing activity (PsVNA50 assay) using 6 hyperimmune immunoglobulin preparations from convalescent plasma was seen against authentic B.1.351 lineage virus (9.2-fold). Neutralization against 10 convalescent plasma was poorer (18.7x).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	environmental condition stability	n/a	n/a	Meister	2021	doi:10.1093/infdis/jiab260	pmid:33993274	https://doi.org/10.1093/infdis/jiab260	True	Meister et al. (2021)	n/a	Treatment with heat, soap and ethanol revealed similar inactivation profiles indicative of a comparable susceptibility  towards disinfection. Furthermore, we observed comparable surface stability on steel, silver, copper and face masks.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	environmental condition stability	n/a	n/a	Tada	2021	doi:10.1101/2021.02.05.430003	pmid:33564768	https://doi.org/10.1101/2021.02.05.430003	False	Tada et al. (2021)	n/a	Relative to D614G, this mutation set (B.1.351+) demonstrated significant increase in infectivity (i.e. heat stability) after incubation at 50C after 1 hour.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.2 (from South Africa/CERI-KRISP-K032307/2021) were 3.9x-fold lower (95% CI: 0.14x-0.17x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Uhal B	2022	doi:10.1101/2022.06.23.497326	n/a	https://doi.org/10.1101/2022.06.23.497326	False	Uhal B et al. (2022)	n/a	L27, V34 and E90 mutation resulted in ultrahigh affinity binding of the LVE-ACE-2 domain to the widest variety of VOCs, with KDs of 78fM for binding to the Omicron  BA.2. Values were obtained with LVE-ACE-2/mAB chimeras containing the Y-T-E sequence that enhances binding to the FcRn receptor, which in turn is expected to  extend biological half-life 3-4-fold.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.2 (from South Africa/CERI-KRISP-K032307/2021) were 4.5-fold lower (95% CI: 4.3x-4.7x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.2.12.1 (from USA/NY-CDC-ASC210722700/2022) were 4.2-fold lower (95% CI: 5.8x-6.6x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.2.12.1 (from USA/NY-CDC-ASC210722700/2022) were 3.9x-fold lower (95% CI: 0.14x-0.18x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Cathcart	2021	doi:10.1101/2021.03.09.434607v9	n/a	https://doi.org/10.1101/2021.03.09.434607v9	False	Cathcart et al. (2021)	n/a	Omicron (a.k.a. B.1.1.529) Spike pseudotyped VSV and Vero E6 cells has somewhat  reduced neutralization (2.7x) vs wild type with monoclonal antibody Sotrovimab (a.k.a. VIR-7831).  [delins at 214 omitted for syntax compatibility]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Wang	2022	doi:10.1101/2022.08.11.503601	n/a	https://doi.org/10.1101/2022.08.11.503601	False	Wang et al. (2022)	n/a	Omicron breakthrough infection after 3-dose vaccination resulted in a further 3.5-fold and 2.9-fold increase of Omicron BA.1 and BA.2 neutralizing titers. Omicron  BA.4/5 showed the highest neutralization resistance of all variants tested, resulting in low geometric mean neutralizing titers in plasma samples  obtained after  the second vaccine dose (NT50	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs Bi-Nab47D10-35B5. Omicron BA.1 has an IC50 fold change of 0.08x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron B.1.1.529 (BA.1) neutralization of the Omicron variants by antibodies induced by three doses of Pfizer/BNT162b2 mRNA vaccine was 7-8-fold less potent than  the D614G, and the Omicron variants still evade neutralization more efficiently.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron (B.1.1.529 [BA.1]) have higher sensitivity to inhibition by soluble angiotensin converting enzyme 2 (ACE2) and the endosomal inhibitor chloroquine compared  to D614G	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs Bi-Nab35B5-47D10. Omicron BA.1 has an IC50 fold change of 0.30x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Uhal B	2022	doi:10.1101/2022.06.23.497326	n/a	https://doi.org/10.1101/2022.06.23.497326	False	Uhal B et al. (2022)	n/a	Paradigms’ ACE-2 variant LVE/STR chimera binds to SARS-2 Omicron variant B.1.1.529 spike protein trimer with high affinity. Determined using Surrogate Viral Neutralization Tests.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Uhal B	2022	doi:10.1101/2022.06.23.497326	n/a	https://doi.org/10.1101/2022.06.23.497326	False	Uhal B et al. (2022)	n/a	L27, V34 and E90 mutation resulted in ultrahigh affinity binding of the LVE-ACE-2 domain to the widest variety of VOCs, with KDs of 73 pM for binding to the Omicron  B.1.1.529. Values were obtained with LVE-ACE-2/mAB chimeras containing the Y-T-E sequence that enhances binding to the FcRn receptor, which in turn is expected to  extend biological half-life 3-4-fold.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs 35B5. Omicron BA.1 has an IC50 fold change of 0.38x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Arora	2022	doi:10.1038/s41423-022-00870-5	pmid:35581351	https://doi.org/10.1038/s41423-022-00870-5	True	Arora et al. (2022)	n/a	All 10 individuals with 2 doses of the BNT162b2/BNT162b2 vaccine had a neutralizing titer in B.1 variant at an average of 729 NT50.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Shete	2022	doi:10.1101/2022.05.12.491584	n/a	https://doi.org/10.1101/2022.05.12.491584	False	Shete et al. (2022)	n/a	Plaque reduction neutralization test (PRNT) was used uring primary infection, post sixty daysof second dose vaccination, pre-reinfection and reinfection against Delta variant and was used to determine neutralizing antibodytitres. There was a 24.63x fold increase in antibody response from first infection to recovered and vaccinated with 2 doses (60 days). There was a 4.21x fold increase in antibody response pre-reinfection. There was a 39.27x fold increase in antibody response during reinfection.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Shete	2022	doi:10.1101/2022.05.12.491584	n/a	https://doi.org/10.1101/2022.05.12.491584	False	Shete et al. (2022)	n/a	Plaque reduction neutralization test (PRNT) was used uring primary infection, post sixty daysof second dose vaccination, pre-reinfection and reinfection against B.1 variant and was used to determine neutralizing antibodytitres. There was a 6.76x fold increase in antibody response from first infection to recovered and vaccinated with 2 doses (60 days). There was a 2.06x fold increase in antibody response pre-reinfection. There was a 8.18x fold increase in antibody response during reinfection.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Arora	2022	doi:10.1038/s41423-022-00870-5	pmid:35581351	https://doi.org/10.1038/s41423-022-00870-5	True	Arora et al. (2022)	n/a	All 10 individuals with 3 doses of the BNT162b2/BNT162b2 vaccine had a neutralizing titer in B.1 variant at an average of 3319 NT50.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Shete	2022	doi:10.1101/2022.05.12.491584	n/a	https://doi.org/10.1101/2022.05.12.491584	False	Shete et al. (2022)	n/a	Plaque reduction neutralization test (PRNT) was used uring primary infection, post sixty daysof second dose vaccination, pre-reinfection and reinfection against Omicron variant and was used to determine neutralizing antibodytitres. There was a 114.84x fold increase in antibody response from first infection to recovered and vaccinated with 2 doses (60 days). There was a 6.61x fold increase in antibody response pre-reinfection. There was a 1194.9x fold increase in antibody response during reinfection.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Kumar	2022	doi:10.1101/2022.05.13.491770	n/a	https://doi.org/10.1101/2022.05.13.491770	False	Kumar et al. (2022)	n/a	BnAb 002-S21F2 IC50 on the Omicron BA.1 variant is 1.0x fold the wildtype.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs 47D10. Omicron BA.1 has an IC50 fold change of 1.26x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron BA.3 have higher sensitivity to inhibition by soluble angiotensin converting enzyme 2 (ACE2) and the endosomal inhibitor chloroquine compared  to D614G	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron BA.3 neutralization of the Omicron variants by antibodies induced by three doses of Pfizer/BNT162b2 mRNA vaccine was 7-8-fold less potent than the D614G, and  the Omicron variants still evade neutralization more efficiently.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.3 (from South Africa/NICD-N22404/2021) were 4.2x-fold lower (95% CI: 0.15x-0.20x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.3 (from South Africa/NICD-N22404/2021) were 6.2-fold lower (95% CI: 11.8x-14.3x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Hao	2022	doi:10.1101/2022.08.12.22278720	pmid:36032965	https://doi.org/10.1101/2022.08.12.22278720	False	Hao et al. (2022)	n/a	paired testing of vaccine sera against ancestral virus compared to Omicron BA.1 shows that 3-dose vaccine regimen provides over 50x fold increase in protection against Omicron(B.1.1.529 [BA.1]) compared to a 2-dose regimen.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Wang	2022	doi:10.1101/2022.08.11.503601	n/a	https://doi.org/10.1101/2022.08.11.503601	False	Wang et al. (2022)	n/a	4th antigenic exposure with Omicron (B.1.1.529 [BA.1])(n	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.1 (from Botswana/R40B59_BHP_3321001248/2021) were 3.4-fold lower (95% CI: 3.2x-3.6x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.1 (from Botswana/R40B59_BHP_3321001248/2021) were 28.7x-fold lower (95% CI: 0.03x-0.05) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.4/5 (from ) were 17.2x-fold lower (95% CI: 0.6x-0.7x) than against 208-428 972-1834 4.3-4.7 US-WA1/2020 usiong an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.4/5 (from ) were 13.0-fold lower (95% CI: 4.2x-4.6x) than against 208-428 972-1834 4.3-4.7 US-WA1/2020 usiong an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	outcome hazard ratio	n/a	n/a	Ulloa	2021	doi:10.1101/2021.12.24.21268382	n/a	https://doi.org/10.1101/2021.12.24.21268382	False	Ulloa et al. (2021)	n/a	In Ontario, using a retrospective matched case (age, gender and onset date) study of 6,312 Omicron cases vs 8,875 Delta,  the adjusted risk of hospitalization or death was 54% lower (HR	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Stamatatos	2021	doi:10.1126/science.abg9175	pmid:33766944	https://doi.org/10.1126/science.abg9175	True	Stamatatos et al. (2021)	n/a	In sera collected from 15 early pandemic patients (Seattle Flu Study), mean 16 days post first dose with either Pfizer/BioNTech or Moderna vaccines,  the median ID50 titers were ~10-fold lower against this B.1.351 pseudotyped virus relative to wild type. A single asymptomatic patient, who had no detectable RBD-specific IgG memory before vaccination, also did not elicit nAbs against the B.1.351 variant. [compare to ~3 fold without the deletion] ID50 titres in non-infected mRNA vaccines more than two weeks post-booster were significant, but ~500x weaker than in previously infected patients  after first dose.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Pegu	2021	doi:10.1101/2021.05.13.444010	pmid:34031659	https://doi.org/10.1101/2021.05.13.444010	False	Pegu et al. (2021)	n/a	Detectable antibodies against B.1.351 at various time points using pseudotyped lentivirus neutralization in Moderna vaccinee cohort: Day 29 8%, Day 43 100%, Day 119 71%, Day 209 54%. Detectable antibodies against B.1.351 at various time points using live virus FRNT neutralization in Moderna vaccinee cohort: Day 29 8%, Day 43 100%, Day 119 79%, Day 209 58%. Detectable antibodies against B.1.351 at various time points using ACE2 blocking assay in Moderna vaccinee cohort: Day 29 63%, Day 43 100%, Day 119 71%, Day 209 79%. Decreased neutralization on some assays was seen especially in those vaccinees tested that were 71+.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Abe	2021	doi:10.1101/2021.08.06.21261721	n/a	https://doi.org/10.1101/2021.08.06.21261721	False	Abe et al. (2021)	n/a	In an Ontario long term care facility, cumulatively, weaker BNT162b2 vaccine stimulation, age/comorbidities, produced a ∼130-fold reduction  in apparent neutralization titers in mean 88yo LTCH residents against Beta (B.1.351), relative to staff vaccinees against D614G wild type.  37.9% of 116 two-dose-mRNA-vaccinated residents had undetectable neutralizing antibodies to B.1.351. mRNA-1273 vaccinee sera displayed ~2 better neutralization than BNT162b2. [common defining B.1.351 mutations noted, as the manuscript does not provide details]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Stamatatos	2021	doi:10.1126/science.abg9175	pmid:33766944	https://doi.org/10.1126/science.abg9175	True	Stamatatos et al. (2021)	n/a	Anti-NTD CV1 mAb isolated from an early pandemic case was unable to neutralize either partial B.1.351 variant pseudovirus used (A701V or L242del). The neutralization potency of mAb CV30, which contacts K417 and N501 but not E484, was ~10-fold weaker toward both B.1.351 variants. The neutralization potency of anti-RBD mAb CV3-1 was 3-4-fold less potent against the B.1.351 variants, while anti-RBD mAb CV2-75 was modestly less effective.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Stamatatos	2021	doi:10.1126/science.abg9175	pmid:33766944	https://doi.org/10.1126/science.abg9175	True	Stamatatos et al. (2021)	n/a	Using convalescent sera from 15 early pandemic patients (Seattle Flu Study), mean 220 days post symptom onset (IQR 125-269, and three asymptomatic cases) with 27% WHO disease severity scale 3, 7 of 15 neutralized this B.1.351 pseudotype that includes the L242del, and only one had titers above 100.  Only one of the 15 sera achieved 80% neutralization. [compare to 5 and 1 for pseudotype without the deletion]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Tada	2021	doi:10.1101/2021.05.14.444076	n/a	https://doi.org/10.1101/2021.05.14.444076	False	Tada et al. (2021)	n/a	Pseudotyped viruses for B.1.351 was 3.4-fold resistant to neutralization by 6 BNT162b2 vaccine sera 28 days post-booster compared to wild type. Neutralization by 3 Moderna vaccine sera 28 days post-booster was 2.2-fold resistant. [Exact list of B.1.351 mutations used in these assays was not included in the preprint]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs Bi-Nab35B5-47D10. Beta (B.1.351) has an IC50 fold change of 0.13x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Rosenke	2022	doi:10.1172/jci.insight.160108	pmid:35579953	https://doi.org/10.1172/jci.insight.160108	True	Rosenke et al. (2022)	n/a	Infectious viral titers in lung tissue determined using a tissue culture infectious dose (TCID) assay in 10 hamsters showed that Beta Molnupiravir (MK-4482) had ~1.75x fold drop.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Zhou	2021	doi:10.1016/j.cell.2021.02.037	pmid:33730597	https://doi.org/10.1016/j.cell.2021.02.037	True	Zhou et al. (2021)	n/a	The B.1.351 variant constellation causes an ∼20-fold increase in affinity for ACE2 compared with Wuhan RBD, which may influence transmissibility.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	humoral response durability	n/a	n/a	Betton	2020	doi:10.1093/cid/ciab308	pmid:33851216	https://doi.org/10.1093/cid/ciab308	True	Betton et al. (2020)	n/a	In a prospective study of 107 hospitalized patients, decrease of IgG rates and serological assays becoming  negative did not imply loss of neutralizing capacity. Our results indicate a sustained humoral response against the  ancestral strain and the D614G, B.1.1.7 and P.1 variants for at least 6 months (last of two samples taken)  in patients previously hospitalized for COVID-19. A weaker protection was however observed for the B.1.351 variant.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	trafficking	n/a	n/a	Esclera	2021	doi:10.1101/2021.08.05.455290	n/a	https://doi.org/10.1101/2021.08.05.455290	False	Esclera et al. (2021)	n/a	~6x cleavage of S2 relative to WA1 (D614G) wildtype by Beta variant as measured by mass spectrometry of Vero-TMPRSS culture  [no mutations directly at furin cleavage site, but A701V is downstream] Compare to 4.5x or less for variants of concern with  direct furin clevage site mutations.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	outcome hazard ratio	n/a	n/a	Abu-Raddad	2021	doi:10.1101/2021.08.02.21261465	n/a	https://doi.org/10.1101/2021.08.02.21261465	False	Abu-Raddad et al. (2021)	n/a	Compared to Alpha (B.1.1.7) variant, odds of progressing to severe disease were 1.24-fold (95% CI: 1.11-1.39) higher for Beta.  Odds of progressing to critical disease were 1.49-fold (95% CI: 1.13-1.97) higher. Odds of COVID-19 death were 1.57-fold (95% CI: 1.03-2.43) higher.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Kumar	2022	doi:10.1101/2022.05.13.491770	n/a	https://doi.org/10.1101/2022.05.13.491770	False	Kumar et al. (2022)	n/a	BnAb 002-S21F2 IC50 on the Beta (B.1.351) variant is 0.4x fold the wildtype.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Zhou	2021	doi:10.1016/j.cell.2021.02.037	pmid:33730597	https://doi.org/10.1016/j.cell.2021.02.037	True	Zhou et al. (2021)	n/a	In 34 convalescent cases 4–9 weeks following infection in June 2020, before the emergence of B.1.1.7, neutralization titers  against B.1.351 were, on average, 13.3-fold reduced compared with an early Victoria sample (p < 0.0001). Significantly, 18  of 34 samples failed to reach 50% neutralization at a plasma dilution of 1:20, with a number showing a near total reduction of neutralization activity. In 13 convalescent cases 4–9 weeks following infection with B.1.1.7, neutralization titers  against B.1.351 were, on average, 3.1-fold reduced compared with an early Victoria sample (p < 0.0001).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs Bi-Nab47D10-35B5. Beta (B.1.351) has an IC50 fold change of 0.15x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Liu	2021	doi:10.1056/NEJMc2102017	pmid:33684280	https://doi.org/10.1056/NEJMc2102017	True	Liu et al. (2021)	n/a	Vaccine plasma neutralization of B.1.351-spike virus was nominally robust but lower (~3x) than other variants of concern.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Choi	2021	doi:10.1101/2021.06.28.449914	n/a	https://doi.org/10.1101/2021.06.28.449914	False	Choi et al. (2021)	n/a	Neutralization efficiency (ID50) against B.1.1.351-v3 reduced 8.4x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Zhou	2021	doi:10.1016/j.cell.2021.02.037	pmid:33730597	https://doi.org/10.1016/j.cell.2021.02.037	True	Zhou et al. (2021)	n/a	Testing against B.1.351 the 20 most effective mAbs (19 anti-RBD, 1 anti-NTD) from a screen of 377 against wild type,  4 of 20 antibodies had >10-fold fall in neutralization titers, with most of these showing a complete knockout of  activity. This is in line with the key roles of K417, E484, and N501, in particular E484, in antibody recognition  of the ACE2 interaction surface of the RBD. Regeneron mAb cocktail: The neutralization of REGN10987 was unaffected by B.1.351, while REGN10933 was severely impaired (773-fold). AstraZeneca mAb cocktail: Neutralization by the AZ pair of antibodies was little affected on B.1.351 compared with Victoria.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Madhi	2021	doi:10.1101/2021.02.10.21251247	n/a	https://doi.org/10.1101/2021.02.10.21251247	False	Madhi et al. (2021)	n/a	A two-dose regimen of (AstraZeneca) ChAdOx1-nCoV19 did not show protection against mild-moderate Covid-19 due to B.1.351 variant, however,  vaccine efficacy against severe Covid-19 is undetermined.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	UNKNOWN	n/a	n/a	n/a	n/a	n/a	UNKNOWN et al. ()	n/a	The Janssen single dose vaccine showed 72% efficacy at preventing moderate and severe disease, which was  reduced to 57% in South Africa, where 92.6% of infections are estimated to have been B.1.351. 100% reduction in  hospitalization risk remains across variants after 28 days post-vaccination.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	anthropozoonotic events	n/a	n/a	Montagutelli	2021	doi:10.1101/2021.03.18.436013	n/a	https://doi.org/10.1101/2021.03.18.436013	False	Montagutelli et al. (2021)	n/a	Unlike wild type or B.1.1.7, B.1.351 lineage virus was able to infect and replicate in common lab mouse strains, with high titer. PG: The virus used in these expriments has a non-typical deletion+sub in the 242 region.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs 35B5. Beta (B.1.351) has an IC50 fold change of 0.13x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Zhou	2021	doi:10.1016/j.cell.2021.02.037	pmid:33730597	http://doi.org/10.1016/j.cell.2021.02.037	True	Zhou et al. (2021)	n/a	Sera from healthcare workers (n 	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs 47D10. Beta (B.1.351) has an IC50 fold change of 0.88x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	outcome hazard ratio	n/a	n/a	Funk	2021	doi:10.2807/1560-7917.ES.2021.26.16.2100348	pmid:33890566	https://doi.org/10.2807/1560-7917.ES.2021.26.16.2100348	True	Funk et al. (2021)	n/a	On average across 7 European countries studied, using B.1.351 defining mutations: Significant shift to infection in those without pre-existing conditions (79.6% vs 89% for non-VOC cases). Significant increase in hospitalization rate (19.3% vs 7.5% for non-VOC cases). Significant increase in ICU rate (2.3% vs 0.6% for non-VOC cases). PG: seems to be different notations around the LAL deletion, using the minimal shared definition to catch as many as possible.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Garcia-Beltran	2021	doi:10.1016/j.cell.2021.03.013	pmid:33743213	https://doi.org/10.1016/j.cell.2021.03.013	True	Garcia-Beltran et al. (2021)	n/a	Pseudotyped B.1.351 v1 virus has reduced neutralization activity vs wild type: 34.5x (30 sera Pfizer median 9 days post 2nd dose)  and 27.7x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA. Notably, 36.7% (11/30) recipients of two-dose Pfizer and 42.9% (15/35) recipients of two-dose Moderna vaccines did not have  detectable neutralization of at least one of the B.1.351 variants.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Gallagher	2021	doi:10.1101/2021.05.03.442455	pmid:33972942	https://doi.org/10.1101/2021.05.03.442455	False	Gallagher et al. (2021)	n/a	ELISpot assays show T cell neutralization reduced by 29.8% in this B.1.351 pseudotype relative to wild type in 18-20 pooled patient samples post second mRNA vaccine dose, with no significant difference between Pfizer and Moderna cohorts. Reduction was stronger in the S1 subunit than S2 (separate peptide pools were used).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Alenquer	2021	doi:10.1101/2021.04.22.441007	n/a	https://doi.org/10.1101/2021.04.22.441007	False	Alenquer et al. (2021)	n/a	Using B.1.351 defining mutations for Spike, observed 4x average decrease in neutralization efficiency  (but still relevant titres) for sera from 10 BNT162b2 vaccinees 12 days after second dose, but only one  relevant titre 12 days after first dose. Compares unfavorably to wild type or B.1.1.7 titres.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Stamatatos	2021	doi:10.1126/science.abg9175	pmid:33766944	https://doi.org/10.1126/science.abg9175	True	Stamatatos et al. (2021)	n/a	Using convalescent sera from 15 early pandemic patients (Seattle Flu Study), mean 220 days post symptom onset (IQR 125-269, and three asymptomatic cases) with 27% WHO disease severity scale 3, one third (5/15) of sera neutralized this B.1.351 pseudotype and only three had ID50 titers above 100. Only two of the 15 sera achieved 80% neutralization.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Stamatatos	2021	doi:10.1126/science.abg9175	pmid:33766944	https://doi.org/10.1126/science.abg9175	True	Stamatatos et al. (2021)	n/a	In sera collected from 15 early pandemic patients (Seattle Flu Study), mean 16 days post first dose with either Pfizer/BioNTech or Moderna vaccines,  the median ID50 titers were ~3-fold lower against this B.1.351 pseudotyped virus relative to wild type. A single asymptomatic patient, who had no detectable RBD-specific IgG memory before vaccination, also did not elicit nAbs against the B.1.351 variant. [compare to ~10 fold with L242del] ID50 titres in non-infected mRNA vaccines more than two weeks post-booster were signficiant, but >100x weaker than in previously infected  patients after first dose.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	reinfection	n/a	n/a	Staub	2021	doi:10.2807/1560-7917.ES.2021.26.18.2100423	pmid:33960291	https://doi.org/10.2807/1560-7917.ES.2021.26.18.2100423	True	Staub et al. (2021)	n/a	4 health care workers in the 20's and 30's with no underlying conditions and seropositivity or confirmed 2020 SARS-CoV-2 infections were confirmed to have B.1.351 infection during a Februrary 2021 hospital outbreak in Luxembourg. Symptoms were mostly mild on first infection, and milder on second infection.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	reinfection	n/a	n/a	Yinda	2021	doi:10.1101/2021.05.05.442780	n/a	https://doi.org/10.1101/2021.05.05.442780	False	Yinda et al. (2021)	n/a	Hamsters re-infected with B.1.351 virus after seroversion from previous infection with a lineage A virus did not transmit  virus to naive sentinels via direct contact transmission, in contrast to the non-seroconverted animals. They had little  infectious virus and no pathology in the lungs. Initial infection with SARS-CoV-2 lineage A does not prevent heterologous reinfection with B.1.351, but prevents disease and onward transmission.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	symptom prevalence	n/a	n/a	Munster	2021	doi:10.1101/2021.05.07.443115	pmid:34382034	https://doi.org/10.1101/2021.05.07.443115	False	Munster et al. (2021)	n/a	Inoculation with the B.1.351 isolate resulted in lower clinical scores in 6 rhesus macaques that correlated with lower virus  titers in the lungs, less severe histologic lung lesions and less viral antigen detected in the lungs. Our comparative  pathogenicity study suggests that ongoing circulation under diverse evolutionary pressure favors transmissibility and  immune evasion rather than an increase in intrinsic pathogenicity.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Garcia-Beltran	2021	doi:10.1016/j.cell.2021.03.013	pmid:33743213	https://doi.org/10.1016/j.cell.2021.03.013	True	Garcia-Beltran et al. (2021)	n/a	Pseudotyped B.1.351 v3 virus has reduced neutralization activity vs wild type: 42.4x (30 sera Pfizer median 9 days post 2nd dose)  and 19.2x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA. Notably, 36.7% (11/30) recipients of two-dose Pfizer and 42.9% (15/35) recipients of two-dose Moderna vaccines did not have  detectable neutralization of at least one of the B.1.351 variants.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Huang	2021	doi:10.1101/2021.02.01.429069	n/a	https://doi.org/10.1101/2021.02.01.429069	False	Huang et al. (2021)	n/a	The neutralization activities of two vaccines developed in China were tested against 501Y.V2 authentic virus: inactivated BBIBP-CorV (no  significant change) and recombinant dimeric RBD vaccine ZF2001 (~1.6x reduction vs wildtype, p	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Röltgen	2021	doi:10.1101/2021.04.05.21254952	pmid:33851181	https://doi.org/10.1101/2021.04.05.21254952	False	Röltgen et al. (2021)	n/a	Most of the plasma from 55 Pfizer vaccinees developed high percentages of Wuhan-Hu-1 S-ACE2 blocking activity, peaking at day 28 (7 days post-boost).  A strikingly consistent hierarchy of reduction in plasma antibody binding by variant S and RBD antigens was observed among study  participants, with progressively decreased binding for B.1.1.7 (not significant), P.1 (significant) and B.1.351 (significant) compared to Wuhan-Hu-1 antigens.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Bailly	2021	doi:10.1093/cid/ciab446	pmid:33993228	https://doi.org/10.1093/cid/ciab446	True	Bailly et al. (2021)	n/a	During an outbreak of SARS-CoV-2 501Y.V2 in a nursing home, all non-vaccinated residents (5/5) versus  half of those fully vaccinated 2-5 weeks prior with BNT162b2 (13/26) were infected. Two of 13 vaccinated versus 4 of 5  non-vaccinated residents presented severe disease. BNT162b2 did not prevent the outbreak, but reduced  transmission and disease severity. Among the 13 fully vaccinated residents who were infected, 2 (15.4%) presented with an asymptomatic disease, 9 (69.2%) developed mild to moderate symptoms, and 2 (15.4%) progressed to severe disease with fatal evolution secondary to acute respiratory distress syndrome (ARDS). There was no relationship between anti-S antibody levels at diagnosis and disease severity. Overall, the proportion of residents with severe disease in the non-vaccinated group (4/5)  was higher than that in the vaccinated group (2/13). Only 1 vaccinated staff, but 10 unvaccinated were infected in the outbreak (no severe disease).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Chen	2021	doi:10.1038/s41591-021-01294-w	pmid:33664494	https://doi.org/10.1038/s41591-021-01294-w	True	Chen et al. (2021)	n/a	The neutralizing activity of vaccine was significantly lower against B.1.351 in sera from all 24 patients with the BNT162b2 mRNA vaccine. (Fig. 4)	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Luftig	2021	doi:10.1056/NEJMc2104036	pmid:33826815	https://doi.org/10.1056/NEJMc2104036	True	Luftig et al. (2021)	n/a	In sera 1-2 weeks after BNT162b2 first dose, from six patients previously infected with B.1, antibody titer in a microneutralization assay  was on average 1625 for B.1.351 virus. This compares favorably (stronger) to most post-infection neutralization titer against all variants tested in the same sera (wild type, B.1.1.7, B.1.351, and P.1).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Wang	2021	doi:10.1056/NEJMc2103022	pmid:33822491	https://doi.org/10.1056/NEJMc2103022	True	Wang et al. (2021)	n/a	2.5x reduction in neutralization by serum collected 2 to 3 weeks after the second dose from vaccinees who had received  BBIBP-CorV (pVNT50 against VSV pseudotyped as B.1.351). Convalescent plasma had similar titer against wild type as the BBIBP-CorV vaccinee sera. >3x reduction in neutralization by serum collected 2 to 3 weeks after the second dose from vaccinees who had received  CoronaVac (pVNT50 against VSV pseudotyped as B.1.351). Convalescent plasma had similar titer against wild type as the CoronaVac vaccinee sera.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Chen	2021	doi:10.1038/s41591-021-01294-w	pmid:33664494	https://doi.org/10.1038/s41591-021-01294-w	True	Chen et al. (2021)	n/a	B.1.1.351 variant constellation two-tailed Wilcoxon matched-pairs signed-rank test against 10 convalescent sera P	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	UNKNOWN	2021	n/a	n/a	https://www.fda.gov/media/146217/download	False	UNKNOWN et al. (2021)	n/a	Study 3001 on Ad26.COV2.S (Jannsen vaccine) conducted September 21, 2020 through January 22, 2021 overlaps the emergence and dominance  of the B.1.351 lineage of SARS-CoV-2 in South Africa. The SA arms of the Phase 3 double blind study showed severe/critical disease VE of 73.1%  (95% CI: 40.0-89.4), and moderate to severe/critical disease VE of 52.0% (95% CI: 30.3-67.4). Compare to 78.0% and 74.4% for North American arm of the study during the same period (with low B.1.351 prevalence). Of the 66.9% of SA severe infections that have been sequenced as of this report, 94.5% are B.1.351.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Solfrosi	2021	doi:10.1084/jem.20202756	pmid:33909009	https://doi.org/10.1084/jem.20202756	True	Solfrosi et al. (2021)	n/a	The dominant circulating B.1.351 spike variant originating in RSA, which harbors E484K and additional substitutions in the  RBD, NTD, and S2 and deletions in the NTD (amino acids 242–244), was neutralized with a 5.02-fold reduced titer	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Chen	2021	doi:10.1038/s41591-021-01294-w	pmid:33664494	https://doi.org/10.1038/s41591-021-01294-w	True	Chen et al. (2021)	n/a	B.1.1.351 in 19 convalescent human sera ~1mo post infection had mild to moderate resistance against all samples	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Chen	2021	doi:10.1038/s41591-021-01294-w	pmid:33664494	https://doi.org/10.1038/s41591-021-01294-w	True	Chen et al. (2021)	n/a	B.1.1.351 variant constellation ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07, COVOX-384, and S2H58. B.1.1.351 variant constellation ablates Class 3 N-terminal domain targeting antibodies COV2-2489 and COV2-2676 (the only two tested).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Cochin	2021	doi:10.1101/2021.04.19.440435	n/a	https://doi.org/10.1101/2021.04.19.440435	False	Cochin et al. (2021)	n/a	In a Syrian hamster model, B.1.351 variant virus had >4x reduction in YRNT90 (measure of neutralization) using wild type convalescent sera. PG: Note that exact sequence for B.1.351 used was not disclosed.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	McCallum	2021	doi:10.1101/2021.03.31.437925	pmid:33821281	https://doi.org/10.1101/2021.03.31.437925	False	McCallum et al. (2021)	n/a	In 13 plasma collected ~1mo after B.1.1.7 infection (nursing home in Ticino, Switzerland), neutralization  reduced to undetectable levels in many plasma for B.1.351 pseudotyped virus, as well as WT and other VOCs.  [paper does not detail the B.1.351 variants used, using the most popular as a stad in]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma binding	n/a	n/a	Hoffman	2021	doi:10.1016/j.cell.2021.03.036	pmid:33794143	https://doi.org/10.1016/j.cell.2021.03.036	True	Hoffman et al. (2021)	n/a	VSV pseudotype B.1.351 showed 7.86-fold decrease in NT50 vs wild type in sera from 9 ICU patients undergoing treatment in Germany (pre-variant infections).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Hoffman	2021	doi:10.1101/2021.05.04.442663	n/a	https://doi.org/10.1101/2021.05.04.442663	False	Hoffman et al. (2021)	n/a	Abrogates Bamlanivimab, Etesevimab, or their combined use neutralization as quantified by measuring virus-encoded luciferase  activity in cell lysates at 16-18 h post transduction.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Hoffman	2021	doi:10.1101/2021.05.04.442663	n/a	https://doi.org/10.1101/2021.05.04.442663	False	Hoffman et al. (2021)	n/a	Approximately 6-fold reduction in 15 ICU patient convalescent plasma neutralization as quantified by measuring virus-encoded luciferase  activity in cell lysates at 16-18 h post transduction.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Tada	2021	doi:10.1101/2021.02.05.430003	pmid:33564768	https://doi.org/10.1101/2021.02.05.430003	False	Tada et al. (2021)	n/a	Vaccine elicited antibodies neutralized virus with the B.1.351 spike protein had an average 3-fold reduction in titer (1:500),  a titer that was still higher than the average titer with which convalescent sera neutralized D614G (1:139). Serum specimens  from individuals vaccinated with the BNT162b2 mRNA vaccine neutralized D614G virus with titers that were on average 7-fold greater  than convalescent sera.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	trafficking	n/a	n/a	Hoffman	2021	doi:10.1101/2021.05.04.442663	n/a	https://doi.org/10.1101/2021.05.04.442663	False	Hoffman et al. (2021)	n/a	In one of eight cell lines tested (293T lung cells), a modest increase in cell entry was observed.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Leier	2021	doi:10.1101/2021.04.25.21256049	pmid:33948601	https://doi.org/10.1101/2021.04.25.21256049	False	Leier et al. (2021)	n/a	Neutralizing antibody titers increased in previously infected vaccinees relative to uninfected vaccinees  6.5-fold against B.1.351 (contrast with 3.4 fold against original SARS-CoV-2).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Hoffman	2021	doi:10.1016/j.cell.2021.03.036	pmid:33794143	https://doi.org/10.1016/j.cell.2021.03.036	True	Hoffman et al. (2021)	n/a	VSV pseudotype B.1.351 entry mediated by the S proteins of the B.1.351 variant was completely resistant to blocking by REGN10989 and Bamlanivimab. Entry driven by the S proteins of the B.1.351 was partially resistant against Casirivimab.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Zhou	2021	doi:10.1101/2021.03.24.436620	pmid:33791698	https://doi.org/10.1101/2021.03.24.436620	False	Zhou et al. (2021)	n/a	B.1.351 pseudotyped lentivirus showed 3.4 and 3.8x reduction in IC50 serum dilution concentration for sera from BNT162b2 (Pzifer) or mRNA1273 (Moderna) vacinees collected 28 days following booster dose.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Hoffman	2021	doi:10.1016/j.cell.2021.03.036	pmid:33794143	https://doi.org/10.1016/j.cell.2021.03.036	True	Hoffman et al. (2021)	n/a	VSV pseudotype B.1.351 showed 7.85-fold reduction in neutralization efficiency vs wild type in 15 Pfizer BNT162b2 vaccinee sera 13-15 days post second dose. Cell fusion proficiency was slight impaired.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Reynolds	2021	doi:10.1126/science.abh1282	pmid:33931567	https://doi.org/10.1126/science.abh1282	True	Reynolds et al. (2021)	n/a	After one dose, individuals with prior infection showed enhanced T cell immunity,  antibody secreting memory B cell response to spike and neutralizing antibodies effective  against B.1.351 (authentic cell culture supernatants). By comparison, HCW receiving one vaccine dose without prior  infection showed reduced immunity against variants. B.1.351 spike mutations  resulted in increased, abrogated or unchanged T cell responses depending on human leukocyte  antigen (HLA) polymorphisms. Study was 26 each post-infection and post first dose HCWs.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	trafficking	n/a	n/a	Hoffman	2021	doi:10.1016/j.cell.2021.03.036	pmid:33794143	https://doi.org/10.1016/j.cell.2021.03.036	True	Hoffman et al. (2021)	n/a	VSV pseudotype B.1.351 showed slight decrease in cell entry relative to wild type in 263T-ACE2 (kidney) cell line, and slight increase in Calu-3 (lung). Cell fusion proficiency was slight impaired.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma binding	n/a	n/a	Supasa	2021	doi:10.1016/j.cell.2021.02.033	pmid:33743891	https://doi.org/10.1016/j.cell.2021.02.033	True	Supasa et al. (2021)	n/a	We analyzed 34 convalescent samples including the WHONIBSC 20/130 reference serum, and, although  a few sera showed near identical FRNT 50 values, the FRNT50 dilutions for the B.1.1.7 strain  were 2.9-fold lower (geometric mean) than those for the Victoria strain (p < 0.0001). Sera from 13 subjects post-B.1.1.7 infection showed no significant change in neutralization against Victoria (~wild type), suggesting that B.1.1.7 infection also protects against ancestral virus. [Note that D1119H was included in the original paper, assuming typographical error and correcting to D1118H]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	UNKNOWN	n/a	n/a	n/a	,	n/a	UNKNOWN et al. ()	n/a	n/a	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Hoffman	2021	doi:10.1101/2021.05.04.442663	n/a	https://doi.org/10.1101/2021.05.04.442663	False	Hoffman et al. (2021)	n/a	In 15 Pzifer non-senior vaccinee sera collected 3-4 weeks post-booster [using Table S1, not the text that says 2-3 weeks], neutralization was reduced ~11x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	UNKNOWN	n/a	n/a	n/a	,	n/a	UNKNOWN et al. ()	n/a	In Qatar, where Pfizer vaccine use is prevalent (<10% of the population covered in the time period of the study ending Mar 31, 2021), any time after one dose  (including the 2 weeks where no major effect is expected) B.1.351 lineage effectiveness was observed as 16.9% (95% CI [10.4,23.0]) against infection, and 0% against severe/critical/fatal disease  (95% CI [0-19.0]). Two weeks or more after 2nd dose, effectiveness climbed to 75.0% [70.5,78.9] against infection, and 100% against  severe/critical/fatal disease (95% CI [73.7,100]).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  XD (from ) were 1.5x-fold lower (95% CI: 0.05x-0.07x) than against 208-428 972-1834 4.3-4.7 US-WA1/2020 usiong an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  XD (from ) were 4.4-fold lower (95% CI: 4.3x-4.7x) than against 208-428 972-1834 4.3-4.7 US-WA1/2020 usiong an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Yue	2023	doi:10.1101/2023.01.03.522427	n/a	https://doi.org/10.1101/2023.01.03.522427	False	Yue et al. (2023)	n/a	The hACE2-binding affinity of XBB.1.5 RBD has a dissociation constant KD of 3.4 nM, where S486P is the distinguishing Spike mutation vs parent  XBB.1 RBD with a much weaker KD (19 nM), as measured by surface plasmon resonance (SPR) assays.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Sun	2021	doi:10.1101/2021.03.22.436481	n/a	https://doi.org/10.1101/2021.03.22.436481	False	Sun et al. (2021)	n/a	>20% (ELISA significance threshold) drop in antibody binding (ELISA) by this variant against IgG1 monoclonal antibody ab1.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Zhang	2021	doi:10.1038/s41467-021-24514-w	pmid:34244522	https://doi.org/10.1038/s41467-021-24514-w	True	Zhang et al. (2021)	n/a	Causes no detectable change in KD value for antibody binding of P5A-1D2.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Tian	2021	doi:10.1101/2021.02.14.431117	n/a	https://doi.org/10.1101/2021.02.14.431117	False	Tian et al. (2021)	n/a	Reported 3-fold decrease in affinity compared to wild-type RBD on the cell surface (Kd 	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Zhang	2021	doi:10.1038/s41467-021-24514-w	pmid:34244522	https://doi.org/10.1038/s41467-021-24514-w	True	Zhang et al. (2021)	n/a	Causes no detectable change in KD value for antibody binding of P22A-1D1.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Barton	2021	doi:10.1101/2021.05.18.444646	n/a	https://doi.org/10.1101/2021.05.18.444646	False	Barton et al. (2021)	n/a	The K417N mutation decreased the affinity ~4 fold, mainly by decreasing the k(on) but also by increasing the k(off) as measured by surface plasmon resonance.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	monoclonal antibody serial passage escape	n/a	n/a	Starr	2021	doi:10.1101/2021.02.17.431683	pmid:33655250	https://doi.org/10.1101/2021.02.17.431683	False	Starr et al. (2021)	n/a	Escape mutation against monoclonal antibody LY-CoV016	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Zhang	2021	doi:10.1038/s41467-021-24514-w	pmid:34244522	https://doi.org/10.1038/s41467-021-24514-w	True	Zhang et al. (2021)	n/a	No detectable fold drop in IC50 of P5A-3C8.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	monoclonal antibody serial passage escape	n/a	n/a	Wang	2021	doi:10.1101/2021.01.15.426911	pmid:33501451	https://doi.org/10.1101/2021.01.15.426911	False	Wang et al. (2021)	n/a	In vitro selection against class 1 (Spike 'up' conformation) monoclonal antibody C682, and to a lesser extent C614 and C660	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Zhang	2021	doi:10.1038/s41467-021-24514-w	pmid:34244522	https://doi.org/10.1038/s41467-021-24514-w	True	Zhang et al. (2021)	n/a	Causes 7.5 fold decrease in KD value for antibody binding of P2C-1F11.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Zhang	2021	doi:10.1038/s41467-021-24514-w	pmid:34244522	https://doi.org/10.1038/s41467-021-24514-w	True	Zhang et al. (2021)	n/a	Causes 1.5 fold decrease in KD value of antibody binding of ACE2.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Chen	2021	doi:10.1038/s41591-021-01294-w	pmid:33664494	https://doi.org/10.1038/s41591-021-01294-w	True	Chen et al. (2021)	n/a	In 19 convalescent human sera ~1mo post infection, Two-tailed Wilcoxon matched-pairs signed-rank test shows mild resistance P	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Zhang	2021	doi:10.1038/s41467-021-24514-w	pmid:34244522	https://doi.org/10.1038/s41467-021-24514-w	True	Zhang et al. (2021)	n/a	No detectable fold drop in IC50 of P5A-1D2.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Zhang	2021	doi:10.1038/s41467-021-24514-w	pmid:34244522	https://doi.org/10.1038/s41467-021-24514-w	True	Zhang et al. (2021)	n/a	Causes 36.9 fold decrease in KD value for antibody binding of P5A-3C8.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	trafficking	n/a	n/a	Tada	2021	doi:10.1101/2021.02.05.430003	pmid:33564768	https://doi.org/10.1101/2021.02.05.430003	False	Tada et al. (2021)	n/a	Lentiviral pseudotyped with this individual mutation from B.1.351 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing mild decrease in infection rate amongst the cells, suggesting that this  mutation does not contributing to cell entry fitness.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Engelhart	2021	doi:10.1101/2021.04.27.440939	n/a	https://doi.org/10.1101/2021.04.27.440939	False	Engelhart et al. (2021)	n/a	COR-101 lost ~6x binding against this isolated mutation. Estesevimab lost ~100x binding against this isolated mutation.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	gene expression increase	n/a	n/a	Starr	2020	doi:10.1016/j.cell.2020.08.012	pmid:32841599	https://doi.org/10.1016/j.cell.2020.08.012	True	Starr et al. (2020)	n/a	Experimentally, Spike gene expression increased 0.1 fold	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Wang	2021	doi:10.1038/s41586-021-03398-2	n/a	https://doi.org/10.1038/s41586-021-03398-2	True	Wang et al. (2021)	n/a	Pseudotyped virus model ablates binding by RBD-directed mAbs CB6 and 910-30 (targeting the inner side of the RBD). Pseudotyped virus model impairs binding by RBD-directed mAbs 4-20 and REGN10933.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Wang	2021	doi:10.1101/2021.01.15.426911	pmid:33501451	https://doi.org/10.1101/2021.01.15.426911	False	Wang et al. (2021)	n/a	5 antibodies tested were less potent against K417N by ten-fold or more (class 1 mAbs)	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	virion structure	n/a	n/a	Spratt	2021	doi:10.1101/2021.03.24.436850	pmid:33791700	https://doi.org/10.1101/2021.03.24.436850	False	Spratt et al. (2021)	n/a	Estimated free energy change (ddG) for this variant is -0.86 kcal/mol (i.e. destabilizing relative to wild type)	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Zhang	2021	doi:10.1038/s41467-021-24514-w	pmid:34244522	https://doi.org/10.1038/s41467-021-24514-w	True	Zhang et al. (2021)	n/a	1.1 fold drop in IC50 of P2C-1F11.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Zhang	2021	doi:10.1038/s41467-021-24514-w	pmid:34244522	https://doi.org/10.1038/s41467-021-24514-w	True	Zhang et al. (2021)	n/a	No detectable fold drop in IC50 of P22A-1D1.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Wu	2021	doi:10.1101/2021.01.25.427948	pmid:33501442	https://doi.org/10.1101/2021.01.25.427948	False	Wu et al. (2021)	n/a	In Moderna vaccinee sera, 2.7x reduction in neutralization, and 6.4 for the full B.1.351 Spike mutation complement, but despite the observed decreases,  titers in human vaccinee sera against the B.1.351 variant remained at clinically significant level of ~1/300.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Wibmer	2021	doi:10.1101/2021.01.18.427166	pmid:33501446	https://doi.org/10.1101/2021.01.18.427166	False	Wibmer et al. (2021)	n/a	27% of 44 early pandemic exposure convalescent plasma/sera lose all activity against a RBD triple mutant pseudovirus (RBD mutatants of the 501Y.V2 'South African' lineage), while only 23% retained high titres	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	viral load	n/a	n/a	Roquebert	2021	doi:10.1101/2021.03.19.21253971	n/a	https://doi.org/10.1101/2021.03.19.21253971	False	Roquebert et al. (2021)	n/a	B.1.351 and P.1 samples showed average Ct cycle threshold of 22.2 vs 23 for wildtype (i.e. ~60% higher viral load) comparing 3360 and 22535 samples respectively.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Liu	2021	doi:10.1101/2021.02.16.431305	pmid:33619479	https://doi.org/10.1101/2021.02.16.431305	False	Liu et al. (2021)	n/a	This mutated version of RBD completely abolishes the binding to a therapeutic antibody, Bamlanivimab, in vitro.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Chen	2021	doi:10.1038/s41591-021-01294-w	pmid:33664494	https://doi.org/10.1038/s41591-021-01294-w	True	Chen et al. (2021)	n/a	Ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07, COVOX-384, and S2H58.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Wang	2021	doi:10.1101/2021.01.15.426911	pmid:33501451	https://doi.org/10.1101/2021.01.15.426911	False	Wang et al. (2021)	n/a	In a cohort of 20 patients 8+ weeks after second vaccine dose of Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines,  a significant (0.5 to 20-fold, but average ~2x) decrease in neutralization by vaccine plasma was observed.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Barton	2021	doi:10.1101/2021.05.18.444646	n/a	https://doi.org/10.1101/2021.05.18.444646	False	Barton et al. (2021)	n/a	The affinity of the B.1.351 RBD variants for ACE2 increased by 3.7 fold as measured by surface plasmon resonance relative to wild  type RBD by increasing the k(on) and decreasing the k(off) rate constants.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Wibmer	2021	doi:10.1101/2021.01.18.427166	pmid:33501446	https://doi.org/10.1101/2021.01.18.427166	False	Wibmer et al. (2021)	n/a	Ablates ELISA test binding for class 1 (Spike 'up' conformation only, RBD targeting) monoclonal antibody CA1 on 501Y.V2 ('South African') lineage background  Ablates ELISA test binding for class 1 (Spike 'up' conformation only, RBD targeting) monoclonal antibody LyCoV016 (also known as CB6 or JS016) on 501Y.V2 ('South African') lineage background Ablates ELISA test binding for class 1 (Spike 'up' conformation only, RBD targeting) monoclonal antibody CC12.1 on 501Y.V2 ('South African') lineage background Ablates ELISA test binding for class 2 (Spike 'up' or 'down' conformation, RBD targeting) monoclonal antibody BD23 on 501Y.V2 ('South African') lineage background  Ablates ELISA test binding for class 2 (Spike 'up' or 'down' conformation, RBD targeting) monoclonal antibody C119 (also known as CB6 or JS016) on 501Y.V2 ('South African') lineage background Ablates ELISA test binding for class 2 (Spike 'up' or 'down' conformation, RBD targeting) monoclonal antibody P2B-2F6 on 501Y.V2 ('South African') lineage background	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Chen	2021	doi:10.1038/s41591-021-01294-w	pmid:33664494	https://doi.org/10.1038/s41591-021-01294-w	True	Chen et al. (2021)	n/a	In 19 convalescent human sera ~1mo post infection had mild to moderate resistance against most samples	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Engelhart	2021	doi:10.1101/2021.04.27.440939	n/a	https://doi.org/10.1101/2021.04.27.440939	False	Engelhart et al. (2021)	n/a	Tixagevimab, Regdanvimab and COR-101 display reduced binding affinity to virus pseudotyped as RBD from B.1.351.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Collier	2021	doi:10.1038/s41586-021-03412-7	n/a	https://doi.org/10.1038/s41586-021-03412-7	True	Collier et al. (2021)	n/a	This combination showed ~3x increase binding to ACE2 vs wild type, about half that of the B.1.1.7 lineage, suggesting that the K417N mutation is slightly detrimental to ACE2 binding, probably as a result of disrupting the salt bridge formed with ACE2 residue D30	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Bates	2021	doi:10.1101/2021.04.04.21254881	pmid:33851185	https://doi.org/10.1101/2021.04.04.21254881	False	Bates et al. (2021)	n/a	Observed 1.4-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose)  against pseudotype B.1.351 key variants lentivirus. Compare to 8.8-fold reduction against cultured B.1.351 virus.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Sun	2021	doi:10.1101/2021.03.22.436481	n/a	https://doi.org/10.1101/2021.03.22.436481	False	Sun et al. (2021)	n/a	Complete loss of binding in ELISA by the variant against monoclonal antibodies ab8 and IgG1 ab1. Complete loss for the same antibodies was also observed against S1 pseudotyped and full Spike  protein trimers with both B.1.351 and P.1 lineage variants, with slight binding signal for P.1 against IgG1 at the highest concentration tested (1uM). Complete loss of neutralization by these two antibodies was also observed.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Ramanathan	2021	doi:10.1101/2021.02.22.432359	pmid:33655251	https://doi.org/10.1101/2021.02.22.432359	False	Ramanathan et al. (2021)	n/a	Using Mircoscale Thermopheresis, the B.1.351 variant harboring three mutations, binds ACE2 at nearly  five-fold greater affinity than the original SARS-COV-2 RBD (Kd 87.6, vs 402.5 nM).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Laffeber	2021	doi:10.1101/2021.02.22.432357	n/a	https://doi.org/10.1101/2021.02.22.432357	False	Laffeber et al. (2021)	n/a	RBD containing the N501Y mutation results in 9-fold stronger binding to the hACE2 receptor than  wild type RBD. The E484K mutation does not significantly influence the affinity for the receptor,  while K417N attenuates affinity. As a result, RBD from B.1.351 containing all three mutations binds  3-fold stronger to hACE2 than wild type RBD but 3-fold weaker than N501Y.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	viral load	n/a	n/a	Teyssou	2021	doi:10.1101/2021.03.21.21253498	n/a	https://doi.org/10.1101/2021.03.21.21253498	False	Teyssou et al. (2021)	n/a	The 62 B.1.351 (a.k.a. N501Y.V2) variant cases in three Paris hospital labs had a ~2-fold viral load increase  (~1 Ct drop in both N and ORF1ab probes) compared to 332 ancestral lineage cases from the same time frame (2020-12-20 to 2021-02-26).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Tian	2021	doi:10.1101/2021.02.14.431117	n/a	https://doi.org/10.1101/2021.02.14.431117	False	Tian et al. (2021)	n/a	Reported slight increase in affinity compared to wild-type RBD on the cell surface (Kd 	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Liu	2021	doi:10.1101/2021.02.16.431305	pmid:33619479	https://doi.org/10.1101/2021.02.16.431305	False	Liu et al. (2021)	n/a	Studying the key covariants in lineage of concern 501Y.V2,  observed about 2-fold increase in ACE2 binding vs wildtype, but greatly decreased mAb binding, suggesting evolutionary optimum tension between  immune evasion and ACE2 binding affinity as the N501Y variant alone has 10x increase in affinity but no effect on tested mAb binding.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Vogel	2021	doi:10.1101/2021.03.04.433887	n/a	https://doi.org/10.1101/2021.03.04.433887	False	Vogel et al. (2021)	n/a	The affinity of ACE2 for this mutation combination was twice as high as for wild type. Having in mind that the affinity of SARS-CoV-2 for ACE2 is only 4-fold higher compared to SARS-CoV-1, this factor of 2 is expected to be biologically significant.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	trafficking	n/a	n/a	Hu	2021	doi:10.1101/2021.01.22.427749	n/a	https://doi.org/10.1101/2021.01.22.427749	False	Hu et al. (2021)	n/a	The entry efficiencies of Spike pseudotyped viruses bearing N501Y Variant 2 (B.1.351) mutant were about 3 to 4.4 times higher than that of the WT pseudovirus when viral input was normalized, suggesting that these spike variants promote the infectivity of SARS-CoV-2.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	transmissibility	n/a	n/a	Roquebert	2021	doi:10.1101/2021.05.12.21257130	n/a	https://doi.org/10.1101/2021.05.12.21257130	False	Roquebert et al. (2021)	n/a	36,590 variant-specific RT-PCR tests were performed on samples collected between April 12 and May 7, 2021  in France to compare variant spread. Compared to January to March 2021, B.1.351 variant had a significant  transmission advantage over B.1.1.7 in some regions (15.1 to 16.1% in Île-de-France and 16.1 to 18.8% in Hauts-de-France). This shift in transmission advantage is consistent with the immune evasion abilities of B.1.351 and the high levels of immunization in these regions.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	transmissibility	n/a	n/a	Pearson	2021	n/a	n/a	https://cmmid.github.io/topics/covid19/reports/sa-novel-variant/2021_01_11_Transmissibility_and_severity_of_501Y_V2_in_SA.pdf	False	Pearson et al. (2021)	n/a	Assuming complete cross-protection, we estimate 501Y.V2/B.1.351 was 1.50 (95% CrI: 1.20-2.13) times as transmissible than previously circulating variants. Assuming instead that 501Y.V2 is identically transmissible, the new variant evades 21% (95% CrI: 11-36%) of previously acquired immunity. Reality may lie between these extremes, with an intermediate increase in transmissibility and mildly imperfect cross-protection from past exposure.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Alenquer	2021	doi:10.1101/2021.04.22.441007	n/a	https://doi.org/10.1101/2021.04.22.441007	False	Alenquer et al. (2021)	n/a	Average ~10-fold reduction in neutralization efficacy in convalescent sera of 16 health workers infected in Spring 2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Madhi	2021	doi:10.1056/NEJMoa2102214	pmid:33725432	https://doi.org/10.1056/NEJMoa2102214	True	Madhi et al. (2021)	n/a	In a multicenter, double-blind, randomized, controlled trial to assess the safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) with enrollment June 24 and November 9, 2020 from ~2000 HIV-negative 18-64 year olds (1:1 placebo to treatment), incidence of serious  adverse events 14 or more days post- 2nd dose was balanced between the vaccine and placebo groups. A two-dose regimen of the ChAdOx1  nCoV-19 vaccine did not show protection against mild-to-moderate Covid-19 due to the B.1.351 variant. Serum samples obtained from 13 ChAdOx1 nCoV-19 vaccine recipients without SARS-CoV-2 infection through 41 days after vaccination  showed 3.5x reduction in neutralization (ID50) for B.1.351 RBD pseudotype HIB-1 virus compared to D614G alone. This  RBD variant combination's neutralization by a placebo control  group of 6 naturally infected patients showed a similar 3.2x drop (though with D614G starting at a 1.7x higher titre than vaccinee sera).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Hu	2021	doi:10.1101/2021.01.22.427749	n/a	https://doi.org/10.1101/2021.01.22.427749	False	Hu et al. (2021)	n/a	Neutralizing antibody titers of 18 samples (90%) decreased against this B.1.351 pseudotyped virus below an ID50 threshold of 40 (sera  collected ~8mo post Jan 2020 first wave in China).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Hu	2021	doi:10.1101/2021.01.22.427749	n/a	https://doi.org/10.1101/2021.01.22.427749	False	Hu et al. (2021)	n/a	Abolished neutralization by mAbs CQ026 and CQ038, greatly diminished neutralization by CQ012 and CQ046.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kuzmina	2021	doi:10.1016/j.chom.2021.03.008	pmid:33789085	https://doi.org/10.1016/j.chom.2021.03.008	True	Kuzmina et al. (2021)	n/a	This variant of key B.1.351 lineage mutations showed ~10x decrease in Pfizer sera (3 weeks post-first dose: n 	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kuzmina	2021	doi:10.1016/j.chom.2021.03.008	pmid:33789085	https://doi.org/10.1016/j.chom.2021.03.008	True	Kuzmina et al. (2021)	n/a	This variant showed ~10x decrease in Pfizer sera (3 weeks post-first dose: n 	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Li	2022	doi:10.1186/s13578-022-00794-7	pmid:35581593	https://doi.org/10.1186/s13578-022-00794-7	True	Li et al. (2022)	n/a	Trachea viral loads were tested by qRT‑PCR and RNA scope at 3 dpi on 5 8‑month‑old male mice and there was a ~750x fold drop in the R3P1-E4 antibody in comparison to  the IgG control.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Li	2022	doi:10.1186/s13578-022-00794-7	pmid:35581593	https://doi.org/10.1186/s13578-022-00794-7	True	Li et al. (2022)	n/a	Lung viral loads were tested by qRT‑PCR and RNA scope at 3 dpi on 5 8‑month‑old male mice and there was a ~2266x fold drop in the R3P1-E4 antibody in comparison to  the IgG control.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Li	2022	doi:10.1186/s13578-022-00794-7	pmid:35581593	https://doi.org/10.1186/s13578-022-00794-7	True	Li et al. (2022)	n/a	100% of the 5 8‑month‑old male R3P1-E4 antibody treated mice suvived 14 days after infection while only 60% the control group mice survived 5 days post infection.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	trafficking	n/a	n/a	Kim	2021	doi:10.3390/v13040633	pmid:33917138	https://doi.org/10.3390/v13040633	True	Kim et al. (2021)	n/a	~5x more efficient S2 domain cleavage compared to wild type, compared to 4x by D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).  [N501Y+D614G does not show an increase in cleavage, therefore a synergistic effect of the trio is implied]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kuzmina	2021	doi:10.1016/j.chom.2021.03.008	pmid:33789085	https://doi.org/10.1016/j.chom.2021.03.008	True	Kuzmina et al. (2021)	n/a	This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n 	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	trafficking	n/a	n/a	Kuzmina	2021	doi:10.1016/j.chom.2021.03.008	pmid:33789085	https://doi.org/10.1016/j.chom.2021.03.008	True	Kuzmina et al. (2021)	n/a	~9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (no synergy as level approx. that of N501Y alone).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kuzmina	2021	doi:10.1016/j.chom.2021.03.008	pmid:33789085	https://doi.org/10.1016/j.chom.2021.03.008	True	Kuzmina et al. (2021)	n/a	This variant showed only minor in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	trafficking	n/a	n/a	Kuzmina	2021	doi:10.1016/j.chom.2021.03.008	pmid:33789085	https://doi.org/10.1016/j.chom.2021.03.008	True	Kuzmina et al. (2021)	n/a	~2x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Engelhart	2021	doi:10.1101/2021.04.27.440939	n/a	https://doi.org/10.1101/2021.04.27.440939	False	Engelhart et al. (2021)	n/a	Bamlanivimab (LY-CoV555) lost ~32x binding against this double mutation. COR-101 lost ~160x binding against this double mutation. Casirivimab lost ~16x binding against this double mutation. Estesevimab lost ~32x binding against this double mutation. Regdanvimab lost ~4x binding against this double mutation. Tixagevimab lost ~12x binding against this double mutation.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	trafficking	n/a	n/a	Kuzmina	2021	doi:10.1016/j.chom.2021.03.008	pmid:33789085	https://doi.org/10.1016/j.chom.2021.03.008	True	Kuzmina et al. (2021)	n/a	~13x more infective as D614G alone in HEK293T-ACE2 cells 48h post-transduction.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	trafficking	n/a	n/a	Kuzmina	2021	doi:10.1016/j.chom.2021.03.008	pmid:33789085	https://doi.org/10.1016/j.chom.2021.03.008	True	Kuzmina et al. (2021)	n/a	Approximately as infective as D614G alone in HEK293T-ACE2 cells 48h post-transduction (~additive effects of the individual variants).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Engelhart	2021	doi:10.1101/2021.04.27.440939	n/a	https://doi.org/10.1101/2021.04.27.440939	False	Engelhart et al. (2021)	n/a	COR-101 lost ~20x binding against this double mutation. Estesevimab lost ~16x binding against this double mutation. Regdanvimab lost ~6x binding against this double mutation. M396 lost ~10x binding against this double mutation.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kuzmina	2021	doi:10.1016/j.chom.2021.03.008	pmid:33789085	https://doi.org/10.1016/j.chom.2021.03.008	True	Kuzmina et al. (2021)	n/a	In post-vaccination sera from individuals who received one (3 weeks post-first dose: n 	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Kuzmina	2021	doi:10.1016/j.chom.2021.03.008	pmid:33789085	https://doi.org/10.1016/j.chom.2021.03.008	True	Kuzmina et al. (2021)	n/a	~7x reduction in neutralization by key B.1.351 lineage RBD variant combination in sera collected from cohort of 10 with severe  disease 21 to 63 days post-onset. Two of the cohort showed no neutralization against this variant.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	This variant combination (representing B.1.351 aka Beta)  showed a 1.04x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset, in contrast to the largely positive binding values for each individual mutation that comprises the set.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing B.1.351 aka Beta)  showed a 3.56x increase in binding (KD) relative to D614G.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	This variant combination (representing B.1.351 aka Beta)  showed a 1.28x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. It shows a 1.17x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.5x decrease in binding (KD) relative to D614G.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	2.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22813	K417N	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G1251T	p.K417N	NC_045512.2(GU280_gp02):g.1251G>T	YP_009724390.1:p.Lys417Asn	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	1.76x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.75x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
22992	ST477NK	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	GCAC	ACAA	g.GCAC1430_1433ACAA	p.ST477NK	n/a	YP_009724390.1:p.SerThr477AsnLys	n/a	n/a	S	n/a	KP.2.3.5	n/a	n/a	n/a	1.0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	Pokay	n/a	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	n/a	n/a	n/a	n/a	n/a	n/a
23005	N481_E484delinsKGK	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	TGGTGTTG	AGGTA	g.TGGTGTTG1443_1450AGGTA	p.N481_E484delinsKGK	n/a	YP_009724390.1:p.Asn481_Glu484delinsLysGlyLys	n/a	n/a	S	n/a	KP.2.3.5	n/a	n/a	n/a	1.0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	Pokay	n/a	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	n/a	n/a	n/a	n/a	n/a	n/a
23018	F486P	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	TT	CC	g.TT1456_1457CC	p.F486P	n/a	YP_009724390.1:p.Phe486Pro	n/a	n/a	S	n/a	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Yue	2023	doi:10.1101/2023.01.03.522427	n/a	https://doi.org/10.1101/2023.01.03.522427	False	Yue et al. (2023)	n/a	The hACE2-binding affinity of XBB.1.5 RBD has a dissociation constant KD of 3.4 nM, where S486P is the distinguishing Spike mutation vs parent  XBB.1 RBD with a much weaker KD (19 nM), as measured by surface plasmon resonance (SPR) assays.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23018	F486P	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	TT	CC	g.TT1456_1457CC	p.F486P	n/a	YP_009724390.1:p.Phe486Pro	n/a	n/a	S	n/a	KP.2.3.5	n/a	n/a	n/a	1.0	gene expression increase	n/a	n/a	Starr	2020	doi:10.1016/j.cell.2020.08.012	pmid:32841599	https://doi.org/10.1016/j.cell.2020.08.012	True	Starr et al. (2020)	n/a	Experimentally, Spike gene expression increased 0.22 fold	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23018	F486P	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	TT	CC	g.TT1456_1457CC	p.F486P	n/a	YP_009724390.1:p.Phe486Pro	n/a	n/a	S	n/a	KP.2.3.5	n/a	n/a	n/a	1.0	monoclonal antibody serial passage escape	n/a	n/a	Greaney	2020	doi:10.1016/j.chom.2020.11.007	pmid:33259788	https://doi.org/10.1016/j.chom.2020.11.007	True	Greaney et al. (2020)	n/a	Ranked modestly effective mutant against this position in the RBD for highly neutralizing COV2-2832 monoclonal antibody	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23018	F486P	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	TT	CC	g.TT1456_1457CC	p.F486P	n/a	YP_009724390.1:p.Phe486Pro	n/a	n/a	S	n/a	KP.2.3.5	n/a	n/a	n/a	1.0	monoclonal antibody serial passage escape	n/a	n/a	Starr	2021	doi:10.1101/2021.02.17.431683	pmid:33655250	https://doi.org/10.1101/2021.02.17.431683	False	Starr et al. (2021)	n/a	Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23055	Q498R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1493G	p.Q498R	NC_045512.2(GU280_gp02):g.1493A>G	YP_009724390.1:p.Gln498Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron BA.2 have higher sensitivity to inhibition by soluble angiotensin converting enzyme 2 (ACE2) and the endosomal inhibitor chloroquine compared  to D614G	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23055	Q498R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1493G	p.Q498R	NC_045512.2(GU280_gp02):g.1493A>G	YP_009724390.1:p.Gln498Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs Bi-Nab35B5-47D10. Omicron BA.2 has an IC50 fold change of 0.07x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23055	Q498R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1493G	p.Q498R	NC_045512.2(GU280_gp02):g.1493A>G	YP_009724390.1:p.Gln498Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs 35B5. Omicron BA.2 has an IC50 fold change of 0.09x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23055	Q498R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1493G	p.Q498R	NC_045512.2(GU280_gp02):g.1493A>G	YP_009724390.1:p.Gln498Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs 47D10. Omicron BA.2 has an IC50 fold change of 0.08x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23055	Q498R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1493G	p.Q498R	NC_045512.2(GU280_gp02):g.1493A>G	YP_009724390.1:p.Gln498Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs Bi-Nab47D10-35B5. Omicron BA.2 has an IC50 fold change of 0.04x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23055	Q498R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1493G	p.Q498R	NC_045512.2(GU280_gp02):g.1493A>G	YP_009724390.1:p.Gln498Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron BA.2 neutralization of the Omicron variants by antibodies induced by three doses of Pfizer/BNT162b2 mRNA vaccine was 7-8-fold less potent than the D614G, and  the Omicron variants still evade neutralization more efficiently.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23055	Q498R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1493G	p.Q498R	NC_045512.2(GU280_gp02):g.1493A>G	YP_009724390.1:p.Gln498Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Kumar	2022	doi:10.1101/2022.05.13.491770	n/a	https://doi.org/10.1101/2022.05.13.491770	False	Kumar et al. (2022)	n/a	BnAb 002-S21F2 IC50 on the Omicron BA.2 variant is 0.8x fold the wildtype.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23055	Q498R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1493G	p.Q498R	NC_045512.2(GU280_gp02):g.1493A>G	YP_009724390.1:p.Gln498Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.2 (from South Africa/CERI-KRISP-K032307/2021) were 3.9x-fold lower (95% CI: 0.14x-0.17x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23055	Q498R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1493G	p.Q498R	NC_045512.2(GU280_gp02):g.1493A>G	YP_009724390.1:p.Gln498Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Uhal B	2022	doi:10.1101/2022.06.23.497326	n/a	https://doi.org/10.1101/2022.06.23.497326	False	Uhal B et al. (2022)	n/a	L27, V34 and E90 mutation resulted in ultrahigh affinity binding of the LVE-ACE-2 domain to the widest variety of VOCs, with KDs of 78fM for binding to the Omicron  BA.2. Values were obtained with LVE-ACE-2/mAB chimeras containing the Y-T-E sequence that enhances binding to the FcRn receptor, which in turn is expected to  extend biological half-life 3-4-fold.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23055	Q498R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1493G	p.Q498R	NC_045512.2(GU280_gp02):g.1493A>G	YP_009724390.1:p.Gln498Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.2 (from South Africa/CERI-KRISP-K032307/2021) were 4.5-fold lower (95% CI: 4.3x-4.7x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23055	Q498R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1493G	p.Q498R	NC_045512.2(GU280_gp02):g.1493A>G	YP_009724390.1:p.Gln498Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.2.12.1 (from USA/NY-CDC-ASC210722700/2022) were 4.2-fold lower (95% CI: 5.8x-6.6x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23055	Q498R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1493G	p.Q498R	NC_045512.2(GU280_gp02):g.1493A>G	YP_009724390.1:p.Gln498Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.2.12.1 (from USA/NY-CDC-ASC210722700/2022) were 3.9x-fold lower (95% CI: 0.14x-0.18x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23055	Q498R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1493G	p.Q498R	NC_045512.2(GU280_gp02):g.1493A>G	YP_009724390.1:p.Gln498Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs Bi-Nab47D10-35B5. Omicron BA.1 has an IC50 fold change of 0.08x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23055	Q498R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1493G	p.Q498R	NC_045512.2(GU280_gp02):g.1493A>G	YP_009724390.1:p.Gln498Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron B.1.1.529 (BA.1) neutralization of the Omicron variants by antibodies induced by three doses of Pfizer/BNT162b2 mRNA vaccine was 7-8-fold less potent than  the D614G, and the Omicron variants still evade neutralization more efficiently.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23055	Q498R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1493G	p.Q498R	NC_045512.2(GU280_gp02):g.1493A>G	YP_009724390.1:p.Gln498Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron (B.1.1.529 [BA.1]) have higher sensitivity to inhibition by soluble angiotensin converting enzyme 2 (ACE2) and the endosomal inhibitor chloroquine compared  to D614G	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23055	Q498R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1493G	p.Q498R	NC_045512.2(GU280_gp02):g.1493A>G	YP_009724390.1:p.Gln498Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs Bi-Nab35B5-47D10. Omicron BA.1 has an IC50 fold change of 0.30x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23055	Q498R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1493G	p.Q498R	NC_045512.2(GU280_gp02):g.1493A>G	YP_009724390.1:p.Gln498Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Uhal B	2022	doi:10.1101/2022.06.23.497326	n/a	https://doi.org/10.1101/2022.06.23.497326	False	Uhal B et al. (2022)	n/a	Paradigms’ ACE-2 variant LVE/STR chimera binds to SARS-2 Omicron variant B.1.1.529 spike protein trimer with high affinity. Determined using Surrogate Viral Neutralization Tests.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23055	Q498R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1493G	p.Q498R	NC_045512.2(GU280_gp02):g.1493A>G	YP_009724390.1:p.Gln498Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Uhal B	2022	doi:10.1101/2022.06.23.497326	n/a	https://doi.org/10.1101/2022.06.23.497326	False	Uhal B et al. (2022)	n/a	L27, V34 and E90 mutation resulted in ultrahigh affinity binding of the LVE-ACE-2 domain to the widest variety of VOCs, with KDs of 73 pM for binding to the Omicron  B.1.1.529. Values were obtained with LVE-ACE-2/mAB chimeras containing the Y-T-E sequence that enhances binding to the FcRn receptor, which in turn is expected to  extend biological half-life 3-4-fold.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23055	Q498R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1493G	p.Q498R	NC_045512.2(GU280_gp02):g.1493A>G	YP_009724390.1:p.Gln498Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs 35B5. Omicron BA.1 has an IC50 fold change of 0.38x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23055	Q498R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1493G	p.Q498R	NC_045512.2(GU280_gp02):g.1493A>G	YP_009724390.1:p.Gln498Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Arora	2022	doi:10.1038/s41423-022-00870-5	pmid:35581351	https://doi.org/10.1038/s41423-022-00870-5	True	Arora et al. (2022)	n/a	All 10 individuals with 2 doses of the BNT162b2/BNT162b2 vaccine had a neutralizing titer in B.1 variant at an average of 729 NT50.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23055	Q498R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1493G	p.Q498R	NC_045512.2(GU280_gp02):g.1493A>G	YP_009724390.1:p.Gln498Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Shete	2022	doi:10.1101/2022.05.12.491584	n/a	https://doi.org/10.1101/2022.05.12.491584	False	Shete et al. (2022)	n/a	Plaque reduction neutralization test (PRNT) was used uring primary infection, post sixty daysof second dose vaccination, pre-reinfection and reinfection against Delta variant and was used to determine neutralizing antibodytitres. There was a 24.63x fold increase in antibody response from first infection to recovered and vaccinated with 2 doses (60 days). There was a 4.21x fold increase in antibody response pre-reinfection. There was a 39.27x fold increase in antibody response during reinfection.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23055	Q498R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1493G	p.Q498R	NC_045512.2(GU280_gp02):g.1493A>G	YP_009724390.1:p.Gln498Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Shete	2022	doi:10.1101/2022.05.12.491584	n/a	https://doi.org/10.1101/2022.05.12.491584	False	Shete et al. (2022)	n/a	Plaque reduction neutralization test (PRNT) was used uring primary infection, post sixty daysof second dose vaccination, pre-reinfection and reinfection against B.1 variant and was used to determine neutralizing antibodytitres. There was a 6.76x fold increase in antibody response from first infection to recovered and vaccinated with 2 doses (60 days). There was a 2.06x fold increase in antibody response pre-reinfection. There was a 8.18x fold increase in antibody response during reinfection.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23055	Q498R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1493G	p.Q498R	NC_045512.2(GU280_gp02):g.1493A>G	YP_009724390.1:p.Gln498Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Arora	2022	doi:10.1038/s41423-022-00870-5	pmid:35581351	https://doi.org/10.1038/s41423-022-00870-5	True	Arora et al. (2022)	n/a	All 10 individuals with 3 doses of the BNT162b2/BNT162b2 vaccine had a neutralizing titer in B.1 variant at an average of 3319 NT50.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23055	Q498R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1493G	p.Q498R	NC_045512.2(GU280_gp02):g.1493A>G	YP_009724390.1:p.Gln498Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Shete	2022	doi:10.1101/2022.05.12.491584	n/a	https://doi.org/10.1101/2022.05.12.491584	False	Shete et al. (2022)	n/a	Plaque reduction neutralization test (PRNT) was used uring primary infection, post sixty daysof second dose vaccination, pre-reinfection and reinfection against Omicron variant and was used to determine neutralizing antibodytitres. There was a 114.84x fold increase in antibody response from first infection to recovered and vaccinated with 2 doses (60 days). There was a 6.61x fold increase in antibody response pre-reinfection. There was a 1194.9x fold increase in antibody response during reinfection.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23055	Q498R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1493G	p.Q498R	NC_045512.2(GU280_gp02):g.1493A>G	YP_009724390.1:p.Gln498Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Kumar	2022	doi:10.1101/2022.05.13.491770	n/a	https://doi.org/10.1101/2022.05.13.491770	False	Kumar et al. (2022)	n/a	BnAb 002-S21F2 IC50 on the Omicron BA.1 variant is 1.0x fold the wildtype.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23055	Q498R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1493G	p.Q498R	NC_045512.2(GU280_gp02):g.1493A>G	YP_009724390.1:p.Gln498Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs 47D10. Omicron BA.1 has an IC50 fold change of 1.26x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23055	Q498R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1493G	p.Q498R	NC_045512.2(GU280_gp02):g.1493A>G	YP_009724390.1:p.Gln498Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron BA.3 have higher sensitivity to inhibition by soluble angiotensin converting enzyme 2 (ACE2) and the endosomal inhibitor chloroquine compared  to D614G	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23055	Q498R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1493G	p.Q498R	NC_045512.2(GU280_gp02):g.1493A>G	YP_009724390.1:p.Gln498Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron BA.3 neutralization of the Omicron variants by antibodies induced by three doses of Pfizer/BNT162b2 mRNA vaccine was 7-8-fold less potent than the D614G, and  the Omicron variants still evade neutralization more efficiently.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23055	Q498R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1493G	p.Q498R	NC_045512.2(GU280_gp02):g.1493A>G	YP_009724390.1:p.Gln498Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.3 (from South Africa/NICD-N22404/2021) were 4.2x-fold lower (95% CI: 0.15x-0.20x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23055	Q498R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1493G	p.Q498R	NC_045512.2(GU280_gp02):g.1493A>G	YP_009724390.1:p.Gln498Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.3 (from South Africa/NICD-N22404/2021) were 6.2-fold lower (95% CI: 11.8x-14.3x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23055	Q498R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1493G	p.Q498R	NC_045512.2(GU280_gp02):g.1493A>G	YP_009724390.1:p.Gln498Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Hao	2022	doi:10.1101/2022.08.12.22278720	pmid:36032965	https://doi.org/10.1101/2022.08.12.22278720	False	Hao et al. (2022)	n/a	paired testing of vaccine sera against ancestral virus compared to Omicron BA.1 shows that 3-dose vaccine regimen provides over 50x fold increase in protection against Omicron(B.1.1.529 [BA.1]) compared to a 2-dose regimen.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23055	Q498R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1493G	p.Q498R	NC_045512.2(GU280_gp02):g.1493A>G	YP_009724390.1:p.Gln498Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Wang	2022	doi:10.1101/2022.08.11.503601	n/a	https://doi.org/10.1101/2022.08.11.503601	False	Wang et al. (2022)	n/a	4th antigenic exposure with Omicron (B.1.1.529 [BA.1])(n	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23055	Q498R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1493G	p.Q498R	NC_045512.2(GU280_gp02):g.1493A>G	YP_009724390.1:p.Gln498Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.1 (from Botswana/R40B59_BHP_3321001248/2021) were 3.4-fold lower (95% CI: 3.2x-3.6x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23055	Q498R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1493G	p.Q498R	NC_045512.2(GU280_gp02):g.1493A>G	YP_009724390.1:p.Gln498Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.1 (from Botswana/R40B59_BHP_3321001248/2021) were 28.7x-fold lower (95% CI: 0.03x-0.05) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23055	Q498R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1493G	p.Q498R	NC_045512.2(GU280_gp02):g.1493A>G	YP_009724390.1:p.Gln498Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.4/5 (from ) were 17.2x-fold lower (95% CI: 0.6x-0.7x) than against 208-428 972-1834 4.3-4.7 US-WA1/2020 usiong an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23055	Q498R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1493G	p.Q498R	NC_045512.2(GU280_gp02):g.1493A>G	YP_009724390.1:p.Gln498Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.4/5 (from ) were 13.0-fold lower (95% CI: 4.2x-4.6x) than against 208-428 972-1834 4.3-4.7 US-WA1/2020 usiong an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23055	Q498R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1493G	p.Q498R	NC_045512.2(GU280_gp02):g.1493A>G	YP_009724390.1:p.Gln498Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  XD (from ) were 1.5x-fold lower (95% CI: 0.05x-0.07x) than against 208-428 972-1834 4.3-4.7 US-WA1/2020 usiong an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23055	Q498R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1493G	p.Q498R	NC_045512.2(GU280_gp02):g.1493A>G	YP_009724390.1:p.Gln498Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  XD (from ) were 4.4-fold lower (95% CI: 4.3x-4.7x) than against 208-428 972-1834 4.3-4.7 US-WA1/2020 usiong an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23055	Q498R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1493G	p.Q498R	NC_045512.2(GU280_gp02):g.1493A>G	YP_009724390.1:p.Gln498Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Yue	2023	doi:10.1101/2023.01.03.522427	n/a	https://doi.org/10.1101/2023.01.03.522427	False	Yue et al. (2023)	n/a	The hACE2-binding affinity of XBB.1.5 RBD has a dissociation constant KD of 3.4 nM, where S486P is the distinguishing Spike mutation vs parent  XBB.1 RBD with a much weaker KD (19 nM), as measured by surface plasmon resonance (SPR) assays.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23055	Q498R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1493G	p.Q498R	NC_045512.2(GU280_gp02):g.1493A>G	YP_009724390.1:p.Gln498Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Zahradnik	2021	doi:10.1101/2021.01.06.425392	n/a	https://doi.org/10.1101/2021.01.06.425392	False	Zahradnik et al. (2021)	n/a	Y501 makes a pi interaction with Y41 and places R498 to make a hydrogen bond and salt bridge to Q42 and D38 of ACE2, forming a strong network of new interactions supporting the impact of these residues on affinity.  Q498R alone appears to decrease ACE2 binding. The synergism of Q498R with N501Y (and E484K) increases ACE2 binding by ~50- fold relative to WT.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23055	Q498R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1493G	p.Q498R	NC_045512.2(GU280_gp02):g.1493A>G	YP_009724390.1:p.Gln498Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Zahradnik	2021	doi:10.1101/2021.01.06.425392	n/a	https://doi.org/10.1101/2021.01.06.425392	False	Zahradnik et al. (2021)	n/a	Y501 makes a pi interaction with Y41 and places R498 to make a hydrogen bond and salt bridge to Q42 and D38 of ACE2,  forming a strong network of new interactions supporting the impact of these residues on affinity. Q498R alone appears  to decrease ACE2 binding. The synergism of Q498R with N501Y (and E484K) increases ACE2 binding by ~50- fold relative  to WT. The extent of affinity increase with Q498R and N501Y is not exactly quantified, as E484K always emerged with  this duo during in vitro evolution.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Arora	2022	doi:10.1038/s41423-022-00870-5	pmid:35581351	https://doi.org/10.1038/s41423-022-00870-5	True	Arora et al. (2022)	n/a	Out of 10 individuals with 3 doses of the BNT162b2/BNT162b2/BNT162b2 vaccine had a neutralizing titer in B.1.640.2 variant was ~5.6x folds more significant in 9  individuals.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Arora	2022	doi:10.1038/s41423-022-00870-5	pmid:35581351	https://doi.org/10.1038/s41423-022-00870-5	True	Arora et al. (2022)	n/a	Out of 10 individuals with 2 doses of the BNT162b2/BNT162b2 vaccine, neutralizing titer in B.1.640.2 variant was ~1000x folds more significant in 8 individuals.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron BA.2 have higher sensitivity to inhibition by soluble angiotensin converting enzyme 2 (ACE2) and the endosomal inhibitor chloroquine compared  to D614G	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs Bi-Nab35B5-47D10. Omicron BA.2 has an IC50 fold change of 0.07x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs 35B5. Omicron BA.2 has an IC50 fold change of 0.09x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs 47D10. Omicron BA.2 has an IC50 fold change of 0.08x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs Bi-Nab47D10-35B5. Omicron BA.2 has an IC50 fold change of 0.04x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron BA.2 neutralization of the Omicron variants by antibodies induced by three doses of Pfizer/BNT162b2 mRNA vaccine was 7-8-fold less potent than the D614G, and  the Omicron variants still evade neutralization more efficiently.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Kumar	2022	doi:10.1101/2022.05.13.491770	n/a	https://doi.org/10.1101/2022.05.13.491770	False	Kumar et al. (2022)	n/a	BnAb 002-S21F2 IC50 on the Omicron BA.2 variant is 0.8x fold the wildtype.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	virion structure	n/a	n/a	Wang	2021	doi:10.1101/2021.03.01.433466	pmid:33688656	https://doi.org/10.1101/2021.03.01.433466	False	Wang et al. (2021)	n/a	CryoEM reveals the P.1 trimer to adopt exclusively a conformation in which one of the receptor-binding domains is in the “up” position.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Wang	2021	doi:10.1101/2021.03.01.433466	pmid:33688656	https://doi.org/10.1101/2021.03.01.433466	False	Wang et al. (2021)	n/a	In 12 Moderna vaccinee sera 15 days post second dose (43 days since first vaccination), an average 2.8x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 4.8x decrease against the full P.1 type vs WA-1 was observed, though overall with  a higher ID50 reciprocal value. In 10 Pfizer vaccinee sera 7 days or more post second dose (28 days or more since first vaccination), an average 2.2x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.8x decrease against the full P.1 type vs WA-1 was observed, with  similar variant ID50 reciprocal value.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Wang	2021	doi:10.1101/2021.03.01.433466	pmid:33688656	https://doi.org/10.1101/2021.03.01.433466	False	Wang et al. (2021)	n/a	In convalescent sera one month or more post-infection in Spring 2020, an average 6.5x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.4x decrease against the full P.1 type vs WA-1 was observed, with  better full P.1 ID50 reciprocal value compared to the 10-mutation model.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Wang	2021	doi:10.1101/2021.03.01.433466	pmid:33688656	https://doi.org/10.1101/2021.03.01.433466	False	Wang et al. (2021)	n/a	Amongst RBD-targeting Emergency Use Authorized monoclonal antibody treatments CB6, LY-CoV555 and REGN10933 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1, but REGN10987 activity remains strong. RBD-targeting monoclonal antibodies 2-15 and C121 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1. N terminal domain targeting monoclonal antibodies 5-7, 4-8, 4-18 and 2-17 have abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	reinfection	n/a	n/a	Malta Romano	2021	doi:10.1590/S1678-9946202163036	pmid:33909850	https://doi.org/10.1590/S1678-9946202163036	True	Malta Romano et al. (2021)	n/a	After a 128 day interval, a patient in Sao Paulo State, Brazil reinfected with P.1 (first episode likely predates P.1 emergence). Both cases were fairly mild (difficulty breathing, tiredness, dizziness and fatigue).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine efficacy	n/a	n/a	Bruxvoort	2021	doi:10.1101/2021.09.29.21264199	n/a	https://doi.org/10.1101/2021.09.29.21264199	False	Bruxvoort et al. (2021)	n/a	In a 1:5 test-negative matched control study of 8153 individuals who received the Moderna mRNA-1273 vaccine, 349 test-positive were Gamma. Two dose vaccine efficacy against Gamma was 95.5 (90.9-97.8%), one dose VE was 74.2 (43.8-88.1%).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	trafficking	n/a	n/a	Esclera	2021	doi:10.1101/2021.08.05.455290	n/a	https://doi.org/10.1101/2021.08.05.455290	False	Esclera et al. (2021)	n/a	~6x cleavage of S2 relative to WA1 (D614G) wildtype by Gamma variant as measured by mass spectrometry of Vero-TMPRSS culture  [no mutations directly at furin cleavage site, but H655Y is upstream] Compare to 4.5x or less for variants of concern with  direct furin clevage site mutations.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	reinfection	n/a	n/a	Naveca	2021	doi:10.21203/rs.3.rs-318392/v1	n/a	https://doi.org/10.21203/rs.3.rs-318392/v1	False	Naveca et al. (2021)	n/a	Three healthcare workers (29-50yo) had confirmed P.1 [Gamma] re-infection in the Amazonas region of Brazil 3-9 months after initial  infection from viruses with distinct lineage from P.1, but mild symptoms upon re-infection and evidence for infectiousness during re-infection.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Uriu	2021	doi:10.1101/2021.09.06.459005	n/a	https://doi.org/10.1101/2021.09.06.459005	False	Uriu et al. (2021)	n/a	Mean 3.0x reduction of NT50 value P.1 (Gamma) relative to wild type in 8 sera from adult BNT162b2 vaccinees (28-47yo) collected ~1m post booster.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Uriu	2021	doi:10.1101/2021.09.06.459005	n/a	https://doi.org/10.1101/2021.09.06.459005	False	Uriu et al. (2021)	n/a	Mean 4.1x reduction of NT50 value P.1 (Gamma) relative to wild type in 8 sera from older convalescent patients (52-92yo) collected 1-3m post symptom onset.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Kumar	2022	doi:10.1101/2022.05.13.491770	n/a	https://doi.org/10.1101/2022.05.13.491770	False	Kumar et al. (2022)	n/a	BnAb 002-S21F2 IC50 on the Gamma (P.1) variant is 0.6x fold the wildtype.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Chen	2021	doi:10.1038/s41591-021-01294-w	pmid:33664494	https://doi.org/10.1038/s41591-021-01294-w	True	Chen et al. (2021)	n/a	The neutralizing activity of vaccine was slightly lower against B.1.1.248 variant constellation in sera tested from most of the 15 patients with  the BNT162b2 mRNA vaccine. (Fig. 4)	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Gallagher	2021	doi:10.1101/2021.05.03.442455	pmid:33972942	https://doi.org/10.1101/2021.05.03.442455	False	Gallagher et al. (2021)	n/a	ELISpot assays show T cell neutralization reduced by 16.6% in this B.1.1.248 pseudotype relative to wild type in 18-20 pooled patient samples post second mRNA vaccine dose, with no significant difference between Pfizer and Moderna cohorts. Reduction was stronger in the S1 subunit than S2 (separate peptide pools were used).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Chen	2021	doi:10.1038/s41591-021-01294-w	pmid:33664494	https://doi.org/10.1038/s41591-021-01294-w	True	Chen et al. (2021)	n/a	B.1.1.248 variant constellation ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07. B.1.1.248 variant constellation ablates Class 3 N-terminal domain targeting antibody COV2-2676.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Chen	2021	doi:10.1038/s41591-021-01294-w	pmid:33664494	https://doi.org/10.1038/s41591-021-01294-w	True	Chen et al. (2021)	n/a	B.1.1.7 variant constellation two-tailed Wilcoxon matched-pairs signed-rank test against 10 convalescent sera P	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	anthropozoonotic events	n/a	n/a	Montagutelli	2021	doi:10.1101/2021.03.18.436013	n/a	https://doi.org/10.1101/2021.03.18.436013	False	Montagutelli et al. (2021)	n/a	Unlike wild type or B.1.1.7, P.1 lineage virus was able to infect and replicate in common lab mouse strains, with high titer.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Chen	2021	doi:10.1038/s41591-021-01294-w	pmid:33664494	https://doi.org/10.1038/s41591-021-01294-w	True	Chen et al. (2021)	n/a	B.1.1.248 variant constellation in 10 convalescent human sera ~1mo post infection had mild to moderate resistance against most samples, P	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Leier	2021	doi:10.1101/2021.04.25.21256049	pmid:33948601	https://doi.org/10.1101/2021.04.25.21256049	False	Leier et al. (2021)	n/a	Neutralizing antibody titers increased in previously infected vaccinees relative to uninfected vaccinees  4.3-fold against P.1 (contrast with 3.4 fold against original SARS-CoV-2).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Garcia-Beltran	2021	doi:10.1016/j.cell.2021.03.013	pmid:33743213	https://doi.org/10.1016/j.cell.2021.03.013	True	Garcia-Beltran et al. (2021)	n/a	Pseudotyped P.1 virus has reduced neutralization activity vs wild type: 6.7x (30 sera Pfizer median 9 days post 2nd dose)  and 4.5x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Alenquer	2021	doi:10.1101/2021.04.22.441007	n/a	https://doi.org/10.1101/2021.04.22.441007	False	Alenquer et al. (2021)	n/a	Using P.1 defining mutations for Spike, observed 4x average decrease in neutralization efficiency  (but still relevant titres) for sera from 10 BNT162b2 vaccinees 12 days after second dose, but only one  relevant titre 12 days after first dose. Compares unfavorably to wild type or B.1.1.7 titres.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Andrade	2021	doi:10.1101/2021.04.14.439719	n/a	https://doi.org/10.1101/2021.04.14.439719	False	Andrade et al. (2021)	n/a	In human sera 8 weeks post-vaccination with INO-4800, a ~2-fold reduction in P.1 neutralization was observed.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Hitchlings	2021	doi:10.1101/2021.04.07.21255081	n/a	https://doi.org/10.1101/2021.04.07.21255081	False	Hitchlings et al. (2021)	n/a	Among 46,884 HCWs in Manaus, Brazil vaccinated with at least one dose of CoronaVac, a 0.50-fold reduction (adjusted vaccine  effectiveness, 49.6%: 95% CI, 11.3 - 71.4) in the odds of  symptomatic SARS-CoV-2 infection was observed during the period 14 days or more after receiving the first dose. Estimated vaccine effectiveness of at least one dose against any SARS-CoV-2 infection was 35.1% (95% CI, −6.6 - 60.5) in the same time period.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Hoffman	2021	doi:10.1016/j.cell.2021.03.036	pmid:33794143	https://doi.org/10.1016/j.cell.2021.03.036	True	Hoffman et al. (2021)	n/a	VSV pseudotype P.1 entry mediated by the S proteins of the P.1 variant was completely resistant to blocking by REGN10989 and Bamlanivimab. Cell fusion proficiency was slight impaired. Entry driven by the S proteins of the B.1.351 was partially resistant against Casirivimab.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma binding	n/a	n/a	Hoffman	2021	doi:10.1016/j.cell.2021.03.036	pmid:33794143	https://doi.org/10.1016/j.cell.2021.03.036	True	Hoffman et al. (2021)	n/a	VSV pseudotype P.1 showed 4.8-fold decrease in NT50 vs wild type in sera from 9 ICU patients undergoing treatment in Germany (pre-variant infections).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Hoffman	2021	doi:10.1016/j.cell.2021.03.036	pmid:33794143	https://doi.org/10.1016/j.cell.2021.03.036	True	Hoffman et al. (2021)	n/a	VSV pseudotype P.1 showed 5.12-fold reduction in neutralization efficiency vs wild type in 15 Pfizer BNT162b2 vaccinee sera 13-15 days post second dose. Cell fusion proficiency was slight impaired.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	trafficking	n/a	n/a	Hoffman	2021	doi:10.1016/j.cell.2021.03.036	pmid:33794143	https://doi.org/10.1016/j.cell.2021.03.036	True	Hoffman et al. (2021)	n/a	VSV pseudotype P.1 showed slight decrease in cell entry relative to wild type in 262T and 263T-ACE2 (kidney) cell lines. Cell fusion proficiency was slight impaired.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma binding	n/a	n/a	Mendes-Correa	2021	doi:10.1101/2021.05.11.21256908	n/a	https://doi.org/10.1101/2021.05.11.21256908	False	Mendes-Correa et al. (2021)	n/a	Neutralizing antibodies that were generated following a mild infection with SARS-CoV-2 B.1.128 were effective in vitro,  and likely protective, against the SARS-CoV-2 P.1. variant in the majority of individuals based on 60 convalescent sera tested.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Tarke	2021	doi:10.1101/2021.02.27.433180	pmid:33688655	https://doi.org/10.1101/2021.02.27.433180	False	Tarke et al. (2021)	n/a	PBMCs of Pfizer/BioNTech BNT162b2 (n	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	McCallum	2021	doi:10.1101/2021.03.31.437925	pmid:33821281	https://doi.org/10.1101/2021.03.31.437925	False	McCallum et al. (2021)	n/a	In 13 plasma collected ~1mo after B.1.1.7 infection (nursing home in Ticino, Switzerland), neutralization  reduced to undetectable levels in many plasma for P.1 pseudotyped virus, as well as WT and other VOCs.  [paper does not detail the P.1 variants used, using the most popular as a stand in]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	1.15x *increase* in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees)	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Choi	2021	doi:10.1101/2021.06.28.449914	n/a	https://doi.org/10.1101/2021.06.28.449914	False	Choi et al. (2021)	n/a	Neutralization efficiency (ID50) against P.1 reduced 3.2x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Dejnirattisai	2021	doi:10.1016/j.cell.2021.03.055	pmid:33852911	https://doi.org/10.1016/j.cell.2021.03.055	True	Dejnirattisai et al. (2021)	n/a	P.1 virus neutralization (as tested using biolayer interferometry) of both Lilly antibodies was severely impacted,  with Lilly mAb combination LY-CoV16 and LY-CoV555  (due to mutations at 416 and 484 respectively) shows almost complete loss of neutralization of P.1.  There was also escape from neutralization of P.1 by REGN10933 (one of 2 in Regeneron's mAb cocktail)  and a modest reduction in neutralization of P.1 by AstraZeneca's AZD8895 (while AZD1061 and AZD7442 showed  equal neutralization of all SARS-CoV-2 variants tested). The three Adagio antibodies neutralized P.1 with all reaching a plateau at 100% neutralization: interestingly, ADG30  showed a slight increase of neutralization of P.1. S309 Vir was largely unaffected, although for several viruses, including P.1, the antibody failed to completely  neutralize, conceivably reflecting incomplete glycosylation at N343, since the sugar interaction is key to binding of this antibody.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Dejnirattisai	2021	doi:10.1016/j.cell.2021.03.055	pmid:33852911	https://doi.org/10.1016/j.cell.2021.03.055	True	Dejnirattisai et al. (2021)	n/a	P.1 lineage titers were reduced 7.6-fold and 9-fold for the BNT162b2 Pfizer (sera collected 4-14 days post-booster)  and ChAdOx1 nCoV-19 AstraZeneca (sera collected 14 or 28 days post-booster) vaccines respectively.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Luftig	2021	doi:10.1056/NEJMc2104036	pmid:33826815	https://doi.org/10.1056/NEJMc2104036	True	Luftig et al. (2021)	n/a	In sera 1-2 weeks after BNT162b2 first dose, from six patients previously infected with B.1, antibody titer in a microneutralization assay  was on average 2896 for P.1 virus. This compares favorably (stronger) to post-infection neutralization titer against all variants tested in the same sera (wild type, B.1.1.7, B.1.351, and P.1).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma binding	n/a	n/a	Luftig	2021	doi:10.1056/NEJMc2104036	pmid:33826815	https://doi.org/10.1056/NEJMc2104036	True	Luftig et al. (2021)	n/a	In sera from six patients collected 1 to 12 weeks post-infection with B.1, antibody titer in a microneutralization assay was on average 256 for B.1.1.7 virus. Compare to somewhat stronger neutralization titer for wild type (456.1) in the same sera.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Pegu	2021	doi:10.1101/2021.05.13.444010	pmid:34031659	https://doi.org/10.1101/2021.05.13.444010	False	Pegu et al. (2021)	n/a	Detectable antibodies against P.1 at various time points using pseudovirus neutralization in Moderna vaccinee cohort: Day 43 100%, Day 209 85%.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	T cell evasion	n/a	n/a	Tarke	2021	doi:10.1101/2021.02.27.433180	pmid:33688655	https://doi.org/10.1101/2021.02.27.433180	False	Tarke et al. (2021)	n/a	PBMCs of 11 mild COVID-19 patients collected 38-80 days after symptom onset were stimulated with the 15-mer peptide pools (w/ 10 residue overlaps) from the wholle viral proteome,  showing no significant CD4+ cell count effect for P.1,  and a slight increase in CD8+ percentage (p	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	transmissibility	n/a	n/a	Stefanelli	2021	doi:10.1101/2021.04.06.21254923	n/a	https://doi.org/10.1101/2021.04.06.21254923	False	Stefanelli et al. (2021)	n/a	The relative transmissibility of P.1 estimated at the national level (Italy) varied according to the assumed  degree of cross-protection granted by infection with other lineages and ranged from 1.12 (95%CI 1.03-1.23) in the  case of complete immune evasion by P.1 to 1.39 (95%CI 1.26-1.56) in the case of complete cross-protection. PG: variant list has been abbreviated due to mixed K417 bases in this lineage, potential miscalls of deletions	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Schmidt	2021	doi:10.1101/2021.08.06.455491	n/a	https://doi.org/10.1101/2021.08.06.455491	False	Schmidt et al. (2021)	n/a	Artificially constructed HIV-1 pseudovirus with set of mutations drawn from plasma passage escape experiments and mutations from variants of concern completely ablates neutralization in 19 of 21 convalescents plasma collected mean 1.3 months post infection. [actual Y145del from manuscript substituted with more common Y144del description]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Cele	2021	doi:10.1038/s41586-021-03471-w	pmid:33780970	https://doi.org/10.1038/s41586-021-03471-w	True	Cele et al. (2021)	n/a	The 501Y.V2 to first wave IC50 ratio ranged from 6 to 200-fold. Averaging across all 7 participant convalescent sera highlighted the dramatic decrease in sensitivity to neutralization of authentic 501Y.V2 variants. PG: I'm purposefully ignoring D614G and A701V as contributors	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Andrade	2021	doi:10.1101/2021.04.14.439719	n/a	https://doi.org/10.1101/2021.04.14.439719	False	Andrade et al. (2021)	n/a	In human sera 8 weeks post-vaccination with INO-4800, a ~7-fold reduction in B.1.351 neutralization was observed.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Riddell	2021	doi:10.1101/2021.04.17.440246	n/a	https://doi.org/10.1101/2021.04.17.440246	False	Riddell et al. (2021)	n/a	Four fold reduction in neutralization efficiency was observed in sera of ferrets post-vaccination with  INO-4800 (DNA plasmid pGX9501 encoding full length Spike).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Wu	2021	doi:10.1101/2021.04.13.439482	pmid:33880468	https://doi.org/10.1101/2021.04.13.439482	False	Wu et al. (2021)	n/a	Monovalent mRNA-1273.351 encodes for the S protein found in the B.1.351 lineage and (2) mRNA-1273.211 comprising a 1:1 mix of mRNA-1273 and mRNA-1273.351.  In a mouse study, primary vaccination series of mRNA-1273.351 was effective at increasing neutralizing antibody titers against the B.1.351 lineage,  while mRNA-1273.211 was most effective at providing broad cross-variant neutralization. In addition, these results demonstrated a third dose of  mRNA-1273.351 significantly increased both wild-type and B.1.351-specific neutralization titers.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kustin	2021	doi:10.1101/2021.04.06.21254882	n/a	https://doi.org/10.1101/2021.04.06.21254882	False	Kustin et al. (2021)	n/a	Pzifer vaccinees that tested positive at least a week after the second dose were indeed disproportionally infected with B.1.351,  as compared with unvaccinated individuals (odds ratio of 8:1), but were all infected before 14 days post second vaccination.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Uriu	2021	doi:10.1101/2021.09.06.459005	n/a	https://doi.org/10.1101/2021.09.06.459005	False	Uriu et al. (2021)	n/a	Mean 8.2x reduction of NT50 value B.1.351 (Beta) relative to wild type in 8 sera from older convalescent patients (52-92yo) collected 1-3m post symptom onset.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Uriu	2021	doi:10.1101/2021.09.06.459005	n/a	https://doi.org/10.1101/2021.09.06.459005	False	Uriu et al. (2021)	n/a	Mean 6.3x reduction of NT50 value B.1.351 (Beta) relative to wild type in 8 sera from adult BNT162b2 vaccinees (28-47yo) collected ~1m post booster.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Skelly	2021	doi:10.21203/rs.3.rs-226857/v1	n/a	https://doi.org/10.21203/rs.3.rs-226857/v1	False	Skelly et al. (2021)	n/a	In over 90% of two dose mRNA vaccinees, heterotypic neutralizing titres (NT50) against B.1.1.7 and B.1.351 remain comfortably  above the level associated with immune protection in recent vaccine trials. However, in over 50% of convalescent COVID-19  individuals (5/9) and recipients of a only a single dose of mRNA vaccine (10/11) – heterotypic neutralization dropped to negligible levels,  particularly against B.1.351.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma binding	n/a	n/a	Luftig	2021	doi:10.1056/NEJMc2104036	pmid:33826815	https://doi.org/10.1056/NEJMc2104036	True	Luftig et al. (2021)	n/a	In sera from six patients collected 1 to 12 weeks post-infection with B.1, antibody titer in a microneutralization assay was on average 8 for B.1.351 virus. Compare to much stronger neutralization titers for B.1.1.7 (256) and wild type (456.1) in the same sera.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Bates	2021	doi:10.1101/2021.04.04.21254881	pmid:33851185	https://doi.org/10.1101/2021.04.04.21254881	False	Bates et al. (2021)	n/a	Observed 8.8-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose) against cultured B.1.351 sample. Contrast this with 1.4-fold reduction for just the pseudovirus combination of 'key' B.1.351 mutations K417N+E484K+N501Y. WA1 and B.1.351 FRNT50 titers correlated weakly at the individual level, with some individual’s serum potently neutralizing WA1 while having FRNT50 for B.1.351 below the assay limit of detection (1:20).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma binding	n/a	n/a	UNKNOWN	2021	n/a	n/a	https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1009243/Technical_Briefing_20.pdf	False	UNKNOWN et al. (2021)	n/a	Sera from individuals who have been infected with Delta does not have strong neutralising activity against Beta.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Planas	2021	doi:10.1038/s41591-021-01318-5	n/a	https://doi.org/10.1038/s41591-021-01318-5	True	Planas et al. (2021)	n/a	Using a new rapid neutralization assay, based on reporter cells that become positive for GFP after overnight infection, sera from 58  convalescent individuals collected up to 9 months after symptoms had mean ~6x reduction in neutralizing titers, and 40% of the samples  lacked any activity against B.1.351.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	UNKNOWN	2021	n/a	n/a	https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1009243/Technical_Briefing_20.pdf	False	UNKNOWN et al. (2021)	n/a	Sera from individuals who have been vaccinated and have had subsequent recent Delta infection have a high level of neutralising activity against Beta.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Uhal B	2022	doi:10.1101/2022.06.23.497326	n/a	https://doi.org/10.1101/2022.06.23.497326	False	Uhal B et al. (2022)	n/a	Paradigm’s ACE-2 variant LVE/STR chimera neutralizes Beta Variant B.1.351 RBD significantly better than w.t. SARS-CoV-2 RBD. Determined using Surrogate Viral Neutralization Tests.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Garcia-Beltran	2021	doi:10.1016/j.cell.2021.03.013	pmid:33743213	https://doi.org/10.1016/j.cell.2021.03.013	True	Garcia-Beltran et al. (2021)	n/a	Pseudotyped B.1.351 v2 virus has reduced neutralization activity vs wild type: 41.2x (30 sera Pfizer median 9 days post 2nd dose)  and 20.8x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA. Notably, 36.7% (11/30) recipients of two-dose Pfizer and 42.9% (15/35) recipients of two-dose Moderna vaccines did not have  detectable neutralization of at least one of the B.1.351 variants.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Tada	2021	doi:10.1101/2021.02.05.430003	pmid:33564768	https://doi.org/10.1101/2021.02.05.430003	False	Tada et al. (2021)	n/a	Pseudotype lentivirus for the full B.1.351 Spike variant list shows increase affinity for ACE2 as measured by IC50. This is in contrast to B.1.1.7 which showed no major change, indicating that the shared N501Y mutation is the driver of affinity change, attentuated in the B.1.1.7 mutatioon set, but maintained in the B.1.351 lineage.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Voysey	2021	doi:10.1016/S0140-6736(20	n/a	https://doi.org/10.1016/S0140-6736(20	n/a	Voysey et al. (2021)	n/a	[Contrary to how this paper has been cited, Voysey et al. do NOT show evidence of decreased effectiveness of ChAdOx1 (AstraZeneca) against  the South African B.1.351 lineage. Insufficient numbers reaching the primary study endpoint were available in that arm of the vaccine study to report any statistics from the South African participants. Additionally, the study period of the paper ended in November 2020, while the earliest reported case of this lineage is October (covariants.org), only becoming dominant by mid-November.]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Planas	2021	doi:10.1038/s41591-021-01318-5	n/a	https://doi.org/10.1038/s41591-021-01318-5	True	Planas et al. (2021)	n/a	Flow cytometry was used on recombinant VSV proteins and yeast surface display to assess the binding of a labeled soluble ACE2  protein to cells expressing B.1.351. We observed an increase (relative to D614G) in binding of soluble  ACE2 to B.1.351, and to a much gearter extent to B.1.1.7, which both carry the N501Y mutation (see Fig 3).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Tarke	2021	doi:10.1101/2021.02.27.433180	pmid:33688655	https://doi.org/10.1101/2021.02.27.433180	False	Tarke et al. (2021)	n/a	PBMCs of Pfizer/BioNTech BNT162b2 (n	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Madhi	2021	doi:10.1056/NEJMoa2102214	pmid:33725432	https://doi.org/10.1056/NEJMoa2102214	True	Madhi et al. (2021)	n/a	Relative to B.1.1.117, PRNT50 line virus neutralizating antibody activity assay of B.1.351 showed ~11x reduction in 13 vacinees's sera  collected through 41 days after vaccination. Neutralization by a placebo control group of 6 naturally infected patients showed a smaller ~8x drop (starting from a ~50% higher PRNT50 value than vacinees for B.1.1.117 neutralization). Serum samples obtained from 13 ChAdOx1 nCoV-19 vaccine recipients without SARS-CoV-2 infection through 41 days after vaccination  showed ~4x reduction in neutralization (ID50) for full B.1.351 pseudotype HIV-1 virus compared to D614G alone. This  RBD variant combination's neutralization by a placebo control  group of 6 naturally infected patients showed a slightly higher 4.6x drop (though with D614G starting at a 1.7x higher titre than vaccinee sera).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	McEvoy C	2022	doi:10.1101/2022.06.24.22276144	n/a	https://doi.org/10.1101/2022.06.24.22276144	False	McEvoy C et al. (2022)	n/a	Log10ID50 of Beta neutralizing antibodies is 0.899x the WT 1 month post-third dose of pfizer-BioNTech BNT162b2 in 13 Kidney transplant recipients (KTR) with median  age of 55.5.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Bates	2021	doi:10.1101/2021.04.04.21254881	pmid:33851185	https://doi.org/10.1101/2021.04.04.21254881	False	Bates et al. (2021)	n/a	A 1.8-fold drop in FRNT50 for B.1.351 was observed in 44 sera collected between 1 and 301 post-infection.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	3.2x reduction in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees)	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Choi	2021	doi:10.1101/2021.06.28.449914	n/a	https://doi.org/10.1101/2021.06.28.449914	False	Choi et al. (2021)	n/a	Neutralization efficiency (ID50) against B.1.1.351-v1 reduced 6.9x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	T cell evasion	n/a	n/a	Skelly	2021	doi:10.21203/rs.3.rs-226857/v1	n/a	https://doi.org/10.21203/rs.3.rs-226857/v1	False	Skelly et al. (2021)	n/a	Encouragingly, we find that the majority of T cell responses in recipients of two doses of the BNT162b2 vaccine are generated  by epitopes that are invariant between the [wildtype] and two of the current variants of concern (B.1.1.7 and B.1.351). In over 90% of two dose mRNA vaccinees, heterotypic neutralizing titres (NT50) against B.1.1.7 and B.1.351 remain comfortably  above the level associated with immune protection in recent vaccine trials. However, in over 50% of convalescent COVID-19  individuals and recipients of a only a single dose of mRNA vaccine – heterotypic neutralization dropped to negligible levels,  particularly against B.1.351.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Wang	2021	doi:10.1038/s41586-021-03398-2	n/a	https://doi.org/10.1038/s41586-021-03398-2	True	Wang et al. (2021)	n/a	The neutralizing activity of 16/20 convalescent sera was significantly lower against this pseudotyped virus model of B.1.351, with similar results for the live virus.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	McEvoy C	2022	doi:10.1101/2022.06.24.22276144	n/a	https://doi.org/10.1101/2022.06.24.22276144	False	McEvoy C et al. (2022)	n/a	Log10ID50 of Beta neutralizing antibodies is 0.803x the WT pre-third dose of pfizer-BioNTech BNT162b2 in 13 Kidney transplant recipients (KTR) with median age of  55.5.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Wang	2021	doi:10.1038/s41586-021-03398-2	n/a	https://doi.org/10.1038/s41586-021-03398-2	True	Wang et al. (2021)	n/a	B.1.351 pseudotyped virus model ablates neutralization by RBD-directed mAbs CB6, 4-20, 2-4, 2-43, 910-30, 2-302-15, LY-Cov555, C121. B.1.351 pseudotyped virus model severely impairs neutralization by RBD-directed mAb 1-20. B.1.351 pseudotyped virus model impairs neutralization by RBD-directed mAb REGN10933. B.1.351 pseudotyped virus model ablates neutralization by N-terminal-domain-directed mAbs 5-24, 4-8, 4A8, 4-19. B.1.351 pseudotyped virus model severely impairs neutralization by N-terminal-domain-directed mAb 2-17. B.1.351 pseudotyped virus model impairs neutralization by N-terminal-domain-directed mAb 5-7. PG: Live virus data for the same mAbs is similar, but 1-20 becomes severally impaired, REGN10933 activity is ablated, and Brii-196 becomes impaired.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Wang	2021	doi:10.1038/s41586-021-03398-2	n/a	https://doi.org/10.1038/s41586-021-03398-2	True	Wang et al. (2021)	n/a	The neutralizing activity of vaccine was significantly lower against B.1.351 (12.4x in twelve Moderna-recipient sera: 10.3x in ten Pfizer-recipient sera). [this is a larger list of B.1.351 than modeled by Wang et al. (2021) by including L18F and R246I, less effective at neutralizing]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Planas	2021	doi:10.1038/s41591-021-01318-5	n/a	https://doi.org/10.1038/s41591-021-01318-5	True	Planas et al. (2021)	n/a	The sera of 16 individuals with time course collection was evaluated against VSV pseudotypes: while BD614G and B.1.1.7 were  neutralized earlier, the anti-B.1.351 response was negative up to week 3, and became detectable at week 4 (1 week after booster dose), at a level lower  than the two other viruses (~10x vs D614G) through week 6, the last timepoint measured. Three vaccinees never showed detectable neutralization to B.1.351 even after second dose.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Chonira	2022	doi:10.1101/2022.05.30.493765	pmid:35677079	https://doi.org/10.1101/2022.05.30.493765	False	Chonira et al. (2022)	n/a	DARPin SR16m molecule had a 0.036x fold change in IC50 in B.1.351 Beta	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	tissue specific neutralization	n/a	n/a	Planas	2021	doi:10.1038/s41591-021-01318-5	n/a	https://doi.org/10.1038/s41591-021-01318-5	True	Planas et al. (2021)	n/a	The nasal mucosa of Pfizer vaccinees with time course collection was evaluated against VSV pseudotypes: while B.1.1.7 and D614G showed neutralization by nasal swab from only one different previously infected vacinee neutralizing at weeks 3 and 6, B.1.351 showed zero neutralization at either time point in any sample (and relatively impaired serum neutralization).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Choi	2021	doi:10.1101/2021.06.28.449914	n/a	https://doi.org/10.1101/2021.06.28.449914	False	Choi et al. (2021)	n/a	Neutralization efficiency (ID50) against B.1.1.351-v2 reduced 7.3x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Woldemeskel	2021	doi:10.1172/JCI149335	pmid:33822770	https://doi.org/10.1172/JCI149335	True	Woldemeskel et al. (2021)	n/a	No significant difference in T-cell response to B.1.351 was observed (vs. ancestral) in blood drawn from 28 participants received the Pfizer-BioNTech vaccine  and 2 received the Moderna vaccine.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Ikegame	2021	doi:10.21203/rs.3.rs-400230/v1	pmid:33851150	https://doi.org/10.21203/rs.3.rs-400230/v1	False	Ikegame et al. (2021)	n/a	B.1.351 pseudotyped VSV was tested for neutralization in a clonal HEK-293T ACE2 TMPRSS2 cell line optimized for highly efficient  S-mediated infection. Only 1 out of 12 serum samples from a cohort of Argentinian recipients of the Gamaleya Sputnik V Ad26 / Ad5 vaccine  showed effective neutralization (IC90) at full serum strength (average realtive decrease was 6.1x vs wild type).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Chonira	2022	doi:10.1101/2022.05.30.493765	pmid:35677079	https://doi.org/10.1101/2022.05.30.493765	False	Chonira et al. (2022)	n/a	Trimeric proteins FSR22 had a 0.07x fold change in IC50 in B.1.351 Beta	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Shinde	2021	doi:10.1056/NEJMoa2103055	pmid:33951374	https://doi.org/10.1056/NEJMoa2103055	True	Shinde et al. (2021)	n/a	In a randomized phase 2a-b control trial of the Novavax (NVX-CoV2373) vaccine in South Africa, where B.1.351 virus dominates, efficacy was 60.1% (95% CI, 19.9 to 80.1) in HIV-negative and initially SARS-CoV-2 seronegative participants using the  primary endpoint of laboratory-confirmed symptomatic Covid-19 at 7 days or more after the second dose among participants.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Chonira	2022	doi:10.1101/2022.05.30.493765	pmid:35677079	https://doi.org/10.1101/2022.05.30.493765	False	Chonira et al. (2022)	n/a	DARPin SR22 molecule had a 1.57x fold change in IC50 in B.1.351 Beta	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Chonira	2022	doi:10.1101/2022.05.30.493765	pmid:35677079	https://doi.org/10.1101/2022.05.30.493765	False	Chonira et al. (2022)	n/a	Trimeric proteins FSR16m had a 0.054x fold change in IC50 in B.1.351 Beta	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Dejnirattisai	2021	doi:10.1016/j.cell.2021.03.055	pmid:33852911	https://doi.org/10.1016/j.cell.2021.03.055	True	Dejnirattisai et al. (2021)	n/a	B.1.351 virus neutralization (as tested using biolayer interferometry) of both Lilly antibodies was severely impacted, with LY-CoV16 and LY-CoV555  (due to mutations at 416 and 484 respectively) shows almost complete loss of neutralization of B.1.351. There was also escape from neutralization of B.1.351 by REGN10933 and a modest reduction in neutralization of B.1.351 by AZD8895  (while AZD1061 and AZD7442 showed equal neutralization of all SARS-CoV-2 variants tested). The three Adagio antibodies neutralized B.1.351.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Chonira	2022	doi:10.1101/2022.05.30.493765	pmid:35677079	https://doi.org/10.1101/2022.05.30.493765	False	Chonira et al. (2022)	n/a	DARPin SR16m molecule had a 6.7x fold change in IC50 in B.1.617.2 Delta	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Chonira	2022	doi:10.1101/2022.05.30.493765	pmid:35677079	https://doi.org/10.1101/2022.05.30.493765	False	Chonira et al. (2022)	n/a	DARPin SR16m molecule had a 99.7x fold change in IC50 in B.1.617.2 Delta	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	trafficking	n/a	n/a	Tada	2021	doi:10.1101/2021.02.05.430003	pmid:33564768	https://doi.org/10.1101/2021.02.05.430003	False	Tada et al. (2021)	n/a	Lentiviral pseudotyped with all key mutations from B.1.351 lineage was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing modest decrease in infection rate amongst the cells, suggesting some synergy between the mutations to decrease cell entry fitness (i.e. cell entry is liklely not the driver of this lineage's dominance).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Tang	2021	doi:10.1101/2021.03.19.436183	n/a	https://doi.org/10.1101/2021.03.19.436183	False	Tang et al. (2021)	n/a	The most significant loss of neutralizing activity (PsVNA50 assay) using 6 hyperimmune immunoglobulin preparations from convalescent plasma was seen against authentic B.1.351 lineage virus (9.2-fold). Neutralization against 10 convalescent plasma was poorer (18.7x).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	environmental condition stability	n/a	n/a	Meister	2021	doi:10.1093/infdis/jiab260	pmid:33993274	https://doi.org/10.1093/infdis/jiab260	True	Meister et al. (2021)	n/a	Treatment with heat, soap and ethanol revealed similar inactivation profiles indicative of a comparable susceptibility  towards disinfection. Furthermore, we observed comparable surface stability on steel, silver, copper and face masks.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	environmental condition stability	n/a	n/a	Tada	2021	doi:10.1101/2021.02.05.430003	pmid:33564768	https://doi.org/10.1101/2021.02.05.430003	False	Tada et al. (2021)	n/a	Relative to D614G, this mutation set (B.1.351+) demonstrated significant increase in infectivity (i.e. heat stability) after incubation at 50C after 1 hour.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	outcome hazard ratio	n/a	n/a	Santos de Oliviera	2021	doi:10.1101/2021.03.24.21254046	n/a	https://doi.org/10.1101/2021.03.24.21254046	False	Santos de Oliviera et al. (2021)	n/a	In the Parana state of Brazil, patients aged 20-29 years experienced a tripling of their case fatality rate (CFR), from 0.04% to 0.13%, while those aged  30-39, 40-49, 50-59 experienced approximate CFR doubling comparing February to January in 2021. Notably,  the observed CFR increase coincided with the second consecutive month of declining number of diagnosed SARS-CoV-2 cases.  Taken together, these preliminary findings suggest significant increases in CFR in young and middle-aged adults after  identification of a novel SARS-CoV-2 strain circulating in Brazil.  [this is somewhat indirect evidence that assume greatly increasing proportion of P.1 cases in March (70%) compared to  February, but the first official ID of P.1 in Parana state (Feb 16th) may be due to testing procedures rather than actual prevalence]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	outcome hazard ratio	n/a	n/a	Ribas Freitas	2021	doi:10.1101/2021.04.13.21255281	n/a	https://doi.org/10.1101/2021.04.13.21255281	False	Ribas Freitas et al. (2021)	n/a	In the Southern Brazilian stats of Rio Grande do Sul, comparing pre-P.1 and post-P.1 waves:  The increase in Case Fatality Rate occurred in a greatest intensity in the population between 20 and 59 years old and among patients without pre-existing risk conditions. Female 20 to 39 years old, with no pre-existing risk conditions, were at risk of death 5.65 times higher in February (95%CI 	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	outcome hazard ratio	n/a	n/a	Funk	2021	doi:10.2807/1560-7917.ES.2021.26.16.2100348	pmid:33890566	https://doi.org/10.2807/1560-7917.ES.2021.26.16.2100348	True	Funk et al. (2021)	n/a	On average across 7 European countries studied, using P.1 defining mutations: Significant shift to infection in those without pre-existing conditions (27.8% vs 89% for non-VOC cases). Significant increase in hospitalization rate (20% vs 7.5% for non-VOC cases). Significant increase in ICU rate (2.1% vs 0.6% for non-VOC cases). Significant increase in health care worker rate (19.8% vs 8.0% for non-VOC cases).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Mallm	2021	doi:10.1101/2021.04.27.21254849	n/a	https://doi.org/10.1101/2021.04.27.21254849	False	Mallm et al. (2021)	n/a	This variant was designated A.27.RN according to its phylogenetic clade classification. It emerged in parallel  with the B.1.1.7 variant, increased to >50% of all SARS-CoV-2 variants by week five. Subsequently it decreased  to <10% of all variants by calendar week eight when B.1.1.7 had become the dominant strain. Antibodies induced  by BNT162b2 (Pfizer) vaccination neutralized A.27.RN but with a two-to-threefold reduced efficacy as compared to the  wild-type and B.1.1.7 strains.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.2 (from South Africa/CERI-KRISP-K032307/2021) were 3.9x-fold lower (95% CI: 0.14x-0.17x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Uhal B	2022	doi:10.1101/2022.06.23.497326	n/a	https://doi.org/10.1101/2022.06.23.497326	False	Uhal B et al. (2022)	n/a	L27, V34 and E90 mutation resulted in ultrahigh affinity binding of the LVE-ACE-2 domain to the widest variety of VOCs, with KDs of 78fM for binding to the Omicron  BA.2. Values were obtained with LVE-ACE-2/mAB chimeras containing the Y-T-E sequence that enhances binding to the FcRn receptor, which in turn is expected to  extend biological half-life 3-4-fold.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.2 (from South Africa/CERI-KRISP-K032307/2021) were 4.5-fold lower (95% CI: 4.3x-4.7x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.2.12.1 (from USA/NY-CDC-ASC210722700/2022) were 4.2-fold lower (95% CI: 5.8x-6.6x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.2.12.1 (from USA/NY-CDC-ASC210722700/2022) were 3.9x-fold lower (95% CI: 0.14x-0.18x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Cathcart	2021	doi:10.1101/2021.03.09.434607v9	n/a	https://doi.org/10.1101/2021.03.09.434607v9	False	Cathcart et al. (2021)	n/a	Omicron (a.k.a. B.1.1.529) Spike pseudotyped VSV and Vero E6 cells has somewhat  reduced neutralization (2.7x) vs wild type with monoclonal antibody Sotrovimab (a.k.a. VIR-7831).  [delins at 214 omitted for syntax compatibility]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Wang	2022	doi:10.1101/2022.08.11.503601	n/a	https://doi.org/10.1101/2022.08.11.503601	False	Wang et al. (2022)	n/a	Omicron breakthrough infection after 3-dose vaccination resulted in a further 3.5-fold and 2.9-fold increase of Omicron BA.1 and BA.2 neutralizing titers. Omicron  BA.4/5 showed the highest neutralization resistance of all variants tested, resulting in low geometric mean neutralizing titers in plasma samples  obtained after  the second vaccine dose (NT50	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs Bi-Nab47D10-35B5. Omicron BA.1 has an IC50 fold change of 0.08x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron B.1.1.529 (BA.1) neutralization of the Omicron variants by antibodies induced by three doses of Pfizer/BNT162b2 mRNA vaccine was 7-8-fold less potent than  the D614G, and the Omicron variants still evade neutralization more efficiently.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron (B.1.1.529 [BA.1]) have higher sensitivity to inhibition by soluble angiotensin converting enzyme 2 (ACE2) and the endosomal inhibitor chloroquine compared  to D614G	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs Bi-Nab35B5-47D10. Omicron BA.1 has an IC50 fold change of 0.30x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Uhal B	2022	doi:10.1101/2022.06.23.497326	n/a	https://doi.org/10.1101/2022.06.23.497326	False	Uhal B et al. (2022)	n/a	Paradigms’ ACE-2 variant LVE/STR chimera binds to SARS-2 Omicron variant B.1.1.529 spike protein trimer with high affinity. Determined using Surrogate Viral Neutralization Tests.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Uhal B	2022	doi:10.1101/2022.06.23.497326	n/a	https://doi.org/10.1101/2022.06.23.497326	False	Uhal B et al. (2022)	n/a	L27, V34 and E90 mutation resulted in ultrahigh affinity binding of the LVE-ACE-2 domain to the widest variety of VOCs, with KDs of 73 pM for binding to the Omicron  B.1.1.529. Values were obtained with LVE-ACE-2/mAB chimeras containing the Y-T-E sequence that enhances binding to the FcRn receptor, which in turn is expected to  extend biological half-life 3-4-fold.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs 35B5. Omicron BA.1 has an IC50 fold change of 0.38x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Arora	2022	doi:10.1038/s41423-022-00870-5	pmid:35581351	https://doi.org/10.1038/s41423-022-00870-5	True	Arora et al. (2022)	n/a	All 10 individuals with 2 doses of the BNT162b2/BNT162b2 vaccine had a neutralizing titer in B.1 variant at an average of 729 NT50.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Shete	2022	doi:10.1101/2022.05.12.491584	n/a	https://doi.org/10.1101/2022.05.12.491584	False	Shete et al. (2022)	n/a	Plaque reduction neutralization test (PRNT) was used uring primary infection, post sixty daysof second dose vaccination, pre-reinfection and reinfection against Delta variant and was used to determine neutralizing antibodytitres. There was a 24.63x fold increase in antibody response from first infection to recovered and vaccinated with 2 doses (60 days). There was a 4.21x fold increase in antibody response pre-reinfection. There was a 39.27x fold increase in antibody response during reinfection.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Shete	2022	doi:10.1101/2022.05.12.491584	n/a	https://doi.org/10.1101/2022.05.12.491584	False	Shete et al. (2022)	n/a	Plaque reduction neutralization test (PRNT) was used uring primary infection, post sixty daysof second dose vaccination, pre-reinfection and reinfection against B.1 variant and was used to determine neutralizing antibodytitres. There was a 6.76x fold increase in antibody response from first infection to recovered and vaccinated with 2 doses (60 days). There was a 2.06x fold increase in antibody response pre-reinfection. There was a 8.18x fold increase in antibody response during reinfection.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Arora	2022	doi:10.1038/s41423-022-00870-5	pmid:35581351	https://doi.org/10.1038/s41423-022-00870-5	True	Arora et al. (2022)	n/a	All 10 individuals with 3 doses of the BNT162b2/BNT162b2 vaccine had a neutralizing titer in B.1 variant at an average of 3319 NT50.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Shete	2022	doi:10.1101/2022.05.12.491584	n/a	https://doi.org/10.1101/2022.05.12.491584	False	Shete et al. (2022)	n/a	Plaque reduction neutralization test (PRNT) was used uring primary infection, post sixty daysof second dose vaccination, pre-reinfection and reinfection against Omicron variant and was used to determine neutralizing antibodytitres. There was a 114.84x fold increase in antibody response from first infection to recovered and vaccinated with 2 doses (60 days). There was a 6.61x fold increase in antibody response pre-reinfection. There was a 1194.9x fold increase in antibody response during reinfection.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Kumar	2022	doi:10.1101/2022.05.13.491770	n/a	https://doi.org/10.1101/2022.05.13.491770	False	Kumar et al. (2022)	n/a	BnAb 002-S21F2 IC50 on the Omicron BA.1 variant is 1.0x fold the wildtype.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs 47D10. Omicron BA.1 has an IC50 fold change of 1.26x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron BA.3 have higher sensitivity to inhibition by soluble angiotensin converting enzyme 2 (ACE2) and the endosomal inhibitor chloroquine compared  to D614G	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron BA.3 neutralization of the Omicron variants by antibodies induced by three doses of Pfizer/BNT162b2 mRNA vaccine was 7-8-fold less potent than the D614G, and  the Omicron variants still evade neutralization more efficiently.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.3 (from South Africa/NICD-N22404/2021) were 4.2x-fold lower (95% CI: 0.15x-0.20x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.3 (from South Africa/NICD-N22404/2021) were 6.2-fold lower (95% CI: 11.8x-14.3x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Hao	2022	doi:10.1101/2022.08.12.22278720	pmid:36032965	https://doi.org/10.1101/2022.08.12.22278720	False	Hao et al. (2022)	n/a	paired testing of vaccine sera against ancestral virus compared to Omicron BA.1 shows that 3-dose vaccine regimen provides over 50x fold increase in protection against Omicron(B.1.1.529 [BA.1]) compared to a 2-dose regimen.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Wang	2022	doi:10.1101/2022.08.11.503601	n/a	https://doi.org/10.1101/2022.08.11.503601	False	Wang et al. (2022)	n/a	4th antigenic exposure with Omicron (B.1.1.529 [BA.1])(n	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.1 (from Botswana/R40B59_BHP_3321001248/2021) were 3.4-fold lower (95% CI: 3.2x-3.6x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.1 (from Botswana/R40B59_BHP_3321001248/2021) were 28.7x-fold lower (95% CI: 0.03x-0.05) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Chen	2021	doi:10.1038/s41591-021-01294-w	pmid:33664494	https://doi.org/10.1038/s41591-021-01294-w	True	Chen et al. (2021)	n/a	The neutralizing activity of vaccine was somewhat lower against B.1.1.7 in sera tested from most of the 24 patients with the BNT162b2 mRNA vaccine. (Fig. 4)	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Chen	2021	doi:10.1038/s41591-021-01294-w	pmid:33664494	https://doi.org/10.1038/s41591-021-01294-w	True	Chen et al. (2021)	n/a	B.1.1.7 variant constellation ablates Class 3 N-terminal domain targeting antibody COV2-2489.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Bates	2021	doi:10.1101/2021.04.04.21254881	pmid:33851185	https://doi.org/10.1101/2021.04.04.21254881	False	Bates et al. (2021)	n/a	Observed 8.8-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose) against cultured B.1.1.7 sample. Contrast this with 1.3-fold reduction for just the pseudovirus combination of 'key' B.1.1.7 mutation N501Y.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Choi	2021	doi:10.1101/2021.06.28.449914	n/a	https://doi.org/10.1101/2021.06.28.449914	False	Choi et al. (2021)	n/a	Neutralization efficiency (ID50) against B.1.1.7+E484K reduced 2.8x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster. Compare with 1.2x reduction for B.1.1.7 without E484K.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Collier	2021	doi:10.1038/s41586-021-03412-7	n/a	https://doi.org/10.1038/s41586-021-03412-7	True	Collier et al. (2021)	n/a	Sera after the second dose of Pfizer showed an average reduction in neutralization titres against the B.1.1.7 + E484K  variant of ~6.7x, markedly higher than B.1.1.7 alone. For first dose sera, a 9.7x drop was observed.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Collier	2021	doi:10.1038/s41586-021-03412-7	n/a	https://doi.org/10.1038/s41586-021-03412-7	True	Collier et al. (2021)	n/a	Neutralization capacity GMT of 27 subjects' sera post-infection was markedly worse against B.1.1.7 + E484K than the lineage alone, with a 11.4x drop.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Chen	2021	doi:10.1038/s41591-021-01294-w	pmid:33664494	https://doi.org/10.1038/s41591-021-01294-w	True	Chen et al. (2021)	n/a	Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	trafficking	n/a	n/a	Tada	2021	doi:10.1101/2021.02.05.430003	pmid:33564768	https://doi.org/10.1101/2021.02.05.430003	False	Tada et al. (2021)	n/a	Lentiviral pseudotyped with this mutation set from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing significant (40%) increase in infection rate amongst the cells, much more than the effect of  either the deletion or the point mutation alone, suggetsing that this combination has a synergistic effect  contributing to cell entry fitness, moreso than this combination with the addition of P681H.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	symptom prevalence	n/a	n/a	van Loon	2021	doi:10.1101/2021.04.15.21255389	n/a	https://doi.org/10.1101/2021.04.15.21255389	False	van Loon et al. (2021)	n/a	In comparison of B.1.1.7 lineage (193 cases) vs. 'wildtype' (125) in Berlin Jan 18 to March 29 2021,  significant symptom changes are absent loss of smell/taste (P	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Tada	2021	doi:10.1101/2021.02.05.430003	pmid:33564768	https://doi.org/10.1101/2021.02.05.430003	False	Tada et al. (2021)	n/a	This mutation combination causes major increase in binding affinity vs. wild type as measured by IC50 vs pseudotyped  lentivirus, but combined with the complete set of B.1.1.7   lineage variants no major change vs wild type affnity is observed.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Shen	2021	doi:10.1101/2021.01.27.428516	pmid:33532764	https://doi.org/10.1101/2021.01.27.428516	False	Shen et al. (2021)	n/a	Reduction in neutralization by mAbs COVA1-18 (~4x), COVA2-15 (~9x). PG: these effects are laregly missing in the deletion-alone data	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	symptom prevalence	n/a	n/a	Snell	2021	doi:10.1101/2021.03.16.21253377	n/a	https://doi.org/10.1101/2021.03.16.21253377	False	Snell et al. (2021)	n/a	A higher proportion of cases infected with the B.1.1.7 variant were hypoxic on admission compared to other variants (70.0% vs 62.5%, p	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	virion structure	n/a	n/a	Tada	2021	doi:10.1101/2021.02.05.430003	pmid:33564768	https://doi.org/10.1101/2021.02.05.430003	False	Tada et al. (2021)	n/a	The Ratio of S2 (processed Spike) to full length Spike is higher for this mutation combination,  due to a drop in the full length Spike measured, suggesting that this mutation compensates for decreased Spike production by improved proteolytic processing.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Reynolds	2021	doi:10.1126/science.abh1282	pmid:33931567	https://doi.org/10.1126/science.abh1282	True	Reynolds et al. (2021)	n/a	After one dose, individuals with prior infection showed enhanced T cell immunity,  antibody secreting memory B cell response to spike and neutralizing antibodies effective  against B.1.1.7 (authentic cell culture supernatants). By comparison, HCW receiving one vaccine dose without prior  infection showed reduced immunity against variants. B.1.1.7 spike mutations  resulted in increased, abrogated or unchanged T cell responses depending on human leukocyte  antigen (HLA) polymorphisms. Study was 26 each post-infection and post first dose HCWs.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Uriu	2021	doi:10.1101/2021.09.06.459005	n/a	https://doi.org/10.1101/2021.09.06.459005	False	Uriu et al. (2021)	n/a	Mean 2.6x reduction of NT50 value B.1.1.7 (Alpha) relative to wild type in 8 sera from older convalescent patients (52-92yo) collected 1-3m post symptom onset.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Pegu	2021	doi:10.1101/2021.05.13.444010	pmid:34031659	https://doi.org/10.1101/2021.05.13.444010	False	Pegu et al. (2021)	n/a	Detectable antibodies against B.1.1.7 at various time points using pseudotyped lentivirus neutralization in Moderna vaccinee cohort: Day 29 33%, Day 43 100%, Day 119 100%, Day 209 96%. Detectable antibodies against B.1.1.7 at various time points using live virus FRNT neutralization in Moderna vaccinee cohort: Day 29 54%, Day 43 100%, Day 119 100%, Day 209 88%. Detectable antibodies against B.1.1.7 at various time points using ACE2 blocking assay in Moderna vaccinee cohort: Day 29 83%, Days 43,119,209 100%.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Haas	2021	doi:10.1016/S0140-6736(21	n/a	https://doi.org/10.1016/S0140-6736(21	n/a	Haas et al. (2021)	n/a	Using national surveillance data from Israel, using Pfizer vaccine and an estimated prevalence of the B.1.1.7 variant of 94.5% among SARS-CoV-2 infections: Adjusted estimates of vaccine effectiveness 7+ days after second dose were 95·3% (95% CI 94.9–95.7):  91.5% against asymptomatic SARS-CoV-2 infection (90·7–92·2: 40.9 vs 1.8 per 100 000 person-days), 97·0% against symptomatic  COVID-19 (96.7–97.2%), 97.2% against COVID-19-related hospitalisation (96.8–97.5%),  97.5% against severe or critical COVID-19-related hospitalisation (97.1–97.8%), and 96.7% against COVID-19-related death (96.0–97.3%).  In all age groups, as vaccine coverage increased, the incidence of SARS-CoV-2 outcomes declined	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Luftig	2021	doi:10.1056/NEJMc2104036	pmid:33826815	https://doi.org/10.1056/NEJMc2104036	True	Luftig et al. (2021)	n/a	In sera 1-2 weeks after BNT162b2 first dose, from six patients previously infected with B.1, antibody titer in a microneutralization assay  was on average 8192 for B.1.351 virus. This compares favorably (stronger) to post-infection neutralization titer against all variants tested in the same sera (wild type, B.1.1.7, B.1.351, and P.1).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	virion structure	n/a	n/a	Cai	2021	doi:10.1101/2021.04.13.439709	pmid:33880477	https://doi.org/10.1101/2021.04.13.439709	False	Cai et al. (2021)	n/a	CryoEM analysis of B.1.1.7 demonstrates an increased propensity for 'up', receptor accessible conformation of the Spike protein trimer.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Loconsole	2021	doi:10.1016/j.cmi.2021.05.007	pmid:33984489	https://doi.org/10.1016/j.cmi.2021.05.007	True	Loconsole et al. (2021)	n/a	SARS-CoV-2 infection was confirmed in three HCWs working a single shift: all presented with mild symptoms of COVID-19. The two physicians  were fully vaccinated with BNT162b2 vaccine, with the second dose administered 1 month before symptom onset. Both had high titres of IgG  anti-spike antibodies at the time of diagnosis. WGS confirmed that all virus strains were VOC 202012/01-lineage B.1.1.7, suggesting a  common source of exposure. Epidemiological investigation revealed that the suspected source was a SARS-CoV-2-positive patient who  required endotracheal intubation due to severe COVID-19. All procedures were carried out using a full suite of personal protective equipment (PPE).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine efficacy	n/a	n/a	Bruxvoort	2021	doi:10.1101/2021.09.29.21264199	n/a	https://doi.org/10.1101/2021.09.29.21264199	False	Bruxvoort et al. (2021)	n/a	In a 1:5 test-negative matched control study of 8153 individuals who received the Moderna mRNA-1273 vaccine, 1422 test-positive were Alpha. Two dose vaccine efficacy against Alpha was 98.4% [96.9-99.1%], one dose VE was 90.1% (82.9-94.2%).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Planas	2021	doi:10.1038/s41591-021-01318-5	n/a	https://doi.org/10.1038/s41591-021-01318-5	True	Planas et al. (2021)	n/a	Using a new rapid neutralization assay, based on reporter cells that become positive for GFP after overnight infection, sera from 58  convalescent individuals collected up to 9 months after symptoms, similarly neutralized B.1.1.7 and D614G.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs Bi-Nab35B5-47D10. Alpha (B.1.1.7) has an IC50 fold change of 1.19x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Wang	2021	doi:10.1038/s41586-021-03398-2	n/a	https://doi.org/10.1038/s41586-021-03398-2	True	Wang et al. (2021)	n/a	B.1.1.7 pseudotyped virus model impairs binding by RBD-directed mAb 910-30. B.1.1.7 pseudotyped virus model abolishes N-terminal-domain-directed mAbs 5-24, 4-8, and 4A8. B.1.1.7 pseudotyped virus model impairs binding by N-terminal-domain-directed mAbs 2-17, 4-19, 5-7.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Wang	2021	doi:10.1056/NEJMc2103022	pmid:33822491	https://doi.org/10.1056/NEJMc2103022	True	Wang et al. (2021)	n/a	1.4x improvement in neutralization by serum collected 2 to 3 weeks after the second dose from vaccinees who had received  BBIBP-CorV (pVNT50 against VSV pseudotyped as B.1.1.7). Convalescent plasma had similar titer against wild type as the BBIBP-CorV vaccinee sera. 2x reduction in neutralization by serum collected 2 to 3 weeks after the second dose from vaccinees who had received  CoronaVac (pVNT50 against VSV pseudotyped as B.1.1.7). Convalescent plasma had similar titer against wild type as the CoronaVac vaccinee sera.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	aerosolization	n/a	n/a	Adenaiye	2021	doi:10.1093/cid/ciab797	pmid:34519774	https://doi.org/10.1093/cid/ciab797	True	Adenaiye et al. (2021)	n/a	Alpha variant cases in a large campus study showed fine-aerosol shedding amongst unmasked participants remained significantly greater for alpha variant infections (18-fold, 95% CI, 3.4 to 92-fold) after adjusting for the increased viral RNA in MTS and saliva, the number of coughs during sampling sessions, and symptom. After controlling for the effect of masks and numbers of coughs during sampling, alpha variant infection was associated with a 100-fold (95% CI, 16 to 650-fold) increase in coarse- and a 73-fold (95% CI, 15 to 350-fold) increase in fine-aerosol RNA shedding.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	environmental condition stability	n/a	n/a	Schuit	2021	doi:10.1093/infdis/jiab171	pmid:33822064	https://doi.org/10.1093/infdis/jiab171	True	Schuit et al. (2021)	n/a	No differences in the stability of B.1.1.7 observed in the absence of simulated sunlight at either 20°C or 40°C (with a mean time for  a 90% loss of viral infectivity across all dark conditions of 6.2 hours). However, a small but statistically  significant difference in the stability was observed in simulated sunlight at 20°C and 20% relative humidity, with B.1.1.7 restoring  wild type 90% loss time of 11 minutes vs. 7 and 8 minutes for B.1.319 (D614G) and B.28 (V367F) early 2020 viruses respectively.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	trafficking	n/a	n/a	Liu	2021	doi:10.1101/2021.08.12.456173v3	n/a	https://doi.org/10.1101/2021.08.12.456173v3	False	Liu et al. (2021)	n/a	Modelling the Alpha variant in primary human airway epithelial (HAE) cultures, S1 to full length Spike ratio  (measuring Spike furin cleavage processivity) increase 3.9x relative to wild type (5.4 vs 1.4). This is less efficient than Delta (11x vs wildtype using a P681R mutation instead). [del ~144 changed due to ambiguity] Furthermore the RNA ratio of Delta versus Alpha-spike/Delta-backbone continuously increased from 2.8 on day 1  to 9.8 on day 5 post infection in a co-infection model in HAEs, suggesting the spike gene drives the improved replication of Delta variant.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Woldemeskel	2021	doi:10.1172/JCI149335	pmid:33822770	https://doi.org/10.1172/JCI149335	True	Woldemeskel et al. (2021)	n/a	No significant difference in T-cell response to B.1.1.7 was observed (vs. ancestral) in blood drawn from 28 participants received the Pfizer-BioNTech vaccine  and 2 received the Moderna vaccine. This is despite three mutations (Y144del, D614G, and P681H) overlapping T-cell epitope hotspots.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Sapkal	2021	doi:10.1093/jtm/taab051	pmid:33772577	https://doi.org/10.1093/jtm/taab051	True	Sapkal et al. (2021)	n/a	The NAb titers (PRNT50) of sera collected from 38 vaccine recipients four-weeks after the second dose of inactivated whole-virion SARS-CoV-2 BBV152/COVAXIN vaccine [which contains D614G] were not significantly  different between B.1.1.7 virus and ancestral D614G virus.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Tarke	2021	doi:10.1101/2021.02.27.433180	pmid:33688655	https://doi.org/10.1101/2021.02.27.433180	False	Tarke et al. (2021)	n/a	PBMCs of Pfizer/BioNTech BNT162b2 (n	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Hall	2021	doi:10.1016/S0140-6736(21	n/a	https://doi.org/10.1016/S0140-6736(21	n/a	Hall et al. (2021)	n/a	A single dose of BNT162b2 vaccine demonstrated vaccine effectiveness [symptomatic or asymptomatic in cohort opf routinely NAAT-monitored UK HCWs]  of 72% (95% CI 58-86) 21 days after first dose and 86% (95% CI 76-97) seven days after two doses in the antibody negative cohort.  This cohort was vaccinated when the dominant variant in circulation was B.1.1.7 and demonstrates effectiveness against this variant.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Amit	2021	doi:10.1016/S0140-6736(21	n/a	https://doi.org/10.1016/S0140-6736(21	n/a	Amit et al. (2021)	n/a	Between December 19, 2020 and Jan 24, 2021, 7214 of 9109 eligible HCWs at Sheba Medical Center in Israel had received one or more doses of  BNT162b2 (Pfizer) vaccine. Adjusted rate reduction in SARS-CoV-2 NAAT positivity infection compared with unvaccinated workers 1-14 days  after 1st dose was 30% (95% CI: 2-50), and 75% (95% CI: 72-84) after 15-28 days. Adjusted rate reduction in symptomatic COVID-19 compared with  unvaccinated workers 1-14 days after 1st dose was 47% (95% CI: 17-66), and 85% (95% CI: 71-92) after 15-28 days. [Though often cited as an indicator of VE for B.1.1.7, during this time period in Israel, the prevalence of the B.1.1.7 variant increased from ~20% to 50% of  cases (covariants.org), therefore these VE numbers likely represent a mix of B.1.1.7 and other lineage effects.]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Lopez Bernal	2021	doi:10.1136/bmj.n1088	pmid:33985964	https://doi.org/10.1136/bmj.n1088	True	Lopez Bernal et al. (2021)	n/a	We found that a single dose of the BNT162b2 vaccine is about 60-70% effective at preventing symptomatic disease in adults aged 70 years  and older in England and that two doses are about 85-90% effective. Those who were vaccinated and went on to have symptoms had a 44%  lower risk of being admitted hospital and a 51% lower risk of death compared with people who were unvaccinated. We also found that a single dose  of the ChAdOx1-S vaccine was about 60-75% effective against symptomatic disease and provided an additional protective effect against hospital  admission—it is too early to assess the effect on mortality. The B.1.1.7 variant now dominates in the UK and these results will largely  reflect vaccine effectiveness against this variant.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the 47D10. Alpha (B.1.1.7) has an IC50 fold change of 0.40x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	anthropozoonotic events	n/a	n/a	Hamer	2021	doi:10.1111/tbed.14122	pmid:33955193	https://doi.org/10.1111/tbed.14122	True	Hamer et al. (2021)	n/a	First documented cases of domestic cat and dog infections with the B.1.1.7 strain.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine efficacy	n/a	n/a	Lopez Bernal	2021	doi:10.1056/NEJMoa2108891	pmid:34289274	https://doi.org/10.1056/NEJMoa2108891	True	Lopez Bernal et al. (2021)	n/a	Effectiveness after one dose of vaccine (BNT162b2 or ChAdOx1 nCoV-19) with the delta variant was (48.7%: 95% confidence interval [CI], 45.5 to 51.7): the results were similar for both vaccines.  With the BNT162b2 vaccine, the effectiveness of two doses was 93.7% (95% CI, 91.6 to 95.3) among those with the alpha variant.  With the ChAdOx1 nCoV-19 vaccine, the effectiveness of two doses was 74.5% (95% CI, 68.4 to 79.4) among those with the alpha variant.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Shen	2021	doi:10.1101/2021.01.27.428516	pmid:33532764	https://doi.org/10.1101/2021.01.27.428516	False	Shen et al. (2021)	n/a	Reduction in neutralization by mAbs COVA2-15 (~9x), B38 (~14x), S309 (~190x) by this B.1.1.7 pseudotyped virus model.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Munitz	2021	doi:10.1016/j.xcrm.2021.100264	pmid:33899031	https://doi.org/10.1016/j.xcrm.2021.100264	True	Munitz et al. (2021)	n/a	We observed a sharp decline in cases when ∼50% of the elderly population was 2 weeks beyond their first  vaccination dose and at a time point during which the B.1.1.7 variant gained transmission dominance.  In support of this finding, it was suggested that, after the first vaccination dose, more than 70% of  patients develop neutralization antibodies,15 and the vaccine efficiency can reach 85%.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Hu	2021	doi:10.1101/2021.01.22.427749	n/a	https://doi.org/10.1101/2021.01.22.427749	False	Hu et al. (2021)	n/a	Neutralizing antibody titers of 2/20 (10%) samples showed >10x reduction (sera collected ~1mo post Jan 2020 first wave in China). Neutralizing antibody titers of 8/20 samples (40%) decreased below an ID50 threshold of 40 (sera  collected ~8mo post Jan 2020 first wave in China).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Rees-Spear	2021	doi:10.1101/2021.01.15.426849	n/a	https://doi.org/10.1101/2021.01.15.426849	False	Rees-Spear et al. (2021)	n/a	Lessens the potency of mAbs COVA2-17 (~5x, similar to N501Y alone), COVA1-12 (~11x) and COVA1-21 (>100x), which do not compete allosterically.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	reinfection	n/a	n/a	Graham	2021	doi:10.1016/s2468-2667(21	n/a	https://doi.org/10.1016/s2468-2667(21	n/a	Graham et al. (2021)	n/a	36920 COVID Symptom Study app users reported SARS-CoV-2 test positivity in late 2020. Possible reinfections were  identified in 249 (0.7% [95% CI 0.6-0.8]) of 36509 app users who reported a positive swab test before Oct 1, 2020,  but there was no evidence that the frequency of reinfections was higher for the B.1.1.7 variant than for pre-existing variants.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Garcia-Beltran	2021	doi:10.1016/j.cell.2021.03.013	pmid:33743213	https://doi.org/10.1016/j.cell.2021.03.013	True	Garcia-Beltran et al. (2021)	n/a	Pseudotyped B.1.1.7 virus has reduced neutralization activity vs wild type: 2.1x (30 sera Pfizer median 9 days post 2nd dose)  and 2.3x (35 sera Moderna median 18 days post 2nd dose). This was NOT significant by ANOVA. Note that Y145del was actually noted in the paper as the effect of their DNA construct, but this is  equivalent at the protein level to the more commonly annotated Y144del.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Planas	2021	doi:10.1038/s41591-021-01318-5	n/a	https://doi.org/10.1038/s41591-021-01318-5	True	Planas et al. (2021)	n/a	The sera of 16 individuals with time course collection was evaulated against VSV pseudotypes: neutralized D614G at week 2,  whereas B.1.1.7 started to be neutralized at week 3, although less efficiently than D614G. B.1.1.7 and D614G strains were  similarly neutralized at week 4 (1 week after booster dose).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Supasa	2021	doi:10.1016/j.cell.2021.02.033	pmid:33743891	https://doi.org/10.1016/j.cell.2021.02.033	True	Supasa et al. (2021)	n/a	Neutralization assays of B.1.1.7 virus showed a reduction of 2.5-fold (14 days post 2nd dose AstraZeneca, n	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs 35B5. Alpha (B.1.1.7) has an IC50 fold change of 1.39x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine efficacy	n/a	n/a	Puranik	2021	doi:10.1101/2021.08.06.21261707	pmid:34401884	https://doi.org/10.1101/2021.08.06.21261707	False	Puranik et al. (2021)	n/a	In Minnesota in early 2021 when Alpha was prevalent, vaccine efficacy was estimated as: mRNA-1273 86% (95%CI: 81-90.6%) and BNT162b2: 76% (95%CI: 69-81%) using age, sex, race, PCR testing and vaccination date matched cohorts of unvaccinated, Pfizer and Moderna vaccinees.  [variant list included is ancestral Alpha, as this was an observational study no variant list was given]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Hu	2021	doi:10.1101/2021.01.22.427749	n/a	https://doi.org/10.1101/2021.01.22.427749	False	Hu et al. (2021)	n/a	~20x resistence to mAb CQ038 by B.1.1.7 pseudotyped virus	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	reinfection	n/a	n/a	Marquez	2021	doi:10.1017/ice.2021.195	pmid:33934744	https://doi.org/10.1017/ice.2021.195	True	Marquez et al. (2021)	n/a	Reinfection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) B.1.1.7 variant in an immunocompromised 16yo female with end stage renal disease 94 days after initial infection with a B.1.2 lineage virus. Both lineages were the prevalent one at the time of 1st and 2nd infections respectively in Texas, where the patient was located (suggesting exposure risk rather than lineage immune evasion).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Uhal B	2022	doi:10.1101/2022.06.23.497326	n/a	https://doi.org/10.1101/2022.06.23.497326	False	Uhal B et al. (2022)	n/a	Paradigm’s ACE-2 variant LVE/STR chimera neutralizes Alpha Variant B.1.1.7 RBD significantly better than GenScript IgG FL18-740 w.t. ACE-2 mAB. Determined using Surrogate Viral Neutralization Tests.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs Bi-Nab47D10-35B5. Alpha (B.1.1.7) has an IC50 fold change of 1.44x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Hall	2021	doi:10.1016/S0140-6736(21	n/a	https://doi.org/10.1016/S0140-6736(21	n/a	Hall et al. (2021)	n/a	A single dose of BNT162b2 (Pfizer) vaccine showed vaccine effectiveness of 70% (95% CI 55-85) 21 days after first dose  and 85% (74-96) 7 days after two doses in the study population. Our findings show that the BNT162b2 vaccine can prevent both symptomatic and asymptomatic infection in working-age adults. This cohort (8203 treatment, 15121 control) was vaccinated when the  dominant variant in circulation was B.1.1.7 and shows effectiveness against this variant.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Graham	2021	doi:10.1016/j.immuni.2021.03.023	pmid:33836142	https://doi.org/10.1016/j.immuni.2021.03.023	True	Graham et al. (2021)	n/a	NTD-specific nAbs showed a substantial (3-450x) decrease in neutralization potency against the recently reported highly  transmissible B.1.1.7 variant of concern, whereas RBD-specific nAbs were either unaffected or showed lower decreases in potency.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	tissue specific neutralization	n/a	n/a	Planas	2021	doi:10.1038/s41591-021-01318-5	n/a	https://doi.org/10.1038/s41591-021-01318-5	True	Planas et al. (2021)	n/a	The nasal mucosa of Pfizer vaccinees with time course collection was evaluated against VSV pseudotypes: results (only one nasal  swab from different previously infected vacinee neutralizing at weeks 3 and 6 against B.1.1.7 and D614G) suggest that vaccinees probably  do not elicit an early humoral response detectable at mucosal surfaces even though sera neutralization was observed. They strengthen the hypothesis that some vaccines may not protect against  viral acquisition and infection of the oral–nasal region, but may prevent severe disease associated with viral dissemination in the lower respiratory tract.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Rosenke	2022	doi:10.1172/jci.insight.160108	pmid:35579953	https://doi.org/10.1172/jci.insight.160108	True	Rosenke et al. (2022)	n/a	Infectious viral titers in lung tissue determined using a tissue culture infectious dose (TCID) assay in 10 hamsters showed that Alpha Molnupiravir (MK-4482) had ~2.75x fold drop.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Choi	2021	doi:10.1101/2021.06.28.449914	n/a	https://doi.org/10.1101/2021.06.28.449914	False	Choi et al. (2021)	n/a	Neutralization efficiency (ID50) against B.1.1.7 reduced 1.2x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	reinfection	n/a	n/a	Harrington	2021	doi:10.1093/cid/ciab014	pmid:33421056	https://doi.org/10.1093/cid/ciab014	True	Harrington et al. (2021)	n/a	Second infection in December 2020 with B.1.1.7 after April 2020 initial infection with B.2 in a 78-year-old man with a history of Type 2 diabetes mellitus,  diabetic nephropathy on hemodialysis, chronic obstructive pulmonary disease (COPD), mixed central  and obstructive sleep apnea, ischemic heart disease, with no history of immunosuppression.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	trafficking	n/a	n/a	Hu	2021	doi:10.1101/2021.01.22.427749	n/a	https://doi.org/10.1101/2021.01.22.427749	False	Hu et al. (2021)	n/a	The entry efficiencies of Spike pseudotyped viruses bearing N501Y Variant 1 (B.1.1.7) mutant were about 3 to 4.4 times higher than that of the WT pseudovirus when viral input was normalized, suggesting that these spike variants promote the infectivity of SARS-CoV-2.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	trafficking	n/a	n/a	Esclera	2021	doi:10.1101/2021.08.05.455290	n/a	https://doi.org/10.1101/2021.08.05.455290	False	Esclera et al. (2021)	n/a	~2.5x cleavage of S2 relative to WA1 (D614G) wildtype by Alpha variant variant as measured by mass spectrometry of Vero-TMPRSS culture.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Emary	2021	doi:10.2139/ssrn.3779160	n/a	https://doi.org/10.2139/ssrn.3779160	False	Emary et al. (2021)	n/a	Virus neutralisation activity (using a live SARS-CoV-2 microneutralisation assay (ND50)) by vaccine induced antibodies was 9-fold lower  against the B.1.1.7 variant than against a canonical non B.1.1.7 lineage. Vaccine efficacy against symptomatic NAAT positive infection  was similar for B.1.1.7 and non-B.1.1.7 lineages (74.6% [95%CI 41.6-88.9] and 84% [95% CI 70.7-91.4] respectively). Furthermore, vaccination with ChAdOx1 nCoV-19 results in a reduction in the duration of shedding and viral load, which may translate into a material impact on transmission of disease.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Kumar	2022	doi:10.1101/2022.05.13.491770	n/a	https://doi.org/10.1101/2022.05.13.491770	False	Kumar et al. (2022)	n/a	BnAb 002-S21F2 IC50 on the Alpha (B.1.1.7) variant is 1.0x fold the wildtype in 42 COVI.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Gallagher	2021	doi:10.1101/2021.05.03.442455	pmid:33972942	https://doi.org/10.1101/2021.05.03.442455	False	Gallagher et al. (2021)	n/a	ELISpot assays show T cell neutralization reduced by 15.4% in this B.1.1.7 pseudotype relative to wild type in 18-20 pooled patient samples post second mRNA vaccine dose, with no significant difference between Pfizer and Moderna cohorts. Reduction was stronger in the S1 subunit than S2 (separate peptide pools were used).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Edara	2021	doi:10.1101/2021.02.02.21250799	pmid:33564782	https://doi.org/10.1101/2021.02.02.21250799	False	Edara et al. (2021)	n/a	2.1x drop in neutralization using sera collected from 14 healthy adult participants that received two injections of the mRNA-1273 (Moderna) vaccine  at a dose of 100 µg (18-55 years: day 1 (n	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Ikegame	2021	doi:10.21203/rs.3.rs-400230/v1	pmid:33851150	https://doi.org/10.21203/rs.3.rs-400230/v1	False	Ikegame et al. (2021)	n/a	B.1.1.7 pseudotyped VSV was tested for neutralization in a clonal HEK-293T ACE2 TMPRSS2 cell line optimized for highly efficient  S-mediated infection. A cohort of 12 Argentinian recipients of the Gamaleya Sputnik V Ad26 / Ad5 vaccine showed no statistically sognificant change in neutralization effiacacy.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Heath	2021	doi:10.1101/2021.05.13.21256639	n/a	https://doi.org/10.1101/2021.05.13.21256639	False	Heath et al. (2021)	n/a	NVX-CoV2373 [Novavax] vaccine in phase 3 trial was 89.7% (95% CI, 80.2-94.6) effective in preventing COVID-19, with no hospitalizations or  deaths reported. There were five cases of severe Covid-19, all in the placebo group. Post hoc analysis revealed efficacies of  96.4% (73.8-99.5) and 86.3% (71.3-93.5) against the prototype strain and B.1.1.7 variant, respectively.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Shen	2021	doi:10.1101/2021.01.27.428516	pmid:33532764	https://doi.org/10.1101/2021.01.27.428516	False	Shen et al. (2021)	n/a	Pseudotyped B.1.1.7 Spike variants lentivirus. 3.5x reduction in neutralization with Moderna vaccinated patient sera after 29 days (1st dose). 2.0x reduction in neutralization with Moderna vaccinated patient sera after 57 days (2nd dose). 2.1x reduction in neutralization with Novavax Phase 1 post-vaccination sera.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	clinical indicators	n/a	n/a	Song	2021	doi:10.1101/2021.05.04.21256655	n/a	https://doi.org/10.1101/2021.05.04.21256655	False	Song et al. (2021)	n/a	After adjusting for the age factor, in a prospective Chinese cohort study B.1.1.7 variant infection (compared to B.1.140) was the risk factor for  C-reactive protein (P 	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine efficacy	n/a	n/a	Nasreen	2021	doi:10.1101/2021.06.28.21259420	n/a	https://doi.org/10.1101/2021.06.28.21259420	False	Nasreen et al. (2021)	n/a	Using a test-negative design using Ontario data between Dec 14, 2020 and May 30, 2021, 421,073 symptomatic community-dwelling individuals were tested. Against symptomatic infection caused by Alpha, vaccine effectiveness with partial vaccination (≥14 days after dose 1) was higher for mRNA-1273 (83%) than BNT162b2 (66%) and ChAdOx1 (64%), and full vaccination (≥7 days after dose 2) increased vaccine effectiveness for BNT162b2 (89%) and mRNA-1273 (92%).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	trafficking	n/a	n/a	Touret	2021	doi:10.1101/2021.03.22.436427	n/a	https://doi.org/10.1101/2021.03.22.436427	False	Touret et al. (2021)	n/a	Live virus was tested ex vivo in reconstituted brochial epithelium, and out competed wild type.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Uriu	2021	doi:10.1101/2021.09.06.459005	n/a	https://doi.org/10.1101/2021.09.06.459005	False	Uriu et al. (2021)	n/a	Mean 1.7x reduction of NT50 value B.1.1.7 (Alpha) relative to wild type in 8 sera from adult BNT162b2 vaccinees (28-47yo) collected ~1m post booster.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Planas	2021	doi:10.1038/s41591-021-01318-5	n/a	https://doi.org/10.1038/s41591-021-01318-5	True	Planas et al. (2021)	n/a	Flow cytometry was used on recombinant VSV proteins and yeast surface display to assess the binding of a labeled soluble ACE2  protein to cells expressing B.1.1.7. We observed a dramatic increase (relative to D614G) in binding of soluble  ACE2 to B.1.1.7, and to a lesser extent to B.1.351, which both carry the N501Y mutation (see Fig 3).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Uhal B	2022	doi:10.1101/2022.06.23.497326	n/a	https://doi.org/10.1101/2022.06.23.497326	False	Uhal B et al. (2022)	n/a	L27, V34 and E90 mutation resulted in ultrahigh affinity binding of the LVE-ACE-2 domain to the widest variety of VOCs, with KDs of 93 pM for binding to the Alpha  B1.1.7. Values were obtained with LVE-ACE-2/mAB chimeras containing the Y-T-E sequence that enhances binding to the FcRn receptor, which in turn is expected to  extend biological half-life 3-4-fold.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	1.5x reduction in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees)	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	UNKNOWN	n/a	n/a	n/a	,	n/a	UNKNOWN et al. ()	n/a	n/a	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	UNKNOWN	n/a	n/a	n/a	,	n/a	UNKNOWN et al. ()	n/a	In Qatar, where Pfizer vaccine use is prevalent (<10% of the population covered in the time period of the study ending Mar 31, 2021), any time after one dose  (including the 2 weeks where no major effect is expected) B.1.1.7 lineage effectiveness was observed as 29.5% (95% CI [22.9,35.5]) against infection, and 54.1% against severe/critical/fatal disease  (95% CI [26.1-71.9]). Two weeks or more after 2nd dose, effectiveness climbed to 89.5% [85.9,92.3] against infection, and 100% against  severe/critical/fatal disease (95% CI [81.7,100]).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Dejnirattisai	2021	doi:10.1016/j.cell.2021.03.055	pmid:33852911	https://doi.org/10.1016/j.cell.2021.03.055	True	Dejnirattisai et al. (2021)	n/a	Lilly's LY-CoV16 showed marked reduction in neutralization of B.1.1.7.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Skelly	2021	doi:10.21203/rs.3.rs-226857/v1	n/a	https://doi.org/10.21203/rs.3.rs-226857/v1	False	Skelly et al. (2021)	n/a	Sera neutralized the B1.1.7 isolate with a lower potency (2-fold: 95% CL: 1.5 – 3-fold), and those with the lowest homotypic neutralizing potency had undetectable heterotypic potency (2/25).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	tissue specific replication effects	n/a	n/a	Mok	2021	doi:10.1101/2021.04.19.440414	n/a	https://doi.org/10.1101/2021.04.19.440414	False	Mok et al. (2021)	n/a	In this report, by using a lower infectious dose, we demonstrate that B.1.1.7  (cultured sample Hong Kong/HKPU-00015/2021) exhibits higher infectivity and/or  replication efficiency in the nasal epithelium. (Hamster model of infection)	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Collier	2021	doi:10.1038/s41586-021-03412-7	n/a	https://doi.org/10.1038/s41586-021-03412-7	True	Collier et al. (2021)	n/a	Neutralization capacity GMT of 27 subjects' sera post-infection was considerably higher (stronger) than after the second  Pfizer dose, and 4.5x drop in B.1.1.7 neutralization was observed.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Collier	2021	doi:10.1038/s41586-021-03412-7	n/a	https://doi.org/10.1038/s41586-021-03412-7	True	Collier et al. (2021)	n/a	20/29 sera after the first dose of Pfizer showed an average reduction in neutralization titres against the B.1.1.7 variant of 3.2 ± 5.7. After the second dose, the GMT was markedly increased compared with the first-dose titres, with a fold change of 1.9 ± 0.9 (mean ± s.d.). Neutralization GMT of 27 subjects post-infection was considerably higher (stronger) than after the second Pfizer dose, and 4.5x drop in B.1.1.7 neutralization was observed.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	transmissibility	n/a	n/a	Davies	2021	doi:10.1126/science.abg3055	pmid:33658326	https://doi.org/10.1126/science.abg3055	True	Davies et al. (2021)	n/a	We estimate that this [B.1.1.17] variant has a 43–90% (range of 95% credible intervals 38–130%) higher reproduction number than preexisting variants. Data from other countries yield similar results: we estimate that R for VOC 202012/01 relative to other lineages is 55% (45–66%) higher in Denmark,  74% (66–82%) higher in Switzerland, and 59% (56–63%) higher in the United States, with consistent rates of displacement across regions within each country.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Muik	2021	doi:10.1126/science.abg6105	pmid:33514629	https://doi.org/10.1126/science.abg6105	True	Muik et al. (2021)	n/a	Lineage B.1.1.7 spike–pseudotyped VSV was tested for neutralization vs Wuhan reference genome pseudotype in 40 sera collected 7 or 21 days post-booster dose. Statistically significant change (22%) in neutralization was observed among the 26 sera from those <	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	transmissibility	n/a	n/a	Stefanelli	2021	doi:10.1101/2021.04.06.21254923	n/a	https://doi.org/10.1101/2021.04.06.21254923	False	Stefanelli et al. (2021)	n/a	At the national level (Italy), we estimated a mean relative transmissibility of B.1.1.7 (compared to historical lineages) ranging  between 1.55 and 1.57 (with confidence intervals between 1.45 and 1.66).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	outcome hazard ratio	n/a	n/a	Funk	2021	doi:10.2807/1560-7917.ES.2021.26.16.2100348	pmid:33890566	https://doi.org/10.2807/1560-7917.ES.2021.26.16.2100348	True	Funk et al. (2021)	n/a	On average across 7 European countries studied, using B.1.1.7 defining mutations: Significant shift to asymptomatic cases (27.4% vs 18.6% for non-VOC cases).  Significant shift to infection in those without pre-existing conditions (44.8% vs 89% for non-VOC cases). Significant increase in hospitalization rate (11% vs 7.5% for non-VOC cases). Significant increase in ICU rate (1.4% vs 0.6% for non-VOC cases). Significant decrease in death rate (2.0% vs vs 4.0% for non-VOC cases).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Tada	2021	doi:10.1101/2021.02.05.430003	pmid:33564768	https://doi.org/10.1101/2021.02.05.430003	False	Tada et al. (2021)	n/a	Vaccine elicited antibodies neutralized virus with the B.1.1.7 spike protein with titers similar to D614G virus. Serum specimens  from individuals vaccinated with the BNT162b2 mRNA vaccine neutralized D614G virus with titers that were on average 7-fold greater than convalescent sera.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	transmissibility	n/a	n/a	Lindstrøm	2021	doi:10.1101/2021.03.29.21254122	n/a	https://doi.org/10.1101/2021.03.29.21254122	False	Lindstrøm et al. (2021)	n/a	Oslo, Norway: Within households, we find an increase in the secondary attack rate by 60% (20% 114%) compared to other variants.  In general, we find a significant increase in the estimated reproduction number of 24% (95% CI 0% - 52%), or an absolute  increase of 0.19 compared to other variants.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	transmissibility	n/a	n/a	Munitz	2021	doi:10.1016/j.xcrm.2021.100264	pmid:33899031	https://doi.org/10.1016/j.xcrm.2021.100264	True	Munitz et al. (2021)	n/a	Based on ∼300,000 RT-PCR samples collected from December 6th 2020 to February 10th 2021 in Israel,  the B.1.1.7 is 45% (95% CI:20-60%) more transmissible than the wild-type strain, and become dominant in Israel within 3.5 weeks.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	outcome hazard ratio	n/a	n/a	Nyberg	2021	doi:10.48550/arXiv.2104.05560	n/a	https://doi.org/10.48550/arXiv.2104.05560	False	Nyberg et al. (2021)	n/a	The matching-adjusted conditional odds ratio of hospitalisation was 1.58 (95% confidence interval 1.50 to 1.67) for COVID-19 patients  infected with a SGTF-associated variant [primarily B.1.1.7], compared to those infected with non-SGTF-associated variants.  The effect was modified by age (p<0.001), with ORs of 0.96-1.13 below age 20 years and 1.57-1.67 in age groups 40 years or older.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	outcome hazard ratio	n/a	n/a	Davies	2021	doi:10.1038/s41586-021-03426-1	pmid:33723411	https://doi.org/10.1038/s41586-021-03426-1	True	Davies et al. (2021)	n/a	Using UK data 1 November 2020 to 14 February 2021, while correcting for misclassification of PCR test Spike Gene Target Failure (SGTF) and missingness in SGTF status, we estimate that the hazard of death associated with B.1.1.7 is 61% (42–82%) higher than with  pre-existing variants after adjustment for age, sex, ethnicity, deprivation, residence in a care home, the local authority of residence and test date.  This corresponds to the absolute risk of death for a 55–69-year-old man increasing from  0.6% to 0.9% (95% confidence interval, 0.8–1.0%) within 28 days of a positive test in the community.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	viral load	n/a	n/a	Roquebert	2021	doi:10.1101/2021.03.19.21253971	n/a	https://doi.org/10.1101/2021.03.19.21253971	False	Roquebert et al. (2021)	n/a	B.1.1.7 samples showed average Ct cycle threshold of 21.9 vs 23 for wildtype (i.e. ~2x higher viral load) comparing 37758 and 22535 samples respectively.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	transmissibility	n/a	n/a	Graham	2021	doi:10.1016/s2468-2667(21	n/a	https://doi.org/10.1016/s2468-2667(21	n/a	Graham et al. (2021)	n/a	Based on 36920 COVID Symptom Study app users reported SARS-CoV-2 test positivity in late 2020,  Rt of B.1.1.7 was 1.35x (95% CI 1.02-1.69) relative to pre-existing variants. However, Rt fell below 1 during regional and  national lockdowns, even in regions with high proportions of infections with the B.1.1.7 variant.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	outcome hazard ratio	n/a	n/a	Frampton	2021	doi:10.1016/s1473-3099(21	n/a	https://doi.org/10.1016/s1473-3099(21	n/a	Frampton et al. (2021)	n/a	341 samples collected Nov 9 to Dec 20, 2020 were sequenced from two London (UK) hospitals.  198 (58%) of 341 had B.1.1.7 infection and 143 (42%) had non-B.1.1.7 infection. No evidence was found of an association  between severe disease and death and lineage (B.1.1.7 vs non-B.1.1.7) in unadjusted analyses (prevalence ratio [PR] 0·97  [95% CI 0·72-1·31]), or in analyses adjusted for hospital, sex, age, comorbidities, and ethnicity (adjusted PR 1·02 [0·76-1·38]).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	outcome hazard ratio	n/a	n/a	Graham	2021	doi:10.1016/s2468-2667(21	n/a	https://doi.org/10.1016/s2468-2667(21	n/a	Graham et al. (2021)	n/a	From Sept 28 to Dec 27, 2020, positive COVID-19 tests were reported by 36 920 COVID Symptom Study app users whose region was  known and who reported as healthy on app sign-up. We found no changes in reported symptoms or disease duration associated with B.1.1.7.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	viral load	n/a	n/a	Teyssou	2021	doi:10.1101/2021.03.21.21253498	n/a	https://doi.org/10.1101/2021.03.21.21253498	False	Teyssou et al. (2021)	n/a	The 249 B.1.1.7 (a.k.a. N501Y.V1) variant cases in three Paris hospital labs had a ~10-fold viral load increase  (~3.3 Ct drop in N gene probe) compared to 332 ancestral lineage cases from the same time frame (2020-12-20 to 2021-02-26).  PG: BUT there is a discrepancy in drop between the ORF1ab and N probes, with the former suggesting only a 2-fold drop,  consistent with the drop observed in B.1.351. This might indicate higher subgenomic RNA content in B.1.1.7 skewing the change.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	viral load	n/a	n/a	Couzens	2021	doi:10.1101/2021.04.02.21254832	n/a	https://doi.org/10.1101/2021.04.02.21254832	False	Couzens et al. (2021)	n/a	Using lack of S probe detection as a proxy for B.1.1.7 status, 275 putative B.1.1.7 samples and 390 'wild type' SARS-CoV-2 positive samples in Wales were compared for Ct values, suggesting ~12-fold increase (~3.5 Ct decrease) in viral load for B.1.1.7 samples.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	outcome hazard ratio	n/a	n/a	Challen	2021	doi:10.1136/bmj.n579	pmid:33687922	https://doi.org/10.1136/bmj.n579	True	Challen et al. (2021)	n/a	The mortality hazard ratio associated with infection with [B.1.1.7] compared with infection with previously circulating variants was  1.64 (95% confidence interval 1.32 to 2.04) in patients who tested positive for covid-19 in the community (54906 matched pairs of  participants who tested positive for SARS-CoV-2 in pillar 2 between 1 October 2020 and 29 January 2021). In this comparatively low risk  group, this represents an increase in deaths from 2.5 to 4.1 per 1000 detected cases.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	viral load	n/a	n/a	Ratcliff	2021	doi:10.1101/2021.02.24.21251989	n/a	https://doi.org/10.1101/2021.02.24.21251989	False	Ratcliff et al. (2021)	n/a	In a study of 1260 ICU subjects, viral load distributions (collected within 48h of admission) were elevated in  both seropositive and seronegative subjects infected with B.1.1.7 ('UK variant').  PG: The PANGO tool defining Spike variants for B.1.1.7 are listed here, whereas the paper only used a test for D1118H.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	viral load	n/a	n/a	Nyayanit	2021	doi:10.1101/2021.04.30.442222	n/a	https://doi.org/10.1101/2021.04.30.442222	False	Nyayanit et al. (2021)	n/a	This study reveals that B.1.1.7 SARS-CoV-2 variant is a slower-growing virus than parental B.1. Further, a higher replication along with reduced infectious viral titer was hypothesized to be linked to higher transmission with reduced pathogenicity.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	viral load	n/a	n/a	Lamers	2021	doi:10.1101/2021.05.03.441080	n/a	https://doi.org/10.1101/2021.05.03.441080	False	Lamers et al. (2021)	n/a	We found that the British variant (clade B.1.1.7), compared to an ancestral SARS-CoV-2 clade B virus, produced higher  levels of infectious virus late in infection and had a higher replicative fitness in human airway, alveolar and intestinal organoid models.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	outcome hazard ratio	n/a	n/a	Bager	2021	doi:10.2139/ssrn.3792894	n/a	https://doi.org/10.2139/ssrn.3792894	False	Bager et al. (2021)	n/a	Danish study of the B.1.1.7 lineage shows hospital admission odds ratio of 1.63 vs other lineages. The adjusted OR was increased in all strata of age.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Tada	2021	doi:10.1101/2021.02.05.430003	pmid:33564768	https://doi.org/10.1101/2021.02.05.430003	False	Tada et al. (2021)	n/a	This mutation causes major decrease in binding affinity vs. wild type as measured by IC50 vs pseudotyped lentivirus.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	transmissibility	n/a	n/a	Buchan	2021	n/a	n/a	https://www.medrxiv.org/content/10.1101/2021.03.31.21254502v1	n/a	Buchan et al. (2021)	n/a	Ontario, Feb 2021: The secondary attack rate for VOC index cases in this matched cohort was 1.31 times higher than non-VOC index cases (RR	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	viral load	n/a	n/a	Song	2021	doi:10.1101/2021.05.04.21256655	n/a	https://doi.org/10.1101/2021.05.04.21256655	False	Song et al. (2021)	n/a	The median Ct value of RT-qPCR tests of the N-gene target in the Daxing B.1.1.7 group was significantly lower than the Shunyi B.1.470 group (P	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	transmissibility	n/a	n/a	Lyngse	2021	doi:10.1101/2021.04.16.21255459	n/a	https://doi.org/10.1101/2021.04.16.21255459	False	Lyngse et al. (2021)	n/a	Primary cases infected with B.1.1.7 had an increased transmissibility of 1.5-1.7 times that of primary cases infected with other  lineages. The increased transmissibility of B.1.1.7 was multiplicative across age and viral load.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Hoffman	2021	doi:10.1016/j.cell.2021.03.036	pmid:33794143	https://doi.org/10.1016/j.cell.2021.03.036	True	Hoffman et al. (2021)	n/a	VSV pseudotype B.1.1.7 showed 1.77-fold reduction in neutralization efficiency vs wild type in 15 Pfizer BNT162b2 vaccinee sera 13-15 days post second dose. Cell fusion proficiency was unchanged.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Leier	2021	doi:10.1101/2021.04.25.21256049	pmid:33948601	https://doi.org/10.1101/2021.04.25.21256049	False	Leier et al. (2021)	n/a	Neutralizing antibody titers increased in previously infected vaccinees relative to uninfected vaccinees  5.2-fold against B.1.1.7 (contrast with 3.4 fold against original SARS-CoV-2).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	outcome hazard ratio	n/a	n/a	UNKNOWN	2021	n/a	n/a	https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/961042/S1095_NERVTAG_update_note_on_B.1.1.7_severity_20210211.pdf	False	UNKNOWN et al. (2021)	n/a	Using primarily S-defining mutations for lineage B.1.1.7, most models of hospitalization and fatality risk ratios from consortium members show elevated ratios (~1.3-1.7x).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	trafficking	n/a	n/a	Hoffman	2021	doi:10.1016/j.cell.2021.03.036	pmid:33794143	https://doi.org/10.1016/j.cell.2021.03.036	True	Hoffman et al. (2021)	n/a	VSV pseudotype B.1.1.7 showed no significant difference in cell entry relative to wild type in 6 cell lines. Cell fusion proficiency was unchanged.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Collier	2021	doi:10.1038/s41586-021-03412-7	n/a	https://doi.org/10.1038/s41586-021-03412-7	True	Collier et al. (2021)	n/a	Six fold increase in affinity for ACE2 by the B.1.1.7 lineage vs wild type is driven by a drop in observed dissociation rate constant.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	environmental condition stability	n/a	n/a	Tada	2021	doi:10.1101/2021.02.05.430003	pmid:33564768	https://doi.org/10.1101/2021.02.05.430003	False	Tada et al. (2021)	n/a	Relative to D614G, this mutation demonstrated significant increase in infectivity (i.e. heat stability) after incubation at 50C after 1 hour.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	trafficking	n/a	n/a	Tada	2021	doi:10.1101/2021.02.05.430003	pmid:33564768	https://doi.org/10.1101/2021.02.05.430003	False	Tada et al. (2021)	n/a	Lentiviral pseudotyped with this mutation set from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing significant (40%) increase in infection rate amongst the cells, much more than the effect of  either the deletion or the point mutation alone, suggetsing that this combination has a synergistic effect  contributing to cell entry fitness, but to a smaller extent than N501Y and the deletion alone.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma binding	n/a	n/a	Tada	2021	doi:10.1101/2021.02.05.430003	pmid:33564768	https://doi.org/10.1101/2021.02.05.430003	False	Tada et al. (2021)	n/a	These key B.1.1.7 mutations as a combination neutralized slightly less well than D614G and this was noticeable in the lack of sera with high neutralizing titer for the viruses  across 10 convalescent sera from April 2020 infectees.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma binding	n/a	n/a	Alenquer	2021	doi:10.1101/2021.04.22.441007	n/a	https://doi.org/10.1101/2021.04.22.441007	False	Alenquer et al. (2021)	n/a	Slight neutralization improvement on average in 16 health workers' convalescent sera.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Alenquer	2021	doi:10.1101/2021.04.22.441007	n/a	https://doi.org/10.1101/2021.04.22.441007	False	Alenquer et al. (2021)	n/a	One convalescent sera tested showed 4-fold or greater reduction in neutralization efficiency.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.4/5 (from ) were 17.2x-fold lower (95% CI: 0.6x-0.7x) than against 208-428 972-1834 4.3-4.7 US-WA1/2020 usiong an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.4/5 (from ) were 13.0-fold lower (95% CI: 4.2x-4.6x) than against 208-428 972-1834 4.3-4.7 US-WA1/2020 usiong an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Stamatatos	2021	doi:10.1126/science.abg9175	pmid:33766944	https://doi.org/10.1126/science.abg9175	True	Stamatatos et al. (2021)	n/a	In sera collected from 15 early pandemic patients (Seattle Flu Study), mean 16 days post first dose with either Pfizer/BioNTech or Moderna vaccines,  the median ID50 titers were ~10-fold lower against this B.1.351 pseudotyped virus relative to wild type. A single asymptomatic patient, who had no detectable RBD-specific IgG memory before vaccination, also did not elicit nAbs against the B.1.351 variant. [compare to ~3 fold without the deletion] ID50 titres in non-infected mRNA vaccines more than two weeks post-booster were significant, but ~500x weaker than in previously infected patients  after first dose.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Pegu	2021	doi:10.1101/2021.05.13.444010	pmid:34031659	https://doi.org/10.1101/2021.05.13.444010	False	Pegu et al. (2021)	n/a	Detectable antibodies against B.1.351 at various time points using pseudotyped lentivirus neutralization in Moderna vaccinee cohort: Day 29 8%, Day 43 100%, Day 119 71%, Day 209 54%. Detectable antibodies against B.1.351 at various time points using live virus FRNT neutralization in Moderna vaccinee cohort: Day 29 8%, Day 43 100%, Day 119 79%, Day 209 58%. Detectable antibodies against B.1.351 at various time points using ACE2 blocking assay in Moderna vaccinee cohort: Day 29 63%, Day 43 100%, Day 119 71%, Day 209 79%. Decreased neutralization on some assays was seen especially in those vaccinees tested that were 71+.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Abe	2021	doi:10.1101/2021.08.06.21261721	n/a	https://doi.org/10.1101/2021.08.06.21261721	False	Abe et al. (2021)	n/a	In an Ontario long term care facility, cumulatively, weaker BNT162b2 vaccine stimulation, age/comorbidities, produced a ∼130-fold reduction  in apparent neutralization titers in mean 88yo LTCH residents against Beta (B.1.351), relative to staff vaccinees against D614G wild type.  37.9% of 116 two-dose-mRNA-vaccinated residents had undetectable neutralizing antibodies to B.1.351. mRNA-1273 vaccinee sera displayed ~2 better neutralization than BNT162b2. [common defining B.1.351 mutations noted, as the manuscript does not provide details]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Stamatatos	2021	doi:10.1126/science.abg9175	pmid:33766944	https://doi.org/10.1126/science.abg9175	True	Stamatatos et al. (2021)	n/a	Anti-NTD CV1 mAb isolated from an early pandemic case was unable to neutralize either partial B.1.351 variant pseudovirus used (A701V or L242del). The neutralization potency of mAb CV30, which contacts K417 and N501 but not E484, was ~10-fold weaker toward both B.1.351 variants. The neutralization potency of anti-RBD mAb CV3-1 was 3-4-fold less potent against the B.1.351 variants, while anti-RBD mAb CV2-75 was modestly less effective.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Stamatatos	2021	doi:10.1126/science.abg9175	pmid:33766944	https://doi.org/10.1126/science.abg9175	True	Stamatatos et al. (2021)	n/a	Using convalescent sera from 15 early pandemic patients (Seattle Flu Study), mean 220 days post symptom onset (IQR 125-269, and three asymptomatic cases) with 27% WHO disease severity scale 3, 7 of 15 neutralized this B.1.351 pseudotype that includes the L242del, and only one had titers above 100.  Only one of the 15 sera achieved 80% neutralization. [compare to 5 and 1 for pseudotype without the deletion]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Tada	2021	doi:10.1101/2021.05.14.444076	n/a	https://doi.org/10.1101/2021.05.14.444076	False	Tada et al. (2021)	n/a	Pseudotyped viruses for B.1.351 was 3.4-fold resistant to neutralization by 6 BNT162b2 vaccine sera 28 days post-booster compared to wild type. Neutralization by 3 Moderna vaccine sera 28 days post-booster was 2.2-fold resistant. [Exact list of B.1.351 mutations used in these assays was not included in the preprint]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs Bi-Nab35B5-47D10. Beta (B.1.351) has an IC50 fold change of 0.13x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Rosenke	2022	doi:10.1172/jci.insight.160108	pmid:35579953	https://doi.org/10.1172/jci.insight.160108	True	Rosenke et al. (2022)	n/a	Infectious viral titers in lung tissue determined using a tissue culture infectious dose (TCID) assay in 10 hamsters showed that Beta Molnupiravir (MK-4482) had ~1.75x fold drop.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Zhou	2021	doi:10.1016/j.cell.2021.02.037	pmid:33730597	https://doi.org/10.1016/j.cell.2021.02.037	True	Zhou et al. (2021)	n/a	The B.1.351 variant constellation causes an ∼20-fold increase in affinity for ACE2 compared with Wuhan RBD, which may influence transmissibility.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	humoral response durability	n/a	n/a	Betton	2020	doi:10.1093/cid/ciab308	pmid:33851216	https://doi.org/10.1093/cid/ciab308	True	Betton et al. (2020)	n/a	In a prospective study of 107 hospitalized patients, decrease of IgG rates and serological assays becoming  negative did not imply loss of neutralizing capacity. Our results indicate a sustained humoral response against the  ancestral strain and the D614G, B.1.1.7 and P.1 variants for at least 6 months (last of two samples taken)  in patients previously hospitalized for COVID-19. A weaker protection was however observed for the B.1.351 variant.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	trafficking	n/a	n/a	Esclera	2021	doi:10.1101/2021.08.05.455290	n/a	https://doi.org/10.1101/2021.08.05.455290	False	Esclera et al. (2021)	n/a	~6x cleavage of S2 relative to WA1 (D614G) wildtype by Beta variant as measured by mass spectrometry of Vero-TMPRSS culture  [no mutations directly at furin cleavage site, but A701V is downstream] Compare to 4.5x or less for variants of concern with  direct furin clevage site mutations.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	outcome hazard ratio	n/a	n/a	Abu-Raddad	2021	doi:10.1101/2021.08.02.21261465	n/a	https://doi.org/10.1101/2021.08.02.21261465	False	Abu-Raddad et al. (2021)	n/a	Compared to Alpha (B.1.1.7) variant, odds of progressing to severe disease were 1.24-fold (95% CI: 1.11-1.39) higher for Beta.  Odds of progressing to critical disease were 1.49-fold (95% CI: 1.13-1.97) higher. Odds of COVID-19 death were 1.57-fold (95% CI: 1.03-2.43) higher.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Kumar	2022	doi:10.1101/2022.05.13.491770	n/a	https://doi.org/10.1101/2022.05.13.491770	False	Kumar et al. (2022)	n/a	BnAb 002-S21F2 IC50 on the Beta (B.1.351) variant is 0.4x fold the wildtype.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Zhou	2021	doi:10.1016/j.cell.2021.02.037	pmid:33730597	https://doi.org/10.1016/j.cell.2021.02.037	True	Zhou et al. (2021)	n/a	In 34 convalescent cases 4–9 weeks following infection in June 2020, before the emergence of B.1.1.7, neutralization titers  against B.1.351 were, on average, 13.3-fold reduced compared with an early Victoria sample (p < 0.0001). Significantly, 18  of 34 samples failed to reach 50% neutralization at a plasma dilution of 1:20, with a number showing a near total reduction of neutralization activity. In 13 convalescent cases 4–9 weeks following infection with B.1.1.7, neutralization titers  against B.1.351 were, on average, 3.1-fold reduced compared with an early Victoria sample (p < 0.0001).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs Bi-Nab47D10-35B5. Beta (B.1.351) has an IC50 fold change of 0.15x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Liu	2021	doi:10.1056/NEJMc2102017	pmid:33684280	https://doi.org/10.1056/NEJMc2102017	True	Liu et al. (2021)	n/a	Vaccine plasma neutralization of B.1.351-spike virus was nominally robust but lower (~3x) than other variants of concern.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Choi	2021	doi:10.1101/2021.06.28.449914	n/a	https://doi.org/10.1101/2021.06.28.449914	False	Choi et al. (2021)	n/a	Neutralization efficiency (ID50) against B.1.1.351-v3 reduced 8.4x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Zhou	2021	doi:10.1016/j.cell.2021.02.037	pmid:33730597	https://doi.org/10.1016/j.cell.2021.02.037	True	Zhou et al. (2021)	n/a	Testing against B.1.351 the 20 most effective mAbs (19 anti-RBD, 1 anti-NTD) from a screen of 377 against wild type,  4 of 20 antibodies had >10-fold fall in neutralization titers, with most of these showing a complete knockout of  activity. This is in line with the key roles of K417, E484, and N501, in particular E484, in antibody recognition  of the ACE2 interaction surface of the RBD. Regeneron mAb cocktail: The neutralization of REGN10987 was unaffected by B.1.351, while REGN10933 was severely impaired (773-fold). AstraZeneca mAb cocktail: Neutralization by the AZ pair of antibodies was little affected on B.1.351 compared with Victoria.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Madhi	2021	doi:10.1101/2021.02.10.21251247	n/a	https://doi.org/10.1101/2021.02.10.21251247	False	Madhi et al. (2021)	n/a	A two-dose regimen of (AstraZeneca) ChAdOx1-nCoV19 did not show protection against mild-moderate Covid-19 due to B.1.351 variant, however,  vaccine efficacy against severe Covid-19 is undetermined.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	UNKNOWN	n/a	n/a	n/a	n/a	n/a	UNKNOWN et al. ()	n/a	The Janssen single dose vaccine showed 72% efficacy at preventing moderate and severe disease, which was  reduced to 57% in South Africa, where 92.6% of infections are estimated to have been B.1.351. 100% reduction in  hospitalization risk remains across variants after 28 days post-vaccination.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	anthropozoonotic events	n/a	n/a	Montagutelli	2021	doi:10.1101/2021.03.18.436013	n/a	https://doi.org/10.1101/2021.03.18.436013	False	Montagutelli et al. (2021)	n/a	Unlike wild type or B.1.1.7, B.1.351 lineage virus was able to infect and replicate in common lab mouse strains, with high titer. PG: The virus used in these expriments has a non-typical deletion+sub in the 242 region.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs 35B5. Beta (B.1.351) has an IC50 fold change of 0.13x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Zhou	2021	doi:10.1016/j.cell.2021.02.037	pmid:33730597	http://doi.org/10.1016/j.cell.2021.02.037	True	Zhou et al. (2021)	n/a	Sera from healthcare workers (n 	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs 47D10. Beta (B.1.351) has an IC50 fold change of 0.88x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	outcome hazard ratio	n/a	n/a	Funk	2021	doi:10.2807/1560-7917.ES.2021.26.16.2100348	pmid:33890566	https://doi.org/10.2807/1560-7917.ES.2021.26.16.2100348	True	Funk et al. (2021)	n/a	On average across 7 European countries studied, using B.1.351 defining mutations: Significant shift to infection in those without pre-existing conditions (79.6% vs 89% for non-VOC cases). Significant increase in hospitalization rate (19.3% vs 7.5% for non-VOC cases). Significant increase in ICU rate (2.3% vs 0.6% for non-VOC cases). PG: seems to be different notations around the LAL deletion, using the minimal shared definition to catch as many as possible.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Garcia-Beltran	2021	doi:10.1016/j.cell.2021.03.013	pmid:33743213	https://doi.org/10.1016/j.cell.2021.03.013	True	Garcia-Beltran et al. (2021)	n/a	Pseudotyped B.1.351 v1 virus has reduced neutralization activity vs wild type: 34.5x (30 sera Pfizer median 9 days post 2nd dose)  and 27.7x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA. Notably, 36.7% (11/30) recipients of two-dose Pfizer and 42.9% (15/35) recipients of two-dose Moderna vaccines did not have  detectable neutralization of at least one of the B.1.351 variants.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Gallagher	2021	doi:10.1101/2021.05.03.442455	pmid:33972942	https://doi.org/10.1101/2021.05.03.442455	False	Gallagher et al. (2021)	n/a	ELISpot assays show T cell neutralization reduced by 29.8% in this B.1.351 pseudotype relative to wild type in 18-20 pooled patient samples post second mRNA vaccine dose, with no significant difference between Pfizer and Moderna cohorts. Reduction was stronger in the S1 subunit than S2 (separate peptide pools were used).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Alenquer	2021	doi:10.1101/2021.04.22.441007	n/a	https://doi.org/10.1101/2021.04.22.441007	False	Alenquer et al. (2021)	n/a	Using B.1.351 defining mutations for Spike, observed 4x average decrease in neutralization efficiency  (but still relevant titres) for sera from 10 BNT162b2 vaccinees 12 days after second dose, but only one  relevant titre 12 days after first dose. Compares unfavorably to wild type or B.1.1.7 titres.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Stamatatos	2021	doi:10.1126/science.abg9175	pmid:33766944	https://doi.org/10.1126/science.abg9175	True	Stamatatos et al. (2021)	n/a	Using convalescent sera from 15 early pandemic patients (Seattle Flu Study), mean 220 days post symptom onset (IQR 125-269, and three asymptomatic cases) with 27% WHO disease severity scale 3, one third (5/15) of sera neutralized this B.1.351 pseudotype and only three had ID50 titers above 100. Only two of the 15 sera achieved 80% neutralization.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Stamatatos	2021	doi:10.1126/science.abg9175	pmid:33766944	https://doi.org/10.1126/science.abg9175	True	Stamatatos et al. (2021)	n/a	In sera collected from 15 early pandemic patients (Seattle Flu Study), mean 16 days post first dose with either Pfizer/BioNTech or Moderna vaccines,  the median ID50 titers were ~3-fold lower against this B.1.351 pseudotyped virus relative to wild type. A single asymptomatic patient, who had no detectable RBD-specific IgG memory before vaccination, also did not elicit nAbs against the B.1.351 variant. [compare to ~10 fold with L242del] ID50 titres in non-infected mRNA vaccines more than two weeks post-booster were signficiant, but >100x weaker than in previously infected  patients after first dose.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	reinfection	n/a	n/a	Staub	2021	doi:10.2807/1560-7917.ES.2021.26.18.2100423	pmid:33960291	https://doi.org/10.2807/1560-7917.ES.2021.26.18.2100423	True	Staub et al. (2021)	n/a	4 health care workers in the 20's and 30's with no underlying conditions and seropositivity or confirmed 2020 SARS-CoV-2 infections were confirmed to have B.1.351 infection during a Februrary 2021 hospital outbreak in Luxembourg. Symptoms were mostly mild on first infection, and milder on second infection.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	reinfection	n/a	n/a	Yinda	2021	doi:10.1101/2021.05.05.442780	n/a	https://doi.org/10.1101/2021.05.05.442780	False	Yinda et al. (2021)	n/a	Hamsters re-infected with B.1.351 virus after seroversion from previous infection with a lineage A virus did not transmit  virus to naive sentinels via direct contact transmission, in contrast to the non-seroconverted animals. They had little  infectious virus and no pathology in the lungs. Initial infection with SARS-CoV-2 lineage A does not prevent heterologous reinfection with B.1.351, but prevents disease and onward transmission.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	symptom prevalence	n/a	n/a	Munster	2021	doi:10.1101/2021.05.07.443115	pmid:34382034	https://doi.org/10.1101/2021.05.07.443115	False	Munster et al. (2021)	n/a	Inoculation with the B.1.351 isolate resulted in lower clinical scores in 6 rhesus macaques that correlated with lower virus  titers in the lungs, less severe histologic lung lesions and less viral antigen detected in the lungs. Our comparative  pathogenicity study suggests that ongoing circulation under diverse evolutionary pressure favors transmissibility and  immune evasion rather than an increase in intrinsic pathogenicity.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Garcia-Beltran	2021	doi:10.1016/j.cell.2021.03.013	pmid:33743213	https://doi.org/10.1016/j.cell.2021.03.013	True	Garcia-Beltran et al. (2021)	n/a	Pseudotyped B.1.351 v3 virus has reduced neutralization activity vs wild type: 42.4x (30 sera Pfizer median 9 days post 2nd dose)  and 19.2x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA. Notably, 36.7% (11/30) recipients of two-dose Pfizer and 42.9% (15/35) recipients of two-dose Moderna vaccines did not have  detectable neutralization of at least one of the B.1.351 variants.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Huang	2021	doi:10.1101/2021.02.01.429069	n/a	https://doi.org/10.1101/2021.02.01.429069	False	Huang et al. (2021)	n/a	The neutralization activities of two vaccines developed in China were tested against 501Y.V2 authentic virus: inactivated BBIBP-CorV (no  significant change) and recombinant dimeric RBD vaccine ZF2001 (~1.6x reduction vs wildtype, p	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Röltgen	2021	doi:10.1101/2021.04.05.21254952	pmid:33851181	https://doi.org/10.1101/2021.04.05.21254952	False	Röltgen et al. (2021)	n/a	Most of the plasma from 55 Pfizer vaccinees developed high percentages of Wuhan-Hu-1 S-ACE2 blocking activity, peaking at day 28 (7 days post-boost).  A strikingly consistent hierarchy of reduction in plasma antibody binding by variant S and RBD antigens was observed among study  participants, with progressively decreased binding for B.1.1.7 (not significant), P.1 (significant) and B.1.351 (significant) compared to Wuhan-Hu-1 antigens.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Bailly	2021	doi:10.1093/cid/ciab446	pmid:33993228	https://doi.org/10.1093/cid/ciab446	True	Bailly et al. (2021)	n/a	During an outbreak of SARS-CoV-2 501Y.V2 in a nursing home, all non-vaccinated residents (5/5) versus  half of those fully vaccinated 2-5 weeks prior with BNT162b2 (13/26) were infected. Two of 13 vaccinated versus 4 of 5  non-vaccinated residents presented severe disease. BNT162b2 did not prevent the outbreak, but reduced  transmission and disease severity. Among the 13 fully vaccinated residents who were infected, 2 (15.4%) presented with an asymptomatic disease, 9 (69.2%) developed mild to moderate symptoms, and 2 (15.4%) progressed to severe disease with fatal evolution secondary to acute respiratory distress syndrome (ARDS). There was no relationship between anti-S antibody levels at diagnosis and disease severity. Overall, the proportion of residents with severe disease in the non-vaccinated group (4/5)  was higher than that in the vaccinated group (2/13). Only 1 vaccinated staff, but 10 unvaccinated were infected in the outbreak (no severe disease).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Chen	2021	doi:10.1038/s41591-021-01294-w	pmid:33664494	https://doi.org/10.1038/s41591-021-01294-w	True	Chen et al. (2021)	n/a	The neutralizing activity of vaccine was significantly lower against B.1.351 in sera from all 24 patients with the BNT162b2 mRNA vaccine. (Fig. 4)	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Luftig	2021	doi:10.1056/NEJMc2104036	pmid:33826815	https://doi.org/10.1056/NEJMc2104036	True	Luftig et al. (2021)	n/a	In sera 1-2 weeks after BNT162b2 first dose, from six patients previously infected with B.1, antibody titer in a microneutralization assay  was on average 1625 for B.1.351 virus. This compares favorably (stronger) to most post-infection neutralization titer against all variants tested in the same sera (wild type, B.1.1.7, B.1.351, and P.1).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Wang	2021	doi:10.1056/NEJMc2103022	pmid:33822491	https://doi.org/10.1056/NEJMc2103022	True	Wang et al. (2021)	n/a	2.5x reduction in neutralization by serum collected 2 to 3 weeks after the second dose from vaccinees who had received  BBIBP-CorV (pVNT50 against VSV pseudotyped as B.1.351). Convalescent plasma had similar titer against wild type as the BBIBP-CorV vaccinee sera. >3x reduction in neutralization by serum collected 2 to 3 weeks after the second dose from vaccinees who had received  CoronaVac (pVNT50 against VSV pseudotyped as B.1.351). Convalescent plasma had similar titer against wild type as the CoronaVac vaccinee sera.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Chen	2021	doi:10.1038/s41591-021-01294-w	pmid:33664494	https://doi.org/10.1038/s41591-021-01294-w	True	Chen et al. (2021)	n/a	B.1.1.351 variant constellation two-tailed Wilcoxon matched-pairs signed-rank test against 10 convalescent sera P	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	UNKNOWN	2021	n/a	n/a	https://www.fda.gov/media/146217/download	False	UNKNOWN et al. (2021)	n/a	Study 3001 on Ad26.COV2.S (Jannsen vaccine) conducted September 21, 2020 through January 22, 2021 overlaps the emergence and dominance  of the B.1.351 lineage of SARS-CoV-2 in South Africa. The SA arms of the Phase 3 double blind study showed severe/critical disease VE of 73.1%  (95% CI: 40.0-89.4), and moderate to severe/critical disease VE of 52.0% (95% CI: 30.3-67.4). Compare to 78.0% and 74.4% for North American arm of the study during the same period (with low B.1.351 prevalence). Of the 66.9% of SA severe infections that have been sequenced as of this report, 94.5% are B.1.351.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Solfrosi	2021	doi:10.1084/jem.20202756	pmid:33909009	https://doi.org/10.1084/jem.20202756	True	Solfrosi et al. (2021)	n/a	The dominant circulating B.1.351 spike variant originating in RSA, which harbors E484K and additional substitutions in the  RBD, NTD, and S2 and deletions in the NTD (amino acids 242–244), was neutralized with a 5.02-fold reduced titer	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Chen	2021	doi:10.1038/s41591-021-01294-w	pmid:33664494	https://doi.org/10.1038/s41591-021-01294-w	True	Chen et al. (2021)	n/a	B.1.1.351 in 19 convalescent human sera ~1mo post infection had mild to moderate resistance against all samples	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Chen	2021	doi:10.1038/s41591-021-01294-w	pmid:33664494	https://doi.org/10.1038/s41591-021-01294-w	True	Chen et al. (2021)	n/a	B.1.1.351 variant constellation ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07, COVOX-384, and S2H58. B.1.1.351 variant constellation ablates Class 3 N-terminal domain targeting antibodies COV2-2489 and COV2-2676 (the only two tested).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Cochin	2021	doi:10.1101/2021.04.19.440435	n/a	https://doi.org/10.1101/2021.04.19.440435	False	Cochin et al. (2021)	n/a	In a Syrian hamster model, B.1.351 variant virus had >4x reduction in YRNT90 (measure of neutralization) using wild type convalescent sera. PG: Note that exact sequence for B.1.351 used was not disclosed.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	McCallum	2021	doi:10.1101/2021.03.31.437925	pmid:33821281	https://doi.org/10.1101/2021.03.31.437925	False	McCallum et al. (2021)	n/a	In 13 plasma collected ~1mo after B.1.1.7 infection (nursing home in Ticino, Switzerland), neutralization  reduced to undetectable levels in many plasma for B.1.351 pseudotyped virus, as well as WT and other VOCs.  [paper does not detail the B.1.351 variants used, using the most popular as a stad in]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma binding	n/a	n/a	Hoffman	2021	doi:10.1016/j.cell.2021.03.036	pmid:33794143	https://doi.org/10.1016/j.cell.2021.03.036	True	Hoffman et al. (2021)	n/a	VSV pseudotype B.1.351 showed 7.86-fold decrease in NT50 vs wild type in sera from 9 ICU patients undergoing treatment in Germany (pre-variant infections).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Hoffman	2021	doi:10.1101/2021.05.04.442663	n/a	https://doi.org/10.1101/2021.05.04.442663	False	Hoffman et al. (2021)	n/a	Abrogates Bamlanivimab, Etesevimab, or their combined use neutralization as quantified by measuring virus-encoded luciferase  activity in cell lysates at 16-18 h post transduction.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Hoffman	2021	doi:10.1101/2021.05.04.442663	n/a	https://doi.org/10.1101/2021.05.04.442663	False	Hoffman et al. (2021)	n/a	Approximately 6-fold reduction in 15 ICU patient convalescent plasma neutralization as quantified by measuring virus-encoded luciferase  activity in cell lysates at 16-18 h post transduction.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Tada	2021	doi:10.1101/2021.02.05.430003	pmid:33564768	https://doi.org/10.1101/2021.02.05.430003	False	Tada et al. (2021)	n/a	Vaccine elicited antibodies neutralized virus with the B.1.351 spike protein had an average 3-fold reduction in titer (1:500),  a titer that was still higher than the average titer with which convalescent sera neutralized D614G (1:139). Serum specimens  from individuals vaccinated with the BNT162b2 mRNA vaccine neutralized D614G virus with titers that were on average 7-fold greater  than convalescent sera.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	trafficking	n/a	n/a	Hoffman	2021	doi:10.1101/2021.05.04.442663	n/a	https://doi.org/10.1101/2021.05.04.442663	False	Hoffman et al. (2021)	n/a	In one of eight cell lines tested (293T lung cells), a modest increase in cell entry was observed.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Leier	2021	doi:10.1101/2021.04.25.21256049	pmid:33948601	https://doi.org/10.1101/2021.04.25.21256049	False	Leier et al. (2021)	n/a	Neutralizing antibody titers increased in previously infected vaccinees relative to uninfected vaccinees  6.5-fold against B.1.351 (contrast with 3.4 fold against original SARS-CoV-2).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Hoffman	2021	doi:10.1016/j.cell.2021.03.036	pmid:33794143	https://doi.org/10.1016/j.cell.2021.03.036	True	Hoffman et al. (2021)	n/a	VSV pseudotype B.1.351 entry mediated by the S proteins of the B.1.351 variant was completely resistant to blocking by REGN10989 and Bamlanivimab. Entry driven by the S proteins of the B.1.351 was partially resistant against Casirivimab.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Zhou	2021	doi:10.1101/2021.03.24.436620	pmid:33791698	https://doi.org/10.1101/2021.03.24.436620	False	Zhou et al. (2021)	n/a	B.1.351 pseudotyped lentivirus showed 3.4 and 3.8x reduction in IC50 serum dilution concentration for sera from BNT162b2 (Pzifer) or mRNA1273 (Moderna) vacinees collected 28 days following booster dose.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Hoffman	2021	doi:10.1016/j.cell.2021.03.036	pmid:33794143	https://doi.org/10.1016/j.cell.2021.03.036	True	Hoffman et al. (2021)	n/a	VSV pseudotype B.1.351 showed 7.85-fold reduction in neutralization efficiency vs wild type in 15 Pfizer BNT162b2 vaccinee sera 13-15 days post second dose. Cell fusion proficiency was slight impaired.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Reynolds	2021	doi:10.1126/science.abh1282	pmid:33931567	https://doi.org/10.1126/science.abh1282	True	Reynolds et al. (2021)	n/a	After one dose, individuals with prior infection showed enhanced T cell immunity,  antibody secreting memory B cell response to spike and neutralizing antibodies effective  against B.1.351 (authentic cell culture supernatants). By comparison, HCW receiving one vaccine dose without prior  infection showed reduced immunity against variants. B.1.351 spike mutations  resulted in increased, abrogated or unchanged T cell responses depending on human leukocyte  antigen (HLA) polymorphisms. Study was 26 each post-infection and post first dose HCWs.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	trafficking	n/a	n/a	Hoffman	2021	doi:10.1016/j.cell.2021.03.036	pmid:33794143	https://doi.org/10.1016/j.cell.2021.03.036	True	Hoffman et al. (2021)	n/a	VSV pseudotype B.1.351 showed slight decrease in cell entry relative to wild type in 263T-ACE2 (kidney) cell line, and slight increase in Calu-3 (lung). Cell fusion proficiency was slight impaired.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma binding	n/a	n/a	Supasa	2021	doi:10.1016/j.cell.2021.02.033	pmid:33743891	https://doi.org/10.1016/j.cell.2021.02.033	True	Supasa et al. (2021)	n/a	We analyzed 34 convalescent samples including the WHONIBSC 20/130 reference serum, and, although  a few sera showed near identical FRNT 50 values, the FRNT50 dilutions for the B.1.1.7 strain  were 2.9-fold lower (geometric mean) than those for the Victoria strain (p < 0.0001). Sera from 13 subjects post-B.1.1.7 infection showed no significant change in neutralization against Victoria (~wild type), suggesting that B.1.1.7 infection also protects against ancestral virus. [Note that D1119H was included in the original paper, assuming typographical error and correcting to D1118H]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Hoffman	2021	doi:10.1101/2021.05.04.442663	n/a	https://doi.org/10.1101/2021.05.04.442663	False	Hoffman et al. (2021)	n/a	In 15 Pzifer non-senior vaccinee sera collected 3-4 weeks post-booster [using Table S1, not the text that says 2-3 weeks], neutralization was reduced ~11x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	UNKNOWN	n/a	n/a	n/a	,	n/a	UNKNOWN et al. ()	n/a	In Qatar, where Pfizer vaccine use is prevalent (<10% of the population covered in the time period of the study ending Mar 31, 2021), any time after one dose  (including the 2 weeks where no major effect is expected) B.1.351 lineage effectiveness was observed as 16.9% (95% CI [10.4,23.0]) against infection, and 0% against severe/critical/fatal disease  (95% CI [0-19.0]). Two weeks or more after 2nd dose, effectiveness climbed to 75.0% [70.5,78.9] against infection, and 100% against  severe/critical/fatal disease (95% CI [73.7,100]).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	UNKNOWN	2021	n/a	n/a	https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1009243/Technical_Briefing_20.pdf	False	UNKNOWN et al. (2021)	n/a	Sera from vaccinees [ChAdOx1 and BNT162b2 primarily used in UK] shows decreased ability to neutralize B.1.621 compared to first wave virus and Alpha, with a magnitude of change similar to Beta.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine efficacy	n/a	n/a	Bruxvoort	2021	doi:10.1101/2021.09.29.21264199	n/a	https://doi.org/10.1101/2021.09.29.21264199	False	Bruxvoort et al. (2021)	n/a	In a 1:5 test-negative matched control study of 8153 individuals who received the Moderna mRNA-1273 vaccine, 69 test-positive were Mu. Two dose vaccine efficacy against Mu was 90.4% (73.9-96.5%), one dose VE was 45.8% (0.0-88.9%).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	UNKNOWN	2021	n/a	n/a	https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1009243/Technical_Briefing_20.pdf	False	UNKNOWN et al. (2021)	n/a	Sera from individuals who have been vaccinated and have had subsequent recent Delta infection have a high level of neutralising activity against B.1.621.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma binding	n/a	n/a	UNKNOWN	2021	n/a	n/a	https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1009243/Technical_Briefing_20.pdf	False	UNKNOWN et al. (2021)	n/a	Sera from individuals who have been infected with Delta does not have strong neutralising activity against B.1.621	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma binding	n/a	n/a	Luftig	2021	doi:10.1056/NEJMc2104036	pmid:33826815	https://doi.org/10.1056/NEJMc2104036	True	Luftig et al. (2021)	n/a	In sera from six patients collected 1 to 12 weeks post-infection with B.1, antibody titer in a microneutralization assay was on average 71.46 for P.1 virus. Compare to much stronger neutralization titers for B.1.1.7 (256) and wild type (456.1) in the same sera.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Uriu	2021	doi:10.1101/2021.09.06.459005	n/a	https://doi.org/10.1101/2021.09.06.459005	False	Uriu et al. (2021)	n/a	Mean 7.6x reduction of NT50 value B.1.621 (Mu) relative to wild type in 8 sera from adult BNT162b2 vaccinees (28-47yo) collected ~1m post booster. [This is a greater reduction than Beta @ 6.3x]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Messali	2021	doi:10.1002/jmv.27247	pmid:34329486	https://doi.org/10.1002/jmv.27247	True	Messali et al. (2021)	n/a	Using live B.1.621 virus and a cytopathic effect-based assay, sera from 37 Pfizer/BioNTech BNT162b2 vaccinees collected 10-20 days post-booster showed significantly lower (95) but still 'robust' neutralization than against ancestral B.1 virus (107).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Uriu	2021	doi:10.1101/2021.09.06.459005	n/a	https://doi.org/10.1101/2021.09.06.459005	False	Uriu et al. (2021)	n/a	Mean 12.4x reduction of NT50 value B.1.621 (Mu) relative to wild type in 8 sera from older convalescent patients (52-92yo) collected 1-3m post symptom onset. [This is a greater reduction than Beta @ 8.2x]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  XD (from ) were 1.5x-fold lower (95% CI: 0.05x-0.07x) than against 208-428 972-1834 4.3-4.7 US-WA1/2020 usiong an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  XD (from ) were 4.4-fold lower (95% CI: 4.3x-4.7x) than against 208-428 972-1834 4.3-4.7 US-WA1/2020 usiong an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Yue	2023	doi:10.1101/2023.01.03.522427	n/a	https://doi.org/10.1101/2023.01.03.522427	False	Yue et al. (2023)	n/a	The hACE2-binding affinity of XBB.1.5 RBD has a dissociation constant KD of 3.4 nM, where S486P is the distinguishing Spike mutation vs parent  XBB.1 RBD with a much weaker KD (19 nM), as measured by surface plasmon resonance (SPR) assays.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine efficacy	n/a	n/a	Zhou	2022	doi:10.1101/2022.05.09.491254	n/a	https://doi.org/10.1101/2022.05.09.491254	False	Zhou et al. (2022)	n/a	In a study of 481 vaccinees going from lowest to highest infection rate, 2 doses of CoronaVac and 1 dose of BNT162b2 had the lowest infection rate at 6.3%, then it was 3 doses of BNT162b2 having a infection rate of 16.6%. 2 and 3 doses of CoronaVac had 48.6% and 20.6% infection rate respectively. 2 doses of BNT162b2 has  the highest infection rate at 49.2%.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Wu	2021	doi:10.1101/2021.01.25.427948	pmid:33501442	https://doi.org/10.1101/2021.01.25.427948	False	Wu et al. (2021)	n/a	In Moderna vaccinee sera, 2.7x reduction in neutralization, and 6.4 for the full B.1.351 Spike mutation complement, but despite the observed decreases,  titers in human vaccinee sera against the B.1.351 variant remained at clinically significant level of ~1/300.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Wibmer	2021	doi:10.1101/2021.01.18.427166	pmid:33501446	https://doi.org/10.1101/2021.01.18.427166	False	Wibmer et al. (2021)	n/a	27% of 44 early pandemic exposure convalescent plasma/sera lose all activity against a RBD triple mutant pseudovirus (RBD mutatants of the 501Y.V2 'South African' lineage), while only 23% retained high titres	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	viral load	n/a	n/a	Roquebert	2021	doi:10.1101/2021.03.19.21253971	n/a	https://doi.org/10.1101/2021.03.19.21253971	False	Roquebert et al. (2021)	n/a	B.1.351 and P.1 samples showed average Ct cycle threshold of 22.2 vs 23 for wildtype (i.e. ~60% higher viral load) comparing 3360 and 22535 samples respectively.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Liu	2021	doi:10.1101/2021.02.16.431305	pmid:33619479	https://doi.org/10.1101/2021.02.16.431305	False	Liu et al. (2021)	n/a	This mutated version of RBD completely abolishes the binding to a therapeutic antibody, Bamlanivimab, in vitro.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Chen	2021	doi:10.1038/s41591-021-01294-w	pmid:33664494	https://doi.org/10.1038/s41591-021-01294-w	True	Chen et al. (2021)	n/a	Ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07, COVOX-384, and S2H58.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Wang	2021	doi:10.1101/2021.01.15.426911	pmid:33501451	https://doi.org/10.1101/2021.01.15.426911	False	Wang et al. (2021)	n/a	In a cohort of 20 patients 8+ weeks after second vaccine dose of Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines,  a significant (0.5 to 20-fold, but average ~2x) decrease in neutralization by vaccine plasma was observed.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Barton	2021	doi:10.1101/2021.05.18.444646	n/a	https://doi.org/10.1101/2021.05.18.444646	False	Barton et al. (2021)	n/a	The affinity of the B.1.351 RBD variants for ACE2 increased by 3.7 fold as measured by surface plasmon resonance relative to wild  type RBD by increasing the k(on) and decreasing the k(off) rate constants.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Wibmer	2021	doi:10.1101/2021.01.18.427166	pmid:33501446	https://doi.org/10.1101/2021.01.18.427166	False	Wibmer et al. (2021)	n/a	Ablates ELISA test binding for class 1 (Spike 'up' conformation only, RBD targeting) monoclonal antibody CA1 on 501Y.V2 ('South African') lineage background  Ablates ELISA test binding for class 1 (Spike 'up' conformation only, RBD targeting) monoclonal antibody LyCoV016 (also known as CB6 or JS016) on 501Y.V2 ('South African') lineage background Ablates ELISA test binding for class 1 (Spike 'up' conformation only, RBD targeting) monoclonal antibody CC12.1 on 501Y.V2 ('South African') lineage background Ablates ELISA test binding for class 2 (Spike 'up' or 'down' conformation, RBD targeting) monoclonal antibody BD23 on 501Y.V2 ('South African') lineage background  Ablates ELISA test binding for class 2 (Spike 'up' or 'down' conformation, RBD targeting) monoclonal antibody C119 (also known as CB6 or JS016) on 501Y.V2 ('South African') lineage background Ablates ELISA test binding for class 2 (Spike 'up' or 'down' conformation, RBD targeting) monoclonal antibody P2B-2F6 on 501Y.V2 ('South African') lineage background	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Chen	2021	doi:10.1038/s41591-021-01294-w	pmid:33664494	https://doi.org/10.1038/s41591-021-01294-w	True	Chen et al. (2021)	n/a	In 19 convalescent human sera ~1mo post infection had mild to moderate resistance against most samples	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Engelhart	2021	doi:10.1101/2021.04.27.440939	n/a	https://doi.org/10.1101/2021.04.27.440939	False	Engelhart et al. (2021)	n/a	Tixagevimab, Regdanvimab and COR-101 display reduced binding affinity to virus pseudotyped as RBD from B.1.351.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Collier	2021	doi:10.1038/s41586-021-03412-7	n/a	https://doi.org/10.1038/s41586-021-03412-7	True	Collier et al. (2021)	n/a	This combination showed ~3x increase binding to ACE2 vs wild type, about half that of the B.1.1.7 lineage, suggesting that the K417N mutation is slightly detrimental to ACE2 binding, probably as a result of disrupting the salt bridge formed with ACE2 residue D30	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Bates	2021	doi:10.1101/2021.04.04.21254881	pmid:33851185	https://doi.org/10.1101/2021.04.04.21254881	False	Bates et al. (2021)	n/a	Observed 1.4-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose)  against pseudotype B.1.351 key variants lentivirus. Compare to 8.8-fold reduction against cultured B.1.351 virus.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Sun	2021	doi:10.1101/2021.03.22.436481	n/a	https://doi.org/10.1101/2021.03.22.436481	False	Sun et al. (2021)	n/a	Complete loss of binding in ELISA by the variant against monoclonal antibodies ab8 and IgG1 ab1. Complete loss for the same antibodies was also observed against S1 pseudotyped and full Spike  protein trimers with both B.1.351 and P.1 lineage variants, with slight binding signal for P.1 against IgG1 at the highest concentration tested (1uM). Complete loss of neutralization by these two antibodies was also observed.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Ramanathan	2021	doi:10.1101/2021.02.22.432359	pmid:33655251	https://doi.org/10.1101/2021.02.22.432359	False	Ramanathan et al. (2021)	n/a	Using Mircoscale Thermopheresis, the B.1.351 variant harboring three mutations, binds ACE2 at nearly  five-fold greater affinity than the original SARS-COV-2 RBD (Kd 87.6, vs 402.5 nM).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Laffeber	2021	doi:10.1101/2021.02.22.432357	n/a	https://doi.org/10.1101/2021.02.22.432357	False	Laffeber et al. (2021)	n/a	RBD containing the N501Y mutation results in 9-fold stronger binding to the hACE2 receptor than  wild type RBD. The E484K mutation does not significantly influence the affinity for the receptor,  while K417N attenuates affinity. As a result, RBD from B.1.351 containing all three mutations binds  3-fold stronger to hACE2 than wild type RBD but 3-fold weaker than N501Y.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	viral load	n/a	n/a	Teyssou	2021	doi:10.1101/2021.03.21.21253498	n/a	https://doi.org/10.1101/2021.03.21.21253498	False	Teyssou et al. (2021)	n/a	The 62 B.1.351 (a.k.a. N501Y.V2) variant cases in three Paris hospital labs had a ~2-fold viral load increase  (~1 Ct drop in both N and ORF1ab probes) compared to 332 ancestral lineage cases from the same time frame (2020-12-20 to 2021-02-26).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Tian	2021	doi:10.1101/2021.02.14.431117	n/a	https://doi.org/10.1101/2021.02.14.431117	False	Tian et al. (2021)	n/a	Reported slight increase in affinity compared to wild-type RBD on the cell surface (Kd 	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Liu	2021	doi:10.1101/2021.02.16.431305	pmid:33619479	https://doi.org/10.1101/2021.02.16.431305	False	Liu et al. (2021)	n/a	Studying the key covariants in lineage of concern 501Y.V2,  observed about 2-fold increase in ACE2 binding vs wildtype, but greatly decreased mAb binding, suggesting evolutionary optimum tension between  immune evasion and ACE2 binding affinity as the N501Y variant alone has 10x increase in affinity but no effect on tested mAb binding.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Vogel	2021	doi:10.1101/2021.03.04.433887	n/a	https://doi.org/10.1101/2021.03.04.433887	False	Vogel et al. (2021)	n/a	The affinity of ACE2 for this mutation combination was twice as high as for wild type. Having in mind that the affinity of SARS-CoV-2 for ACE2 is only 4-fold higher compared to SARS-CoV-1, this factor of 2 is expected to be biologically significant.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	trafficking	n/a	n/a	Hu	2021	doi:10.1101/2021.01.22.427749	n/a	https://doi.org/10.1101/2021.01.22.427749	False	Hu et al. (2021)	n/a	The entry efficiencies of Spike pseudotyped viruses bearing N501Y Variant 2 (B.1.351) mutant were about 3 to 4.4 times higher than that of the WT pseudovirus when viral input was normalized, suggesting that these spike variants promote the infectivity of SARS-CoV-2.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	transmissibility	n/a	n/a	Roquebert	2021	doi:10.1101/2021.05.12.21257130	n/a	https://doi.org/10.1101/2021.05.12.21257130	False	Roquebert et al. (2021)	n/a	36,590 variant-specific RT-PCR tests were performed on samples collected between April 12 and May 7, 2021  in France to compare variant spread. Compared to January to March 2021, B.1.351 variant had a significant  transmission advantage over B.1.1.7 in some regions (15.1 to 16.1% in Île-de-France and 16.1 to 18.8% in Hauts-de-France). This shift in transmission advantage is consistent with the immune evasion abilities of B.1.351 and the high levels of immunization in these regions.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	transmissibility	n/a	n/a	Pearson	2021	n/a	n/a	https://cmmid.github.io/topics/covid19/reports/sa-novel-variant/2021_01_11_Transmissibility_and_severity_of_501Y_V2_in_SA.pdf	False	Pearson et al. (2021)	n/a	Assuming complete cross-protection, we estimate 501Y.V2/B.1.351 was 1.50 (95% CrI: 1.20-2.13) times as transmissible than previously circulating variants. Assuming instead that 501Y.V2 is identically transmissible, the new variant evades 21% (95% CrI: 11-36%) of previously acquired immunity. Reality may lie between these extremes, with an intermediate increase in transmissibility and mildly imperfect cross-protection from past exposure.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Alenquer	2021	doi:10.1101/2021.04.22.441007	n/a	https://doi.org/10.1101/2021.04.22.441007	False	Alenquer et al. (2021)	n/a	Average ~10-fold reduction in neutralization efficacy in convalescent sera of 16 health workers infected in Spring 2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Madhi	2021	doi:10.1056/NEJMoa2102214	pmid:33725432	https://doi.org/10.1056/NEJMoa2102214	True	Madhi et al. (2021)	n/a	In a multicenter, double-blind, randomized, controlled trial to assess the safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) with enrollment June 24 and November 9, 2020 from ~2000 HIV-negative 18-64 year olds (1:1 placebo to treatment), incidence of serious  adverse events 14 or more days post- 2nd dose was balanced between the vaccine and placebo groups. A two-dose regimen of the ChAdOx1  nCoV-19 vaccine did not show protection against mild-to-moderate Covid-19 due to the B.1.351 variant. Serum samples obtained from 13 ChAdOx1 nCoV-19 vaccine recipients without SARS-CoV-2 infection through 41 days after vaccination  showed 3.5x reduction in neutralization (ID50) for B.1.351 RBD pseudotype HIB-1 virus compared to D614G alone. This  RBD variant combination's neutralization by a placebo control  group of 6 naturally infected patients showed a similar 3.2x drop (though with D614G starting at a 1.7x higher titre than vaccinee sera).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Hu	2021	doi:10.1101/2021.01.22.427749	n/a	https://doi.org/10.1101/2021.01.22.427749	False	Hu et al. (2021)	n/a	Neutralizing antibody titers of 18 samples (90%) decreased against this B.1.351 pseudotyped virus below an ID50 threshold of 40 (sera  collected ~8mo post Jan 2020 first wave in China).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Hu	2021	doi:10.1101/2021.01.22.427749	n/a	https://doi.org/10.1101/2021.01.22.427749	False	Hu et al. (2021)	n/a	Abolished neutralization by mAbs CQ026 and CQ038, greatly diminished neutralization by CQ012 and CQ046.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kuzmina	2021	doi:10.1016/j.chom.2021.03.008	pmid:33789085	https://doi.org/10.1016/j.chom.2021.03.008	True	Kuzmina et al. (2021)	n/a	This variant of key B.1.351 lineage mutations showed ~10x decrease in Pfizer sera (3 weeks post-first dose: n 	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Li	2022	doi:10.1186/s13578-022-00794-7	pmid:35581593	https://doi.org/10.1186/s13578-022-00794-7	True	Li et al. (2022)	n/a	Trachea viral loads were tested by qRT‑PCR and RNA scope at 3 dpi on 5 8‑month‑old male mice and there was a ~750x fold drop in the R3P1-E4 antibody in comparison to  the IgG control.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Li	2022	doi:10.1186/s13578-022-00794-7	pmid:35581593	https://doi.org/10.1186/s13578-022-00794-7	True	Li et al. (2022)	n/a	Lung viral loads were tested by qRT‑PCR and RNA scope at 3 dpi on 5 8‑month‑old male mice and there was a ~2266x fold drop in the R3P1-E4 antibody in comparison to  the IgG control.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Li	2022	doi:10.1186/s13578-022-00794-7	pmid:35581593	https://doi.org/10.1186/s13578-022-00794-7	True	Li et al. (2022)	n/a	100% of the 5 8‑month‑old male R3P1-E4 antibody treated mice suvived 14 days after infection while only 60% the control group mice survived 5 days post infection.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	trafficking	n/a	n/a	Kim	2021	doi:10.3390/v13040633	pmid:33917138	https://doi.org/10.3390/v13040633	True	Kim et al. (2021)	n/a	~5x more efficient S2 domain cleavage compared to wild type, compared to 4x by D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).  [N501Y+D614G does not show an increase in cleavage, therefore a synergistic effect of the trio is implied]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kuzmina	2021	doi:10.1016/j.chom.2021.03.008	pmid:33789085	https://doi.org/10.1016/j.chom.2021.03.008	True	Kuzmina et al. (2021)	n/a	This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n 	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	trafficking	n/a	n/a	Kuzmina	2021	doi:10.1016/j.chom.2021.03.008	pmid:33789085	https://doi.org/10.1016/j.chom.2021.03.008	True	Kuzmina et al. (2021)	n/a	~9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (no synergy as level approx. that of N501Y alone).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Engelhart	2021	doi:10.1101/2021.04.27.440939	n/a	https://doi.org/10.1101/2021.04.27.440939	False	Engelhart et al. (2021)	n/a	Tixagevimab, Regdanvimab and COR-101 display reduced binding affinity to virus pseudotyped as RBD from P.1.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Barton	2021	doi:10.1101/2021.05.18.444646	n/a	https://doi.org/10.1101/2021.05.18.444646	False	Barton et al. (2021)	n/a	The affinity of the P.1 RBD variants for ACE2 increased by 5.3 fold as measured by surface plasmon resonance relative to wild  type RBD by increasing the k(on) and decreasing the k(off) rate constants.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Dejnirattisai	2021	doi:10.1016/j.cell.2021.03.055	pmid:33852911	https://doi.org/10.1016/j.cell.2021.03.055	True	Dejnirattisai et al. (2021)	n/a	The KD for the pseudotyped P.1-ACE2 interaction is 4.8 nM, showing that binding to P.1 is essentially indistinguishable from B.1.351 (4.0 nM), which binds with ~19x greater affinity that wild type.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Jacobson	2021	doi:10.1101/2021.04.14.21255431	pmid:33907767	https://doi.org/10.1101/2021.04.14.21255431	False	Jacobson et al. (2021)	n/a	The presence of these B.1.417/B.1.429 defining variants in 189 post-mRNA-vaccination COVID-19 cases was proportionally in line with lineage prevalence in Northen California during the study period, suggesting no effect of these variants on immune escape.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Clark	2021	doi:10.1016/j.cell.2021.03.027	pmid:33831372	https://doi.org/10.1016/j.cell.2021.03.027	True	Clark et al. (2021)	n/a	Pseudotype for Day 152 virus from a chronically infected patient, neutralizing activity of purified IgG  from 3 donors was mostly unaffected by the single mutations (Q493K/R or N439K), but the day 152 S pseudotype was resistant to neutralization.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Clark	2021	doi:10.1016/j.cell.2021.03.027	pmid:33831372	https://doi.org/10.1016/j.cell.2021.03.027	True	Clark et al. (2021)	n/a	This Spike pseudotype for Day 152 virus from a chronically infected patient was completely resistent to REGN10933.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Clark	2021	doi:10.1016/j.cell.2021.03.027	pmid:33831372	https://doi.org/10.1016/j.cell.2021.03.027	True	Clark et al. (2021)	n/a	Pseudotype for Day 152 virus from a chronically infected patient: although mAb C1A-B12 had no activity against this pseudotype,  all three affinity optimized versions were active: the antibody containing the most mutations,  C1A-B12.3, was the most potent (IC50 <0.5 μg/mL).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Wang	2022	doi:10.1101/2022.08.11.503601	n/a	https://doi.org/10.1101/2022.08.11.503601	False	Wang et al. (2022)	n/a	3rd exposure to antigen by Delta (B.1.617.2) (n	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine efficacy	n/a	n/a	Sheward	2021	n/a	n/a	https://drive.google.com/file/d/1CuxmNYj5cpIuxWXhjjVmuDqntxXwlfXQ/view	False	Sheward et al. (2021)	n/a	In sera from 17 sero-positive blood donors, and 18 months post-infection (May 2020) sera from 17 health  care workers in Sweden, a 40x drop in neutralization by Omicron (B.1.1.529) pseudotyped lentivirus  was observed in HEK293T cells using the First WHO International Standard (20/136). Median IC50 reduction was ~6x for the blood donors, and ~4.5x for the health care workers.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine efficacy	n/a	n/a	Braeye	2022	doi:10.1101/2022.05.09.22274623	n/a	https://doi.org/10.1101/2022.05.09.22274623	False	Braeye et al. (2022)	n/a	In a Belgian study including 1,433,135 persons (vaccinated between July 2021 to April 2022) infection-acquired immunity offered additional protection  against symptomatic infection with Omicron in vaccinated persons compared to those without previous infection, when the infection was up to one year previous.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine efficacy	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Pseudotyped virus neutralization demonstrated that Bi-Nab35B5-47D10 can efficiently neutralize VBMs including Alpha (B.1.1.7), Beta (B.1.351) and Kappa  (B.1.617.1) and VOCs including Delta (B.1.617.2).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Zhang	2022	doi:10.1101/2022.06.05.493249	n/a	https://doi.org/10.1101/2022.06.05.493249	False	Zhang et al. (2022)	n/a	Using molecular dynamics simulation, ACE2-RBD (Omicron) complex is destabilized by the E484A and Y505H mutations and stabilized by S477N and N501Y mutations.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	trafficking	n/a	n/a	Kuzmina	2021	doi:10.1016/j.chom.2021.03.008	pmid:33789085	https://doi.org/10.1016/j.chom.2021.03.008	True	Kuzmina et al. (2021)	n/a	~13x more infective as D614G alone in HEK293T-ACE2 cells 48h post-transduction.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Zahradnik	2021	doi:10.1101/2021.01.06.425392	n/a	https://doi.org/10.1101/2021.01.06.425392	False	Zahradnik et al. (2021)	n/a	Y501 makes a pi interaction with Y41 and places R498 to make a hydrogen bond and salt bridge to Q42 and D38 of ACE2, forming a strong network of new interactions supporting the impact of these residues on affinity.  Q498R alone appears to decrease ACE2 binding. The synergism of Q498R with N501Y (and E484K) increases ACE2 binding by ~50- fold relative to WT.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	McEvoy C	2022	doi:10.1101/2022.06.24.22276144	n/a	https://doi.org/10.1101/2022.06.24.22276144	False	McEvoy C et al. (2022)	n/a	Log10ID50 of Omicron neutralizing antibodies is 0.686x the WT 1 month post-third dose of pfizer-BioNTech BNT162b2 in 13 Kidney transplant recipients (KTR) with median age of 55.5.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron BA.4 have higher sensitivity to inhibition by soluble angiotensin converting enzyme 2 (ACE2) and the endosomal inhibitor chloroquine compared  to D614G	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	viral load	n/a	n/a	Rosenke	2022	doi:10.1172/jci.insight.160108	pmid:35579953	https://doi.org/10.1172/jci.insight.160108	True	Rosenke et al. (2022)	n/a	Viral load from lung tissue from 11 hamsters in 10 treatments for Omicron MK-4482 had the greatest drop 3 days post-infection determined by quantitative RT-PCR  targeting sgE in comparison to Alpha MK-4482, Beta MK-4482 and Delta MK-4482.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Chen	2021	doi:10.1038/s41591-021-01294-w	pmid:33664494	https://doi.org/10.1038/s41591-021-01294-w	True	Chen et al. (2021)	n/a	Ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07, COVOX-384, and S2H58. Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Chonira	2022	doi:10.1101/2022.05.30.493765	pmid:35677079	https://doi.org/10.1101/2022.05.30.493765	False	Chonira et al. (2022)	n/a	Trimeric proteins FSR22 had a 0.0015x fold change in IC50 in B.1.1.529 Omicron	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron BA.5 have higher sensitivity to inhibition by soluble angiotensin converting enzyme 2 (ACE2) and the endosomal inhibitor chloroquine compared  to D614G	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Xie	2021	doi:10.1038/s41591-021-01270-4	n/a	https://doi.org/10.1038/s41591-021-01270-4	True	Xie et al. (2021)	n/a	In 20 sera from BNT162b2 mRNA vaccine inoculated participants, 6 displayed mild (2x) reductions in neutralization. This variant combination showed the highest reduction, but the magnitude of the differences was small  compared to the >4x differences in HA-inhibition titers that have been used to signal potential need for a strain change in influenza vaccines.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Chen	2021	doi:10.1038/s41591-021-01294-w	pmid:33664494	https://doi.org/10.1038/s41591-021-01294-w	True	Chen et al. (2021)	n/a	The neutralizing activity of vaccine was slightly to significantly lower against this variant combination in sera from all 24 patients with  the BNT162b2 mRNA vaccine. (Fig. 4) [In stark contrast to this combination plus K417N, which had no effect (P<0.0001 vs. P	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Arora	2022	doi:10.1038/s41423-022-00870-5	pmid:35581351	https://doi.org/10.1038/s41423-022-00870-5	True	Arora et al. (2022)	n/a	Out of 10 individuals with 2 doses of the BNT162b2/BNT162b2 vaccine, neutralizing titer in Omicron was ~100x folds more significant in 3 individuals.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Yao T	2022	doi:10.1101/2022.06.22.22276690	n/a	https://doi.org/10.1101/2022.06.22.22276690	False	Yao T et al. (2022)	n/a	Values taken 28 days after booster dose was given for BBIBP-CorVvaccine to 390 participants with 130 participants in the 0-14d-10m, 0-21d-10m and 0-28d-10m group. The geometric mean titers (GMT) of neutralizing antibody in 0-28d-10m and 0-21d-10m group were significantly higher than 0-14d-10m group at month 3, month 6 and month 10 after the second dose. A sharply decrease by 4.85-fold (GMT: 94.4-20.3), 4.67-fold (GMT: 134.4-28.8) and 4.49-fold (GMT: 145.5-32.4) was observed from day 28 to month 10 after the second dose in 0-14d-10m, 0-21d-10m and 0-28d-10m group, respectively, and they had similar decline kinetics.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Arora	2022	doi:10.1038/s41423-022-00870-5	pmid:35581351	https://doi.org/10.1038/s41423-022-00870-5	True	Arora et al. (2022)	n/a	Out of 10 individuals with 3 doses of the BNT162b2/BNT162b2/BNT162b2 vaccine, neutralizing titer in Omicron was ~17.5x folds more significant in 9 individuals.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron BA.4 neutralization of the Omicron variants by antibodies induced by three doses of Pfizer/BNT162b2 mRNA vaccine was 7-8-fold less potent than the D614G, and  the Omicron variants still evade neutralization more efficiently.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron BA.5 neutralization of the Omicron variants by antibodies induced by three doses of Pfizer/BNT162b2 mRNA vaccine was 7-8-fold less potent than the D614G, and  the Omicron variants still evade neutralization more efficiently.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine efficacy	n/a	n/a	Nasreen	2021	doi:10.1101/2021.06.28.21259420	n/a	https://doi.org/10.1101/2021.06.28.21259420	False	Nasreen et al. (2021)	n/a	Protection against symptomatic infection caused by Beta/Gamma (assumed by combined presence of N501Y and E484K) was also higher with partial  vaccination for mRNA-1273 (77%) than BNT162b2 (60%) and ChAdOx1 (48%), and full vaccination increased effectiveness for BNT162b2 (84%).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Rosenke	2022	doi:10.1172/jci.insight.160108	pmid:35579953	https://doi.org/10.1172/jci.insight.160108	True	Rosenke et al. (2022)	n/a	Infectious viral titers in lung tissue determined using a tissue culture infectious dose (TCID) assay in 10 hamsters showed that Omicron Molnupiravir (MK-4482) had no statistically  significant change.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	McEvoy C	2022	doi:10.1101/2022.06.24.22276144	n/a	https://doi.org/10.1101/2022.06.24.22276144	False	McEvoy C et al. (2022)	n/a	Log10ID50 of Omicron neutralizing antibodies is 0.722x the WT pre-third dose of pfizer-BioNTech BNT162b2 in  13 Kidney transplant recipients (KTR) with median age  of 55.5.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	viral load	n/a	n/a	Rosenke	2022	doi:10.1172/jci.insight.160108	pmid:35579953	https://doi.org/10.1172/jci.insight.160108	True	Rosenke et al. (2022)	n/a	Viral load from oral swabs from 11 hamsters in 10 treatments for Omicron MK-4482 had the greatest drop 3 days post-infection determined by quantitative RT-PCR  targeting sgE in comparison to Alpha MK-4482, Beta MK-4482 and Delta MK-4482.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Chonira	2022	doi:10.1101/2022.05.30.493765	pmid:35677079	https://doi.org/10.1101/2022.05.30.493765	False	Chonira et al. (2022)	n/a	Trimeric proteins FSR16m had a 0.025x fold change in IC50 in B.1.1.529 Omicron	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Barton	2021	doi:10.1101/2021.05.18.444646	n/a	https://doi.org/10.1101/2021.05.18.444646	False	Barton et al. (2021)	n/a	In the case of VOC B.1.1.7+E484K, the addition of the E484K mutation to N501Y further increased the affinity, to ~15 fold higher than WT RBD (KD ~5 nM), by further increasing the k(on) as measured by surface plasmon resonance. Because the higher k(on) could result in mass transfer limiting binding, we confirmed that the kinetic measurement for this variant was not substantially affected by varying levels of immobilization.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Chen	2021	doi:10.1038/s41591-021-01294-w	pmid:33664494	https://doi.org/10.1038/s41591-021-01294-w	True	Chen et al. (2021)	n/a	In 19 convalescent human sera ~1mo post infection had mild to moderate resistance against all samples.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	syncytium formation	n/a	n/a	Kim	2021	doi:10.3390/v13040633	pmid:33917138	https://doi.org/10.3390/v13040633	True	Kim et al. (2021)	n/a	~50% Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, signficantly higher than D614G.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	trafficking	n/a	n/a	Kuzmina	2021	doi:10.1016/j.chom.2021.03.008	pmid:33789085	https://doi.org/10.1016/j.chom.2021.03.008	True	Kuzmina et al. (2021)	n/a	~12x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (~additive effects of 501 and 484).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	trafficking	n/a	n/a	Kim	2021	doi:10.3390/v13040633	pmid:33917138	https://doi.org/10.3390/v13040633	True	Kim et al. (2021)	n/a	~6x more efficient S2 domain cleavage compared to wild type, compared to 4x by D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3). [N501Y+D614G does not show an increase in cleavage, therefore a synergistic effect of the trio is implied]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	trafficking	n/a	n/a	Kim	2021	doi:10.3390/v13040633	pmid:33917138	https://doi.org/10.3390/v13040633	True	Kim et al. (2021)	n/a	More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~11x, Vero ~10x, and Calu-3 ~11x. Compare to wild type at ~5x across cell types.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Clark	2021	doi:10.1016/j.cell.2021.03.027	pmid:33831372	https://doi.org/10.1016/j.cell.2021.03.027	True	Clark et al. (2021)	n/a	Pseudotype for Day 146 virus from a chronically infected patient, neutralizing activity of purified IgG  from 3 donors was mostly unaffected by the single mutations (Q493K/R or N439K), but the day 146 S pseudotype was resistant to neutralization.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Clark	2021	doi:10.1016/j.cell.2021.03.027	pmid:33831372	https://doi.org/10.1016/j.cell.2021.03.027	True	Clark et al. (2021)	n/a	Pseudotype for Day 146 virus from a chronically infected patient: resistant to neutralization by mAb C1A-B12, and  was still resistant to the affinity enhanced antibodies derived from it (i.e. no affinity maturation effect on neutralization).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Clark	2021	doi:10.1016/j.cell.2021.03.027	pmid:33831372	https://doi.org/10.1016/j.cell.2021.03.027	True	Clark et al. (2021)	n/a	This Spike pseudotype for Day 146 virus from a chronically infected patient was completely resistent to REGN10933. The variant had a 4-fold decrease in REGN10987 neutralization sensitivity (2nd component of the Regeneron mAb cocktail).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Zahradnik	2021	doi:10.1101/2021.01.06.425392	n/a	https://doi.org/10.1101/2021.01.06.425392	False	Zahradnik et al. (2021)	n/a	Y501 makes a pi interaction with Y41 and places R498 to make a hydrogen bond and salt bridge to Q42 and D38 of ACE2,  forming a strong network of new interactions supporting the impact of these residues on affinity. Q498R alone appears  to decrease ACE2 binding. The synergism of Q498R with N501Y (and E484K) increases ACE2 binding by ~50- fold relative  to WT. The extent of affinity increase with Q498R and N501Y is not exactly quantified, as E484K always emerged with  this duo during in vitro evolution.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Ramanathan	2021	doi:10.1101/2021.02.22.432359	pmid:33655251	https://doi.org/10.1101/2021.02.22.432359	False	Ramanathan et al. (2021)	n/a	Using Microscale Thermopheresis, this variant binds ACE2 at nearly  two-fold greater affinity than the original SARS-COV-2 RBD (203.7 nM vs 402.5 nM).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	trafficking	n/a	n/a	Motozono	2021	doi:10.1101/2021.04.02.438288	n/a	https://doi.org/10.1101/2021.04.02.438288	False	Motozono et al. (2021)	n/a	Decreased stability of RBD expression in yeast, suggesting decreased Spike protein stability.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Zhu	2021	doi:10.1101/2021.01.11.426269	n/a	https://doi.org/10.1101/2021.01.11.426269	False	Zhu et al. (2021)	n/a	N501Y residue inserts into a cavity at the binding interface near Y41 of ACE2.  The additional interactions result in increased affinity of ACE2 for the N501Y mutant,  accounting for its increased infectivity.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	virion structure	n/a	n/a	Spratt	2021	doi:10.1101/2021.03.24.436850	pmid:33791700	https://doi.org/10.1101/2021.03.24.436850	False	Spratt et al. (2021)	n/a	Estimated free energy change (ddG) for this variant is 0.69 kcal/mol (i.e. stabilizing relative to wild type)	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Tian	2021	doi:10.1101/2021.02.14.431117	n/a	https://doi.org/10.1101/2021.02.14.431117	False	Tian et al. (2021)	n/a	Reported 4-fold increase in affinity compared to wild-type RBD on the cell surface (Kd 	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	environmental condition stability	n/a	n/a	Tada	2021	doi:10.1101/2021.02.05.430003	pmid:33564768	https://doi.org/10.1101/2021.02.05.430003	False	Tada et al. (2021)	n/a	Relative to D614G, this mutation demonstrated significant increase in infectivity (i.e. heat stability) after incubation at 50C after 30 minutes or 1 hour	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Starr	2020	doi:10.1016/j.cell.2020.08.012	pmid:32841599	https://doi.org/10.1016/j.cell.2020.08.012	True	Starr et al. (2020)	n/a	Experimentally, ACE2 binding affinity increased 0.24 fold	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Feng	2022	doi:10.1002/smtd.202200387	pmid:35583124	https://doi.org/10.1002/smtd.202200387	True	Feng et al. (2022)	n/a	Utilizing shark derived vnarbodies, S375F mutation on Omicron RBD disrupts the structure of β-strand, which inhibits binding with 20G6. 20G6 binds to a hidden  epitope on RBD which is highly conserved in sarbecoviruses.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Tada	2021	doi:10.1101/2021.02.05.430003	pmid:33564768	https://doi.org/10.1101/2021.02.05.430003	False	Tada et al. (2021)	n/a	This single mutation causes major increase in binding affinity vs. wild type as measured by IC50 vs pseudotyped lentivirus,  but combined with the complete set of B.1.1.7   lineage variants no major change vs wild type affnity is observed.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Motozono	2021	doi:10.1101/2021.04.02.438288	n/a	https://doi.org/10.1101/2021.04.02.438288	False	Motozono et al. (2021)	n/a	~4-fold increase in binding affinity vs wild type.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	UNKNOWN	2021	doi:10.1101/2020.12.29.424708	n/a	https://doi.org/10.1101/2020.12.29.424708	False	UNKNOWN et al. (2021)	n/a	In silico methods (PyMOL and PDBePISA) involving mutagenesis (N501Y mutation) and interface analysis focusing on the Spike  RDB-ACE2 interaction showed that the SARS-CoV-2 N501Y mutant (lineage B.1.1.7) establishes a more significant number of  interactions relating to the mutant residue Y501 (Spike RDB) with residues Y41 and K353 (ACE2). This finding shows that the  increased infectivity of SARS-CoV-2 lineage B.1.1.7 is associated with the interaction force between the Spike RBD Y501  mutant residue with the ACE2 receptor, which in this strain is increased.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Liu	2021	doi:10.1101/2021.02.02.428884	pmid:33564771	https://doi.org/10.1101/2021.02.02.428884	False	Liu et al. (2021)	n/a	Reported 10-fold increase in ACE2 binding vs wildtype (Kd 	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Zahradnik	2021	doi:10.1101/2021.01.06.425392	n/a	https://doi.org/10.1101/2021.01.06.425392	False	Zahradnik et al. (2021)	n/a	Among the first selected and fixed variants in an in vitro evolution experiment for ACE2 binding. Calculated disassociation constant for this variant is nearly four fold lower than wild type (Kd 	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Gamez	2021	doi:10.1101/2021.04.09.439154	n/a	https://doi.org/10.1101/2021.04.09.439154	False	Gamez et al. (2021)	n/a	The most frequent RBM mutation N501Y (165,519 instances) makes defective the atypical N-glycosylation  sequon NGV 501-503, becoming a key RBM position for the interaction with hACE2-binding hotspot 353.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma binding	n/a	n/a	Tada	2021	doi:10.1101/2021.02.05.430003	pmid:33564768	https://doi.org/10.1101/2021.02.05.430003	False	Tada et al. (2021)	n/a	Viruses containing the point mutations of B.1.1.7 showed that the single point mutations (Δ69-70 and N501Y) were neutralized as efficiently as D614G across 10 convalescent sera from April 2020 infectees.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma binding	n/a	n/a	Rathnasinghe	2021	doi:10.1101/2021.01.19.21249592	pmid:33501468	https://doi.org/10.1101/2021.01.19.21249592	False	Rathnasinghe et al. (2021)	n/a	In 30 samples collected 111 to 260 days post onset of symptoms, the covalescent plasma can neutralize both  the reference USA-WA1/2020 strain and the mouse adapted strain that contains the N501Y spike mutation with similar efficiency.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Engelhart	2021	doi:10.1101/2021.04.27.440939	n/a	https://doi.org/10.1101/2021.04.27.440939	False	Engelhart et al. (2021)	n/a	COR-101 lost ~8x binding against this isolated mutation. Regdanvimab lost ~6x binding against this isolated mutation.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Haynes	2021	doi:10.1101/2021.01.06.20248960	n/a	https://doi.org/10.1101/2021.01.06.20248960	False	Haynes et al. (2021)	n/a	Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 3% to 1.2% (poorer immune recognition) Together with other B1.1.7 lineage mutational changes (Spike: Y144del, A570D, P681H, Nucleoprotein: D3L, S235F) resulted in only 2 or 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Wang	2021	doi:10.1101/2021.01.15.426911	pmid:33501451	https://doi.org/10.1101/2021.01.15.426911	False	Wang et al. (2021)	n/a	4 antibodies tested were less potent against K417N by ten-fold or more, in both mAb classes 1 and 3	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Shen	2021	doi:10.1101/2021.01.27.428516	pmid:33532764	https://doi.org/10.1101/2021.01.27.428516	False	Shen et al. (2021)	n/a	Reduction in neutralization by mAbs COVA1-18 (~4x), COVA2-15 (~9x), S309 (~3x)	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Rees-Spear	2021	doi:10.1101/2021.01.15.426849	n/a	https://doi.org/10.1101/2021.01.15.426849	False	Rees-Spear et al. (2021)	n/a	Lowered the neutralization potency of mAb COVA1-12 to the limit of the assay. Decrease in potency was observed against the N501Y pseudotype for the cluster IX mAb COVA2-17.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	immunosuppression variant emergence	n/a	n/a	Choi	2020	doi:10.1056/NEJMc2031364	pmid:33176080	https://doi.org/10.1056/NEJMc2031364	True	Choi et al. (2020)	n/a	Appeared (day 128) and persisted in chronic (152 day) SARS-CoV-2 infection of immunocompromised patient with severe antiphospholipid syndrome	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Kuzmina	2021	doi:10.1016/j.chom.2021.03.008	pmid:33789085	https://doi.org/10.1016/j.chom.2021.03.008	True	Kuzmina et al. (2021)	n/a	0.7x reduction in neutralization by key variant in several variants of concern in sera collected from cohort of 10 with severe  disease 21 to 63 days post-onset.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	trafficking	n/a	n/a	Liu	2021	doi:10.1101/2021.03.08.434499	pmid:33758836	https://doi.org/10.1101/2021.03.08.434499	False	Liu et al. (2021)	n/a	This mutation alone accounts for most of the increased infectivity of the Alpha variant, as determined by modelling the infectivity of each Spike mutation independently in a competitive infection model of hamsters, and Vero E6 (NHP) and Calu-3 (human) cell lines.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Tang	2021	doi:10.1101/2021.03.19.436183	n/a	https://doi.org/10.1101/2021.03.19.436183	False	Tang et al. (2021)	n/a	As measured by surface plasmon resonance, RBD with the N501Y mutation alone showed a mean 2.1x decrease in binding affinity for  six batches of hyperimmune immunoglobulin (hCoV-2IG) preparations generated from SARS-CoV-2 convalescent plasma.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Barton	2021	doi:10.1101/2021.05.18.444646	n/a	https://doi.org/10.1101/2021.05.18.444646	False	Barton et al. (2021)	n/a	The N501Y mutation had the biggest effect on ACE2 affinity of any VOC mutation tested, increasing the affinity ~10 fold to KD ~7 nM, by increasing the k(on) ~1.8 fold and decreasing the k(off) by ~ 7 fold as measured by surface plasmon resonance.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine efficacy	n/a	n/a	Chung	2021	doi:10.1136/bmj.n1943	pmid:34417165	https://doi.org/10.1136/bmj.n1943	True	Chung et al. (2021)	n/a	In this Canadian test-negative study of 324033 individuals, two doses of either mRNA vaccine (BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna))  was not associated with appreciable vaccine escape by lineage Alpha [defined here as N501Y positive, but E484K negative].	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	T cell evasion	n/a	n/a	Reynolds	2021	doi:10.1126/science.abh1282	pmid:33931567	https://doi.org/10.1126/science.abh1282	True	Reynolds et al. (2021)	n/a	Vaccinated, but not post-infection sera, show decreased average T cell response to an N501Y peptide. When we primed transgenic mice expressing human HLA-DRB1*0401 with the Wuhan Hu-1 peptide pool,  T cell responses to the B.1.1.7 variant peptide pool were significantly reduced (p 	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Edara	2021	doi:10.1101/2021.02.02.21250799	pmid:33564782	https://doi.org/10.1101/2021.02.02.21250799	False	Edara et al. (2021)	n/a	1.2x drop in neutralization using sera collected from 14 healthy adult participants that received two injections of the mRNA-1273 (Moderna) vaccine  at a dose of 100 µg (18-55 years: day 1 and day 14 post-2nd dose) against a recombinant single variant virus (modified replicating WA-1 cDNA clone)  relative to contemporary circulating D614G variant (USA/GA-EHC-083E/2020) using a live-virus Focus Reduction Neutralization Test (FRNT) assay.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Wang	2021	doi:10.1101/2021.01.15.426911	pmid:33501451	https://doi.org/10.1101/2021.01.15.426911	False	Wang et al. (2021)	n/a	In a cohort of 20 patients 8+ weeks after second vaccine dose of Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines,  a modest decrease in neutralization by vaccine plasma was observed.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Jacobson	2021	doi:10.1101/2021.04.14.21255431	pmid:33907767	https://doi.org/10.1101/2021.04.14.21255431	False	Jacobson et al. (2021)	n/a	The presence of this variant in 189 post-mRNA-vaccination COVID-19 cases was proportionally in line with lineage prevalence in Northen California during the study period, suggesting no effect of these variants on immune escape.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Rathnasinghe	2021	doi:10.1101/2021.01.19.21249592	pmid:33501468	https://doi.org/10.1101/2021.01.19.21249592	False	Rathnasinghe et al. (2021)	n/a	Human sera from 6 two-dose Pfizer vaccinated individuals (47-68 days post 1st-dose) can neutralize both the reference  USA-WA1/2020 strain and the mouse adapted SARS-CoV-2 strain that contains the N501Y spike mutation with similar efficiency.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Klegerman	2021	doi:10.1101/2021.04.26.441517	n/a	https://doi.org/10.1101/2021.04.26.441517	False	Klegerman et al. (2021)	n/a	Contrary to other reports on N501Y containing lineages (i.e. with additional mutations), N501Y alone may have an even greater affinity for a human monoclonal antibody specific for wild type. These results suggest that the individual N501Y mutation does not contribute to altered viral properties by itself, but may contribute to a collective conformational shift produced by multiple mutations.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	trafficking	n/a	n/a	Tada	2021	doi:10.1101/2021.02.05.430003	pmid:33564768	https://doi.org/10.1101/2021.02.05.430003	False	Tada et al. (2021)	n/a	Lentiviral pseudotyped with this individual mutation from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing slightly increased infection rate amongst the cells.  [in what is essentially a replicate experiment in the same paper, because  each B.1.351 lineage variant was independetly evaluated and N501 is in both lineages,  a significant decrease was observed, therefore the error bars described in this paper should be interpreted carefully]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Bates	2021	doi:10.1101/2021.04.04.21254881	pmid:33851185	https://doi.org/10.1101/2021.04.04.21254881	False	Bates et al. (2021)	n/a	Observed 1.3-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose)  against pseudotype B.1.1.7 key variant lentivirus. Compare to 2.6-fold reduction against cultured B.1.1.7 virus.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	homoplasy	n/a	n/a	Flores-Alanis	2021	doi:10.3390/pathogens10020184	pmid:33572190	https://doi.org/10.3390/pathogens10020184	True	Flores-Alanis et al. (2021)	n/a	Variant within the six key residues in the receptor binding domain (RBD). Independently reported in UK, Australia  (same origin as UK), and South Africa (independent origin).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	monoclonal antibody serial passage escape	n/a	n/a	Wang	2021	doi:10.1101/2021.01.15.426911	pmid:33501451	https://doi.org/10.1101/2021.01.15.426911	False	Wang et al. (2021)	n/a	In vitro selection against class 1 (Spike 'up' conformation) monoclonal antibody C663, and to a lesser extent C613.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Collier	2021	doi:10.1038/s41586-021-03412-7	n/a	https://doi.org/10.1038/s41586-021-03412-7	True	Collier et al. (2021)	n/a	Of 50 mAbs tested, major loss of neutralization observed for S2X128, S2D8, S2X192, S2D19, S2H14, S2H19.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Engelhart	2021	doi:10.1101/2021.04.27.440939	n/a	https://doi.org/10.1101/2021.04.27.440939	False	Engelhart et al. (2021)	n/a	COR-101 lost ~20x binding against this double mutation. Estesevimab lost ~16x binding against this double mutation. Regdanvimab lost ~6x binding against this double mutation. M396 lost ~10x binding against this double mutation.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kuzmina	2021	doi:10.1016/j.chom.2021.03.008	pmid:33789085	https://doi.org/10.1016/j.chom.2021.03.008	True	Kuzmina et al. (2021)	n/a	In post-vaccination sera from individuals who received one (3 weeks post-first dose: n 	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Kuzmina	2021	doi:10.1016/j.chom.2021.03.008	pmid:33789085	https://doi.org/10.1016/j.chom.2021.03.008	True	Kuzmina et al. (2021)	n/a	~7x reduction in neutralization by key B.1.351 lineage RBD variant combination in sera collected from cohort of 10 with severe  disease 21 to 63 days post-onset. Two of the cohort showed no neutralization against this variant.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Engelhart	2021	doi:10.1101/2021.04.27.440939	n/a	https://doi.org/10.1101/2021.04.27.440939	False	Engelhart et al. (2021)	n/a	Bamlanivimab (LY-CoV555) lost ~64x binding against this double mutation. COR-101 lost ~50x binding against this double mutation. Casirivimab lost ~250x binding against this double mutation. Estesevimab lost ~16x binding against this double mutation. Regdanvimab lost ~32x binding against this double mutation. Tixagevimab lost ~10x binding against this double mutation.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	reinfection	n/a	n/a	Novazzi	2021	doi:10.1002/jmv.27066	pmid:33969504	https://doi.org/10.1002/jmv.27066	True	Novazzi et al. (2021)	n/a	Partial sequencing of S gene reveals two cases of probable early 2021 B.1.1.7 lineage reinfection from non-B.1.1.7 original cases in Lombardy, with 45 to 90 days between infections (less than the typical 90 day guideline for this call). Patients were 56 and 58yo, immunocompenent, with one a former smoker with obesity and dyslipidemia. One case required intubation during first infection,  but presented with mild symptoms upon reinfection. The other case convalesced at home during the first episode, but required CPAP support  in the subacute clinical unit upon reinfection.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kuzmina	2021	doi:10.1016/j.chom.2021.03.008	pmid:33789085	https://doi.org/10.1016/j.chom.2021.03.008	True	Kuzmina et al. (2021)	n/a	This variant showed no change in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	syncytium formation	n/a	n/a	Kim	2021	doi:10.3390/v13040633	pmid:33917138	https://doi.org/10.3390/v13040633	True	Kim et al. (2021)	n/a	Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, no change relative to D614G.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	trafficking	n/a	n/a	Kim	2021	doi:10.3390/v13040633	pmid:33917138	https://doi.org/10.3390/v13040633	True	Kim et al. (2021)	n/a	More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~13x, Vero ~10x, and Calu-3 ~10x. Compare to wild type at ~5x across cell types.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	trafficking	n/a	n/a	Kim	2021	doi:10.3390/v13040633	pmid:33917138	https://doi.org/10.3390/v13040633	True	Kim et al. (2021)	n/a	~4x more efficient S2 domain cleavage compared to wild type, no change relative to D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	trafficking	n/a	n/a	Kuzmina	2021	doi:10.1016/j.chom.2021.03.008	pmid:33789085	https://doi.org/10.1016/j.chom.2021.03.008	True	Kuzmina et al. (2021)	n/a	9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	trafficking	n/a	n/a	Kim	2021	doi:10.3390/v13040633	pmid:33917138	https://doi.org/10.3390/v13040633	True	Kim et al. (2021)	n/a	More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~9x, Vero ~8x, and Calu-3 ~8x. Compare to wild type at ~5x across cell types.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	trafficking	n/a	n/a	Tada	2021	doi:10.1101/2021.02.05.430003	pmid:33564768	https://doi.org/10.1101/2021.02.05.430003	False	Tada et al. (2021)	n/a	Lentiviral pseudotyped with the key mutations from COH.20G/677H lineage was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing no significant change in infection rate amongst the cells, suggesting that this  mutation does not contributing to cell entry fitness.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma binding	n/a	n/a	Tada	2021	doi:10.1101/2021.02.05.430003	pmid:33564768	https://doi.org/10.1101/2021.02.05.430003	False	Tada et al. (2021)	n/a	Lentiviral pseudotyped with the key mutations from COH.20G/677H ('Ohio') lineage was neutralized similarly to D614G in 10 convalescent sera from April 2020 infectees.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Tada	2021	doi:10.1101/2021.02.05.430003	pmid:33564768	https://doi.org/10.1101/2021.02.05.430003	False	Tada et al. (2021)	n/a	Lentiviral pseudotyped with the key mutations from COH.20G/677H lineage was tested on ACE2.293T cells for ACE2 affinity changes vs D614G alone, showing a ~70% drop in IC50 (i.e. increased affinity).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	anthropozoonotic events	n/a	n/a	Rathnasinghe	2021	doi:10.1101/2021.01.19.21249592	pmid:33501468	https://doi.org/10.1101/2021.01.19.21249592	False	Rathnasinghe et al. (2021)	n/a	Mouse-adapted SARS-CoV-2 mutations after 11 serial passages in various immunocompromised mice strains.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	This variant combination (representing P.1 aka Gamma)  showed a 1.3x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	This variant combination (representing P.1 aka Gamma)  showed a 1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.27x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing P.1 aka Gamma)  showed a 4.24x increase in binding (KD) relative to D614G.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	This variant combination (representing B.1.351 aka Beta)  showed a 1.04x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset, in contrast to the largely positive binding values for each individual mutation that comprises the set.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing B.1.351 aka Beta)  showed a 3.56x increase in binding (KD) relative to D614G.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	This variant combination (representing B.1.351 aka Beta)  showed a 1.28x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. It shows a 1.17x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing B.1.1.7 aka Alpha) had 5.43x increased binding relative to D614G alone.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	This variant combination (representing B.1.1.7 aka Alpha) showed a 1.15x increase in Spike binding  (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	This variant combination (representing B.1.1.7 aka Alpha) showed no change in Spike binding  (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.28x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of  Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.52x increase in binding (KD) relative to D614G, mostly due to decreased in 'off-rate' a.k.a. dissociation rate (Kdis). Compare to full Spike variant complements for major lineages containing this variant subset: 5.43x (B.1.1.7 aka Alpha), 3.56x (B.1.351 aka Beta), 4.24x (P.1 aka Gamma).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	1.65x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23063	N501Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A1501T	p.N501Y	NC_045512.2(GU280_gp02):g.1501A>T	YP_009724390.1:p.Asn501Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	1.17x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23075	Y505H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	C	g.T1513C	p.Y505H	NC_045512.2(GU280_gp02):g.1513T>C	YP_009724390.1:p.Tyr505His	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron BA.2 have higher sensitivity to inhibition by soluble angiotensin converting enzyme 2 (ACE2) and the endosomal inhibitor chloroquine compared  to D614G	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23075	Y505H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	C	g.T1513C	p.Y505H	NC_045512.2(GU280_gp02):g.1513T>C	YP_009724390.1:p.Tyr505His	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs Bi-Nab35B5-47D10. Omicron BA.2 has an IC50 fold change of 0.07x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23075	Y505H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	C	g.T1513C	p.Y505H	NC_045512.2(GU280_gp02):g.1513T>C	YP_009724390.1:p.Tyr505His	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs 35B5. Omicron BA.2 has an IC50 fold change of 0.09x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23075	Y505H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	C	g.T1513C	p.Y505H	NC_045512.2(GU280_gp02):g.1513T>C	YP_009724390.1:p.Tyr505His	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs 47D10. Omicron BA.2 has an IC50 fold change of 0.08x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23075	Y505H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	C	g.T1513C	p.Y505H	NC_045512.2(GU280_gp02):g.1513T>C	YP_009724390.1:p.Tyr505His	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs Bi-Nab47D10-35B5. Omicron BA.2 has an IC50 fold change of 0.04x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23075	Y505H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	C	g.T1513C	p.Y505H	NC_045512.2(GU280_gp02):g.1513T>C	YP_009724390.1:p.Tyr505His	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron BA.2 neutralization of the Omicron variants by antibodies induced by three doses of Pfizer/BNT162b2 mRNA vaccine was 7-8-fold less potent than the D614G, and  the Omicron variants still evade neutralization more efficiently.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23075	Y505H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	C	g.T1513C	p.Y505H	NC_045512.2(GU280_gp02):g.1513T>C	YP_009724390.1:p.Tyr505His	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Kumar	2022	doi:10.1101/2022.05.13.491770	n/a	https://doi.org/10.1101/2022.05.13.491770	False	Kumar et al. (2022)	n/a	BnAb 002-S21F2 IC50 on the Omicron BA.2 variant is 0.8x fold the wildtype.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23075	Y505H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	C	g.T1513C	p.Y505H	NC_045512.2(GU280_gp02):g.1513T>C	YP_009724390.1:p.Tyr505His	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.2 (from South Africa/CERI-KRISP-K032307/2021) were 3.9x-fold lower (95% CI: 0.14x-0.17x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23075	Y505H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	C	g.T1513C	p.Y505H	NC_045512.2(GU280_gp02):g.1513T>C	YP_009724390.1:p.Tyr505His	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Uhal B	2022	doi:10.1101/2022.06.23.497326	n/a	https://doi.org/10.1101/2022.06.23.497326	False	Uhal B et al. (2022)	n/a	L27, V34 and E90 mutation resulted in ultrahigh affinity binding of the LVE-ACE-2 domain to the widest variety of VOCs, with KDs of 78fM for binding to the Omicron  BA.2. Values were obtained with LVE-ACE-2/mAB chimeras containing the Y-T-E sequence that enhances binding to the FcRn receptor, which in turn is expected to  extend biological half-life 3-4-fold.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23075	Y505H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	C	g.T1513C	p.Y505H	NC_045512.2(GU280_gp02):g.1513T>C	YP_009724390.1:p.Tyr505His	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.2 (from South Africa/CERI-KRISP-K032307/2021) were 4.5-fold lower (95% CI: 4.3x-4.7x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23075	Y505H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	C	g.T1513C	p.Y505H	NC_045512.2(GU280_gp02):g.1513T>C	YP_009724390.1:p.Tyr505His	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.2.12.1 (from USA/NY-CDC-ASC210722700/2022) were 4.2-fold lower (95% CI: 5.8x-6.6x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23075	Y505H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	C	g.T1513C	p.Y505H	NC_045512.2(GU280_gp02):g.1513T>C	YP_009724390.1:p.Tyr505His	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.2.12.1 (from USA/NY-CDC-ASC210722700/2022) were 3.9x-fold lower (95% CI: 0.14x-0.18x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23075	Y505H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	C	g.T1513C	p.Y505H	NC_045512.2(GU280_gp02):g.1513T>C	YP_009724390.1:p.Tyr505His	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Cathcart	2021	doi:10.1101/2021.03.09.434607v9	n/a	https://doi.org/10.1101/2021.03.09.434607v9	False	Cathcart et al. (2021)	n/a	Omicron (a.k.a. B.1.1.529) Spike pseudotyped VSV and Vero E6 cells has somewhat  reduced neutralization (2.7x) vs wild type with monoclonal antibody Sotrovimab (a.k.a. VIR-7831).  [delins at 214 omitted for syntax compatibility]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23075	Y505H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	C	g.T1513C	p.Y505H	NC_045512.2(GU280_gp02):g.1513T>C	YP_009724390.1:p.Tyr505His	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Wang	2022	doi:10.1101/2022.08.11.503601	n/a	https://doi.org/10.1101/2022.08.11.503601	False	Wang et al. (2022)	n/a	Omicron breakthrough infection after 3-dose vaccination resulted in a further 3.5-fold and 2.9-fold increase of Omicron BA.1 and BA.2 neutralizing titers. Omicron  BA.4/5 showed the highest neutralization resistance of all variants tested, resulting in low geometric mean neutralizing titers in plasma samples  obtained after  the second vaccine dose (NT50	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23075	Y505H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	C	g.T1513C	p.Y505H	NC_045512.2(GU280_gp02):g.1513T>C	YP_009724390.1:p.Tyr505His	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs Bi-Nab47D10-35B5. Omicron BA.1 has an IC50 fold change of 0.08x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23075	Y505H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	C	g.T1513C	p.Y505H	NC_045512.2(GU280_gp02):g.1513T>C	YP_009724390.1:p.Tyr505His	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron B.1.1.529 (BA.1) neutralization of the Omicron variants by antibodies induced by three doses of Pfizer/BNT162b2 mRNA vaccine was 7-8-fold less potent than  the D614G, and the Omicron variants still evade neutralization more efficiently.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23075	Y505H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	C	g.T1513C	p.Y505H	NC_045512.2(GU280_gp02):g.1513T>C	YP_009724390.1:p.Tyr505His	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron (B.1.1.529 [BA.1]) have higher sensitivity to inhibition by soluble angiotensin converting enzyme 2 (ACE2) and the endosomal inhibitor chloroquine compared  to D614G	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23075	Y505H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	C	g.T1513C	p.Y505H	NC_045512.2(GU280_gp02):g.1513T>C	YP_009724390.1:p.Tyr505His	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs Bi-Nab35B5-47D10. Omicron BA.1 has an IC50 fold change of 0.30x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23075	Y505H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	C	g.T1513C	p.Y505H	NC_045512.2(GU280_gp02):g.1513T>C	YP_009724390.1:p.Tyr505His	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Uhal B	2022	doi:10.1101/2022.06.23.497326	n/a	https://doi.org/10.1101/2022.06.23.497326	False	Uhal B et al. (2022)	n/a	Paradigms’ ACE-2 variant LVE/STR chimera binds to SARS-2 Omicron variant B.1.1.529 spike protein trimer with high affinity. Determined using Surrogate Viral Neutralization Tests.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23075	Y505H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	C	g.T1513C	p.Y505H	NC_045512.2(GU280_gp02):g.1513T>C	YP_009724390.1:p.Tyr505His	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Uhal B	2022	doi:10.1101/2022.06.23.497326	n/a	https://doi.org/10.1101/2022.06.23.497326	False	Uhal B et al. (2022)	n/a	L27, V34 and E90 mutation resulted in ultrahigh affinity binding of the LVE-ACE-2 domain to the widest variety of VOCs, with KDs of 73 pM for binding to the Omicron  B.1.1.529. Values were obtained with LVE-ACE-2/mAB chimeras containing the Y-T-E sequence that enhances binding to the FcRn receptor, which in turn is expected to  extend biological half-life 3-4-fold.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23075	Y505H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	C	g.T1513C	p.Y505H	NC_045512.2(GU280_gp02):g.1513T>C	YP_009724390.1:p.Tyr505His	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs 35B5. Omicron BA.1 has an IC50 fold change of 0.38x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23075	Y505H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	C	g.T1513C	p.Y505H	NC_045512.2(GU280_gp02):g.1513T>C	YP_009724390.1:p.Tyr505His	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Arora	2022	doi:10.1038/s41423-022-00870-5	pmid:35581351	https://doi.org/10.1038/s41423-022-00870-5	True	Arora et al. (2022)	n/a	All 10 individuals with 2 doses of the BNT162b2/BNT162b2 vaccine had a neutralizing titer in B.1 variant at an average of 729 NT50.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23075	Y505H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	C	g.T1513C	p.Y505H	NC_045512.2(GU280_gp02):g.1513T>C	YP_009724390.1:p.Tyr505His	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Shete	2022	doi:10.1101/2022.05.12.491584	n/a	https://doi.org/10.1101/2022.05.12.491584	False	Shete et al. (2022)	n/a	Plaque reduction neutralization test (PRNT) was used uring primary infection, post sixty daysof second dose vaccination, pre-reinfection and reinfection against Delta variant and was used to determine neutralizing antibodytitres. There was a 24.63x fold increase in antibody response from first infection to recovered and vaccinated with 2 doses (60 days). There was a 4.21x fold increase in antibody response pre-reinfection. There was a 39.27x fold increase in antibody response during reinfection.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23075	Y505H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	C	g.T1513C	p.Y505H	NC_045512.2(GU280_gp02):g.1513T>C	YP_009724390.1:p.Tyr505His	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Shete	2022	doi:10.1101/2022.05.12.491584	n/a	https://doi.org/10.1101/2022.05.12.491584	False	Shete et al. (2022)	n/a	Plaque reduction neutralization test (PRNT) was used uring primary infection, post sixty daysof second dose vaccination, pre-reinfection and reinfection against B.1 variant and was used to determine neutralizing antibodytitres. There was a 6.76x fold increase in antibody response from first infection to recovered and vaccinated with 2 doses (60 days). There was a 2.06x fold increase in antibody response pre-reinfection. There was a 8.18x fold increase in antibody response during reinfection.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23075	Y505H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	C	g.T1513C	p.Y505H	NC_045512.2(GU280_gp02):g.1513T>C	YP_009724390.1:p.Tyr505His	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Arora	2022	doi:10.1038/s41423-022-00870-5	pmid:35581351	https://doi.org/10.1038/s41423-022-00870-5	True	Arora et al. (2022)	n/a	All 10 individuals with 3 doses of the BNT162b2/BNT162b2 vaccine had a neutralizing titer in B.1 variant at an average of 3319 NT50.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23075	Y505H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	C	g.T1513C	p.Y505H	NC_045512.2(GU280_gp02):g.1513T>C	YP_009724390.1:p.Tyr505His	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Shete	2022	doi:10.1101/2022.05.12.491584	n/a	https://doi.org/10.1101/2022.05.12.491584	False	Shete et al. (2022)	n/a	Plaque reduction neutralization test (PRNT) was used uring primary infection, post sixty daysof second dose vaccination, pre-reinfection and reinfection against Omicron variant and was used to determine neutralizing antibodytitres. There was a 114.84x fold increase in antibody response from first infection to recovered and vaccinated with 2 doses (60 days). There was a 6.61x fold increase in antibody response pre-reinfection. There was a 1194.9x fold increase in antibody response during reinfection.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23075	Y505H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	C	g.T1513C	p.Y505H	NC_045512.2(GU280_gp02):g.1513T>C	YP_009724390.1:p.Tyr505His	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Kumar	2022	doi:10.1101/2022.05.13.491770	n/a	https://doi.org/10.1101/2022.05.13.491770	False	Kumar et al. (2022)	n/a	BnAb 002-S21F2 IC50 on the Omicron BA.1 variant is 1.0x fold the wildtype.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23075	Y505H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	C	g.T1513C	p.Y505H	NC_045512.2(GU280_gp02):g.1513T>C	YP_009724390.1:p.Tyr505His	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs 47D10. Omicron BA.1 has an IC50 fold change of 1.26x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23075	Y505H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	C	g.T1513C	p.Y505H	NC_045512.2(GU280_gp02):g.1513T>C	YP_009724390.1:p.Tyr505His	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron BA.3 have higher sensitivity to inhibition by soluble angiotensin converting enzyme 2 (ACE2) and the endosomal inhibitor chloroquine compared  to D614G	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23075	Y505H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	C	g.T1513C	p.Y505H	NC_045512.2(GU280_gp02):g.1513T>C	YP_009724390.1:p.Tyr505His	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron BA.3 neutralization of the Omicron variants by antibodies induced by three doses of Pfizer/BNT162b2 mRNA vaccine was 7-8-fold less potent than the D614G, and  the Omicron variants still evade neutralization more efficiently.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23075	Y505H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	C	g.T1513C	p.Y505H	NC_045512.2(GU280_gp02):g.1513T>C	YP_009724390.1:p.Tyr505His	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.3 (from South Africa/NICD-N22404/2021) were 4.2x-fold lower (95% CI: 0.15x-0.20x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23075	Y505H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	C	g.T1513C	p.Y505H	NC_045512.2(GU280_gp02):g.1513T>C	YP_009724390.1:p.Tyr505His	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.3 (from South Africa/NICD-N22404/2021) were 6.2-fold lower (95% CI: 11.8x-14.3x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23075	Y505H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	C	g.T1513C	p.Y505H	NC_045512.2(GU280_gp02):g.1513T>C	YP_009724390.1:p.Tyr505His	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Hao	2022	doi:10.1101/2022.08.12.22278720	pmid:36032965	https://doi.org/10.1101/2022.08.12.22278720	False	Hao et al. (2022)	n/a	paired testing of vaccine sera against ancestral virus compared to Omicron BA.1 shows that 3-dose vaccine regimen provides over 50x fold increase in protection against Omicron(B.1.1.529 [BA.1]) compared to a 2-dose regimen.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23075	Y505H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	C	g.T1513C	p.Y505H	NC_045512.2(GU280_gp02):g.1513T>C	YP_009724390.1:p.Tyr505His	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Wang	2022	doi:10.1101/2022.08.11.503601	n/a	https://doi.org/10.1101/2022.08.11.503601	False	Wang et al. (2022)	n/a	4th antigenic exposure with Omicron (B.1.1.529 [BA.1])(n	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23075	Y505H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	C	g.T1513C	p.Y505H	NC_045512.2(GU280_gp02):g.1513T>C	YP_009724390.1:p.Tyr505His	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.1 (from Botswana/R40B59_BHP_3321001248/2021) were 3.4-fold lower (95% CI: 3.2x-3.6x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23075	Y505H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	C	g.T1513C	p.Y505H	NC_045512.2(GU280_gp02):g.1513T>C	YP_009724390.1:p.Tyr505His	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.1 (from Botswana/R40B59_BHP_3321001248/2021) were 28.7x-fold lower (95% CI: 0.03x-0.05) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23075	Y505H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	C	g.T1513C	p.Y505H	NC_045512.2(GU280_gp02):g.1513T>C	YP_009724390.1:p.Tyr505His	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.4/5 (from ) were 17.2x-fold lower (95% CI: 0.6x-0.7x) than against 208-428 972-1834 4.3-4.7 US-WA1/2020 usiong an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23075	Y505H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	C	g.T1513C	p.Y505H	NC_045512.2(GU280_gp02):g.1513T>C	YP_009724390.1:p.Tyr505His	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.4/5 (from ) were 13.0-fold lower (95% CI: 4.2x-4.6x) than against 208-428 972-1834 4.3-4.7 US-WA1/2020 usiong an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23075	Y505H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	C	g.T1513C	p.Y505H	NC_045512.2(GU280_gp02):g.1513T>C	YP_009724390.1:p.Tyr505His	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  XD (from ) were 1.5x-fold lower (95% CI: 0.05x-0.07x) than against 208-428 972-1834 4.3-4.7 US-WA1/2020 usiong an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23075	Y505H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	C	g.T1513C	p.Y505H	NC_045512.2(GU280_gp02):g.1513T>C	YP_009724390.1:p.Tyr505His	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  XD (from ) were 4.4-fold lower (95% CI: 4.3x-4.7x) than against 208-428 972-1834 4.3-4.7 US-WA1/2020 usiong an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23075	Y505H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	C	g.T1513C	p.Y505H	NC_045512.2(GU280_gp02):g.1513T>C	YP_009724390.1:p.Tyr505His	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Yue	2023	doi:10.1101/2023.01.03.522427	n/a	https://doi.org/10.1101/2023.01.03.522427	False	Yue et al. (2023)	n/a	The hACE2-binding affinity of XBB.1.5 RBD has a dissociation constant KD of 3.4 nM, where S486P is the distinguishing Spike mutation vs parent  XBB.1 RBD with a much weaker KD (19 nM), as measured by surface plasmon resonance (SPR) assays.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23075	Y505H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	C	g.T1513C	p.Y505H	NC_045512.2(GU280_gp02):g.1513T>C	YP_009724390.1:p.Tyr505His	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Zhang	2022	doi:10.1101/2022.06.05.493249	n/a	https://doi.org/10.1101/2022.06.05.493249	False	Zhang et al. (2022)	n/a	Using molecular dynamics simulation, ACE2-RBD (Omicron) complex is destabilized by the E484A and Y505H mutations and stabilized by S477N and N501Y mutations.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23075	Y505H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	C	g.T1513C	p.Y505H	NC_045512.2(GU280_gp02):g.1513T>C	YP_009724390.1:p.Tyr505His	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	gene expression increase	n/a	n/a	Starr	2020	doi:10.1016/j.cell.2020.08.012	pmid:32841599	https://doi.org/10.1016/j.cell.2020.08.012	True	Starr et al. (2020)	n/a	Experimentally, Spike gene expression increased 0.16 fold	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23075	Y505H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	C	g.T1513C	p.Y505H	NC_045512.2(GU280_gp02):g.1513T>C	YP_009724390.1:p.Tyr505His	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	anthropozoonotic events	n/a	n/a	McAloose	2020	doi:10.1128/mBio.02220-20	pmid:33051368	https://doi.org/10.1128/mBio.02220-20	True	McAloose et al. (2020)	n/a	Observed first in a single tiger (cohort of 5), potential adaptation.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23166	K535T	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	C	g.A1604C	p.K535T	NC_045512.2(GU280_gp02):g.1604A>C	YP_009724390.1:p.Lys535Thr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	Pokay	n/a	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	n/a	n/a	n/a	n/a	n/a	n/a
23222	E554K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	A	g.G1660A	p.E554K	NC_045512.2(GU280_gp02):g.1660G>A	YP_009724390.1:p.Glu554Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	Pokay	n/a	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	n/a	n/a	n/a	n/a	n/a	n/a
23271	A570V	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1709T	p.A570V	NC_045512.2(GU280_gp02):g.1709C>T	YP_009724390.1:p.Ala570Val	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	Pokay	n/a	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	n/a	n/a	n/a	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Zhou	2021	doi:10.1101/2021.03.24.436620	pmid:33791698	https://doi.org/10.1101/2021.03.24.436620	False	Zhou et al. (2021)	n/a	Subtype of the B.1.526 'New York' lineage, lentivirus pseudotyped with this mutation combination in showed no significant change in IC50 serum dilution concentration for sera from BNT162b2 (Pzifer) or mRNA1273 (Moderna) vacinees collected 28 days following booster dose.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Choi	2021	doi:10.1101/2021.06.28.449914	n/a	https://doi.org/10.1101/2021.06.28.449914	False	Choi et al. (2021)	n/a	Neutralization efficiency (ID50) against B.1.526 reduced 2.3x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma binding	n/a	n/a	Zhou	2021	doi:10.1101/2021.03.24.436620	pmid:33791698	https://doi.org/10.1101/2021.03.24.436620	False	Zhou et al. (2021)	n/a	Subtype of the B.1.526 'New York' lineage, lentivirus pseudotyped with this mutation combination in showed no significant  change in IC50 serum dilution concentration for 6 convalescent sera.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Zhou	2021	doi:10.1101/2021.03.24.436620	pmid:33791698	https://doi.org/10.1101/2021.03.24.436620	False	Zhou et al. (2021)	n/a	Subtype of the B.1.526 'New York' lineage, lentivirus pseudotyped with this mutation combination in showed 3.6x reduction in both IC50 serum dilution concentration for sera from 5 BNT162b2 (Pzifer) or 3 mRNA1273 (Moderna) vacinees collected 28 days following booster dose.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Pegu	2021	doi:10.1101/2021.05.13.444010	pmid:34031659	https://doi.org/10.1101/2021.05.13.444010	False	Pegu et al. (2021)	n/a	Detectable antibodies against B.1.526+E484K at various time points using pseudotyped lentivirus neutralization in Moderna vaccinee cohort: Day 43 100%, Day 209 88%.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	2.3x reduction in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees)	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma binding	n/a	n/a	Zhou	2021	doi:10.1101/2021.03.24.436620	pmid:33791698	https://doi.org/10.1101/2021.03.24.436620	False	Zhou et al. (2021)	n/a	Subtype of the B.1.526 'New York' lineage, lentivirus pseudotyped with this mutation combination in showed 3.8x reduction in  IC50 serum dilution concentration for 6 convalescent sera.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Arora	2022	doi:10.1038/s41423-022-00870-5	pmid:35581351	https://doi.org/10.1038/s41423-022-00870-5	True	Arora et al. (2022)	n/a	Out of 10 individuals with 3 doses of the BNT162b2/BNT162b2/BNT162b2 vaccine had a neutralizing titer in B.1.640.2 variant was ~5.6x folds more significant in 9  individuals.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Arora	2022	doi:10.1038/s41423-022-00870-5	pmid:35581351	https://doi.org/10.1038/s41423-022-00870-5	True	Arora et al. (2022)	n/a	Out of 10 individuals with 2 doses of the BNT162b2/BNT162b2 vaccine, neutralizing titer in B.1.640.2 variant was ~1000x folds more significant in 8 individuals.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron BA.2 have higher sensitivity to inhibition by soluble angiotensin converting enzyme 2 (ACE2) and the endosomal inhibitor chloroquine compared  to D614G	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs Bi-Nab35B5-47D10. Omicron BA.2 has an IC50 fold change of 0.07x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs 35B5. Omicron BA.2 has an IC50 fold change of 0.09x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs 47D10. Omicron BA.2 has an IC50 fold change of 0.08x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs Bi-Nab47D10-35B5. Omicron BA.2 has an IC50 fold change of 0.04x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron BA.2 neutralization of the Omicron variants by antibodies induced by three doses of Pfizer/BNT162b2 mRNA vaccine was 7-8-fold less potent than the D614G, and  the Omicron variants still evade neutralization more efficiently.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Kumar	2022	doi:10.1101/2022.05.13.491770	n/a	https://doi.org/10.1101/2022.05.13.491770	False	Kumar et al. (2022)	n/a	BnAb 002-S21F2 IC50 on the Omicron BA.2 variant is 0.8x fold the wildtype.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Choi	2021	doi:10.1101/2021.06.28.449914	n/a	https://doi.org/10.1101/2021.06.28.449914	False	Choi et al. (2021)	n/a	Neutralization efficiency (ID50) against B.1.1.427/429 reduced 2.1x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Pegu	2021	doi:10.1101/2021.05.13.444010	pmid:34031659	https://doi.org/10.1101/2021.05.13.444010	False	Pegu et al. (2021)	n/a	Detectable antibodies against B.1.1.7 in all samples at Day 43 and Day 209 using pseudotyped lentivirus neutralization in Moderna vaccinee cohort.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Garcia-Beltran	2021	doi:10.1016/j.cell.2021.03.013	pmid:33743213	https://doi.org/10.1016/j.cell.2021.03.013	True	Garcia-Beltran et al. (2021)	n/a	Pseudotyped B.1.1.429 virus has reduced neutralization activity vs wild type: 2.0x (30 sera Pfizer median 9  days post 2nd dose, 35 sera Moderna median 18 days post 2nd dose). This was NOT significant by ANOVA.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Uriu	2021	doi:10.1101/2021.09.06.459005	n/a	https://doi.org/10.1101/2021.09.06.459005	False	Uriu et al. (2021)	n/a	Mean 2.7x reduction of NT50 value B.1.427 (Epsilon) relative to wild type in 8 sera from older convalescent patients (52-92yo) collected 1-3m post symptom onset.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Deng	2021	doi:10.1101/2021.03.07.21252647	pmid:33758899	https://doi.org/10.1101/2021.03.07.21252647	False	Deng et al. (2021)	n/a	6 of 11 (55%) vaccine recipients (Moderna or Pfizer), showed 2x reduction in neutralization to a B.1.429 lineage virus.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Uriu	2021	doi:10.1101/2021.09.06.459005	n/a	https://doi.org/10.1101/2021.09.06.459005	False	Uriu et al. (2021)	n/a	Mean 2.3x reduction of NT50 value B.1.427 (Epsilon) relative to wild type in 8 sera from adult BNT162b2 vaccinees (28-47yo) collected ~1m post booster.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Tarke	2021	doi:10.1101/2021.02.27.433180	pmid:33688655	https://doi.org/10.1101/2021.02.27.433180	False	Tarke et al. (2021)	n/a	PBMCs of Pfizer/BioNTech BNT162b2 (n	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	virion structure	n/a	n/a	Wang	2021	doi:10.1101/2021.03.01.433466	pmid:33688656	https://doi.org/10.1101/2021.03.01.433466	False	Wang et al. (2021)	n/a	CryoEM reveals the P.1 trimer to adopt exclusively a conformation in which one of the receptor-binding domains is in the “up” position.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Wang	2021	doi:10.1101/2021.03.01.433466	pmid:33688656	https://doi.org/10.1101/2021.03.01.433466	False	Wang et al. (2021)	n/a	In 12 Moderna vaccinee sera 15 days post second dose (43 days since first vaccination), an average 2.8x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 4.8x decrease against the full P.1 type vs WA-1 was observed, though overall with  a higher ID50 reciprocal value. In 10 Pfizer vaccinee sera 7 days or more post second dose (28 days or more since first vaccination), an average 2.2x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.8x decrease against the full P.1 type vs WA-1 was observed, with  similar variant ID50 reciprocal value.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Wang	2021	doi:10.1101/2021.03.01.433466	pmid:33688656	https://doi.org/10.1101/2021.03.01.433466	False	Wang et al. (2021)	n/a	In convalescent sera one month or more post-infection in Spring 2020, an average 6.5x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.4x decrease against the full P.1 type vs WA-1 was observed, with  better full P.1 ID50 reciprocal value compared to the 10-mutation model.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Wang	2021	doi:10.1101/2021.03.01.433466	pmid:33688656	https://doi.org/10.1101/2021.03.01.433466	False	Wang et al. (2021)	n/a	Amongst RBD-targeting Emergency Use Authorized monoclonal antibody treatments CB6, LY-CoV555 and REGN10933 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1, but REGN10987 activity remains strong. RBD-targeting monoclonal antibodies 2-15 and C121 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1. N terminal domain targeting monoclonal antibodies 5-7, 4-8, 4-18 and 2-17 have abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	reinfection	n/a	n/a	Malta Romano	2021	doi:10.1590/S1678-9946202163036	pmid:33909850	https://doi.org/10.1590/S1678-9946202163036	True	Malta Romano et al. (2021)	n/a	After a 128 day interval, a patient in Sao Paulo State, Brazil reinfected with P.1 (first episode likely predates P.1 emergence). Both cases were fairly mild (difficulty breathing, tiredness, dizziness and fatigue).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine efficacy	n/a	n/a	Bruxvoort	2021	doi:10.1101/2021.09.29.21264199	n/a	https://doi.org/10.1101/2021.09.29.21264199	False	Bruxvoort et al. (2021)	n/a	In a 1:5 test-negative matched control study of 8153 individuals who received the Moderna mRNA-1273 vaccine, 349 test-positive were Gamma. Two dose vaccine efficacy against Gamma was 95.5 (90.9-97.8%), one dose VE was 74.2 (43.8-88.1%).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	trafficking	n/a	n/a	Esclera	2021	doi:10.1101/2021.08.05.455290	n/a	https://doi.org/10.1101/2021.08.05.455290	False	Esclera et al. (2021)	n/a	~6x cleavage of S2 relative to WA1 (D614G) wildtype by Gamma variant as measured by mass spectrometry of Vero-TMPRSS culture  [no mutations directly at furin cleavage site, but H655Y is upstream] Compare to 4.5x or less for variants of concern with  direct furin clevage site mutations.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	reinfection	n/a	n/a	Naveca	2021	doi:10.21203/rs.3.rs-318392/v1	n/a	https://doi.org/10.21203/rs.3.rs-318392/v1	False	Naveca et al. (2021)	n/a	Three healthcare workers (29-50yo) had confirmed P.1 [Gamma] re-infection in the Amazonas region of Brazil 3-9 months after initial  infection from viruses with distinct lineage from P.1, but mild symptoms upon re-infection and evidence for infectiousness during re-infection.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Uriu	2021	doi:10.1101/2021.09.06.459005	n/a	https://doi.org/10.1101/2021.09.06.459005	False	Uriu et al. (2021)	n/a	Mean 3.0x reduction of NT50 value P.1 (Gamma) relative to wild type in 8 sera from adult BNT162b2 vaccinees (28-47yo) collected ~1m post booster.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Uriu	2021	doi:10.1101/2021.09.06.459005	n/a	https://doi.org/10.1101/2021.09.06.459005	False	Uriu et al. (2021)	n/a	Mean 4.1x reduction of NT50 value P.1 (Gamma) relative to wild type in 8 sera from older convalescent patients (52-92yo) collected 1-3m post symptom onset.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Kumar	2022	doi:10.1101/2022.05.13.491770	n/a	https://doi.org/10.1101/2022.05.13.491770	False	Kumar et al. (2022)	n/a	BnAb 002-S21F2 IC50 on the Gamma (P.1) variant is 0.6x fold the wildtype.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Chen	2021	doi:10.1038/s41591-021-01294-w	pmid:33664494	https://doi.org/10.1038/s41591-021-01294-w	True	Chen et al. (2021)	n/a	The neutralizing activity of vaccine was slightly lower against B.1.1.248 variant constellation in sera tested from most of the 15 patients with  the BNT162b2 mRNA vaccine. (Fig. 4)	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Gallagher	2021	doi:10.1101/2021.05.03.442455	pmid:33972942	https://doi.org/10.1101/2021.05.03.442455	False	Gallagher et al. (2021)	n/a	ELISpot assays show T cell neutralization reduced by 16.6% in this B.1.1.248 pseudotype relative to wild type in 18-20 pooled patient samples post second mRNA vaccine dose, with no significant difference between Pfizer and Moderna cohorts. Reduction was stronger in the S1 subunit than S2 (separate peptide pools were used).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Chen	2021	doi:10.1038/s41591-021-01294-w	pmid:33664494	https://doi.org/10.1038/s41591-021-01294-w	True	Chen et al. (2021)	n/a	B.1.1.248 variant constellation ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07. B.1.1.248 variant constellation ablates Class 3 N-terminal domain targeting antibody COV2-2676.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Chen	2021	doi:10.1038/s41591-021-01294-w	pmid:33664494	https://doi.org/10.1038/s41591-021-01294-w	True	Chen et al. (2021)	n/a	B.1.1.7 variant constellation two-tailed Wilcoxon matched-pairs signed-rank test against 10 convalescent sera P	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	anthropozoonotic events	n/a	n/a	Montagutelli	2021	doi:10.1101/2021.03.18.436013	n/a	https://doi.org/10.1101/2021.03.18.436013	False	Montagutelli et al. (2021)	n/a	Unlike wild type or B.1.1.7, P.1 lineage virus was able to infect and replicate in common lab mouse strains, with high titer.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Chen	2021	doi:10.1038/s41591-021-01294-w	pmid:33664494	https://doi.org/10.1038/s41591-021-01294-w	True	Chen et al. (2021)	n/a	B.1.1.248 variant constellation in 10 convalescent human sera ~1mo post infection had mild to moderate resistance against most samples, P	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Leier	2021	doi:10.1101/2021.04.25.21256049	pmid:33948601	https://doi.org/10.1101/2021.04.25.21256049	False	Leier et al. (2021)	n/a	Neutralizing antibody titers increased in previously infected vaccinees relative to uninfected vaccinees  4.3-fold against P.1 (contrast with 3.4 fold against original SARS-CoV-2).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Garcia-Beltran	2021	doi:10.1016/j.cell.2021.03.013	pmid:33743213	https://doi.org/10.1016/j.cell.2021.03.013	True	Garcia-Beltran et al. (2021)	n/a	Pseudotyped P.1 virus has reduced neutralization activity vs wild type: 6.7x (30 sera Pfizer median 9 days post 2nd dose)  and 4.5x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Dejnirattisai	2021	doi:10.1016/j.cell.2021.03.055	pmid:33852911	https://doi.org/10.1016/j.cell.2021.03.055	True	Dejnirattisai et al. (2021)	n/a	P.1 virus neutralization (as tested using biolayer interferometry) of both Lilly antibodies was severely impacted,  with Lilly mAb combination LY-CoV16 and LY-CoV555  (due to mutations at 416 and 484 respectively) shows almost complete loss of neutralization of P.1.  There was also escape from neutralization of P.1 by REGN10933 (one of 2 in Regeneron's mAb cocktail)  and a modest reduction in neutralization of P.1 by AstraZeneca's AZD8895 (while AZD1061 and AZD7442 showed  equal neutralization of all SARS-CoV-2 variants tested). The three Adagio antibodies neutralized P.1 with all reaching a plateau at 100% neutralization: interestingly, ADG30  showed a slight increase of neutralization of P.1. S309 Vir was largely unaffected, although for several viruses, including P.1, the antibody failed to completely  neutralize, conceivably reflecting incomplete glycosylation at N343, since the sugar interaction is key to binding of this antibody.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Dejnirattisai	2021	doi:10.1016/j.cell.2021.03.055	pmid:33852911	https://doi.org/10.1016/j.cell.2021.03.055	True	Dejnirattisai et al. (2021)	n/a	P.1 lineage titers were reduced 7.6-fold and 9-fold for the BNT162b2 Pfizer (sera collected 4-14 days post-booster)  and ChAdOx1 nCoV-19 AstraZeneca (sera collected 14 or 28 days post-booster) vaccines respectively.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Luftig	2021	doi:10.1056/NEJMc2104036	pmid:33826815	https://doi.org/10.1056/NEJMc2104036	True	Luftig et al. (2021)	n/a	In sera 1-2 weeks after BNT162b2 first dose, from six patients previously infected with B.1, antibody titer in a microneutralization assay  was on average 2896 for P.1 virus. This compares favorably (stronger) to post-infection neutralization titer against all variants tested in the same sera (wild type, B.1.1.7, B.1.351, and P.1).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma binding	n/a	n/a	Luftig	2021	doi:10.1056/NEJMc2104036	pmid:33826815	https://doi.org/10.1056/NEJMc2104036	True	Luftig et al. (2021)	n/a	In sera from six patients collected 1 to 12 weeks post-infection with B.1, antibody titer in a microneutralization assay was on average 256 for B.1.1.7 virus. Compare to somewhat stronger neutralization titer for wild type (456.1) in the same sera.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Pegu	2021	doi:10.1101/2021.05.13.444010	pmid:34031659	https://doi.org/10.1101/2021.05.13.444010	False	Pegu et al. (2021)	n/a	Detectable antibodies against P.1 at various time points using pseudovirus neutralization in Moderna vaccinee cohort: Day 43 100%, Day 209 85%.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	T cell evasion	n/a	n/a	Tarke	2021	doi:10.1101/2021.02.27.433180	pmid:33688655	https://doi.org/10.1101/2021.02.27.433180	False	Tarke et al. (2021)	n/a	PBMCs of 11 mild COVID-19 patients collected 38-80 days after symptom onset were stimulated with the 15-mer peptide pools (w/ 10 residue overlaps) from the wholle viral proteome,  showing no significant CD4+ cell count effect for P.1,  and a slight increase in CD8+ percentage (p	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	transmissibility	n/a	n/a	Stefanelli	2021	doi:10.1101/2021.04.06.21254923	n/a	https://doi.org/10.1101/2021.04.06.21254923	False	Stefanelli et al. (2021)	n/a	The relative transmissibility of P.1 estimated at the national level (Italy) varied according to the assumed  degree of cross-protection granted by infection with other lineages and ranged from 1.12 (95%CI 1.03-1.23) in the  case of complete immune evasion by P.1 to 1.39 (95%CI 1.26-1.56) in the case of complete cross-protection. PG: variant list has been abbreviated due to mixed K417 bases in this lineage, potential miscalls of deletions	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Schmidt	2021	doi:10.1101/2021.08.06.455491	n/a	https://doi.org/10.1101/2021.08.06.455491	False	Schmidt et al. (2021)	n/a	Artificially constructed HIV-1 pseudovirus with set of mutations drawn from plasma passage escape experiments and mutations from variants of concern completely ablates neutralization in 19 of 21 convalescents plasma collected mean 1.3 months post infection. [actual Y145del from manuscript substituted with more common Y144del description]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Andrade	2021	doi:10.1101/2021.04.14.439719	n/a	https://doi.org/10.1101/2021.04.14.439719	False	Andrade et al. (2021)	n/a	In human sera 8 weeks post-vaccination with INO-4800, a ~7-fold reduction in B.1.351 neutralization was observed.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Riddell	2021	doi:10.1101/2021.04.17.440246	n/a	https://doi.org/10.1101/2021.04.17.440246	False	Riddell et al. (2021)	n/a	Four fold reduction in neutralization efficiency was observed in sera of ferrets post-vaccination with  INO-4800 (DNA plasmid pGX9501 encoding full length Spike).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Wu	2021	doi:10.1101/2021.04.13.439482	pmid:33880468	https://doi.org/10.1101/2021.04.13.439482	False	Wu et al. (2021)	n/a	Monovalent mRNA-1273.351 encodes for the S protein found in the B.1.351 lineage and (2) mRNA-1273.211 comprising a 1:1 mix of mRNA-1273 and mRNA-1273.351.  In a mouse study, primary vaccination series of mRNA-1273.351 was effective at increasing neutralizing antibody titers against the B.1.351 lineage,  while mRNA-1273.211 was most effective at providing broad cross-variant neutralization. In addition, these results demonstrated a third dose of  mRNA-1273.351 significantly increased both wild-type and B.1.351-specific neutralization titers.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kustin	2021	doi:10.1101/2021.04.06.21254882	n/a	https://doi.org/10.1101/2021.04.06.21254882	False	Kustin et al. (2021)	n/a	Pzifer vaccinees that tested positive at least a week after the second dose were indeed disproportionally infected with B.1.351,  as compared with unvaccinated individuals (odds ratio of 8:1), but were all infected before 14 days post second vaccination.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Uriu	2021	doi:10.1101/2021.09.06.459005	n/a	https://doi.org/10.1101/2021.09.06.459005	False	Uriu et al. (2021)	n/a	Mean 8.2x reduction of NT50 value B.1.351 (Beta) relative to wild type in 8 sera from older convalescent patients (52-92yo) collected 1-3m post symptom onset.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Uriu	2021	doi:10.1101/2021.09.06.459005	n/a	https://doi.org/10.1101/2021.09.06.459005	False	Uriu et al. (2021)	n/a	Mean 6.3x reduction of NT50 value B.1.351 (Beta) relative to wild type in 8 sera from adult BNT162b2 vaccinees (28-47yo) collected ~1m post booster.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Skelly	2021	doi:10.21203/rs.3.rs-226857/v1	n/a	https://doi.org/10.21203/rs.3.rs-226857/v1	False	Skelly et al. (2021)	n/a	In over 90% of two dose mRNA vaccinees, heterotypic neutralizing titres (NT50) against B.1.1.7 and B.1.351 remain comfortably  above the level associated with immune protection in recent vaccine trials. However, in over 50% of convalescent COVID-19  individuals (5/9) and recipients of a only a single dose of mRNA vaccine (10/11) – heterotypic neutralization dropped to negligible levels,  particularly against B.1.351.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma binding	n/a	n/a	Luftig	2021	doi:10.1056/NEJMc2104036	pmid:33826815	https://doi.org/10.1056/NEJMc2104036	True	Luftig et al. (2021)	n/a	In sera from six patients collected 1 to 12 weeks post-infection with B.1, antibody titer in a microneutralization assay was on average 8 for B.1.351 virus. Compare to much stronger neutralization titers for B.1.1.7 (256) and wild type (456.1) in the same sera.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Bates	2021	doi:10.1101/2021.04.04.21254881	pmid:33851185	https://doi.org/10.1101/2021.04.04.21254881	False	Bates et al. (2021)	n/a	Observed 8.8-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose) against cultured B.1.351 sample. Contrast this with 1.4-fold reduction for just the pseudovirus combination of 'key' B.1.351 mutations K417N+E484K+N501Y. WA1 and B.1.351 FRNT50 titers correlated weakly at the individual level, with some individual’s serum potently neutralizing WA1 while having FRNT50 for B.1.351 below the assay limit of detection (1:20).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma binding	n/a	n/a	UNKNOWN	2021	n/a	n/a	https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1009243/Technical_Briefing_20.pdf	False	UNKNOWN et al. (2021)	n/a	Sera from individuals who have been infected with Delta does not have strong neutralising activity against Beta.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Planas	2021	doi:10.1038/s41591-021-01318-5	n/a	https://doi.org/10.1038/s41591-021-01318-5	True	Planas et al. (2021)	n/a	Using a new rapid neutralization assay, based on reporter cells that become positive for GFP after overnight infection, sera from 58  convalescent individuals collected up to 9 months after symptoms had mean ~6x reduction in neutralizing titers, and 40% of the samples  lacked any activity against B.1.351.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	UNKNOWN	2021	n/a	n/a	https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1009243/Technical_Briefing_20.pdf	False	UNKNOWN et al. (2021)	n/a	Sera from individuals who have been vaccinated and have had subsequent recent Delta infection have a high level of neutralising activity against Beta.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Uhal B	2022	doi:10.1101/2022.06.23.497326	n/a	https://doi.org/10.1101/2022.06.23.497326	False	Uhal B et al. (2022)	n/a	Paradigm’s ACE-2 variant LVE/STR chimera neutralizes Beta Variant B.1.351 RBD significantly better than w.t. SARS-CoV-2 RBD. Determined using Surrogate Viral Neutralization Tests.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Garcia-Beltran	2021	doi:10.1016/j.cell.2021.03.013	pmid:33743213	https://doi.org/10.1016/j.cell.2021.03.013	True	Garcia-Beltran et al. (2021)	n/a	Pseudotyped B.1.351 v2 virus has reduced neutralization activity vs wild type: 41.2x (30 sera Pfizer median 9 days post 2nd dose)  and 20.8x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA. Notably, 36.7% (11/30) recipients of two-dose Pfizer and 42.9% (15/35) recipients of two-dose Moderna vaccines did not have  detectable neutralization of at least one of the B.1.351 variants.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Tada	2021	doi:10.1101/2021.02.05.430003	pmid:33564768	https://doi.org/10.1101/2021.02.05.430003	False	Tada et al. (2021)	n/a	Pseudotype lentivirus for the full B.1.351 Spike variant list shows increase affinity for ACE2 as measured by IC50. This is in contrast to B.1.1.7 which showed no major change, indicating that the shared N501Y mutation is the driver of affinity change, attentuated in the B.1.1.7 mutatioon set, but maintained in the B.1.351 lineage.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Voysey	2021	doi:10.1016/S0140-6736(20	n/a	https://doi.org/10.1016/S0140-6736(20	n/a	Voysey et al. (2021)	n/a	[Contrary to how this paper has been cited, Voysey et al. do NOT show evidence of decreased effectiveness of ChAdOx1 (AstraZeneca) against  the South African B.1.351 lineage. Insufficient numbers reaching the primary study endpoint were available in that arm of the vaccine study to report any statistics from the South African participants. Additionally, the study period of the paper ended in November 2020, while the earliest reported case of this lineage is October (covariants.org), only becoming dominant by mid-November.]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Planas	2021	doi:10.1038/s41591-021-01318-5	n/a	https://doi.org/10.1038/s41591-021-01318-5	True	Planas et al. (2021)	n/a	Flow cytometry was used on recombinant VSV proteins and yeast surface display to assess the binding of a labeled soluble ACE2  protein to cells expressing B.1.351. We observed an increase (relative to D614G) in binding of soluble  ACE2 to B.1.351, and to a much gearter extent to B.1.1.7, which both carry the N501Y mutation (see Fig 3).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Tarke	2021	doi:10.1101/2021.02.27.433180	pmid:33688655	https://doi.org/10.1101/2021.02.27.433180	False	Tarke et al. (2021)	n/a	PBMCs of Pfizer/BioNTech BNT162b2 (n	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Madhi	2021	doi:10.1056/NEJMoa2102214	pmid:33725432	https://doi.org/10.1056/NEJMoa2102214	True	Madhi et al. (2021)	n/a	Relative to B.1.1.117, PRNT50 line virus neutralizating antibody activity assay of B.1.351 showed ~11x reduction in 13 vacinees's sera  collected through 41 days after vaccination. Neutralization by a placebo control group of 6 naturally infected patients showed a smaller ~8x drop (starting from a ~50% higher PRNT50 value than vacinees for B.1.1.117 neutralization). Serum samples obtained from 13 ChAdOx1 nCoV-19 vaccine recipients without SARS-CoV-2 infection through 41 days after vaccination  showed ~4x reduction in neutralization (ID50) for full B.1.351 pseudotype HIV-1 virus compared to D614G alone. This  RBD variant combination's neutralization by a placebo control  group of 6 naturally infected patients showed a slightly higher 4.6x drop (though with D614G starting at a 1.7x higher titre than vaccinee sera).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	McEvoy C	2022	doi:10.1101/2022.06.24.22276144	n/a	https://doi.org/10.1101/2022.06.24.22276144	False	McEvoy C et al. (2022)	n/a	Log10ID50 of Beta neutralizing antibodies is 0.899x the WT 1 month post-third dose of pfizer-BioNTech BNT162b2 in 13 Kidney transplant recipients (KTR) with median  age of 55.5.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Bates	2021	doi:10.1101/2021.04.04.21254881	pmid:33851185	https://doi.org/10.1101/2021.04.04.21254881	False	Bates et al. (2021)	n/a	A 1.8-fold drop in FRNT50 for B.1.351 was observed in 44 sera collected between 1 and 301 post-infection.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	3.2x reduction in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees)	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Choi	2021	doi:10.1101/2021.06.28.449914	n/a	https://doi.org/10.1101/2021.06.28.449914	False	Choi et al. (2021)	n/a	Neutralization efficiency (ID50) against B.1.1.351-v1 reduced 6.9x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	T cell evasion	n/a	n/a	Skelly	2021	doi:10.21203/rs.3.rs-226857/v1	n/a	https://doi.org/10.21203/rs.3.rs-226857/v1	False	Skelly et al. (2021)	n/a	Encouragingly, we find that the majority of T cell responses in recipients of two doses of the BNT162b2 vaccine are generated  by epitopes that are invariant between the [wildtype] and two of the current variants of concern (B.1.1.7 and B.1.351). In over 90% of two dose mRNA vaccinees, heterotypic neutralizing titres (NT50) against B.1.1.7 and B.1.351 remain comfortably  above the level associated with immune protection in recent vaccine trials. However, in over 50% of convalescent COVID-19  individuals and recipients of a only a single dose of mRNA vaccine – heterotypic neutralization dropped to negligible levels,  particularly against B.1.351.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Wang	2021	doi:10.1038/s41586-021-03398-2	n/a	https://doi.org/10.1038/s41586-021-03398-2	True	Wang et al. (2021)	n/a	The neutralizing activity of 16/20 convalescent sera was significantly lower against this pseudotyped virus model of B.1.351, with similar results for the live virus.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	McEvoy C	2022	doi:10.1101/2022.06.24.22276144	n/a	https://doi.org/10.1101/2022.06.24.22276144	False	McEvoy C et al. (2022)	n/a	Log10ID50 of Beta neutralizing antibodies is 0.803x the WT pre-third dose of pfizer-BioNTech BNT162b2 in 13 Kidney transplant recipients (KTR) with median age of  55.5.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Wang	2021	doi:10.1038/s41586-021-03398-2	n/a	https://doi.org/10.1038/s41586-021-03398-2	True	Wang et al. (2021)	n/a	B.1.351 pseudotyped virus model ablates neutralization by RBD-directed mAbs CB6, 4-20, 2-4, 2-43, 910-30, 2-302-15, LY-Cov555, C121. B.1.351 pseudotyped virus model severely impairs neutralization by RBD-directed mAb 1-20. B.1.351 pseudotyped virus model impairs neutralization by RBD-directed mAb REGN10933. B.1.351 pseudotyped virus model ablates neutralization by N-terminal-domain-directed mAbs 5-24, 4-8, 4A8, 4-19. B.1.351 pseudotyped virus model severely impairs neutralization by N-terminal-domain-directed mAb 2-17. B.1.351 pseudotyped virus model impairs neutralization by N-terminal-domain-directed mAb 5-7. PG: Live virus data for the same mAbs is similar, but 1-20 becomes severally impaired, REGN10933 activity is ablated, and Brii-196 becomes impaired.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Wang	2021	doi:10.1038/s41586-021-03398-2	n/a	https://doi.org/10.1038/s41586-021-03398-2	True	Wang et al. (2021)	n/a	The neutralizing activity of vaccine was significantly lower against B.1.351 (12.4x in twelve Moderna-recipient sera: 10.3x in ten Pfizer-recipient sera). [this is a larger list of B.1.351 than modeled by Wang et al. (2021) by including L18F and R246I, less effective at neutralizing]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Planas	2021	doi:10.1038/s41591-021-01318-5	n/a	https://doi.org/10.1038/s41591-021-01318-5	True	Planas et al. (2021)	n/a	The sera of 16 individuals with time course collection was evaluated against VSV pseudotypes: while BD614G and B.1.1.7 were  neutralized earlier, the anti-B.1.351 response was negative up to week 3, and became detectable at week 4 (1 week after booster dose), at a level lower  than the two other viruses (~10x vs D614G) through week 6, the last timepoint measured. Three vaccinees never showed detectable neutralization to B.1.351 even after second dose.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Chonira	2022	doi:10.1101/2022.05.30.493765	pmid:35677079	https://doi.org/10.1101/2022.05.30.493765	False	Chonira et al. (2022)	n/a	DARPin SR16m molecule had a 0.036x fold change in IC50 in B.1.351 Beta	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	tissue specific neutralization	n/a	n/a	Planas	2021	doi:10.1038/s41591-021-01318-5	n/a	https://doi.org/10.1038/s41591-021-01318-5	True	Planas et al. (2021)	n/a	The nasal mucosa of Pfizer vaccinees with time course collection was evaluated against VSV pseudotypes: while B.1.1.7 and D614G showed neutralization by nasal swab from only one different previously infected vacinee neutralizing at weeks 3 and 6, B.1.351 showed zero neutralization at either time point in any sample (and relatively impaired serum neutralization).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Choi	2021	doi:10.1101/2021.06.28.449914	n/a	https://doi.org/10.1101/2021.06.28.449914	False	Choi et al. (2021)	n/a	Neutralization efficiency (ID50) against B.1.1.351-v2 reduced 7.3x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Woldemeskel	2021	doi:10.1172/JCI149335	pmid:33822770	https://doi.org/10.1172/JCI149335	True	Woldemeskel et al. (2021)	n/a	No significant difference in T-cell response to B.1.351 was observed (vs. ancestral) in blood drawn from 28 participants received the Pfizer-BioNTech vaccine  and 2 received the Moderna vaccine.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Ikegame	2021	doi:10.21203/rs.3.rs-400230/v1	pmid:33851150	https://doi.org/10.21203/rs.3.rs-400230/v1	False	Ikegame et al. (2021)	n/a	B.1.351 pseudotyped VSV was tested for neutralization in a clonal HEK-293T ACE2 TMPRSS2 cell line optimized for highly efficient  S-mediated infection. Only 1 out of 12 serum samples from a cohort of Argentinian recipients of the Gamaleya Sputnik V Ad26 / Ad5 vaccine  showed effective neutralization (IC90) at full serum strength (average realtive decrease was 6.1x vs wild type).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Chonira	2022	doi:10.1101/2022.05.30.493765	pmid:35677079	https://doi.org/10.1101/2022.05.30.493765	False	Chonira et al. (2022)	n/a	Trimeric proteins FSR22 had a 0.07x fold change in IC50 in B.1.351 Beta	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Shinde	2021	doi:10.1056/NEJMoa2103055	pmid:33951374	https://doi.org/10.1056/NEJMoa2103055	True	Shinde et al. (2021)	n/a	In a randomized phase 2a-b control trial of the Novavax (NVX-CoV2373) vaccine in South Africa, where B.1.351 virus dominates, efficacy was 60.1% (95% CI, 19.9 to 80.1) in HIV-negative and initially SARS-CoV-2 seronegative participants using the  primary endpoint of laboratory-confirmed symptomatic Covid-19 at 7 days or more after the second dose among participants.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Chonira	2022	doi:10.1101/2022.05.30.493765	pmid:35677079	https://doi.org/10.1101/2022.05.30.493765	False	Chonira et al. (2022)	n/a	DARPin SR22 molecule had a 1.57x fold change in IC50 in B.1.351 Beta	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Chonira	2022	doi:10.1101/2022.05.30.493765	pmid:35677079	https://doi.org/10.1101/2022.05.30.493765	False	Chonira et al. (2022)	n/a	Trimeric proteins FSR16m had a 0.054x fold change in IC50 in B.1.351 Beta	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Dejnirattisai	2021	doi:10.1016/j.cell.2021.03.055	pmid:33852911	https://doi.org/10.1016/j.cell.2021.03.055	True	Dejnirattisai et al. (2021)	n/a	B.1.351 virus neutralization (as tested using biolayer interferometry) of both Lilly antibodies was severely impacted, with LY-CoV16 and LY-CoV555  (due to mutations at 416 and 484 respectively) shows almost complete loss of neutralization of B.1.351. There was also escape from neutralization of B.1.351 by REGN10933 and a modest reduction in neutralization of B.1.351 by AZD8895  (while AZD1061 and AZD7442 showed equal neutralization of all SARS-CoV-2 variants tested). The three Adagio antibodies neutralized B.1.351.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Chonira	2022	doi:10.1101/2022.05.30.493765	pmid:35677079	https://doi.org/10.1101/2022.05.30.493765	False	Chonira et al. (2022)	n/a	DARPin SR16m molecule had a 6.7x fold change in IC50 in B.1.617.2 Delta	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Chonira	2022	doi:10.1101/2022.05.30.493765	pmid:35677079	https://doi.org/10.1101/2022.05.30.493765	False	Chonira et al. (2022)	n/a	DARPin SR16m molecule had a 99.7x fold change in IC50 in B.1.617.2 Delta	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Tang	2021	doi:10.1101/2021.03.19.436183	n/a	https://doi.org/10.1101/2021.03.19.436183	False	Tang et al. (2021)	n/a	The most significant loss of neutralizing activity (PsVNA50 assay) using 6 hyperimmune immunoglobulin preparations from convalescent plasma was seen against authentic B.1.351 lineage virus (9.2-fold). Neutralization against 10 convalescent plasma was poorer (18.7x).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	environmental condition stability	n/a	n/a	Meister	2021	doi:10.1093/infdis/jiab260	pmid:33993274	https://doi.org/10.1093/infdis/jiab260	True	Meister et al. (2021)	n/a	Treatment with heat, soap and ethanol revealed similar inactivation profiles indicative of a comparable susceptibility  towards disinfection. Furthermore, we observed comparable surface stability on steel, silver, copper and face masks.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	environmental condition stability	n/a	n/a	Tada	2021	doi:10.1101/2021.02.05.430003	pmid:33564768	https://doi.org/10.1101/2021.02.05.430003	False	Tada et al. (2021)	n/a	Relative to D614G, this mutation set (B.1.351+) demonstrated significant increase in infectivity (i.e. heat stability) after incubation at 50C after 1 hour.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	trafficking	n/a	n/a	Hoffman	2021	doi:10.1101/2021.05.04.442663	n/a	https://doi.org/10.1101/2021.05.04.442663	False	Hoffman et al. (2021)	n/a	In two of eight cell lines tested (Caco-2 intenstinal and Calu-3 lung), a modest increase in cell entry was observed. This increase was not observed in a Calu-3 cell line with overexpressed ACE2. [the virus tested as B.1.617 overlaps only partially with the Spike mutation lists used by PANGO, CDC, etc. for this lineage therefore the results should be interpreted carefully as transferable to B.1.617 generally]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Hoffman	2021	doi:10.1101/2021.05.04.442663	n/a	https://doi.org/10.1101/2021.05.04.442663	False	Hoffman et al. (2021)	n/a	Approximately 2-fold reduction in 15 ICU patient convalescent plasma neutralization as quantified by measuring virus-encoded  luciferase activity in cell lysates at 16-18 h post transduction. [PG: note that the virus tested as B.1.617 overlaps only partially with the Spike mutation lists used by PANGO, CDC, etc. for this lineage therefore the results should be interpreted carefully as transferable to B.1.617 generally]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Hoffman	2021	doi:10.1101/2021.05.04.442663	n/a	https://doi.org/10.1101/2021.05.04.442663	False	Hoffman et al. (2021)	n/a	Abrogates Bamlanivimab neutralization as quantified by measuring virus-encoded luciferase activity in cell lysates at 16-18 h post transduction. Significant decrease in combined Etesevimab+Bamlanivimab neutralization except at the highest concentration measured. [PG: note that the virus tested as B.1.617 overlaps only partially with the Spike mutation lists used by PANGO, CDC, etc. for this lineage therefore the results should be interpreted carefully as transferable to B.1.617 generally]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Hoffman	2021	doi:10.1101/2021.05.04.442663	n/a	https://doi.org/10.1101/2021.05.04.442663	False	Hoffman et al. (2021)	n/a	In 15 Pfizer non-senior vaccinee sera collected 3-4 weeks post-booster [using Table S1, not the text that says 2-3 weeks], neutralization was reduced ~3x (compared to ~11x for B.1.351). [the virus tested as B.1.617 overlaps only partially with the Spike mutation lists used by PANGO, CDC, etc. for this lineage therefore the results should be interpreted carefully as transferable to B.1.617 generally]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.2 (from South Africa/CERI-KRISP-K032307/2021) were 3.9x-fold lower (95% CI: 0.14x-0.17x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Uhal B	2022	doi:10.1101/2022.06.23.497326	n/a	https://doi.org/10.1101/2022.06.23.497326	False	Uhal B et al. (2022)	n/a	L27, V34 and E90 mutation resulted in ultrahigh affinity binding of the LVE-ACE-2 domain to the widest variety of VOCs, with KDs of 78fM for binding to the Omicron  BA.2. Values were obtained with LVE-ACE-2/mAB chimeras containing the Y-T-E sequence that enhances binding to the FcRn receptor, which in turn is expected to  extend biological half-life 3-4-fold.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.2 (from South Africa/CERI-KRISP-K032307/2021) were 4.5-fold lower (95% CI: 4.3x-4.7x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.2.12.1 (from USA/NY-CDC-ASC210722700/2022) were 4.2-fold lower (95% CI: 5.8x-6.6x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.2.12.1 (from USA/NY-CDC-ASC210722700/2022) were 3.9x-fold lower (95% CI: 0.14x-0.18x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Choi	2021	doi:10.1101/2021.06.28.449914	n/a	https://doi.org/10.1101/2021.06.28.449914	False	Choi et al. (2021)	n/a	Neutralization efficiency (ID50) against B.1.525 reduced 4.2x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Cathcart	2021	doi:10.1101/2021.03.09.434607v9	n/a	https://doi.org/10.1101/2021.03.09.434607v9	False	Cathcart et al. (2021)	n/a	Omicron (a.k.a. B.1.1.529) Spike pseudotyped VSV and Vero E6 cells has somewhat  reduced neutralization (2.7x) vs wild type with monoclonal antibody Sotrovimab (a.k.a. VIR-7831).  [delins at 214 omitted for syntax compatibility]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Wang	2022	doi:10.1101/2022.08.11.503601	n/a	https://doi.org/10.1101/2022.08.11.503601	False	Wang et al. (2022)	n/a	Omicron breakthrough infection after 3-dose vaccination resulted in a further 3.5-fold and 2.9-fold increase of Omicron BA.1 and BA.2 neutralizing titers. Omicron  BA.4/5 showed the highest neutralization resistance of all variants tested, resulting in low geometric mean neutralizing titers in plasma samples  obtained after  the second vaccine dose (NT50	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs Bi-Nab47D10-35B5. Omicron BA.1 has an IC50 fold change of 0.08x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron B.1.1.529 (BA.1) neutralization of the Omicron variants by antibodies induced by three doses of Pfizer/BNT162b2 mRNA vaccine was 7-8-fold less potent than  the D614G, and the Omicron variants still evade neutralization more efficiently.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron (B.1.1.529 [BA.1]) have higher sensitivity to inhibition by soluble angiotensin converting enzyme 2 (ACE2) and the endosomal inhibitor chloroquine compared  to D614G	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs Bi-Nab35B5-47D10. Omicron BA.1 has an IC50 fold change of 0.30x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Uhal B	2022	doi:10.1101/2022.06.23.497326	n/a	https://doi.org/10.1101/2022.06.23.497326	False	Uhal B et al. (2022)	n/a	Paradigms’ ACE-2 variant LVE/STR chimera binds to SARS-2 Omicron variant B.1.1.529 spike protein trimer with high affinity. Determined using Surrogate Viral Neutralization Tests.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Uhal B	2022	doi:10.1101/2022.06.23.497326	n/a	https://doi.org/10.1101/2022.06.23.497326	False	Uhal B et al. (2022)	n/a	L27, V34 and E90 mutation resulted in ultrahigh affinity binding of the LVE-ACE-2 domain to the widest variety of VOCs, with KDs of 73 pM for binding to the Omicron  B.1.1.529. Values were obtained with LVE-ACE-2/mAB chimeras containing the Y-T-E sequence that enhances binding to the FcRn receptor, which in turn is expected to  extend biological half-life 3-4-fold.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs 35B5. Omicron BA.1 has an IC50 fold change of 0.38x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Arora	2022	doi:10.1038/s41423-022-00870-5	pmid:35581351	https://doi.org/10.1038/s41423-022-00870-5	True	Arora et al. (2022)	n/a	All 10 individuals with 2 doses of the BNT162b2/BNT162b2 vaccine had a neutralizing titer in B.1 variant at an average of 729 NT50.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Shete	2022	doi:10.1101/2022.05.12.491584	n/a	https://doi.org/10.1101/2022.05.12.491584	False	Shete et al. (2022)	n/a	Plaque reduction neutralization test (PRNT) was used uring primary infection, post sixty daysof second dose vaccination, pre-reinfection and reinfection against Delta variant and was used to determine neutralizing antibodytitres. There was a 24.63x fold increase in antibody response from first infection to recovered and vaccinated with 2 doses (60 days). There was a 4.21x fold increase in antibody response pre-reinfection. There was a 39.27x fold increase in antibody response during reinfection.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Shete	2022	doi:10.1101/2022.05.12.491584	n/a	https://doi.org/10.1101/2022.05.12.491584	False	Shete et al. (2022)	n/a	Plaque reduction neutralization test (PRNT) was used uring primary infection, post sixty daysof second dose vaccination, pre-reinfection and reinfection against B.1 variant and was used to determine neutralizing antibodytitres. There was a 6.76x fold increase in antibody response from first infection to recovered and vaccinated with 2 doses (60 days). There was a 2.06x fold increase in antibody response pre-reinfection. There was a 8.18x fold increase in antibody response during reinfection.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Arora	2022	doi:10.1038/s41423-022-00870-5	pmid:35581351	https://doi.org/10.1038/s41423-022-00870-5	True	Arora et al. (2022)	n/a	All 10 individuals with 3 doses of the BNT162b2/BNT162b2 vaccine had a neutralizing titer in B.1 variant at an average of 3319 NT50.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Shete	2022	doi:10.1101/2022.05.12.491584	n/a	https://doi.org/10.1101/2022.05.12.491584	False	Shete et al. (2022)	n/a	Plaque reduction neutralization test (PRNT) was used uring primary infection, post sixty daysof second dose vaccination, pre-reinfection and reinfection against Omicron variant and was used to determine neutralizing antibodytitres. There was a 114.84x fold increase in antibody response from first infection to recovered and vaccinated with 2 doses (60 days). There was a 6.61x fold increase in antibody response pre-reinfection. There was a 1194.9x fold increase in antibody response during reinfection.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Kumar	2022	doi:10.1101/2022.05.13.491770	n/a	https://doi.org/10.1101/2022.05.13.491770	False	Kumar et al. (2022)	n/a	BnAb 002-S21F2 IC50 on the Omicron BA.1 variant is 1.0x fold the wildtype.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs 47D10. Omicron BA.1 has an IC50 fold change of 1.26x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron BA.3 have higher sensitivity to inhibition by soluble angiotensin converting enzyme 2 (ACE2) and the endosomal inhibitor chloroquine compared  to D614G	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron BA.3 neutralization of the Omicron variants by antibodies induced by three doses of Pfizer/BNT162b2 mRNA vaccine was 7-8-fold less potent than the D614G, and  the Omicron variants still evade neutralization more efficiently.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.3 (from South Africa/NICD-N22404/2021) were 4.2x-fold lower (95% CI: 0.15x-0.20x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.3 (from South Africa/NICD-N22404/2021) were 6.2-fold lower (95% CI: 11.8x-14.3x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Hao	2022	doi:10.1101/2022.08.12.22278720	pmid:36032965	https://doi.org/10.1101/2022.08.12.22278720	False	Hao et al. (2022)	n/a	paired testing of vaccine sera against ancestral virus compared to Omicron BA.1 shows that 3-dose vaccine regimen provides over 50x fold increase in protection against Omicron(B.1.1.529 [BA.1]) compared to a 2-dose regimen.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Wang	2022	doi:10.1101/2022.08.11.503601	n/a	https://doi.org/10.1101/2022.08.11.503601	False	Wang et al. (2022)	n/a	4th antigenic exposure with Omicron (B.1.1.529 [BA.1])(n	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.1 (from Botswana/R40B59_BHP_3321001248/2021) were 3.4-fold lower (95% CI: 3.2x-3.6x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.1 (from Botswana/R40B59_BHP_3321001248/2021) were 28.7x-fold lower (95% CI: 0.03x-0.05) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Chen	2021	doi:10.1038/s41591-021-01294-w	pmid:33664494	https://doi.org/10.1038/s41591-021-01294-w	True	Chen et al. (2021)	n/a	The neutralizing activity of vaccine was somewhat lower against B.1.1.7 in sera tested from most of the 24 patients with the BNT162b2 mRNA vaccine. (Fig. 4)	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Chen	2021	doi:10.1038/s41591-021-01294-w	pmid:33664494	https://doi.org/10.1038/s41591-021-01294-w	True	Chen et al. (2021)	n/a	B.1.1.7 variant constellation ablates Class 3 N-terminal domain targeting antibody COV2-2489.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Bates	2021	doi:10.1101/2021.04.04.21254881	pmid:33851185	https://doi.org/10.1101/2021.04.04.21254881	False	Bates et al. (2021)	n/a	Observed 8.8-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose) against cultured B.1.1.7 sample. Contrast this with 1.3-fold reduction for just the pseudovirus combination of 'key' B.1.1.7 mutation N501Y.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Garcia-Beltran	2021	doi:10.1016/j.cell.2021.03.013	pmid:33743213	https://doi.org/10.1016/j.cell.2021.03.013	True	Garcia-Beltran et al. (2021)	n/a	Pseudotyped B.1.1.298 virus has reduced neutralization activity vs wild type: 1.4x (30 sera Pfizer median 9 days post 2nd dose)  and 1.3x (35 sera Moderna median 18 days post 2nd dose). This was NOT significant by ANOVA.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Reynolds	2021	doi:10.1126/science.abh1282	pmid:33931567	https://doi.org/10.1126/science.abh1282	True	Reynolds et al. (2021)	n/a	After one dose, individuals with prior infection showed enhanced T cell immunity,  antibody secreting memory B cell response to spike and neutralizing antibodies effective  against B.1.1.7 (authentic cell culture supernatants). By comparison, HCW receiving one vaccine dose without prior  infection showed reduced immunity against variants. B.1.1.7 spike mutations  resulted in increased, abrogated or unchanged T cell responses depending on human leukocyte  antigen (HLA) polymorphisms. Study was 26 each post-infection and post first dose HCWs.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Uriu	2021	doi:10.1101/2021.09.06.459005	n/a	https://doi.org/10.1101/2021.09.06.459005	False	Uriu et al. (2021)	n/a	Mean 2.6x reduction of NT50 value B.1.1.7 (Alpha) relative to wild type in 8 sera from older convalescent patients (52-92yo) collected 1-3m post symptom onset.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Pegu	2021	doi:10.1101/2021.05.13.444010	pmid:34031659	https://doi.org/10.1101/2021.05.13.444010	False	Pegu et al. (2021)	n/a	Detectable antibodies against B.1.1.7 at various time points using pseudotyped lentivirus neutralization in Moderna vaccinee cohort: Day 29 33%, Day 43 100%, Day 119 100%, Day 209 96%. Detectable antibodies against B.1.1.7 at various time points using live virus FRNT neutralization in Moderna vaccinee cohort: Day 29 54%, Day 43 100%, Day 119 100%, Day 209 88%. Detectable antibodies against B.1.1.7 at various time points using ACE2 blocking assay in Moderna vaccinee cohort: Day 29 83%, Days 43,119,209 100%.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Haas	2021	doi:10.1016/S0140-6736(21	n/a	https://doi.org/10.1016/S0140-6736(21	n/a	Haas et al. (2021)	n/a	Using national surveillance data from Israel, using Pfizer vaccine and an estimated prevalence of the B.1.1.7 variant of 94.5% among SARS-CoV-2 infections: Adjusted estimates of vaccine effectiveness 7+ days after second dose were 95·3% (95% CI 94.9–95.7):  91.5% against asymptomatic SARS-CoV-2 infection (90·7–92·2: 40.9 vs 1.8 per 100 000 person-days), 97·0% against symptomatic  COVID-19 (96.7–97.2%), 97.2% against COVID-19-related hospitalisation (96.8–97.5%),  97.5% against severe or critical COVID-19-related hospitalisation (97.1–97.8%), and 96.7% against COVID-19-related death (96.0–97.3%).  In all age groups, as vaccine coverage increased, the incidence of SARS-CoV-2 outcomes declined	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Luftig	2021	doi:10.1056/NEJMc2104036	pmid:33826815	https://doi.org/10.1056/NEJMc2104036	True	Luftig et al. (2021)	n/a	In sera 1-2 weeks after BNT162b2 first dose, from six patients previously infected with B.1, antibody titer in a microneutralization assay  was on average 8192 for B.1.351 virus. This compares favorably (stronger) to post-infection neutralization titer against all variants tested in the same sera (wild type, B.1.1.7, B.1.351, and P.1).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	virion structure	n/a	n/a	Cai	2021	doi:10.1101/2021.04.13.439709	pmid:33880477	https://doi.org/10.1101/2021.04.13.439709	False	Cai et al. (2021)	n/a	CryoEM analysis of B.1.1.7 demonstrates an increased propensity for 'up', receptor accessible conformation of the Spike protein trimer.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Loconsole	2021	doi:10.1016/j.cmi.2021.05.007	pmid:33984489	https://doi.org/10.1016/j.cmi.2021.05.007	True	Loconsole et al. (2021)	n/a	SARS-CoV-2 infection was confirmed in three HCWs working a single shift: all presented with mild symptoms of COVID-19. The two physicians  were fully vaccinated with BNT162b2 vaccine, with the second dose administered 1 month before symptom onset. Both had high titres of IgG  anti-spike antibodies at the time of diagnosis. WGS confirmed that all virus strains were VOC 202012/01-lineage B.1.1.7, suggesting a  common source of exposure. Epidemiological investigation revealed that the suspected source was a SARS-CoV-2-positive patient who  required endotracheal intubation due to severe COVID-19. All procedures were carried out using a full suite of personal protective equipment (PPE).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine efficacy	n/a	n/a	Bruxvoort	2021	doi:10.1101/2021.09.29.21264199	n/a	https://doi.org/10.1101/2021.09.29.21264199	False	Bruxvoort et al. (2021)	n/a	In a 1:5 test-negative matched control study of 8153 individuals who received the Moderna mRNA-1273 vaccine, 1422 test-positive were Alpha. Two dose vaccine efficacy against Alpha was 98.4% [96.9-99.1%], one dose VE was 90.1% (82.9-94.2%).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Planas	2021	doi:10.1038/s41591-021-01318-5	n/a	https://doi.org/10.1038/s41591-021-01318-5	True	Planas et al. (2021)	n/a	Using a new rapid neutralization assay, based on reporter cells that become positive for GFP after overnight infection, sera from 58  convalescent individuals collected up to 9 months after symptoms, similarly neutralized B.1.1.7 and D614G.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs Bi-Nab35B5-47D10. Alpha (B.1.1.7) has an IC50 fold change of 1.19x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Wang	2021	doi:10.1038/s41586-021-03398-2	n/a	https://doi.org/10.1038/s41586-021-03398-2	True	Wang et al. (2021)	n/a	B.1.1.7 pseudotyped virus model impairs binding by RBD-directed mAb 910-30. B.1.1.7 pseudotyped virus model abolishes N-terminal-domain-directed mAbs 5-24, 4-8, and 4A8. B.1.1.7 pseudotyped virus model impairs binding by N-terminal-domain-directed mAbs 2-17, 4-19, 5-7.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Wang	2021	doi:10.1056/NEJMc2103022	pmid:33822491	https://doi.org/10.1056/NEJMc2103022	True	Wang et al. (2021)	n/a	1.4x improvement in neutralization by serum collected 2 to 3 weeks after the second dose from vaccinees who had received  BBIBP-CorV (pVNT50 against VSV pseudotyped as B.1.1.7). Convalescent plasma had similar titer against wild type as the BBIBP-CorV vaccinee sera. 2x reduction in neutralization by serum collected 2 to 3 weeks after the second dose from vaccinees who had received  CoronaVac (pVNT50 against VSV pseudotyped as B.1.1.7). Convalescent plasma had similar titer against wild type as the CoronaVac vaccinee sera.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	aerosolization	n/a	n/a	Adenaiye	2021	doi:10.1093/cid/ciab797	pmid:34519774	https://doi.org/10.1093/cid/ciab797	True	Adenaiye et al. (2021)	n/a	Alpha variant cases in a large campus study showed fine-aerosol shedding amongst unmasked participants remained significantly greater for alpha variant infections (18-fold, 95% CI, 3.4 to 92-fold) after adjusting for the increased viral RNA in MTS and saliva, the number of coughs during sampling sessions, and symptom. After controlling for the effect of masks and numbers of coughs during sampling, alpha variant infection was associated with a 100-fold (95% CI, 16 to 650-fold) increase in coarse- and a 73-fold (95% CI, 15 to 350-fold) increase in fine-aerosol RNA shedding.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	environmental condition stability	n/a	n/a	Schuit	2021	doi:10.1093/infdis/jiab171	pmid:33822064	https://doi.org/10.1093/infdis/jiab171	True	Schuit et al. (2021)	n/a	No differences in the stability of B.1.1.7 observed in the absence of simulated sunlight at either 20°C or 40°C (with a mean time for  a 90% loss of viral infectivity across all dark conditions of 6.2 hours). However, a small but statistically  significant difference in the stability was observed in simulated sunlight at 20°C and 20% relative humidity, with B.1.1.7 restoring  wild type 90% loss time of 11 minutes vs. 7 and 8 minutes for B.1.319 (D614G) and B.28 (V367F) early 2020 viruses respectively.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	trafficking	n/a	n/a	Liu	2021	doi:10.1101/2021.08.12.456173v3	n/a	https://doi.org/10.1101/2021.08.12.456173v3	False	Liu et al. (2021)	n/a	Modelling the Alpha variant in primary human airway epithelial (HAE) cultures, S1 to full length Spike ratio  (measuring Spike furin cleavage processivity) increase 3.9x relative to wild type (5.4 vs 1.4). This is less efficient than Delta (11x vs wildtype using a P681R mutation instead). [del ~144 changed due to ambiguity] Furthermore the RNA ratio of Delta versus Alpha-spike/Delta-backbone continuously increased from 2.8 on day 1  to 9.8 on day 5 post infection in a co-infection model in HAEs, suggesting the spike gene drives the improved replication of Delta variant.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Woldemeskel	2021	doi:10.1172/JCI149335	pmid:33822770	https://doi.org/10.1172/JCI149335	True	Woldemeskel et al. (2021)	n/a	No significant difference in T-cell response to B.1.1.7 was observed (vs. ancestral) in blood drawn from 28 participants received the Pfizer-BioNTech vaccine  and 2 received the Moderna vaccine. This is despite three mutations (Y144del, D614G, and P681H) overlapping T-cell epitope hotspots.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Sapkal	2021	doi:10.1093/jtm/taab051	pmid:33772577	https://doi.org/10.1093/jtm/taab051	True	Sapkal et al. (2021)	n/a	The NAb titers (PRNT50) of sera collected from 38 vaccine recipients four-weeks after the second dose of inactivated whole-virion SARS-CoV-2 BBV152/COVAXIN vaccine [which contains D614G] were not significantly  different between B.1.1.7 virus and ancestral D614G virus.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Tarke	2021	doi:10.1101/2021.02.27.433180	pmid:33688655	https://doi.org/10.1101/2021.02.27.433180	False	Tarke et al. (2021)	n/a	PBMCs of Pfizer/BioNTech BNT162b2 (n	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Hall	2021	doi:10.1016/S0140-6736(21	n/a	https://doi.org/10.1016/S0140-6736(21	n/a	Hall et al. (2021)	n/a	A single dose of BNT162b2 vaccine demonstrated vaccine effectiveness [symptomatic or asymptomatic in cohort opf routinely NAAT-monitored UK HCWs]  of 72% (95% CI 58-86) 21 days after first dose and 86% (95% CI 76-97) seven days after two doses in the antibody negative cohort.  This cohort was vaccinated when the dominant variant in circulation was B.1.1.7 and demonstrates effectiveness against this variant.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Amit	2021	doi:10.1016/S0140-6736(21	n/a	https://doi.org/10.1016/S0140-6736(21	n/a	Amit et al. (2021)	n/a	Between December 19, 2020 and Jan 24, 2021, 7214 of 9109 eligible HCWs at Sheba Medical Center in Israel had received one or more doses of  BNT162b2 (Pfizer) vaccine. Adjusted rate reduction in SARS-CoV-2 NAAT positivity infection compared with unvaccinated workers 1-14 days  after 1st dose was 30% (95% CI: 2-50), and 75% (95% CI: 72-84) after 15-28 days. Adjusted rate reduction in symptomatic COVID-19 compared with  unvaccinated workers 1-14 days after 1st dose was 47% (95% CI: 17-66), and 85% (95% CI: 71-92) after 15-28 days. [Though often cited as an indicator of VE for B.1.1.7, during this time period in Israel, the prevalence of the B.1.1.7 variant increased from ~20% to 50% of  cases (covariants.org), therefore these VE numbers likely represent a mix of B.1.1.7 and other lineage effects.]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Lopez Bernal	2021	doi:10.1136/bmj.n1088	pmid:33985964	https://doi.org/10.1136/bmj.n1088	True	Lopez Bernal et al. (2021)	n/a	We found that a single dose of the BNT162b2 vaccine is about 60-70% effective at preventing symptomatic disease in adults aged 70 years  and older in England and that two doses are about 85-90% effective. Those who were vaccinated and went on to have symptoms had a 44%  lower risk of being admitted hospital and a 51% lower risk of death compared with people who were unvaccinated. We also found that a single dose  of the ChAdOx1-S vaccine was about 60-75% effective against symptomatic disease and provided an additional protective effect against hospital  admission—it is too early to assess the effect on mortality. The B.1.1.7 variant now dominates in the UK and these results will largely  reflect vaccine effectiveness against this variant.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the 47D10. Alpha (B.1.1.7) has an IC50 fold change of 0.40x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	anthropozoonotic events	n/a	n/a	Hamer	2021	doi:10.1111/tbed.14122	pmid:33955193	https://doi.org/10.1111/tbed.14122	True	Hamer et al. (2021)	n/a	First documented cases of domestic cat and dog infections with the B.1.1.7 strain.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine efficacy	n/a	n/a	Lopez Bernal	2021	doi:10.1056/NEJMoa2108891	pmid:34289274	https://doi.org/10.1056/NEJMoa2108891	True	Lopez Bernal et al. (2021)	n/a	Effectiveness after one dose of vaccine (BNT162b2 or ChAdOx1 nCoV-19) with the delta variant was (48.7%: 95% confidence interval [CI], 45.5 to 51.7): the results were similar for both vaccines.  With the BNT162b2 vaccine, the effectiveness of two doses was 93.7% (95% CI, 91.6 to 95.3) among those with the alpha variant.  With the ChAdOx1 nCoV-19 vaccine, the effectiveness of two doses was 74.5% (95% CI, 68.4 to 79.4) among those with the alpha variant.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Shen	2021	doi:10.1101/2021.01.27.428516	pmid:33532764	https://doi.org/10.1101/2021.01.27.428516	False	Shen et al. (2021)	n/a	Reduction in neutralization by mAbs COVA2-15 (~9x), B38 (~14x), S309 (~190x) by this B.1.1.7 pseudotyped virus model.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Munitz	2021	doi:10.1016/j.xcrm.2021.100264	pmid:33899031	https://doi.org/10.1016/j.xcrm.2021.100264	True	Munitz et al. (2021)	n/a	We observed a sharp decline in cases when ∼50% of the elderly population was 2 weeks beyond their first  vaccination dose and at a time point during which the B.1.1.7 variant gained transmission dominance.  In support of this finding, it was suggested that, after the first vaccination dose, more than 70% of  patients develop neutralization antibodies,15 and the vaccine efficiency can reach 85%.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Hu	2021	doi:10.1101/2021.01.22.427749	n/a	https://doi.org/10.1101/2021.01.22.427749	False	Hu et al. (2021)	n/a	Neutralizing antibody titers of 2/20 (10%) samples showed >10x reduction (sera collected ~1mo post Jan 2020 first wave in China). Neutralizing antibody titers of 8/20 samples (40%) decreased below an ID50 threshold of 40 (sera  collected ~8mo post Jan 2020 first wave in China).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Rees-Spear	2021	doi:10.1101/2021.01.15.426849	n/a	https://doi.org/10.1101/2021.01.15.426849	False	Rees-Spear et al. (2021)	n/a	Lessens the potency of mAbs COVA2-17 (~5x, similar to N501Y alone), COVA1-12 (~11x) and COVA1-21 (>100x), which do not compete allosterically.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	reinfection	n/a	n/a	Graham	2021	doi:10.1016/s2468-2667(21	n/a	https://doi.org/10.1016/s2468-2667(21	n/a	Graham et al. (2021)	n/a	36920 COVID Symptom Study app users reported SARS-CoV-2 test positivity in late 2020. Possible reinfections were  identified in 249 (0.7% [95% CI 0.6-0.8]) of 36509 app users who reported a positive swab test before Oct 1, 2020,  but there was no evidence that the frequency of reinfections was higher for the B.1.1.7 variant than for pre-existing variants.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Garcia-Beltran	2021	doi:10.1016/j.cell.2021.03.013	pmid:33743213	https://doi.org/10.1016/j.cell.2021.03.013	True	Garcia-Beltran et al. (2021)	n/a	Pseudotyped B.1.1.7 virus has reduced neutralization activity vs wild type: 2.1x (30 sera Pfizer median 9 days post 2nd dose)  and 2.3x (35 sera Moderna median 18 days post 2nd dose). This was NOT significant by ANOVA. Note that Y145del was actually noted in the paper as the effect of their DNA construct, but this is  equivalent at the protein level to the more commonly annotated Y144del.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Planas	2021	doi:10.1038/s41591-021-01318-5	n/a	https://doi.org/10.1038/s41591-021-01318-5	True	Planas et al. (2021)	n/a	The sera of 16 individuals with time course collection was evaulated against VSV pseudotypes: neutralized D614G at week 2,  whereas B.1.1.7 started to be neutralized at week 3, although less efficiently than D614G. B.1.1.7 and D614G strains were  similarly neutralized at week 4 (1 week after booster dose).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Supasa	2021	doi:10.1016/j.cell.2021.02.033	pmid:33743891	https://doi.org/10.1016/j.cell.2021.02.033	True	Supasa et al. (2021)	n/a	Neutralization assays of B.1.1.7 virus showed a reduction of 2.5-fold (14 days post 2nd dose AstraZeneca, n	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs 35B5. Alpha (B.1.1.7) has an IC50 fold change of 1.39x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine efficacy	n/a	n/a	Puranik	2021	doi:10.1101/2021.08.06.21261707	pmid:34401884	https://doi.org/10.1101/2021.08.06.21261707	False	Puranik et al. (2021)	n/a	In Minnesota in early 2021 when Alpha was prevalent, vaccine efficacy was estimated as: mRNA-1273 86% (95%CI: 81-90.6%) and BNT162b2: 76% (95%CI: 69-81%) using age, sex, race, PCR testing and vaccination date matched cohorts of unvaccinated, Pfizer and Moderna vaccinees.  [variant list included is ancestral Alpha, as this was an observational study no variant list was given]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Hu	2021	doi:10.1101/2021.01.22.427749	n/a	https://doi.org/10.1101/2021.01.22.427749	False	Hu et al. (2021)	n/a	~20x resistence to mAb CQ038 by B.1.1.7 pseudotyped virus	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	reinfection	n/a	n/a	Marquez	2021	doi:10.1017/ice.2021.195	pmid:33934744	https://doi.org/10.1017/ice.2021.195	True	Marquez et al. (2021)	n/a	Reinfection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) B.1.1.7 variant in an immunocompromised 16yo female with end stage renal disease 94 days after initial infection with a B.1.2 lineage virus. Both lineages were the prevalent one at the time of 1st and 2nd infections respectively in Texas, where the patient was located (suggesting exposure risk rather than lineage immune evasion).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Uhal B	2022	doi:10.1101/2022.06.23.497326	n/a	https://doi.org/10.1101/2022.06.23.497326	False	Uhal B et al. (2022)	n/a	Paradigm’s ACE-2 variant LVE/STR chimera neutralizes Alpha Variant B.1.1.7 RBD significantly better than GenScript IgG FL18-740 w.t. ACE-2 mAB. Determined using Surrogate Viral Neutralization Tests.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs Bi-Nab47D10-35B5. Alpha (B.1.1.7) has an IC50 fold change of 1.44x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Hall	2021	doi:10.1016/S0140-6736(21	n/a	https://doi.org/10.1016/S0140-6736(21	n/a	Hall et al. (2021)	n/a	A single dose of BNT162b2 (Pfizer) vaccine showed vaccine effectiveness of 70% (95% CI 55-85) 21 days after first dose  and 85% (74-96) 7 days after two doses in the study population. Our findings show that the BNT162b2 vaccine can prevent both symptomatic and asymptomatic infection in working-age adults. This cohort (8203 treatment, 15121 control) was vaccinated when the  dominant variant in circulation was B.1.1.7 and shows effectiveness against this variant.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Graham	2021	doi:10.1016/j.immuni.2021.03.023	pmid:33836142	https://doi.org/10.1016/j.immuni.2021.03.023	True	Graham et al. (2021)	n/a	NTD-specific nAbs showed a substantial (3-450x) decrease in neutralization potency against the recently reported highly  transmissible B.1.1.7 variant of concern, whereas RBD-specific nAbs were either unaffected or showed lower decreases in potency.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	tissue specific neutralization	n/a	n/a	Planas	2021	doi:10.1038/s41591-021-01318-5	n/a	https://doi.org/10.1038/s41591-021-01318-5	True	Planas et al. (2021)	n/a	The nasal mucosa of Pfizer vaccinees with time course collection was evaluated against VSV pseudotypes: results (only one nasal  swab from different previously infected vacinee neutralizing at weeks 3 and 6 against B.1.1.7 and D614G) suggest that vaccinees probably  do not elicit an early humoral response detectable at mucosal surfaces even though sera neutralization was observed. They strengthen the hypothesis that some vaccines may not protect against  viral acquisition and infection of the oral–nasal region, but may prevent severe disease associated with viral dissemination in the lower respiratory tract.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Rosenke	2022	doi:10.1172/jci.insight.160108	pmid:35579953	https://doi.org/10.1172/jci.insight.160108	True	Rosenke et al. (2022)	n/a	Infectious viral titers in lung tissue determined using a tissue culture infectious dose (TCID) assay in 10 hamsters showed that Alpha Molnupiravir (MK-4482) had ~2.75x fold drop.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Choi	2021	doi:10.1101/2021.06.28.449914	n/a	https://doi.org/10.1101/2021.06.28.449914	False	Choi et al. (2021)	n/a	Neutralization efficiency (ID50) against B.1.1.7 reduced 1.2x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	reinfection	n/a	n/a	Harrington	2021	doi:10.1093/cid/ciab014	pmid:33421056	https://doi.org/10.1093/cid/ciab014	True	Harrington et al. (2021)	n/a	Second infection in December 2020 with B.1.1.7 after April 2020 initial infection with B.2 in a 78-year-old man with a history of Type 2 diabetes mellitus,  diabetic nephropathy on hemodialysis, chronic obstructive pulmonary disease (COPD), mixed central  and obstructive sleep apnea, ischemic heart disease, with no history of immunosuppression.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	trafficking	n/a	n/a	Hu	2021	doi:10.1101/2021.01.22.427749	n/a	https://doi.org/10.1101/2021.01.22.427749	False	Hu et al. (2021)	n/a	The entry efficiencies of Spike pseudotyped viruses bearing N501Y Variant 1 (B.1.1.7) mutant were about 3 to 4.4 times higher than that of the WT pseudovirus when viral input was normalized, suggesting that these spike variants promote the infectivity of SARS-CoV-2.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	trafficking	n/a	n/a	Esclera	2021	doi:10.1101/2021.08.05.455290	n/a	https://doi.org/10.1101/2021.08.05.455290	False	Esclera et al. (2021)	n/a	~2.5x cleavage of S2 relative to WA1 (D614G) wildtype by Alpha variant variant as measured by mass spectrometry of Vero-TMPRSS culture.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Emary	2021	doi:10.2139/ssrn.3779160	n/a	https://doi.org/10.2139/ssrn.3779160	False	Emary et al. (2021)	n/a	Virus neutralisation activity (using a live SARS-CoV-2 microneutralisation assay (ND50)) by vaccine induced antibodies was 9-fold lower  against the B.1.1.7 variant than against a canonical non B.1.1.7 lineage. Vaccine efficacy against symptomatic NAAT positive infection  was similar for B.1.1.7 and non-B.1.1.7 lineages (74.6% [95%CI 41.6-88.9] and 84% [95% CI 70.7-91.4] respectively). Furthermore, vaccination with ChAdOx1 nCoV-19 results in a reduction in the duration of shedding and viral load, which may translate into a material impact on transmission of disease.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Kumar	2022	doi:10.1101/2022.05.13.491770	n/a	https://doi.org/10.1101/2022.05.13.491770	False	Kumar et al. (2022)	n/a	BnAb 002-S21F2 IC50 on the Alpha (B.1.1.7) variant is 1.0x fold the wildtype in 42 COVI.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Gallagher	2021	doi:10.1101/2021.05.03.442455	pmid:33972942	https://doi.org/10.1101/2021.05.03.442455	False	Gallagher et al. (2021)	n/a	ELISpot assays show T cell neutralization reduced by 15.4% in this B.1.1.7 pseudotype relative to wild type in 18-20 pooled patient samples post second mRNA vaccine dose, with no significant difference between Pfizer and Moderna cohorts. Reduction was stronger in the S1 subunit than S2 (separate peptide pools were used).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Edara	2021	doi:10.1101/2021.02.02.21250799	pmid:33564782	https://doi.org/10.1101/2021.02.02.21250799	False	Edara et al. (2021)	n/a	2.1x drop in neutralization using sera collected from 14 healthy adult participants that received two injections of the mRNA-1273 (Moderna) vaccine  at a dose of 100 µg (18-55 years: day 1 (n	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Ikegame	2021	doi:10.21203/rs.3.rs-400230/v1	pmid:33851150	https://doi.org/10.21203/rs.3.rs-400230/v1	False	Ikegame et al. (2021)	n/a	B.1.1.7 pseudotyped VSV was tested for neutralization in a clonal HEK-293T ACE2 TMPRSS2 cell line optimized for highly efficient  S-mediated infection. A cohort of 12 Argentinian recipients of the Gamaleya Sputnik V Ad26 / Ad5 vaccine showed no statistically sognificant change in neutralization effiacacy.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Heath	2021	doi:10.1101/2021.05.13.21256639	n/a	https://doi.org/10.1101/2021.05.13.21256639	False	Heath et al. (2021)	n/a	NVX-CoV2373 [Novavax] vaccine in phase 3 trial was 89.7% (95% CI, 80.2-94.6) effective in preventing COVID-19, with no hospitalizations or  deaths reported. There were five cases of severe Covid-19, all in the placebo group. Post hoc analysis revealed efficacies of  96.4% (73.8-99.5) and 86.3% (71.3-93.5) against the prototype strain and B.1.1.7 variant, respectively.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Shen	2021	doi:10.1101/2021.01.27.428516	pmid:33532764	https://doi.org/10.1101/2021.01.27.428516	False	Shen et al. (2021)	n/a	Pseudotyped B.1.1.7 Spike variants lentivirus. 3.5x reduction in neutralization with Moderna vaccinated patient sera after 29 days (1st dose). 2.0x reduction in neutralization with Moderna vaccinated patient sera after 57 days (2nd dose). 2.1x reduction in neutralization with Novavax Phase 1 post-vaccination sera.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	clinical indicators	n/a	n/a	Song	2021	doi:10.1101/2021.05.04.21256655	n/a	https://doi.org/10.1101/2021.05.04.21256655	False	Song et al. (2021)	n/a	After adjusting for the age factor, in a prospective Chinese cohort study B.1.1.7 variant infection (compared to B.1.140) was the risk factor for  C-reactive protein (P 	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine efficacy	n/a	n/a	Nasreen	2021	doi:10.1101/2021.06.28.21259420	n/a	https://doi.org/10.1101/2021.06.28.21259420	False	Nasreen et al. (2021)	n/a	Using a test-negative design using Ontario data between Dec 14, 2020 and May 30, 2021, 421,073 symptomatic community-dwelling individuals were tested. Against symptomatic infection caused by Alpha, vaccine effectiveness with partial vaccination (≥14 days after dose 1) was higher for mRNA-1273 (83%) than BNT162b2 (66%) and ChAdOx1 (64%), and full vaccination (≥7 days after dose 2) increased vaccine effectiveness for BNT162b2 (89%) and mRNA-1273 (92%).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	trafficking	n/a	n/a	Touret	2021	doi:10.1101/2021.03.22.436427	n/a	https://doi.org/10.1101/2021.03.22.436427	False	Touret et al. (2021)	n/a	Live virus was tested ex vivo in reconstituted brochial epithelium, and out competed wild type.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Uriu	2021	doi:10.1101/2021.09.06.459005	n/a	https://doi.org/10.1101/2021.09.06.459005	False	Uriu et al. (2021)	n/a	Mean 1.7x reduction of NT50 value B.1.1.7 (Alpha) relative to wild type in 8 sera from adult BNT162b2 vaccinees (28-47yo) collected ~1m post booster.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Planas	2021	doi:10.1038/s41591-021-01318-5	n/a	https://doi.org/10.1038/s41591-021-01318-5	True	Planas et al. (2021)	n/a	Flow cytometry was used on recombinant VSV proteins and yeast surface display to assess the binding of a labeled soluble ACE2  protein to cells expressing B.1.1.7. We observed a dramatic increase (relative to D614G) in binding of soluble  ACE2 to B.1.1.7, and to a lesser extent to B.1.351, which both carry the N501Y mutation (see Fig 3).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Uhal B	2022	doi:10.1101/2022.06.23.497326	n/a	https://doi.org/10.1101/2022.06.23.497326	False	Uhal B et al. (2022)	n/a	L27, V34 and E90 mutation resulted in ultrahigh affinity binding of the LVE-ACE-2 domain to the widest variety of VOCs, with KDs of 93 pM for binding to the Alpha  B1.1.7. Values were obtained with LVE-ACE-2/mAB chimeras containing the Y-T-E sequence that enhances binding to the FcRn receptor, which in turn is expected to  extend biological half-life 3-4-fold.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	1.5x reduction in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees)	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	UNKNOWN	n/a	n/a	n/a	,	n/a	UNKNOWN et al. ()	n/a	n/a	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	UNKNOWN	n/a	n/a	n/a	,	n/a	UNKNOWN et al. ()	n/a	In Qatar, where Pfizer vaccine use is prevalent (<10% of the population covered in the time period of the study ending Mar 31, 2021), any time after one dose  (including the 2 weeks where no major effect is expected) B.1.1.7 lineage effectiveness was observed as 29.5% (95% CI [22.9,35.5]) against infection, and 54.1% against severe/critical/fatal disease  (95% CI [26.1-71.9]). Two weeks or more after 2nd dose, effectiveness climbed to 89.5% [85.9,92.3] against infection, and 100% against  severe/critical/fatal disease (95% CI [81.7,100]).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Dejnirattisai	2021	doi:10.1016/j.cell.2021.03.055	pmid:33852911	https://doi.org/10.1016/j.cell.2021.03.055	True	Dejnirattisai et al. (2021)	n/a	Lilly's LY-CoV16 showed marked reduction in neutralization of B.1.1.7.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Skelly	2021	doi:10.21203/rs.3.rs-226857/v1	n/a	https://doi.org/10.21203/rs.3.rs-226857/v1	False	Skelly et al. (2021)	n/a	Sera neutralized the B1.1.7 isolate with a lower potency (2-fold: 95% CL: 1.5 – 3-fold), and those with the lowest homotypic neutralizing potency had undetectable heterotypic potency (2/25).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	tissue specific replication effects	n/a	n/a	Mok	2021	doi:10.1101/2021.04.19.440414	n/a	https://doi.org/10.1101/2021.04.19.440414	False	Mok et al. (2021)	n/a	In this report, by using a lower infectious dose, we demonstrate that B.1.1.7  (cultured sample Hong Kong/HKPU-00015/2021) exhibits higher infectivity and/or  replication efficiency in the nasal epithelium. (Hamster model of infection)	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.4/5 (from ) were 17.2x-fold lower (95% CI: 0.6x-0.7x) than against 208-428 972-1834 4.3-4.7 US-WA1/2020 usiong an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.4/5 (from ) were 13.0-fold lower (95% CI: 4.2x-4.6x) than against 208-428 972-1834 4.3-4.7 US-WA1/2020 usiong an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Uriu	2021	doi:10.1101/2021.09.06.459005	n/a	https://doi.org/10.1101/2021.09.06.459005	False	Uriu et al. (2021)	n/a	Mean 1.7x reduction of NT50 value for C.37 (Lambda) relative to wild type in 8 sera from adult BNT162b2 vaccinees (28-47yo) collected ~1m post booster.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Uriu	2021	doi:10.1101/2021.09.06.459005	n/a	https://doi.org/10.1101/2021.09.06.459005	False	Uriu et al. (2021)	n/a	Mean 3.4x reduction of NT50 value for C.37 (Lambda) relative to wild type in 8 sera from older convalescent patients (52-92yo) collected 1-3m post symptom onset.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Chonira	2022	doi:10.1101/2022.05.30.493765	pmid:35677079	https://doi.org/10.1101/2022.05.30.493765	False	Chonira et al. (2022)	n/a	Trimeric proteins FSR22 had a 0.048x fold change in IC50 in C.37 Lambda	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Chonira	2022	doi:10.1101/2022.05.30.493765	pmid:35677079	https://doi.org/10.1101/2022.05.30.493765	False	Chonira et al. (2022)	n/a	Trimeric proteins FSR16m had a 0.038x fold change in IC50 in C.37 Lambda	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Stamatatos	2021	doi:10.1126/science.abg9175	pmid:33766944	https://doi.org/10.1126/science.abg9175	True	Stamatatos et al. (2021)	n/a	In sera collected from 15 early pandemic patients (Seattle Flu Study), mean 16 days post first dose with either Pfizer/BioNTech or Moderna vaccines,  the median ID50 titers were ~10-fold lower against this B.1.351 pseudotyped virus relative to wild type. A single asymptomatic patient, who had no detectable RBD-specific IgG memory before vaccination, also did not elicit nAbs against the B.1.351 variant. [compare to ~3 fold without the deletion] ID50 titres in non-infected mRNA vaccines more than two weeks post-booster were significant, but ~500x weaker than in previously infected patients  after first dose.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Pegu	2021	doi:10.1101/2021.05.13.444010	pmid:34031659	https://doi.org/10.1101/2021.05.13.444010	False	Pegu et al. (2021)	n/a	Detectable antibodies against B.1.351 at various time points using pseudotyped lentivirus neutralization in Moderna vaccinee cohort: Day 29 8%, Day 43 100%, Day 119 71%, Day 209 54%. Detectable antibodies against B.1.351 at various time points using live virus FRNT neutralization in Moderna vaccinee cohort: Day 29 8%, Day 43 100%, Day 119 79%, Day 209 58%. Detectable antibodies against B.1.351 at various time points using ACE2 blocking assay in Moderna vaccinee cohort: Day 29 63%, Day 43 100%, Day 119 71%, Day 209 79%. Decreased neutralization on some assays was seen especially in those vaccinees tested that were 71+.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Abe	2021	doi:10.1101/2021.08.06.21261721	n/a	https://doi.org/10.1101/2021.08.06.21261721	False	Abe et al. (2021)	n/a	In an Ontario long term care facility, cumulatively, weaker BNT162b2 vaccine stimulation, age/comorbidities, produced a ∼130-fold reduction  in apparent neutralization titers in mean 88yo LTCH residents against Beta (B.1.351), relative to staff vaccinees against D614G wild type.  37.9% of 116 two-dose-mRNA-vaccinated residents had undetectable neutralizing antibodies to B.1.351. mRNA-1273 vaccinee sera displayed ~2 better neutralization than BNT162b2. [common defining B.1.351 mutations noted, as the manuscript does not provide details]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Stamatatos	2021	doi:10.1126/science.abg9175	pmid:33766944	https://doi.org/10.1126/science.abg9175	True	Stamatatos et al. (2021)	n/a	Anti-NTD CV1 mAb isolated from an early pandemic case was unable to neutralize either partial B.1.351 variant pseudovirus used (A701V or L242del). The neutralization potency of mAb CV30, which contacts K417 and N501 but not E484, was ~10-fold weaker toward both B.1.351 variants. The neutralization potency of anti-RBD mAb CV3-1 was 3-4-fold less potent against the B.1.351 variants, while anti-RBD mAb CV2-75 was modestly less effective.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Stamatatos	2021	doi:10.1126/science.abg9175	pmid:33766944	https://doi.org/10.1126/science.abg9175	True	Stamatatos et al. (2021)	n/a	Using convalescent sera from 15 early pandemic patients (Seattle Flu Study), mean 220 days post symptom onset (IQR 125-269, and three asymptomatic cases) with 27% WHO disease severity scale 3, 7 of 15 neutralized this B.1.351 pseudotype that includes the L242del, and only one had titers above 100.  Only one of the 15 sera achieved 80% neutralization. [compare to 5 and 1 for pseudotype without the deletion]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Tada	2021	doi:10.1101/2021.05.14.444076	n/a	https://doi.org/10.1101/2021.05.14.444076	False	Tada et al. (2021)	n/a	Pseudotyped viruses for B.1.351 was 3.4-fold resistant to neutralization by 6 BNT162b2 vaccine sera 28 days post-booster compared to wild type. Neutralization by 3 Moderna vaccine sera 28 days post-booster was 2.2-fold resistant. [Exact list of B.1.351 mutations used in these assays was not included in the preprint]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs Bi-Nab35B5-47D10. Beta (B.1.351) has an IC50 fold change of 0.13x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Rosenke	2022	doi:10.1172/jci.insight.160108	pmid:35579953	https://doi.org/10.1172/jci.insight.160108	True	Rosenke et al. (2022)	n/a	Infectious viral titers in lung tissue determined using a tissue culture infectious dose (TCID) assay in 10 hamsters showed that Beta Molnupiravir (MK-4482) had ~1.75x fold drop.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Zhou	2021	doi:10.1016/j.cell.2021.02.037	pmid:33730597	https://doi.org/10.1016/j.cell.2021.02.037	True	Zhou et al. (2021)	n/a	The B.1.351 variant constellation causes an ∼20-fold increase in affinity for ACE2 compared with Wuhan RBD, which may influence transmissibility.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	humoral response durability	n/a	n/a	Betton	2020	doi:10.1093/cid/ciab308	pmid:33851216	https://doi.org/10.1093/cid/ciab308	True	Betton et al. (2020)	n/a	In a prospective study of 107 hospitalized patients, decrease of IgG rates and serological assays becoming  negative did not imply loss of neutralizing capacity. Our results indicate a sustained humoral response against the  ancestral strain and the D614G, B.1.1.7 and P.1 variants for at least 6 months (last of two samples taken)  in patients previously hospitalized for COVID-19. A weaker protection was however observed for the B.1.351 variant.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	trafficking	n/a	n/a	Esclera	2021	doi:10.1101/2021.08.05.455290	n/a	https://doi.org/10.1101/2021.08.05.455290	False	Esclera et al. (2021)	n/a	~6x cleavage of S2 relative to WA1 (D614G) wildtype by Beta variant as measured by mass spectrometry of Vero-TMPRSS culture  [no mutations directly at furin cleavage site, but A701V is downstream] Compare to 4.5x or less for variants of concern with  direct furin clevage site mutations.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	outcome hazard ratio	n/a	n/a	Abu-Raddad	2021	doi:10.1101/2021.08.02.21261465	n/a	https://doi.org/10.1101/2021.08.02.21261465	False	Abu-Raddad et al. (2021)	n/a	Compared to Alpha (B.1.1.7) variant, odds of progressing to severe disease were 1.24-fold (95% CI: 1.11-1.39) higher for Beta.  Odds of progressing to critical disease were 1.49-fold (95% CI: 1.13-1.97) higher. Odds of COVID-19 death were 1.57-fold (95% CI: 1.03-2.43) higher.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Kumar	2022	doi:10.1101/2022.05.13.491770	n/a	https://doi.org/10.1101/2022.05.13.491770	False	Kumar et al. (2022)	n/a	BnAb 002-S21F2 IC50 on the Beta (B.1.351) variant is 0.4x fold the wildtype.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Zhou	2021	doi:10.1016/j.cell.2021.02.037	pmid:33730597	https://doi.org/10.1016/j.cell.2021.02.037	True	Zhou et al. (2021)	n/a	In 34 convalescent cases 4–9 weeks following infection in June 2020, before the emergence of B.1.1.7, neutralization titers  against B.1.351 were, on average, 13.3-fold reduced compared with an early Victoria sample (p < 0.0001). Significantly, 18  of 34 samples failed to reach 50% neutralization at a plasma dilution of 1:20, with a number showing a near total reduction of neutralization activity. In 13 convalescent cases 4–9 weeks following infection with B.1.1.7, neutralization titers  against B.1.351 were, on average, 3.1-fold reduced compared with an early Victoria sample (p < 0.0001).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs Bi-Nab47D10-35B5. Beta (B.1.351) has an IC50 fold change of 0.15x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Liu	2021	doi:10.1056/NEJMc2102017	pmid:33684280	https://doi.org/10.1056/NEJMc2102017	True	Liu et al. (2021)	n/a	Vaccine plasma neutralization of B.1.351-spike virus was nominally robust but lower (~3x) than other variants of concern.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Choi	2021	doi:10.1101/2021.06.28.449914	n/a	https://doi.org/10.1101/2021.06.28.449914	False	Choi et al. (2021)	n/a	Neutralization efficiency (ID50) against B.1.1.351-v3 reduced 8.4x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Zhou	2021	doi:10.1016/j.cell.2021.02.037	pmid:33730597	https://doi.org/10.1016/j.cell.2021.02.037	True	Zhou et al. (2021)	n/a	Testing against B.1.351 the 20 most effective mAbs (19 anti-RBD, 1 anti-NTD) from a screen of 377 against wild type,  4 of 20 antibodies had >10-fold fall in neutralization titers, with most of these showing a complete knockout of  activity. This is in line with the key roles of K417, E484, and N501, in particular E484, in antibody recognition  of the ACE2 interaction surface of the RBD. Regeneron mAb cocktail: The neutralization of REGN10987 was unaffected by B.1.351, while REGN10933 was severely impaired (773-fold). AstraZeneca mAb cocktail: Neutralization by the AZ pair of antibodies was little affected on B.1.351 compared with Victoria.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Madhi	2021	doi:10.1101/2021.02.10.21251247	n/a	https://doi.org/10.1101/2021.02.10.21251247	False	Madhi et al. (2021)	n/a	A two-dose regimen of (AstraZeneca) ChAdOx1-nCoV19 did not show protection against mild-moderate Covid-19 due to B.1.351 variant, however,  vaccine efficacy against severe Covid-19 is undetermined.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	UNKNOWN	n/a	n/a	n/a	n/a	n/a	UNKNOWN et al. ()	n/a	The Janssen single dose vaccine showed 72% efficacy at preventing moderate and severe disease, which was  reduced to 57% in South Africa, where 92.6% of infections are estimated to have been B.1.351. 100% reduction in  hospitalization risk remains across variants after 28 days post-vaccination.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	anthropozoonotic events	n/a	n/a	Montagutelli	2021	doi:10.1101/2021.03.18.436013	n/a	https://doi.org/10.1101/2021.03.18.436013	False	Montagutelli et al. (2021)	n/a	Unlike wild type or B.1.1.7, B.1.351 lineage virus was able to infect and replicate in common lab mouse strains, with high titer. PG: The virus used in these expriments has a non-typical deletion+sub in the 242 region.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs 35B5. Beta (B.1.351) has an IC50 fold change of 0.13x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Zhou	2021	doi:10.1016/j.cell.2021.02.037	pmid:33730597	http://doi.org/10.1016/j.cell.2021.02.037	True	Zhou et al. (2021)	n/a	Sera from healthcare workers (n 	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs 47D10. Beta (B.1.351) has an IC50 fold change of 0.88x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	outcome hazard ratio	n/a	n/a	Funk	2021	doi:10.2807/1560-7917.ES.2021.26.16.2100348	pmid:33890566	https://doi.org/10.2807/1560-7917.ES.2021.26.16.2100348	True	Funk et al. (2021)	n/a	On average across 7 European countries studied, using B.1.351 defining mutations: Significant shift to infection in those without pre-existing conditions (79.6% vs 89% for non-VOC cases). Significant increase in hospitalization rate (19.3% vs 7.5% for non-VOC cases). Significant increase in ICU rate (2.3% vs 0.6% for non-VOC cases). PG: seems to be different notations around the LAL deletion, using the minimal shared definition to catch as many as possible.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Garcia-Beltran	2021	doi:10.1016/j.cell.2021.03.013	pmid:33743213	https://doi.org/10.1016/j.cell.2021.03.013	True	Garcia-Beltran et al. (2021)	n/a	Pseudotyped B.1.351 v1 virus has reduced neutralization activity vs wild type: 34.5x (30 sera Pfizer median 9 days post 2nd dose)  and 27.7x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA. Notably, 36.7% (11/30) recipients of two-dose Pfizer and 42.9% (15/35) recipients of two-dose Moderna vaccines did not have  detectable neutralization of at least one of the B.1.351 variants.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Gallagher	2021	doi:10.1101/2021.05.03.442455	pmid:33972942	https://doi.org/10.1101/2021.05.03.442455	False	Gallagher et al. (2021)	n/a	ELISpot assays show T cell neutralization reduced by 29.8% in this B.1.351 pseudotype relative to wild type in 18-20 pooled patient samples post second mRNA vaccine dose, with no significant difference between Pfizer and Moderna cohorts. Reduction was stronger in the S1 subunit than S2 (separate peptide pools were used).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Stamatatos	2021	doi:10.1126/science.abg9175	pmid:33766944	https://doi.org/10.1126/science.abg9175	True	Stamatatos et al. (2021)	n/a	Using convalescent sera from 15 early pandemic patients (Seattle Flu Study), mean 220 days post symptom onset (IQR 125-269, and three asymptomatic cases) with 27% WHO disease severity scale 3, one third (5/15) of sera neutralized this B.1.351 pseudotype and only three had ID50 titers above 100. Only two of the 15 sera achieved 80% neutralization.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Stamatatos	2021	doi:10.1126/science.abg9175	pmid:33766944	https://doi.org/10.1126/science.abg9175	True	Stamatatos et al. (2021)	n/a	In sera collected from 15 early pandemic patients (Seattle Flu Study), mean 16 days post first dose with either Pfizer/BioNTech or Moderna vaccines,  the median ID50 titers were ~3-fold lower against this B.1.351 pseudotyped virus relative to wild type. A single asymptomatic patient, who had no detectable RBD-specific IgG memory before vaccination, also did not elicit nAbs against the B.1.351 variant. [compare to ~10 fold with L242del] ID50 titres in non-infected mRNA vaccines more than two weeks post-booster were signficiant, but >100x weaker than in previously infected  patients after first dose.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Garcia-Beltran	2021	doi:10.1016/j.cell.2021.03.013	pmid:33743213	https://doi.org/10.1016/j.cell.2021.03.013	True	Garcia-Beltran et al. (2021)	n/a	Pseudotyped B.1.351 v3 virus has reduced neutralization activity vs wild type: 42.4x (30 sera Pfizer median 9 days post 2nd dose)  and 19.2x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA. Notably, 36.7% (11/30) recipients of two-dose Pfizer and 42.9% (15/35) recipients of two-dose Moderna vaccines did not have  detectable neutralization of at least one of the B.1.351 variants.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Huang	2021	doi:10.1101/2021.02.01.429069	n/a	https://doi.org/10.1101/2021.02.01.429069	False	Huang et al. (2021)	n/a	The neutralization activities of two vaccines developed in China were tested against 501Y.V2 authentic virus: inactivated BBIBP-CorV (no  significant change) and recombinant dimeric RBD vaccine ZF2001 (~1.6x reduction vs wildtype, p	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Röltgen	2021	doi:10.1101/2021.04.05.21254952	pmid:33851181	https://doi.org/10.1101/2021.04.05.21254952	False	Röltgen et al. (2021)	n/a	Most of the plasma from 55 Pfizer vaccinees developed high percentages of Wuhan-Hu-1 S-ACE2 blocking activity, peaking at day 28 (7 days post-boost).  A strikingly consistent hierarchy of reduction in plasma antibody binding by variant S and RBD antigens was observed among study  participants, with progressively decreased binding for B.1.1.7 (not significant), P.1 (significant) and B.1.351 (significant) compared to Wuhan-Hu-1 antigens.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Bailly	2021	doi:10.1093/cid/ciab446	pmid:33993228	https://doi.org/10.1093/cid/ciab446	True	Bailly et al. (2021)	n/a	During an outbreak of SARS-CoV-2 501Y.V2 in a nursing home, all non-vaccinated residents (5/5) versus  half of those fully vaccinated 2-5 weeks prior with BNT162b2 (13/26) were infected. Two of 13 vaccinated versus 4 of 5  non-vaccinated residents presented severe disease. BNT162b2 did not prevent the outbreak, but reduced  transmission and disease severity. Among the 13 fully vaccinated residents who were infected, 2 (15.4%) presented with an asymptomatic disease, 9 (69.2%) developed mild to moderate symptoms, and 2 (15.4%) progressed to severe disease with fatal evolution secondary to acute respiratory distress syndrome (ARDS). There was no relationship between anti-S antibody levels at diagnosis and disease severity. Overall, the proportion of residents with severe disease in the non-vaccinated group (4/5)  was higher than that in the vaccinated group (2/13). Only 1 vaccinated staff, but 10 unvaccinated were infected in the outbreak (no severe disease).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Chen	2021	doi:10.1038/s41591-021-01294-w	pmid:33664494	https://doi.org/10.1038/s41591-021-01294-w	True	Chen et al. (2021)	n/a	The neutralizing activity of vaccine was significantly lower against B.1.351 in sera from all 24 patients with the BNT162b2 mRNA vaccine. (Fig. 4)	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Luftig	2021	doi:10.1056/NEJMc2104036	pmid:33826815	https://doi.org/10.1056/NEJMc2104036	True	Luftig et al. (2021)	n/a	In sera 1-2 weeks after BNT162b2 first dose, from six patients previously infected with B.1, antibody titer in a microneutralization assay  was on average 1625 for B.1.351 virus. This compares favorably (stronger) to most post-infection neutralization titer against all variants tested in the same sera (wild type, B.1.1.7, B.1.351, and P.1).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Wang	2021	doi:10.1056/NEJMc2103022	pmid:33822491	https://doi.org/10.1056/NEJMc2103022	True	Wang et al. (2021)	n/a	2.5x reduction in neutralization by serum collected 2 to 3 weeks after the second dose from vaccinees who had received  BBIBP-CorV (pVNT50 against VSV pseudotyped as B.1.351). Convalescent plasma had similar titer against wild type as the BBIBP-CorV vaccinee sera. >3x reduction in neutralization by serum collected 2 to 3 weeks after the second dose from vaccinees who had received  CoronaVac (pVNT50 against VSV pseudotyped as B.1.351). Convalescent plasma had similar titer against wild type as the CoronaVac vaccinee sera.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Chen	2021	doi:10.1038/s41591-021-01294-w	pmid:33664494	https://doi.org/10.1038/s41591-021-01294-w	True	Chen et al. (2021)	n/a	B.1.1.351 variant constellation two-tailed Wilcoxon matched-pairs signed-rank test against 10 convalescent sera P	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	UNKNOWN	2021	n/a	n/a	https://www.fda.gov/media/146217/download	False	UNKNOWN et al. (2021)	n/a	Study 3001 on Ad26.COV2.S (Jannsen vaccine) conducted September 21, 2020 through January 22, 2021 overlaps the emergence and dominance  of the B.1.351 lineage of SARS-CoV-2 in South Africa. The SA arms of the Phase 3 double blind study showed severe/critical disease VE of 73.1%  (95% CI: 40.0-89.4), and moderate to severe/critical disease VE of 52.0% (95% CI: 30.3-67.4). Compare to 78.0% and 74.4% for North American arm of the study during the same period (with low B.1.351 prevalence). Of the 66.9% of SA severe infections that have been sequenced as of this report, 94.5% are B.1.351.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Solfrosi	2021	doi:10.1084/jem.20202756	pmid:33909009	https://doi.org/10.1084/jem.20202756	True	Solfrosi et al. (2021)	n/a	The dominant circulating B.1.351 spike variant originating in RSA, which harbors E484K and additional substitutions in the  RBD, NTD, and S2 and deletions in the NTD (amino acids 242–244), was neutralized with a 5.02-fold reduced titer	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Chen	2021	doi:10.1038/s41591-021-01294-w	pmid:33664494	https://doi.org/10.1038/s41591-021-01294-w	True	Chen et al. (2021)	n/a	B.1.1.351 in 19 convalescent human sera ~1mo post infection had mild to moderate resistance against all samples	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Chen	2021	doi:10.1038/s41591-021-01294-w	pmid:33664494	https://doi.org/10.1038/s41591-021-01294-w	True	Chen et al. (2021)	n/a	B.1.1.351 variant constellation ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07, COVOX-384, and S2H58. B.1.1.351 variant constellation ablates Class 3 N-terminal domain targeting antibodies COV2-2489 and COV2-2676 (the only two tested).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Cochin	2021	doi:10.1101/2021.04.19.440435	n/a	https://doi.org/10.1101/2021.04.19.440435	False	Cochin et al. (2021)	n/a	In a Syrian hamster model, B.1.351 variant virus had >4x reduction in YRNT90 (measure of neutralization) using wild type convalescent sera. PG: Note that exact sequence for B.1.351 used was not disclosed.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	McCallum	2021	doi:10.1101/2021.03.31.437925	pmid:33821281	https://doi.org/10.1101/2021.03.31.437925	False	McCallum et al. (2021)	n/a	In 13 plasma collected ~1mo after B.1.1.7 infection (nursing home in Ticino, Switzerland), neutralization  reduced to undetectable levels in many plasma for B.1.351 pseudotyped virus, as well as WT and other VOCs.  [paper does not detail the B.1.351 variants used, using the most popular as a stad in]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Choi	2021	doi:10.1101/2021.06.28.449914	n/a	https://doi.org/10.1101/2021.06.28.449914	False	Choi et al. (2021)	n/a	Neutralization efficiency (ID50) against B.1.617.1-v1 ('Kappa') reduced 3.4x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Wilhelm	2021	doi:10.1101/2021.08.09.21261704	n/a	https://doi.org/10.1101/2021.08.09.21261704	False	Wilhelm et al. (2021)	n/a	Relative to B.1, Delta (B.1.617.2) shows mean 2.1x decrease in neutralization efficiency by 18 vaccinee sera (BNT162b2 and mRNA1273).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Wilhelm	2021	doi:10.1101/2021.08.09.21261704	n/a	https://doi.org/10.1101/2021.08.09.21261704	False	Wilhelm et al. (2021)	n/a	Relative to B.1, Delta (B.1.617.2) shows 3.64x decrease in neutralization efficiency by convalescent plasma [no cohort details provided]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	outcome hazard ratio	n/a	n/a	Yang	2021	doi:10.1101/2021.08.04.21261596	n/a	https://doi.org/10.1101/2021.08.04.21261596	False	Yang et al. (2021)	n/a	B.1.526 (Iota) substantially increased IFR in older adults: by 46% (95% CI: 7.4 – 84%) among 45-64 year-olds,  82% (95% CI: 20 – 140%) among 65-74 year-olds, and 62% (95% CI: 45 – 80%) among 75+ during Nov 2020 – Apr 2021,  compared to baseline IFR estimated for preexisting variants. [minimum clade defining mutations listed]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	UNKNOWN	2021	n/a	n/a	https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1009243/Technical_Briefing_20.pdf	False	UNKNOWN et al. (2021)	n/a	Sera from vaccinees [ChAdOx1 and BNT162b2 primarily used in UK] shows decreased ability to neutralize B.1.621 compared to first wave virus and Alpha, with a magnitude of change similar to Beta.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine efficacy	n/a	n/a	Bruxvoort	2021	doi:10.1101/2021.09.29.21264199	n/a	https://doi.org/10.1101/2021.09.29.21264199	False	Bruxvoort et al. (2021)	n/a	In a 1:5 test-negative matched control study of 8153 individuals who received the Moderna mRNA-1273 vaccine, 69 test-positive were Mu. Two dose vaccine efficacy against Mu was 90.4% (73.9-96.5%), one dose VE was 45.8% (0.0-88.9%).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	UNKNOWN	2021	n/a	n/a	https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1009243/Technical_Briefing_20.pdf	False	UNKNOWN et al. (2021)	n/a	Sera from individuals who have been vaccinated and have had subsequent recent Delta infection have a high level of neutralising activity against B.1.621.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma binding	n/a	n/a	UNKNOWN	2021	n/a	n/a	https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1009243/Technical_Briefing_20.pdf	False	UNKNOWN et al. (2021)	n/a	Sera from individuals who have been infected with Delta does not have strong neutralising activity against B.1.621	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma binding	n/a	n/a	Luftig	2021	doi:10.1056/NEJMc2104036	pmid:33826815	https://doi.org/10.1056/NEJMc2104036	True	Luftig et al. (2021)	n/a	In sera from six patients collected 1 to 12 weeks post-infection with B.1, antibody titer in a microneutralization assay was on average 71.46 for P.1 virus. Compare to much stronger neutralization titers for B.1.1.7 (256) and wild type (456.1) in the same sera.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Uriu	2021	doi:10.1101/2021.09.06.459005	n/a	https://doi.org/10.1101/2021.09.06.459005	False	Uriu et al. (2021)	n/a	Mean 7.6x reduction of NT50 value B.1.621 (Mu) relative to wild type in 8 sera from adult BNT162b2 vaccinees (28-47yo) collected ~1m post booster. [This is a greater reduction than Beta @ 6.3x]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Messali	2021	doi:10.1002/jmv.27247	pmid:34329486	https://doi.org/10.1002/jmv.27247	True	Messali et al. (2021)	n/a	Using live B.1.621 virus and a cytopathic effect-based assay, sera from 37 Pfizer/BioNTech BNT162b2 vaccinees collected 10-20 days post-booster showed significantly lower (95) but still 'robust' neutralization than against ancestral B.1 virus (107).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Uriu	2021	doi:10.1101/2021.09.06.459005	n/a	https://doi.org/10.1101/2021.09.06.459005	False	Uriu et al. (2021)	n/a	Mean 12.4x reduction of NT50 value B.1.621 (Mu) relative to wild type in 8 sera from older convalescent patients (52-92yo) collected 1-3m post symptom onset. [This is a greater reduction than Beta @ 8.2x]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  XD (from ) were 1.5x-fold lower (95% CI: 0.05x-0.07x) than against 208-428 972-1834 4.3-4.7 US-WA1/2020 usiong an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  XD (from ) were 4.4-fold lower (95% CI: 4.3x-4.7x) than against 208-428 972-1834 4.3-4.7 US-WA1/2020 usiong an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Mishra	2021	doi:10.1101/2021.10.04.463028	n/a	https://doi.org/10.1101/2021.10.04.463028	False	Mishra et al. (2021)	n/a	Using a pseudovirus assay and 6 ChAdOx1 vaccinee sera, this lineage defining mutation combination from B.1.617.3 conferred a ~11.8x drop in neutralization (NT50) [suggesting role for T19R and T95I in half the sera].	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	syncytium formation	n/a	n/a	Mishra	2021	doi:10.1101/2021.10.04.463028	n/a	https://doi.org/10.1101/2021.10.04.463028	False	Mishra et al. (2021)	n/a	Using ACE2-GFP+Spike-RFP fluorescence assay, this lineage defining mutation combination from B.1.617.3 increased syncytium formation ~2.3x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	transmissibility	n/a	n/a	Mishra	2021	doi:10.1101/2021.10.04.463028	n/a	https://doi.org/10.1101/2021.10.04.463028	False	Mishra et al. (2021)	n/a	Using a pseudovirus assay, this lineage defining mutation combination from B.1.617.3 conferred a ~4.5x infectivity advantage to the spike particles.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Hacisuleyman	2021	doi:10.1056/NEJMoa2105000	pmid:33882219	https://doi.org/10.1056/NEJMoa2105000	True	Hacisuleyman et al. (2021)	n/a	51yo female with no severe COVID-19 risk factors tested positive 19 days after second dose of mRNA-1273 (Moderna) vaccine. Presented with sore throat, congestion, and headache developed: the next day she lost her sense of smell. Symptoms resolved over a one week period. Serum obtained 4 days after symptom onset was tested for neutralization against wild-type  virus, the E484K mutant, and the B.1.526 variant. It was equally effective against each.  These data suggest that the antibody response recognized these variants but was nonetheless insufficient to prevent a  breakthrough infection. The virus detected matched neither B.1.1.7 nor B.1.526 VOC strains in wide circulation in New York at the time of infection, though shared some mutations.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	transmissibility	n/a	n/a	Mishra	2021	doi:10.1101/2021.10.04.463028	n/a	https://doi.org/10.1101/2021.10.04.463028	False	Mishra et al. (2021)	n/a	Using a pseudovirus assay, this NTD mutation combination from B.1.617.3 did not confer an infectivity advantage to the spike particles.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	transmissibility	n/a	n/a	Mishra	2021	doi:10.1101/2021.10.04.463028	n/a	https://doi.org/10.1101/2021.10.04.463028	False	Mishra et al. (2021)	n/a	Using a pseudovirus assay, this NTD mutation from B.1.617.3 did not confer an infectivity advantage to the spike particles.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	trafficking	n/a	n/a	Esclera	2021	doi:10.1101/2021.08.05.455290	n/a	https://doi.org/10.1101/2021.08.05.455290	False	Esclera et al. (2021)	n/a	~3.5x cleavage of S2 relative to WA1 (D614G) wildtype by Kappa (B.1.617.1) variant as measured by mass spectrometry of Vero-TMPRSS culture (compare to ~4.5x for closely related Delta B.1.617.2 also with P681R at the cleavage site).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	1.5x reduction in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees) [exact set of variants used is not listed in the manuscript]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Choi	2021	doi:10.1101/2021.06.28.449914	n/a	https://doi.org/10.1101/2021.06.28.449914	False	Choi et al. (2021)	n/a	Inferring from two B.1.617.1 variants tested, estimate baseline 3.3x reduction in ID50 relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	This variant combination (representing lineage B.1.617.1) showed a 2x decrease in Spike binding (relative to D614G alone)  by 5 plasma collected 8 months post-symptom-onset. [exact variant list not provided in manuscript, is inferred and  represents minimal set agreed upon commonly]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Yadav	2021	doi:10.1101/2021.04.23.441101	n/a	https://doi.org/10.1101/2021.04.23.441101	False	Yadav et al. (2021)	n/a	Average 2x neutralization efficiency decrease against sera from 26 Phase II trial Covaxin (BBV152) vaccine recipents.  Very similar to B.1.1.7 (~2x) in the same study, and the neutralization from 17 sera of natural infections across B1 lineages.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Wilhelm	2021	doi:10.1101/2021.08.09.21261704	n/a	https://doi.org/10.1101/2021.08.09.21261704	False	Wilhelm et al. (2021)	n/a	Relative to B.1, Kappa (B.1.617.1) shows 5.71x decrease in neutralization efficiency by convalescent plasma [no cohort details provided]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Wilhelm	2021	doi:10.1101/2021.08.09.21261704	n/a	https://doi.org/10.1101/2021.08.09.21261704	False	Wilhelm et al. (2021)	n/a	Relative to B.1, Kappa (B.1.617.1) shows mean 1.97x decrease in neutralization efficiency by 18 vaccinee sera (BNT162b2 and mRNA1273).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	This variant combination (representing lineage B.1.617.1) showed a 1.79x decrease in Spike binding (relative to D614G alone)  by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.64x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees. [exact variant list not provided in manuscript, is inferred and  represents minimal set agreed upon commonly]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing lineage B.1.617.1) showed a 1.12x increase  in binding (KD) relative to D614G, but described as 'not significant'. [exact variant list not provided in manuscript, is inferred and  represents minimal set agreed upon commonly]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs 47D10. Kappa (B.1.617.1) has an IC50 fold change of 80.2x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs Bi-Nab47D10-35B5. Kappa (B.1.617.1) has an IC50 fold change of 2.3x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs 35B5. Kappa (B.1.617.1) has an IC50 fold change of 0.68x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs Bi-Nab35B5-47D10. Kappa (B.1.617.1) has an IC50 fold change of 0.13x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Choi	2021	doi:10.1101/2021.06.28.449914	n/a	https://doi.org/10.1101/2021.06.28.449914	False	Choi et al. (2021)	n/a	Neutralization efficiency (ID50) against B.1.617.1-v1 ('Kappa') reduced 3.3x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Verghese	2021	doi:10.1128/JCM.00741-21	pmid:33952596	https://doi.org/10.1128/JCM.00741-21	True	Verghese et al. (2021)	n/a	In a cluster of B.1.617[.1] infections related to travel from India to USA, one patient with mild symptoms had received their second dose of Pfizer vaccine more than two weeks before the infection [i.e. vaccine breakthrough].	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	trafficking	n/a	n/a	Esclera	2021	doi:10.1101/2021.08.05.455290	n/a	https://doi.org/10.1101/2021.08.05.455290	False	Esclera et al. (2021)	n/a	~4.5x cleavage of S2 relative to WA1 (D614G) wildtype by Delta (B.1.617.2) variant as measured by mass spectrometry of Vero-TMPRSS culture (compare to ~3.5x for closely related Kappa B.1.617.1 also with P681R at the cleavage site).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Choi	2021	doi:10.1101/2021.06.28.449914	n/a	https://doi.org/10.1101/2021.06.28.449914	False	Choi et al. (2021)	n/a	Neutralization efficiency (ID50) against B.1.617.1-v1 ('Kappa') reduced 3.3x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster. [Mutation list in publication appears to contain a typo with R158del instead of R158G]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Uriu	2021	doi:10.1101/2021.09.06.459005	n/a	https://doi.org/10.1101/2021.09.06.459005	False	Uriu et al. (2021)	n/a	Mean 2.6x reduction of NT50 value B.1.617.2 (Delta) relative to wild type in 8 sera from adult BNT162b2 vaccinees (28-47yo) collected ~1m post booster.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Uriu	2021	doi:10.1101/2021.09.06.459005	n/a	https://doi.org/10.1101/2021.09.06.459005	False	Uriu et al. (2021)	n/a	Mean 4.0x reduction of NT50 value B.1.617.2 (Delta) relative to wild type in 8 sera from older convalescent patients (52-92yo) collected 1-3m post symptom onset.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	trafficking	n/a	n/a	Liu	2021	doi:10.1101/2021.08.12.456173v3	n/a	https://doi.org/10.1101/2021.08.12.456173v3	False	Liu et al. (2021)	n/a	Modelling the Delta variant in primary human airway epithelial (HAE) cultures, S1 to full length Spike ratio  (measuring Spike furin cleavage processivity) increased 11x relative to wild type (15.3 vs 1.4). [del ~157 truncated due to ambiguity] Furthermore the RNA ratio of Delta versus Alpha-spike/Delta-backbone continuously increased from 2.8 on day 1  to 9.8 on day 5 post infection in a coinfection model in HAEs, suggesting the spike gene drives the improved replication of Delta variant.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Chonira	2022	doi:10.1101/2022.05.30.493765	pmid:35677079	https://doi.org/10.1101/2022.05.30.493765	False	Chonira et al. (2022)	n/a	Trimeric proteins FSR22 had a 0.10x fold change in IC50 in B.1.617.2 Delta	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Chonira	2022	doi:10.1101/2022.05.30.493765	pmid:35677079	https://doi.org/10.1101/2022.05.30.493765	False	Chonira et al. (2022)	n/a	Trimeric proteins FSR16m had a 0.020x fold change in IC50 in B.1.617.2 Delta	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	trafficking	n/a	n/a	Liu	2021	doi:10.1101/2021.08.12.456173v3	n/a	https://doi.org/10.1101/2021.08.12.456173v3	False	Liu et al. (2021)	n/a	In primary human airway epithelial cultures, S1 to full length Spike ratio (measuring Spike furin cleavage  processivity) increase 1.9x relative to wild type (2.7 vs 1.4).  This is the Delta variant with the P681R furin cleavage site mutation absent. [del ~157 truncated due to ambiguity]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	immunosuppression variant emergence	n/a	n/a	Landis	2021	doi:10.1101/2021.05.08.21256775	n/a	https://doi.org/10.1101/2021.05.08.21256775	False	Landis et al. (2021)	n/a	Studying 94 COVID-19 extended infection cases with genomics April 1 to October 17, 2020, one case developed 23 mutations in a 19 day period, including this combination in Spike.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	transmissibility	n/a	n/a	Tada	2021	doi:10.1101/2021.05.14.444076	n/a	https://doi.org/10.1101/2021.05.14.444076	False	Tada et al. (2021)	n/a	Normalized for particle number, on ACE2.293T cells showed that the B.1.618 spike protein was about as infective as D614G wild type.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Cavanaugh	2021	doi:10.15585/mmwr.mm7017e2	pmid:33914720	https://doi.org/10.15585/mmwr.mm7017e2	False	Cavanaugh et al. (2021)	n/a	The estimated vaccine effectiveness against R.1 strain SARS-CoV-2 infection among residents in a Kentucky skilled nursing facility was  66.2% (95% CI 	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Wang	2022	doi:10.1101/2022.08.11.503601	n/a	https://doi.org/10.1101/2022.08.11.503601	False	Wang et al. (2022)	n/a	Plasma neutralizing activity was also assessed against SARS-CoV-2 Delta, Omicron BA.1, BA.2 and BA.4/5 variants using viruses pseudotyped with appropriate  variant spikeproteins. Delta breakthrough infection resulted in 15-fold increased neutralizing titers.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Uhal B	2022	doi:10.1101/2022.06.23.497326	n/a	https://doi.org/10.1101/2022.06.23.497326	False	Uhal B et al. (2022)	n/a	L27, V34 and E90 mutation resulted in ultrahigh affinity binding of the LVE-ACE-2 domain to the widest variety of VOCs, with KDs of 507 pM for binding to the Delta  B.1.617.2. Values were obtained with LVE-ACE-2/mAB chimeras containing the Y-T-E sequence that enhances binding to the FcRn receptor, which in turn is expected to  extend biological half-life 3-4-fold.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Wang	2022	doi:10.1101/2022.08.11.503601	n/a	https://doi.org/10.1101/2022.08.11.503601	False	Wang et al. (2022)	n/a	Plasma neutralizing activity in 49 participants was measured using HIV-1 pseudotyped with the 100 WT SARS-CoV-2 spike protein. Delta breakthrough infection  resulted in 11-fold increased geometric mean half-maximal neutralizing titer (NT50).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	McEvoy C	2022	doi:10.1101/2022.06.24.22276144	n/a	https://doi.org/10.1101/2022.06.24.22276144	False	McEvoy C et al. (2022)	n/a	Log10ID50 of Delta neutralizing antibodies is 0.872x the WT pre-third dose of pfizer-BioNTech BNT162b2 in 13 Kidney transplant recipients (KTR) with median age of  55.5.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Uhal B	2022	doi:10.1101/2022.06.23.497326	n/a	https://doi.org/10.1101/2022.06.23.497326	False	Uhal B et al. (2022)	n/a	Paradigm’s ACE-2 variant LVE/STR chimera neutralizes Delta Variant B.1.617.2 RBD or w.t. SARS-CoV-2 RBD with nearly equal potency determined using Surrogate Viral Neutralization Tests.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	McEvoy C	2022	doi:10.1101/2022.06.24.22276144	n/a	https://doi.org/10.1101/2022.06.24.22276144	False	McEvoy C et al. (2022)	n/a	Log10ID50 of Delta neutralizing antibodies is 0.952x the WT 1 month post-third dose of pfizer-BioNTech BNT162b2 in 13 Kidney transplant recipients (KTR) with median  age of 55.5.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	outcome hazard ratio	n/a	n/a	Twohig	2021	doi:10.1016/S1473-3099(21	n/a	https://doi.org/10.1016/S1473-3099(21	n/a	Twohig et al. (2021)	n/a	In the UK, of 43338 COVID-19-positive patients, 8682 had the Delta variant (median age 31 years [IQR 17–43]) and 196 were admitted to hospital within 14  days after the specimen was taken (adjusted hazard ratio [HR] 2.26 [95% CI 1.32–3.89] relative to Alpha cases). Being admitted to hospital or attending emergency care within 14 days for Delta cases had an adjusted HR 1.45 [95% CI 1.08–1.95] relative to Alpha. Most patients were unvaccinated (32 078 [74·0%] across both groups). The HRs for vaccinated patients were similar: 1.94 [95% CI 0.47–8.05] for hospitalization and 1.58 [0.69–3.61]) for hospital admission or  emergency care attendance.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine efficacy	n/a	n/a	Fowlkes	2021	doi:10.15585/mmwr.mm7034e4	pmid:34437521	https://doi.org/10.15585/mmwr.mm7034e4	False	Fowlkes et al. (2021)	n/a	During December 14, 2020–August 14, 2021, frontline worker without previous documented SARS-CoV-2 infection were monitored regularly.  Of 4,217 participants, 3,483 (83%) were vaccinated: 2,278 (65%) received Pfizer-BioNTech, 1,138 (33%) Moderna, and 67 (2%) Janssen  (Johnson & Johnson) COVID-19 vaccines. Adjusted VE during this Delta predominant period was 66% (95% CI 	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	UNKNOWN	n/a	n/a	n/a	n/a	n/a	UNKNOWN et al. ()	n/a	Case 62541 cluster in Singapore included a fully vaccinated nurse 2 months post-vaccine [likely Pfizer based on dates and supply],  and a doctor of unknown vaccine status. This cluster was caused by a B.1.617.2 virus [via crossreference to	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	This variant combination (representing lineage B.1.617.2 aka Delta) showed a 1.64x decrease in Spike binding (relative to D614G alone)  by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.   1.89x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees. [exact variant list not provided in manuscript, is inferred and  represents minimal set agreed upon commonly]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	UNKNOWN	n/a	n/a	n/a	https://www.moh.gov.sg/news-highlights/details/3-new-cases-of-locally-transmitted-covid-19-infection-28apr2021-update	False	UNKNOWN et al. ()	n/a	n/a	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine efficacy	n/a	n/a	Nanduri	2021	doi:10.15585/mmwr.mm7034e3	pmid:34437519	https://doi.org/10.15585/mmwr.mm7034e3	False	Nanduri et al. (2021)	n/a	136,160 reports from 14,997 nursing care facilities were broken into pre-Delta (Mar 1-May 9, 2021), intermediate (May 10-Jun 20, 2021)  and Delta (Jun 21-Aug 1, 2021). Two doses of mRNA vaccines were 74.7% effective against infection among nursing home residents early in the vaccination program  (March–May 2021). During June–July 2021, when B.1.617.2 (Delta) variant circulation predominated, effectiveness declined significantly to 53.1%.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine efficacy	n/a	n/a	Tang	2021	doi:10.1101/2021.08.11.21261885	n/a	https://doi.org/10.1101/2021.08.11.21261885	False	Tang et al. (2021)	n/a	Using a matched test-negative, case- control study design in Qatar, BNT162b2 effectiveness against any Delta infection, symptomatic or asymptomatic,  was 64.2% (95% CI: 38.1-80.1%) ≥14 days after the first dose and before the second dose, but was only 53.5% (95% CI: 43.9-61.4%) ≥14 days after the  second dose, in a population in which a large proportion of fully vaccinated persons received their second dose several months earlier.  Corresponding effectiveness measures for mRNA-1273 were 79.0% (95% CI: 58.9-90.1%) and 84.8% (95% CI: 75.9-90.8%), respectively. Effectiveness against any severe, critical, or fatal COVID-19 disease due to Delta was 89.7% (95% CI: 61.0-98.1%) for BNT162b2 and 100.0% (95% CI: 41.2-100.0%) for  mRNA-1273, ≥14 days after the second dose. The lower VE in Qatar relative to those reported in some other jurisdictions such as the UK and Canada (75%+) may reflect waning of vaccine protection for  those who received their second dose by end of 2020 or early 2021. Risk perception and behaviour amongst vaccinated individuals opver time may also  play a role.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	outcome hazard ratio	n/a	n/a	Bager	2021	doi:10.1016/S1473-3099(21	n/a	https://doi.org/10.1016/S1473-3099(21	n/a	Bager et al. (2021)	n/a	In Denmark, for the period Jan 1 to Jun 27, 2021, Delta variant was associated with increased an risk ratio of 2.83 [95% CI 2.02–3.98] for hospitalization.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine efficacy	n/a	n/a	Chia	2021	doi:10.1101/2021.07.28.21261295	n/a	https://doi.org/10.1101/2021.07.28.21261295	False	Chia et al. (2021)	n/a	Of 218 individuals with B.1.617.2 infection in Singapore, 84 had received a mRNA vaccine of which 71 were fully vaccinated,  130 were unvaccinated and 4 received a non-mRNA. Despite significantly older age in the vaccine breakthrough group, the odds of  severe COVID-19 requiring oxygen supplementation was significantly lower following vaccination (adjusted odds ratio 0.07 95%CI: 0.015-0.335, p	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine efficacy	n/a	n/a	Baden	2021	doi:10.1101/2021.09.17.21263624	pmid:34611666	https://doi.org/10.1101/2021.09.17.21263624	False	Baden et al. (2021)	n/a	The incidence rate of Covid-19 during the Delta-dominant period (Jul-Aug 2021) was lower for late vaccinated (49.0/1000 person-years) [formerly placebo]  versus early vaccinated (77.1/1000 person-years) participants in the Moderna mRNA-1273 Phase 3 trials, representing a 36.4% VE reduction (95% CI 17.1%-51.5%). There were fewer severe Covid-19 cases in the late group (6: 6.2/1000 person-years) than early (13: 3.3/1000 person-years), representing a 46.0%  reduction (95% CI −52.4%-83.2%). Three Covid-19 related hospitalizations occurred with two resulting deaths in the early group.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	2.3x reduction in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees) [exact set of variants used is not listed in the manuscript]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Rosenke	2022	doi:10.1172/jci.insight.160108	pmid:35579953	https://doi.org/10.1172/jci.insight.160108	True	Rosenke et al. (2022)	n/a	Infectious viral titers in lung tissue determined using a tissue culture infectious dose (TCID) assay in 10 hamsters showed that Delta Molnupiravir (MK-4482) had ~4x fold drop.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine efficacy	n/a	n/a	Nasreen	2021	doi:10.1101/2021.06.28.21259420	n/a	https://doi.org/10.1101/2021.06.28.21259420	False	Nasreen et al. (2021)	n/a	Using a test-negative design using Ontario data between Dec 14, 2020 and May 30, 2021, 421,073 symptomatic community-dwelling individuals were tested. Against Delta, vaccine effectiveness after partial vaccination tended to be lower compared to Alpha for mRNA-1273 (72% vs. 83%) and BNT162b2 (56% vs. 66%),  but was similar to Alpha for ChAdOx1 (67% vs. 64%). Full vaccination with BNT162b2 increased protection against Delta (87%) to levels comparable to  Alpha (89%) and Beta/Gamma (84%). Delta-positive cases were biased towards young male residents of the Peel region.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	outcome hazard ratio	n/a	n/a	UNKNOWN	2021	doi:10.1503/cmaj.211248	pmid:34610919	https://doi.org/10.1503/cmaj.211248	True	UNKNOWN et al. (2021)	n/a	In Ontario between Feb 7 and Jun 27, 2021, increased risk with the Delta variant was 108% (95% CI 78%–140%) for hospitalization,  235% (95% CI 160%–331%) for ICU admission and 133% (95% CI 54%–231%) for death.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Ferreira	2021	doi:10.1101/2021.05.08.443253	n/a	https://doi.org/10.1101/2021.05.08.443253	False	Ferreira et al. (2021)	n/a	Vaccination of health care workers in Delhi was started in early 2021, with the ChdOx-1 (Astra Zeneca) vaccine. Surveillance has suggested B.1.1.7 dominance in the Delhi area during early 2021, with growth of B.1.617 since March 2021. During the wave of infections during March and April an outbreak of SARS-CoV-2 was confirmed in 33 vaccinated staff  members at a single tertiary centre (age 27-77 years). Sequencing revealed that 16/33 were B.1.617.2, with a range of other B lineage viruses including B.1.1.7 for the rest except one A lineage case.  Importantly no severe cases were documented in this event.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine efficacy	n/a	n/a	Lopez Bernal	2021	doi:10.1056/NEJMoa2108891	pmid:34289274	https://doi.org/10.1056/NEJMoa2108891	True	Lopez Bernal et al. (2021)	n/a	Effectiveness after one dose of vaccine (BNT162b2 or ChAdOx1 nCoV-19) with the delta variant was (30.7%: 95% confidence interval [CI], 25.2 to 35.7): the results were similar for both vaccines.  With the BNT162b2 vaccine, the effectiveness of two doses was 88.0% (95% CI, 85.3 to 90.1) among those with the delta variant.  With the ChAdOx1 nCoV-19 vaccine, the effectiveness of two doses was 67.0% (95% CI, 61.3 to 71.8) among those with the delta variant.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	This variant combination (representing lineage B.1.617.2 aka Delta) showed a 1.92x decrease in Spike binding (relative to D614G alone)  by 5 plasma collected 8 months post-symptom-onset. [exact variant list not provided in manuscript, is inferred and  represents minimal set agreed upon commonly]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing lineage B.1.617.2 aka Delta) showed a 2.34x increase  in binding (KD) relative to D614G. [exact variant list not provided in manuscript, is inferred and represents minimal set agreed upon commonly]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine efficacy	n/a	n/a	Puranik	2021	doi:10.1101/2021.08.06.21261707	pmid:34401884	https://doi.org/10.1101/2021.08.06.21261707	False	Puranik et al. (2021)	n/a	In Minnesota in July 2020 (when Delta variant prevalence was >70%), the effectiveness against infection for mRNA-1273 was estimated at 76%  (95% CI: 58-87%) using age, sex, race, PCR testing and vaccination date matched cohorts of unvaccinated, Pfizer and Moderna vaccinees.  An even more pronounced reduction in effectiveness was observed for BNT162b2 of 42% (95% CI: 13-62%).  mRNA-1273 conferred a two-fold risk reduction against breakthrough infection compared to BNT162b2 (IRR 	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine efficacy	n/a	n/a	Bruxvoort	2021	doi:10.1101/2021.09.29.21264199	n/a	https://doi.org/10.1101/2021.09.29.21264199	False	Bruxvoort et al. (2021)	n/a	In a 1:5 test-negative matched control study of 8153 individuals who received the Moderna mRNA-1273 vaccine, 2027 test-positive cases were Delta. Two dose vaccine efficacy against Delta decreased from 94.1% (90.5-96.3%) 14-60 days after vaccination to 80.0%  (70.2-86.6%) 151-180 days after vaccination. Waning was less pronounced for non-Delta variants. VE against Delta  was lower among individuals aged ≥65 years (75.2% [59.6-84.8%]) than those aged 18-64 years (87.9% [85.5-89.9%]).  VE against Delta hospitalization was 97.6% (92.8-99.2%). One-dose VE was 77.0% (60.7-86.5%) against Delta infection.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs 47D10. Delta (B.1.617.2) has an IC50 fold change of 46.5x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs Bi-Nab35B5-47D10. Delta (B.1.617.2) has an IC50 fold change of 0.57x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs Bi-Nab47D10-35B5. Delta (B.1.617.2) has an IC50 fold change of 0.15x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs 35B5. Delta (B.1.617.2) has an IC50 fold change of 0.87x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Kumar	2022	doi:10.1101/2022.05.13.491770	n/a	https://doi.org/10.1101/2022.05.13.491770	False	Kumar et al. (2022)	n/a	BnAb 002-S21F2 IC50 on the Delta (B.1.617.2) variant is 0.6x fold the wildtype.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	reinfection	n/a	n/a	Salehi-Vaziri	2021	doi:10.1016/j.virusres.2021.198421	pmid:33836204	https://doi.org/10.1016/j.virusres.2021.198421	True	Salehi-Vaziri et al. (2021)	n/a	A 42yo Iranian male was reinfected with B.1.36 lineage virus 128 days after infection with genetically distinct B.1.36 virus, with negative PCR tests in between. In the first instance patient presented with cough, headache, severe diarrhea. In the second instance symptoms were more severe: body pain, shortness of breath, headache and anosmia. Anti-SARS-CoV-2 IgG and IgM tests were negative after both episodes. [Non-seroconversion may be associated with elevated risk of re-infection] [I210del is a homoplasy that has appeared in several disparate parts of the global phylogenetic tree, including A and B lineages, primarily in LMICs]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	humoral response durability	n/a	n/a	Brehm	2021	doi:10.3390/v13040661	pmid:33921216	https://doi.org/10.3390/v13040661	True	Brehm et al. (2021)	n/a	27yo female nurse reinfected in December 2020 (B.1.177) after initial infection in March 2020 (B.3), i.e. with a  9 month interval. Both cases were mild. No significant differences in the neutralizing capacity of the two lineages were observed in 4 sera taken (1 pre-reinfection,  three post-reinfection). Neutralizing antibody titres (IC50) before and immediately after re-infection were <300 against  both strains, and jumped >7x upon re-infection. Viral titres were also higher in the second case. Second case also includes N:p.A220V	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	reinfection	n/a	n/a	Brehm	2021	doi:10.3390/v13040661	pmid:33921216	https://doi.org/10.3390/v13040661	True	Brehm et al. (2021)	n/a	27yo female nurse reinfected in December 2020 (B.1.177) after initial infection in March 2020 (B.3). Both cases were mild. Second case also includes N:p.A220V	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	syncytium formation	n/a	n/a	Kim	2021	doi:10.3390/v13040633	pmid:33917138	https://doi.org/10.3390/v13040633	True	Kim et al. (2021)	n/a	Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, no change relative to D614G.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	trafficking	n/a	n/a	Kim	2021	doi:10.3390/v13040633	pmid:33917138	https://doi.org/10.3390/v13040633	True	Kim et al. (2021)	n/a	~4x more efficient S2 domain cleavage compared to wild type, no change relative to D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	trafficking	n/a	n/a	Kim	2021	doi:10.3390/v13040633	pmid:33917138	https://doi.org/10.3390/v13040633	True	Kim et al. (2021)	n/a	No change in infectivity (24h) relative to D614G alone in Caco-2 cells, Vero or Calu-3.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	trafficking	n/a	n/a	Hu	2021	doi:10.1101/2021.01.22.427749	n/a	https://doi.org/10.1101/2021.01.22.427749	False	Hu et al. (2021)	n/a	The entry efficiencies of Spike pseudotyped viruses bearing N501Y Variant 2 (B.1.351) mutant were about 3 to 4.4 times higher than that of the WT pseudovirus when viral input was normalized, suggesting that these spike variants promote the infectivity of SARS-CoV-2.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	transmissibility	n/a	n/a	Roquebert	2021	doi:10.1101/2021.05.12.21257130	n/a	https://doi.org/10.1101/2021.05.12.21257130	False	Roquebert et al. (2021)	n/a	36,590 variant-specific RT-PCR tests were performed on samples collected between April 12 and May 7, 2021  in France to compare variant spread. Compared to January to March 2021, B.1.351 variant had a significant  transmission advantage over B.1.1.7 in some regions (15.1 to 16.1% in Île-de-France and 16.1 to 18.8% in Hauts-de-France). This shift in transmission advantage is consistent with the immune evasion abilities of B.1.351 and the high levels of immunization in these regions.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	transmissibility	n/a	n/a	Pearson	2021	n/a	n/a	https://cmmid.github.io/topics/covid19/reports/sa-novel-variant/2021_01_11_Transmissibility_and_severity_of_501Y_V2_in_SA.pdf	False	Pearson et al. (2021)	n/a	Assuming complete cross-protection, we estimate 501Y.V2/B.1.351 was 1.50 (95% CrI: 1.20-2.13) times as transmissible than previously circulating variants. Assuming instead that 501Y.V2 is identically transmissible, the new variant evades 21% (95% CrI: 11-36%) of previously acquired immunity. Reality may lie between these extremes, with an intermediate increase in transmissibility and mildly imperfect cross-protection from past exposure.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Alenquer	2021	doi:10.1101/2021.04.22.441007	n/a	https://doi.org/10.1101/2021.04.22.441007	False	Alenquer et al. (2021)	n/a	Average ~10-fold reduction in neutralization efficacy in convalescent sera of 16 health workers infected in Spring 2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Madhi	2021	doi:10.1056/NEJMoa2102214	pmid:33725432	https://doi.org/10.1056/NEJMoa2102214	True	Madhi et al. (2021)	n/a	In a multicenter, double-blind, randomized, controlled trial to assess the safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) with enrollment June 24 and November 9, 2020 from ~2000 HIV-negative 18-64 year olds (1:1 placebo to treatment), incidence of serious  adverse events 14 or more days post- 2nd dose was balanced between the vaccine and placebo groups. A two-dose regimen of the ChAdOx1  nCoV-19 vaccine did not show protection against mild-to-moderate Covid-19 due to the B.1.351 variant. Serum samples obtained from 13 ChAdOx1 nCoV-19 vaccine recipients without SARS-CoV-2 infection through 41 days after vaccination  showed 3.5x reduction in neutralization (ID50) for B.1.351 RBD pseudotype HIB-1 virus compared to D614G alone. This  RBD variant combination's neutralization by a placebo control  group of 6 naturally infected patients showed a similar 3.2x drop (though with D614G starting at a 1.7x higher titre than vaccinee sera).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Hu	2021	doi:10.1101/2021.01.22.427749	n/a	https://doi.org/10.1101/2021.01.22.427749	False	Hu et al. (2021)	n/a	Neutralizing antibody titers of 18 samples (90%) decreased against this B.1.351 pseudotyped virus below an ID50 threshold of 40 (sera  collected ~8mo post Jan 2020 first wave in China).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Hu	2021	doi:10.1101/2021.01.22.427749	n/a	https://doi.org/10.1101/2021.01.22.427749	False	Hu et al. (2021)	n/a	Abolished neutralization by mAbs CQ026 and CQ038, greatly diminished neutralization by CQ012 and CQ046.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kuzmina	2021	doi:10.1016/j.chom.2021.03.008	pmid:33789085	https://doi.org/10.1016/j.chom.2021.03.008	True	Kuzmina et al. (2021)	n/a	This variant of key B.1.351 lineage mutations showed ~10x decrease in Pfizer sera (3 weeks post-first dose: n 	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kuzmina	2021	doi:10.1016/j.chom.2021.03.008	pmid:33789085	https://doi.org/10.1016/j.chom.2021.03.008	True	Kuzmina et al. (2021)	n/a	This variant showed ~10x decrease in Pfizer sera (3 weeks post-first dose: n 	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	trafficking	n/a	n/a	Kim	2021	doi:10.3390/v13040633	pmid:33917138	https://doi.org/10.3390/v13040633	True	Kim et al. (2021)	n/a	~5x more efficient S2 domain cleavage compared to wild type, compared to 4x by D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).  [N501Y+D614G does not show an increase in cleavage, therefore a synergistic effect of the trio is implied]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kuzmina	2021	doi:10.1016/j.chom.2021.03.008	pmid:33789085	https://doi.org/10.1016/j.chom.2021.03.008	True	Kuzmina et al. (2021)	n/a	This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n 	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	trafficking	n/a	n/a	Kuzmina	2021	doi:10.1016/j.chom.2021.03.008	pmid:33789085	https://doi.org/10.1016/j.chom.2021.03.008	True	Kuzmina et al. (2021)	n/a	~9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (no synergy as level approx. that of N501Y alone).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kuzmina	2021	doi:10.1016/j.chom.2021.03.008	pmid:33789085	https://doi.org/10.1016/j.chom.2021.03.008	True	Kuzmina et al. (2021)	n/a	This variant showed only minor in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	trafficking	n/a	n/a	Kuzmina	2021	doi:10.1016/j.chom.2021.03.008	pmid:33789085	https://doi.org/10.1016/j.chom.2021.03.008	True	Kuzmina et al. (2021)	n/a	~2x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Dejnirattisai	2021	doi:10.1016/j.cell.2021.03.055	pmid:33852911	https://doi.org/10.1016/j.cell.2021.03.055	True	Dejnirattisai et al. (2021)	n/a	The KD for the pseudotyped P.1-ACE2 interaction is 4.8 nM, showing that binding to P.1 is essentially indistinguishable from B.1.351 (4.0 nM), which binds with ~19x greater affinity that wild type.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	reinfection	n/a	n/a	Rani	2021	doi:10.1002/jmv.26997	pmid:33818797	https://doi.org/10.1002/jmv.26997	True	Rani et al. (2021)	n/a	A 47yo Indian male was reinfected with B.1.36 lineage virus in September 2020 after infection with genetically distinct B.1.36 virus in  July, with negative PCR tests in between. While the forst episode was asymptomatic, the second included fever, cough, and malaise.  The second case additionally contained stopgain ORF3a:E261*	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	transmissibility	n/a	n/a	Mishra	2021	doi:10.1101/2021.10.04.463028	n/a	https://doi.org/10.1101/2021.10.04.463028	False	Mishra et al. (2021)	n/a	Using a pseudovirus assay, this NTD+RBD mutation combination from B.1.617.3 conferred a ~3x infectivity advantage to the spike particles  [less than L452R or E484Q alone working with the delins].	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing lineage B.1.617) showed a 1.85x increase  in binding (KD) relative to D614G. [exact variant list not provided in manuscript, is inferred fro common knowledge]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	1.4x reduction in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees)	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	transmissibility	n/a	n/a	Tada	2021	doi:10.1101/2021.05.14.444076	n/a	https://doi.org/10.1101/2021.05.14.444076	False	Tada et al. (2021)	n/a	The combination caused a 3-fold increase in infectivity relative to D614G wild type. [compare to 3.5x for L452R alone]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Tada	2021	doi:10.1101/2021.05.14.444076	n/a	https://doi.org/10.1101/2021.05.14.444076	False	Tada et al. (2021)	n/a	Pseudotyped viruses for B.1.617 was 2.3-fold resistant to neutralization by convalescent sera compared to wild type - a finding that was similar to that of the 3-fold resistance of the South Africa B.1.351 variant using the same assay. The resistance of B.1.617 was caused by the L452R and E484Q mutation, based on results from viruses pseudotyped for individual variants within B.1.617. [details on the convalescent patient sera collection are not abundantly clear in the preprint]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Mishra	2021	doi:10.1101/2021.10.04.463028	n/a	https://doi.org/10.1101/2021.10.04.463028	False	Mishra et al. (2021)	n/a	Using a pseudovirus assay and 6 ChAdOx1 vaccinee sera, this NTD+RBD mutation combination from B.1.617.3 conferred a ~3x drop in neutralization (NT50)  [working with the delins, less than just L452R but more than just E484Q].	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	This variant combination (representing lineage B.1.617) showed a 1.30x decrease in Spike binding (relative  to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.   1.18x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees. [exact variant list not provided in manuscript, is inferred fro common knowledge]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Tada	2021	doi:10.1101/2021.05.14.444076	n/a	https://doi.org/10.1101/2021.05.14.444076	False	Tada et al. (2021)	n/a	Pseudotyped viruses for B.1.617 was 4-fold resistant to neutralization by 6 BNT162b2 vaccine sera 28 days post-booster compared to wild type - a finding that was similar to that of the 3.4-fold resistance of the South Africa B.1.351 variant using the same assay. Neutralization by 3 Moderna vaccine sera 28 days post-booster was 5-fold resistant (vs. 2.2-fold for B.1.351). The resistance of B.1.617 was caused by the L452R and E484Q mutation, based on results from viruses pseudotyped for individual variants within B.1.617.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	This variant combination (representing lineage B.1.617) showed a 1.22x decrease in Spike binding (relative  to D614G alone) by 5 plasma collected 8 months post-symptom-onset. [exact variant list not provided in manuscript, is inferred fro common knowledge]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	syncytium formation	n/a	n/a	Mishra	2021	doi:10.1101/2021.10.04.463028	n/a	https://doi.org/10.1101/2021.10.04.463028	False	Mishra et al. (2021)	n/a	Using ACE2-GFP+Spike-RFP fluorescence assay, this NTD+RBD mutation combination from B.1.617.3 increased syncytium formation ~2.5x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	transmissibility	n/a	n/a	Tada	2021	doi:10.1101/2021.05.14.444076	n/a	https://doi.org/10.1101/2021.05.14.444076	False	Tada et al. (2021)	n/a	Normalized for particle number, on ACE2.293T cells showed that the B.1.617 spike protein was >2-fold increase in infectivity relative to D614G wild type.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Mishra	2021	doi:10.1101/2021.10.04.463028	n/a	https://doi.org/10.1101/2021.10.04.463028	False	Mishra et al. (2021)	n/a	Using a pseudovirus assay and 6 ChAdOx1 vaccinee sera, this NTD+RBD mutation combination from B.1.617.3 conferred a  7.42x drop in neutralization (NT50) [mostly from 3 of the sera].	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine efficacy	n/a	n/a	Bruxvoort	2021	doi:10.1101/2021.09.29.21264199	n/a	https://doi.org/10.1101/2021.09.29.21264199	False	Bruxvoort et al. (2021)	n/a	In a 1:5 test-negative matched control study of 8153 individuals who received the Moderna mRNA-1273 vaccine, 583 test-positive were Epsilon. Two dose vaccine efficacy against Epsilon was 97.6 (90.2-99.4%), one dose VE was 76.3 (48.1-89.1%).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Mishra	2021	doi:10.1101/2021.10.04.463028	n/a	https://doi.org/10.1101/2021.10.04.463028	False	Mishra et al. (2021)	n/a	Using a pseudovirus assay and 6 ChAdOx1 vaccinee sera, this RBD mutation conferred a 2.36x drop in neutralization (NT50).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	transmissibility	n/a	n/a	Tada	2021	doi:10.1101/2021.05.14.444076	n/a	https://doi.org/10.1101/2021.05.14.444076	False	Tada et al. (2021)	n/a	Increased infectivity of the B.1.617 spike was attributed to L452R, which itself caused a 3.5-fold increase in infectivity relative to D614G wild type.  [In combination with E484Q caused a somewhat less 3-fold increase]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	transmissibility	n/a	n/a	Mishra	2021	doi:10.1101/2021.10.04.463028	n/a	https://doi.org/10.1101/2021.10.04.463028	False	Mishra et al. (2021)	n/a	The L452R mutation increased the infectivity more than two-fold in these conditions.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	transmissibility	n/a	n/a	Mishra	2021	doi:10.1101/2021.10.04.463028	n/a	https://doi.org/10.1101/2021.10.04.463028	False	Mishra et al. (2021)	n/a	Using a pseudovirus assay, this NTD+RBD mutation combination from B.1.617.3 conferred a ~2x infectivity advantage to the spike particles.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	syncytium formation	n/a	n/a	Mishra	2021	doi:10.1101/2021.10.04.463028	n/a	https://doi.org/10.1101/2021.10.04.463028	False	Mishra et al. (2021)	n/a	Using ACE2-GFP+Spike-RFP fluorescence assay, this NTD+RBD mutation combination from B.1.617.3 increased syncytium formation ~2x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	symptom prevalence	n/a	n/a	Fournier	2021	doi:10.1016/j.ijid.2021.03.068	pmid:33785459	https://doi.org/10.1016/j.ijid.2021.03.068	True	Fournier et al. (2021)	n/a	Compared to the clade 20A strains that predominated during phase 1 between March and May 2020, the Marseille-4 variant (characterized  by this mutation plus N:p.M234I:A376T) was associated with a lower frequency of cough, rhinitis, and olfactory and gustatory disorders.  By contrast, hypoxemia was more frequent in patients infected with the Marseille-4 variant.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	reinfection	n/a	n/a	Fournier	2021	doi:10.1016/j.ijid.2021.03.068	pmid:33785459	https://doi.org/10.1016/j.ijid.2021.03.068	True	Fournier et al. (2021)	n/a	11 cases of re-infection with the 'Marseille-4' variant found within 1028 positive tests, where all of the earlier infections were from different strains. This lineage is also characterized by N:p.M234I:A376T	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma binding	n/a	n/a	Tada	2021	doi:10.1101/2021.02.05.430003	pmid:33564768	https://doi.org/10.1101/2021.02.05.430003	False	Tada et al. (2021)	n/a	Lentiviral pseudotyped with the key mutations from 20A.EU2 lineage was neutralized slightly less than D614G in 10 convalescent sera from April 2020 infectees.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	trafficking	n/a	n/a	Tada	2021	doi:10.1101/2021.02.05.430003	pmid:33564768	https://doi.org/10.1101/2021.02.05.430003	False	Tada et al. (2021)	n/a	Lentiviral pseudotyped with the key mutations from 20A.EU2 lineage was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing no significant change in infection rate amongst the cells, suggesting that this  mutation does not contributing to cell entry fitness.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	trafficking	n/a	n/a	Kuzmina	2021	doi:10.1016/j.chom.2021.03.008	pmid:33789085	https://doi.org/10.1016/j.chom.2021.03.008	True	Kuzmina et al. (2021)	n/a	~13x more infective as D614G alone in HEK293T-ACE2 cells 48h post-transduction.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	trafficking	n/a	n/a	Kuzmina	2021	doi:10.1016/j.chom.2021.03.008	pmid:33789085	https://doi.org/10.1016/j.chom.2021.03.008	True	Kuzmina et al. (2021)	n/a	Approximately as infective as D614G alone in HEK293T-ACE2 cells 48h post-transduction (~additive effects of the individual variants).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	syncytium formation	n/a	n/a	Kim	2021	doi:10.3390/v13040633	pmid:33917138	https://doi.org/10.3390/v13040633	True	Kim et al. (2021)	n/a	~50% Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, signficantly higher than D614G.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	trafficking	n/a	n/a	Kuzmina	2021	doi:10.1016/j.chom.2021.03.008	pmid:33789085	https://doi.org/10.1016/j.chom.2021.03.008	True	Kuzmina et al. (2021)	n/a	~12x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (~additive effects of 501 and 484).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	trafficking	n/a	n/a	Kim	2021	doi:10.3390/v13040633	pmid:33917138	https://doi.org/10.3390/v13040633	True	Kim et al. (2021)	n/a	~6x more efficient S2 domain cleavage compared to wild type, compared to 4x by D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3). [N501Y+D614G does not show an increase in cleavage, therefore a synergistic effect of the trio is implied]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	trafficking	n/a	n/a	Kim	2021	doi:10.3390/v13040633	pmid:33917138	https://doi.org/10.3390/v13040633	True	Kim et al. (2021)	n/a	More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~11x, Vero ~10x, and Calu-3 ~11x. Compare to wild type at ~5x across cell types.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Sapkal	2021	doi:10.1101/2021.04.30.441559	n/a	https://doi.org/10.1101/2021.04.30.441559	False	Sapkal et al. (2021)	n/a	The study demonstrated 1.92 and 1.09 fold reductions (ELISA) in the neutralizing titer against B.1.1.28.2 (P2) variant (n	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	UNKNOWN	2021	n/a	n/a	https://www.fda.gov/media/146217/download	False	UNKNOWN et al. (2021)	n/a	Study 3001 on Ad26.COV2.S (Jannsen vaccine) conducted September 21, 2020 through January 22, 2021 overlaps the emergence and dominance  of the P.1 & P.2 lineages of SARS-CoV-2 in Brazil. The Brazilian arm of the Phase 3 double blind study showed severe/critical disease VE of 81.9%  (95% CI: 17.0-98.1), and moderate to severe/critical disease VE of 66.2% (95% CI: 51.0-77.1). Compare to 78.0% and 74.4% for North American arm of the study during the same period (with low B.1.351 prevalence). Of the 69.3% of mostly severe infections sequenced as of this report, 69.4% were of P.2 lineage [defining lineage SNPs reported here].	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Tada	2021	doi:10.1101/2021.05.14.444076	n/a	https://doi.org/10.1101/2021.05.14.444076	False	Tada et al. (2021)	n/a	Pseudotyped viruses for B.1.618 was 2.7-fold resistant to neutralization by 6 BNT162b2 vaccine sera 28 days post-booster compared to wild type - a finding that was similar to that of the 3.4-fold resistance of the South Africa B.1.351 variant using the same assay. Neutralization by 3 Moderna vaccine sera 28 days post-booster was 3-fold resistant (vs. 2.2-fold for B.1.351). The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Tada	2021	doi:10.1101/2021.05.14.444076	n/a	https://doi.org/10.1101/2021.05.14.444076	False	Tada et al. (2021)	n/a	Pseudotyped viruses for B.1.618 was 2.5-fold resistant to neutralization by convalescent sera compared to wild type - a finding that was similar to that of the 3-fold resistance of the South Africa B.1.351 variant using the same assay. The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618. [details on the convalescent patient sera collection are not abundantly clear in the preprint]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Garcia-Beltran	2021	doi:10.1016/j.cell.2021.03.013	pmid:33743213	https://doi.org/10.1016/j.cell.2021.03.013	True	Garcia-Beltran et al. (2021)	n/a	Pseudotyped P.2 virus has reduced neutralization activity vs wild type: 5.8x (30 sera Pfizer median 9 days post 2nd dose)  and 2.9x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Mishra	2021	doi:10.1101/2021.10.04.463028	n/a	https://doi.org/10.1101/2021.10.04.463028	False	Mishra et al. (2021)	n/a	Using a pseudovirus assay and 6 ChAdOx1 vaccinee sera, this NTD+RBD mutation combination from B.1.617.3 conferred a  1.34x drop in neutralization (NT50) [mostly from a single serum].	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	transmissibility	n/a	n/a	Mishra	2021	doi:10.1101/2021.10.04.463028	n/a	https://doi.org/10.1101/2021.10.04.463028	False	Mishra et al. (2021)	n/a	Using a pseudovirus assay, this NTD+RBD mutation combination from B.1.617.3 conferred a ~4x infectivity advantage to the spike particles.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	transmissibility	n/a	n/a	Mishra	2021	doi:10.1101/2021.10.04.463028	n/a	https://doi.org/10.1101/2021.10.04.463028	False	Mishra et al. (2021)	n/a	Using a pseudovirus assay, RBD-specific mutation E484Q did not significantly confer infectivity advantage to the spike particles.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	syncytium formation	n/a	n/a	Mishra	2021	doi:10.1101/2021.10.04.463028	n/a	https://doi.org/10.1101/2021.10.04.463028	False	Mishra et al. (2021)	n/a	Using ACE2-GFP+Spike-RFP fluorescence assay, this NTD+RBD mutation combination from B.1.617.3 did not affect syncytium formation.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kuzmina	2021	doi:10.1016/j.chom.2021.03.008	pmid:33789085	https://doi.org/10.1016/j.chom.2021.03.008	True	Kuzmina et al. (2021)	n/a	This variant showed no change in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	trafficking	n/a	n/a	Kim	2021	doi:10.3390/v13040633	pmid:33917138	https://doi.org/10.3390/v13040633	True	Kim et al. (2021)	n/a	More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~13x, Vero ~10x, and Calu-3 ~10x. Compare to wild type at ~5x across cell types.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	trafficking	n/a	n/a	Kuzmina	2021	doi:10.1016/j.chom.2021.03.008	pmid:33789085	https://doi.org/10.1016/j.chom.2021.03.008	True	Kuzmina et al. (2021)	n/a	9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	trafficking	n/a	n/a	Kim	2021	doi:10.3390/v13040633	pmid:33917138	https://doi.org/10.3390/v13040633	True	Kim et al. (2021)	n/a	More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~9x, Vero ~8x, and Calu-3 ~8x. Compare to wild type at ~5x across cell types.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	trafficking	n/a	n/a	Tada	2021	doi:10.1101/2021.02.05.430003	pmid:33564768	https://doi.org/10.1101/2021.02.05.430003	False	Tada et al. (2021)	n/a	Lentiviral pseudotyped with the key mutations from COH.20G/677H lineage was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing no significant change in infection rate amongst the cells, suggesting that this  mutation does not contributing to cell entry fitness.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma binding	n/a	n/a	Tada	2021	doi:10.1101/2021.02.05.430003	pmid:33564768	https://doi.org/10.1101/2021.02.05.430003	False	Tada et al. (2021)	n/a	Lentiviral pseudotyped with the key mutations from COH.20G/677H ('Ohio') lineage was neutralized similarly to D614G in 10 convalescent sera from April 2020 infectees.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Tada	2021	doi:10.1101/2021.02.05.430003	pmid:33564768	https://doi.org/10.1101/2021.02.05.430003	False	Tada et al. (2021)	n/a	Lentiviral pseudotyped with the key mutations from COH.20G/677H lineage was tested on ACE2.293T cells for ACE2 affinity changes vs D614G alone, showing a ~70% drop in IC50 (i.e. increased affinity).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	anthropozoonotic events	n/a	n/a	Li	2023	doi:10.1038/s41396-023-01368-2	pmid:36690780	https://doi.org/10.1038/s41396-023-01368-2	True	Li et al. (2023)	n/a	This mutation (a.k.a. 'Doug') outside the receptor binding domain, while highly favorable to improved human-human transmission,  decreases transduction in naked mole-rat (Heterocephalus glaber)  fibroblast and Japanese pipistrelle bat (Pipistrellus abramus) cell cultures using a pseudotyped VSV assay.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	trafficking	n/a	n/a	Daniloski	2021	doi:10.7554/eLife.65365	pmid:33570490	https://doi.org/10.7554/eLife.65365	True	Daniloski et al. (2021)	n/a	The increased transduction with Spike D614G ranged from 1.3- to 2.4-fold in Caco-2 and Calu-3 cells expressing  endogenous ACE2 and from 1.5- to 7.7-fold in A549ACE2 and Huh7.5ACE2 overexpressing ACE2.  Although there is minimal difference in ACE2 receptor binding between the D614 and G614 Spike variants,  the G614 variant is more resistant to proteolytic cleavage, suggesting a possible mechanism for the increased transduction.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	trafficking	n/a	n/a	Kim	2021	doi:10.3390/v13040633	pmid:33917138	https://doi.org/10.3390/v13040633	True	Kim et al. (2021)	n/a	~4x more efficient S2 domain cleavage compared to wild type in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	1.14x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kuzmina	2021	doi:10.1016/j.chom.2021.03.008	pmid:33789085	https://doi.org/10.1016/j.chom.2021.03.008	True	Kuzmina et al. (2021)	n/a	Using a lentivirus virus pseudotyped with D614G Spike, sera from vaccinated individuals who received the second dose (9–11 days post-second dose of Pfizer) exhibited a robust  neutralizing potential, with a mean NT50 value of 99,000. This was an average of a 2-fold increase, relative to sera drawn from the  individuals who received one dose of vaccination—mean NT50 dilution of 51,300. Importantly, a 6-fold increase in mean NT50 dilution was  obtained when sera from the first vaccination dose was compared to convalescent sera from cohort with severe disease (NT50 51,000 vs 8,700)  21 to 63 days post-onset.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	1.08x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.11x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Li	2020	doi:10.1016/j.cell.2020.07.012	pmid:32730807	https://doi.org/10.1016/j.cell.2020.07.012	True	Li et al. (2020)	n/a	In four cell lines (including 293T-hACE2 cells), this mutation combination increases infectivity vs D614G alone	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Mishra	2021	doi:10.1101/2021.10.04.463028	n/a	https://doi.org/10.1101/2021.10.04.463028	False	Mishra et al. (2021)	n/a	Using a pseudovirus assay and 6 ChAdOx1 vaccinee sera, this NTD mutation conferred a 4.85x drop in neutralization (NT50).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Garcia-Beltran	2021	doi:10.1016/j.cell.2021.03.013	pmid:33743213	https://doi.org/10.1016/j.cell.2021.03.013	True	Garcia-Beltran et al. (2021)	n/a	Pseudotyped D614G virus has reduced neutralization activity vs wild type: 1.2x (37 sera Pfizer median 9  days post 2nd dose, 37 sera Moderna median 18 days post 2nd dose). This was NOT significant by ANOVA.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	virion structure	n/a	n/a	Yurkovetskiy	2020	doi:10.1016/j.cell.2020.09.032	pmid:32991842	https://doi.org/10.1016/j.cell.2020.09.032	True	Yurkovetskiy et al. (2020)	n/a	CryoEM shows increased proportion of 'one-up' trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Cathcart	2021	doi:10.1101/2021.03.09.434607v9	n/a	https://doi.org/10.1101/2021.03.09.434607v9	False	Cathcart et al. (2021)	n/a	This individual mutation found in the epitope from Sotrovimab causes a 1.0x reduction in neutralization efficacy using a VSV model on Vero E6 cells.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	virion structure	n/a	n/a	Zhang	2020	doi:10.1038/s41467-020-19808-4	pmid:33243994	https://doi.org/10.1038/s41467-020-19808-4	True	Zhang et al. (2020)	n/a	Based on pseudotyped virus experiments, D614G may increase infectivity by assembling more functional S protein into the virion.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	1.43x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.37x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	transmissibility	n/a	n/a	Mishra	2021	doi:10.1101/2021.10.04.463028	n/a	https://doi.org/10.1101/2021.10.04.463028	False	Mishra et al. (2021)	n/a	Using a pseudovirus assay, this NTD mutation combination from B.1.617.3 conferred a nearly two-fold infectivity advantage to the spike particles.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	trafficking	n/a	n/a	Ozono	2020	doi:10.1038/s41467-021-21118-2	pmid:33558493	https://doi.org/10.1038/s41467-021-21118-2	True	Ozono et al. (2020)	n/a	Among S variants tested, the D614G mutant shows the highest cell entry (~3.5x wild type), as supported by  structural and binding analyses.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	trafficking	n/a	n/a	UNKNOWN	2020	doi:10.1038/s41467-020-19808-4	pmid:33243994	https://doi.org/10.1038/s41467-020-19808-4	True	UNKNOWN et al. (2020)	n/a	We report here pseudoviruses carrying SG614 enter ACE2-expressing cells more efficiently than wild type (~9-fold).  This increased entry correlates with less S1-domain shedding and higher S-protein incorporation into the virion.  D614G does not alter S-protein binding to ACE2 or neutralization sensitivity of pseudoviruses. Thus, D614G may  increase infectivity by assembling more functional S protein into the virion.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	trafficking	n/a	n/a	Barrett	2021	doi:10.1101/2021.01.24.428007	pmid:33532777	https://doi.org/10.1101/2021.01.24.428007	False	Barrett et al. (2021)	n/a	Circulating variant shown in vitro to not have major defects or enhancement of cell surface protein trafficking (i.e. Spike cleavage or fusion required for cell entry)	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	environmental condition stability	n/a	n/a	Huang	2021	doi:10.1128/msphere.00104-21	n/a	https://doi.org/10.1128/msphere.00104-21	n/a	Huang et al. (2021)	n/a	Relative to wild type, D614G showed increased infectivity (ie. cold stability) after storage at -20°C for up to 30 days.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	1.53x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a slight decrease in binding (KD) relative to D614G.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	viral load	n/a	n/a	Plante	2020	doi:10.1038/s41586-020-2895-3	pmid:33106671	https://doi.org/10.1038/s41586-020-2895-3	True	Plante et al. (2020)	n/a	Hamsters infected with SARS-CoV-2 expressing spike(D614G) (G614 virus) produced higher infectious titres in nasal washes and the trachea, but not in the lungs,  supporting clinical evidence showing that the mutation enhances viral loads in the upper respiratory tract of COVID-19 patients and may increase transmission.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	virion structure	n/a	n/a	Spratt	2021	doi:10.1101/2021.03.24.436850	pmid:33791700	https://doi.org/10.1101/2021.03.24.436850	False	Spratt et al. (2021)	n/a	Estimated free energy change (ddG) for this variant is 2.5 kcal/mol (i.e. stabilizing relative to wild type)	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	syncytium formation	n/a	n/a	Kim	2021	doi:10.3390/v13040633	pmid:33917138	https://doi.org/10.3390/v13040633	True	Kim et al. (2021)	n/a	Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.35x decrease in binding (KD) relative to D614G.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	1.05x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.45x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	1.97x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.5x decrease in binding (KD) relative to D614G.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	virion structure	n/a	n/a	Weissman	2020	doi:10.1101/2020.07.22.20159905	n/a	https://doi.org/10.1101/2020.07.22.20159905	False	Weissman et al. (2020)	n/a	Negative stain EM shows increased proportion of 'one-up' trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	1.23x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.1x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	No change in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.1x decrease in binding (KD) relative to D614G.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	This variant combination (representing lineage B.1.526) showed a 1.34x increase in Spike binding (relative  to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.19x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	This variant combination (representing lineage B.1.526) showed a 1.02x increase in Spike binding (relative  to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing lineage B.1.526) showed a 1.78x increase  in binding (KD) relative to D614G, even though each variant independently decreases binding.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.42x increase in binding (KD) relative to D614G.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	1.08x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.27x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	1.19x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing lineage B.1.429 aka Epsilon) showed a 2.82x increase  in binding (KD) relative to D614G, indicating a strong marginal effect for L452R.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	This variant combination (representing lineage B.1.429 aka Epsilon) showed a 1.1x decrease in Spike binding  (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. [Stark contrast to 2.15x increase in binding by convalescent plasma 8 months post infection, presumably via memory B cell affinity maturation  against L452R effects] 1.12x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	This variant combination (representing lineage B.1.429 aka Epsilon) showed a 1.1x decrease in Spike binding  (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset, indicating ablated marginal effect from L452R.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	1.30x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  Compare to varied binding in full Spike variant complements for major lineages containing this variant subset: 1.28x increase (B.1.351 aka Beta), and 1.14x decrease (P.1 aka Gamma). 1.47x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees. Compare to varied binding in full Spike variant complements for major lineages containing this variant subset: 1.17x increase (B.1.351 aka Beta), and 1.47x decrease (P.1 aka Gamma).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.07x decrease in binding (KD) relative to D614G. Compare to increased binding in full Spike variant complements for major lineages containing this variant subset: 3.56x (B.1.351 aka Beta), 4.24x (P.1 aka Gamma).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	1.66x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset. Compare to decreased binding in full Spike variant complements for major lineages containing this variant subset: 0.96x (B.1.351 aka Beta), 0.77x (P.1 aka Gamma).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	This variant combination (representing P.1 aka Gamma)  showed a 1.3x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	This variant combination (representing P.1 aka Gamma)  showed a 1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.27x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing P.1 aka Gamma)  showed a 4.24x increase in binding (KD) relative to D614G.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	This variant combination (representing B.1.351 aka Beta)  showed a 1.04x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset, in contrast to the largely positive binding values for each individual mutation that comprises the set.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing B.1.351 aka Beta)  showed a 3.56x increase in binding (KD) relative to D614G.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	This variant combination (representing B.1.351 aka Beta)  showed a 1.28x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. It shows a 1.17x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	1.29x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.39x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.96x increase in binding (KD) relative to D614G.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	1.65x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	1.08x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	1.23x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.37x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.58x increase in binding (KD) relative to D614G.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	1.14x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.51x increase in binding (KD) relative to D614G, mostly due to decreased in 'off-rate' a.k.a. dissociation rate (Kdis).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	1.33x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing B.1.1.7 aka Alpha) had 5.43x increased binding relative to D614G alone.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	This variant combination (representing B.1.1.7 aka Alpha) showed a 1.15x increase in Spike binding  (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	This variant combination (representing B.1.1.7 aka Alpha) showed no change in Spike binding  (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.28x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of  Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination showed no change relative to D614G.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	1.64x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.35x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	2.11x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.33x decrease in binding (KD) relative to D614G.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	1.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.02x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	1.56x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.32x increase in binding (KD) relative to D614G.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	1.37x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.56x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.33x increase in binding (KD) relative to D614G.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	1.15x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	1.03x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.32x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	1.09x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	1.19x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.59x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.82x increase in binding (KD) relative to D614G.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.19x increase in binding (KD) relative to D614G.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	2.29x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	1.79x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.3x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.08x decrease in binding (KD) relative to D614G.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	No significant change in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.19x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	2.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	1.76x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.75x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	1.04x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.1x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.28x increase in binding (KD) relative to D614G.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Wilhelm	2021	doi:10.1101/2021.08.09.21261704	n/a	https://doi.org/10.1101/2021.08.09.21261704	False	Wilhelm et al. (2021)	n/a	Relative to B.1, Epsilon (B.1.417/429) shows 1.74x-2.35x decrease in neutralization efficiency by convalescent plasma [no cohort details provided]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Wilhelm	2021	doi:10.1101/2021.08.09.21261704	n/a	https://doi.org/10.1101/2021.08.09.21261704	False	Wilhelm et al. (2021)	n/a	Relative to B.1, Epsilon (B.1.417/429) shows 1.74x-2.35x decrease in neutralization efficiency by 18 vaccinee sera (BNT162b2 and mRNA1273).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	1.05x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.16x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	2.15x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.66x increase in binding (KD) relative to D614G.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	1.42x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	This variant appears twice in the experiments, with slightly different affinities (both ~1.2x decrease in binding relative to D614G)  using flow cytometry and ACE2 ectodomains-Fc portion IgG complex.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	1.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.06x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.52x increase in binding (KD) relative to D614G, mostly due to decreased in 'off-rate' a.k.a. dissociation rate (Kdis). Compare to full Spike variant complements for major lineages containing this variant subset: 5.43x (B.1.1.7 aka Alpha), 3.56x (B.1.351 aka Beta), 4.24x (P.1 aka Gamma).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	1.17x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	1.29x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.18x increase in binding (KD) relative to D614G, mostly due to decreased in 'off-rate' a.k.a. dissociation rate (Kdis).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	No significant change in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.04x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	1.48x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.21x increase in binding (KD) relative to D614G.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	1.04x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Zuckerman	2021	doi:10.1101/2021.03.25.21253908	n/a	https://doi.org/10.1101/2021.03.25.21253908	False	Zuckerman et al. (2021)	n/a	No significant change in virus neutralzation by 18 Pfizer two dose vaccinee sera compared to B.1.1.7. [results without including the used mutation A27S likely generalizable, as this is not a lineage defining mutation]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.11x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.23x decrease in binding (KD) relative to D614G.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	1.26x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	1.11x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	1.19x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.1x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed essentially no change in binding (KD) relative to D614G.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.12x decrease in binding (KD) relative to D614G.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	1.58x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	1.02x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.47x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	1.06x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	2x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.12x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.3x decrease in binding (KD) relative to D614G.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	1.32x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.22x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	1.56x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.69x decrease in binding (KD) relative to D614G.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	1.96x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.23x increase in binding (KD) relative to D614G, mostly due to decreased in 'off-rate' a.k.a. dissociation rate (Kdis).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	1.09x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.08x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23403	D614G	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A1841G	p.D614G	NC_045512.2(GU280_gp02):g.1841A>G	YP_009724390.1:p.Asp614Gly	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	trafficking	n/a	n/a	Tada	2021	doi:10.1101/2021.05.14.444076	n/a	https://doi.org/10.1101/2021.05.14.444076	False	Tada et al. (2021)	n/a	Quantification of the band intensities showed that the P681R mutation, which lies near the proteolytic processing site,  caused a small increase in proteolytic processing as measured by a 2-fold decrease in the ratio of S/S2.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23423	P621S	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1861T	p.P621S	NC_045512.2(GU280_gp02):g.1861C>T	YP_009724390.1:p.Pro621Ser	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	Pokay	n/a	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	n/a	n/a	n/a	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron BA.2 have higher sensitivity to inhibition by soluble angiotensin converting enzyme 2 (ACE2) and the endosomal inhibitor chloroquine compared  to D614G	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs Bi-Nab35B5-47D10. Omicron BA.2 has an IC50 fold change of 0.07x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs 35B5. Omicron BA.2 has an IC50 fold change of 0.09x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs 47D10. Omicron BA.2 has an IC50 fold change of 0.08x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs Bi-Nab47D10-35B5. Omicron BA.2 has an IC50 fold change of 0.04x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron BA.2 neutralization of the Omicron variants by antibodies induced by three doses of Pfizer/BNT162b2 mRNA vaccine was 7-8-fold less potent than the D614G, and  the Omicron variants still evade neutralization more efficiently.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Kumar	2022	doi:10.1101/2022.05.13.491770	n/a	https://doi.org/10.1101/2022.05.13.491770	False	Kumar et al. (2022)	n/a	BnAb 002-S21F2 IC50 on the Omicron BA.2 variant is 0.8x fold the wildtype.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	virion structure	n/a	n/a	Wang	2021	doi:10.1101/2021.03.01.433466	pmid:33688656	https://doi.org/10.1101/2021.03.01.433466	False	Wang et al. (2021)	n/a	CryoEM reveals the P.1 trimer to adopt exclusively a conformation in which one of the receptor-binding domains is in the “up” position.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Wang	2021	doi:10.1101/2021.03.01.433466	pmid:33688656	https://doi.org/10.1101/2021.03.01.433466	False	Wang et al. (2021)	n/a	In 12 Moderna vaccinee sera 15 days post second dose (43 days since first vaccination), an average 2.8x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 4.8x decrease against the full P.1 type vs WA-1 was observed, though overall with  a higher ID50 reciprocal value. In 10 Pfizer vaccinee sera 7 days or more post second dose (28 days or more since first vaccination), an average 2.2x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.8x decrease against the full P.1 type vs WA-1 was observed, with  similar variant ID50 reciprocal value.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Wang	2021	doi:10.1101/2021.03.01.433466	pmid:33688656	https://doi.org/10.1101/2021.03.01.433466	False	Wang et al. (2021)	n/a	In convalescent sera one month or more post-infection in Spring 2020, an average 6.5x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.4x decrease against the full P.1 type vs WA-1 was observed, with  better full P.1 ID50 reciprocal value compared to the 10-mutation model.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Wang	2021	doi:10.1101/2021.03.01.433466	pmid:33688656	https://doi.org/10.1101/2021.03.01.433466	False	Wang et al. (2021)	n/a	Amongst RBD-targeting Emergency Use Authorized monoclonal antibody treatments CB6, LY-CoV555 and REGN10933 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1, but REGN10987 activity remains strong. RBD-targeting monoclonal antibodies 2-15 and C121 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1. N terminal domain targeting monoclonal antibodies 5-7, 4-8, 4-18 and 2-17 have abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	reinfection	n/a	n/a	Malta Romano	2021	doi:10.1590/S1678-9946202163036	pmid:33909850	https://doi.org/10.1590/S1678-9946202163036	True	Malta Romano et al. (2021)	n/a	After a 128 day interval, a patient in Sao Paulo State, Brazil reinfected with P.1 (first episode likely predates P.1 emergence). Both cases were fairly mild (difficulty breathing, tiredness, dizziness and fatigue).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine efficacy	n/a	n/a	Bruxvoort	2021	doi:10.1101/2021.09.29.21264199	n/a	https://doi.org/10.1101/2021.09.29.21264199	False	Bruxvoort et al. (2021)	n/a	In a 1:5 test-negative matched control study of 8153 individuals who received the Moderna mRNA-1273 vaccine, 349 test-positive were Gamma. Two dose vaccine efficacy against Gamma was 95.5 (90.9-97.8%), one dose VE was 74.2 (43.8-88.1%).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	trafficking	n/a	n/a	Esclera	2021	doi:10.1101/2021.08.05.455290	n/a	https://doi.org/10.1101/2021.08.05.455290	False	Esclera et al. (2021)	n/a	~6x cleavage of S2 relative to WA1 (D614G) wildtype by Gamma variant as measured by mass spectrometry of Vero-TMPRSS culture  [no mutations directly at furin cleavage site, but H655Y is upstream] Compare to 4.5x or less for variants of concern with  direct furin clevage site mutations.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	reinfection	n/a	n/a	Naveca	2021	doi:10.21203/rs.3.rs-318392/v1	n/a	https://doi.org/10.21203/rs.3.rs-318392/v1	False	Naveca et al. (2021)	n/a	Three healthcare workers (29-50yo) had confirmed P.1 [Gamma] re-infection in the Amazonas region of Brazil 3-9 months after initial  infection from viruses with distinct lineage from P.1, but mild symptoms upon re-infection and evidence for infectiousness during re-infection.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Uriu	2021	doi:10.1101/2021.09.06.459005	n/a	https://doi.org/10.1101/2021.09.06.459005	False	Uriu et al. (2021)	n/a	Mean 3.0x reduction of NT50 value P.1 (Gamma) relative to wild type in 8 sera from adult BNT162b2 vaccinees (28-47yo) collected ~1m post booster.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Uriu	2021	doi:10.1101/2021.09.06.459005	n/a	https://doi.org/10.1101/2021.09.06.459005	False	Uriu et al. (2021)	n/a	Mean 4.1x reduction of NT50 value P.1 (Gamma) relative to wild type in 8 sera from older convalescent patients (52-92yo) collected 1-3m post symptom onset.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Kumar	2022	doi:10.1101/2022.05.13.491770	n/a	https://doi.org/10.1101/2022.05.13.491770	False	Kumar et al. (2022)	n/a	BnAb 002-S21F2 IC50 on the Gamma (P.1) variant is 0.6x fold the wildtype.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Chen	2021	doi:10.1038/s41591-021-01294-w	pmid:33664494	https://doi.org/10.1038/s41591-021-01294-w	True	Chen et al. (2021)	n/a	The neutralizing activity of vaccine was slightly lower against B.1.1.248 variant constellation in sera tested from most of the 15 patients with  the BNT162b2 mRNA vaccine. (Fig. 4)	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Gallagher	2021	doi:10.1101/2021.05.03.442455	pmid:33972942	https://doi.org/10.1101/2021.05.03.442455	False	Gallagher et al. (2021)	n/a	ELISpot assays show T cell neutralization reduced by 16.6% in this B.1.1.248 pseudotype relative to wild type in 18-20 pooled patient samples post second mRNA vaccine dose, with no significant difference between Pfizer and Moderna cohorts. Reduction was stronger in the S1 subunit than S2 (separate peptide pools were used).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Chen	2021	doi:10.1038/s41591-021-01294-w	pmid:33664494	https://doi.org/10.1038/s41591-021-01294-w	True	Chen et al. (2021)	n/a	B.1.1.248 variant constellation ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07. B.1.1.248 variant constellation ablates Class 3 N-terminal domain targeting antibody COV2-2676.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Chen	2021	doi:10.1038/s41591-021-01294-w	pmid:33664494	https://doi.org/10.1038/s41591-021-01294-w	True	Chen et al. (2021)	n/a	B.1.1.7 variant constellation two-tailed Wilcoxon matched-pairs signed-rank test against 10 convalescent sera P	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	anthropozoonotic events	n/a	n/a	Montagutelli	2021	doi:10.1101/2021.03.18.436013	n/a	https://doi.org/10.1101/2021.03.18.436013	False	Montagutelli et al. (2021)	n/a	Unlike wild type or B.1.1.7, P.1 lineage virus was able to infect and replicate in common lab mouse strains, with high titer.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Chen	2021	doi:10.1038/s41591-021-01294-w	pmid:33664494	https://doi.org/10.1038/s41591-021-01294-w	True	Chen et al. (2021)	n/a	B.1.1.248 variant constellation in 10 convalescent human sera ~1mo post infection had mild to moderate resistance against most samples, P	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Leier	2021	doi:10.1101/2021.04.25.21256049	pmid:33948601	https://doi.org/10.1101/2021.04.25.21256049	False	Leier et al. (2021)	n/a	Neutralizing antibody titers increased in previously infected vaccinees relative to uninfected vaccinees  4.3-fold against P.1 (contrast with 3.4 fold against original SARS-CoV-2).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Garcia-Beltran	2021	doi:10.1016/j.cell.2021.03.013	pmid:33743213	https://doi.org/10.1016/j.cell.2021.03.013	True	Garcia-Beltran et al. (2021)	n/a	Pseudotyped P.1 virus has reduced neutralization activity vs wild type: 6.7x (30 sera Pfizer median 9 days post 2nd dose)  and 4.5x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Alenquer	2021	doi:10.1101/2021.04.22.441007	n/a	https://doi.org/10.1101/2021.04.22.441007	False	Alenquer et al. (2021)	n/a	Using P.1 defining mutations for Spike, observed 4x average decrease in neutralization efficiency  (but still relevant titres) for sera from 10 BNT162b2 vaccinees 12 days after second dose, but only one  relevant titre 12 days after first dose. Compares unfavorably to wild type or B.1.1.7 titres.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Andrade	2021	doi:10.1101/2021.04.14.439719	n/a	https://doi.org/10.1101/2021.04.14.439719	False	Andrade et al. (2021)	n/a	In human sera 8 weeks post-vaccination with INO-4800, a ~2-fold reduction in P.1 neutralization was observed.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Hitchlings	2021	doi:10.1101/2021.04.07.21255081	n/a	https://doi.org/10.1101/2021.04.07.21255081	False	Hitchlings et al. (2021)	n/a	Among 46,884 HCWs in Manaus, Brazil vaccinated with at least one dose of CoronaVac, a 0.50-fold reduction (adjusted vaccine  effectiveness, 49.6%: 95% CI, 11.3 - 71.4) in the odds of  symptomatic SARS-CoV-2 infection was observed during the period 14 days or more after receiving the first dose. Estimated vaccine effectiveness of at least one dose against any SARS-CoV-2 infection was 35.1% (95% CI, −6.6 - 60.5) in the same time period.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Hoffman	2021	doi:10.1016/j.cell.2021.03.036	pmid:33794143	https://doi.org/10.1016/j.cell.2021.03.036	True	Hoffman et al. (2021)	n/a	VSV pseudotype P.1 entry mediated by the S proteins of the P.1 variant was completely resistant to blocking by REGN10989 and Bamlanivimab. Cell fusion proficiency was slight impaired. Entry driven by the S proteins of the B.1.351 was partially resistant against Casirivimab.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma binding	n/a	n/a	Hoffman	2021	doi:10.1016/j.cell.2021.03.036	pmid:33794143	https://doi.org/10.1016/j.cell.2021.03.036	True	Hoffman et al. (2021)	n/a	VSV pseudotype P.1 showed 4.8-fold decrease in NT50 vs wild type in sera from 9 ICU patients undergoing treatment in Germany (pre-variant infections).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Hoffman	2021	doi:10.1016/j.cell.2021.03.036	pmid:33794143	https://doi.org/10.1016/j.cell.2021.03.036	True	Hoffman et al. (2021)	n/a	VSV pseudotype P.1 showed 5.12-fold reduction in neutralization efficiency vs wild type in 15 Pfizer BNT162b2 vaccinee sera 13-15 days post second dose. Cell fusion proficiency was slight impaired.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	trafficking	n/a	n/a	Hoffman	2021	doi:10.1016/j.cell.2021.03.036	pmid:33794143	https://doi.org/10.1016/j.cell.2021.03.036	True	Hoffman et al. (2021)	n/a	VSV pseudotype P.1 showed slight decrease in cell entry relative to wild type in 262T and 263T-ACE2 (kidney) cell lines. Cell fusion proficiency was slight impaired.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma binding	n/a	n/a	Mendes-Correa	2021	doi:10.1101/2021.05.11.21256908	n/a	https://doi.org/10.1101/2021.05.11.21256908	False	Mendes-Correa et al. (2021)	n/a	Neutralizing antibodies that were generated following a mild infection with SARS-CoV-2 B.1.128 were effective in vitro,  and likely protective, against the SARS-CoV-2 P.1. variant in the majority of individuals based on 60 convalescent sera tested.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Tarke	2021	doi:10.1101/2021.02.27.433180	pmid:33688655	https://doi.org/10.1101/2021.02.27.433180	False	Tarke et al. (2021)	n/a	PBMCs of Pfizer/BioNTech BNT162b2 (n	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	McCallum	2021	doi:10.1101/2021.03.31.437925	pmid:33821281	https://doi.org/10.1101/2021.03.31.437925	False	McCallum et al. (2021)	n/a	In 13 plasma collected ~1mo after B.1.1.7 infection (nursing home in Ticino, Switzerland), neutralization  reduced to undetectable levels in many plasma for P.1 pseudotyped virus, as well as WT and other VOCs.  [paper does not detail the P.1 variants used, using the most popular as a stand in]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	1.15x *increase* in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees)	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Choi	2021	doi:10.1101/2021.06.28.449914	n/a	https://doi.org/10.1101/2021.06.28.449914	False	Choi et al. (2021)	n/a	Neutralization efficiency (ID50) against P.1 reduced 3.2x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Dejnirattisai	2021	doi:10.1016/j.cell.2021.03.055	pmid:33852911	https://doi.org/10.1016/j.cell.2021.03.055	True	Dejnirattisai et al. (2021)	n/a	P.1 virus neutralization (as tested using biolayer interferometry) of both Lilly antibodies was severely impacted,  with Lilly mAb combination LY-CoV16 and LY-CoV555  (due to mutations at 416 and 484 respectively) shows almost complete loss of neutralization of P.1.  There was also escape from neutralization of P.1 by REGN10933 (one of 2 in Regeneron's mAb cocktail)  and a modest reduction in neutralization of P.1 by AstraZeneca's AZD8895 (while AZD1061 and AZD7442 showed  equal neutralization of all SARS-CoV-2 variants tested). The three Adagio antibodies neutralized P.1 with all reaching a plateau at 100% neutralization: interestingly, ADG30  showed a slight increase of neutralization of P.1. S309 Vir was largely unaffected, although for several viruses, including P.1, the antibody failed to completely  neutralize, conceivably reflecting incomplete glycosylation at N343, since the sugar interaction is key to binding of this antibody.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Dejnirattisai	2021	doi:10.1016/j.cell.2021.03.055	pmid:33852911	https://doi.org/10.1016/j.cell.2021.03.055	True	Dejnirattisai et al. (2021)	n/a	P.1 lineage titers were reduced 7.6-fold and 9-fold for the BNT162b2 Pfizer (sera collected 4-14 days post-booster)  and ChAdOx1 nCoV-19 AstraZeneca (sera collected 14 or 28 days post-booster) vaccines respectively.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Luftig	2021	doi:10.1056/NEJMc2104036	pmid:33826815	https://doi.org/10.1056/NEJMc2104036	True	Luftig et al. (2021)	n/a	In sera 1-2 weeks after BNT162b2 first dose, from six patients previously infected with B.1, antibody titer in a microneutralization assay  was on average 2896 for P.1 virus. This compares favorably (stronger) to post-infection neutralization titer against all variants tested in the same sera (wild type, B.1.1.7, B.1.351, and P.1).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma binding	n/a	n/a	Luftig	2021	doi:10.1056/NEJMc2104036	pmid:33826815	https://doi.org/10.1056/NEJMc2104036	True	Luftig et al. (2021)	n/a	In sera from six patients collected 1 to 12 weeks post-infection with B.1, antibody titer in a microneutralization assay was on average 256 for B.1.1.7 virus. Compare to somewhat stronger neutralization titer for wild type (456.1) in the same sera.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Pegu	2021	doi:10.1101/2021.05.13.444010	pmid:34031659	https://doi.org/10.1101/2021.05.13.444010	False	Pegu et al. (2021)	n/a	Detectable antibodies against P.1 at various time points using pseudovirus neutralization in Moderna vaccinee cohort: Day 43 100%, Day 209 85%.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	T cell evasion	n/a	n/a	Tarke	2021	doi:10.1101/2021.02.27.433180	pmid:33688655	https://doi.org/10.1101/2021.02.27.433180	False	Tarke et al. (2021)	n/a	PBMCs of 11 mild COVID-19 patients collected 38-80 days after symptom onset were stimulated with the 15-mer peptide pools (w/ 10 residue overlaps) from the wholle viral proteome,  showing no significant CD4+ cell count effect for P.1,  and a slight increase in CD8+ percentage (p	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	transmissibility	n/a	n/a	Stefanelli	2021	doi:10.1101/2021.04.06.21254923	n/a	https://doi.org/10.1101/2021.04.06.21254923	False	Stefanelli et al. (2021)	n/a	The relative transmissibility of P.1 estimated at the national level (Italy) varied according to the assumed  degree of cross-protection granted by infection with other lineages and ranged from 1.12 (95%CI 1.03-1.23) in the  case of complete immune evasion by P.1 to 1.39 (95%CI 1.26-1.56) in the case of complete cross-protection. PG: variant list has been abbreviated due to mixed K417 bases in this lineage, potential miscalls of deletions	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	outcome hazard ratio	n/a	n/a	Santos de Oliviera	2021	doi:10.1101/2021.03.24.21254046	n/a	https://doi.org/10.1101/2021.03.24.21254046	False	Santos de Oliviera et al. (2021)	n/a	In the Parana state of Brazil, patients aged 20-29 years experienced a tripling of their case fatality rate (CFR), from 0.04% to 0.13%, while those aged  30-39, 40-49, 50-59 experienced approximate CFR doubling comparing February to January in 2021. Notably,  the observed CFR increase coincided with the second consecutive month of declining number of diagnosed SARS-CoV-2 cases.  Taken together, these preliminary findings suggest significant increases in CFR in young and middle-aged adults after  identification of a novel SARS-CoV-2 strain circulating in Brazil.  [this is somewhat indirect evidence that assume greatly increasing proportion of P.1 cases in March (70%) compared to  February, but the first official ID of P.1 in Parana state (Feb 16th) may be due to testing procedures rather than actual prevalence]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	outcome hazard ratio	n/a	n/a	Ribas Freitas	2021	doi:10.1101/2021.04.13.21255281	n/a	https://doi.org/10.1101/2021.04.13.21255281	False	Ribas Freitas et al. (2021)	n/a	In the Southern Brazilian stats of Rio Grande do Sul, comparing pre-P.1 and post-P.1 waves:  The increase in Case Fatality Rate occurred in a greatest intensity in the population between 20 and 59 years old and among patients without pre-existing risk conditions. Female 20 to 39 years old, with no pre-existing risk conditions, were at risk of death 5.65 times higher in February (95%CI 	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	outcome hazard ratio	n/a	n/a	Funk	2021	doi:10.2807/1560-7917.ES.2021.26.16.2100348	pmid:33890566	https://doi.org/10.2807/1560-7917.ES.2021.26.16.2100348	True	Funk et al. (2021)	n/a	On average across 7 European countries studied, using P.1 defining mutations: Significant shift to infection in those without pre-existing conditions (27.8% vs 89% for non-VOC cases). Significant increase in hospitalization rate (20% vs 7.5% for non-VOC cases). Significant increase in ICU rate (2.1% vs 0.6% for non-VOC cases). Significant increase in health care worker rate (19.8% vs 8.0% for non-VOC cases).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Mallm	2021	doi:10.1101/2021.04.27.21254849	n/a	https://doi.org/10.1101/2021.04.27.21254849	False	Mallm et al. (2021)	n/a	This variant was designated A.27.RN according to its phylogenetic clade classification. It emerged in parallel  with the B.1.1.7 variant, increased to >50% of all SARS-CoV-2 variants by week five. Subsequently it decreased  to <10% of all variants by calendar week eight when B.1.1.7 had become the dominant strain. Antibodies induced  by BNT162b2 (Pfizer) vaccination neutralized A.27.RN but with a two-to-threefold reduced efficacy as compared to the  wild-type and B.1.1.7 strains.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.2 (from South Africa/CERI-KRISP-K032307/2021) were 3.9x-fold lower (95% CI: 0.14x-0.17x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Uhal B	2022	doi:10.1101/2022.06.23.497326	n/a	https://doi.org/10.1101/2022.06.23.497326	False	Uhal B et al. (2022)	n/a	L27, V34 and E90 mutation resulted in ultrahigh affinity binding of the LVE-ACE-2 domain to the widest variety of VOCs, with KDs of 78fM for binding to the Omicron  BA.2. Values were obtained with LVE-ACE-2/mAB chimeras containing the Y-T-E sequence that enhances binding to the FcRn receptor, which in turn is expected to  extend biological half-life 3-4-fold.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.2 (from South Africa/CERI-KRISP-K032307/2021) were 4.5-fold lower (95% CI: 4.3x-4.7x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.2.12.1 (from USA/NY-CDC-ASC210722700/2022) were 4.2-fold lower (95% CI: 5.8x-6.6x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.2.12.1 (from USA/NY-CDC-ASC210722700/2022) were 3.9x-fold lower (95% CI: 0.14x-0.18x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Cathcart	2021	doi:10.1101/2021.03.09.434607v9	n/a	https://doi.org/10.1101/2021.03.09.434607v9	False	Cathcart et al. (2021)	n/a	Omicron (a.k.a. B.1.1.529) Spike pseudotyped VSV and Vero E6 cells has somewhat  reduced neutralization (2.7x) vs wild type with monoclonal antibody Sotrovimab (a.k.a. VIR-7831).  [delins at 214 omitted for syntax compatibility]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Wang	2022	doi:10.1101/2022.08.11.503601	n/a	https://doi.org/10.1101/2022.08.11.503601	False	Wang et al. (2022)	n/a	Omicron breakthrough infection after 3-dose vaccination resulted in a further 3.5-fold and 2.9-fold increase of Omicron BA.1 and BA.2 neutralizing titers. Omicron  BA.4/5 showed the highest neutralization resistance of all variants tested, resulting in low geometric mean neutralizing titers in plasma samples  obtained after  the second vaccine dose (NT50	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs Bi-Nab47D10-35B5. Omicron BA.1 has an IC50 fold change of 0.08x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron B.1.1.529 (BA.1) neutralization of the Omicron variants by antibodies induced by three doses of Pfizer/BNT162b2 mRNA vaccine was 7-8-fold less potent than  the D614G, and the Omicron variants still evade neutralization more efficiently.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron (B.1.1.529 [BA.1]) have higher sensitivity to inhibition by soluble angiotensin converting enzyme 2 (ACE2) and the endosomal inhibitor chloroquine compared  to D614G	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs Bi-Nab35B5-47D10. Omicron BA.1 has an IC50 fold change of 0.30x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Uhal B	2022	doi:10.1101/2022.06.23.497326	n/a	https://doi.org/10.1101/2022.06.23.497326	False	Uhal B et al. (2022)	n/a	Paradigms’ ACE-2 variant LVE/STR chimera binds to SARS-2 Omicron variant B.1.1.529 spike protein trimer with high affinity. Determined using Surrogate Viral Neutralization Tests.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Uhal B	2022	doi:10.1101/2022.06.23.497326	n/a	https://doi.org/10.1101/2022.06.23.497326	False	Uhal B et al. (2022)	n/a	L27, V34 and E90 mutation resulted in ultrahigh affinity binding of the LVE-ACE-2 domain to the widest variety of VOCs, with KDs of 73 pM for binding to the Omicron  B.1.1.529. Values were obtained with LVE-ACE-2/mAB chimeras containing the Y-T-E sequence that enhances binding to the FcRn receptor, which in turn is expected to  extend biological half-life 3-4-fold.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs 35B5. Omicron BA.1 has an IC50 fold change of 0.38x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Arora	2022	doi:10.1038/s41423-022-00870-5	pmid:35581351	https://doi.org/10.1038/s41423-022-00870-5	True	Arora et al. (2022)	n/a	All 10 individuals with 2 doses of the BNT162b2/BNT162b2 vaccine had a neutralizing titer in B.1 variant at an average of 729 NT50.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Shete	2022	doi:10.1101/2022.05.12.491584	n/a	https://doi.org/10.1101/2022.05.12.491584	False	Shete et al. (2022)	n/a	Plaque reduction neutralization test (PRNT) was used uring primary infection, post sixty daysof second dose vaccination, pre-reinfection and reinfection against Delta variant and was used to determine neutralizing antibodytitres. There was a 24.63x fold increase in antibody response from first infection to recovered and vaccinated with 2 doses (60 days). There was a 4.21x fold increase in antibody response pre-reinfection. There was a 39.27x fold increase in antibody response during reinfection.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Shete	2022	doi:10.1101/2022.05.12.491584	n/a	https://doi.org/10.1101/2022.05.12.491584	False	Shete et al. (2022)	n/a	Plaque reduction neutralization test (PRNT) was used uring primary infection, post sixty daysof second dose vaccination, pre-reinfection and reinfection against B.1 variant and was used to determine neutralizing antibodytitres. There was a 6.76x fold increase in antibody response from first infection to recovered and vaccinated with 2 doses (60 days). There was a 2.06x fold increase in antibody response pre-reinfection. There was a 8.18x fold increase in antibody response during reinfection.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Arora	2022	doi:10.1038/s41423-022-00870-5	pmid:35581351	https://doi.org/10.1038/s41423-022-00870-5	True	Arora et al. (2022)	n/a	All 10 individuals with 3 doses of the BNT162b2/BNT162b2 vaccine had a neutralizing titer in B.1 variant at an average of 3319 NT50.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Shete	2022	doi:10.1101/2022.05.12.491584	n/a	https://doi.org/10.1101/2022.05.12.491584	False	Shete et al. (2022)	n/a	Plaque reduction neutralization test (PRNT) was used uring primary infection, post sixty daysof second dose vaccination, pre-reinfection and reinfection against Omicron variant and was used to determine neutralizing antibodytitres. There was a 114.84x fold increase in antibody response from first infection to recovered and vaccinated with 2 doses (60 days). There was a 6.61x fold increase in antibody response pre-reinfection. There was a 1194.9x fold increase in antibody response during reinfection.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Kumar	2022	doi:10.1101/2022.05.13.491770	n/a	https://doi.org/10.1101/2022.05.13.491770	False	Kumar et al. (2022)	n/a	BnAb 002-S21F2 IC50 on the Omicron BA.1 variant is 1.0x fold the wildtype.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs 47D10. Omicron BA.1 has an IC50 fold change of 1.26x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron BA.3 have higher sensitivity to inhibition by soluble angiotensin converting enzyme 2 (ACE2) and the endosomal inhibitor chloroquine compared  to D614G	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron BA.3 neutralization of the Omicron variants by antibodies induced by three doses of Pfizer/BNT162b2 mRNA vaccine was 7-8-fold less potent than the D614G, and  the Omicron variants still evade neutralization more efficiently.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.3 (from South Africa/NICD-N22404/2021) were 4.2x-fold lower (95% CI: 0.15x-0.20x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.3 (from South Africa/NICD-N22404/2021) were 6.2-fold lower (95% CI: 11.8x-14.3x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Hao	2022	doi:10.1101/2022.08.12.22278720	pmid:36032965	https://doi.org/10.1101/2022.08.12.22278720	False	Hao et al. (2022)	n/a	paired testing of vaccine sera against ancestral virus compared to Omicron BA.1 shows that 3-dose vaccine regimen provides over 50x fold increase in protection against Omicron(B.1.1.529 [BA.1]) compared to a 2-dose regimen.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Wang	2022	doi:10.1101/2022.08.11.503601	n/a	https://doi.org/10.1101/2022.08.11.503601	False	Wang et al. (2022)	n/a	4th antigenic exposure with Omicron (B.1.1.529 [BA.1])(n	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.1 (from Botswana/R40B59_BHP_3321001248/2021) were 3.4-fold lower (95% CI: 3.2x-3.6x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.1 (from Botswana/R40B59_BHP_3321001248/2021) were 28.7x-fold lower (95% CI: 0.03x-0.05) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.4/5 (from ) were 17.2x-fold lower (95% CI: 0.6x-0.7x) than against 208-428 972-1834 4.3-4.7 US-WA1/2020 usiong an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.4/5 (from ) were 13.0-fold lower (95% CI: 4.2x-4.6x) than against 208-428 972-1834 4.3-4.7 US-WA1/2020 usiong an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Choi	2021	doi:10.1101/2021.06.28.449914	n/a	https://doi.org/10.1101/2021.06.28.449914	False	Choi et al. (2021)	n/a	Neutralization efficiency (ID50) against A.VOI.V2 (first identified in Angola) reduced 8.0x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  XD (from ) were 1.5x-fold lower (95% CI: 0.05x-0.07x) than against 208-428 972-1834 4.3-4.7 US-WA1/2020 usiong an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  XD (from ) were 4.4-fold lower (95% CI: 4.3x-4.7x) than against 208-428 972-1834 4.3-4.7 US-WA1/2020 usiong an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	anthropozoonotic events	n/a	n/a	Rathnasinghe	2021	doi:10.1101/2021.01.19.21249592	pmid:33501468	https://doi.org/10.1101/2021.01.19.21249592	False	Rathnasinghe et al. (2021)	n/a	Mouse-adapted SARS-CoV-2 mutations after 11 serial passages in various immunocompromised mice strains.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	This variant combination (representing P.1 aka Gamma)  showed a 1.3x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	This variant combination (representing P.1 aka Gamma)  showed a 1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.27x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing P.1 aka Gamma)  showed a 4.24x increase in binding (KD) relative to D614G.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	1.48x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.21x increase in binding (KD) relative to D614G.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	1.04x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	homoplasy	n/a	n/a	Borges	2021	doi:10.1101/2021.05.19.444774	n/a	https://doi.org/10.1101/2021.05.19.444774	False	Borges et al. (2021)	n/a	In experimental models of SARS-CoV-2 mutational evolution (without immune pressure), this mutation in the N terminal domain appears convergent.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	anthropozoonotic events	n/a	n/a	Esclera	2021	doi:10.1101/2021.08.05.455290	n/a	https://doi.org/10.1101/2021.08.05.455290	False	Esclera et al. (2021)	n/a	Six minks were intranasally infected with WA1 isolate, all developed this mutation during infection.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	anthropozoonotic events	n/a	n/a	Li	2023	doi:10.1038/s41396-023-01368-2	pmid:36690780	https://doi.org/10.1038/s41396-023-01368-2	True	Li et al. (2023)	n/a	This mutation outside the receptor binding domain increases the virus transduction rate in tree shrew (Tupaia belangeri),  (as it does in humans) according to pseudotyped VSV experiments.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23525	H655Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C1963T	p.H655Y	NC_045512.2(GU280_gp02):g.1963C>T	YP_009724390.1:p.His655Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	virion structure	n/a	n/a	Spratt	2021	doi:10.1101/2021.03.24.436850	pmid:33791700	https://doi.org/10.1101/2021.03.24.436850	False	Spratt et al. (2021)	n/a	Estimated free energy change (ddG) for this variant is 0.87 kcal/mol (i.e. stabilizing relative to wild type)	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23599	N679K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	G	g.T2037G	p.N679K	NC_045512.2(GU280_gp02):g.2037T>G	YP_009724390.1:p.Asn679Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron BA.2 have higher sensitivity to inhibition by soluble angiotensin converting enzyme 2 (ACE2) and the endosomal inhibitor chloroquine compared  to D614G	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23599	N679K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	G	g.T2037G	p.N679K	NC_045512.2(GU280_gp02):g.2037T>G	YP_009724390.1:p.Asn679Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs Bi-Nab35B5-47D10. Omicron BA.2 has an IC50 fold change of 0.07x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23599	N679K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	G	g.T2037G	p.N679K	NC_045512.2(GU280_gp02):g.2037T>G	YP_009724390.1:p.Asn679Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs 35B5. Omicron BA.2 has an IC50 fold change of 0.09x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23599	N679K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	G	g.T2037G	p.N679K	NC_045512.2(GU280_gp02):g.2037T>G	YP_009724390.1:p.Asn679Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs 47D10. Omicron BA.2 has an IC50 fold change of 0.08x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23599	N679K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	G	g.T2037G	p.N679K	NC_045512.2(GU280_gp02):g.2037T>G	YP_009724390.1:p.Asn679Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs Bi-Nab47D10-35B5. Omicron BA.2 has an IC50 fold change of 0.04x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23599	N679K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	G	g.T2037G	p.N679K	NC_045512.2(GU280_gp02):g.2037T>G	YP_009724390.1:p.Asn679Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron BA.2 neutralization of the Omicron variants by antibodies induced by three doses of Pfizer/BNT162b2 mRNA vaccine was 7-8-fold less potent than the D614G, and  the Omicron variants still evade neutralization more efficiently.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23599	N679K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	G	g.T2037G	p.N679K	NC_045512.2(GU280_gp02):g.2037T>G	YP_009724390.1:p.Asn679Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Kumar	2022	doi:10.1101/2022.05.13.491770	n/a	https://doi.org/10.1101/2022.05.13.491770	False	Kumar et al. (2022)	n/a	BnAb 002-S21F2 IC50 on the Omicron BA.2 variant is 0.8x fold the wildtype.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23599	N679K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	G	g.T2037G	p.N679K	NC_045512.2(GU280_gp02):g.2037T>G	YP_009724390.1:p.Asn679Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.2 (from South Africa/CERI-KRISP-K032307/2021) were 3.9x-fold lower (95% CI: 0.14x-0.17x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23599	N679K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	G	g.T2037G	p.N679K	NC_045512.2(GU280_gp02):g.2037T>G	YP_009724390.1:p.Asn679Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Uhal B	2022	doi:10.1101/2022.06.23.497326	n/a	https://doi.org/10.1101/2022.06.23.497326	False	Uhal B et al. (2022)	n/a	L27, V34 and E90 mutation resulted in ultrahigh affinity binding of the LVE-ACE-2 domain to the widest variety of VOCs, with KDs of 78fM for binding to the Omicron  BA.2. Values were obtained with LVE-ACE-2/mAB chimeras containing the Y-T-E sequence that enhances binding to the FcRn receptor, which in turn is expected to  extend biological half-life 3-4-fold.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23599	N679K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	G	g.T2037G	p.N679K	NC_045512.2(GU280_gp02):g.2037T>G	YP_009724390.1:p.Asn679Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.2 (from South Africa/CERI-KRISP-K032307/2021) were 4.5-fold lower (95% CI: 4.3x-4.7x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23599	N679K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	G	g.T2037G	p.N679K	NC_045512.2(GU280_gp02):g.2037T>G	YP_009724390.1:p.Asn679Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.2.12.1 (from USA/NY-CDC-ASC210722700/2022) were 4.2-fold lower (95% CI: 5.8x-6.6x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23599	N679K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	G	g.T2037G	p.N679K	NC_045512.2(GU280_gp02):g.2037T>G	YP_009724390.1:p.Asn679Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.2.12.1 (from USA/NY-CDC-ASC210722700/2022) were 3.9x-fold lower (95% CI: 0.14x-0.18x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23599	N679K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	G	g.T2037G	p.N679K	NC_045512.2(GU280_gp02):g.2037T>G	YP_009724390.1:p.Asn679Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Cathcart	2021	doi:10.1101/2021.03.09.434607v9	n/a	https://doi.org/10.1101/2021.03.09.434607v9	False	Cathcart et al. (2021)	n/a	Omicron (a.k.a. B.1.1.529) Spike pseudotyped VSV and Vero E6 cells has somewhat  reduced neutralization (2.7x) vs wild type with monoclonal antibody Sotrovimab (a.k.a. VIR-7831).  [delins at 214 omitted for syntax compatibility]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23599	N679K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	G	g.T2037G	p.N679K	NC_045512.2(GU280_gp02):g.2037T>G	YP_009724390.1:p.Asn679Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Wang	2022	doi:10.1101/2022.08.11.503601	n/a	https://doi.org/10.1101/2022.08.11.503601	False	Wang et al. (2022)	n/a	Omicron breakthrough infection after 3-dose vaccination resulted in a further 3.5-fold and 2.9-fold increase of Omicron BA.1 and BA.2 neutralizing titers. Omicron  BA.4/5 showed the highest neutralization resistance of all variants tested, resulting in low geometric mean neutralizing titers in plasma samples  obtained after  the second vaccine dose (NT50	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23599	N679K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	G	g.T2037G	p.N679K	NC_045512.2(GU280_gp02):g.2037T>G	YP_009724390.1:p.Asn679Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs Bi-Nab47D10-35B5. Omicron BA.1 has an IC50 fold change of 0.08x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23599	N679K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	G	g.T2037G	p.N679K	NC_045512.2(GU280_gp02):g.2037T>G	YP_009724390.1:p.Asn679Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron B.1.1.529 (BA.1) neutralization of the Omicron variants by antibodies induced by three doses of Pfizer/BNT162b2 mRNA vaccine was 7-8-fold less potent than  the D614G, and the Omicron variants still evade neutralization more efficiently.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23599	N679K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	G	g.T2037G	p.N679K	NC_045512.2(GU280_gp02):g.2037T>G	YP_009724390.1:p.Asn679Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron (B.1.1.529 [BA.1]) have higher sensitivity to inhibition by soluble angiotensin converting enzyme 2 (ACE2) and the endosomal inhibitor chloroquine compared  to D614G	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23599	N679K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	G	g.T2037G	p.N679K	NC_045512.2(GU280_gp02):g.2037T>G	YP_009724390.1:p.Asn679Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs Bi-Nab35B5-47D10. Omicron BA.1 has an IC50 fold change of 0.30x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23599	N679K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	G	g.T2037G	p.N679K	NC_045512.2(GU280_gp02):g.2037T>G	YP_009724390.1:p.Asn679Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Uhal B	2022	doi:10.1101/2022.06.23.497326	n/a	https://doi.org/10.1101/2022.06.23.497326	False	Uhal B et al. (2022)	n/a	Paradigms’ ACE-2 variant LVE/STR chimera binds to SARS-2 Omicron variant B.1.1.529 spike protein trimer with high affinity. Determined using Surrogate Viral Neutralization Tests.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23599	N679K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	G	g.T2037G	p.N679K	NC_045512.2(GU280_gp02):g.2037T>G	YP_009724390.1:p.Asn679Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Uhal B	2022	doi:10.1101/2022.06.23.497326	n/a	https://doi.org/10.1101/2022.06.23.497326	False	Uhal B et al. (2022)	n/a	L27, V34 and E90 mutation resulted in ultrahigh affinity binding of the LVE-ACE-2 domain to the widest variety of VOCs, with KDs of 73 pM for binding to the Omicron  B.1.1.529. Values were obtained with LVE-ACE-2/mAB chimeras containing the Y-T-E sequence that enhances binding to the FcRn receptor, which in turn is expected to  extend biological half-life 3-4-fold.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23599	N679K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	G	g.T2037G	p.N679K	NC_045512.2(GU280_gp02):g.2037T>G	YP_009724390.1:p.Asn679Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs 35B5. Omicron BA.1 has an IC50 fold change of 0.38x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23599	N679K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	G	g.T2037G	p.N679K	NC_045512.2(GU280_gp02):g.2037T>G	YP_009724390.1:p.Asn679Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Arora	2022	doi:10.1038/s41423-022-00870-5	pmid:35581351	https://doi.org/10.1038/s41423-022-00870-5	True	Arora et al. (2022)	n/a	All 10 individuals with 2 doses of the BNT162b2/BNT162b2 vaccine had a neutralizing titer in B.1 variant at an average of 729 NT50.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23599	N679K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	G	g.T2037G	p.N679K	NC_045512.2(GU280_gp02):g.2037T>G	YP_009724390.1:p.Asn679Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Shete	2022	doi:10.1101/2022.05.12.491584	n/a	https://doi.org/10.1101/2022.05.12.491584	False	Shete et al. (2022)	n/a	Plaque reduction neutralization test (PRNT) was used uring primary infection, post sixty daysof second dose vaccination, pre-reinfection and reinfection against Delta variant and was used to determine neutralizing antibodytitres. There was a 24.63x fold increase in antibody response from first infection to recovered and vaccinated with 2 doses (60 days). There was a 4.21x fold increase in antibody response pre-reinfection. There was a 39.27x fold increase in antibody response during reinfection.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23599	N679K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	G	g.T2037G	p.N679K	NC_045512.2(GU280_gp02):g.2037T>G	YP_009724390.1:p.Asn679Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Shete	2022	doi:10.1101/2022.05.12.491584	n/a	https://doi.org/10.1101/2022.05.12.491584	False	Shete et al. (2022)	n/a	Plaque reduction neutralization test (PRNT) was used uring primary infection, post sixty daysof second dose vaccination, pre-reinfection and reinfection against B.1 variant and was used to determine neutralizing antibodytitres. There was a 6.76x fold increase in antibody response from first infection to recovered and vaccinated with 2 doses (60 days). There was a 2.06x fold increase in antibody response pre-reinfection. There was a 8.18x fold increase in antibody response during reinfection.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23599	N679K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	G	g.T2037G	p.N679K	NC_045512.2(GU280_gp02):g.2037T>G	YP_009724390.1:p.Asn679Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Arora	2022	doi:10.1038/s41423-022-00870-5	pmid:35581351	https://doi.org/10.1038/s41423-022-00870-5	True	Arora et al. (2022)	n/a	All 10 individuals with 3 doses of the BNT162b2/BNT162b2 vaccine had a neutralizing titer in B.1 variant at an average of 3319 NT50.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23599	N679K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	G	g.T2037G	p.N679K	NC_045512.2(GU280_gp02):g.2037T>G	YP_009724390.1:p.Asn679Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Shete	2022	doi:10.1101/2022.05.12.491584	n/a	https://doi.org/10.1101/2022.05.12.491584	False	Shete et al. (2022)	n/a	Plaque reduction neutralization test (PRNT) was used uring primary infection, post sixty daysof second dose vaccination, pre-reinfection and reinfection against Omicron variant and was used to determine neutralizing antibodytitres. There was a 114.84x fold increase in antibody response from first infection to recovered and vaccinated with 2 doses (60 days). There was a 6.61x fold increase in antibody response pre-reinfection. There was a 1194.9x fold increase in antibody response during reinfection.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23599	N679K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	G	g.T2037G	p.N679K	NC_045512.2(GU280_gp02):g.2037T>G	YP_009724390.1:p.Asn679Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Kumar	2022	doi:10.1101/2022.05.13.491770	n/a	https://doi.org/10.1101/2022.05.13.491770	False	Kumar et al. (2022)	n/a	BnAb 002-S21F2 IC50 on the Omicron BA.1 variant is 1.0x fold the wildtype.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23599	N679K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	G	g.T2037G	p.N679K	NC_045512.2(GU280_gp02):g.2037T>G	YP_009724390.1:p.Asn679Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs 47D10. Omicron BA.1 has an IC50 fold change of 1.26x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23599	N679K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	G	g.T2037G	p.N679K	NC_045512.2(GU280_gp02):g.2037T>G	YP_009724390.1:p.Asn679Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron BA.3 have higher sensitivity to inhibition by soluble angiotensin converting enzyme 2 (ACE2) and the endosomal inhibitor chloroquine compared  to D614G	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23599	N679K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	G	g.T2037G	p.N679K	NC_045512.2(GU280_gp02):g.2037T>G	YP_009724390.1:p.Asn679Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron BA.3 neutralization of the Omicron variants by antibodies induced by three doses of Pfizer/BNT162b2 mRNA vaccine was 7-8-fold less potent than the D614G, and  the Omicron variants still evade neutralization more efficiently.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23599	N679K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	G	g.T2037G	p.N679K	NC_045512.2(GU280_gp02):g.2037T>G	YP_009724390.1:p.Asn679Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.3 (from South Africa/NICD-N22404/2021) were 4.2x-fold lower (95% CI: 0.15x-0.20x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23599	N679K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	G	g.T2037G	p.N679K	NC_045512.2(GU280_gp02):g.2037T>G	YP_009724390.1:p.Asn679Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.3 (from South Africa/NICD-N22404/2021) were 6.2-fold lower (95% CI: 11.8x-14.3x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23599	N679K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	G	g.T2037G	p.N679K	NC_045512.2(GU280_gp02):g.2037T>G	YP_009724390.1:p.Asn679Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Hao	2022	doi:10.1101/2022.08.12.22278720	pmid:36032965	https://doi.org/10.1101/2022.08.12.22278720	False	Hao et al. (2022)	n/a	paired testing of vaccine sera against ancestral virus compared to Omicron BA.1 shows that 3-dose vaccine regimen provides over 50x fold increase in protection against Omicron(B.1.1.529 [BA.1]) compared to a 2-dose regimen.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23599	N679K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	G	g.T2037G	p.N679K	NC_045512.2(GU280_gp02):g.2037T>G	YP_009724390.1:p.Asn679Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Wang	2022	doi:10.1101/2022.08.11.503601	n/a	https://doi.org/10.1101/2022.08.11.503601	False	Wang et al. (2022)	n/a	4th antigenic exposure with Omicron (B.1.1.529 [BA.1])(n	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23599	N679K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	G	g.T2037G	p.N679K	NC_045512.2(GU280_gp02):g.2037T>G	YP_009724390.1:p.Asn679Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.1 (from Botswana/R40B59_BHP_3321001248/2021) were 3.4-fold lower (95% CI: 3.2x-3.6x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23599	N679K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	G	g.T2037G	p.N679K	NC_045512.2(GU280_gp02):g.2037T>G	YP_009724390.1:p.Asn679Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.1 (from Botswana/R40B59_BHP_3321001248/2021) were 28.7x-fold lower (95% CI: 0.03x-0.05) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23599	N679K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	G	g.T2037G	p.N679K	NC_045512.2(GU280_gp02):g.2037T>G	YP_009724390.1:p.Asn679Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.4/5 (from ) were 17.2x-fold lower (95% CI: 0.6x-0.7x) than against 208-428 972-1834 4.3-4.7 US-WA1/2020 usiong an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23599	N679K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	G	g.T2037G	p.N679K	NC_045512.2(GU280_gp02):g.2037T>G	YP_009724390.1:p.Asn679Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.4/5 (from ) were 13.0-fold lower (95% CI: 4.2x-4.6x) than against 208-428 972-1834 4.3-4.7 US-WA1/2020 usiong an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23599	N679K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	G	g.T2037G	p.N679K	NC_045512.2(GU280_gp02):g.2037T>G	YP_009724390.1:p.Asn679Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  XD (from ) were 1.5x-fold lower (95% CI: 0.05x-0.07x) than against 208-428 972-1834 4.3-4.7 US-WA1/2020 usiong an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23599	N679K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	G	g.T2037G	p.N679K	NC_045512.2(GU280_gp02):g.2037T>G	YP_009724390.1:p.Asn679Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  XD (from ) were 4.4-fold lower (95% CI: 4.3x-4.7x) than against 208-428 972-1834 4.3-4.7 US-WA1/2020 usiong an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23604	P681R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	G	g.C2042G	p.P681R	NC_045512.2(GU280_gp02):g.2042C>G	YP_009724390.1:p.Pro681Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Chonira	2022	doi:10.1101/2022.05.30.493765	pmid:35677079	https://doi.org/10.1101/2022.05.30.493765	False	Chonira et al. (2022)	n/a	DARPin SR16m molecule had a 6.7x fold change in IC50 in B.1.617.2 Delta	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23604	P681R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	G	g.C2042G	p.P681R	NC_045512.2(GU280_gp02):g.2042C>G	YP_009724390.1:p.Pro681Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Chonira	2022	doi:10.1101/2022.05.30.493765	pmid:35677079	https://doi.org/10.1101/2022.05.30.493765	False	Chonira et al. (2022)	n/a	DARPin SR16m molecule had a 99.7x fold change in IC50 in B.1.617.2 Delta	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23604	P681R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	G	g.C2042G	p.P681R	NC_045512.2(GU280_gp02):g.2042C>G	YP_009724390.1:p.Pro681Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	trafficking	n/a	n/a	Hoffman	2021	doi:10.1101/2021.05.04.442663	n/a	https://doi.org/10.1101/2021.05.04.442663	False	Hoffman et al. (2021)	n/a	In two of eight cell lines tested (Caco-2 intenstinal and Calu-3 lung), a modest increase in cell entry was observed. This increase was not observed in a Calu-3 cell line with overexpressed ACE2. [the virus tested as B.1.617 overlaps only partially with the Spike mutation lists used by PANGO, CDC, etc. for this lineage therefore the results should be interpreted carefully as transferable to B.1.617 generally]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23604	P681R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	G	g.C2042G	p.P681R	NC_045512.2(GU280_gp02):g.2042C>G	YP_009724390.1:p.Pro681Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Hoffman	2021	doi:10.1101/2021.05.04.442663	n/a	https://doi.org/10.1101/2021.05.04.442663	False	Hoffman et al. (2021)	n/a	Approximately 2-fold reduction in 15 ICU patient convalescent plasma neutralization as quantified by measuring virus-encoded  luciferase activity in cell lysates at 16-18 h post transduction. [PG: note that the virus tested as B.1.617 overlaps only partially with the Spike mutation lists used by PANGO, CDC, etc. for this lineage therefore the results should be interpreted carefully as transferable to B.1.617 generally]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23604	P681R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	G	g.C2042G	p.P681R	NC_045512.2(GU280_gp02):g.2042C>G	YP_009724390.1:p.Pro681Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Hoffman	2021	doi:10.1101/2021.05.04.442663	n/a	https://doi.org/10.1101/2021.05.04.442663	False	Hoffman et al. (2021)	n/a	Abrogates Bamlanivimab neutralization as quantified by measuring virus-encoded luciferase activity in cell lysates at 16-18 h post transduction. Significant decrease in combined Etesevimab+Bamlanivimab neutralization except at the highest concentration measured. [PG: note that the virus tested as B.1.617 overlaps only partially with the Spike mutation lists used by PANGO, CDC, etc. for this lineage therefore the results should be interpreted carefully as transferable to B.1.617 generally]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23604	P681R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	G	g.C2042G	p.P681R	NC_045512.2(GU280_gp02):g.2042C>G	YP_009724390.1:p.Pro681Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Hoffman	2021	doi:10.1101/2021.05.04.442663	n/a	https://doi.org/10.1101/2021.05.04.442663	False	Hoffman et al. (2021)	n/a	In 15 Pfizer non-senior vaccinee sera collected 3-4 weeks post-booster [using Table S1, not the text that says 2-3 weeks], neutralization was reduced ~3x (compared to ~11x for B.1.351). [the virus tested as B.1.617 overlaps only partially with the Spike mutation lists used by PANGO, CDC, etc. for this lineage therefore the results should be interpreted carefully as transferable to B.1.617 generally]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23604	P681R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	G	g.C2042G	p.P681R	NC_045512.2(GU280_gp02):g.2042C>G	YP_009724390.1:p.Pro681Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Choi	2021	doi:10.1101/2021.06.28.449914	n/a	https://doi.org/10.1101/2021.06.28.449914	False	Choi et al. (2021)	n/a	Neutralization efficiency (ID50) against B.1.617.1-v1 ('Kappa') reduced 3.4x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23604	P681R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	G	g.C2042G	p.P681R	NC_045512.2(GU280_gp02):g.2042C>G	YP_009724390.1:p.Pro681Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Wilhelm	2021	doi:10.1101/2021.08.09.21261704	n/a	https://doi.org/10.1101/2021.08.09.21261704	False	Wilhelm et al. (2021)	n/a	Relative to B.1, Delta (B.1.617.2) shows mean 2.1x decrease in neutralization efficiency by 18 vaccinee sera (BNT162b2 and mRNA1273).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23604	P681R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	G	g.C2042G	p.P681R	NC_045512.2(GU280_gp02):g.2042C>G	YP_009724390.1:p.Pro681Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Wilhelm	2021	doi:10.1101/2021.08.09.21261704	n/a	https://doi.org/10.1101/2021.08.09.21261704	False	Wilhelm et al. (2021)	n/a	Relative to B.1, Delta (B.1.617.2) shows 3.64x decrease in neutralization efficiency by convalescent plasma [no cohort details provided]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23604	P681R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	G	g.C2042G	p.P681R	NC_045512.2(GU280_gp02):g.2042C>G	YP_009724390.1:p.Pro681Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	trafficking	n/a	n/a	Esclera	2021	doi:10.1101/2021.08.05.455290	n/a	https://doi.org/10.1101/2021.08.05.455290	False	Esclera et al. (2021)	n/a	~3.5x cleavage of S2 relative to WA1 (D614G) wildtype by Kappa (B.1.617.1) variant as measured by mass spectrometry of Vero-TMPRSS culture (compare to ~4.5x for closely related Delta B.1.617.2 also with P681R at the cleavage site).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23604	P681R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	G	g.C2042G	p.P681R	NC_045512.2(GU280_gp02):g.2042C>G	YP_009724390.1:p.Pro681Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	1.5x reduction in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees) [exact set of variants used is not listed in the manuscript]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23604	P681R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	G	g.C2042G	p.P681R	NC_045512.2(GU280_gp02):g.2042C>G	YP_009724390.1:p.Pro681Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Choi	2021	doi:10.1101/2021.06.28.449914	n/a	https://doi.org/10.1101/2021.06.28.449914	False	Choi et al. (2021)	n/a	Inferring from two B.1.617.1 variants tested, estimate baseline 3.3x reduction in ID50 relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23604	P681R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	G	g.C2042G	p.P681R	NC_045512.2(GU280_gp02):g.2042C>G	YP_009724390.1:p.Pro681Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	This variant combination (representing lineage B.1.617.1) showed a 2x decrease in Spike binding (relative to D614G alone)  by 5 plasma collected 8 months post-symptom-onset. [exact variant list not provided in manuscript, is inferred and  represents minimal set agreed upon commonly]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23604	P681R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	G	g.C2042G	p.P681R	NC_045512.2(GU280_gp02):g.2042C>G	YP_009724390.1:p.Pro681Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Yadav	2021	doi:10.1101/2021.04.23.441101	n/a	https://doi.org/10.1101/2021.04.23.441101	False	Yadav et al. (2021)	n/a	Average 2x neutralization efficiency decrease against sera from 26 Phase II trial Covaxin (BBV152) vaccine recipents.  Very similar to B.1.1.7 (~2x) in the same study, and the neutralization from 17 sera of natural infections across B1 lineages.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23604	P681R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	G	g.C2042G	p.P681R	NC_045512.2(GU280_gp02):g.2042C>G	YP_009724390.1:p.Pro681Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Wilhelm	2021	doi:10.1101/2021.08.09.21261704	n/a	https://doi.org/10.1101/2021.08.09.21261704	False	Wilhelm et al. (2021)	n/a	Relative to B.1, Kappa (B.1.617.1) shows 5.71x decrease in neutralization efficiency by convalescent plasma [no cohort details provided]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23604	P681R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	G	g.C2042G	p.P681R	NC_045512.2(GU280_gp02):g.2042C>G	YP_009724390.1:p.Pro681Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Wilhelm	2021	doi:10.1101/2021.08.09.21261704	n/a	https://doi.org/10.1101/2021.08.09.21261704	False	Wilhelm et al. (2021)	n/a	Relative to B.1, Kappa (B.1.617.1) shows mean 1.97x decrease in neutralization efficiency by 18 vaccinee sera (BNT162b2 and mRNA1273).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23604	P681R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	G	g.C2042G	p.P681R	NC_045512.2(GU280_gp02):g.2042C>G	YP_009724390.1:p.Pro681Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	This variant combination (representing lineage B.1.617.1) showed a 1.79x decrease in Spike binding (relative to D614G alone)  by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.64x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees. [exact variant list not provided in manuscript, is inferred and  represents minimal set agreed upon commonly]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23604	P681R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	G	g.C2042G	p.P681R	NC_045512.2(GU280_gp02):g.2042C>G	YP_009724390.1:p.Pro681Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing lineage B.1.617.1) showed a 1.12x increase  in binding (KD) relative to D614G, but described as 'not significant'. [exact variant list not provided in manuscript, is inferred and  represents minimal set agreed upon commonly]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23604	P681R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	G	g.C2042G	p.P681R	NC_045512.2(GU280_gp02):g.2042C>G	YP_009724390.1:p.Pro681Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs 47D10. Kappa (B.1.617.1) has an IC50 fold change of 80.2x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23604	P681R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	G	g.C2042G	p.P681R	NC_045512.2(GU280_gp02):g.2042C>G	YP_009724390.1:p.Pro681Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs Bi-Nab47D10-35B5. Kappa (B.1.617.1) has an IC50 fold change of 2.3x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23604	P681R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	G	g.C2042G	p.P681R	NC_045512.2(GU280_gp02):g.2042C>G	YP_009724390.1:p.Pro681Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs 35B5. Kappa (B.1.617.1) has an IC50 fold change of 0.68x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23604	P681R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	G	g.C2042G	p.P681R	NC_045512.2(GU280_gp02):g.2042C>G	YP_009724390.1:p.Pro681Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs Bi-Nab35B5-47D10. Kappa (B.1.617.1) has an IC50 fold change of 0.13x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23604	P681R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	G	g.C2042G	p.P681R	NC_045512.2(GU280_gp02):g.2042C>G	YP_009724390.1:p.Pro681Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Choi	2021	doi:10.1101/2021.06.28.449914	n/a	https://doi.org/10.1101/2021.06.28.449914	False	Choi et al. (2021)	n/a	Neutralization efficiency (ID50) against B.1.617.1-v1 ('Kappa') reduced 3.3x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23604	P681R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	G	g.C2042G	p.P681R	NC_045512.2(GU280_gp02):g.2042C>G	YP_009724390.1:p.Pro681Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Verghese	2021	doi:10.1128/JCM.00741-21	pmid:33952596	https://doi.org/10.1128/JCM.00741-21	True	Verghese et al. (2021)	n/a	In a cluster of B.1.617[.1] infections related to travel from India to USA, one patient with mild symptoms had received their second dose of Pfizer vaccine more than two weeks before the infection [i.e. vaccine breakthrough].	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23604	P681R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	G	g.C2042G	p.P681R	NC_045512.2(GU280_gp02):g.2042C>G	YP_009724390.1:p.Pro681Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	trafficking	n/a	n/a	Esclera	2021	doi:10.1101/2021.08.05.455290	n/a	https://doi.org/10.1101/2021.08.05.455290	False	Esclera et al. (2021)	n/a	~4.5x cleavage of S2 relative to WA1 (D614G) wildtype by Delta (B.1.617.2) variant as measured by mass spectrometry of Vero-TMPRSS culture (compare to ~3.5x for closely related Kappa B.1.617.1 also with P681R at the cleavage site).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23604	P681R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	G	g.C2042G	p.P681R	NC_045512.2(GU280_gp02):g.2042C>G	YP_009724390.1:p.Pro681Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Choi	2021	doi:10.1101/2021.06.28.449914	n/a	https://doi.org/10.1101/2021.06.28.449914	False	Choi et al. (2021)	n/a	Neutralization efficiency (ID50) against B.1.617.1-v1 ('Kappa') reduced 3.3x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster. [Mutation list in publication appears to contain a typo with R158del instead of R158G]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23604	P681R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	G	g.C2042G	p.P681R	NC_045512.2(GU280_gp02):g.2042C>G	YP_009724390.1:p.Pro681Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Uriu	2021	doi:10.1101/2021.09.06.459005	n/a	https://doi.org/10.1101/2021.09.06.459005	False	Uriu et al. (2021)	n/a	Mean 2.6x reduction of NT50 value B.1.617.2 (Delta) relative to wild type in 8 sera from adult BNT162b2 vaccinees (28-47yo) collected ~1m post booster.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23604	P681R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	G	g.C2042G	p.P681R	NC_045512.2(GU280_gp02):g.2042C>G	YP_009724390.1:p.Pro681Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma escape	n/a	n/a	Uriu	2021	doi:10.1101/2021.09.06.459005	n/a	https://doi.org/10.1101/2021.09.06.459005	False	Uriu et al. (2021)	n/a	Mean 4.0x reduction of NT50 value B.1.617.2 (Delta) relative to wild type in 8 sera from older convalescent patients (52-92yo) collected 1-3m post symptom onset.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23604	P681R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	G	g.C2042G	p.P681R	NC_045512.2(GU280_gp02):g.2042C>G	YP_009724390.1:p.Pro681Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	trafficking	n/a	n/a	Liu	2021	doi:10.1101/2021.08.12.456173v3	n/a	https://doi.org/10.1101/2021.08.12.456173v3	False	Liu et al. (2021)	n/a	Modelling the Delta variant in primary human airway epithelial (HAE) cultures, S1 to full length Spike ratio  (measuring Spike furin cleavage processivity) increased 11x relative to wild type (15.3 vs 1.4). [del ~157 truncated due to ambiguity] Furthermore the RNA ratio of Delta versus Alpha-spike/Delta-backbone continuously increased from 2.8 on day 1  to 9.8 on day 5 post infection in a coinfection model in HAEs, suggesting the spike gene drives the improved replication of Delta variant.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23604	P681R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	G	g.C2042G	p.P681R	NC_045512.2(GU280_gp02):g.2042C>G	YP_009724390.1:p.Pro681Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Chonira	2022	doi:10.1101/2022.05.30.493765	pmid:35677079	https://doi.org/10.1101/2022.05.30.493765	False	Chonira et al. (2022)	n/a	Trimeric proteins FSR22 had a 0.10x fold change in IC50 in B.1.617.2 Delta	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23604	P681R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	G	g.C2042G	p.P681R	NC_045512.2(GU280_gp02):g.2042C>G	YP_009724390.1:p.Pro681Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Chonira	2022	doi:10.1101/2022.05.30.493765	pmid:35677079	https://doi.org/10.1101/2022.05.30.493765	False	Chonira et al. (2022)	n/a	Trimeric proteins FSR16m had a 0.020x fold change in IC50 in B.1.617.2 Delta	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23604	P681R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	G	g.C2042G	p.P681R	NC_045512.2(GU280_gp02):g.2042C>G	YP_009724390.1:p.Pro681Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Wang	2022	doi:10.1101/2022.08.11.503601	n/a	https://doi.org/10.1101/2022.08.11.503601	False	Wang et al. (2022)	n/a	Plasma neutralizing activity was also assessed against SARS-CoV-2 Delta, Omicron BA.1, BA.2 and BA.4/5 variants using viruses pseudotyped with appropriate  variant spikeproteins. Delta breakthrough infection resulted in 15-fold increased neutralizing titers.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23604	P681R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	G	g.C2042G	p.P681R	NC_045512.2(GU280_gp02):g.2042C>G	YP_009724390.1:p.Pro681Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Uhal B	2022	doi:10.1101/2022.06.23.497326	n/a	https://doi.org/10.1101/2022.06.23.497326	False	Uhal B et al. (2022)	n/a	L27, V34 and E90 mutation resulted in ultrahigh affinity binding of the LVE-ACE-2 domain to the widest variety of VOCs, with KDs of 507 pM for binding to the Delta  B.1.617.2. Values were obtained with LVE-ACE-2/mAB chimeras containing the Y-T-E sequence that enhances binding to the FcRn receptor, which in turn is expected to  extend biological half-life 3-4-fold.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23604	P681R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	G	g.C2042G	p.P681R	NC_045512.2(GU280_gp02):g.2042C>G	YP_009724390.1:p.Pro681Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Wang	2022	doi:10.1101/2022.08.11.503601	n/a	https://doi.org/10.1101/2022.08.11.503601	False	Wang et al. (2022)	n/a	Plasma neutralizing activity in 49 participants was measured using HIV-1 pseudotyped with the 100 WT SARS-CoV-2 spike protein. Delta breakthrough infection  resulted in 11-fold increased geometric mean half-maximal neutralizing titer (NT50).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23604	P681R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	G	g.C2042G	p.P681R	NC_045512.2(GU280_gp02):g.2042C>G	YP_009724390.1:p.Pro681Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	McEvoy C	2022	doi:10.1101/2022.06.24.22276144	n/a	https://doi.org/10.1101/2022.06.24.22276144	False	McEvoy C et al. (2022)	n/a	Log10ID50 of Delta neutralizing antibodies is 0.872x the WT pre-third dose of pfizer-BioNTech BNT162b2 in 13 Kidney transplant recipients (KTR) with median age of  55.5.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23604	P681R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	G	g.C2042G	p.P681R	NC_045512.2(GU280_gp02):g.2042C>G	YP_009724390.1:p.Pro681Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Uhal B	2022	doi:10.1101/2022.06.23.497326	n/a	https://doi.org/10.1101/2022.06.23.497326	False	Uhal B et al. (2022)	n/a	Paradigm’s ACE-2 variant LVE/STR chimera neutralizes Delta Variant B.1.617.2 RBD or w.t. SARS-CoV-2 RBD with nearly equal potency determined using Surrogate Viral Neutralization Tests.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23604	P681R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	G	g.C2042G	p.P681R	NC_045512.2(GU280_gp02):g.2042C>G	YP_009724390.1:p.Pro681Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	McEvoy C	2022	doi:10.1101/2022.06.24.22276144	n/a	https://doi.org/10.1101/2022.06.24.22276144	False	McEvoy C et al. (2022)	n/a	Log10ID50 of Delta neutralizing antibodies is 0.952x the WT 1 month post-third dose of pfizer-BioNTech BNT162b2 in 13 Kidney transplant recipients (KTR) with median  age of 55.5.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23604	P681R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	G	g.C2042G	p.P681R	NC_045512.2(GU280_gp02):g.2042C>G	YP_009724390.1:p.Pro681Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	outcome hazard ratio	n/a	n/a	Twohig	2021	doi:10.1016/S1473-3099(21	n/a	https://doi.org/10.1016/S1473-3099(21	n/a	Twohig et al. (2021)	n/a	In the UK, of 43338 COVID-19-positive patients, 8682 had the Delta variant (median age 31 years [IQR 17–43]) and 196 were admitted to hospital within 14  days after the specimen was taken (adjusted hazard ratio [HR] 2.26 [95% CI 1.32–3.89] relative to Alpha cases). Being admitted to hospital or attending emergency care within 14 days for Delta cases had an adjusted HR 1.45 [95% CI 1.08–1.95] relative to Alpha. Most patients were unvaccinated (32 078 [74·0%] across both groups). The HRs for vaccinated patients were similar: 1.94 [95% CI 0.47–8.05] for hospitalization and 1.58 [0.69–3.61]) for hospital admission or  emergency care attendance.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23604	P681R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	G	g.C2042G	p.P681R	NC_045512.2(GU280_gp02):g.2042C>G	YP_009724390.1:p.Pro681Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine efficacy	n/a	n/a	Fowlkes	2021	doi:10.15585/mmwr.mm7034e4	pmid:34437521	https://doi.org/10.15585/mmwr.mm7034e4	False	Fowlkes et al. (2021)	n/a	During December 14, 2020–August 14, 2021, frontline worker without previous documented SARS-CoV-2 infection were monitored regularly.  Of 4,217 participants, 3,483 (83%) were vaccinated: 2,278 (65%) received Pfizer-BioNTech, 1,138 (33%) Moderna, and 67 (2%) Janssen  (Johnson & Johnson) COVID-19 vaccines. Adjusted VE during this Delta predominant period was 66% (95% CI 	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23604	P681R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	G	g.C2042G	p.P681R	NC_045512.2(GU280_gp02):g.2042C>G	YP_009724390.1:p.Pro681Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	UNKNOWN	n/a	n/a	n/a	n/a	n/a	UNKNOWN et al. ()	n/a	Case 62541 cluster in Singapore included a fully vaccinated nurse 2 months post-vaccine [likely Pfizer based on dates and supply],  and a doctor of unknown vaccine status. This cluster was caused by a B.1.617.2 virus [via crossreference to	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23604	P681R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	G	g.C2042G	p.P681R	NC_045512.2(GU280_gp02):g.2042C>G	YP_009724390.1:p.Pro681Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	This variant combination (representing lineage B.1.617.2 aka Delta) showed a 1.64x decrease in Spike binding (relative to D614G alone)  by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.   1.89x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees. [exact variant list not provided in manuscript, is inferred and  represents minimal set agreed upon commonly]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23604	P681R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	G	g.C2042G	p.P681R	NC_045512.2(GU280_gp02):g.2042C>G	YP_009724390.1:p.Pro681Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	UNKNOWN	n/a	n/a	n/a	https://www.moh.gov.sg/news-highlights/details/3-new-cases-of-locally-transmitted-covid-19-infection-28apr2021-update	False	UNKNOWN et al. ()	n/a	n/a	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23604	P681R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	G	g.C2042G	p.P681R	NC_045512.2(GU280_gp02):g.2042C>G	YP_009724390.1:p.Pro681Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine efficacy	n/a	n/a	Nanduri	2021	doi:10.15585/mmwr.mm7034e3	pmid:34437519	https://doi.org/10.15585/mmwr.mm7034e3	False	Nanduri et al. (2021)	n/a	136,160 reports from 14,997 nursing care facilities were broken into pre-Delta (Mar 1-May 9, 2021), intermediate (May 10-Jun 20, 2021)  and Delta (Jun 21-Aug 1, 2021). Two doses of mRNA vaccines were 74.7% effective against infection among nursing home residents early in the vaccination program  (March–May 2021). During June–July 2021, when B.1.617.2 (Delta) variant circulation predominated, effectiveness declined significantly to 53.1%.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23604	P681R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	G	g.C2042G	p.P681R	NC_045512.2(GU280_gp02):g.2042C>G	YP_009724390.1:p.Pro681Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine efficacy	n/a	n/a	Tang	2021	doi:10.1101/2021.08.11.21261885	n/a	https://doi.org/10.1101/2021.08.11.21261885	False	Tang et al. (2021)	n/a	Using a matched test-negative, case- control study design in Qatar, BNT162b2 effectiveness against any Delta infection, symptomatic or asymptomatic,  was 64.2% (95% CI: 38.1-80.1%) ≥14 days after the first dose and before the second dose, but was only 53.5% (95% CI: 43.9-61.4%) ≥14 days after the  second dose, in a population in which a large proportion of fully vaccinated persons received their second dose several months earlier.  Corresponding effectiveness measures for mRNA-1273 were 79.0% (95% CI: 58.9-90.1%) and 84.8% (95% CI: 75.9-90.8%), respectively. Effectiveness against any severe, critical, or fatal COVID-19 disease due to Delta was 89.7% (95% CI: 61.0-98.1%) for BNT162b2 and 100.0% (95% CI: 41.2-100.0%) for  mRNA-1273, ≥14 days after the second dose. The lower VE in Qatar relative to those reported in some other jurisdictions such as the UK and Canada (75%+) may reflect waning of vaccine protection for  those who received their second dose by end of 2020 or early 2021. Risk perception and behaviour amongst vaccinated individuals opver time may also  play a role.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23604	P681R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	G	g.C2042G	p.P681R	NC_045512.2(GU280_gp02):g.2042C>G	YP_009724390.1:p.Pro681Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	outcome hazard ratio	n/a	n/a	Bager	2021	doi:10.1016/S1473-3099(21	n/a	https://doi.org/10.1016/S1473-3099(21	n/a	Bager et al. (2021)	n/a	In Denmark, for the period Jan 1 to Jun 27, 2021, Delta variant was associated with increased an risk ratio of 2.83 [95% CI 2.02–3.98] for hospitalization.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23604	P681R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	G	g.C2042G	p.P681R	NC_045512.2(GU280_gp02):g.2042C>G	YP_009724390.1:p.Pro681Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine efficacy	n/a	n/a	Chia	2021	doi:10.1101/2021.07.28.21261295	n/a	https://doi.org/10.1101/2021.07.28.21261295	False	Chia et al. (2021)	n/a	Of 218 individuals with B.1.617.2 infection in Singapore, 84 had received a mRNA vaccine of which 71 were fully vaccinated,  130 were unvaccinated and 4 received a non-mRNA. Despite significantly older age in the vaccine breakthrough group, the odds of  severe COVID-19 requiring oxygen supplementation was significantly lower following vaccination (adjusted odds ratio 0.07 95%CI: 0.015-0.335, p	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23604	P681R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	G	g.C2042G	p.P681R	NC_045512.2(GU280_gp02):g.2042C>G	YP_009724390.1:p.Pro681Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine efficacy	n/a	n/a	Baden	2021	doi:10.1101/2021.09.17.21263624	pmid:34611666	https://doi.org/10.1101/2021.09.17.21263624	False	Baden et al. (2021)	n/a	The incidence rate of Covid-19 during the Delta-dominant period (Jul-Aug 2021) was lower for late vaccinated (49.0/1000 person-years) [formerly placebo]  versus early vaccinated (77.1/1000 person-years) participants in the Moderna mRNA-1273 Phase 3 trials, representing a 36.4% VE reduction (95% CI 17.1%-51.5%). There were fewer severe Covid-19 cases in the late group (6: 6.2/1000 person-years) than early (13: 3.3/1000 person-years), representing a 46.0%  reduction (95% CI −52.4%-83.2%). Three Covid-19 related hospitalizations occurred with two resulting deaths in the early group.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23604	P681R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	G	g.C2042G	p.P681R	NC_045512.2(GU280_gp02):g.2042C>G	YP_009724390.1:p.Pro681Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	2.3x reduction in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees) [exact set of variants used is not listed in the manuscript]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23604	P681R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	G	g.C2042G	p.P681R	NC_045512.2(GU280_gp02):g.2042C>G	YP_009724390.1:p.Pro681Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Rosenke	2022	doi:10.1172/jci.insight.160108	pmid:35579953	https://doi.org/10.1172/jci.insight.160108	True	Rosenke et al. (2022)	n/a	Infectious viral titers in lung tissue determined using a tissue culture infectious dose (TCID) assay in 10 hamsters showed that Delta Molnupiravir (MK-4482) had ~4x fold drop.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23604	P681R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	G	g.C2042G	p.P681R	NC_045512.2(GU280_gp02):g.2042C>G	YP_009724390.1:p.Pro681Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine efficacy	n/a	n/a	Nasreen	2021	doi:10.1101/2021.06.28.21259420	n/a	https://doi.org/10.1101/2021.06.28.21259420	False	Nasreen et al. (2021)	n/a	Using a test-negative design using Ontario data between Dec 14, 2020 and May 30, 2021, 421,073 symptomatic community-dwelling individuals were tested. Against Delta, vaccine effectiveness after partial vaccination tended to be lower compared to Alpha for mRNA-1273 (72% vs. 83%) and BNT162b2 (56% vs. 66%),  but was similar to Alpha for ChAdOx1 (67% vs. 64%). Full vaccination with BNT162b2 increased protection against Delta (87%) to levels comparable to  Alpha (89%) and Beta/Gamma (84%). Delta-positive cases were biased towards young male residents of the Peel region.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23604	P681R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	G	g.C2042G	p.P681R	NC_045512.2(GU280_gp02):g.2042C>G	YP_009724390.1:p.Pro681Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	outcome hazard ratio	n/a	n/a	UNKNOWN	2021	doi:10.1503/cmaj.211248	pmid:34610919	https://doi.org/10.1503/cmaj.211248	True	UNKNOWN et al. (2021)	n/a	In Ontario between Feb 7 and Jun 27, 2021, increased risk with the Delta variant was 108% (95% CI 78%–140%) for hospitalization,  235% (95% CI 160%–331%) for ICU admission and 133% (95% CI 54%–231%) for death.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23604	P681R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	G	g.C2042G	p.P681R	NC_045512.2(GU280_gp02):g.2042C>G	YP_009724390.1:p.Pro681Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Ferreira	2021	doi:10.1101/2021.05.08.443253	n/a	https://doi.org/10.1101/2021.05.08.443253	False	Ferreira et al. (2021)	n/a	Vaccination of health care workers in Delhi was started in early 2021, with the ChdOx-1 (Astra Zeneca) vaccine. Surveillance has suggested B.1.1.7 dominance in the Delhi area during early 2021, with growth of B.1.617 since March 2021. During the wave of infections during March and April an outbreak of SARS-CoV-2 was confirmed in 33 vaccinated staff  members at a single tertiary centre (age 27-77 years). Sequencing revealed that 16/33 were B.1.617.2, with a range of other B lineage viruses including B.1.1.7 for the rest except one A lineage case.  Importantly no severe cases were documented in this event.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23604	P681R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	G	g.C2042G	p.P681R	NC_045512.2(GU280_gp02):g.2042C>G	YP_009724390.1:p.Pro681Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine efficacy	n/a	n/a	Lopez Bernal	2021	doi:10.1056/NEJMoa2108891	pmid:34289274	https://doi.org/10.1056/NEJMoa2108891	True	Lopez Bernal et al. (2021)	n/a	Effectiveness after one dose of vaccine (BNT162b2 or ChAdOx1 nCoV-19) with the delta variant was (30.7%: 95% confidence interval [CI], 25.2 to 35.7): the results were similar for both vaccines.  With the BNT162b2 vaccine, the effectiveness of two doses was 88.0% (95% CI, 85.3 to 90.1) among those with the delta variant.  With the ChAdOx1 nCoV-19 vaccine, the effectiveness of two doses was 67.0% (95% CI, 61.3 to 71.8) among those with the delta variant.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23604	P681R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	G	g.C2042G	p.P681R	NC_045512.2(GU280_gp02):g.2042C>G	YP_009724390.1:p.Pro681Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	convalescent plasma binding	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	This variant combination (representing lineage B.1.617.2 aka Delta) showed a 1.92x decrease in Spike binding (relative to D614G alone)  by 5 plasma collected 8 months post-symptom-onset. [exact variant list not provided in manuscript, is inferred and  represents minimal set agreed upon commonly]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23604	P681R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	G	g.C2042G	p.P681R	NC_045512.2(GU280_gp02):g.2042C>G	YP_009724390.1:p.Pro681Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Gong	2021	doi:10.1101/2021.08.04.455140	n/a	https://doi.org/10.1101/2021.08.04.455140	False	Gong et al. (2021)	n/a	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing lineage B.1.617.2 aka Delta) showed a 2.34x increase  in binding (KD) relative to D614G. [exact variant list not provided in manuscript, is inferred and represents minimal set agreed upon commonly]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23604	P681R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	G	g.C2042G	p.P681R	NC_045512.2(GU280_gp02):g.2042C>G	YP_009724390.1:p.Pro681Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine efficacy	n/a	n/a	Puranik	2021	doi:10.1101/2021.08.06.21261707	pmid:34401884	https://doi.org/10.1101/2021.08.06.21261707	False	Puranik et al. (2021)	n/a	In Minnesota in July 2020 (when Delta variant prevalence was >70%), the effectiveness against infection for mRNA-1273 was estimated at 76%  (95% CI: 58-87%) using age, sex, race, PCR testing and vaccination date matched cohorts of unvaccinated, Pfizer and Moderna vaccinees.  An even more pronounced reduction in effectiveness was observed for BNT162b2 of 42% (95% CI: 13-62%).  mRNA-1273 conferred a two-fold risk reduction against breakthrough infection compared to BNT162b2 (IRR 	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23604	P681R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	G	g.C2042G	p.P681R	NC_045512.2(GU280_gp02):g.2042C>G	YP_009724390.1:p.Pro681Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine efficacy	n/a	n/a	Bruxvoort	2021	doi:10.1101/2021.09.29.21264199	n/a	https://doi.org/10.1101/2021.09.29.21264199	False	Bruxvoort et al. (2021)	n/a	In a 1:5 test-negative matched control study of 8153 individuals who received the Moderna mRNA-1273 vaccine, 2027 test-positive cases were Delta. Two dose vaccine efficacy against Delta decreased from 94.1% (90.5-96.3%) 14-60 days after vaccination to 80.0%  (70.2-86.6%) 151-180 days after vaccination. Waning was less pronounced for non-Delta variants. VE against Delta  was lower among individuals aged ≥65 years (75.2% [59.6-84.8%]) than those aged 18-64 years (87.9% [85.5-89.9%]).  VE against Delta hospitalization was 97.6% (92.8-99.2%). One-dose VE was 77.0% (60.7-86.5%) against Delta infection.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23604	P681R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	G	g.C2042G	p.P681R	NC_045512.2(GU280_gp02):g.2042C>G	YP_009724390.1:p.Pro681Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs 47D10. Delta (B.1.617.2) has an IC50 fold change of 46.5x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23604	P681R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	G	g.C2042G	p.P681R	NC_045512.2(GU280_gp02):g.2042C>G	YP_009724390.1:p.Pro681Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs Bi-Nab35B5-47D10. Delta (B.1.617.2) has an IC50 fold change of 0.57x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23604	P681R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	G	g.C2042G	p.P681R	NC_045512.2(GU280_gp02):g.2042C>G	YP_009724390.1:p.Pro681Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs Bi-Nab47D10-35B5. Delta (B.1.617.2) has an IC50 fold change of 0.15x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23604	P681R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	G	g.C2042G	p.P681R	NC_045512.2(GU280_gp02):g.2042C>G	YP_009724390.1:p.Pro681Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs 35B5. Delta (B.1.617.2) has an IC50 fold change of 0.87x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23604	P681R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	G	g.C2042G	p.P681R	NC_045512.2(GU280_gp02):g.2042C>G	YP_009724390.1:p.Pro681Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Kumar	2022	doi:10.1101/2022.05.13.491770	n/a	https://doi.org/10.1101/2022.05.13.491770	False	Kumar et al. (2022)	n/a	BnAb 002-S21F2 IC50 on the Delta (B.1.617.2) variant is 0.6x fold the wildtype.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23604	P681R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	G	g.C2042G	p.P681R	NC_045512.2(GU280_gp02):g.2042C>G	YP_009724390.1:p.Pro681Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Choi	2021	doi:10.1101/2021.06.28.449914	n/a	https://doi.org/10.1101/2021.06.28.449914	False	Choi et al. (2021)	n/a	Neutralization efficiency (ID50) against A.23.1-v2 reduced 2.3x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23604	P681R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	G	g.C2042G	p.P681R	NC_045512.2(GU280_gp02):g.2042C>G	YP_009724390.1:p.Pro681Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Choi	2021	doi:10.1101/2021.06.28.449914	n/a	https://doi.org/10.1101/2021.06.28.449914	False	Choi et al. (2021)	n/a	Neutralization efficiency (ID50) against A.23.1-v1 reduced 1.1x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23604	P681R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	G	g.C2042G	p.P681R	NC_045512.2(GU280_gp02):g.2042C>G	YP_009724390.1:p.Pro681Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	trafficking	n/a	n/a	Ferriera	2021	doi:10.1101/2021.05.08.443253	n/a	https://doi.org/10.1101/2021.05.08.443253	False	Ferriera et al. (2021)	n/a	This variant combination shows a ~3x decrease in cell entry efficiency (RLU measurement in 293T cells) compared to D614G, significantly less of a decrease than any B.1.617 lineage variants alone, suggesting a synergistic effect on cell entry while maintaining known immunity esacpe mutants.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23604	P681R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	G	g.C2042G	p.P681R	NC_045512.2(GU280_gp02):g.2042C>G	YP_009724390.1:p.Pro681Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	viral load	n/a	n/a	Yadav	2021	doi:10.1101/2021.05.05.442760	n/a	https://doi.org/10.1101/2021.05.05.442760	False	Yadav et al. (2021)	n/a	In 9 infected hamsters each for B.1 and B.1.617.1, no significant change in viral load or subgenomic RNA levels were detected.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23604	P681R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	G	g.C2042G	p.P681R	NC_045512.2(GU280_gp02):g.2042C>G	YP_009724390.1:p.Pro681Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	symptom prevalence	n/a	n/a	Yadav	2021	doi:10.1101/2021.05.05.442760	n/a	https://doi.org/10.1101/2021.05.05.442760	False	Yadav et al. (2021)	n/a	Gross examination of 3+3 hamster lung specimens showed pronounced congestion and hemorrhages on days 5 and 7 post-infection in the case of the B.1.617.1 as compared with the B.1. The lung lesions with  the B.1 variant were minimal to mild whereas with B.1.617.1 they were moderate. For B.1 pneumonic changes were minimal to mild (inflammatory cell infiltration, focal consolidation and mild congestion). The pronounced changes (moderate to severe) with mononuclear infiltration in the alveolar interstitial space, interstitial septal thickening, consolidation and pneumocyte hyperplasia were observed with B.1.617.1 variant consistently.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23604	P681R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	G	g.C2042G	p.P681R	NC_045512.2(GU280_gp02):g.2042C>G	YP_009724390.1:p.Pro681Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	transmissibility	n/a	n/a	Tada	2021	doi:10.1101/2021.05.14.444076	n/a	https://doi.org/10.1101/2021.05.14.444076	False	Tada et al. (2021)	n/a	Normalized for particle number, on ACE2.293T cells showed that the B.1.617 spike protein was >2-fold increase in infectivity relative to D614G wild type.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23604	P681R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	G	g.C2042G	p.P681R	NC_045512.2(GU280_gp02):g.2042C>G	YP_009724390.1:p.Pro681Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	trafficking	n/a	n/a	UNKNOWN	2021	n/a	n/a	https://www.researchgate.net/publication/348943694_The_mutation_P681H_in_the_B117_variant_of_SARS-CoV-2_probably_enhances_viral_entry_and_replication	False	UNKNOWN et al. (2021)	n/a	This mutation in the first base of the furin clevage site maintains the RXXR recognition motif, and is presumed to enhance cleavage based on the removal of a proline-directed phosphotase recognition site at S680. In a homologuous site in Infectious  Bronchitis Virus (IBV, Gammacoronaviruses), abolition of S680 phosphorylation improves furin cleavage  (and presumably cell entry). [Inference from similar positively charged substitution P681H actually described in the work]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23604	P681R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	G	g.C2042G	p.P681R	NC_045512.2(GU280_gp02):g.2042C>G	YP_009724390.1:p.Pro681Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	virion structure	n/a	n/a	Tada	2021	doi:10.1101/2021.02.05.430003	pmid:33564768	https://doi.org/10.1101/2021.02.05.430003	False	Tada et al. (2021)	n/a	The Ratio of S2 (processed Spike) to full length Spike is higher for this mutation,  due to a drop in the full length Spike measured, suggesting that this mutation compensates for decreased Spike production by improved proteolytic processing. [PG: Inferred by conservative AA substitution of described P681H]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23604	P681R	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	G	g.C2042G	p.P681R	NC_045512.2(GU280_gp02):g.2042C>G	YP_009724390.1:p.Pro681Arg	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	trafficking	n/a	n/a	Tada	2021	doi:10.1101/2021.05.14.444076	n/a	https://doi.org/10.1101/2021.05.14.444076	False	Tada et al. (2021)	n/a	Quantification of the band intensities showed that the P681R mutation, which lies near the proteolytic processing site,  caused a small increase in proteolytic processing as measured by a 2-fold decrease in the ratio of S/S2.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23854	N764K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	A	g.C2292A	p.N764K	NC_045512.2(GU280_gp02):g.2292C>A	YP_009724390.1:p.Asn764Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron BA.2 have higher sensitivity to inhibition by soluble angiotensin converting enzyme 2 (ACE2) and the endosomal inhibitor chloroquine compared  to D614G	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23854	N764K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	A	g.C2292A	p.N764K	NC_045512.2(GU280_gp02):g.2292C>A	YP_009724390.1:p.Asn764Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs Bi-Nab35B5-47D10. Omicron BA.2 has an IC50 fold change of 0.07x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23854	N764K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	A	g.C2292A	p.N764K	NC_045512.2(GU280_gp02):g.2292C>A	YP_009724390.1:p.Asn764Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs 35B5. Omicron BA.2 has an IC50 fold change of 0.09x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23854	N764K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	A	g.C2292A	p.N764K	NC_045512.2(GU280_gp02):g.2292C>A	YP_009724390.1:p.Asn764Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs 47D10. Omicron BA.2 has an IC50 fold change of 0.08x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23854	N764K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	A	g.C2292A	p.N764K	NC_045512.2(GU280_gp02):g.2292C>A	YP_009724390.1:p.Asn764Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs Bi-Nab47D10-35B5. Omicron BA.2 has an IC50 fold change of 0.04x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23854	N764K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	A	g.C2292A	p.N764K	NC_045512.2(GU280_gp02):g.2292C>A	YP_009724390.1:p.Asn764Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron BA.2 neutralization of the Omicron variants by antibodies induced by three doses of Pfizer/BNT162b2 mRNA vaccine was 7-8-fold less potent than the D614G, and  the Omicron variants still evade neutralization more efficiently.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23854	N764K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	A	g.C2292A	p.N764K	NC_045512.2(GU280_gp02):g.2292C>A	YP_009724390.1:p.Asn764Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Kumar	2022	doi:10.1101/2022.05.13.491770	n/a	https://doi.org/10.1101/2022.05.13.491770	False	Kumar et al. (2022)	n/a	BnAb 002-S21F2 IC50 on the Omicron BA.2 variant is 0.8x fold the wildtype.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23854	N764K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	A	g.C2292A	p.N764K	NC_045512.2(GU280_gp02):g.2292C>A	YP_009724390.1:p.Asn764Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.2 (from South Africa/CERI-KRISP-K032307/2021) were 3.9x-fold lower (95% CI: 0.14x-0.17x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23854	N764K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	A	g.C2292A	p.N764K	NC_045512.2(GU280_gp02):g.2292C>A	YP_009724390.1:p.Asn764Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Uhal B	2022	doi:10.1101/2022.06.23.497326	n/a	https://doi.org/10.1101/2022.06.23.497326	False	Uhal B et al. (2022)	n/a	L27, V34 and E90 mutation resulted in ultrahigh affinity binding of the LVE-ACE-2 domain to the widest variety of VOCs, with KDs of 78fM for binding to the Omicron  BA.2. Values were obtained with LVE-ACE-2/mAB chimeras containing the Y-T-E sequence that enhances binding to the FcRn receptor, which in turn is expected to  extend biological half-life 3-4-fold.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23854	N764K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	A	g.C2292A	p.N764K	NC_045512.2(GU280_gp02):g.2292C>A	YP_009724390.1:p.Asn764Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.2 (from South Africa/CERI-KRISP-K032307/2021) were 4.5-fold lower (95% CI: 4.3x-4.7x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23854	N764K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	A	g.C2292A	p.N764K	NC_045512.2(GU280_gp02):g.2292C>A	YP_009724390.1:p.Asn764Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.2.12.1 (from USA/NY-CDC-ASC210722700/2022) were 4.2-fold lower (95% CI: 5.8x-6.6x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23854	N764K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	A	g.C2292A	p.N764K	NC_045512.2(GU280_gp02):g.2292C>A	YP_009724390.1:p.Asn764Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.2.12.1 (from USA/NY-CDC-ASC210722700/2022) were 3.9x-fold lower (95% CI: 0.14x-0.18x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23854	N764K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	A	g.C2292A	p.N764K	NC_045512.2(GU280_gp02):g.2292C>A	YP_009724390.1:p.Asn764Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Cathcart	2021	doi:10.1101/2021.03.09.434607v9	n/a	https://doi.org/10.1101/2021.03.09.434607v9	False	Cathcart et al. (2021)	n/a	Omicron (a.k.a. B.1.1.529) Spike pseudotyped VSV and Vero E6 cells has somewhat  reduced neutralization (2.7x) vs wild type with monoclonal antibody Sotrovimab (a.k.a. VIR-7831).  [delins at 214 omitted for syntax compatibility]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23854	N764K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	A	g.C2292A	p.N764K	NC_045512.2(GU280_gp02):g.2292C>A	YP_009724390.1:p.Asn764Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Wang	2022	doi:10.1101/2022.08.11.503601	n/a	https://doi.org/10.1101/2022.08.11.503601	False	Wang et al. (2022)	n/a	Omicron breakthrough infection after 3-dose vaccination resulted in a further 3.5-fold and 2.9-fold increase of Omicron BA.1 and BA.2 neutralizing titers. Omicron  BA.4/5 showed the highest neutralization resistance of all variants tested, resulting in low geometric mean neutralizing titers in plasma samples  obtained after  the second vaccine dose (NT50	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23854	N764K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	A	g.C2292A	p.N764K	NC_045512.2(GU280_gp02):g.2292C>A	YP_009724390.1:p.Asn764Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs Bi-Nab47D10-35B5. Omicron BA.1 has an IC50 fold change of 0.08x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23854	N764K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	A	g.C2292A	p.N764K	NC_045512.2(GU280_gp02):g.2292C>A	YP_009724390.1:p.Asn764Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron B.1.1.529 (BA.1) neutralization of the Omicron variants by antibodies induced by three doses of Pfizer/BNT162b2 mRNA vaccine was 7-8-fold less potent than  the D614G, and the Omicron variants still evade neutralization more efficiently.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23854	N764K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	A	g.C2292A	p.N764K	NC_045512.2(GU280_gp02):g.2292C>A	YP_009724390.1:p.Asn764Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron (B.1.1.529 [BA.1]) have higher sensitivity to inhibition by soluble angiotensin converting enzyme 2 (ACE2) and the endosomal inhibitor chloroquine compared  to D614G	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23854	N764K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	A	g.C2292A	p.N764K	NC_045512.2(GU280_gp02):g.2292C>A	YP_009724390.1:p.Asn764Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs Bi-Nab35B5-47D10. Omicron BA.1 has an IC50 fold change of 0.30x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23854	N764K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	A	g.C2292A	p.N764K	NC_045512.2(GU280_gp02):g.2292C>A	YP_009724390.1:p.Asn764Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Uhal B	2022	doi:10.1101/2022.06.23.497326	n/a	https://doi.org/10.1101/2022.06.23.497326	False	Uhal B et al. (2022)	n/a	Paradigms’ ACE-2 variant LVE/STR chimera binds to SARS-2 Omicron variant B.1.1.529 spike protein trimer with high affinity. Determined using Surrogate Viral Neutralization Tests.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23854	N764K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	A	g.C2292A	p.N764K	NC_045512.2(GU280_gp02):g.2292C>A	YP_009724390.1:p.Asn764Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Uhal B	2022	doi:10.1101/2022.06.23.497326	n/a	https://doi.org/10.1101/2022.06.23.497326	False	Uhal B et al. (2022)	n/a	L27, V34 and E90 mutation resulted in ultrahigh affinity binding of the LVE-ACE-2 domain to the widest variety of VOCs, with KDs of 73 pM for binding to the Omicron  B.1.1.529. Values were obtained with LVE-ACE-2/mAB chimeras containing the Y-T-E sequence that enhances binding to the FcRn receptor, which in turn is expected to  extend biological half-life 3-4-fold.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23854	N764K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	A	g.C2292A	p.N764K	NC_045512.2(GU280_gp02):g.2292C>A	YP_009724390.1:p.Asn764Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs 35B5. Omicron BA.1 has an IC50 fold change of 0.38x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23854	N764K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	A	g.C2292A	p.N764K	NC_045512.2(GU280_gp02):g.2292C>A	YP_009724390.1:p.Asn764Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Arora	2022	doi:10.1038/s41423-022-00870-5	pmid:35581351	https://doi.org/10.1038/s41423-022-00870-5	True	Arora et al. (2022)	n/a	All 10 individuals with 2 doses of the BNT162b2/BNT162b2 vaccine had a neutralizing titer in B.1 variant at an average of 729 NT50.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23854	N764K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	A	g.C2292A	p.N764K	NC_045512.2(GU280_gp02):g.2292C>A	YP_009724390.1:p.Asn764Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Shete	2022	doi:10.1101/2022.05.12.491584	n/a	https://doi.org/10.1101/2022.05.12.491584	False	Shete et al. (2022)	n/a	Plaque reduction neutralization test (PRNT) was used uring primary infection, post sixty daysof second dose vaccination, pre-reinfection and reinfection against Delta variant and was used to determine neutralizing antibodytitres. There was a 24.63x fold increase in antibody response from first infection to recovered and vaccinated with 2 doses (60 days). There was a 4.21x fold increase in antibody response pre-reinfection. There was a 39.27x fold increase in antibody response during reinfection.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23854	N764K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	A	g.C2292A	p.N764K	NC_045512.2(GU280_gp02):g.2292C>A	YP_009724390.1:p.Asn764Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Shete	2022	doi:10.1101/2022.05.12.491584	n/a	https://doi.org/10.1101/2022.05.12.491584	False	Shete et al. (2022)	n/a	Plaque reduction neutralization test (PRNT) was used uring primary infection, post sixty daysof second dose vaccination, pre-reinfection and reinfection against B.1 variant and was used to determine neutralizing antibodytitres. There was a 6.76x fold increase in antibody response from first infection to recovered and vaccinated with 2 doses (60 days). There was a 2.06x fold increase in antibody response pre-reinfection. There was a 8.18x fold increase in antibody response during reinfection.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23854	N764K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	A	g.C2292A	p.N764K	NC_045512.2(GU280_gp02):g.2292C>A	YP_009724390.1:p.Asn764Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Arora	2022	doi:10.1038/s41423-022-00870-5	pmid:35581351	https://doi.org/10.1038/s41423-022-00870-5	True	Arora et al. (2022)	n/a	All 10 individuals with 3 doses of the BNT162b2/BNT162b2 vaccine had a neutralizing titer in B.1 variant at an average of 3319 NT50.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23854	N764K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	A	g.C2292A	p.N764K	NC_045512.2(GU280_gp02):g.2292C>A	YP_009724390.1:p.Asn764Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Shete	2022	doi:10.1101/2022.05.12.491584	n/a	https://doi.org/10.1101/2022.05.12.491584	False	Shete et al. (2022)	n/a	Plaque reduction neutralization test (PRNT) was used uring primary infection, post sixty daysof second dose vaccination, pre-reinfection and reinfection against Omicron variant and was used to determine neutralizing antibodytitres. There was a 114.84x fold increase in antibody response from first infection to recovered and vaccinated with 2 doses (60 days). There was a 6.61x fold increase in antibody response pre-reinfection. There was a 1194.9x fold increase in antibody response during reinfection.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23854	N764K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	A	g.C2292A	p.N764K	NC_045512.2(GU280_gp02):g.2292C>A	YP_009724390.1:p.Asn764Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Kumar	2022	doi:10.1101/2022.05.13.491770	n/a	https://doi.org/10.1101/2022.05.13.491770	False	Kumar et al. (2022)	n/a	BnAb 002-S21F2 IC50 on the Omicron BA.1 variant is 1.0x fold the wildtype.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23854	N764K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	A	g.C2292A	p.N764K	NC_045512.2(GU280_gp02):g.2292C>A	YP_009724390.1:p.Asn764Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs 47D10. Omicron BA.1 has an IC50 fold change of 1.26x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23854	N764K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	A	g.C2292A	p.N764K	NC_045512.2(GU280_gp02):g.2292C>A	YP_009724390.1:p.Asn764Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron BA.3 have higher sensitivity to inhibition by soluble angiotensin converting enzyme 2 (ACE2) and the endosomal inhibitor chloroquine compared  to D614G	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23854	N764K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	A	g.C2292A	p.N764K	NC_045512.2(GU280_gp02):g.2292C>A	YP_009724390.1:p.Asn764Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron BA.3 neutralization of the Omicron variants by antibodies induced by three doses of Pfizer/BNT162b2 mRNA vaccine was 7-8-fold less potent than the D614G, and  the Omicron variants still evade neutralization more efficiently.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23854	N764K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	A	g.C2292A	p.N764K	NC_045512.2(GU280_gp02):g.2292C>A	YP_009724390.1:p.Asn764Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.3 (from South Africa/NICD-N22404/2021) were 4.2x-fold lower (95% CI: 0.15x-0.20x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23854	N764K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	A	g.C2292A	p.N764K	NC_045512.2(GU280_gp02):g.2292C>A	YP_009724390.1:p.Asn764Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.3 (from South Africa/NICD-N22404/2021) were 6.2-fold lower (95% CI: 11.8x-14.3x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23854	N764K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	A	g.C2292A	p.N764K	NC_045512.2(GU280_gp02):g.2292C>A	YP_009724390.1:p.Asn764Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Hao	2022	doi:10.1101/2022.08.12.22278720	pmid:36032965	https://doi.org/10.1101/2022.08.12.22278720	False	Hao et al. (2022)	n/a	paired testing of vaccine sera against ancestral virus compared to Omicron BA.1 shows that 3-dose vaccine regimen provides over 50x fold increase in protection against Omicron(B.1.1.529 [BA.1]) compared to a 2-dose regimen.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23854	N764K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	A	g.C2292A	p.N764K	NC_045512.2(GU280_gp02):g.2292C>A	YP_009724390.1:p.Asn764Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Wang	2022	doi:10.1101/2022.08.11.503601	n/a	https://doi.org/10.1101/2022.08.11.503601	False	Wang et al. (2022)	n/a	4th antigenic exposure with Omicron (B.1.1.529 [BA.1])(n	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23854	N764K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	A	g.C2292A	p.N764K	NC_045512.2(GU280_gp02):g.2292C>A	YP_009724390.1:p.Asn764Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.1 (from Botswana/R40B59_BHP_3321001248/2021) were 3.4-fold lower (95% CI: 3.2x-3.6x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23854	N764K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	A	g.C2292A	p.N764K	NC_045512.2(GU280_gp02):g.2292C>A	YP_009724390.1:p.Asn764Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.1 (from Botswana/R40B59_BHP_3321001248/2021) were 28.7x-fold lower (95% CI: 0.03x-0.05) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23854	N764K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	A	g.C2292A	p.N764K	NC_045512.2(GU280_gp02):g.2292C>A	YP_009724390.1:p.Asn764Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.4/5 (from ) were 17.2x-fold lower (95% CI: 0.6x-0.7x) than against 208-428 972-1834 4.3-4.7 US-WA1/2020 usiong an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23854	N764K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	A	g.C2292A	p.N764K	NC_045512.2(GU280_gp02):g.2292C>A	YP_009724390.1:p.Asn764Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.4/5 (from ) were 13.0-fold lower (95% CI: 4.2x-4.6x) than against 208-428 972-1834 4.3-4.7 US-WA1/2020 usiong an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23854	N764K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	A	g.C2292A	p.N764K	NC_045512.2(GU280_gp02):g.2292C>A	YP_009724390.1:p.Asn764Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  XD (from ) were 1.5x-fold lower (95% CI: 0.05x-0.07x) than against 208-428 972-1834 4.3-4.7 US-WA1/2020 usiong an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23854	N764K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	A	g.C2292A	p.N764K	NC_045512.2(GU280_gp02):g.2292C>A	YP_009724390.1:p.Asn764Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  XD (from ) were 4.4-fold lower (95% CI: 4.3x-4.7x) than against 208-428 972-1834 4.3-4.7 US-WA1/2020 usiong an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23948	D796Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G2386T	p.D796Y	NC_045512.2(GU280_gp02):g.2386G>T	YP_009724390.1:p.Asp796Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron BA.2 have higher sensitivity to inhibition by soluble angiotensin converting enzyme 2 (ACE2) and the endosomal inhibitor chloroquine compared  to D614G	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23948	D796Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G2386T	p.D796Y	NC_045512.2(GU280_gp02):g.2386G>T	YP_009724390.1:p.Asp796Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs Bi-Nab35B5-47D10. Omicron BA.2 has an IC50 fold change of 0.07x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23948	D796Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G2386T	p.D796Y	NC_045512.2(GU280_gp02):g.2386G>T	YP_009724390.1:p.Asp796Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs 35B5. Omicron BA.2 has an IC50 fold change of 0.09x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23948	D796Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G2386T	p.D796Y	NC_045512.2(GU280_gp02):g.2386G>T	YP_009724390.1:p.Asp796Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs 47D10. Omicron BA.2 has an IC50 fold change of 0.08x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23948	D796Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G2386T	p.D796Y	NC_045512.2(GU280_gp02):g.2386G>T	YP_009724390.1:p.Asp796Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs Bi-Nab47D10-35B5. Omicron BA.2 has an IC50 fold change of 0.04x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23948	D796Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G2386T	p.D796Y	NC_045512.2(GU280_gp02):g.2386G>T	YP_009724390.1:p.Asp796Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron BA.2 neutralization of the Omicron variants by antibodies induced by three doses of Pfizer/BNT162b2 mRNA vaccine was 7-8-fold less potent than the D614G, and  the Omicron variants still evade neutralization more efficiently.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23948	D796Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G2386T	p.D796Y	NC_045512.2(GU280_gp02):g.2386G>T	YP_009724390.1:p.Asp796Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Kumar	2022	doi:10.1101/2022.05.13.491770	n/a	https://doi.org/10.1101/2022.05.13.491770	False	Kumar et al. (2022)	n/a	BnAb 002-S21F2 IC50 on the Omicron BA.2 variant is 0.8x fold the wildtype.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23948	D796Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G2386T	p.D796Y	NC_045512.2(GU280_gp02):g.2386G>T	YP_009724390.1:p.Asp796Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Mallm	2021	doi:10.1101/2021.04.27.21254849	n/a	https://doi.org/10.1101/2021.04.27.21254849	False	Mallm et al. (2021)	n/a	This variant was designated A.27.RN according to its phylogenetic clade classification. It emerged in parallel  with the B.1.1.7 variant, increased to >50% of all SARS-CoV-2 variants by week five. Subsequently it decreased  to <10% of all variants by calendar week eight when B.1.1.7 had become the dominant strain. Antibodies induced  by BNT162b2 (Pfizer) vaccination neutralized A.27.RN but with a two-to-threefold reduced efficacy as compared to the  wild-type and B.1.1.7 strains.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23948	D796Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G2386T	p.D796Y	NC_045512.2(GU280_gp02):g.2386G>T	YP_009724390.1:p.Asp796Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.2 (from South Africa/CERI-KRISP-K032307/2021) were 3.9x-fold lower (95% CI: 0.14x-0.17x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23948	D796Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G2386T	p.D796Y	NC_045512.2(GU280_gp02):g.2386G>T	YP_009724390.1:p.Asp796Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Uhal B	2022	doi:10.1101/2022.06.23.497326	n/a	https://doi.org/10.1101/2022.06.23.497326	False	Uhal B et al. (2022)	n/a	L27, V34 and E90 mutation resulted in ultrahigh affinity binding of the LVE-ACE-2 domain to the widest variety of VOCs, with KDs of 78fM for binding to the Omicron  BA.2. Values were obtained with LVE-ACE-2/mAB chimeras containing the Y-T-E sequence that enhances binding to the FcRn receptor, which in turn is expected to  extend biological half-life 3-4-fold.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23948	D796Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G2386T	p.D796Y	NC_045512.2(GU280_gp02):g.2386G>T	YP_009724390.1:p.Asp796Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.2 (from South Africa/CERI-KRISP-K032307/2021) were 4.5-fold lower (95% CI: 4.3x-4.7x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23948	D796Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G2386T	p.D796Y	NC_045512.2(GU280_gp02):g.2386G>T	YP_009724390.1:p.Asp796Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.2.12.1 (from USA/NY-CDC-ASC210722700/2022) were 4.2-fold lower (95% CI: 5.8x-6.6x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23948	D796Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G2386T	p.D796Y	NC_045512.2(GU280_gp02):g.2386G>T	YP_009724390.1:p.Asp796Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.2.12.1 (from USA/NY-CDC-ASC210722700/2022) were 3.9x-fold lower (95% CI: 0.14x-0.18x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23948	D796Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G2386T	p.D796Y	NC_045512.2(GU280_gp02):g.2386G>T	YP_009724390.1:p.Asp796Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Cathcart	2021	doi:10.1101/2021.03.09.434607v9	n/a	https://doi.org/10.1101/2021.03.09.434607v9	False	Cathcart et al. (2021)	n/a	Omicron (a.k.a. B.1.1.529) Spike pseudotyped VSV and Vero E6 cells has somewhat  reduced neutralization (2.7x) vs wild type with monoclonal antibody Sotrovimab (a.k.a. VIR-7831).  [delins at 214 omitted for syntax compatibility]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23948	D796Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G2386T	p.D796Y	NC_045512.2(GU280_gp02):g.2386G>T	YP_009724390.1:p.Asp796Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Wang	2022	doi:10.1101/2022.08.11.503601	n/a	https://doi.org/10.1101/2022.08.11.503601	False	Wang et al. (2022)	n/a	Omicron breakthrough infection after 3-dose vaccination resulted in a further 3.5-fold and 2.9-fold increase of Omicron BA.1 and BA.2 neutralizing titers. Omicron  BA.4/5 showed the highest neutralization resistance of all variants tested, resulting in low geometric mean neutralizing titers in plasma samples  obtained after  the second vaccine dose (NT50	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23948	D796Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G2386T	p.D796Y	NC_045512.2(GU280_gp02):g.2386G>T	YP_009724390.1:p.Asp796Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs Bi-Nab47D10-35B5. Omicron BA.1 has an IC50 fold change of 0.08x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23948	D796Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G2386T	p.D796Y	NC_045512.2(GU280_gp02):g.2386G>T	YP_009724390.1:p.Asp796Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron B.1.1.529 (BA.1) neutralization of the Omicron variants by antibodies induced by three doses of Pfizer/BNT162b2 mRNA vaccine was 7-8-fold less potent than  the D614G, and the Omicron variants still evade neutralization more efficiently.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23948	D796Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G2386T	p.D796Y	NC_045512.2(GU280_gp02):g.2386G>T	YP_009724390.1:p.Asp796Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron (B.1.1.529 [BA.1]) have higher sensitivity to inhibition by soluble angiotensin converting enzyme 2 (ACE2) and the endosomal inhibitor chloroquine compared  to D614G	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23948	D796Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G2386T	p.D796Y	NC_045512.2(GU280_gp02):g.2386G>T	YP_009724390.1:p.Asp796Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs Bi-Nab35B5-47D10. Omicron BA.1 has an IC50 fold change of 0.30x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23948	D796Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G2386T	p.D796Y	NC_045512.2(GU280_gp02):g.2386G>T	YP_009724390.1:p.Asp796Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Uhal B	2022	doi:10.1101/2022.06.23.497326	n/a	https://doi.org/10.1101/2022.06.23.497326	False	Uhal B et al. (2022)	n/a	Paradigms’ ACE-2 variant LVE/STR chimera binds to SARS-2 Omicron variant B.1.1.529 spike protein trimer with high affinity. Determined using Surrogate Viral Neutralization Tests.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23948	D796Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G2386T	p.D796Y	NC_045512.2(GU280_gp02):g.2386G>T	YP_009724390.1:p.Asp796Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Uhal B	2022	doi:10.1101/2022.06.23.497326	n/a	https://doi.org/10.1101/2022.06.23.497326	False	Uhal B et al. (2022)	n/a	L27, V34 and E90 mutation resulted in ultrahigh affinity binding of the LVE-ACE-2 domain to the widest variety of VOCs, with KDs of 73 pM for binding to the Omicron  B.1.1.529. Values were obtained with LVE-ACE-2/mAB chimeras containing the Y-T-E sequence that enhances binding to the FcRn receptor, which in turn is expected to  extend biological half-life 3-4-fold.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23948	D796Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G2386T	p.D796Y	NC_045512.2(GU280_gp02):g.2386G>T	YP_009724390.1:p.Asp796Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs 35B5. Omicron BA.1 has an IC50 fold change of 0.38x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23948	D796Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G2386T	p.D796Y	NC_045512.2(GU280_gp02):g.2386G>T	YP_009724390.1:p.Asp796Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Arora	2022	doi:10.1038/s41423-022-00870-5	pmid:35581351	https://doi.org/10.1038/s41423-022-00870-5	True	Arora et al. (2022)	n/a	All 10 individuals with 2 doses of the BNT162b2/BNT162b2 vaccine had a neutralizing titer in B.1 variant at an average of 729 NT50.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23948	D796Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G2386T	p.D796Y	NC_045512.2(GU280_gp02):g.2386G>T	YP_009724390.1:p.Asp796Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Shete	2022	doi:10.1101/2022.05.12.491584	n/a	https://doi.org/10.1101/2022.05.12.491584	False	Shete et al. (2022)	n/a	Plaque reduction neutralization test (PRNT) was used uring primary infection, post sixty daysof second dose vaccination, pre-reinfection and reinfection against Delta variant and was used to determine neutralizing antibodytitres. There was a 24.63x fold increase in antibody response from first infection to recovered and vaccinated with 2 doses (60 days). There was a 4.21x fold increase in antibody response pre-reinfection. There was a 39.27x fold increase in antibody response during reinfection.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23948	D796Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G2386T	p.D796Y	NC_045512.2(GU280_gp02):g.2386G>T	YP_009724390.1:p.Asp796Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Shete	2022	doi:10.1101/2022.05.12.491584	n/a	https://doi.org/10.1101/2022.05.12.491584	False	Shete et al. (2022)	n/a	Plaque reduction neutralization test (PRNT) was used uring primary infection, post sixty daysof second dose vaccination, pre-reinfection and reinfection against B.1 variant and was used to determine neutralizing antibodytitres. There was a 6.76x fold increase in antibody response from first infection to recovered and vaccinated with 2 doses (60 days). There was a 2.06x fold increase in antibody response pre-reinfection. There was a 8.18x fold increase in antibody response during reinfection.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23948	D796Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G2386T	p.D796Y	NC_045512.2(GU280_gp02):g.2386G>T	YP_009724390.1:p.Asp796Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Arora	2022	doi:10.1038/s41423-022-00870-5	pmid:35581351	https://doi.org/10.1038/s41423-022-00870-5	True	Arora et al. (2022)	n/a	All 10 individuals with 3 doses of the BNT162b2/BNT162b2 vaccine had a neutralizing titer in B.1 variant at an average of 3319 NT50.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23948	D796Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G2386T	p.D796Y	NC_045512.2(GU280_gp02):g.2386G>T	YP_009724390.1:p.Asp796Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Shete	2022	doi:10.1101/2022.05.12.491584	n/a	https://doi.org/10.1101/2022.05.12.491584	False	Shete et al. (2022)	n/a	Plaque reduction neutralization test (PRNT) was used uring primary infection, post sixty daysof second dose vaccination, pre-reinfection and reinfection against Omicron variant and was used to determine neutralizing antibodytitres. There was a 114.84x fold increase in antibody response from first infection to recovered and vaccinated with 2 doses (60 days). There was a 6.61x fold increase in antibody response pre-reinfection. There was a 1194.9x fold increase in antibody response during reinfection.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23948	D796Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G2386T	p.D796Y	NC_045512.2(GU280_gp02):g.2386G>T	YP_009724390.1:p.Asp796Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Kumar	2022	doi:10.1101/2022.05.13.491770	n/a	https://doi.org/10.1101/2022.05.13.491770	False	Kumar et al. (2022)	n/a	BnAb 002-S21F2 IC50 on the Omicron BA.1 variant is 1.0x fold the wildtype.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23948	D796Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G2386T	p.D796Y	NC_045512.2(GU280_gp02):g.2386G>T	YP_009724390.1:p.Asp796Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs 47D10. Omicron BA.1 has an IC50 fold change of 1.26x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23948	D796Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G2386T	p.D796Y	NC_045512.2(GU280_gp02):g.2386G>T	YP_009724390.1:p.Asp796Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron BA.3 have higher sensitivity to inhibition by soluble angiotensin converting enzyme 2 (ACE2) and the endosomal inhibitor chloroquine compared  to D614G	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23948	D796Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G2386T	p.D796Y	NC_045512.2(GU280_gp02):g.2386G>T	YP_009724390.1:p.Asp796Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron BA.3 neutralization of the Omicron variants by antibodies induced by three doses of Pfizer/BNT162b2 mRNA vaccine was 7-8-fold less potent than the D614G, and  the Omicron variants still evade neutralization more efficiently.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23948	D796Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G2386T	p.D796Y	NC_045512.2(GU280_gp02):g.2386G>T	YP_009724390.1:p.Asp796Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.3 (from South Africa/NICD-N22404/2021) were 4.2x-fold lower (95% CI: 0.15x-0.20x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23948	D796Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G2386T	p.D796Y	NC_045512.2(GU280_gp02):g.2386G>T	YP_009724390.1:p.Asp796Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.3 (from South Africa/NICD-N22404/2021) were 6.2-fold lower (95% CI: 11.8x-14.3x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23948	D796Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G2386T	p.D796Y	NC_045512.2(GU280_gp02):g.2386G>T	YP_009724390.1:p.Asp796Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Hao	2022	doi:10.1101/2022.08.12.22278720	pmid:36032965	https://doi.org/10.1101/2022.08.12.22278720	False	Hao et al. (2022)	n/a	paired testing of vaccine sera against ancestral virus compared to Omicron BA.1 shows that 3-dose vaccine regimen provides over 50x fold increase in protection against Omicron(B.1.1.529 [BA.1]) compared to a 2-dose regimen.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23948	D796Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G2386T	p.D796Y	NC_045512.2(GU280_gp02):g.2386G>T	YP_009724390.1:p.Asp796Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Wang	2022	doi:10.1101/2022.08.11.503601	n/a	https://doi.org/10.1101/2022.08.11.503601	False	Wang et al. (2022)	n/a	4th antigenic exposure with Omicron (B.1.1.529 [BA.1])(n	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23948	D796Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G2386T	p.D796Y	NC_045512.2(GU280_gp02):g.2386G>T	YP_009724390.1:p.Asp796Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.1 (from Botswana/R40B59_BHP_3321001248/2021) were 3.4-fold lower (95% CI: 3.2x-3.6x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23948	D796Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G2386T	p.D796Y	NC_045512.2(GU280_gp02):g.2386G>T	YP_009724390.1:p.Asp796Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.1 (from Botswana/R40B59_BHP_3321001248/2021) were 28.7x-fold lower (95% CI: 0.03x-0.05) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23948	D796Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G2386T	p.D796Y	NC_045512.2(GU280_gp02):g.2386G>T	YP_009724390.1:p.Asp796Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.4/5 (from ) were 17.2x-fold lower (95% CI: 0.6x-0.7x) than against 208-428 972-1834 4.3-4.7 US-WA1/2020 usiong an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23948	D796Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G2386T	p.D796Y	NC_045512.2(GU280_gp02):g.2386G>T	YP_009724390.1:p.Asp796Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.4/5 (from ) were 13.0-fold lower (95% CI: 4.2x-4.6x) than against 208-428 972-1834 4.3-4.7 US-WA1/2020 usiong an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23948	D796Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G2386T	p.D796Y	NC_045512.2(GU280_gp02):g.2386G>T	YP_009724390.1:p.Asp796Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  XD (from ) were 1.5x-fold lower (95% CI: 0.05x-0.07x) than against 208-428 972-1834 4.3-4.7 US-WA1/2020 usiong an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
23948	D796Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G2386T	p.D796Y	NC_045512.2(GU280_gp02):g.2386G>T	YP_009724390.1:p.Asp796Tyr	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  XD (from ) were 4.4-fold lower (95% CI: 4.3x-4.7x) than against 208-428 972-1834 4.3-4.7 US-WA1/2020 usiong an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
24378	S939F	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C2816T	p.S939F	NC_045512.2(GU280_gp02):g.2816C>T	YP_009724390.1:p.Ser939Phe	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	anthropozoonotic events	n/a	n/a	Li	2023	doi:10.1038/s41396-023-01368-2	pmid:36690780	https://doi.org/10.1038/s41396-023-01368-2	True	Li et al. (2023)	n/a	This mutation outside the receptor binding domain significantly reduced the tropism of SARS-CoV-2 to MfuKi (eastern bent-wing bat kidney cell, Miniopterus fuliginosus) cell cultures using a pseudotyped VSV assay.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
24424	Q954H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A2862T	p.Q954H	NC_045512.2(GU280_gp02):g.2862A>T	YP_009724390.1:p.Gln954His	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron BA.2 have higher sensitivity to inhibition by soluble angiotensin converting enzyme 2 (ACE2) and the endosomal inhibitor chloroquine compared  to D614G	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
24424	Q954H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A2862T	p.Q954H	NC_045512.2(GU280_gp02):g.2862A>T	YP_009724390.1:p.Gln954His	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs Bi-Nab35B5-47D10. Omicron BA.2 has an IC50 fold change of 0.07x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
24424	Q954H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A2862T	p.Q954H	NC_045512.2(GU280_gp02):g.2862A>T	YP_009724390.1:p.Gln954His	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs 35B5. Omicron BA.2 has an IC50 fold change of 0.09x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
24424	Q954H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A2862T	p.Q954H	NC_045512.2(GU280_gp02):g.2862A>T	YP_009724390.1:p.Gln954His	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs 47D10. Omicron BA.2 has an IC50 fold change of 0.08x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
24424	Q954H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A2862T	p.Q954H	NC_045512.2(GU280_gp02):g.2862A>T	YP_009724390.1:p.Gln954His	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs Bi-Nab47D10-35B5. Omicron BA.2 has an IC50 fold change of 0.04x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
24424	Q954H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A2862T	p.Q954H	NC_045512.2(GU280_gp02):g.2862A>T	YP_009724390.1:p.Gln954His	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron BA.2 neutralization of the Omicron variants by antibodies induced by three doses of Pfizer/BNT162b2 mRNA vaccine was 7-8-fold less potent than the D614G, and  the Omicron variants still evade neutralization more efficiently.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
24424	Q954H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A2862T	p.Q954H	NC_045512.2(GU280_gp02):g.2862A>T	YP_009724390.1:p.Gln954His	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Kumar	2022	doi:10.1101/2022.05.13.491770	n/a	https://doi.org/10.1101/2022.05.13.491770	False	Kumar et al. (2022)	n/a	BnAb 002-S21F2 IC50 on the Omicron BA.2 variant is 0.8x fold the wildtype.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
24424	Q954H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A2862T	p.Q954H	NC_045512.2(GU280_gp02):g.2862A>T	YP_009724390.1:p.Gln954His	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.2 (from South Africa/CERI-KRISP-K032307/2021) were 3.9x-fold lower (95% CI: 0.14x-0.17x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
24424	Q954H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A2862T	p.Q954H	NC_045512.2(GU280_gp02):g.2862A>T	YP_009724390.1:p.Gln954His	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Uhal B	2022	doi:10.1101/2022.06.23.497326	n/a	https://doi.org/10.1101/2022.06.23.497326	False	Uhal B et al. (2022)	n/a	L27, V34 and E90 mutation resulted in ultrahigh affinity binding of the LVE-ACE-2 domain to the widest variety of VOCs, with KDs of 78fM for binding to the Omicron  BA.2. Values were obtained with LVE-ACE-2/mAB chimeras containing the Y-T-E sequence that enhances binding to the FcRn receptor, which in turn is expected to  extend biological half-life 3-4-fold.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
24424	Q954H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A2862T	p.Q954H	NC_045512.2(GU280_gp02):g.2862A>T	YP_009724390.1:p.Gln954His	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.2 (from South Africa/CERI-KRISP-K032307/2021) were 4.5-fold lower (95% CI: 4.3x-4.7x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
24424	Q954H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A2862T	p.Q954H	NC_045512.2(GU280_gp02):g.2862A>T	YP_009724390.1:p.Gln954His	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.2.12.1 (from USA/NY-CDC-ASC210722700/2022) were 4.2-fold lower (95% CI: 5.8x-6.6x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
24424	Q954H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A2862T	p.Q954H	NC_045512.2(GU280_gp02):g.2862A>T	YP_009724390.1:p.Gln954His	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.2.12.1 (from USA/NY-CDC-ASC210722700/2022) were 3.9x-fold lower (95% CI: 0.14x-0.18x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
24424	Q954H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A2862T	p.Q954H	NC_045512.2(GU280_gp02):g.2862A>T	YP_009724390.1:p.Gln954His	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Cathcart	2021	doi:10.1101/2021.03.09.434607v9	n/a	https://doi.org/10.1101/2021.03.09.434607v9	False	Cathcart et al. (2021)	n/a	Omicron (a.k.a. B.1.1.529) Spike pseudotyped VSV and Vero E6 cells has somewhat  reduced neutralization (2.7x) vs wild type with monoclonal antibody Sotrovimab (a.k.a. VIR-7831).  [delins at 214 omitted for syntax compatibility]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
24424	Q954H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A2862T	p.Q954H	NC_045512.2(GU280_gp02):g.2862A>T	YP_009724390.1:p.Gln954His	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Wang	2022	doi:10.1101/2022.08.11.503601	n/a	https://doi.org/10.1101/2022.08.11.503601	False	Wang et al. (2022)	n/a	Omicron breakthrough infection after 3-dose vaccination resulted in a further 3.5-fold and 2.9-fold increase of Omicron BA.1 and BA.2 neutralizing titers. Omicron  BA.4/5 showed the highest neutralization resistance of all variants tested, resulting in low geometric mean neutralizing titers in plasma samples  obtained after  the second vaccine dose (NT50	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
24424	Q954H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A2862T	p.Q954H	NC_045512.2(GU280_gp02):g.2862A>T	YP_009724390.1:p.Gln954His	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs Bi-Nab47D10-35B5. Omicron BA.1 has an IC50 fold change of 0.08x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
24424	Q954H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A2862T	p.Q954H	NC_045512.2(GU280_gp02):g.2862A>T	YP_009724390.1:p.Gln954His	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron B.1.1.529 (BA.1) neutralization of the Omicron variants by antibodies induced by three doses of Pfizer/BNT162b2 mRNA vaccine was 7-8-fold less potent than  the D614G, and the Omicron variants still evade neutralization more efficiently.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
24424	Q954H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A2862T	p.Q954H	NC_045512.2(GU280_gp02):g.2862A>T	YP_009724390.1:p.Gln954His	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron (B.1.1.529 [BA.1]) have higher sensitivity to inhibition by soluble angiotensin converting enzyme 2 (ACE2) and the endosomal inhibitor chloroquine compared  to D614G	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
24424	Q954H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A2862T	p.Q954H	NC_045512.2(GU280_gp02):g.2862A>T	YP_009724390.1:p.Gln954His	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs Bi-Nab35B5-47D10. Omicron BA.1 has an IC50 fold change of 0.30x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
24424	Q954H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A2862T	p.Q954H	NC_045512.2(GU280_gp02):g.2862A>T	YP_009724390.1:p.Gln954His	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Uhal B	2022	doi:10.1101/2022.06.23.497326	n/a	https://doi.org/10.1101/2022.06.23.497326	False	Uhal B et al. (2022)	n/a	Paradigms’ ACE-2 variant LVE/STR chimera binds to SARS-2 Omicron variant B.1.1.529 spike protein trimer with high affinity. Determined using Surrogate Viral Neutralization Tests.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
24424	Q954H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A2862T	p.Q954H	NC_045512.2(GU280_gp02):g.2862A>T	YP_009724390.1:p.Gln954His	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Uhal B	2022	doi:10.1101/2022.06.23.497326	n/a	https://doi.org/10.1101/2022.06.23.497326	False	Uhal B et al. (2022)	n/a	L27, V34 and E90 mutation resulted in ultrahigh affinity binding of the LVE-ACE-2 domain to the widest variety of VOCs, with KDs of 73 pM for binding to the Omicron  B.1.1.529. Values were obtained with LVE-ACE-2/mAB chimeras containing the Y-T-E sequence that enhances binding to the FcRn receptor, which in turn is expected to  extend biological half-life 3-4-fold.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
24424	Q954H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A2862T	p.Q954H	NC_045512.2(GU280_gp02):g.2862A>T	YP_009724390.1:p.Gln954His	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs 35B5. Omicron BA.1 has an IC50 fold change of 0.38x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
24424	Q954H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A2862T	p.Q954H	NC_045512.2(GU280_gp02):g.2862A>T	YP_009724390.1:p.Gln954His	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Arora	2022	doi:10.1038/s41423-022-00870-5	pmid:35581351	https://doi.org/10.1038/s41423-022-00870-5	True	Arora et al. (2022)	n/a	All 10 individuals with 2 doses of the BNT162b2/BNT162b2 vaccine had a neutralizing titer in B.1 variant at an average of 729 NT50.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
24424	Q954H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A2862T	p.Q954H	NC_045512.2(GU280_gp02):g.2862A>T	YP_009724390.1:p.Gln954His	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Shete	2022	doi:10.1101/2022.05.12.491584	n/a	https://doi.org/10.1101/2022.05.12.491584	False	Shete et al. (2022)	n/a	Plaque reduction neutralization test (PRNT) was used uring primary infection, post sixty daysof second dose vaccination, pre-reinfection and reinfection against Delta variant and was used to determine neutralizing antibodytitres. There was a 24.63x fold increase in antibody response from first infection to recovered and vaccinated with 2 doses (60 days). There was a 4.21x fold increase in antibody response pre-reinfection. There was a 39.27x fold increase in antibody response during reinfection.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
24424	Q954H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A2862T	p.Q954H	NC_045512.2(GU280_gp02):g.2862A>T	YP_009724390.1:p.Gln954His	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Shete	2022	doi:10.1101/2022.05.12.491584	n/a	https://doi.org/10.1101/2022.05.12.491584	False	Shete et al. (2022)	n/a	Plaque reduction neutralization test (PRNT) was used uring primary infection, post sixty daysof second dose vaccination, pre-reinfection and reinfection against B.1 variant and was used to determine neutralizing antibodytitres. There was a 6.76x fold increase in antibody response from first infection to recovered and vaccinated with 2 doses (60 days). There was a 2.06x fold increase in antibody response pre-reinfection. There was a 8.18x fold increase in antibody response during reinfection.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
24424	Q954H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A2862T	p.Q954H	NC_045512.2(GU280_gp02):g.2862A>T	YP_009724390.1:p.Gln954His	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Arora	2022	doi:10.1038/s41423-022-00870-5	pmid:35581351	https://doi.org/10.1038/s41423-022-00870-5	True	Arora et al. (2022)	n/a	All 10 individuals with 3 doses of the BNT162b2/BNT162b2 vaccine had a neutralizing titer in B.1 variant at an average of 3319 NT50.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
24424	Q954H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A2862T	p.Q954H	NC_045512.2(GU280_gp02):g.2862A>T	YP_009724390.1:p.Gln954His	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Shete	2022	doi:10.1101/2022.05.12.491584	n/a	https://doi.org/10.1101/2022.05.12.491584	False	Shete et al. (2022)	n/a	Plaque reduction neutralization test (PRNT) was used uring primary infection, post sixty daysof second dose vaccination, pre-reinfection and reinfection against Omicron variant and was used to determine neutralizing antibodytitres. There was a 114.84x fold increase in antibody response from first infection to recovered and vaccinated with 2 doses (60 days). There was a 6.61x fold increase in antibody response pre-reinfection. There was a 1194.9x fold increase in antibody response during reinfection.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
24424	Q954H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A2862T	p.Q954H	NC_045512.2(GU280_gp02):g.2862A>T	YP_009724390.1:p.Gln954His	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Kumar	2022	doi:10.1101/2022.05.13.491770	n/a	https://doi.org/10.1101/2022.05.13.491770	False	Kumar et al. (2022)	n/a	BnAb 002-S21F2 IC50 on the Omicron BA.1 variant is 1.0x fold the wildtype.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
24424	Q954H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A2862T	p.Q954H	NC_045512.2(GU280_gp02):g.2862A>T	YP_009724390.1:p.Gln954His	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs 47D10. Omicron BA.1 has an IC50 fold change of 1.26x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
24424	Q954H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A2862T	p.Q954H	NC_045512.2(GU280_gp02):g.2862A>T	YP_009724390.1:p.Gln954His	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron BA.3 have higher sensitivity to inhibition by soluble angiotensin converting enzyme 2 (ACE2) and the endosomal inhibitor chloroquine compared  to D614G	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
24424	Q954H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A2862T	p.Q954H	NC_045512.2(GU280_gp02):g.2862A>T	YP_009724390.1:p.Gln954His	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron BA.3 neutralization of the Omicron variants by antibodies induced by three doses of Pfizer/BNT162b2 mRNA vaccine was 7-8-fold less potent than the D614G, and  the Omicron variants still evade neutralization more efficiently.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
24424	Q954H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A2862T	p.Q954H	NC_045512.2(GU280_gp02):g.2862A>T	YP_009724390.1:p.Gln954His	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.3 (from South Africa/NICD-N22404/2021) were 4.2x-fold lower (95% CI: 0.15x-0.20x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
24424	Q954H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A2862T	p.Q954H	NC_045512.2(GU280_gp02):g.2862A>T	YP_009724390.1:p.Gln954His	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.3 (from South Africa/NICD-N22404/2021) were 6.2-fold lower (95% CI: 11.8x-14.3x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
24424	Q954H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A2862T	p.Q954H	NC_045512.2(GU280_gp02):g.2862A>T	YP_009724390.1:p.Gln954His	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Hao	2022	doi:10.1101/2022.08.12.22278720	pmid:36032965	https://doi.org/10.1101/2022.08.12.22278720	False	Hao et al. (2022)	n/a	paired testing of vaccine sera against ancestral virus compared to Omicron BA.1 shows that 3-dose vaccine regimen provides over 50x fold increase in protection against Omicron(B.1.1.529 [BA.1]) compared to a 2-dose regimen.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
24424	Q954H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A2862T	p.Q954H	NC_045512.2(GU280_gp02):g.2862A>T	YP_009724390.1:p.Gln954His	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Wang	2022	doi:10.1101/2022.08.11.503601	n/a	https://doi.org/10.1101/2022.08.11.503601	False	Wang et al. (2022)	n/a	4th antigenic exposure with Omicron (B.1.1.529 [BA.1])(n	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
24424	Q954H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A2862T	p.Q954H	NC_045512.2(GU280_gp02):g.2862A>T	YP_009724390.1:p.Gln954His	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.1 (from Botswana/R40B59_BHP_3321001248/2021) were 3.4-fold lower (95% CI: 3.2x-3.6x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
24424	Q954H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A2862T	p.Q954H	NC_045512.2(GU280_gp02):g.2862A>T	YP_009724390.1:p.Gln954His	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.1 (from Botswana/R40B59_BHP_3321001248/2021) were 28.7x-fold lower (95% CI: 0.03x-0.05) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
24424	Q954H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A2862T	p.Q954H	NC_045512.2(GU280_gp02):g.2862A>T	YP_009724390.1:p.Gln954His	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.4/5 (from ) were 17.2x-fold lower (95% CI: 0.6x-0.7x) than against 208-428 972-1834 4.3-4.7 US-WA1/2020 usiong an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
24424	Q954H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A2862T	p.Q954H	NC_045512.2(GU280_gp02):g.2862A>T	YP_009724390.1:p.Gln954His	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.4/5 (from ) were 13.0-fold lower (95% CI: 4.2x-4.6x) than against 208-428 972-1834 4.3-4.7 US-WA1/2020 usiong an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
24424	Q954H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A2862T	p.Q954H	NC_045512.2(GU280_gp02):g.2862A>T	YP_009724390.1:p.Gln954His	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  XD (from ) were 1.5x-fold lower (95% CI: 0.05x-0.07x) than against 208-428 972-1834 4.3-4.7 US-WA1/2020 usiong an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
24424	Q954H	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A2862T	p.Q954H	NC_045512.2(GU280_gp02):g.2862A>T	YP_009724390.1:p.Gln954His	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  XD (from ) were 4.4-fold lower (95% CI: 4.3x-4.7x) than against 208-428 972-1834 4.3-4.7 US-WA1/2020 usiong an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
24469	N969K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	A	g.T2907A	p.N969K	NC_045512.2(GU280_gp02):g.2907T>A	YP_009724390.1:p.Asn969Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron BA.2 have higher sensitivity to inhibition by soluble angiotensin converting enzyme 2 (ACE2) and the endosomal inhibitor chloroquine compared  to D614G	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
24469	N969K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	A	g.T2907A	p.N969K	NC_045512.2(GU280_gp02):g.2907T>A	YP_009724390.1:p.Asn969Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs Bi-Nab35B5-47D10. Omicron BA.2 has an IC50 fold change of 0.07x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
24469	N969K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	A	g.T2907A	p.N969K	NC_045512.2(GU280_gp02):g.2907T>A	YP_009724390.1:p.Asn969Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs 35B5. Omicron BA.2 has an IC50 fold change of 0.09x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
24469	N969K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	A	g.T2907A	p.N969K	NC_045512.2(GU280_gp02):g.2907T>A	YP_009724390.1:p.Asn969Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs 47D10. Omicron BA.2 has an IC50 fold change of 0.08x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
24469	N969K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	A	g.T2907A	p.N969K	NC_045512.2(GU280_gp02):g.2907T>A	YP_009724390.1:p.Asn969Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs Bi-Nab47D10-35B5. Omicron BA.2 has an IC50 fold change of 0.04x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
24469	N969K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	A	g.T2907A	p.N969K	NC_045512.2(GU280_gp02):g.2907T>A	YP_009724390.1:p.Asn969Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron BA.2 neutralization of the Omicron variants by antibodies induced by three doses of Pfizer/BNT162b2 mRNA vaccine was 7-8-fold less potent than the D614G, and  the Omicron variants still evade neutralization more efficiently.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
24469	N969K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	A	g.T2907A	p.N969K	NC_045512.2(GU280_gp02):g.2907T>A	YP_009724390.1:p.Asn969Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Kumar	2022	doi:10.1101/2022.05.13.491770	n/a	https://doi.org/10.1101/2022.05.13.491770	False	Kumar et al. (2022)	n/a	BnAb 002-S21F2 IC50 on the Omicron BA.2 variant is 0.8x fold the wildtype.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
24469	N969K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	A	g.T2907A	p.N969K	NC_045512.2(GU280_gp02):g.2907T>A	YP_009724390.1:p.Asn969Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.2 (from South Africa/CERI-KRISP-K032307/2021) were 3.9x-fold lower (95% CI: 0.14x-0.17x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
24469	N969K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	A	g.T2907A	p.N969K	NC_045512.2(GU280_gp02):g.2907T>A	YP_009724390.1:p.Asn969Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Uhal B	2022	doi:10.1101/2022.06.23.497326	n/a	https://doi.org/10.1101/2022.06.23.497326	False	Uhal B et al. (2022)	n/a	L27, V34 and E90 mutation resulted in ultrahigh affinity binding of the LVE-ACE-2 domain to the widest variety of VOCs, with KDs of 78fM for binding to the Omicron  BA.2. Values were obtained with LVE-ACE-2/mAB chimeras containing the Y-T-E sequence that enhances binding to the FcRn receptor, which in turn is expected to  extend biological half-life 3-4-fold.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
24469	N969K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	A	g.T2907A	p.N969K	NC_045512.2(GU280_gp02):g.2907T>A	YP_009724390.1:p.Asn969Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.2 (from South Africa/CERI-KRISP-K032307/2021) were 4.5-fold lower (95% CI: 4.3x-4.7x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
24469	N969K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	A	g.T2907A	p.N969K	NC_045512.2(GU280_gp02):g.2907T>A	YP_009724390.1:p.Asn969Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.2.12.1 (from USA/NY-CDC-ASC210722700/2022) were 4.2-fold lower (95% CI: 5.8x-6.6x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
24469	N969K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	A	g.T2907A	p.N969K	NC_045512.2(GU280_gp02):g.2907T>A	YP_009724390.1:p.Asn969Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.2.12.1 (from USA/NY-CDC-ASC210722700/2022) were 3.9x-fold lower (95% CI: 0.14x-0.18x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
24469	N969K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	A	g.T2907A	p.N969K	NC_045512.2(GU280_gp02):g.2907T>A	YP_009724390.1:p.Asn969Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Cathcart	2021	doi:10.1101/2021.03.09.434607v9	n/a	https://doi.org/10.1101/2021.03.09.434607v9	False	Cathcart et al. (2021)	n/a	Omicron (a.k.a. B.1.1.529) Spike pseudotyped VSV and Vero E6 cells has somewhat  reduced neutralization (2.7x) vs wild type with monoclonal antibody Sotrovimab (a.k.a. VIR-7831).  [delins at 214 omitted for syntax compatibility]	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
24469	N969K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	A	g.T2907A	p.N969K	NC_045512.2(GU280_gp02):g.2907T>A	YP_009724390.1:p.Asn969Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Wang	2022	doi:10.1101/2022.08.11.503601	n/a	https://doi.org/10.1101/2022.08.11.503601	False	Wang et al. (2022)	n/a	Omicron breakthrough infection after 3-dose vaccination resulted in a further 3.5-fold and 2.9-fold increase of Omicron BA.1 and BA.2 neutralizing titers. Omicron  BA.4/5 showed the highest neutralization resistance of all variants tested, resulting in low geometric mean neutralizing titers in plasma samples  obtained after  the second vaccine dose (NT50	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
24469	N969K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	A	g.T2907A	p.N969K	NC_045512.2(GU280_gp02):g.2907T>A	YP_009724390.1:p.Asn969Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs Bi-Nab47D10-35B5. Omicron BA.1 has an IC50 fold change of 0.08x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
24469	N969K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	A	g.T2907A	p.N969K	NC_045512.2(GU280_gp02):g.2907T>A	YP_009724390.1:p.Asn969Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron B.1.1.529 (BA.1) neutralization of the Omicron variants by antibodies induced by three doses of Pfizer/BNT162b2 mRNA vaccine was 7-8-fold less potent than  the D614G, and the Omicron variants still evade neutralization more efficiently.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
24469	N969K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	A	g.T2907A	p.N969K	NC_045512.2(GU280_gp02):g.2907T>A	YP_009724390.1:p.Asn969Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron (B.1.1.529 [BA.1]) have higher sensitivity to inhibition by soluble angiotensin converting enzyme 2 (ACE2) and the endosomal inhibitor chloroquine compared  to D614G	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
24469	N969K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	A	g.T2907A	p.N969K	NC_045512.2(GU280_gp02):g.2907T>A	YP_009724390.1:p.Asn969Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs Bi-Nab35B5-47D10. Omicron BA.1 has an IC50 fold change of 0.30x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
24469	N969K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	A	g.T2907A	p.N969K	NC_045512.2(GU280_gp02):g.2907T>A	YP_009724390.1:p.Asn969Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Uhal B	2022	doi:10.1101/2022.06.23.497326	n/a	https://doi.org/10.1101/2022.06.23.497326	False	Uhal B et al. (2022)	n/a	Paradigms’ ACE-2 variant LVE/STR chimera binds to SARS-2 Omicron variant B.1.1.529 spike protein trimer with high affinity. Determined using Surrogate Viral Neutralization Tests.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
24469	N969K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	A	g.T2907A	p.N969K	NC_045512.2(GU280_gp02):g.2907T>A	YP_009724390.1:p.Asn969Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	ACE2 receptor binding affinity	n/a	n/a	Uhal B	2022	doi:10.1101/2022.06.23.497326	n/a	https://doi.org/10.1101/2022.06.23.497326	False	Uhal B et al. (2022)	n/a	L27, V34 and E90 mutation resulted in ultrahigh affinity binding of the LVE-ACE-2 domain to the widest variety of VOCs, with KDs of 73 pM for binding to the Omicron  B.1.1.529. Values were obtained with LVE-ACE-2/mAB chimeras containing the Y-T-E sequence that enhances binding to the FcRn receptor, which in turn is expected to  extend biological half-life 3-4-fold.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
24469	N969K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	A	g.T2907A	p.N969K	NC_045512.2(GU280_gp02):g.2907T>A	YP_009724390.1:p.Asn969Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs 35B5. Omicron BA.1 has an IC50 fold change of 0.38x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
24469	N969K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	A	g.T2907A	p.N969K	NC_045512.2(GU280_gp02):g.2907T>A	YP_009724390.1:p.Asn969Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Arora	2022	doi:10.1038/s41423-022-00870-5	pmid:35581351	https://doi.org/10.1038/s41423-022-00870-5	True	Arora et al. (2022)	n/a	All 10 individuals with 2 doses of the BNT162b2/BNT162b2 vaccine had a neutralizing titer in B.1 variant at an average of 729 NT50.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
24469	N969K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	A	g.T2907A	p.N969K	NC_045512.2(GU280_gp02):g.2907T>A	YP_009724390.1:p.Asn969Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Shete	2022	doi:10.1101/2022.05.12.491584	n/a	https://doi.org/10.1101/2022.05.12.491584	False	Shete et al. (2022)	n/a	Plaque reduction neutralization test (PRNT) was used uring primary infection, post sixty daysof second dose vaccination, pre-reinfection and reinfection against Delta variant and was used to determine neutralizing antibodytitres. There was a 24.63x fold increase in antibody response from first infection to recovered and vaccinated with 2 doses (60 days). There was a 4.21x fold increase in antibody response pre-reinfection. There was a 39.27x fold increase in antibody response during reinfection.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
24469	N969K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	A	g.T2907A	p.N969K	NC_045512.2(GU280_gp02):g.2907T>A	YP_009724390.1:p.Asn969Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Shete	2022	doi:10.1101/2022.05.12.491584	n/a	https://doi.org/10.1101/2022.05.12.491584	False	Shete et al. (2022)	n/a	Plaque reduction neutralization test (PRNT) was used uring primary infection, post sixty daysof second dose vaccination, pre-reinfection and reinfection against B.1 variant and was used to determine neutralizing antibodytitres. There was a 6.76x fold increase in antibody response from first infection to recovered and vaccinated with 2 doses (60 days). There was a 2.06x fold increase in antibody response pre-reinfection. There was a 8.18x fold increase in antibody response during reinfection.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
24469	N969K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	A	g.T2907A	p.N969K	NC_045512.2(GU280_gp02):g.2907T>A	YP_009724390.1:p.Asn969Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Arora	2022	doi:10.1038/s41423-022-00870-5	pmid:35581351	https://doi.org/10.1038/s41423-022-00870-5	True	Arora et al. (2022)	n/a	All 10 individuals with 3 doses of the BNT162b2/BNT162b2 vaccine had a neutralizing titer in B.1 variant at an average of 3319 NT50.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
24469	N969K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	A	g.T2907A	p.N969K	NC_045512.2(GU280_gp02):g.2907T>A	YP_009724390.1:p.Asn969Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Shete	2022	doi:10.1101/2022.05.12.491584	n/a	https://doi.org/10.1101/2022.05.12.491584	False	Shete et al. (2022)	n/a	Plaque reduction neutralization test (PRNT) was used uring primary infection, post sixty daysof second dose vaccination, pre-reinfection and reinfection against Omicron variant and was used to determine neutralizing antibodytitres. There was a 114.84x fold increase in antibody response from first infection to recovered and vaccinated with 2 doses (60 days). There was a 6.61x fold increase in antibody response pre-reinfection. There was a 1194.9x fold increase in antibody response during reinfection.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
24469	N969K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	A	g.T2907A	p.N969K	NC_045512.2(GU280_gp02):g.2907T>A	YP_009724390.1:p.Asn969Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Kumar	2022	doi:10.1101/2022.05.13.491770	n/a	https://doi.org/10.1101/2022.05.13.491770	False	Kumar et al. (2022)	n/a	BnAb 002-S21F2 IC50 on the Omicron BA.1 variant is 1.0x fold the wildtype.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
24469	N969K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	A	g.T2907A	p.N969K	NC_045512.2(GU280_gp02):g.2907T>A	YP_009724390.1:p.Asn969Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	antibody epitope effects	n/a	n/a	Yuan	2022	doi:10.1101/2022.05.11.491588	n/a	https://doi.org/10.1101/2022.05.11.491588	False	Yuan et al. (2022)	n/a	Neutralization of the bsAbs 47D10. Omicron BA.1 has an IC50 fold change of 1.26x.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
24469	N969K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	A	g.T2907A	p.N969K	NC_045512.2(GU280_gp02):g.2907T>A	YP_009724390.1:p.Asn969Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron BA.3 have higher sensitivity to inhibition by soluble angiotensin converting enzyme 2 (ACE2) and the endosomal inhibitor chloroquine compared  to D614G	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
24469	N969K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	A	g.T2907A	p.N969K	NC_045512.2(GU280_gp02):g.2907T>A	YP_009724390.1:p.Asn969Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Neerukonda	2022	doi:10.1101/2022.06.01.494385	n/a	https://doi.org/10.1101/2022.06.01.494385	False	Neerukonda et al. (2022)	n/a	Omicron BA.3 neutralization of the Omicron variants by antibodies induced by three doses of Pfizer/BNT162b2 mRNA vaccine was 7-8-fold less potent than the D614G, and  the Omicron variants still evade neutralization more efficiently.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
24469	N969K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	A	g.T2907A	p.N969K	NC_045512.2(GU280_gp02):g.2907T>A	YP_009724390.1:p.Asn969Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.3 (from South Africa/NICD-N22404/2021) were 4.2x-fold lower (95% CI: 0.15x-0.20x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
24469	N969K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	A	g.T2907A	p.N969K	NC_045512.2(GU280_gp02):g.2907T>A	YP_009724390.1:p.Asn969Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.3 (from South Africa/NICD-N22404/2021) were 6.2-fold lower (95% CI: 11.8x-14.3x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
24469	N969K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	A	g.T2907A	p.N969K	NC_045512.2(GU280_gp02):g.2907T>A	YP_009724390.1:p.Asn969Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Hao	2022	doi:10.1101/2022.08.12.22278720	pmid:36032965	https://doi.org/10.1101/2022.08.12.22278720	False	Hao et al. (2022)	n/a	paired testing of vaccine sera against ancestral virus compared to Omicron BA.1 shows that 3-dose vaccine regimen provides over 50x fold increase in protection against Omicron(B.1.1.529 [BA.1]) compared to a 2-dose regimen.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
24469	N969K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	A	g.T2907A	p.N969K	NC_045512.2(GU280_gp02):g.2907T>A	YP_009724390.1:p.Asn969Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	pharmaceutical effectiveness	n/a	n/a	Wang	2022	doi:10.1101/2022.08.11.503601	n/a	https://doi.org/10.1101/2022.08.11.503601	False	Wang et al. (2022)	n/a	4th antigenic exposure with Omicron (B.1.1.529 [BA.1])(n	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
24469	N969K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	A	g.T2907A	p.N969K	NC_045512.2(GU280_gp02):g.2907T>A	YP_009724390.1:p.Asn969Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.1 (from Botswana/R40B59_BHP_3321001248/2021) were 3.4-fold lower (95% CI: 3.2x-3.6x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
24469	N969K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	A	g.T2907A	p.N969K	NC_045512.2(GU280_gp02):g.2907T>A	YP_009724390.1:p.Asn969Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.1 (from Botswana/R40B59_BHP_3321001248/2021) were 28.7x-fold lower (95% CI: 0.03x-0.05) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
24469	N969K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	A	g.T2907A	p.N969K	NC_045512.2(GU280_gp02):g.2907T>A	YP_009724390.1:p.Asn969Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.4/5 (from ) were 17.2x-fold lower (95% CI: 0.6x-0.7x) than against 208-428 972-1834 4.3-4.7 US-WA1/2020 usiong an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
24469	N969K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	A	g.T2907A	p.N969K	NC_045512.2(GU280_gp02):g.2907T>A	YP_009724390.1:p.Asn969Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.4/5 (from ) were 13.0-fold lower (95% CI: 4.2x-4.6x) than against 208-428 972-1834 4.3-4.7 US-WA1/2020 usiong an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
24469	N969K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	A	g.T2907A	p.N969K	NC_045512.2(GU280_gp02):g.2907T>A	YP_009724390.1:p.Asn969Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccinee plasma binding	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  XD (from ) were 1.5x-fold lower (95% CI: 0.05x-0.07x) than against 208-428 972-1834 4.3-4.7 US-WA1/2020 usiong an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
24469	N969K	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	T	A	g.T2907A	p.N969K	NC_045512.2(GU280_gp02):g.2907T>A	YP_009724390.1:p.Asn969Lys	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	vaccine neutralization efficacy	n/a	n/a	Kurhade	2022	doi:10.1101/2022.06.05.494889	n/a	https://doi.org/10.1101/2022.06.05.494889	False	Kurhade et al. (2022)	n/a	In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  XD (from ) were 4.4-fold lower (95% CI: 4.3x-4.7x) than against 208-428 972-1834 4.3-4.7 US-WA1/2020 usiong an infectious cDNA clone of mNG USA-WA1/2020.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
24872	V1104L	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G3310T	p.V1104L	NC_045512.2(GU280_gp02):g.3310G>T	YP_009724390.1:p.Val1104Leu	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	Pokay	n/a	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	n/a	n/a	n/a	n/a	n/a	n/a
24990	P1143L	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C3428T	p.P1143L	NC_045512.2(GU280_gp02):g.3428C>T	YP_009724390.1:p.Pro1143Leu	n/a	n/a	S	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	Pokay	n/a	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	n/a	n/a	n/a	n/a	n/a	n/a
25000	D1146D	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C3438T	p.D1146D	NC_045512.2(GU280_gp02):g.3438C>T	YP_009724390.1:p.Asp1146Asp	n/a	n/a	S	SILENT	KP.2.3.5	n/a	n/a	n/a	1.0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	Pokay	n/a	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	n/a	n/a	n/a	n/a	n/a	n/a
25207	Y1215Y	n/a	S	surface glycoprotein gene (SARS-CoV-2)	s gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	surface glycoprotein	n/a	surface glycoprotein (SARS-CoV-2)	S protein (SARS-CoV-2)	YP_009724390.1	n/a	GU280_gp02	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C3645T	p.Y1215Y	NC_045512.2(GU280_gp02):g.3645C>T	YP_009724390.1:p.Tyr1215Tyr	n/a	n/a	S	SILENT	KP.2.3.5	n/a	n/a	n/a	1.0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	Pokay	n/a	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	n/a	n/a	n/a	n/a	n/a	n/a
25584	T64T	n/a	ORF3a	open reading frame 3a gene (SARS-CoV-2)	orf3a gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	ORF3a protein	n/a	open reading frame 3a protein (SARS-CoV-2)	Orf3a protein (SARS-CoV-2)	YP_009724391.1	n/a	GU280_gp03	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C192T	p.T64T	NC_045512.2(GU280_gp03):g.192C>T	YP_009724391.1:p.Thr64Thr	n/a	n/a	ORF3a	SILENT	KP.2.3.5	n/a	n/a	n/a	1.0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	Pokay	n/a	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	n/a	n/a	n/a	n/a	n/a	n/a
25593	K67N	n/a	ORF3a	open reading frame 3a gene (SARS-CoV-2)	orf3a gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	ORF3a protein	n/a	open reading frame 3a protein (SARS-CoV-2)	Orf3a protein (SARS-CoV-2)	YP_009724391.1	n/a	GU280_gp03	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	T	g.G201T	p.K67N	NC_045512.2(GU280_gp03):g.201G>T	YP_009724391.1:p.Lys67Asn	n/a	n/a	ORF3a	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	Pokay	n/a	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	n/a	n/a	n/a	n/a	n/a	n/a
26060	T223I	n/a	ORF3a	open reading frame 3a gene (SARS-CoV-2)	orf3a gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	ORF3a protein	n/a	open reading frame 3a protein (SARS-CoV-2)	Orf3a protein (SARS-CoV-2)	YP_009724391.1	n/a	GU280_gp03	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C668T	p.T223I	NC_045512.2(GU280_gp03):g.668C>T	YP_009724391.1:p.Thr223Ile	n/a	n/a	ORF3a	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	Pokay	n/a	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	n/a	n/a	n/a	n/a	n/a	n/a
26270	T9I	n/a	E	envelope gene (SARS-CoV-2)	e gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	envelope protein	n/a	envelope protein (SARS-CoV-2)	E protein (SARS-CoV-2)	YP_009724392.1	n/a	GU280_gp04	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C26T	p.T9I	NC_045512.2(GU280_gp04):g.26C>T	YP_009724392.1:p.Thr9Ile	n/a	n/a	E	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	homoplasy	n/a	n/a	Borges	2021	doi:10.1101/2021.05.19.444774	n/a	https://doi.org/10.1101/2021.05.19.444774	False	Borges et al. (2021)	n/a	In experimental models of SARS-CoV-2 mutational evolution (without immune pressure), this mutation appears convergent.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
26270	T9I	n/a	E	envelope gene (SARS-CoV-2)	e gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	envelope protein	n/a	envelope protein (SARS-CoV-2)	E protein (SARS-CoV-2)	YP_009724392.1	n/a	GU280_gp04	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C26T	p.T9I	NC_045512.2(GU280_gp04):g.26C>T	YP_009724392.1:p.Thr9Ile	n/a	n/a	E	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	frequency based fitness	n/a	n/a	UNKNOWN	2023	doi:10.1101/2023.01.30.526314	pmid:36778462	https://doi.org/10.1101/2023.01.30.526314	False	UNKNOWN et al. (2023)	n/a	Calculated to have an increased fitness (11x overrepresentation vs expected count of ~300 in public genome datasets), analysis as of 2023-05-11	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
26529	D3H	n/a	M	membrane glycoprotein gene (SARS-CoV-2)	m gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	membrane glycoprotein	n/a	membrane glycoprotein (SARS-CoV-2)	M protein (SARS-CoV-2)	YP_009724393.1	n/a	GU280_gp05	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	C	g.G7C	p.D3H	NC_045512.2(GU280_gp05):g.7G>C	YP_009724393.1:p.Asp3His	n/a	n/a	M	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	frequency based fitness	n/a	n/a	UNKNOWN	2023	doi:10.1101/2023.01.30.526314	pmid:36778462	https://doi.org/10.1101/2023.01.30.526314	False	UNKNOWN et al. (2023)	n/a	Calculated to have an increased fitness (227x overrepresentation vs expected count of ~14 in public genome datasets), analysis as of 2023-05-11	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
26577	Q19E	n/a	M	membrane glycoprotein gene (SARS-CoV-2)	m gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	membrane glycoprotein	n/a	membrane glycoprotein (SARS-CoV-2)	M protein (SARS-CoV-2)	YP_009724393.1	n/a	GU280_gp05	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	G	g.C55G	p.Q19E	NC_045512.2(GU280_gp05):g.55C>G	YP_009724393.1:p.Gln19Glu	n/a	n/a	M	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	frequency based fitness	n/a	n/a	UNKNOWN	2023	doi:10.1101/2023.01.30.526314	pmid:36778462	https://doi.org/10.1101/2023.01.30.526314	False	UNKNOWN et al. (2023)	n/a	Calculated to have an increased fitness (16x overrepresentation vs expected count of ~8 in public genome datasets), analysis as of 2023-05-11	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
26610	T30A	n/a	M	membrane glycoprotein gene (SARS-CoV-2)	m gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	membrane glycoprotein	n/a	membrane glycoprotein (SARS-CoV-2)	M protein (SARS-CoV-2)	YP_009724393.1	n/a	GU280_gp05	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	G	g.A88G	p.T30A	NC_045512.2(GU280_gp05):g.88A>G	YP_009724393.1:p.Thr30Ala	n/a	n/a	M	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	Pokay	n/a	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	n/a	n/a	n/a	n/a	n/a	n/a
26681	F53F	n/a	M	membrane glycoprotein gene (SARS-CoV-2)	m gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	membrane glycoprotein	n/a	membrane glycoprotein (SARS-CoV-2)	M protein (SARS-CoV-2)	YP_009724393.1	n/a	GU280_gp05	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C159T	p.F53F	NC_045512.2(GU280_gp05):g.159C>T	YP_009724393.1:p.Phe53Phe	n/a	n/a	M	SILENT	KP.2.3.5	n/a	n/a	n/a	1.0	frequency based fitness	n/a	n/a	UNKNOWN	2023	doi:10.1101/2023.01.30.526314	pmid:36778462	https://doi.org/10.1101/2023.01.30.526314	False	UNKNOWN et al. (2023)	n/a	Calculated to have an increased fitness (163x overrepresentation vs expected count of ~567 in public genome datasets), analysis as of 2023-05-11	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
26709	A63T	n/a	M	membrane glycoprotein gene (SARS-CoV-2)	m gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	membrane glycoprotein	n/a	membrane glycoprotein (SARS-CoV-2)	M protein (SARS-CoV-2)	YP_009724393.1	n/a	GU280_gp05	n/a	n/a	n/a	n/a	n/a	0	1	1	1	G	A	g.G187A	p.A63T	NC_045512.2(GU280_gp05):g.187G>A	YP_009724393.1:p.Ala63Thr	n/a	n/a	M	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	Pokay	n/a	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	n/a	n/a	n/a	n/a	n/a	n/a
26833	A104V	n/a	M	membrane glycoprotein gene (SARS-CoV-2)	m gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	membrane glycoprotein	n/a	membrane glycoprotein (SARS-CoV-2)	M protein (SARS-CoV-2)	YP_009724393.1	n/a	GU280_gp05	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C311T	p.A104V	NC_045512.2(GU280_gp05):g.311C>T	YP_009724393.1:p.Ala104Val	n/a	n/a	M	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	Pokay	n/a	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	n/a	n/a	n/a	n/a	n/a	n/a
26858	F112F	n/a	M	membrane glycoprotein gene (SARS-CoV-2)	m gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	membrane glycoprotein	n/a	membrane glycoprotein (SARS-CoV-2)	M protein (SARS-CoV-2)	YP_009724393.1	n/a	GU280_gp05	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C336T	p.F112F	NC_045512.2(GU280_gp05):g.336C>T	YP_009724393.1:p.Phe112Phe	n/a	n/a	M	SILENT	KP.2.3.5	n/a	n/a	n/a	1.0	frequency based fitness	n/a	n/a	UNKNOWN	2023	doi:10.1101/2023.01.30.526314	pmid:36778462	https://doi.org/10.1101/2023.01.30.526314	False	UNKNOWN et al. (2023)	n/a	Calculated to have an increased fitness (11x overrepresentation vs expected count of ~463 in public genome datasets), analysis as of 2023-05-11	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
27259	R20R	n/a	ORF6	open reading frame 6 gene (SARS-CoV-2)	orf6 gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	ORF6 protein	n/a	open reading frame 6 protein (SARS-CoV-2)	Orf6 protein (SARS-CoV-2)	YP_009724394.1	n/a	GU280_gp06	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	C	g.A58C	p.R20R	NC_045512.2(GU280_gp06):g.58A>C	YP_009724394.1:p.Arg20Arg	n/a	n/a	ORF6	SILENT	KP.2.3.5	n/a	n/a	n/a	1.0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	Pokay	n/a	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	n/a	n/a	n/a	n/a	n/a	n/a
27382	D61L	n/a	ORF6	open reading frame 6 gene (SARS-CoV-2)	orf6 gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	ORF6 protein	n/a	open reading frame 6 protein (SARS-CoV-2)	Orf6 protein (SARS-CoV-2)	YP_009724394.1	n/a	GU280_gp06	n/a	n/a	n/a	n/a	n/a	0	1	1	1	GAT	CTC	g.GAT181_183CTC	p.D61L	n/a	YP_009724394.1:p.Asp61Leu	n/a	n/a	ORF6	n/a	KP.2.3.5	n/a	n/a	n/a	1.0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	Pokay	n/a	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	n/a	n/a	n/a	n/a	n/a	n/a
27807	F19L	n/a	ORF7b	open reading frame 7b gene (SARS-CoV-2)	orf7b gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	ORF7b	n/a	open reading frame 7b protein (SARS-CoV-2)	Orf7b protein (SARS-CoV-2)	YP_009725318.1	n/a	GU280_gp08	n/a	n/a	n/a	n/a	n/a	0	1	1	1	CTAT	TTAC	g.CTAT52_55TTAC	p.F19L	n/a	YP_009725318.1:p.Phe19Leu	n/a	n/a	ORF7b	n/a	KP.2.3.5	n/a	n/a	n/a	1.0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	Pokay	n/a	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	n/a	n/a	n/a	n/a	n/a	n/a
28271	g.A-3T	n/a	intergenic	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	T	g.A-3T	n/a	NC_045512.2:g.3A>T	n/a	n/a	n/a	N	n/a	KP.2.3.5	n/a	n/a	n/a	1.0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	Pokay	n/a	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	n/a	n/a	n/a	n/a	n/a	n/a
28311	P13L	n/a	N	nucleocapsid phosphoprotein gene (SARS-CoV-2)	n gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	nucleocapsid phosphoprotein	n/a	nucleocapsid phosphoprotein (SARS-CoV-2)	N protein (SARS-CoV-2)	YP_009724397.2	n/a	GU280_gp10	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C38T	p.P13L	NC_045512.2(GU280_gp10):g.38C>T	YP_009724397.2:p.Pro13Leu	n/a	n/a	N	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	homoplasy	n/a	n/a	Borges	2021	doi:10.1101/2021.05.19.444774	n/a	https://doi.org/10.1101/2021.05.19.444774	False	Borges et al. (2021)	n/a	In experimental models of SARS-CoV-2 mutational evolution (without immune pressure), this mutation appears convergent.	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
28311	P13L	n/a	N	nucleocapsid phosphoprotein gene (SARS-CoV-2)	n gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	nucleocapsid phosphoprotein	n/a	nucleocapsid phosphoprotein (SARS-CoV-2)	N protein (SARS-CoV-2)	YP_009724397.2	n/a	GU280_gp10	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C38T	p.P13L	NC_045512.2(GU280_gp10):g.38C>T	YP_009724397.2:p.Pro13Leu	n/a	n/a	N	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	T cell evasion	n/a	n/a	de Silva	2021	doi:10.1101/2021.04.08.438904	n/a	https://doi.org/10.1101/2021.04.08.438904	False	de Silva et al. (2021)	n/a	Variant causes complete loss of T cell line responsiveness to B*27:05-restricted CD8+ N epitope QRNAPRITF 1-17(2,13).	Pokay	Pokay	Paul Gordon	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	Severe acute respiratory syndrome coronavirus 2	NC_045512.2	RefSeq	n/a	n/a	n/a
28361	E31_S33del	n/a	N	nucleocapsid phosphoprotein gene (SARS-CoV-2)	n gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	nucleocapsid phosphoprotein	n/a	nucleocapsid phosphoprotein (SARS-CoV-2)	N protein (SARS-CoV-2)	YP_009724397.2	n/a	GU280_gp10	n/a	n/a	n/a	n/a	n/a	0	1	1	1	GGAGAACGCA	G	g.90_98delAGAACGCAG	p.E31_S33del	NC_045512.2(GU280_gp10):g.90_98del	YP_009724397.2:p.Glu31_Ser33del	n/a	n/a	N	n/a	KP.2.3.5	n/a	n/a	n/a	1.0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	Pokay	n/a	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	n/a	n/a	n/a	n/a	n/a	n/a
28714	G147G	n/a	N	nucleocapsid phosphoprotein gene (SARS-CoV-2)	n gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	nucleocapsid phosphoprotein	n/a	nucleocapsid phosphoprotein (SARS-CoV-2)	N protein (SARS-CoV-2)	YP_009724397.2	n/a	GU280_gp10	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	T	g.C441T	p.G147G	NC_045512.2(GU280_gp10):g.441C>T	YP_009724397.2:p.Gly147Gly	n/a	n/a	N	SILENT	KP.2.3.5	n/a	n/a	n/a	1.0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	Pokay	n/a	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	n/a	n/a	n/a	n/a	n/a	n/a
28881	RG203KR	n/a	N	nucleocapsid phosphoprotein gene (SARS-CoV-2)	n gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	nucleocapsid phosphoprotein	n/a	nucleocapsid phosphoprotein (SARS-CoV-2)	N protein (SARS-CoV-2)	YP_009724397.2	n/a	GU280_gp10	n/a	n/a	n/a	n/a	n/a	0	1	1	1	GGG	AAC	g.GGG608_610AAC	p.RG203KR	n/a	YP_009724397.2:p.ArgGly203LysArg	n/a	n/a	N	n/a	KP.2.3.5	n/a	n/a	n/a	1.0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	Pokay	n/a	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	n/a	n/a	n/a	n/a	n/a	n/a
28958	Q229K	n/a	N	nucleocapsid phosphoprotein gene (SARS-CoV-2)	n gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	nucleocapsid phosphoprotein	n/a	nucleocapsid phosphoprotein (SARS-CoV-2)	N protein (SARS-CoV-2)	YP_009724397.2	n/a	GU280_gp10	n/a	n/a	n/a	n/a	n/a	0	1	1	1	C	A	g.C685A	p.Q229K	NC_045512.2(GU280_gp10):g.685C>A	YP_009724397.2:p.Gln229Lys	n/a	n/a	N	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	Pokay	n/a	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	n/a	n/a	n/a	n/a	n/a	n/a
29510	S413R	n/a	N	nucleocapsid phosphoprotein gene (SARS-CoV-2)	n gene (SARS-CoV-2)	sense strand orientation	forward gene orientation	nucleocapsid phosphoprotein	n/a	nucleocapsid phosphoprotein (SARS-CoV-2)	N protein (SARS-CoV-2)	YP_009724397.2	n/a	GU280_gp10	n/a	n/a	n/a	n/a	n/a	0	1	1	1	A	C	g.A1237C	p.S413R	NC_045512.2(GU280_gp10):g.1237A>C	YP_009724397.2:p.Ser413Arg	n/a	n/a	N	MISSENSE	KP.2.3.5	n/a	n/a	n/a	1.0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	Pokay	n/a	n/a	Omicron	VOC	n/a	26-Nov-2021	24-Nov-2021	actively_circulating	n/a	n/a	n/a	n/a	n/a	n/a
